data_2hi6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2hi6 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -131.06 113.22 13.66 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.513 178.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -93.3 152.85 18.9 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.949 0.404 . . . . 0.0 111.181 -175.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.51 124.39 47.97 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.669 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 56.9 m -119.41 174.0 6.63 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.914 0.388 . . . . 0.0 110.82 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 40.7 ttt180 -92.83 111.7 23.4 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -90.84 137.83 32.06 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.569 -171.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.6 HD13 HD12 ' A' ' 101' ' ' LEU . 4.3 mp -103.87 -52.2 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 48.7 p -102.95 176.42 5.16 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.771 176.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 61.0 mtt180 -122.37 -175.35 3.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.661 0.267 . . . . 0.0 111.076 -176.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.15 171.83 27.35 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -175.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.26 139.5 35.56 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 117.282 0.541 . . . . 0.0 110.52 -178.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.576 ' HB2' ' HB3' ' A' ' 79' ' ' LYS . . . -135.46 145.49 47.23 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.076 0.465 . . . . 0.0 111.65 -174.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.21 123.05 38.73 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.083 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.89 176.4 41.93 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 119.68 -1.248 . . . . 0.0 112.528 179.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.66 137.65 39.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 177.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.562 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.46 124.81 29.24 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.814 -176.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.28 121.23 39.16 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.496 HG11 ' OG1' ' A' ' 115' ' ' THR . 8.9 p -111.4 120.12 61.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.078 0.466 . . . . 0.0 110.185 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.3 t -94.12 -6.74 44.29 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.077 0.465 . . . . 0.0 111.366 -175.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.0 tttt 68.54 -61.07 0.42 Allowed 'General case' 0 CA--C 1.539 0.54 0 CA-C-N 114.958 -1.019 . . . . 0.0 113.605 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -71.64 163.67 27.33 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -82.53 78.2 9.19 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.622 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.6 pt -106.11 135.74 43.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.961 0.41 . . . . 0.0 110.397 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.3 t -111.02 178.02 4.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.941 -178.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -87.53 29.6 0.87 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.257 0.551 . . . . 0.0 111.414 -174.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.39 -21.97 66.74 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 171.04 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.95 -127.61 1.44 Allowed Glycine 0 N--CA 1.444 -0.833 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.184 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.65 ' HA2' ' HB2' ' A' ' 39' ' ' GLU . . . 86.59 -43.78 3.27 Favored Glycine 0 C--O 1.221 -0.687 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.847 172.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.447 HG12 HG13 ' A' ' 37' ' ' VAL . 57.3 mt -109.05 136.94 43.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -66.07 130.03 41.85 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.88 -33.31 73.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -170.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -109.41 -35.12 6.34 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.48 -0.488 . . . . 0.0 111.887 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 m -81.47 -28.57 34.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.583 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.81 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.82 19.55 78.82 Favored Glycine 0 C--N 1.329 0.191 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.505 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.449 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.7 mm -95.87 131.06 43.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.447 HG13 HG12 ' A' ' 30' ' ' ILE . 13.9 m -71.39 107.97 2.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.814 0.816 . . . . 0.0 110.218 175.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mmmm -92.35 -10.44 38.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.047 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.65 ' HB2' ' HA2' ' A' ' 29' ' ' GLY . 9.8 tp10 -80.8 153.4 27.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.792 177.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -100.04 137.95 37.79 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.244 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 16.3 p -161.27 -56.23 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.327 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -173.29 -51.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.477 174.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -92.05 44.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.885 0.85 . . . . 0.0 110.156 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -78.76 129.88 35.14 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.409 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.52 11.3 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.797 179.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.415 ' O ' HG23 ' A' ' 37' ' ' VAL . 26.7 mt-10 -92.86 171.69 8.81 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.299 0.571 . . . . 0.0 111.973 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.449 ' HB3' HD13 ' A' ' 36' ' ' ILE . 15.6 p -105.37 151.12 24.58 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.447 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.41 HG23 HD13 ' A' ' 30' ' ' ILE . 27.2 m -102.66 18.2 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.773 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.8 95.72 2.96 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.759 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.03 21.07 28.91 Favored Glycine 0 C--N 1.315 -0.619 0 CA-C-N 115.163 -0.926 . . . . 0.0 113.472 170.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -123.6 175.0 7.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.479 HD13 ' HB2' ' A' ' 80' ' ' ALA . 50.2 mm -99.11 129.51 49.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 -174.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.584 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 3.6 mm? -110.0 130.69 55.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.098 0.475 . . . . 0.0 111.341 -176.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.436 HG21 HG23 ' A' ' 113' ' ' VAL . 52.8 t -117.9 125.7 74.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.662 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.584 ' CE1' ' HB3' ' A' ' 53' ' ' LEU . 27.3 m-85 -131.5 143.92 51.24 Favored Pre-proline 0 C--N 1.327 -0.385 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -73.15 -42.83 0.86 Allowed 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 121.855 1.704 . . . . 0.0 110.57 171.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.824 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.222 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 . . . . . 0 C--O 1.233 0.226 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.39 -32.22 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 111.648 0.24 . . . . 0.0 111.648 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.3 mt -61.0 -38.8 87.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.942 0.401 . . . . 0.0 110.932 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 59.4 tp -71.74 -41.18 68.79 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.561 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -62.62 -44.18 96.93 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.714 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 94.7 mt -62.75 -39.6 94.64 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.614 178.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.51 ' HG2' ' O ' ' A' ' 97' ' ' ALA . 11.3 tpt180 -67.65 -41.47 83.75 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.365 -175.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.33 -10.08 59.24 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 110.898 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -94.98 -16.58 22.65 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.075 0.464 . . . . 0.0 110.399 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.23 11.66 81.93 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.086 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.81 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.2 m -106.65 13.67 8.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.106 0.479 . . . . 0.0 111.011 -177.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.15 155.57 42.75 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.832 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.557 ' HB3' HD22 ' A' ' 53' ' ' LEU . 37.0 Cg_endo -66.42 147.18 82.32 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.487 2.125 . . . . 0.0 111.201 173.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.576 ' HB3' ' HB2' ' A' ' 13' ' ' ALA . 93.2 mttt -68.15 -42.16 80.52 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.867 0.365 . . . . 0.0 111.14 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HB3' ' HG2' ' A' ' 100' ' ' PRO . . . -151.4 156.54 40.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.778 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.406 ' HB ' ' CD2' ' A' ' 101' ' ' LEU . 74.5 mt -132.83 128.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.392 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.678 HG21 HG23 ' A' ' 102' ' ' VAL . 2.3 mm -112.37 128.39 69.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.344 -0.614 . . . . 0.0 109.344 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.456 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -126.31 159.55 32.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.879 -178.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.508 ' O ' ' HD3' ' A' ' 84' ' ' LYS . 2.7 tmtp? -92.91 -35.69 13.2 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 173.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -142.58 101.99 3.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.813 174.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -95.41 -179.9 4.93 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -174.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.31 150.69 43.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.944 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.447 ' O ' HG23 ' A' ' 92' ' ' VAL . 13.1 m -62.52 -37.7 87.06 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.289 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.98 -29.53 47.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.9 mt -71.83 -42.52 69.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.47 ' HB1' HG22 ' A' ' 8' ' ' ILE . . . -59.43 -42.88 92.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.263 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 88' ' ' THR . 57.1 t -62.76 -47.86 90.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.828 179.287 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.2 -43.41 99.16 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.258 178.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.488 ' HB2' ' O ' ' A' ' 99' ' ' ILE . . . -65.5 -31.08 71.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.358 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -70.09 -35.11 73.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.911 0.386 . . . . 0.0 111.252 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.1 mtm -81.61 -33.62 31.4 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 -178.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.51 ' O ' ' HG2' ' A' ' 72' ' ' ARG . . . -89.99 0.51 57.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.003 -177.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 55.15 61.63 2.84 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.829 0.823 . . . . 0.0 110.098 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.488 ' O ' ' HB2' ' A' ' 94' ' ' ALA . 69.7 mt -123.11 90.05 50.55 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 114.784 -1.098 . . . . 0.0 109.801 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.496 ' HG2' ' HB3' ' A' ' 80' ' ' ALA . 4.2 Cg_exo -40.04 109.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.348 0.541 0 C-N-CA 123.669 2.912 . . . . 0.0 112.891 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.6 HD12 HD13 ' A' ' 8' ' ' ILE . 1.1 tm? -110.59 120.0 40.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.348 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.678 HG23 HG21 ' A' ' 82' ' ' ILE . 24.7 m -130.36 144.21 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.019 0.438 . . . . 0.0 110.634 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -110.16 122.84 48.58 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.03 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.8 134.45 37.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.185 0.517 . . . . 0.0 110.687 -177.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.436 ' HD3' ' O ' ' A' ' 105' ' ' ARG . 0.7 OUTLIER -92.79 -14.8 27.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.929 -174.328 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -109.42 137.61 47.01 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.558 -0.457 . . . . 0.0 111.274 -175.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -72.78 -19.36 61.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.847 -176.172 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 19.0 mmtp -58.3 -26.6 63.21 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.448 ' O ' HG13 ' A' ' 113' ' ' VAL . 79.9 t80 -61.72 -42.81 99.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.755 0.312 . . . . 0.0 110.3 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.496 ' HA ' HG13 ' A' ' 113' ' ' VAL . 87.6 m-85 -75.16 -24.97 57.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.24 -175.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -74.33 -33.45 63.16 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.484 175.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.16 -41.05 17.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.723 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.496 HG13 ' HA ' ' A' ' 110' ' ' PHE . 11.4 p -78.27 124.37 36.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.777 0.799 . . . . 0.0 111.386 -175.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.0 mmtp -132.06 153.25 50.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.706 175.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 60.8 m -62.35 114.87 3.74 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 123.195 0.31 . . . . 0.0 110.932 -178.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.6 -32.13 2.17 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 119.792 -1.194 . . . . 0.0 114.395 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.93 -172.11 2.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 117.736 0.768 . . . . 0.0 111.028 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -112.27 126.04 54.82 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.278 0.561 . . . . 0.0 111.905 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 17' ' ' ALA . 65.8 t -121.52 120.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.892 176.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.522 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 60.7 t -89.29 111.83 23.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.759 177.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 41.9 t -95.54 109.02 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.565 -177.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -110.34 99.08 8.17 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.99 -9.35 53.77 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.022 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -63.81 -47.01 82.58 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 174.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -93.2 -31.18 14.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.736 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 91.92 59.08 1.35 Allowed Glycine 0 N--CA 1.452 -0.295 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 143.49 29.75 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.793 0.33 . . . . 0.0 110.643 -169.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.53 106.31 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.319 0.581 . . . . 0.0 109.962 174.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.522 ' HB2' ' HB ' ' A' ' 120' ' ' VAL . 39.8 mt-10 -96.3 108.46 20.97 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.665 -174.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.6 tp -81.3 110.05 16.39 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.6 mm -112.74 114.9 48.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -176.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 . . . . . 0 C--N 1.312 -1.041 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.157 -170.604 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.226 -0.162 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.487 ' HD3' ' OH ' ' A' ' 127' ' ' TYR . 74.2 mttt -125.54 145.67 50.01 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.529 -177.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.462 ' HB2' HG12 ' A' ' 128' ' ' VAL . 89.6 m-85 -129.48 161.92 29.3 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.398 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.15 126.65 55.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.106 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.453 ' SG ' HG21 ' A' ' 102' ' ' VAL . 5.7 p -119.71 167.74 11.75 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.209 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.552 ' HD3' ' OE2' ' A' ' 103' ' ' GLU . 36.6 ttt180 -93.96 121.95 35.96 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.981 0.42 . . . . 0.0 110.107 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.98 102.9 3.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.123 -175.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.529 HG13 HG23 ' A' ' 86' ' ' THR . 50.0 mm -95.91 -43.57 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.11 177.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.7 p -109.57 -165.0 0.97 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.134 177.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -136.43 164.49 28.03 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -177.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.05 161.62 22.77 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.932 -0.652 . . . . 0.0 111.906 -177.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -147.86 154.12 40.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.09 0.445 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.45 164.97 24.3 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.081 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -127.92 127.05 42.66 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 176.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.62 178.92 32.83 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.056 -1.069 . . . . 0.0 112.69 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -74.44 139.86 44.25 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.33 178.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG22 ' A' ' 119' ' ' VAL . . . -80.56 122.83 27.53 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.07 0.462 . . . . 0.0 111.002 -178.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.3 tt -117.61 117.14 28.59 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 174.438 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.795 HG13 ' HB ' ' A' ' 115' ' ' THR . 8.4 p -101.6 124.99 55.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.442 0.639 . . . . 0.0 110.984 -173.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 1.027 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 13.2 m -95.63 95.03 8.08 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.446 0.641 . . . . 0.0 109.875 179.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -82.25 -2.61 53.1 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.944 -177.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -103.1 130.41 50.25 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.67 -176.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -85.14 98.89 10.72 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -118.95 172.64 5.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.253 -0.43 . . . . 0.0 112.007 -170.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.4 p -79.5 122.41 26.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.175 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -85.48 31.26 0.59 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.568 0.699 . . . . 0.0 109.991 -177.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.481 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -68.89 -23.8 64.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.198 177.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 174.37 -103.84 0.19 Allowed Glycine 0 N--CA 1.444 -0.832 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.294 178.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.72 -51.42 2.31 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.548 176.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.435 HD13 ' N ' ' A' ' 30' ' ' ILE . 3.7 mp -87.47 129.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.73 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 27.5 t70 -78.55 139.96 38.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.038 0.447 . . . . 0.0 111.005 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.479 ' HA ' HD21 ' A' ' 71' ' ' LEU . 0.0 OUTLIER -64.84 -26.33 68.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.548 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.45 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 45.4 mt-10 -95.41 -46.88 6.51 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.7 p -102.88 -19.15 14.76 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 73.93 20.14 79.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.015 -178.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.2 mm -87.68 133.03 31.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.639 -0.28 . . . . 0.0 110.453 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.3 m -74.28 111.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.582 0.706 . . . . 0.0 110.892 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.73 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 57.2 mttt -91.67 -10.89 38.61 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.947 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -66.33 138.27 57.49 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.646 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.41 131.42 44.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.38 -172.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 13.6 p 174.55 -178.22 0.1 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.981 -1.008 . . . . 0.0 108.482 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -79.35 -9.27 59.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.274 0.559 . . . . 0.0 110.095 175.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.414 ' O ' ' HB2' ' A' ' 46' ' ' GLU . 24.3 mt -94.26 -8.83 9.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.183 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.1 tmmm? -56.85 125.83 24.23 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.358 0.599 . . . . 0.0 110.372 -178.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.25 -24.36 12.64 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.964 -176.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' ' 43' ' ' ILE . 1.1 mm-40 -71.15 162.97 28.54 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.311 0.577 . . . . 0.0 111.656 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.2 p -116.89 127.13 53.96 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.61 -178.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -87.53 1.8 5.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.207 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.25 88.04 0.3 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.923 -177.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.514 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 107.36 11.04 26.34 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.519 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 mmm-85 -106.14 156.08 18.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.44 116.58 47.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 176.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.671 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -92.94 124.85 37.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.289 0.566 . . . . 0.0 111.324 -173.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 72.6 t -117.91 107.91 23.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.173 176.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 1.027 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 43.6 p90 -135.7 153.66 77.56 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.461 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -64.07 -49.89 3.42 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 122.591 2.194 . . . . 0.0 111.997 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.558 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 -179.666 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 . . . . . 0 N--CA 1.474 0.762 0 N-CA-C 112.084 0.402 . . . . 0.0 112.084 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.3 m -60.92 -16.84 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -173.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.21 -28.18 69.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.803 0.335 . . . . 0.0 110.699 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.0 tp -62.34 -38.48 89.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.423 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -58.22 -47.67 82.77 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.649 178.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.479 HD21 ' HA ' ' A' ' 32' ' ' LYS . 76.4 mt -56.76 -44.43 81.77 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.706 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.511 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -72.8 -41.32 65.08 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.745 -176.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -61.85 -33.3 73.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.824 0.345 . . . . 0.0 110.374 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -85.53 -19.68 30.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.126 0.489 . . . . 0.0 110.512 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 86.89 23.44 41.79 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.216 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.4 m -113.32 12.47 8.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.603 -179.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.47 ' HB1' ' HD2' ' A' ' 78' ' ' PRO . . . -90.91 162.66 32.39 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.671 ' HB3' HD13 ' A' ' 53' ' ' LEU . 43.7 Cg_endo -69.66 149.9 68.1 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.037 1.825 . . . . 0.0 111.434 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.514 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 88.4 mttt -69.47 -30.46 68.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.938 0.399 . . . . 0.0 110.75 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -163.77 155.3 16.67 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.457 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 68.5 mt -131.09 127.28 60.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.998 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.449 HG23 HG22 ' A' ' 102' ' ' VAL . 5.5 mm -117.85 120.79 65.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 13.6 m120 -120.03 164.03 16.74 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.645 0.26 . . . . 0.0 110.74 -176.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -79.07 -46.11 18.76 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 174.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.502 ' O ' ' HG3' ' A' ' 85' ' ' LYS . 44.2 pttt -125.88 112.75 16.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.762 172.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.649 ' HG1' HD22 ' A' ' 101' ' ' LEU . 5.8 t -92.47 116.3 28.87 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.41 0.624 . . . . 0.0 109.476 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -98.52 167.91 10.52 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.544 -175.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.5 m -53.98 -47.64 71.17 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -169.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.526 HG13 HG13 ' A' ' 90' ' ' ILE . 9.2 pt -55.56 -46.04 78.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 111.984 0.365 . . . . 0.0 111.984 -178.182 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.526 HG13 HG13 ' A' ' 89' ' ' ILE . 36.4 mt -76.77 -40.56 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.325 -176.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.511 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.44 -50.64 73.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.564 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 92.3 t -64.87 -42.37 94.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.791 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.35 -45.56 96.19 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.785 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.93 -33.01 63.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.552 0.215 . . . . 0.0 111.567 -178.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.8 -40.16 95.96 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.963 0.411 . . . . 0.0 111.512 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 69.7 mtm -74.04 -42.87 59.62 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.244 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.511 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -74.3 -14.78 60.95 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -177.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 71.71 59.89 0.16 Allowed 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.662 0.744 . . . . 0.0 109.934 -173.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 59.1 mt -121.96 89.32 48.23 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.481 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -38.29 107.56 0.06 OUTLIER 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 123.792 2.994 . . . . 0.0 113.441 -177.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.649 HD22 ' HG1' ' A' ' 86' ' ' THR . 43.6 tp -128.16 120.72 27.87 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.421 -176.259 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.453 HG21 ' SG ' ' A' ' 5' ' ' CYS . 20.6 m -135.0 166.76 27.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.195 179.366 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.552 ' OE2' ' HD3' ' A' ' 6' ' ' ARG . 9.9 pt-20 -113.59 141.16 47.52 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.066 0.46 . . . . 0.0 111.167 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 5.2 m -105.84 140.75 22.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.454 176.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -88.67 -26.27 21.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.221 -174.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -106.16 140.08 39.68 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.052 0.453 . . . . 0.0 111.372 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -71.14 -20.94 62.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.944 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.524 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 57.2 mttm -64.91 -17.97 64.8 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -60.64 -45.85 92.52 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 173.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.499 ' HA ' HG12 ' A' ' 113' ' ' VAL . 53.2 m-85 -76.12 -32.11 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.006 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.524 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.7 tt0 -57.3 -46.22 83.38 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.996 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -87.75 -24.62 23.74 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.481 -174.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.9 p -76.04 139.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.535 0.684 . . . . 0.0 111.96 -174.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -139.13 159.28 42.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.992 172.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.795 ' HB ' HG13 ' A' ' 19' ' ' VAL . 12.1 t -81.69 138.62 35.24 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.961 0.41 . . . . 0.0 110.434 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.53 -25.3 9.2 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.775 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -85.28 -171.78 3.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.608 0.242 . . . . 0.0 110.797 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 20.0 ttp180 -115.36 133.73 55.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.011 0.434 . . . . 0.0 111.447 -176.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG22 ' HB2' ' A' ' 17' ' ' ALA . 85.6 t -122.58 129.5 75.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.126 175.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.66 ' HB ' ' HB3' ' A' ' 129' ' ' GLU . 50.3 t -101.86 113.56 38.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.79 129.67 61.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.946 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -131.4 100.52 5.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.807 176.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.82 -12.22 55.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.472 -174.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.18 -7.64 58.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.025 0.44 . . . . 0.0 110.804 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -128.3 -20.99 3.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.868 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.29 59.94 2.79 Favored Glycine 0 CA--C 1.509 -0.336 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . 0.487 ' OH ' ' HD3' ' A' ' 2' ' ' LYS . 60.8 t80 -142.71 135.64 28.19 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.316 -167.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.462 HG12 ' HB2' ' A' ' 3' ' ' PHE . 6.6 p -137.76 124.81 28.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.461 0.648 . . . . 0.0 110.579 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.66 ' HB3' ' HB ' ' A' ' 120' ' ' VAL . 34.5 tt0 -115.96 122.45 45.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.413 -175.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 19.6 tp -106.63 127.53 53.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.945 0.402 . . . . 0.0 110.688 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.404 ' N ' HD13 ' A' ' 131' ' ' ILE . 3.5 mp -122.45 122.07 65.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 174.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 132' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.315 -0.91 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.618 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 C--O 1.234 0.25 0 CA-C-O 120.677 0.275 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.511 ' HG2' ' HG2' ' A' ' 129' ' ' GLU . 49.2 mttp -101.7 107.48 18.72 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 177.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -86.76 141.42 28.88 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.27 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.31 127.97 36.31 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.514 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.2 m -120.82 159.02 26.33 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.032 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.438 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 27.1 ttm180 -102.79 115.94 31.58 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 176.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.574 ' HA ' HG13 ' A' ' 102' ' ' VAL . . . -73.0 133.84 44.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.0 -173.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.535 HG13 ' HG1' ' A' ' 86' ' ' THR . 45.0 mm -106.94 -49.36 8.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 174.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 61.7 p -117.42 177.24 4.81 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.786 173.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 10' ' ' ARG . 61.5 mtt180 -101.1 169.49 8.9 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.801 0.334 . . . . 0.0 111.003 -177.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 134.68 153.54 6.89 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.124 178.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.423 HH11 ' HD3' ' A' ' 12' ' ' ARG . 45.9 ttp180 -137.84 130.17 29.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.557 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -146.27 164.22 33.02 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.937 0.398 . . . . 0.0 111.391 -175.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.03 149.12 27.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.833 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 160.36 -167.53 35.65 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.142 -1.028 . . . . 0.0 112.148 175.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 50.9 mm-40 -64.57 128.08 34.26 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.488 ' HB1' HG21 ' A' ' 119' ' ' VAL . . . -81.05 122.13 26.94 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.852 -178.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.3 tp -106.22 108.4 19.89 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 175.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.489 ' HB ' ' HB ' ' A' ' 115' ' ' THR . 43.3 t -110.59 113.52 44.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.967 0.413 . . . . 0.0 110.991 -172.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.2 m -105.0 110.17 22.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.922 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -86.26 26.8 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.263 0.554 . . . . 0.0 110.837 -177.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -115.44 157.51 23.86 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.76 178.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -103.4 94.61 5.58 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 pt -85.32 172.1 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.3 0.571 . . . . 0.0 111.445 -175.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.707 ' HB2' HD21 ' A' ' 27' ' ' LEU . 26.0 p -110.26 122.54 47.9 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.957 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -81.21 64.4 5.93 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.319 0.58 . . . . 0.0 110.476 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.707 HD21 ' HB2' ' A' ' 25' ' ' SER . 3.5 mm? -119.74 -57.03 2.0 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.936 174.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.54 44.52 0.69 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.81 -53.15 6.55 Favored Glycine 0 C--O 1.224 -0.47 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.943 -176.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 65.7 mt -98.61 135.51 33.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.833 0.316 . . . . 0.0 110.815 -177.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -67.06 134.78 52.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.268 177.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -68.52 -25.61 65.03 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.221 0.452 . . . . 0.0 112.221 -171.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -110.77 -38.11 5.23 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.231 0.538 . . . . 0.0 111.288 -168.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.512 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -98.94 -14.97 19.31 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.585 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' A' ' 47' ' ' SER . . . 68.29 21.89 74.3 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.085 -178.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.512 HG12 ' HB ' ' A' ' 34' ' ' THR . 36.4 mm -88.44 127.07 41.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 122.18 0.192 . . . . 0.0 110.625 -177.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 47.1 t -71.62 113.92 9.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -88.62 -28.61 20.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.054 -176.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -65.58 123.01 18.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.587 ' HA ' ' HG3' ' A' ' 44' ' ' LYS . 35.2 t70 -73.26 141.11 47.23 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.968 -173.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 42.0 t -172.81 -73.65 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.071 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -156.58 -51.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.331 179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.9 pp -82.41 15.31 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.078 177.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.587 ' HG3' ' HA ' ' A' ' 40' ' ' ASP . 4.5 tmmm? -65.16 124.99 23.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.698 179.233 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 104.4 -15.29 50.3 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.368 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -91.27 159.24 16.13 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.307 0.575 . . . . 0.0 112.07 177.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.481 ' HB3' HD13 ' A' ' 36' ' ' ILE . 2.5 p -103.74 158.54 16.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.246 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.472 HG13 HD22 ' A' ' 53' ' ' LEU . 26.7 m -108.63 20.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.919 -179.511 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.03 91.93 2.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.647 -173.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.96 20.64 27.75 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.001 -0.999 . . . . 0.0 112.91 174.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -110.33 158.97 17.86 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.863 -0.198 . . . . 0.0 110.64 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.448 ' HB ' ' HA ' ' A' ' 17' ' ' ALA . 49.6 mm -95.59 104.58 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.815 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.606 HD12 ' HB3' ' A' ' 78' ' ' PRO . 9.9 mp -85.58 133.34 34.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.17 0.509 . . . . 0.0 111.688 -172.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.61 121.15 59.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.743 176.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.551 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 78.3 m-85 -128.88 144.42 52.41 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.825 0.345 . . . . 0.0 111.332 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -81.17 -11.32 12.17 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.546 2.164 . . . . 0.0 111.883 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.909 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.054 179.857 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 2.0 t80 . . . . . 0 N--CA 1.47 0.565 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 58.9 t -58.85 -33.74 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.929 0.395 . . . . 0.0 111.323 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.424 ' HB3' HD13 ' A' ' 99' ' ' ILE . 87.1 mt -57.73 -31.37 66.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.573 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.6 tp -67.3 -33.99 76.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.105 0.478 . . . . 0.0 110.514 -178.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -66.01 -41.84 90.48 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.972 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.7 mt -57.42 -42.59 82.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.587 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -59.78 -51.04 71.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.915 -178.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 55.8 mtmt -75.39 -8.07 55.7 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.985 -174.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . 0.454 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.0 t-20 -92.42 -30.91 15.51 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.988 0.423 . . . . 0.0 109.909 175.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.09 15.41 28.34 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.091 -178.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.454 HG22 ' HB3' ' A' ' 74' ' ' ASN . 20.1 m -117.64 14.17 7.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.888 0.375 . . . . 0.0 111.185 -178.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -73.99 150.11 87.9 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.245 179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.606 ' HB3' HD12 ' A' ' 53' ' ' LEU . 7.9 Cg_exo -71.89 138.47 31.45 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.558 2.172 . . . . 0.0 110.383 171.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.557 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 85.5 mttt -63.44 -42.26 98.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.756 0.313 . . . . 0.0 111.346 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -157.92 153.57 26.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.803 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.551 HG12 ' HB2' ' A' ' 53' ' ' LEU . 52.8 mt -134.07 114.44 19.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.423 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.402 HG21 ' CG2' ' A' ' 102' ' ' VAL . 21.3 mm -100.65 124.22 54.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 34.9 m-80 -123.35 155.75 36.71 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.018 0.437 . . . . 0.0 111.228 -174.395 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 88.3 tttt -76.95 -46.98 22.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.502 174.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -116.89 120.71 39.31 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.815 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.535 ' HG1' HG13 ' A' ' 8' ' ' ILE . 9.4 t -99.51 134.77 41.91 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.721 -177.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.51 141.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.459 ' O ' HG22 ' A' ' 92' ' ' VAL . 5.5 m -66.99 -36.18 81.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.503 -175.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 87.0 mt -61.29 -43.88 97.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.976 0.417 . . . . 0.0 110.353 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.5 mt -64.4 -40.58 89.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.006 177.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.502 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.46 -46.57 88.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.527 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 88' ' ' THR . 90.1 t -58.52 -43.65 87.45 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 CA-C-O 120.975 0.417 . . . . 0.0 110.555 179.152 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.27 -41.05 69.73 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.5 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.425 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -71.05 -31.28 67.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.463 0.173 . . . . 0.0 111.412 -177.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.56 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.987 0.422 . . . . 0.0 110.971 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.7 mtm -70.29 -32.99 71.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.003 -179.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.43 3.47 49.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.797 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 56.15 43.1 27.35 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.927 0.87 . . . . 0.0 110.362 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.424 HD13 ' HB3' ' A' ' 68' ' ' LEU . 63.8 mt -109.77 89.26 7.53 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.671 177.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.99 116.0 2.9 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.893 2.395 . . . . 0.0 112.616 -176.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 91' ' ' ALA . 2.6 pt? -118.44 137.07 53.41 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.508 175.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.574 HG13 ' HA ' ' A' ' 7' ' ' ALA . 18.9 m -132.48 163.1 38.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.861 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.438 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 14.7 pt-20 -103.81 135.34 45.53 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.848 0.356 . . . . 0.0 110.094 176.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 15.8 m -116.26 130.92 70.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.102 0.477 . . . . 0.0 110.382 175.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -101.92 1.3 36.68 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.127 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -95.94 123.64 39.62 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.984 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.93 -32.79 67.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.371 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -69.89 -23.7 63.28 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -174.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -54.44 -49.43 70.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 174.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 96.6 m-85 -74.58 -28.25 60.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.981 0.419 . . . . 0.0 110.996 -179.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -66.44 -45.25 80.45 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.599 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.21 -39.45 19.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.454 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.488 HG13 ' HA ' ' A' ' 110' ' ' PHE . 9.4 p -65.45 127.83 27.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-O 121.475 0.655 . . . . 0.0 110.963 -175.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -123.15 135.88 54.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.755 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.489 ' HB ' ' HB ' ' A' ' 19' ' ' VAL . 14.8 t -72.24 113.85 9.71 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-O 121.41 0.624 . . . . 0.0 109.551 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.5 -18.94 3.41 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.392 -176.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . 0.544 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 0.8 OUTLIER -99.02 -171.71 2.14 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.676 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.544 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -114.54 137.34 51.98 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.337 0.589 . . . . 0.0 112.025 -174.92 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.488 HG21 ' HB1' ' A' ' 17' ' ' ALA . 84.3 t -120.38 130.33 74.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.743 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.5 t -98.88 111.44 28.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 174.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 88.3 t -96.0 120.71 45.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.134 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -124.71 99.85 6.36 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -86.18 -11.67 51.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.126 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -67.71 -43.01 81.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.015 0.436 . . . . 0.0 110.009 178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -96.38 -23.92 16.39 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.542 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.16 62.93 1.46 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.521 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . 0.533 ' HE1' ' HG3' ' A' ' 129' ' ' GLU . 25.6 p90 -162.41 163.55 27.67 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.772 0.32 . . . . 0.0 110.168 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.26 126.36 58.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.248 175.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.533 ' HG3' ' HE1' ' A' ' 127' ' ' TYR . 39.5 mt-10 -98.56 107.92 20.49 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.095 176.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 60.7 tp -82.45 102.0 11.03 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.358 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 18.1 pt -92.37 109.94 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.455 0.645 . . . . 0.0 110.291 -175.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 . . . . . 0 C--N 1.316 -0.854 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.085 -177.165 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.525 HG11 ' HB2' ' A' ' 112' ' ' ALA . 13.9 m . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 121.261 0.553 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -130.74 114.93 15.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.739 -176.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.502 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 76.6 m-85 -128.5 164.75 22.1 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.118 0.485 . . . . 0.0 111.036 -176.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -118.49 139.43 51.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.447 174.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.617 ' HG ' HG12 ' A' ' 128' ' ' VAL . 10.3 p -120.21 171.67 8.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.258 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.7 ttt85 -93.88 118.06 30.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.971 0.415 . . . . 0.0 110.116 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.509 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -71.82 96.52 1.66 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.042 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.458 HD13 ' OE1' ' A' ' 103' ' ' GLU . 49.3 mm -82.2 -43.51 19.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.87 175.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.8 p -125.29 -164.25 1.27 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.293 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 60.7 mtt-85 -118.56 -175.28 2.85 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.705 0.288 . . . . 0.0 110.59 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.551 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 115.71 145.21 8.43 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.04 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 68.8 mtm-85 -141.38 115.2 9.11 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.24 169.38 24.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.871 0.367 . . . . 0.0 111.193 -176.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.536 ' OE1' ' HD2' ' A' ' 118' ' ' ARG . 14.2 pt-20 -135.42 146.77 48.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.87 178.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.98 -173.48 34.48 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 120.079 -1.058 . . . . 0.0 112.098 174.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.62 127.97 34.4 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.45 118.98 22.54 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.905 -177.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.8 tp -102.02 111.42 23.68 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.553 ' HA ' ' CG1' ' A' ' 54' ' ' VAL . 47.1 t -98.87 110.92 27.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.385 0.612 . . . . 0.0 110.522 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.444 HG22 HD12 ' A' ' 24' ' ' ILE . 6.8 m -110.55 132.16 54.43 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.092 -176.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -102.77 -10.02 19.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.13 0.491 . . . . 0.0 110.573 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -97.88 161.47 13.73 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -96.0 141.73 29.06 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.553 0.216 . . . . 0.0 110.468 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 20' ' ' THR . 2.5 mp -114.16 132.89 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 55.2 p -78.73 115.23 18.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.148 0.499 . . . . 0.0 110.722 -178.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.95 -6.3 32.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.333 179.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.504 HD11 ' O ' ' A' ' 27' ' ' LEU . 1.8 tm? -65.05 -30.53 71.5 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 175.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 146.55 51.81 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.48 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.16 21.17 32.64 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.161 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.488 HD11 HG23 ' A' ' 48' ' ' VAL . 53.6 mt -130.75 136.74 57.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 -179.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.568 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.1 t70 -69.46 123.79 22.18 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.268 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.597 ' HG2' ' OE1' ' A' ' 33' ' ' GLU . 0.6 OUTLIER -79.28 -12.21 59.94 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -170.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.597 ' OE1' ' HG2' ' A' ' 32' ' ' LYS . 2.4 mp0 -94.33 -41.09 9.61 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 121.137 -0.225 . . . . 0.0 111.254 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.9 p -103.06 -36.97 7.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 -177.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.79 16.45 36.2 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.816 -175.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.0 mm -91.45 128.44 43.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.498 HG22 ' HG2' ' A' ' 44' ' ' LYS . 8.4 m -62.96 142.02 17.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.021 0.439 . . . . 0.0 110.912 177.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.568 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 26.9 mmmt -96.12 -3.67 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.487 0.661 . . . . 0.0 110.823 -174.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -92.39 158.86 15.84 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.642 -175.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -92.29 139.28 30.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.371 0.605 . . . . 0.0 112.127 -176.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.511 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 48.8 t -179.22 168.7 1.52 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 172.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -68.32 -35.97 78.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.049 0.452 . . . . 0.0 110.428 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 32.3 pt -102.62 12.36 7.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.493 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.511 ' HB2' ' HB3' ' A' ' 41' ' ' CYS . 70.2 mttt -99.44 147.5 25.2 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 176.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.48 1.55 15.59 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -175.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -108.82 -179.36 3.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.802 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.6 m -91.83 133.9 35.23 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.933 -171.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.488 HG23 HD11 ' A' ' 30' ' ' ILE . 34.5 m -101.6 4.38 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.3 0.572 . . . . 0.0 110.005 174.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -67.27 100.13 0.78 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.186 -174.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.17 19.99 50.97 Favored Glycine 0 C--N 1.308 -1.001 0 CA-C-N 114.536 -1.211 . . . . 0.0 112.872 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -110.72 155.53 22.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.853 HG13 ' HB1' ' A' ' 80' ' ' ALA . 1.8 mp -84.66 105.48 13.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 175.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 32.1 tp -82.28 126.89 32.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.447 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.553 ' CG1' ' HA ' ' A' ' 19' ' ' VAL . 11.8 p -130.26 106.96 13.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.62 0.724 . . . . 0.0 111.842 177.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.416 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 38.1 p90 -136.16 151.68 73.95 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.175 170.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.91 -55.43 2.33 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.547 2.164 . . . . 0.0 112.808 -177.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.53 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.874 -178.436 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 28.1 p90 . . . . . 0 CA--C 1.53 0.199 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 62.9 t -60.63 -41.79 89.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.983 0.421 . . . . 0.0 110.648 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.417 ' O ' HD13 ' A' ' 68' ' ' LEU . 0.7 OUTLIER -73.38 -32.17 64.33 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.231 0.539 . . . . 0.0 109.871 179.282 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.6 tp -61.33 -32.49 72.38 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.2 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -54.94 -44.23 74.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.213 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 88.0 mt -61.84 -33.15 73.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.005 -178.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.545 ' HD3' ' HA ' ' A' ' 97' ' ' ALA . 8.0 ttp180 -72.16 -35.94 69.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.126 -178.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -61.37 -31.19 71.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.014 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -93.54 -25.17 17.69 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.938 0.399 . . . . 0.0 110.442 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 94.16 26.94 12.94 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.704 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.8 m -107.15 4.56 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.171 0.51 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.96 159.38 73.57 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.733 179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.49 162.38 24.45 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.491 2.127 . . . . 0.0 112.13 175.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -82.83 -28.8 29.94 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.853 ' HB1' HG13 ' A' ' 52' ' ' ILE . . . -166.77 165.22 16.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.673 175.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.68 HG23 HD21 ' A' ' 101' ' ' LEU . 8.3 tt -152.07 121.29 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.45 0.643 . . . . 0.0 110.824 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.801 HG22 HG22 ' A' ' 102' ' ' VAL . 2.7 mm -110.21 118.88 58.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -116.39 165.96 12.61 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.364 0.602 . . . . 0.0 111.758 -174.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.22 -31.49 10.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.302 176.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.9 tttm -121.28 122.41 39.83 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.577 176.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 66.5 p -127.68 158.75 36.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.967 0.413 . . . . 0.0 111.681 -175.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.552 ' HB2' HG13 ' A' ' 90' ' ' ILE . 53.8 mt-10 -123.58 157.66 33.2 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.776 173.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.512 ' O ' HG23 ' A' ' 92' ' ' VAL . 89.2 m -60.09 -44.28 94.92 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.107 178.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.9 pt -63.9 -29.89 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.453 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.552 HG13 ' HB2' ' A' ' 87' ' ' GLU . 64.4 mt -66.98 -42.75 89.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.99 -32.96 74.75 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.198 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 88' ' ' THR . 73.1 t -66.69 -49.87 70.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 120.929 0.395 . . . . 0.0 110.543 177.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.35 -44.11 97.35 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.13 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.09 -37.33 87.04 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 111.585 0.216 . . . . 0.0 111.585 -179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.3 -41.76 96.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.807 0.337 . . . . 0.0 111.12 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 66.5 mtm -74.64 -32.09 62.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.897 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.545 ' HA ' ' HD3' ' A' ' 72' ' ' ARG . . . -82.04 -0.61 45.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 176.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 57.32 38.39 28.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.278 0.561 . . . . 0.0 111.233 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 61.4 mt -111.08 90.93 12.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.198 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.551 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 82.5 Cg_exo -40.57 115.6 0.34 Allowed 'Trans proline' 0 C--N 1.35 0.651 0 C-N-CA 124.027 3.151 . . . . 0.0 113.872 -175.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.68 HD21 HG23 ' A' ' 81' ' ' ILE . 0.1 OUTLIER -108.94 120.67 43.22 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.584 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.801 HG22 HG22 ' A' ' 82' ' ' ILE . 5.5 m -140.5 161.84 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.784 177.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.458 ' OE1' HD13 ' A' ' 8' ' ' ILE . 46.1 mt-10 -101.21 132.99 46.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.529 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 3.4 m -96.48 139.65 18.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -99.97 -46.76 5.25 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.347 -174.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.43 ' OD1' ' HG3' ' A' ' 108' ' ' LYS . 7.1 t70 -92.8 146.51 23.59 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.218 0.532 . . . . 0.0 111.338 -174.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -71.1 -18.76 62.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.103 -0.953 . . . . 0.0 111.177 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.43 ' HG3' ' OD1' ' A' ' 106' ' ' ASP . 67.7 mttm -55.08 -33.08 62.47 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -61.31 -40.6 94.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.421 -178.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.01 -31.14 68.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.295 -176.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -77.98 -45.58 23.44 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.902 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.525 ' HB2' HG11 ' A' ' 1' ' ' VAL . . . -66.51 -37.56 85.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.179 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 12.0 p -75.15 129.28 36.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.405 0.621 . . . . 0.0 111.076 -177.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.424 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 71.1 mmtt -118.91 144.12 46.6 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.431 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.9 m -64.76 110.9 2.55 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.96 0.41 . . . . 0.0 110.631 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.89 -7.57 8.78 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.425 -178.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . 0.424 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 12.2 m-20 -87.39 171.84 10.28 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 174.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.536 ' HD2' ' OE1' ' A' ' 14' ' ' GLU . 11.7 ttp180 -115.67 121.94 44.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.824 0.345 . . . . 0.0 110.862 -178.382 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.95 130.07 66.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.187 0.518 . . . . 0.0 110.409 178.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 45.6 t -99.19 111.21 28.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.1 p -102.25 115.23 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.642 0.734 . . . . 0.0 111.754 -174.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . 0.472 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 50.1 t-20 -99.94 94.15 6.14 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 172.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.411 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -82.4 -19.67 38.64 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.108 0.48 . . . . 0.0 110.266 -178.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.78 -39.07 93.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.643 -179.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -107.46 -28.02 10.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.814 177.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.95 64.45 0.99 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.487 -0.863 . . . . 0.0 111.291 -176.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . 0.472 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 35.6 t80 -144.55 124.39 13.44 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -174.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.617 HG12 ' HG ' ' A' ' 5' ' ' CYS . 5.9 m -126.26 118.09 50.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.481 0.657 . . . . 0.0 110.997 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -121.04 123.38 42.23 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.193 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.481 ' HB3' HG22 ' A' ' 1' ' ' VAL . 17.0 tp -103.81 120.59 41.3 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.152 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.438 HD13 ' N ' ' A' ' 131' ' ' ILE . 4.0 mp -89.43 123.27 41.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.235 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--N 1.317 -0.814 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.309 -178.938 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 2' ' ' LYS . 60.6 t . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 1' ' ' VAL . 49.2 mttp 64.34 77.84 0.3 Allowed 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -170.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -98.97 136.79 38.44 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.053 0.454 . . . . 0.0 110.775 -176.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -107.27 110.64 22.72 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.708 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.879 ' SG ' HG12 ' A' ' 104' ' ' VAL . 58.2 m -119.71 -178.73 3.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.489 -174.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.465 ' HB3' ' HG3' ' A' ' 103' ' ' GLU . 17.5 tpt180 -91.3 119.86 31.7 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.996 0.427 . . . . 0.0 110.639 -171.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.546 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -93.54 140.05 30.05 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.021 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.8 mp -114.0 -45.51 4.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.751 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.424 HG21 ' H ' ' A' ' 10' ' ' ARG . 3.0 m -109.6 177.55 4.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.401 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.424 ' H ' HG21 ' A' ' 9' ' ' THR . 81.6 mtt180 -112.05 -177.97 3.3 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.539 0.209 . . . . 0.0 110.794 -175.118 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.56 172.59 22.97 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.026 -178.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -149.71 119.73 7.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.044 0.45 . . . . 0.0 110.401 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -125.44 139.25 53.8 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.534 -174.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.26 125.23 44.04 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.925 -177.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.97 -160.91 23.1 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.996 175.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.688 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.9 mt-10 -74.67 130.94 40.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 122.822 0.449 . . . . 0.0 111.036 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.36 128.91 34.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.659 177.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.2 tt -118.97 114.74 23.03 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 177.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.21 126.39 60.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.978 0.418 . . . . 0.0 111.039 -173.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.5 m -129.56 95.35 3.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 177.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -84.49 83.79 7.88 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.123 0.487 . . . . 0.0 110.117 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -160.73 161.05 32.09 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.419 -0.81 . . . . 0.0 108.856 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 87.6 m-85 -101.26 89.14 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.582 ' HB ' ' HG2' ' A' ' 39' ' ' GLU . 32.7 pt -108.66 170.88 2.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.543 -172.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.27 123.01 39.75 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.488 -177.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.73 -4.91 51.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.334 0.588 . . . . 0.0 109.96 -178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.1 pp -72.93 -16.21 61.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.147 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.52 44.46 0.72 Allowed Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.29 -84.34 0.37 Allowed Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.265 -179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.472 HD13 ' N ' ' A' ' 30' ' ' ILE . 4.1 mp -92.42 137.8 21.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 178.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -62.01 138.73 58.41 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.694 0.283 . . . . 0.0 110.351 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.532 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.8 pttp -74.5 -8.58 56.79 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -171.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.661 ' HA ' ' ND2' ' A' ' 74' ' ' ASN . 33.4 mt-10 -127.03 -44.47 1.61 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.3 p -96.92 -16.97 20.42 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -177.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.64 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.11 16.74 79.33 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.941 177.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.501 HD11 ' HB3' ' A' ' 47' ' ' SER . 35.5 mm -90.46 133.5 32.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.94 123.14 15.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.89 0.376 . . . . 0.0 110.63 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -87.24 -47.18 9.05 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.759 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.582 ' HG2' ' HB ' ' A' ' 24' ' ' ILE . 4.8 tp10 -62.06 134.76 57.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.671 179.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -93.03 160.85 14.68 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.269 0.557 . . . . 0.0 111.235 -175.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 47.9 t -178.68 -49.63 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -176.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 176.2 -45.98 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 114.642 -1.163 . . . . 0.0 109.718 174.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.78 13.25 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.936 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.2 tmmt? -65.91 128.68 36.99 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 116.74 -21.78 11.15 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.959 -176.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -87.98 156.48 19.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.982 0.42 . . . . 0.0 110.457 177.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.501 ' HB3' HD11 ' A' ' 36' ' ' ILE . 13.3 p -103.02 144.8 30.81 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.944 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.427 HG21 ' H ' ' A' ' 49' ' ' ALA . 0.0 OUTLIER -74.47 -76.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.608 175.046 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.427 ' H ' HG21 ' A' ' 48' ' ' VAL . . . 46.3 81.42 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.925 0.713 . . . . 0.0 112.925 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.09 3.78 88.79 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.64 -0.79 . . . . 0.0 113.303 177.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.688 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 52.0 mtt180 -94.6 162.28 13.86 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.411 -0.464 . . . . 0.0 110.902 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.438 HD13 ' N ' ' A' ' 52' ' ' ILE . 2.6 mp -104.99 120.18 55.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.445 ' O ' HD12 ' A' ' 81' ' ' ILE . 54.8 tp -99.06 132.85 44.08 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.483 -177.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.44 107.3 15.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.038 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.429 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 41.0 p90 -135.76 144.58 49.43 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 172.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -55.13 -55.19 3.37 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.824 2.349 . . . . 0.0 112.883 -177.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 23' ' ' TYR . . . . . . . . 0 N--CA 1.449 -0.484 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.738 -178.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.463 0.187 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 86.3 t -58.37 -32.88 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.521 ' HA ' HD11 ' A' ' 71' ' ' LEU . 10.3 mp -61.85 -28.22 69.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.512 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.493 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 61.6 tp -70.64 -39.8 73.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.905 0.383 . . . . 0.0 110.331 178.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -65.9 -32.35 73.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.911 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' A' ' 68' ' ' LEU . 97.3 mt -57.63 -39.55 77.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.488 175.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 49.2 ttp180 -71.52 -33.36 69.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.572 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -62.41 -33.8 75.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.245 0.545 . . . . 0.0 110.295 177.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . 0.661 ' ND2' ' HA ' ' A' ' 33' ' ' GLU . 92.0 m-20 -88.02 -14.33 39.31 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.906 178.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 79.19 13.56 82.75 Favored Glycine 0 N--CA 1.453 -0.205 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.541 178.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.64 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.5 m -106.79 8.68 9.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.127 0.489 . . . . 0.0 110.966 -176.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -70.7 150.45 95.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.483 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.49 147.68 52.56 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.458 2.105 . . . . 0.0 110.562 171.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.46 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 12.0 mttm -71.81 -35.53 69.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.922 0.391 . . . . 0.0 110.533 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.406 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -155.83 151.99 27.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.368 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.542 HG23 ' HB3' ' A' ' 101' ' ' LEU . 3.8 tp -129.52 120.84 51.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.905 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.696 HD12 HG21 ' A' ' 102' ' ' VAL . 4.7 mm -117.32 116.73 52.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 25.9 m120 -109.1 -179.67 3.91 Favored 'General case' 0 C--O 1.22 -0.471 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.474 ' O ' ' HB2' ' A' ' 103' ' ' GLU . 39.0 ttmt -82.55 -45.04 15.14 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -141.37 100.45 3.79 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 169.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -74.22 150.39 40.34 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -92.3 147.4 22.95 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.254 -175.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.411 ' O ' HG21 ' A' ' 92' ' ' VAL . 6.8 m -52.79 -36.93 59.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.419 -177.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 49.5 mt -56.35 -47.54 81.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.006 178.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.9 mt -68.3 -38.78 79.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.378 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.92 -42.87 94.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.177 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.411 HG21 ' O ' ' A' ' 88' ' ' THR . 93.7 t -66.19 -42.95 92.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.77 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.9 -45.45 73.79 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.769 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.478 ' HB3' ' HB ' ' A' ' 99' ' ' ILE . . . -68.57 -30.06 68.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.677 0.275 . . . . 0.0 111.519 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -62.76 -25.38 68.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.408 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.0 mtm -83.17 -26.42 30.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.349 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.493 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -96.5 1.02 51.09 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.939 -178.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 1.5 mp0 59.0 47.85 11.6 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.124 0.488 . . . . 0.0 110.855 -175.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.478 ' HB ' ' HB3' ' A' ' 94' ' ' ALA . 58.1 mt -107.74 89.39 5.2 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.882 176.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 36.6 Cg_exo -55.87 116.69 3.34 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.904 2.403 . . . . 0.0 112.195 -177.175 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.542 ' HB3' HG23 ' A' ' 81' ' ' ILE . 1.8 pt? -122.71 134.7 54.45 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.44 0.638 . . . . 0.0 110.792 178.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.696 HG21 HD12 ' A' ' 82' ' ' ILE . 14.4 m -130.31 170.16 19.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.546 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 7.9 pt-20 -119.41 132.48 55.83 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.315 0.578 . . . . 0.0 111.676 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.879 HG12 ' SG ' ' A' ' 5' ' ' CYS . 17.3 m -104.47 105.04 17.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.925 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.413 ' HA ' ' HG3' ' A' ' 84' ' ' LYS . 32.6 ttp180 -99.13 27.62 4.97 Favored 'General case' 0 C--N 1.32 -0.717 0 O-C-N 121.837 -0.539 . . . . 0.0 110.614 -177.442 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -123.87 131.88 53.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.125 178.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -71.33 -26.59 62.9 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.212 -176.144 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -65.22 -24.21 67.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.167 -177.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.578 ' O ' HG11 ' A' ' 113' ' ' VAL . 80.6 t80 -65.01 -48.6 73.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -66.69 -25.42 66.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.687 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -78.85 -25.98 44.05 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 115.487 -0.778 . . . . 0.0 111.627 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -94.32 -39.69 10.36 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.032 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.578 HG11 ' O ' ' A' ' 109' ' ' PHE . 11.4 p -89.8 137.97 20.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 111.17 -176.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -137.28 157.62 46.24 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.39 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 32.6 m -64.24 110.09 2.1 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.492 -175.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.08 -17.37 3.85 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.546 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 -82.66 156.86 23.61 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.966 0.413 . . . . 0.0 111.13 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.93 119.38 30.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.079 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.38 136.87 56.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.244 0.545 . . . . 0.0 111.078 -178.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.0 110.51 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.499 173.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.432 HG13 HD13 ' A' ' 82' ' ' ILE . 66.7 t -92.82 104.44 15.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.693 179.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -107.05 98.75 8.37 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.027 -179.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.12 -9.04 58.34 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.342 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -64.27 -39.41 93.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.581 175.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -102.63 -34.46 9.06 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.863 175.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 98.31 68.2 0.91 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.474 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -166.15 166.18 17.19 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.27 121.51 42.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.349 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -120.69 117.79 28.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.317 0.579 . . . . 0.0 110.678 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.569 HD12 HG22 ' A' ' 113' ' ' VAL . 0.9 OUTLIER -109.43 147.87 32.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.143 178.101 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 46.6 mm -110.01 128.58 66.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 173.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 C--N 1.317 -0.815 0 O-C-N 123.954 0.783 . . . . 0.0 109.939 -179.448 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.514 HG21 ' HB3' ' A' ' 130' ' ' LEU . 17.1 m . . . . . 0 N--CA 1.452 -0.341 0 CA-C-O 121.303 0.573 . . . . 0.0 112.219 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.422 ' HB3' ' HE3' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -137.21 140.51 41.77 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.079 173.06 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -127.5 151.09 49.31 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.924 0.392 . . . . 0.0 111.044 -173.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.9 127.02 44.72 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.044 177.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 4.4 p -120.87 173.44 7.23 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.734 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 tpm_? -94.04 121.5 35.59 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 176.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.559 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -86.53 97.39 10.48 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.413 . . . . 0.0 111.302 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.63 -45.12 19.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 173.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.3 172.08 6.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.549 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 55.9 mtt-85 -111.04 176.83 4.87 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.283 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.51 -178.14 16.42 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.668 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -155.51 114.78 3.59 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 156.37 41.25 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -169.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tm-20 -135.85 120.92 18.82 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.041 -0.981 . . . . 0.0 108.735 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.19 162.44 35.72 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 119.717 -1.23 . . . . 0.0 113.4 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.74 140.95 56.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.535 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.94 125.79 30.58 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.969 0.414 . . . . 0.0 111.651 -176.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.495 ' HA ' HG23 ' A' ' 115' ' ' THR . 7.9 tt -111.89 110.43 20.76 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 171.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.1 t -102.7 110.17 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.091 0.472 . . . . 0.0 110.824 -175.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.445 HG22 ' CD2' ' A' ' 18' ' ' LEU . 2.0 p -99.43 112.92 25.04 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.814 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.0 pttt -92.32 0.72 57.47 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.856 0.836 . . . . 0.0 109.105 176.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -79.61 -173.39 3.75 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.54 -1.209 . . . . 0.0 109.675 174.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -121.0 93.99 4.2 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.297 0.57 . . . . 0.0 110.557 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.8 mt -106.21 146.44 12.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.527 -176.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.567 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 33.9 t -131.74 162.27 30.87 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.453 ' HD2' HG12 ' A' ' 90' ' ' ILE . 64.0 m-85 -88.45 23.82 2.11 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.167 0.508 . . . . 0.0 111.007 -177.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.567 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 1.0 OUTLIER -74.93 -14.7 60.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.921 169.466 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.49 ' N ' HD12 ' A' ' 27' ' ' LEU . . . 139.84 57.65 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.727 -178.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.77 -42.23 6.12 Favored Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.866 -178.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.457 HG13 HG12 ' A' ' 37' ' ' VAL . 4.3 mp -93.41 146.46 6.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.668 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 20.0 t70 -70.43 138.98 51.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.825 0.345 . . . . 0.0 110.175 176.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.406 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.2 ptmt -79.77 -10.49 59.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.406 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 43.0 mt-10 -121.21 -40.45 2.59 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -176.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.0 p -92.57 -18.8 22.63 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.997 0.427 . . . . 0.0 111.384 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.452 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 76.51 11.13 85.43 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.093 -179.013 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.0 mm -86.92 132.37 32.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.457 HG12 HG13 ' A' ' 30' ' ' ILE . 11.8 m -67.87 129.49 32.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.281 0.562 . . . . 0.0 111.355 178.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.668 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 72.4 mmtt -84.64 -37.14 21.4 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 174.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -94.51 90.62 6.26 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.512 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.981 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.5 t70 -146.96 -164.47 2.0 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.007 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 45.6 t -166.87 -41.2 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 120.818 0.342 . . . . 0.0 110.469 -177.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -103.93 -48.43 3.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.505 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -111.56 15.93 8.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.891 0.377 . . . . 0.0 111.336 -173.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.981 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 38.6 ttmt -50.26 128.9 20.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.171 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.72 -7.45 12.15 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.107 -175.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.449 ' HB3' ' NH1' ' A' ' 51' ' ' ARG . 22.0 mm-40 -93.3 145.26 24.59 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 110.282 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.474 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 34.6 t -97.7 148.39 23.39 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 20.5 m -86.82 2.06 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.983 0.421 . . . . 0.0 110.706 178.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.492 ' HB3' ' HA ' ' A' ' 76' ' ' VAL . . . -67.22 92.51 0.27 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.538 -176.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.99 5.36 33.16 Favored Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.328 -0.851 . . . . 0.0 113.443 171.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.488 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 0.8 OUTLIER -123.56 178.29 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 O-C-N 122.65 -0.324 . . . . 0.0 110.461 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.491 HD12 ' HB ' ' A' ' 119' ' ' VAL . 72.2 mt -108.1 130.02 61.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.165 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.584 ' HB3' HG12 ' A' ' 81' ' ' ILE . 60.3 tp -96.1 123.93 39.91 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.706 -176.058 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 54.4 t -123.79 108.77 21.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.749 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.432 ' HB3' ' OG1' ' A' ' 20' ' ' THR . 53.4 p90 -134.58 144.56 51.36 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.104 174.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 6.2 Cg_exo -74.81 -38.82 1.53 Allowed 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 123.018 2.479 . . . . 0.0 112.027 177.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.609 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.787 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.473 0.687 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.533 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 23.0 m -56.79 -31.12 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.496 HD23 HG22 ' A' ' 67' ' ' VAL . 4.0 mm? -59.13 -40.52 85.73 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 178.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.497 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.3 tp -63.58 -44.65 93.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.194 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -62.13 -45.73 92.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.267 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 92.7 mt -59.36 -40.38 86.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.589 178.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.646 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -69.12 -37.73 78.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.061 -176.172 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.492 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 32.5 mmmt -70.01 -27.34 64.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.933 0.397 . . . . 0.0 110.709 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -87.61 -21.92 25.06 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.132 0.491 . . . . 0.0 110.435 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.79 20.43 37.0 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.216 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.492 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 21.9 m -118.41 24.24 4.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.015 0.436 . . . . 0.0 110.791 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -95.44 159.34 32.91 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.801 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.463 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 62.5 Cg_endo -76.45 151.69 33.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.178 1.919 . . . . 0.0 111.392 175.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.435 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 89.6 mttt -74.8 -30.96 61.58 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.73 0.3 . . . . 0.0 111.255 -178.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.96 161.73 36.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.43 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.584 HG12 ' HB3' ' A' ' 53' ' ' LEU . 71.2 mt -139.36 129.75 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 O-C-N 123.323 0.39 . . . . 0.0 110.176 178.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.582 HG22 HG21 ' A' ' 102' ' ' VAL . 4.6 mm -117.01 125.0 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -120.21 161.79 20.48 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.735 0.302 . . . . 0.0 111.218 -176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.5 tptp -94.64 -38.0 11.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.596 0.712 . . . . 0.0 109.24 171.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -133.14 116.05 15.8 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.545 175.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.8 t -106.95 171.51 7.33 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.453 -177.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.415 ' CD ' ' H ' ' A' ' 88' ' ' THR . 1.4 tm-20 -137.44 159.82 40.85 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -175.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.415 ' H ' ' CD ' ' A' ' 87' ' ' GLU . 4.3 m -52.44 -47.79 66.2 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 122.941 0.496 . . . . 0.0 111.518 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.1 pp -62.92 -28.89 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-O 121.014 0.435 . . . . 0.0 110.86 -178.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.453 HG12 ' HD2' ' A' ' 26' ' ' PHE . 51.1 mt -75.16 -50.91 22.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.168 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.84 -48.36 82.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.084 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.66 -43.54 98.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.0 -41.74 98.48 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.6 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.546 ' HB2' ' HB ' ' A' ' 99' ' ' ILE . . . -71.6 -40.32 69.91 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.781 0.324 . . . . 0.0 111.056 -179.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.04 -41.15 91.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.516 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.1 mtm -64.84 -31.56 72.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.542 -177.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.646 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -99.96 5.02 45.23 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.289 0.478 . . . . 0.0 112.289 -175.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 63.07 52.4 2.56 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.71 0.766 . . . . 0.0 109.861 -176.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 94' ' ' ALA . 33.3 mm -111.59 89.62 11.15 Favored Pre-proline 0 C--N 1.318 -0.788 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.168 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.435 ' HD2' ' O ' ' A' ' 79' ' ' LYS . 73.2 Cg_exo -47.89 105.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.558 0 C-N-CA 122.979 2.453 . . . . 0.0 112.324 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.553 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 9.8 tt -122.83 129.97 52.33 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.622 -177.142 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.582 HG21 HG22 ' A' ' 82' ' ' ILE . 30.2 m -134.68 164.72 33.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.823 -178.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -110.27 112.53 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.674 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 7.2 p -91.99 122.93 43.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.294 0.568 . . . . 0.0 111.113 -175.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.26 6.01 49.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.187 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 9.8 t70 -108.72 126.03 52.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.117 0.484 . . . . 0.0 111.015 -175.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -71.55 -33.64 69.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.721 -177.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.573 ' HA ' ' HE3' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -61.54 -26.98 68.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.858 -176.993 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -56.48 -49.0 75.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.817 177.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -70.3 -26.86 63.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.089 -175.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.38 -36.11 46.37 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.235 178.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -85.89 -28.2 24.52 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 10.0 p -81.26 127.06 39.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.48 0.657 . . . . 0.0 111.232 -177.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.553 ' HZ2' ' HB3' ' A' ' 114' ' ' LYS . 3.2 mmmp? -122.94 154.82 37.87 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.44 176.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 18' ' ' LEU . 36.7 m -67.87 94.62 0.47 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.065 0.46 . . . . 0.0 110.525 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.32 -29.63 0.97 Allowed Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.181 -178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -71.98 169.37 16.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 174.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 6.9 tmm_? -115.87 132.33 56.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.035 0.445 . . . . 0.0 110.903 -175.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 17' ' ' ALA . 48.2 t -110.43 139.83 32.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.023 -176.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.07 112.57 41.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 172.062 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.415 HG22 HD11 ' A' ' 52' ' ' ILE . 62.9 t -101.91 114.94 42.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.145 -174.129 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 -106.06 92.91 4.35 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.5 -6.83 56.07 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.48 . . . . 0.0 110.639 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -73.38 -36.78 66.13 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.58 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -112.49 -4.24 14.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.134 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.427 ' CA ' ' HB1' ' A' ' 7' ' ' ALA . . . 74.73 71.7 1.11 Allowed Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.251 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -158.4 144.99 17.4 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -130.8 122.93 53.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.311 0.576 . . . . 0.0 110.911 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -109.3 118.34 36.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.514 ' HB3' HG21 ' A' ' 1' ' ' VAL . 64.9 tp -93.38 115.14 27.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.015 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 22.6 mm -91.3 111.73 24.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.5 0.667 . . . . 0.0 109.691 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 . . . . . 0 C--N 1.308 -1.21 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.001 -179.224 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.461 ' HD3' ' HG2' ' A' ' 129' ' ' GLU . 87.8 mttt 63.74 96.86 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.486 0.66 . . . . 0.0 110.113 -175.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -110.34 148.0 32.82 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.066 -172.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.78 130.38 39.81 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.289 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.607 ' SG ' HG21 ' A' ' 104' ' ' VAL . 26.0 m -121.43 179.4 4.45 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.03 0.443 . . . . 0.0 111.001 -176.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.633 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 40.2 ttt180 -94.79 121.88 36.84 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.775 178.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.525 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -84.41 130.71 34.75 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.775 0.321 . . . . 0.0 111.683 -174.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.1 mp -105.32 -48.12 9.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 173.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 26.7 p -117.19 -173.89 2.49 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.957 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -120.69 -177.26 3.43 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.635 0.255 . . . . 0.0 110.649 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 110.46 152.06 13.11 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.247 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.419 HH11 ' HD2' ' A' ' 12' ' ' ARG . 16.7 mtp180 -113.16 136.9 52.21 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.684 0.278 . . . . 0.0 110.271 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -137.35 132.15 33.17 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.433 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.533 ' HG3' HG21 ' A' ' 120' ' ' VAL . 35.6 tt0 -131.11 126.2 35.13 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.947 176.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 177.6 -158.27 23.4 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.048 -1.072 . . . . 0.0 113.086 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -72.2 136.15 46.32 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 122.807 0.443 . . . . 0.0 110.723 -177.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.467 ' HB3' HG23 ' A' ' 119' ' ' VAL . . . -99.75 131.94 45.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.384 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.3 tp -118.78 120.67 38.07 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.533 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.57 117.4 47.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.645 0.736 . . . . 0.0 110.194 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.435 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 8.9 m -108.48 134.57 51.09 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.497 -176.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.49 -21.54 18.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.194 0.521 . . . . 0.0 109.717 177.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -79.06 160.34 27.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.568 -175.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 6.1 p90 -117.67 121.31 40.53 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.68 174.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.0 mp -123.02 123.75 68.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 120.826 0.346 . . . . 0.0 111.138 -174.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.3 p -76.68 127.57 33.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 169.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -74.83 78.67 2.1 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.668 0.747 . . . . 0.0 111.944 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.3 mt -120.06 -47.97 2.36 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 170.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.2 -142.78 3.88 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 113.848 -1.523 . . . . 0.0 110.43 172.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.59 -48.18 3.52 Favored Glycine 0 C--O 1.222 -0.598 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.445 HD13 ' N ' ' A' ' 30' ' ' ILE . 3.1 mp -111.88 131.73 62.46 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 174.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -68.01 123.93 21.99 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.936 0.398 . . . . 0.0 109.952 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 45.8 pttt -80.62 -5.09 56.4 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -172.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -103.92 -33.62 8.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.829 0.347 . . . . 0.0 111.214 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.5 p -109.68 -28.16 8.98 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.914 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.581 ' CA ' HG12 ' A' ' 76' ' ' VAL . . . 89.42 9.7 66.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.43 -177.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.503 HD11 ' HB3' ' A' ' 47' ' ' SER . 48.7 mm -84.05 124.97 40.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.571 0.224 . . . . 0.0 110.614 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 20.7 m -68.78 116.67 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.759 0.79 . . . . 0.0 110.408 175.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 10.4 mmmm -89.58 -24.56 21.68 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.434 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -65.0 132.38 49.08 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.333 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.413 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 25.8 t70 -68.03 133.4 48.96 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.069 0.461 . . . . 0.0 111.403 -177.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 23.1 p -174.22 -170.64 0.54 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.516 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -83.23 -16.92 44.56 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.484 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.1 mt -100.17 15.17 4.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 122.12 0.962 . . . . 0.0 109.32 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.413 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 82.1 tttt -62.04 134.85 57.14 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.489 -1.232 . . . . 0.0 111.45 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 98.46 -10.91 63.23 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.572 -0.74 . . . . 0.0 113.231 177.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -92.47 170.45 9.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.307 0.575 . . . . 0.0 111.732 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.503 ' HB3' HD11 ' A' ' 36' ' ' ILE . 6.2 p -110.97 142.43 43.09 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.683 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.1 9.06 8.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.417 0.627 . . . . 0.0 109.881 175.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.452 ' CB ' ' HA ' ' A' ' 76' ' ' VAL . . . -75.24 95.45 3.15 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.21 28.79 12.42 Favored Glycine 0 C--N 1.317 -0.508 0 CA-C-N 114.705 -1.134 . . . . 0.0 113.609 172.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -130.65 177.76 7.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.719 0.26 . . . . 0.0 110.675 174.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.653 HG13 ' HB2' ' A' ' 80' ' ' ALA . 2.5 mp -89.37 118.55 34.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 35.8 tp -106.4 116.6 32.21 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.15 -177.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.48 107.77 23.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.194 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.435 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 36.7 p90 -134.42 153.43 79.23 Favored Pre-proline 0 C--N 1.32 -0.714 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.843 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 -40.1 79.15 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.717 2.278 . . . . 0.0 111.982 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.776 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.25 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.932 0.396 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.424 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 47.8 t -68.41 -26.84 34.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.585 -177.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.601 HD12 ' HA3' ' A' ' 93' ' ' GLY . 94.9 mt -57.92 -32.75 68.08 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.054 178.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.498 ' HA ' ' HB3' ' A' ' 97' ' ' ALA . 57.7 tp -67.5 -46.08 73.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.322 178.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -65.21 -38.24 89.81 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.484 HD13 HD23 ' A' ' 68' ' ' LEU . 94.2 mt -58.43 -45.14 89.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.389 176.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.412 ' HD3' ' O ' ' A' ' 72' ' ' ARG . 0.2 OUTLIER -68.84 -37.91 79.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.614 -178.042 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -62.93 -33.88 76.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.024 0.44 . . . . 0.0 110.702 176.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -86.35 -18.15 32.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.623 -177.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 95.2 1.31 62.8 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.262 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.581 HG12 ' CA ' ' A' ' 35' ' ' GLY . 71.2 t -79.65 -30.36 13.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 C-N-CA 122.71 0.404 . . . . 0.0 111.585 -175.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.99 144.7 98.9 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.696 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.26 141.86 94.65 Favored 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.304 2.003 . . . . 0.0 110.926 175.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 tttt -74.81 -16.5 60.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.119 0.485 . . . . 0.0 110.005 -175.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.653 ' HB2' HG13 ' A' ' 52' ' ' ILE . . . -164.27 142.94 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.518 176.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.484 HG13 ' HG ' ' A' ' 101' ' ' LEU . 9.3 pt -128.68 120.21 51.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.366 0.603 . . . . 0.0 111.115 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.779 HG22 HG21 ' A' ' 102' ' ' VAL . 1.2 mm -113.1 116.66 53.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -123.16 161.73 23.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 112.076 -171.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -99.46 -34.45 10.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.055 174.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -125.93 131.98 52.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.867 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -130.26 174.44 9.83 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.466 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -135.82 162.45 32.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.896 0.379 . . . . 0.0 110.553 -178.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.501 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.6 m -60.19 -51.57 69.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.47 -177.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.1 pt -58.35 -32.03 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.619 -179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.2 mm -68.7 -45.52 81.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.45 -38.43 89.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.022 178.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 88' ' ' THR . 93.0 t -62.94 -50.48 79.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.716 178.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.601 ' HA3' HD12 ' A' ' 68' ' ' LEU . . . -60.26 -43.97 97.96 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.144 178.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.59 -36.15 82.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 111.38 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -69.18 -42.79 75.38 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.33 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 58.4 mtm -73.86 -36.62 64.87 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.577 -176.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.498 ' HB3' ' HA ' ' A' ' 69' ' ' LEU . . . -89.37 -9.75 49.18 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.764 -176.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.415 ' HA ' ' OE1' ' A' ' 98' ' ' GLU . 2.8 tp10 65.91 72.54 0.4 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.824 0.821 . . . . 0.0 110.161 -175.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.442 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 60.6 mt -127.15 90.11 50.05 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 114.759 -1.109 . . . . 0.0 109.734 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 4.4 Cg_exo -39.3 110.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 123.985 3.123 . . . . 0.0 112.993 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.484 ' HG ' HG13 ' A' ' 81' ' ' ILE . 4.7 tt -119.66 123.43 43.8 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.368 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.779 HG21 HG22 ' A' ' 82' ' ' ILE . 8.6 m -128.17 139.82 50.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.238 0.542 . . . . 0.0 110.651 176.805 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.633 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 43.6 tt0 -88.92 123.14 32.99 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.54 -178.17 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.607 HG21 ' SG ' ' A' ' 5' ' ' CYS . 96.3 t -107.27 117.72 53.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.793 178.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 24.2 mtm180 -107.44 14.09 26.25 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.237 0.541 . . . . 0.0 110.06 177.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -108.62 130.74 55.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.51 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -71.92 -28.07 63.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.65 -175.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -73.39 -18.25 61.18 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -172.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -63.03 -48.31 79.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.955 0.407 . . . . 0.0 109.984 176.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -71.98 -22.71 61.4 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.364 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -72.81 -42.15 64.15 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.733 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.03 -36.86 30.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.009 -175.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.65 136.72 24.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-O 121.314 0.578 . . . . 0.0 111.091 -176.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.548 ' HB2' ' HZ2' ' A' ' 114' ' ' LYS . 9.7 mtmp? -126.18 158.77 34.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.949 176.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 50.0 m -65.16 111.46 2.95 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 172.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.92 1.67 19.16 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.351 -0.928 . . . . 0.0 113.592 176.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . 0.493 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 28.2 m-20 -85.42 177.55 7.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 117.348 0.574 . . . . 0.0 110.519 176.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.401 ' NH2' HG13 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -115.42 119.79 37.42 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.0 110.152 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 17' ' ' ALA . 36.7 t -109.34 126.52 66.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.156 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.533 HG21 ' HG3' ' A' ' 14' ' ' GLU . 14.6 t -106.96 102.24 13.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 173.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.461 HG22 HG23 ' A' ' 128' ' ' VAL . 7.3 p -108.32 131.66 58.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.279 0.562 . . . . 0.0 111.78 -176.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -116.08 103.87 10.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.467 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.83 -18.71 50.16 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.369 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.2 -30.69 70.57 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.063 0.458 . . . . 0.0 110.588 177.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -108.89 -37.06 5.95 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.44 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 97.39 56.09 1.13 Allowed Glycine 0 N--CA 1.45 -0.386 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -145.04 133.46 21.85 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -172.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.461 HG23 HG22 ' A' ' 121' ' ' VAL . 49.0 t -118.8 112.32 37.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.057 -177.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.461 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 45.8 mt-10 -106.72 108.47 20.0 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.166 177.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -106.52 147.8 28.97 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 178.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.401 HG13 ' NH2' ' A' ' 118' ' ' ARG . 42.6 mm -112.27 133.86 56.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.06 177.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.418 -177.526 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.1 p . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 121.362 0.601 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.464 ' HD3' ' HE1' ' A' ' 127' ' ' TYR . 97.5 mttt -121.18 140.16 52.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.689 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -115.77 161.71 18.35 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.327 -177.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.01 127.26 50.08 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.158 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.7 p -120.55 176.11 5.66 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.972 0.415 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.446 ' HA ' ' NE ' ' A' ' 6' ' ' ARG . 2.6 tpm_? -98.43 124.75 43.3 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 175.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.513 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.06 140.0 46.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.9 0.381 . . . . 0.0 111.82 -175.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.1 mm -112.47 -57.26 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.424 HG23 ' HA ' ' A' ' 95' ' ' ALA . 52.7 p -113.13 -164.99 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.627 174.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.497 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 7.9 mpt_? -120.08 167.58 12.06 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.017 0.437 . . . . 0.0 111.486 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.732 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 134.46 145.84 5.31 Favored Glycine 0 CA--C 1.519 0.305 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.69 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.53 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 1.1 tmm_? -139.88 114.14 9.07 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.34 170.32 17.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.636 0.255 . . . . 0.0 111.428 -175.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -110.23 165.5 11.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.393 178.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.445 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -175.43 157.31 23.78 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 173.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.839 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 52.8 mt-10 -61.44 137.37 58.24 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 174.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.733 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -78.84 109.2 12.89 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.712 0.291 . . . . 0.0 110.463 -176.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.9 tt -102.4 109.55 21.24 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 173.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.6 t -120.64 114.09 42.43 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.153 -171.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 t -127.5 118.19 23.54 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.736 174.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 30.5 ttmt -93.53 20.91 6.76 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.89 0.853 . . . . 0.0 109.118 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.552 ' HG2' ' SG ' ' A' ' 41' ' ' CYS . 5.0 mp0 -97.66 147.68 24.08 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.79 -1.096 . . . . 0.0 109.7 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -82.8 100.61 10.42 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.073 0.463 . . . . 0.0 110.317 175.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.452 ' C ' ' H ' ' A' ' 26' ' ' PHE . 27.9 mm -91.44 1.25 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.269 -176.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.8 m 68.57 -26.81 0.14 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 171.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.452 ' H ' ' C ' ' A' ' 24' ' ' ILE . 47.1 t80 75.36 -31.25 0.2 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 123.749 0.82 . . . . 0.0 112.015 175.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -61.72 102.25 0.25 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.042 0.448 . . . . 0.0 110.176 177.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.24 26.13 69.03 Favored Glycine 0 C--N 1.335 0.486 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.2 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.431 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -83.61 -15.32 71.18 Favored Glycine 0 C--O 1.224 -0.523 0 C-N-CA 120.867 -0.683 . . . . 0.0 113.797 -173.377 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 59.7 mt -125.8 130.57 72.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 117.492 0.646 . . . . 0.0 111.18 -177.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.495 ' HA ' ' HE2' ' A' ' 38' ' ' LYS . 12.3 t70 -65.57 130.42 43.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.966 175.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.482 ' HA ' HD21 ' A' ' 71' ' ' LEU . 21.2 pttp -84.76 -0.12 52.62 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -171.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -101.69 -53.63 2.93 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.846 0.355 . . . . 0.0 111.608 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.513 HG21 HG12 ' A' ' 36' ' ' ILE . 3.5 t -109.69 -2.68 17.28 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.253 -0.431 . . . . 0.0 112.057 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.45 43.85 91.56 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.54 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.513 HG12 HG21 ' A' ' 34' ' ' THR . 47.3 mm -110.66 131.48 61.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 53.6 t -61.0 123.44 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.806 0.336 . . . . 0.0 110.599 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.495 ' HE2' ' HA ' ' A' ' 31' ' ' ASP . 63.8 mmtt -72.08 -47.99 47.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.221 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.44 ' HB3' HG23 ' A' ' 24' ' ' ILE . 7.8 tp10 -62.13 125.48 24.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.629 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.52 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 14.1 t70 -83.11 133.23 35.07 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.329 178.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.552 ' SG ' ' HG2' ' A' ' 22' ' ' GLU . 4.0 t -170.8 39.04 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 75.63 -29.94 0.19 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 114.984 -1.007 . . . . 0.0 111.945 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 41.8 mm -84.17 -10.47 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-O 121.623 0.725 . . . . 0.0 110.45 177.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.52 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 21.8 ttpp -59.64 135.94 57.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.126 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 111.34 -14.8 27.86 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.455 -0.879 . . . . 0.0 113.036 176.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -89.47 142.39 27.71 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.008 0.432 . . . . 0.0 111.236 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.435 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 20.3 m -85.36 136.66 33.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.552 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.4 m -89.05 -6.96 10.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.195 173.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.87 94.62 0.13 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.243 -176.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.67 13.66 49.84 Favored Glycine 0 C--N 1.313 -0.749 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.668 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.839 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 95.9 mtt180 -113.46 166.26 11.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.981 0.419 . . . . 0.0 111.051 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.445 HG12 ' HA3' ' A' ' 15' ' ' GLY . 39.3 mm -95.99 122.15 47.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.169 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.453 ' HB3' HG12 ' A' ' 81' ' ' ILE . 58.5 tp -93.2 113.26 25.44 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.768 0.318 . . . . 0.0 110.36 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.6 t -102.93 108.16 23.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 176.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.677 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.0 t80 -134.37 140.27 35.3 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.195 -172.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 15.2 Cg_endo -94.13 -56.5 0.01 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.914 2.409 . . . . 0.0 113.38 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.643 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.309 -176.887 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 . . . . . 0 N--CA 1.46 0.069 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.539 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 66.4 t -62.56 -51.4 72.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.676 0.274 . . . . 0.0 110.689 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.27 -39.58 93.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.956 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.49 ' O ' ' HG2' ' A' ' 73' ' ' LYS . 56.4 tp -62.82 -46.08 89.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.565 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.51 -44.71 93.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.422 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.3 mt -54.43 -41.59 69.56 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.114 0.483 . . . . 0.0 110.397 177.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.556 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -65.04 -37.08 86.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.144 -178.159 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.49 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 34.5 mmtp -69.91 -25.29 63.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.214 -177.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -93.84 -22.82 18.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.285 0.564 . . . . 0.0 110.182 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.37 15.66 37.29 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.221 178.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.47 23.68 3.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.238 0.542 . . . . 0.0 110.701 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.87 156.03 41.03 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.054 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 42.1 Cg_endo -68.14 155.92 67.68 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.4 2.067 . . . . 0.0 112.129 175.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 53.9 mmtt -68.51 -41.86 79.39 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.824 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.427 ' HB1' HG11 ' A' ' 121' ' ' VAL . . . -163.69 165.97 22.71 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.251 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.453 HG12 ' HB3' ' A' ' 53' ' ' LEU . 63.9 mt -131.87 119.34 41.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.094 0.473 . . . . 0.0 110.24 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.592 HG21 HG22 ' A' ' 102' ' ' VAL . 3.8 mm -103.83 116.88 48.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.677 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.7 m120 -111.64 164.49 12.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.949 0.404 . . . . 0.0 111.503 -175.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -69.76 -54.14 15.09 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.711 175.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.596 ' HG2' ' OE2' ' A' ' 103' ' ' GLU . 4.8 tttm -139.75 22.59 2.48 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.515 178.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 30.5 m 72.48 124.03 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.618 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.482 ' HB3' ' HB ' ' A' ' 90' ' ' ILE . 8.8 tp10 -84.13 130.54 34.84 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 172.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.6 m -57.5 -50.2 73.84 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.962 0.41 . . . . 0.0 111.66 -173.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.1 mt -68.95 -35.14 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.199 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.482 ' HB ' ' HB3' ' A' ' 87' ' ' GLU . 59.7 mt -69.23 -38.07 77.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.36 -44.77 92.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.416 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -62.26 -49.28 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.994 0.426 . . . . 0.0 110.576 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.92 -42.24 99.72 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.466 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.499 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.06 -39.17 92.88 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.704 0.287 . . . . 0.0 111.149 -179.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.424 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -63.13 -41.89 99.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.923 178.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.5 mtm -72.49 -35.96 68.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.498 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.556 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -92.36 5.96 48.68 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 56.92 50.78 11.66 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.449 0.643 . . . . 0.0 110.911 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.499 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 62.1 mt -114.29 90.3 20.09 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.816 179.539 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.732 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 91.6 Cg_exo -35.3 112.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.352 0.733 0 C-N-CA 124.071 3.181 . . . . 0.0 113.998 -176.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.15 128.75 55.64 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.836 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.592 HG22 HG21 ' A' ' 82' ' ' ILE . 16.2 m -136.55 162.18 35.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.343 178.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.596 ' OE2' ' HG2' ' A' ' 85' ' ' LYS . 32.1 tt0 -115.88 119.09 34.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.814 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.423 HG12 ' H ' ' A' ' 106' ' ' ASP . 13.5 t -99.52 128.97 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.888 0.375 . . . . 0.0 110.4 177.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.493 ' NE ' ' HA ' ' A' ' 105' ' ' ARG . 3.2 mmp_? -92.02 24.8 3.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.223 0.535 . . . . 0.0 110.42 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.423 ' H ' HG12 ' A' ' 104' ' ' VAL . 35.9 t70 -141.96 111.9 6.81 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.698 -175.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -69.84 -26.68 64.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.846 178.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -63.51 -19.95 65.2 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.527 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.589 ' O ' HG12 ' A' ' 113' ' ' VAL . 49.9 t80 -61.25 -45.1 95.9 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 170.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -68.3 -22.05 64.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.277 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -83.64 -32.75 25.5 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.049 0.452 . . . . 0.0 110.522 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.7 -44.34 28.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.185 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.589 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.9 p -83.21 123.5 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 110.149 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -130.21 152.66 49.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.048 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.733 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 21.6 m -58.4 107.49 0.5 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.042 -179.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.32 -39.04 0.55 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.331 -0.938 . . . . 0.0 113.449 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . 0.729 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 1.7 t0 -101.09 -166.96 1.36 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 117.286 0.543 . . . . 0.0 110.997 -176.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.729 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -110.03 138.54 46.27 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.33 0.586 . . . . 0.0 112.559 -173.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.527 HG22 ' HB3' ' A' ' 17' ' ' ALA . 83.7 t -119.71 122.7 69.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.551 173.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.914 ' HB ' ' HG3' ' A' ' 129' ' ' GLU . 47.1 t -100.06 112.58 33.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.427 HG11 ' HB1' ' A' ' 80' ' ' ALA . 8.9 p -86.54 133.2 30.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.561 -177.545 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . 0.636 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 44.0 t-20 -126.06 94.64 4.15 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.252 0.549 . . . . 0.0 109.767 177.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 9' ' ' THR . . . -90.16 2.66 55.09 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.418 0.627 . . . . 0.0 110.107 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.452 ' HB3' ' OD1' ' A' ' 122' ' ' ASN . 4.5 t70 -73.7 -37.1 65.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.665 175.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -114.11 -15.36 12.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.573 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.06 66.89 1.74 Allowed Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -168.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . 0.636 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 9.2 t80 -146.24 144.75 30.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.146 -0.527 . . . . 0.0 109.744 -167.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.407 HG13 ' CE1' ' A' ' 109' ' ' PHE . 60.1 t -126.87 104.87 13.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 175.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.914 ' HG3' ' HB ' ' A' ' 120' ' ' VAL . 9.0 pt-20 -97.05 108.13 20.81 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.502 0.668 . . . . 0.0 109.931 179.169 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.9 tp -85.57 127.83 34.57 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.497 -178.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 5.2 mm -116.76 111.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -178.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.403 ' HA ' ' OD2' ' A' ' 117' ' ' ASP . 12.4 mp0 . . . . . 0 C--N 1.314 -0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.447 HG23 ' HB3' ' A' ' 130' ' ' LEU . 10.8 m . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 121.464 0.649 . . . . 0.0 111.914 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.422 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 28.1 mtpp -107.78 94.21 4.96 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.143 174.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -96.77 155.62 16.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.018 0.437 . . . . 0.0 111.379 -176.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.41 126.27 52.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.702 174.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.495 ' HB3' ' O ' ' A' ' 103' ' ' GLU . 80.3 m -118.93 179.59 4.1 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.029 -177.17 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.512 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 64.4 ttp85 -92.04 116.12 28.66 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -175.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.55 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -71.65 124.39 24.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.091 -0.958 . . . . 0.0 111.786 -173.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.414 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 44.5 mm -102.81 -47.99 10.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.734 176.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.553 ' OG1' HD22 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -107.16 -171.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.379 177.558 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 10' ' ' ARG . 39.3 mtt180 -115.33 -178.7 3.44 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 173.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.97 -176.81 36.42 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.846 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -161.14 143.31 12.21 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 -178.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.51 179.07 9.46 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.29 0.567 . . . . 0.0 111.494 -175.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -125.77 160.59 29.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.533 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.564 ' HA3' HG13 ' A' ' 52' ' ' ILE . . . 179.61 155.69 15.82 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.832 171.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.515 ' HB3' ' HD3' ' A' ' 51' ' ' ARG . 28.7 tt0 -75.44 137.95 41.32 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 175.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.494 ' HB2' HG22 ' A' ' 119' ' ' VAL . . . -78.0 134.92 37.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.119 0.485 . . . . 0.0 111.825 -169.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.501 HD22 HG21 ' A' ' 43' ' ' ILE . 6.3 tt -130.29 115.41 16.91 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 174.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.545 HG13 ' OG1' ' A' ' 115' ' ' THR . 9.9 p -103.47 130.94 53.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.198 0.523 . . . . 0.0 110.831 -175.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.778 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 29.1 m -108.82 127.52 54.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.031 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -99.88 -1.01 38.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.559 -175.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -96.99 158.98 15.17 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.358 0.599 . . . . 0.0 112.188 -173.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -104.38 91.24 3.82 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 27.4 pt -122.35 16.83 5.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -169.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 59.6 p 51.8 -154.54 0.17 Allowed 'General case' 0 CA--C 1.53 0.202 0 O-C-N 123.606 0.566 . . . . 0.0 110.485 -175.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -143.64 18.25 1.84 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.064 0.459 . . . . 0.0 110.626 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.13 -10.05 57.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.316 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.03 130.64 1.25 Allowed Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.183 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -173.27 -47.37 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.264 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.635 HG13 HG22 ' A' ' 37' ' ' VAL . 4.1 mp -88.27 134.63 27.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.729 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 29.2 t70 -77.89 147.25 35.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.687 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 9.5 ptpp? -82.76 -14.49 54.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.135 -174.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -100.79 -47.82 4.69 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.427 -175.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.9 p -92.91 -37.09 12.44 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.778 0.323 . . . . 0.0 111.735 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.8 20.03 48.91 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.336 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.2 mm -90.24 138.3 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.287 179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.635 HG22 HG13 ' A' ' 30' ' ' ILE . 96.3 t -79.81 102.26 5.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.139 0.495 . . . . 0.0 109.755 174.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.729 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 59.3 mttt -84.32 -28.64 26.93 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.706 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -96.14 78.66 3.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.614 0.721 . . . . 0.0 110.384 178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 1.028 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 9.2 t70 -147.82 -167.78 2.89 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.936 177.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.404 ' H ' ' CG ' ' A' ' 40' ' ' ASP . 71.5 m -144.82 -23.14 0.51 Allowed 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.611 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -133.86 -47.77 0.8 Allowed 'General case' 0 C--O 1.233 0.225 0 O-C-N 122.031 -0.418 . . . . 0.0 110.796 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.501 HG21 HD22 ' A' ' 18' ' ' LEU . 23.0 mm -75.83 -17.75 15.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 109.227 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 1.028 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 54.3 tttm -44.37 118.23 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 CA-C-N 114.166 -1.379 . . . . 0.0 112.156 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 130.83 -19.13 5.02 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.807 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -93.46 156.36 16.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.056 0.455 . . . . 0.0 111.692 -177.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.0 m -95.94 138.69 33.22 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.423 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.1 m -94.2 -3.69 10.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.993 0.425 . . . . 0.0 110.808 176.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.42 89.51 0.5 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.559 0.695 . . . . 0.0 110.868 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.682 ' HA2' ' HE3' ' A' ' 79' ' ' LYS . . . 112.6 2.98 25.64 Favored Glycine 0 C--N 1.313 -0.741 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.703 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.515 ' HD3' ' HB3' ' A' ' 16' ' ' GLU . 20.2 mmt85 -105.59 156.29 18.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.556 -0.322 . . . . 0.0 110.827 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.695 HG12 ' HB1' ' A' ' 80' ' ' ALA . 29.1 mt -97.29 117.65 42.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 169.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.42 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 28.1 tp -93.56 124.57 37.64 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.957 -171.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 62.6 t -123.85 107.51 18.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.892 0.377 . . . . 0.0 110.195 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.778 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 40.9 p90 -136.01 146.09 55.21 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 177.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.97 -29.55 34.02 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.851 2.367 . . . . 0.0 111.462 175.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.747 176.778 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 . . . . . 0 N--CA 1.471 0.619 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.479 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 29.8 m -62.79 -24.65 36.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -175.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.2 mp -69.0 -32.16 71.51 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.664 0.269 . . . . 0.0 110.576 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.4 tp -66.43 -38.48 87.5 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -61.21 -48.85 79.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.129 175.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.479 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 67.6 mt -60.59 -41.68 95.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.674 178.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.459 ' HD3' ' O ' ' A' ' 72' ' ' ARG . 0.0 OUTLIER -72.06 -35.61 69.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.097 -176.402 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -59.75 -38.41 81.68 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.434 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -82.6 -29.66 30.02 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 109.876 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 99.14 22.27 13.51 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.561 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.47 4.9 9.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.998 0.428 . . . . 0.0 111.156 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.32 154.54 66.41 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.767 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 27.7 Cg_endo -63.63 147.33 92.86 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.148 1.899 . . . . 0.0 111.075 174.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.682 ' HE3' ' HA2' ' A' ' 50' ' ' GLY . 97.2 mttt -73.32 -27.25 61.42 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.049 0.452 . . . . 0.0 110.725 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.695 ' HB1' HG12 ' A' ' 52' ' ' ILE . . . -157.79 157.48 33.43 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.305 176.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 34.1 mt -136.57 127.39 41.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 178.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.48 HG21 HG12 ' A' ' 104' ' ' VAL . 3.6 mm -121.67 118.26 55.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.404 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 11.8 m120 -130.43 -179.84 5.5 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.147 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.419 ' O ' ' HD3' ' A' ' 84' ' ' LYS . 4.1 tmtt? -109.86 -37.91 5.51 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 171.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -103.01 114.84 29.46 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -120.67 141.26 50.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.903 0.382 . . . . 0.0 110.266 177.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.49 ' HB2' HG13 ' A' ' 90' ' ' ILE . 81.2 mm-40 -108.94 159.65 16.64 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.11 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 m -60.01 -45.34 93.06 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.83 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.437 HD12 ' N ' ' A' ' 90' ' ' ILE . 2.5 pp -64.82 -31.08 52.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.725 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.49 HG13 ' HB2' ' A' ' 87' ' ' GLU . 69.3 mt -68.38 -45.79 81.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.984 0.421 . . . . 0.0 109.99 177.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.55 -48.27 82.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.965 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.06 -45.49 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.974 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.68 -43.28 99.47 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.61 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.89 -37.15 62.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 111.576 0.213 . . . . 0.0 111.576 -177.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.45 -38.83 85.42 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.737 0.303 . . . . 0.0 111.428 -178.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 59.1 mtm -71.22 -31.03 67.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.039 0.447 . . . . 0.0 111.054 -179.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.55 -2.86 58.47 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.432 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.528 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 3.9 tp10 62.4 43.95 7.66 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-O 121.49 0.662 . . . . 0.0 110.3 -177.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 59.0 mt -107.44 88.6 4.21 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.83 175.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 24.3 Cg_exo -62.14 118.22 5.1 Favored 'Trans proline' 0 C--O 1.233 0.267 0 C-N-CA 122.918 2.412 . . . . 0.0 112.665 -174.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.553 HD22 ' OG1' ' A' ' 9' ' ' THR . 1.9 pt? -118.96 147.09 44.43 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.95 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.55 HG11 ' HA ' ' A' ' 7' ' ' ALA . 26.9 m -136.97 158.33 36.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.014 178.288 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.512 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 30.3 tt0 -94.89 119.82 34.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.491 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.48 HG12 HG21 ' A' ' 82' ' ' ILE . 20.7 m -74.25 144.32 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.135 174.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -117.55 23.47 11.73 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.76 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 10.4 t70 -144.35 127.81 16.95 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -176.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -66.56 -36.76 83.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.367 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.57 ' HZ1' ' HB2' ' A' ' 108' ' ' LYS . 10.0 mtmp? -67.9 -18.35 64.76 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.324 -175.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -58.98 -39.89 83.17 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -67.69 -29.07 68.24 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.754 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.11 -40.14 60.09 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 177.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.03 -46.55 56.65 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.703 -176.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.0 p -66.0 138.02 23.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 121.106 0.479 . . . . 0.0 111.376 -175.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -138.06 151.07 47.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.989 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.545 ' OG1' HG13 ' A' ' 19' ' ' VAL . 80.4 m -70.17 118.37 12.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.605 -0.271 . . . . 0.0 110.319 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 120.69 -12.5 10.11 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.257 177.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.82 179.33 6.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.829 0.314 . . . . 0.0 111.127 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -109.18 120.81 43.64 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 121.046 0.45 . . . . 0.0 111.344 -175.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.494 HG22 ' HB2' ' A' ' 17' ' ' ALA . 52.1 t -123.02 137.39 56.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.485 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.437 ' CG2' ' HB3' ' A' ' 129' ' ' GLU . 6.0 m -114.43 134.56 57.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.654 170.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -112.96 133.95 57.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.165 0.507 . . . . 0.0 110.644 -178.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -129.29 94.85 3.89 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 174.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.39 -16.13 35.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.185 0.516 . . . . 0.0 110.293 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.32 -40.95 73.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.252 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -100.45 -25.26 14.27 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.153 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 90.41 68.76 1.2 Allowed Glycine 0 CA--C 1.516 0.124 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.352 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -158.38 146.94 18.77 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 122.468 0.307 . . . . 0.0 110.832 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.34 125.53 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.705 173.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.437 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 41.1 tt0 -109.1 112.61 24.87 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.234 0.54 . . . . 0.0 110.722 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.447 ' HB3' HG23 ' A' ' 1' ' ' VAL . 55.7 tp -105.86 122.59 46.41 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.957 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.8 mt -115.3 120.49 64.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--N 1.31 -1.148 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.282 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 N--CA 1.454 -0.271 0 CA-C-O 120.934 0.397 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.441 ' N ' ' HD2' ' A' ' 2' ' ' LYS . 11.4 mptt -101.46 113.66 26.96 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -93.85 148.21 22.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.828 0.346 . . . . 0.0 110.764 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.06 125.86 40.0 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.665 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.8 m -120.36 175.14 6.11 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.534 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 40.9 ttm180 -101.28 121.21 41.47 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.526 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -69.83 114.05 7.65 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.765 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 mm -90.75 -66.56 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 174.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.5 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 21.2 p -96.18 -170.95 2.2 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 173.072 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.27 164.71 24.98 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.056 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.05 155.54 10.96 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.052 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 -115.87 117.08 29.18 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.908 0.385 . . . . 0.0 110.143 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.461 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -119.01 138.18 53.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.994 0.426 . . . . 0.0 111.352 -175.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.468 ' HG3' HG22 ' A' ' 120' ' ' VAL . 20.6 tt0 -112.0 139.49 47.47 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.053 178.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.411 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -172.7 170.66 43.75 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.473 175.045 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -82.63 127.48 33.41 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 52' ' ' ILE . . . -90.2 131.58 35.96 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -169.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mp -112.75 130.52 56.04 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.148 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.484 HG13 HG13 ' A' ' 113' ' ' VAL . 48.2 t -119.47 126.16 75.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.552 -172.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.4 t -118.27 139.52 51.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 176.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -91.65 -9.39 44.16 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.239 0.542 . . . . 0.0 110.033 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -95.37 143.86 26.38 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.824 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -85.42 153.62 22.38 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.869 177.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.0 pt -122.0 -178.99 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.197 0.523 . . . . 0.0 111.5 -175.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.3 p -111.32 124.38 52.12 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.767 -0.652 . . . . 0.0 109.641 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.36 95.61 3.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.345 0.593 . . . . 0.0 110.824 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 pp -165.83 -162.57 0.57 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.708 -1.133 . . . . 0.0 109.164 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -73.34 67.12 1.53 Allowed Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.579 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.42 -23.03 10.63 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 121.21 -0.519 . . . . 0.0 112.401 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.459 HG12 HG23 ' A' ' 37' ' ' VAL . 60.3 mt -101.92 138.21 26.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 177.032 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -69.34 133.02 47.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.605 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.467 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 60.8 pttt -78.52 -16.72 57.16 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -173.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.5 mm-40 -94.73 -52.32 4.33 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -174.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.537 HG21 HG12 ' A' ' 36' ' ' ILE . 7.6 t -106.3 -2.94 21.75 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 111.795 0.294 . . . . 0.0 111.795 -176.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.558 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.24 37.8 93.22 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.226 175.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.537 HG12 HG21 ' A' ' 34' ' ' THR . 49.7 mm -104.02 128.74 57.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.459 HG23 HG12 ' A' ' 30' ' ' ILE . 21.3 t -72.29 117.75 16.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.865 0.364 . . . . 0.0 110.181 178.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -83.64 -36.27 23.96 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.266 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -64.98 132.79 50.21 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 176.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.541 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 9.0 t70 -80.38 136.83 36.45 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.287 0.565 . . . . 0.0 111.832 -170.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 79.4 m -144.55 28.04 1.33 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.033 -0.985 . . . . 0.0 109.105 177.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 70.26 -69.12 0.18 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.28 -177.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 46.6 pt -80.39 5.43 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.27 0.557 . . . . 0.0 111.203 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.541 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER -68.18 139.41 56.09 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.254 178.676 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.94 -1.29 1.72 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.635 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -102.58 159.8 15.13 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.663 0.268 . . . . 0.0 110.569 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.4 p -82.1 121.96 27.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-O 121.28 0.562 . . . . 0.0 110.041 176.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.0 m -86.71 19.26 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.438 -176.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.13 92.16 0.17 Allowed 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.706 0.765 . . . . 0.0 111.128 -176.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.499 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 84.92 24.32 45.65 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 114.735 -1.121 . . . . 0.0 112.23 177.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.442 HH11 ' HD2' ' A' ' 51' ' ' ARG . 12.5 mmt180 -98.08 163.96 12.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.627 0.251 . . . . 0.0 110.728 178.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 17' ' ' ALA . 51.0 mm -102.15 118.37 48.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 175.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.517 HD22 ' HB3' ' A' ' 78' ' ' PRO . 4.3 mm? -106.7 125.3 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.922 0.391 . . . . 0.0 111.221 -177.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.459 ' HB ' HG21 ' A' ' 19' ' ' VAL . 59.7 t -110.7 106.38 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.849 176.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -136.59 148.12 62.43 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.787 176.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.433 ' O ' ' HG2' ' A' ' 84' ' ' LYS . 32.1 Cg_exo -59.61 -45.28 26.46 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.416 2.077 . . . . 0.0 111.955 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.666 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -178.834 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.1 p90 . . . . . 0 C--O 1.231 0.097 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.425 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 34.4 m -66.42 -28.58 43.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.239 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 98.9 mt -62.35 -40.77 97.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.988 0.423 . . . . 0.0 110.168 178.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.7 tp -69.4 -43.12 74.1 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.266 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.498 HD21 ' C ' ' A' ' 70' ' ' ASN . 0.2 OUTLIER -57.36 -49.93 74.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.913 178.477 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.537 ' CB ' ' HB3' ' A' ' 77' ' ' ALA . 97.9 mt -63.49 -43.52 97.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.054 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.414 ' HD3' ' C ' ' A' ' 72' ' ' ARG . 0.3 OUTLIER -66.83 -38.95 87.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.708 0.289 . . . . 0.0 110.347 -177.438 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.46 ' HD2' ' O ' ' A' ' 73' ' ' LYS . 2.4 tmmm? -61.48 -32.1 72.09 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.53 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -91.37 -7.73 50.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.267 0.556 . . . . 0.0 110.143 178.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.21 16.34 72.05 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.0 174.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.558 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.9 m -108.25 7.56 9.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.776 0.322 . . . . 0.0 111.448 -177.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.537 ' HB3' ' CB ' ' A' ' 71' ' ' LEU . . . -92.45 159.95 35.79 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.501 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.517 ' HB3' HD22 ' A' ' 53' ' ' LEU . 34.7 Cg_exo -58.41 150.17 69.63 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.373 2.049 . . . . 0.0 111.12 172.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.499 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 79.0 tttt -81.49 -24.68 36.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.151 0.5 . . . . 0.0 109.828 -178.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.47 ' HB2' HD13 ' A' ' 52' ' ' ILE . . . -168.37 154.29 6.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.893 176.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.498 HG21 ' HB2' ' A' ' 53' ' ' LEU . 25.5 pt -136.25 146.1 29.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.821 0.343 . . . . 0.0 111.295 -178.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.587 HG21 HG21 ' A' ' 102' ' ' VAL . 4.7 mm -118.82 124.22 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.477 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 14.2 m120 -122.39 171.22 9.22 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -176.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.433 ' HG2' ' O ' ' A' ' 56' ' ' PRO . 63.1 pttt -96.97 -32.57 11.95 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.4 0.619 . . . . 0.0 110.321 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.406 ' NZ ' ' HA ' ' A' ' 85' ' ' LYS . 1.4 tppm? -138.02 113.15 9.24 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.665 177.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.3 m -99.03 127.68 45.01 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.782 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.68 152.12 22.01 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 16.3 m -56.64 -39.52 73.83 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.693 0.283 . . . . 0.0 110.997 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 80.8 mt -55.38 -41.4 62.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-O 121.335 0.588 . . . . 0.0 110.686 177.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 25.8 mm -71.77 -41.65 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.247 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.41 81.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.227 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -60.31 -45.54 96.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.829 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.22 -48.07 85.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.52 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.28 -33.17 74.73 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.534 0.206 . . . . 0.0 111.472 -178.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.98 -45.07 90.7 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.911 0.386 . . . . 0.0 111.068 178.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.6 mtm -69.02 -33.14 73.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.138 -178.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -85.74 -7.24 58.9 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.54 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.442 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 63.2 mt-10 60.4 48.52 7.74 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.501 0.667 . . . . 0.0 110.471 -177.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.3 90.07 7.85 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.026 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.5 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 50.0 Cg_exo -52.8 115.77 2.46 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.764 2.309 . . . . 0.0 112.202 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pt? -129.77 143.85 51.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.004 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 82' ' ' ILE . 17.4 m -136.18 155.29 34.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.918 -178.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.534 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 2.6 pt-20 -102.93 137.08 41.6 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.057 0.456 . . . . 0.0 111.618 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 2.2 m -125.17 109.41 22.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.53 173.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.404 ' HD3' ' H ' ' A' ' 105' ' ' ARG . 0.0 OUTLIER -87.6 17.42 4.65 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.451 0.643 . . . . 0.0 110.156 176.789 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -95.12 123.28 38.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.058 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -71.45 -38.75 71.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.428 -176.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.53 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 62.3 mttm -70.81 -18.83 62.72 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -171.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -56.07 -49.85 72.62 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 171.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -75.72 -26.48 57.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.511 0.672 . . . . 0.0 110.231 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.53 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.3 tt0 -65.02 -44.57 88.7 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.314 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -96.84 -27.97 14.46 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.484 HG13 HG13 ' A' ' 19' ' ' VAL . 11.0 p -67.24 134.75 29.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 111.225 -175.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -110.98 157.13 20.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.421 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 8.8 t -87.41 127.97 35.21 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.483 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.57 0.4 24.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.169 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -101.78 -172.1 2.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.808 0.304 . . . . 0.0 110.871 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -103.07 127.37 50.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.368 . . . . 0.0 111.574 -172.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.501 ' HA ' ' O ' ' A' ' 129' ' ' GLU . 73.9 t -134.07 123.15 43.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.322 176.083 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.468 HG22 ' HG3' ' A' ' 14' ' ' GLU . 81.2 t -114.82 125.05 72.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.2 p -107.9 123.89 63.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.456 0.646 . . . . 0.0 111.252 -177.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -103.58 95.97 6.41 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.121 173.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.11 6.03 17.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.956 0.408 . . . . 0.0 110.979 -176.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.01 -38.99 79.56 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.264 0.554 . . . . 0.0 109.798 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -115.19 -22.84 9.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.888 175.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 92.72 66.3 1.09 Allowed Glycine 0 C--O 1.228 -0.232 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -174.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -144.29 125.11 14.24 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -169.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 24.6 m -113.33 134.29 56.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.29 0.567 . . . . 0.0 111.823 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 119' ' ' VAL . 46.3 mt-10 -96.55 107.79 20.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.17 176.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.8 tp -101.3 108.99 20.77 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 175.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.5 mm -120.13 125.72 74.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.9 0.381 . . . . 0.0 110.297 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 . . . . . 0 C--N 1.318 -0.79 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.426 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 121.443 0.64 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.693 ' HE3' ' HG2' ' A' ' 129' ' ' GLU . 52.0 mtpt -121.49 121.39 37.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.231 -0.895 . . . . 0.0 108.606 170.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.485 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 96.6 m-85 -97.17 150.11 21.25 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.99 0.424 . . . . 0.0 111.37 -173.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.76 122.15 46.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.733 177.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.466 ' SG ' HG23 ' A' ' 102' ' ' VAL . 7.1 p -120.49 171.16 8.74 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.123 -177.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.637 ' HB3' ' HB2' ' A' ' 103' ' ' GLU . 7.8 tpt180 -93.5 115.8 28.31 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 176.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.538 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -74.88 110.31 9.07 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.589 -178.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.2 mm -85.06 -55.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 172.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.6 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -100.17 174.73 6.01 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 171.925 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 43.1 mtm180 -119.56 174.7 6.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.804 0.335 . . . . 0.0 110.434 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.4 144.8 6.84 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.096 -178.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.494 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 60.1 mtm180 -119.16 131.64 55.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 177.582 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.57 145.29 23.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.519 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.06 140.92 52.5 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.158 -0.473 . . . . 0.0 109.754 177.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -170.26 175.79 44.11 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.522 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -67.08 128.15 35.28 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.482 ' HB3' HG23 ' A' ' 119' ' ' VAL . . . -80.9 125.29 29.94 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.984 -176.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.1 tt -108.39 109.07 20.28 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 175.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.439 HG22 ' HB ' ' A' ' 54' ' ' VAL . 75.1 t -103.15 128.8 55.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.948 0.404 . . . . 0.0 110.669 -174.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.414 HG21 ' HB3' ' A' ' 22' ' ' GLU . 7.2 m -123.94 108.69 12.68 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.523 -177.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -89.54 16.54 7.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.402 0.62 . . . . 0.0 110.315 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.492 ' CG ' HG23 ' A' ' 24' ' ' ILE . 6.0 tp10 -83.87 159.38 21.35 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.419 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . 0.445 ' N ' ' HG3' ' A' ' 22' ' ' GLU . 23.8 m-85 -119.69 81.48 1.73 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.28 0.562 . . . . 0.0 110.007 176.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.492 HG23 ' CG ' ' A' ' 22' ' ' GLU . 18.4 pt -107.63 168.53 3.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.827 0.822 . . . . 0.0 111.744 -176.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.55 123.17 34.0 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 114.306 -1.315 . . . . 0.0 109.063 176.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -56.29 -70.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.205 0 O-C-N 123.276 0.36 . . . . 0.0 110.483 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt 59.28 -85.42 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 O-C-N 123.791 0.682 . . . . 0.0 111.991 176.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 168.75 42.08 0.03 OUTLIER Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.0 -7.91 84.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.255 -174.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.441 HG13 HG11 ' A' ' 37' ' ' VAL . 4.1 mp -79.83 119.49 29.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 176.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.09 127.8 33.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.106 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.445 ' HE3' ' OD1' ' A' ' 70' ' ' ASN . 0.0 OUTLIER -74.64 -10.2 59.31 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -172.749 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -97.81 -35.98 10.35 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.749 0.309 . . . . 0.0 111.34 -176.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.6 p -105.53 -36.42 7.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.342 -0.39 . . . . 0.0 112.013 -178.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.93 15.41 59.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.634 -175.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 49.2 mm -95.44 138.35 21.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.441 HG11 HG13 ' A' ' 30' ' ' ILE . 15.3 m -72.49 116.21 14.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.371 0.605 . . . . 0.0 110.762 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -88.75 -9.41 51.98 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.382 -178.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -90.29 151.16 21.62 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.429 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 10.5 t70 -76.9 134.69 38.89 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.316 -171.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 7.6 p -167.32 173.38 8.94 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.427 ' HG3' ' N ' ' A' ' 43' ' ' ILE . 5.3 pt-20 -62.08 -36.26 81.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 -178.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.427 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 15.1 pt -105.38 43.54 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 122.053 0.93 . . . . 0.0 110.144 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.429 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 86.4 tttt -67.47 121.53 16.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.778 -179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.71 -2.48 29.0 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.886 -178.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -79.54 155.7 28.09 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.937 0.398 . . . . 0.0 111.052 177.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.1 p -102.8 136.49 42.52 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.326 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.1 m -98.11 -1.36 10.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.905 0.383 . . . . 0.0 110.957 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.31 95.03 0.29 Allowed 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.802 -176.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.08 17.6 39.89 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.196 175.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.5 mmt180 -109.64 150.83 27.66 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.484 HD13 HG23 ' A' ' 121' ' ' VAL . 65.8 mt -96.19 105.26 16.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 177.188 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.567 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -80.61 116.6 20.72 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.373 0.606 . . . . 0.0 111.332 -174.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.439 ' HB ' HG22 ' A' ' 19' ' ' VAL . 61.6 t -114.13 106.94 21.66 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.657 175.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -134.86 148.32 66.56 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.126 176.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.27 -41.5 21.14 Favored 'Trans proline' 0 C--O 1.236 0.388 0 C-N-CA 122.53 2.153 . . . . 0.0 112.319 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 C-N-CA 121.114 -0.565 . . . . 0.0 111.936 -179.236 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.1 m-85 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.44 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 17.4 m -52.3 -36.9 21.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -175.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.404 HD21 ' HB1' ' A' ' 94' ' ' ALA . 5.3 mp -68.85 -34.87 76.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.001 0.429 . . . . 0.0 111.075 -178.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.494 HD13 ' HA ' ' A' ' 97' ' ' ALA . 66.1 tp -70.63 -40.06 73.32 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.044 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.445 ' OD1' ' HE3' ' A' ' 32' ' ' LYS . 12.7 t-20 -56.2 -41.88 76.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.776 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 80.6 mt -62.59 -41.47 98.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.34 -179.33 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.55 ' NH1' ' HB3' ' A' ' 98' ' ' GLU . 15.2 ttp180 -74.2 -25.06 59.46 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.856 -0.337 . . . . 0.0 111.09 -174.323 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -73.72 -26.09 60.53 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.825 -0.35 . . . . 0.0 111.282 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -92.56 -27.95 17.05 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.898 176.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.87 22.79 7.43 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.476 -0.869 . . . . 0.0 112.522 177.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.413 HG22 ' HA ' ' A' ' 32' ' ' LYS . 30.4 m -114.27 21.05 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.122 0.487 . . . . 0.0 110.882 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.4 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -92.02 155.52 43.01 Favored Pre-proline 0 C--O 1.237 0.431 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.428 -177.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.567 ' HB3' HD13 ' A' ' 53' ' ' LEU . 15.7 Cg_exo -69.69 158.9 55.43 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.997 2.465 . . . . 0.0 112.021 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -69.76 -44.69 69.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.057 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.98 164.24 25.78 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.204 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.696 ' HB ' ' HB3' ' A' ' 101' ' ' LEU . 37.5 mm -127.0 124.64 65.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.428 -178.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.1 mm -119.19 116.27 50.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.422 ' O ' HG12 ' A' ' 104' ' ' VAL . 13.6 m120 -126.26 157.38 38.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.692 0.282 . . . . 0.0 111.031 -175.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 23.5 ttmm -68.89 -52.07 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 173.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.1 tptm -155.6 109.99 2.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.172 171.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.7 t -91.62 167.03 12.5 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.314 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -83.56 152.08 25.05 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.934 0.397 . . . . 0.0 110.854 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 m -58.87 -34.02 71.14 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.148 -178.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mp -61.22 -39.99 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.098 178.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 50.0 mt -77.15 -42.4 31.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.413 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.509 ' HA ' HD22 ' A' ' 101' ' ' LEU . . . -55.59 -48.76 74.32 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.586 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -71.79 -39.06 67.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.524 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.95 -41.52 99.66 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.601 -178.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.408 ' HB2' ' O ' ' A' ' 99' ' ' ILE . . . -74.56 -31.16 62.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.555 0.217 . . . . 0.0 110.809 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.402 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -61.28 -38.54 87.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.01 0.433 . . . . 0.0 110.112 175.39 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 84.2 mtp -66.22 -42.45 88.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.685 177.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.494 ' HA ' HD13 ' A' ' 69' ' ' LEU . . . -80.94 -4.29 54.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.964 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.55 ' HB3' ' NH1' ' A' ' 72' ' ' ARG . 37.7 tt0 60.24 37.75 20.34 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.85 0.833 . . . . 0.0 109.852 -177.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.408 ' O ' ' HB2' ' A' ' 94' ' ' ALA . 60.1 mt -105.11 89.18 2.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.931 175.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.6 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 12.1 Cg_endo -53.47 117.07 3.42 Favored 'Trans proline' 0 C--O 1.234 0.302 0 C-N-CA 123.17 2.58 . . . . 0.0 113.845 -170.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.696 ' HB3' ' HB ' ' A' ' 81' ' ' ILE . 2.3 pp -117.56 148.11 42.19 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.504 171.183 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.538 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.0 m -136.34 163.92 32.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.083 -175.533 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.637 ' HB2' ' HB3' ' A' ' 6' ' ' ARG . 43.8 mt-10 -97.08 113.91 25.51 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.875 175.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 7.2 p -110.74 112.7 41.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.653 0.74 . . . . 0.0 109.86 174.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 105' ' ' ARG . 52.4 mtt180 -95.81 28.38 3.1 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.992 -173.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.415 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 22.8 t70 -118.07 121.33 40.31 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.625 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -72.6 -33.86 66.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.968 -178.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 49.5 mmtm -60.6 -35.88 77.2 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 -176.305 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.491 ' O ' HG13 ' A' ' 113' ' ' VAL . 44.7 t80 -51.8 -46.04 64.09 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.857 177.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -70.18 -22.63 62.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.195 0.522 . . . . 0.0 111.17 -174.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' HE2' ' A' ' 114' ' ' LYS . 11.5 mm-40 -88.51 -28.19 20.95 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.191 176.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.61 -44.31 64.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.803 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.491 HG13 ' O ' ' A' ' 109' ' ' PHE . 11.9 p -91.93 133.18 34.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.172 0.51 . . . . 0.0 111.151 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.473 ' HE2' ' O ' ' A' ' 111' ' ' GLU . 74.7 mmtt -128.93 160.87 31.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 10.8 t -63.35 125.44 24.17 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.162 0.506 . . . . 0.0 110.37 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.35 -16.36 11.67 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.855 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -91.24 175.28 6.99 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 118' ' ' ARG . 1.3 tmm_? -116.24 129.76 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.135 0.493 . . . . 0.0 111.352 -174.18 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' A' ' 17' ' ' ALA . 86.6 t -116.41 140.41 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.209 178.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 48.6 t -104.94 108.21 24.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 172.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.484 HG23 HD13 ' A' ' 52' ' ' ILE . 96.1 t -92.77 119.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.148 0.499 . . . . 0.0 111.264 -175.227 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . 0.494 ' HA ' ' HG2' ' A' ' 12' ' ' ARG . 55.9 t-20 -115.74 93.81 4.42 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -94.36 -0.61 54.78 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 110.378 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -80.72 -40.25 25.63 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.399 177.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -98.75 -28.07 13.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.849 176.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.43 59.66 1.14 Allowed Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.27 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -148.59 146.33 28.2 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.917 0.389 . . . . 0.0 110.451 -174.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 54.8 t -119.71 108.85 24.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.761 177.136 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.693 ' HG2' ' HE3' ' A' ' 2' ' ' LYS . 39.1 mt-10 -99.81 107.9 20.05 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.961 0.41 . . . . 0.0 110.251 179.434 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 47.6 tp -93.35 132.66 37.37 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.209 178.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.8 mt -119.22 114.98 46.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.575 0.702 . . . . 0.0 109.5 175.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--N 1.312 -1.052 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.889 179.664 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 45.0 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 121.997 0.903 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mtmm -108.21 122.69 47.44 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.164 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -89.64 136.18 33.18 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 176.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.63 114.99 26.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.678 -176.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' HB ' ' A' ' 104' ' ' VAL . 11.7 m -120.33 163.08 18.37 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.38 178.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 45.3 ttt180 -93.74 124.83 38.01 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 120.344 -0.542 . . . . 0.0 109.854 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.491 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -95.71 137.95 34.05 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.69 -172.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.404 ' N ' HD13 ' A' ' 8' ' ' ILE . 4.4 mp -103.18 -48.55 10.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 174.122 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.3 p -102.1 169.57 8.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.378 174.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.417 ' HB3' ' OD1' ' A' ' 124' ' ' ASP . 71.8 mtt85 -125.44 -174.75 3.14 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.928 0.394 . . . . 0.0 111.761 -176.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.35 175.85 23.39 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.401 ' N ' ' HD3' ' A' ' 12' ' ' ARG . 0.0 OUTLIER -147.4 149.38 32.63 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 178.472 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.31 156.19 35.06 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.975 0.417 . . . . 0.0 111.099 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -124.28 132.82 53.59 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.694 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.09 175.33 39.43 Favored Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.051 177.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -72.3 133.21 44.89 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 176.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.491 ' HB2' HG21 ' A' ' 119' ' ' VAL . . . -79.77 121.54 25.49 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.017 0.436 . . . . 0.0 110.808 -177.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.986 HD21 HG21 ' A' ' 43' ' ' ILE . 7.3 tt -113.23 113.59 25.53 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 53.1 t -102.99 109.94 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.105 0.479 . . . . 0.0 110.759 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.727 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 20.9 m -87.37 116.75 25.68 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.348 176.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.893 ' HD3' ' HG3' ' A' ' 42' ' ' GLU . 8.8 mptt -73.37 -25.77 60.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.377 -176.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.448 ' HG3' ' HB3' ' A' ' 41' ' ' CYS . 22.0 mm-40 -91.36 152.97 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -91.14 90.88 8.0 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.956 178.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 pt -86.03 145.39 7.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.135 -178.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.2 m -91.75 150.19 21.23 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.552 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.431 ' CZ ' ' HZ ' ' A' ' 55' ' ' PHE . 74.9 m-85 -86.11 15.17 5.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.905 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.53 -8.45 55.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.179 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 126.48 70.5 0.18 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.245 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -106.74 -25.63 6.16 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.786 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.465 HD11 ' N ' ' A' ' 30' ' ' ILE . 4.2 mp -92.21 133.74 32.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 -177.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.414 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 13.2 t70 -69.68 135.11 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.996 0.426 . . . . 0.0 110.293 175.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.435 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 49.9 pttt -73.38 -14.02 61.2 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -171.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -106.65 -44.53 4.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.996 0.427 . . . . 0.0 111.771 -174.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 36' ' ' ILE . 34.6 p -97.48 -26.88 14.67 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.11 -174.195 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.64 8.5 84.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.559 -175.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.451 HG12 ' HB ' ' A' ' 34' ' ' THR . 34.0 mm -82.56 133.48 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.367 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.443 HG11 HG13 ' A' ' 30' ' ' ILE . 5.5 m -77.39 131.73 34.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.312 0.577 . . . . 0.0 110.974 176.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.414 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 75.1 mmtt -95.39 -14.92 23.41 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.691 177.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -129.01 85.12 2.29 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.674 -176.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.1 t70 -148.14 -162.79 1.63 Allowed 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.597 -178.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.485 ' H ' ' CG ' ' A' ' 40' ' ' ASP . 44.9 t -155.3 -32.47 0.1 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.553 -175.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.893 ' HG3' ' HD3' ' A' ' 21' ' ' LYS . 17.6 mm-40 -109.53 -47.26 3.4 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -177.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.986 HG21 HD21 ' A' ' 18' ' ' LEU . 40.8 pt -101.28 10.08 8.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.351 0.596 . . . . 0.0 109.919 -177.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 79.0 tttt -54.57 114.0 1.51 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.604 177.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 114.18 -14.19 21.24 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.374 -176.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -103.71 169.24 8.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.748 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.404 ' HB2' HD13 ' A' ' 36' ' ' ILE . 40.8 t -109.62 152.28 25.75 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.553 -179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.8 m -103.9 3.54 10.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.848 177.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.0 85.48 1.0 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.394 -176.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 116.18 8.26 13.42 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.516 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -114.46 158.83 21.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.0 mt -93.11 117.5 36.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 37.0 tp -90.32 111.16 22.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.579 -173.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 19' ' ' VAL . 61.3 t -119.0 105.95 18.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.413 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.727 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 19.1 p90 -137.48 163.61 47.4 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.596 ' HD2' ' HB2' ' A' ' 55' ' ' PHE . 10.0 Cg_endo -52.56 -54.92 4.33 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.858 2.372 . . . . 0.0 112.707 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.202 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.012 -179.818 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 . . . . . 0 C--O 1.232 0.158 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.533 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 93.4 t -58.13 -45.34 88.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.895 0.379 . . . . 0.0 110.164 176.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -61.7 -38.94 89.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.593 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 54.4 tp -66.86 -40.29 87.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.878 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -69.55 -40.94 76.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.96 0.41 . . . . 0.0 110.492 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 91.6 mt -62.63 -37.44 86.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.239 176.434 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -63.87 -37.56 87.86 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.216 -178.178 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -69.1 -29.47 67.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.833 0.349 . . . . 0.0 110.749 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -89.41 -14.37 35.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.34 0.59 . . . . 0.0 110.055 -177.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 85.92 10.45 75.49 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.531 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.74 14.01 5.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 -178.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -81.4 154.5 71.67 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.35 176.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.16 159.14 54.16 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.334 2.023 . . . . 0.0 111.775 176.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -71.33 -31.36 67.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.907 0.384 . . . . 0.0 110.717 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -168.25 164.12 13.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.217 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 66.4 mt -137.33 118.62 17.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.257 -0.429 . . . . 0.0 109.978 179.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 10.1 mm -114.9 118.09 57.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 177.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -119.01 158.28 26.1 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.506 -174.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 1.5 tmtp? -83.96 -45.19 13.41 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 174.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -141.81 113.07 7.55 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.069 -0.969 . . . . 0.0 108.878 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.6 t -123.57 -176.92 3.57 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.582 -176.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -115.86 150.7 36.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.265 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.452 ' O ' HG22 ' A' ' 92' ' ' VAL . 2.8 m -61.92 -37.89 86.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.677 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 51.0 mt -61.08 -39.22 81.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.968 0.414 . . . . 0.0 110.793 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 60.4 mt -62.86 -42.13 95.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.055 179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.568 ' HA ' HD22 ' A' ' 101' ' ' LEU . . . -61.72 -38.4 87.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.89 178.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.477 HG11 ' HE1' ' A' ' 96' ' ' MET . 58.3 t -63.87 -43.49 97.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.536 177.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.72 -40.11 97.18 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.13 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 99' ' ' ILE . . . -65.29 -32.67 74.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.748 0.308 . . . . 0.0 111.055 177.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.01 -25.03 67.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 178.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.477 ' HE1' HG11 ' A' ' 92' ' ' VAL . 45.2 mtt -79.37 -43.87 22.62 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.708 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.485 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -83.49 -0.74 51.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.134 -174.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 64.1 38.53 8.34 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.129 0.49 . . . . 0.0 110.769 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.448 ' O ' ' HB2' ' A' ' 94' ' ' ALA . 69.0 mt -109.41 90.07 8.02 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 17.7 Cg_endo -58.16 125.01 17.22 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.899 2.399 . . . . 0.0 112.68 -178.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.568 HD22 ' HA ' ' A' ' 91' ' ' ALA . 2.2 pp -127.35 147.52 50.26 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.17 0.509 . . . . 0.0 111.16 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.491 HG11 ' HA ' ' A' ' 7' ' ' ALA . 27.4 m -134.56 156.2 39.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.05 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.448 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 42.9 mt-10 -95.92 119.46 34.46 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.583 176.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 4.5 p -114.45 116.42 52.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.257 0.551 . . . . 0.0 110.176 176.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -91.53 -29.34 17.02 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.783 -177.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -69.39 117.88 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -177.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -68.64 -21.28 64.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.762 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.4 mttm -62.16 -19.97 63.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.442 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.554 ' O ' HG12 ' A' ' 113' ' ' VAL . 46.9 t80 -65.52 -51.97 56.03 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 173.197 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -69.7 -26.49 64.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.491 0.662 . . . . 0.0 110.412 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -70.38 -37.35 74.52 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.543 176.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.45 -54.64 5.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.1 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 109' ' ' PHE . 9.9 p -69.96 138.9 21.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.254 0.549 . . . . 0.0 110.601 -177.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 55.9 mttp -135.04 151.43 50.78 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.956 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.528 HG23 ' HA ' ' A' ' 18' ' ' LEU . 16.2 m -58.16 113.33 1.87 Allowed 'General case' 0 C--N 1.324 -0.519 0 O-C-N 123.353 0.408 . . . . 0.0 110.397 178.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 106.18 31.73 3.99 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.949 -179.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -132.55 173.72 11.02 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 171.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -97.52 122.51 40.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.022 0.439 . . . . 0.0 111.797 -172.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.491 HG21 ' HB2' ' A' ' 17' ' ' ALA . 83.4 t -117.83 124.18 72.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.065 174.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.4 t -107.17 105.05 18.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 174.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.9 p -92.86 132.31 37.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.555 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -127.23 93.51 3.76 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 176.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.05 -13.34 56.0 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.607 -171.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.417 ' OD1' ' HB3' ' A' ' 10' ' ' ARG . 48.3 m-20 -61.57 -34.77 76.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.909 0.385 . . . . 0.0 109.977 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.401 ' HB3' ' CE1' ' A' ' 127' ' ' TYR . 32.1 tt0 -106.5 -27.74 10.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.1 178.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 93.07 70.13 1.13 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.969 175.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . 0.401 ' CE1' ' HB3' ' A' ' 125' ' ' GLU . 46.1 p90 -170.31 162.13 8.42 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.21 179.147 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.45 HG23 ' CE1' ' A' ' 109' ' ' PHE . 15.0 m -124.61 132.11 71.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.507 178.212 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -105.42 117.77 34.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.743 179.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.8 tp -94.2 125.4 38.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 177.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.4 mm -108.13 111.45 35.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--N 1.312 -1.034 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.436 -173.627 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.855 0.36 . . . . 0.0 111.162 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -121.5 111.67 17.55 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.572 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 90.1 m-85 -92.59 149.46 21.34 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.725 0.297 . . . . 0.0 110.77 -177.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 117.66 34.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.809 176.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.517 ' HB3' HG23 ' A' ' 104' ' ' VAL . 4.5 p -120.35 169.14 10.57 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.166 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 44.2 ttp180 -94.69 128.38 41.33 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.581 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -95.12 127.62 41.32 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.979 0.419 . . . . 0.0 111.458 -174.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.4 mm -101.31 -55.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.549 177.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.618 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -95.42 173.68 7.4 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.553 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -121.25 168.18 11.9 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.402 -175.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.68 -174.41 16.54 Favored Glycine 0 N--CA 1.452 -0.256 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.77 154.7 46.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 117.618 0.709 . . . . 0.0 111.147 176.526 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.479 ' HB2' ' HB3' ' A' ' 79' ' ' LYS . . . -138.61 139.51 38.59 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.959 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 123.92 30.82 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.77 -179.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.95 -166.34 37.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 119.585 -1.293 . . . . 0.0 113.39 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -73.19 135.16 44.58 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 122.598 0.359 . . . . 0.0 110.797 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.72 124.95 32.1 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.929 0.395 . . . . 0.0 111.046 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.536 ' HA ' HG22 ' A' ' 115' ' ' THR . 6.5 tt -108.78 110.71 22.16 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.657 ' HA ' ' HB ' ' A' ' 54' ' ' VAL . 47.0 t -104.58 125.7 59.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.269 0.557 . . . . 0.0 112.425 -168.538 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.439 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 17.5 p -137.22 144.98 43.1 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.614 174.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.541 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 15.8 ptpt -128.89 20.14 5.98 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.193 0.52 . . . . 0.0 111.031 175.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -80.57 125.3 29.82 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.192 173.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -77.83 109.46 11.87 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.212 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.74 ' HB ' ' HZ ' ' A' ' 55' ' ' PHE . 43.8 mt -124.45 -7.62 6.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 110.256 -174.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.0 p 48.94 23.25 0.67 Allowed 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 113.596 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.453 ' CD1' HD13 ' A' ' 90' ' ' ILE . 36.9 m-85 64.51 18.34 11.31 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 178.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.2 27.26 0.81 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.176 0.512 . . . . 0.0 109.878 173.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -94.01 -128.39 5.1 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.488 -176.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 177.39 93.38 0.09 OUTLIER Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.416 -177.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.437 HG12 HG22 ' A' ' 37' ' ' VAL . 54.5 mt -92.82 126.67 45.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 170.212 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -62.92 124.31 20.75 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.695 0.283 . . . . 0.0 110.701 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' HD23 ' A' ' 71' ' ' LEU . 20.7 pttp -85.08 3.97 36.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -173.368 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -101.47 -36.99 8.62 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.94 0.4 . . . . 0.0 110.818 177.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.2 p -113.22 -19.1 11.93 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.645 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.13 25.01 62.61 Favored Glycine 0 N--CA 1.453 -0.176 0 C-N-CA 120.989 -0.624 . . . . 0.0 111.963 -177.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.3 mm -102.3 127.99 55.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.706 0.289 . . . . 0.0 110.416 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.437 HG22 HG12 ' A' ' 30' ' ' ILE . 21.8 t -67.0 111.46 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.854 0.359 . . . . 0.0 110.198 177.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -87.24 -27.96 22.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.467 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -67.76 129.78 40.97 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.492 178.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -74.09 133.84 42.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.293 0.568 . . . . 0.0 110.811 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 3.5 p -160.78 35.17 0.15 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.18 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 32.7 mm-40 72.38 -51.64 0.7 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.77 -174.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -88.55 42.36 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.308 0.575 . . . . 0.0 110.896 178.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.3 tttm -73.22 127.39 32.49 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.27 -2.2 29.66 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.166 -176.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -77.37 150.6 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.228 0.537 . . . . 0.0 111.939 178.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 36.0 t -101.36 131.93 47.17 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.782 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.487 ' HB ' ' HG3' ' A' ' 78' ' ' PRO . 31.2 m -105.53 4.72 10.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.964 0.411 . . . . 0.0 110.877 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.76 92.17 1.99 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.55 0.69 . . . . 0.0 111.242 -174.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 105.65 12.07 27.3 Favored Glycine 0 C--N 1.315 -0.595 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.635 176.245 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -110.46 175.3 5.48 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 54.1 mt -110.19 121.24 62.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.513 ' HB3' HG21 ' A' ' 81' ' ' ILE . 54.4 tp -91.46 120.26 32.13 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.746 -174.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.657 ' HB ' ' HA ' ' A' ' 19' ' ' VAL . 67.5 t -101.99 107.97 22.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.777 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 51.4 t80 -133.99 143.3 46.77 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -173.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.541 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 23.8 Cg_endo -62.95 -36.92 57.31 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 121.955 1.77 . . . . 0.0 111.505 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.025 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.287 176.932 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.605 0.241 . . . . 0.0 111.63 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.469 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 26.8 m -67.15 -31.99 55.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.025 -178.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.42 -36.78 77.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.932 0.396 . . . . 0.0 110.357 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.4 tp -66.15 -39.9 90.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.764 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -60.05 -48.61 81.0 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.587 176.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.525 HD23 ' HA ' ' A' ' 32' ' ' LYS . 96.3 mt -57.45 -47.62 81.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.964 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.435 ' HB2' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -66.07 -37.39 85.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -177.393 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.8 mmtt -61.4 -30.2 70.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.5 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . 0.523 ' HB3' HG23 ' A' ' 76' ' ' VAL . 21.6 t-20 -89.64 -22.78 22.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.195 0.522 . . . . 0.0 109.877 178.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.27 16.49 55.5 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.385 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.645 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 32.2 m -106.94 13.81 8.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.084 0.469 . . . . 0.0 110.821 -176.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.88 49.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.935 -179.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.487 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 13.1 Cg_exo -68.33 143.12 57.1 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.195 1.93 . . . . 0.0 110.185 170.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.479 ' HB3' ' HB2' ' A' ' 13' ' ' ALA . 94.8 mttt -61.58 -33.92 74.71 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.165 0.507 . . . . 0.0 110.618 -179.335 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.62 155.25 34.36 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.438 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.513 HG21 ' HB3' ' A' ' 53' ' ' LEU . 16.1 pt -124.65 114.76 42.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.082 175.308 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.731 HG22 HG22 ' A' ' 102' ' ' VAL . 4.4 mm -102.86 116.78 47.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.777 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -115.1 175.96 5.27 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.822 0.344 . . . . 0.0 111.154 -173.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -101.37 -40.81 6.92 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 171.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -125.15 114.41 18.98 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.502 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.1 t -81.15 154.99 26.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.042 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.29 142.38 51.55 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.497 ' O ' HG22 ' A' ' 92' ' ' VAL . 18.1 m -56.26 -50.02 72.56 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 123.536 0.522 . . . . 0.0 112.033 -174.483 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 72.1 mt -65.24 -44.96 95.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 121.054 0.454 . . . . 0.0 110.702 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.453 HD13 ' CD1' ' A' ' 26' ' ' PHE . 63.9 mt -63.98 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.693 -179.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.4 -41.58 94.18 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.502 HG13 ' HE2' ' A' ' 96' ' ' MET . 98.9 t -61.86 -44.56 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.54 178.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.6 -44.76 97.08 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.358 179.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.427 ' HB3' HD23 ' A' ' 101' ' ' LEU . . . -67.02 -30.96 71.19 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.594 0.235 . . . . 0.0 111.131 179.296 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.72 -38.11 88.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.541 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.502 ' HE2' HG13 ' A' ' 92' ' ' VAL . 61.0 mtt -64.26 -45.92 86.01 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.516 0.674 . . . . 0.0 109.91 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.435 ' HB1' ' HB2' ' A' ' 72' ' ' ARG . . . -80.14 -1.65 41.19 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 114.992 -1.004 . . . . 0.0 111.697 -175.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 58.9 43.17 18.45 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 121.25 0.548 . . . . 0.0 110.569 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.2 mm -104.18 91.08 3.51 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.751 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.618 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 9.3 Cg_endo -49.96 100.41 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.558 2.838 . . . . 0.0 112.667 -176.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.427 HD23 ' HB3' ' A' ' 94' ' ' ALA . 1.5 pp -102.43 137.0 41.25 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.235 0.54 . . . . 0.0 109.994 179.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.731 HG22 HG22 ' A' ' 82' ' ' ILE . 35.1 m -135.17 159.23 41.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 8.3 pt-20 -121.06 135.57 55.17 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.365 0.602 . . . . 0.0 111.838 -178.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.572 HG13 ' HB2' ' A' ' 109' ' ' PHE . 32.4 t -115.9 105.04 17.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 170.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -84.16 35.85 0.55 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.95 -170.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -138.55 145.12 40.28 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.679 176.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -71.22 -23.93 62.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.171 -176.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -60.28 -29.24 68.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.582 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.572 ' HB2' HG13 ' A' ' 104' ' ' VAL . 84.6 t80 -61.25 -46.46 90.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.985 0.422 . . . . 0.0 110.312 177.416 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -71.97 -22.61 61.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.243 -175.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.8 mm-40 -79.04 -36.62 40.71 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.346 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.67 -42.44 22.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.87 -176.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.505 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.0 p -79.86 138.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.014 0.435 . . . . 0.0 110.345 -177.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.3 mttp -122.77 151.61 41.45 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.045 -177.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.536 HG22 ' HA ' ' A' ' 18' ' ' LEU . 33.1 m -71.56 95.76 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.101 0.476 . . . . 0.0 109.921 176.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.2 1.95 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.268 -177.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -77.78 166.98 22.27 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.4 177.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.714 HH21 HG13 ' A' ' 131' ' ' ILE . 2.2 tmm_? -107.67 122.87 47.59 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.372 0.606 . . . . 0.0 109.863 -176.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 91.3 t -119.57 139.33 47.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.262 -175.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.9 t -117.05 111.82 36.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.319 171.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.491 HG22 HD12 ' A' ' 82' ' ' ILE . 55.1 t -107.56 117.53 53.45 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.285 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . 0.719 HD22 ' HB2' ' A' ' 124' ' ' ASP . 9.8 t30 -109.97 118.02 35.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 177.013 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -101.15 8.01 42.91 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.37 -174.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.719 ' HB2' HD22 ' A' ' 122' ' ' ASN . 53.5 m-20 -64.99 -41.43 95.43 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 176.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -117.9 -33.43 4.48 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 173.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 108.93 91.84 2.19 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.195 172.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 25.6 p90 -159.66 153.35 22.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.949 0.404 . . . . 0.0 110.322 174.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.572 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 84.9 t -116.15 111.21 34.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.831 178.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -92.62 108.37 19.92 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 59.2 tp -94.6 114.07 25.98 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.908 -176.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.714 HG13 HH21 ' A' ' 118' ' ' ARG . 33.5 mm -111.58 116.95 53.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.364 174.346 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.876 -179.299 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.234 0.238 0 CA-C-O 120.963 0.411 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -126.98 140.78 52.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.937 -174.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -133.59 149.09 51.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.437 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.79 131.72 45.59 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.649 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.0 m -122.09 169.09 11.2 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.321 176.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -96.2 134.59 39.1 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 174.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.23 96.6 4.59 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.922 0.391 . . . . 0.0 111.473 -174.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.482 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 43.8 mm -82.81 -49.37 16.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 174.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.545 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -109.22 176.19 5.18 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 172.604 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -126.23 178.13 6.0 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.48 -0.193 . . . . 0.0 110.48 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.442 ' H ' ' HB2' ' A' ' 124' ' ' ASP . . . 97.19 -162.39 21.79 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -174.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -156.41 148.01 22.68 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.695 0.283 . . . . 0.0 110.496 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -149.66 151.56 33.94 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -137.82 127.77 25.65 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.958 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.64 172.14 39.47 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.324 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -70.38 128.87 37.69 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.463 ' HB2' HG21 ' A' ' 119' ' ' VAL . . . -80.92 141.69 34.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.267 0.556 . . . . 0.0 111.712 -175.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.5 tt -121.24 114.09 20.88 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 177.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.0 t -102.79 110.84 30.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.196 0.522 . . . . 0.0 111.674 -173.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.436 ' O ' HG21 ' A' ' 20' ' ' THR . 9.7 t -152.36 95.63 2.06 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 172.346 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.77 -72.2 0.18 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.154 -174.257 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.82 ' HG2' ' HB3' ' A' ' 41' ' ' CYS . 0.3 OUTLIER 51.15 -163.52 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 O-C-N 123.469 0.48 . . . . 0.0 111.794 178.368 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 13.3 p90 -158.59 44.49 0.29 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.443 0.639 . . . . 0.0 110.045 176.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.5 pt -73.29 177.84 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.721 -177.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.1 t -88.22 128.52 35.46 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.338 -178.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -82.91 91.19 7.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -124.97 -77.49 0.59 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.033 177.002 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.45 59.17 0.41 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.6 15.65 45.26 Favored Glycine 0 C--O 1.226 -0.387 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 -177.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.424 HD11 HG21 ' A' ' 48' ' ' VAL . 58.2 mt -134.31 134.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.653 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 15.2 t70 -66.26 135.59 54.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.679 0.276 . . . . 0.0 110.357 178.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -81.21 -7.45 59.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -173.012 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -117.65 -30.43 5.47 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.555 HG22 HG12 ' A' ' 36' ' ' ILE . 7.8 t -123.16 -4.88 8.41 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 120.104 -0.638 . . . . 0.0 112.519 179.247 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 70.35 27.95 72.0 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.87 -0.681 . . . . 0.0 113.446 176.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.555 HG12 HG22 ' A' ' 34' ' ' THR . 42.5 mm -87.97 129.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 176.447 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.89 128.69 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.019 0.438 . . . . 0.0 111.032 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.653 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 74.3 mmtt -87.67 -41.43 13.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.669 -179.123 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -89.97 122.19 32.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.87 -172.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.609 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 21.7 t70 -74.35 133.51 42.52 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.359 0.599 . . . . 0.0 111.087 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.82 ' HB3' ' HG2' ' A' ' 22' ' ' GLU . 59.0 m -123.11 -28.09 4.09 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.896 178.354 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 175.52 -62.25 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 pt -114.79 71.02 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.295 179.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.609 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 13.3 tmtt? -93.74 140.76 29.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.698 -178.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 136.62 -8.1 3.95 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.915 175.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -103.89 173.02 6.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.239 0.542 . . . . 0.0 111.58 -175.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 m -93.36 137.7 32.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.653 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.424 HG21 HD11 ' A' ' 30' ' ' ILE . 29.7 m -100.76 2.7 10.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.972 0.415 . . . . 0.0 110.399 174.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.32 94.76 0.17 Allowed 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.861 -177.151 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.482 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 97.43 14.04 42.69 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 114.756 -1.111 . . . . 0.0 112.634 176.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 82.4 mtt180 -104.69 164.85 11.46 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.669 0.271 . . . . 0.0 110.574 176.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.464 HD11 ' HB3' ' A' ' 80' ' ' ALA . 51.5 mm -95.93 111.46 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.077 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.491 ' HB3' HG23 ' A' ' 81' ' ' ILE . 18.3 tp -101.7 125.86 48.45 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -173.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.4 t -113.75 128.61 70.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.958 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -131.99 145.87 59.27 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.46 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.83 -50.31 0.1 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.624 2.216 . . . . 0.0 112.002 175.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.424 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.442 -177.83 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 85.7 m-85 . . . . . 0 N--CA 1.471 0.597 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.77 -39.14 76.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.7 mt -65.07 -34.83 79.35 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.716 0.293 . . . . 0.0 110.847 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.3 tp -65.06 -44.71 88.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.405 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -64.26 -41.49 96.91 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.409 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.57 -38.39 86.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.798 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.451 ' CG ' HD11 ' A' ' 99' ' ' ILE . 2.7 tmt_? -72.04 -39.48 69.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.528 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -64.16 -30.94 71.97 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.278 0.561 . . . . 0.0 110.336 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -84.86 -22.91 29.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.0 178.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.49 23.79 38.64 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.747 176.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.05 -0.26 9.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.057 0.456 . . . . 0.0 111.269 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.14 162.59 40.05 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.685 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 31.5 Cg_exo -59.03 147.8 88.44 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.229 1.953 . . . . 0.0 111.099 172.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.482 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 80.3 tttt -73.72 -26.15 60.56 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.05 0.452 . . . . 0.0 110.43 -175.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.464 ' HB3' HD11 ' A' ' 52' ' ' ILE . . . -166.71 150.19 6.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.753 176.232 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.491 HG23 ' HB3' ' A' ' 53' ' ' LEU . 15.7 pt -126.69 123.31 62.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.922 0.391 . . . . 0.0 110.564 178.381 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.671 HG21 HG21 ' A' ' 102' ' ' VAL . 5.4 mm -111.01 120.56 61.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.264 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 12.4 m120 -129.96 167.15 18.67 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -176.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -104.68 -38.83 6.57 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.4 tttp -128.58 103.43 7.1 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.218 174.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.9 t -112.0 156.8 21.57 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 175.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -79.46 145.93 33.01 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -56.87 -34.01 67.42 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.182 0.515 . . . . 0.0 110.986 -176.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 54.8 mt -64.45 -41.15 91.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.822 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.9 mt -71.83 -42.17 69.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.542 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.61 -47.11 80.35 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.304 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.412 ' O ' ' HG3' ' A' ' 96' ' ' MET . 90.1 t -68.22 -42.25 84.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.615 179.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.97 99.15 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.352 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.54 -40.06 92.46 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.785 0.326 . . . . 0.0 110.833 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.412 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -63.64 -37.18 86.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.941 179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.412 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 89.4 mtp -68.39 -37.73 80.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.683 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.14 -1.28 57.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.342 -175.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 62.36 47.32 5.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.414 0.626 . . . . 0.0 110.467 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.458 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 44.2 mm -107.29 90.55 5.82 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.587 175.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.545 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.3 Cg_endo -48.48 96.51 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.421 2.747 . . . . 0.0 113.277 -175.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.482 ' O ' ' HB ' ' A' ' 8' ' ' ILE . 5.8 tt -102.29 126.0 49.16 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.721 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.671 HG21 HG21 ' A' ' 82' ' ' ILE . 11.0 m -127.71 150.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.257 176.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.529 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 6.5 tm-20 -97.8 114.9 27.04 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.507 -177.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.476 HG13 HG22 ' A' ' 82' ' ' ILE . 14.4 m -71.57 134.12 30.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.333 0.587 . . . . 0.0 111.832 -177.123 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.552 ' HD3' ' O ' ' A' ' 105' ' ' ARG . 1.0 OUTLIER -84.94 -33.95 22.57 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.363 -179.548 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -112.5 140.36 47.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.185 -172.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.34 -20.67 62.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.315 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mmtt -57.54 -24.15 54.46 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.905 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -60.65 -46.23 91.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.691 0.281 . . . . 0.0 110.508 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -65.07 -31.46 72.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.544 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -79.69 -30.91 41.23 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.976 -178.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.38 -33.01 17.02 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.371 -175.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 14.8 p -64.1 134.82 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.083 0.468 . . . . 0.0 110.841 -177.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -116.89 139.57 50.47 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.886 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.4 m -71.34 99.92 2.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.216 175.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.73 -31.6 2.92 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.666 179.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -85.47 161.27 19.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.861 0.362 . . . . 0.0 111.616 -177.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.853 HH21 HG13 ' A' ' 131' ' ' ILE . 18.0 ttp180 -89.17 127.37 35.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.248 0.547 . . . . 0.0 111.61 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 17' ' ' ALA . 96.2 t -108.13 120.91 60.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.742 175.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.84 101.63 12.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 176.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 3.2 p -102.18 114.88 42.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 121.381 0.61 . . . . 0.0 110.907 -178.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -101.94 93.64 5.38 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 175.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.29 -26.68 62.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.374 -173.147 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.442 ' HB2' ' H ' ' A' ' 11' ' ' GLY . 25.8 t70 -63.38 -22.6 66.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.234 -177.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -120.11 -1.44 10.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.719 0.295 . . . . 0.0 110.708 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.18 62.66 5.42 Favored Glycine 0 C--N 1.332 0.356 0 CA-C-N 116.053 -0.521 . . . . 0.0 112.376 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -152.13 141.8 21.84 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.37 -0.488 . . . . 0.0 110.308 -177.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.5 m -122.97 136.28 60.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.199 0.524 . . . . 0.0 111.441 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -120.73 114.66 21.98 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.379 177.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 42.0 tp -90.49 125.18 35.51 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.853 HG13 HH21 ' A' ' 118' ' ' ARG . 19.3 mm -101.36 111.61 31.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.309 -1.181 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.441 -175.828 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.414 ' HB3' ' HE2' ' A' ' 2' ' ' LYS . 14.3 ptpt -145.18 148.87 34.04 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.815 0.341 . . . . 0.0 111.215 -177.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -136.44 152.95 51.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.734 -0.667 . . . . 0.0 109.977 179.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.79 114.09 25.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.209 175.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.719 ' SG ' HG13 ' A' ' 104' ' ' VAL . 83.9 m -120.24 176.93 5.22 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.215 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.9 tpm_? -94.73 119.84 34.0 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.119 -172.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 102' ' ' VAL . . . -86.69 142.55 28.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.174 -179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.517 HG12 ' HG1' ' A' ' 86' ' ' THR . 3.2 mp -105.97 -54.65 6.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.3 p -98.4 161.31 13.75 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 170.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.549 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 46.0 mtm180 -123.73 -175.85 3.32 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 119.574 -0.85 . . . . 0.0 112.681 -174.674 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.85 -164.89 14.07 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 -169.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.5 ttp180 -148.76 143.47 26.41 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 117.542 0.671 . . . . 0.0 109.789 177.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.569 ' HB1' ' HB1' ' A' ' 80' ' ' ALA . . . -154.52 152.15 29.74 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.716 0.293 . . . . 0.0 110.96 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.81 161.21 41.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.494 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 147.85 -160.54 28.35 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.155 -1.022 . . . . 0.0 112.453 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -64.4 124.09 20.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.986 0.422 . . . . 0.0 110.444 177.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.84 117.22 21.3 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.254 179.37 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.479 HD12 HG21 ' A' ' 115' ' ' THR . 13.4 tp -96.54 108.82 21.46 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.42 112.73 40.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.319 0.58 . . . . 0.0 110.96 -174.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -116.45 101.15 8.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.308 176.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -73.59 -12.09 60.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.401 -175.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -71.84 130.12 40.29 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.051 0.453 . . . . 0.0 110.154 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -78.53 69.92 4.8 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.407 0.622 . . . . 0.0 111.338 -177.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -82.14 152.63 4.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.226 176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -116.58 174.73 5.91 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.326 -173.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.489 ' O ' ' HB3' ' A' ' 27' ' ' LEU . 85.3 m-85 -82.97 -163.34 0.71 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.89 -0.596 . . . . 0.0 109.987 175.623 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.489 ' HB3' ' O ' ' A' ' 26' ' ' PHE . 64.9 tp 72.24 14.91 5.46 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.996 0.903 . . . . 0.0 109.831 -176.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.82 44.8 0.12 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.817 177.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.63 -72.51 1.21 Allowed Glycine 0 N--CA 1.452 -0.285 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 174.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.455 HD11 ' N ' ' A' ' 30' ' ' ILE . 4.0 mp -85.84 133.31 29.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 170.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.494 ' HB2' ' HG2' ' A' ' 38' ' ' LYS . 29.0 t70 -72.74 146.08 46.66 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.309 0.576 . . . . 0.0 111.475 -175.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.508 ' HG2' ' HG3' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -82.94 -11.68 57.96 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.958 -173.102 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.508 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 31.0 mt-10 -110.29 -41.32 4.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.636 0.255 . . . . 0.0 111.48 -174.383 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 42.4 p -100.86 -23.01 14.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -177.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.484 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.3 16.84 80.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.521 -175.347 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.3 mm -99.58 143.78 13.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.5 t -67.98 115.14 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.67 0.271 . . . . 0.0 110.395 177.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.494 ' HG2' ' HB2' ' A' ' 31' ' ' ASP . 30.3 mmtp -81.83 -26.67 34.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.65 146.5 53.77 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.86 -178.496 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -77.28 136.92 38.53 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.546 -177.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 53.1 t -165.22 167.66 17.81 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -177.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -63.8 -36.18 83.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.322 0.582 . . . . 0.0 109.464 175.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.637 ' O ' ' HG2' ' A' ' 46' ' ' GLU . 13.6 pt -108.19 53.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.327 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.742 ' HZ2' ' HB3' ' A' ' 44' ' ' LYS . 0.0 OUTLIER -77.94 132.95 38.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 177.89 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.78 8.51 34.48 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.602 179.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.637 ' HG2' ' O ' ' A' ' 43' ' ' ILE . 32.2 mm-40 -63.53 146.97 52.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.227 0.537 . . . . 0.0 110.888 178.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.0 m -106.34 107.58 18.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.179 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.2 m -82.26 0.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.941 -175.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.23 89.15 0.45 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.298 0.571 . . . . 0.0 111.452 -175.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.91 8.58 29.65 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.401 -0.818 . . . . 0.0 113.003 174.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.6 mpt_? -103.78 172.44 6.8 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.753 0.311 . . . . 0.0 111.057 -179.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 50.1 mm -99.92 104.09 15.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 171.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 81' ' ' ILE . 45.3 tp -85.71 113.7 22.11 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.342 -170.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -119.66 106.89 19.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.108 0.48 . . . . 0.0 110.496 178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.415 ' HD1' ' HG ' ' A' ' 53' ' ' LEU . 34.2 p90 -136.97 149.86 67.84 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.82 176.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -63.79 -49.6 3.97 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.106 1.871 . . . . 0.0 110.464 172.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.52 0 CA-C-N 115.41 -0.814 . . . . 0.0 113.061 175.624 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 . . . . . 0 N--CA 1.472 0.643 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.496 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 46.8 t -54.31 -45.56 68.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.755 0.312 . . . . 0.0 111.564 -177.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.505 ' HB3' HD11 ' A' ' 99' ' ' ILE . 84.3 mt -61.28 -36.28 79.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.632 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.56 ' HA ' ' HB1' ' A' ' 97' ' ' ALA . 60.4 tp -69.74 -39.76 76.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.17 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -59.44 -48.79 80.28 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.876 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 85.2 mt -57.55 -41.08 80.26 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.778 -0.647 . . . . 0.0 111.437 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.552 ' HG3' ' HB2' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -71.71 -40.23 69.61 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.306 -178.31 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.481 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 68.3 mttm -62.61 -34.85 77.86 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.248 0.547 . . . . 0.0 109.981 175.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . 0.515 ' HB3' HG21 ' A' ' 76' ' ' VAL . 37.8 t-20 -72.23 -34.0 67.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.008 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.27 6.98 57.45 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.087 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.515 HG21 ' HB3' ' A' ' 74' ' ' ASN . 28.8 m -103.41 10.07 8.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.025 0.441 . . . . 0.0 111.228 -176.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.33 147.12 49.31 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.133 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.77 160.18 49.42 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.683 176.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.536 ' HB3' ' HB3' ' A' ' 13' ' ' ALA . 96.6 mttt -69.29 -38.16 78.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.96 0.409 . . . . 0.0 110.251 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.569 ' HB1' ' HB1' ' A' ' 13' ' ' ALA . . . -148.71 158.83 44.42 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.477 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 73.9 mt -132.98 119.58 37.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.88 178.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.734 HD11 HG21 ' A' ' 102' ' ' VAL . 9.1 mm -114.2 120.17 63.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.48 172.62 7.21 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.753 0.311 . . . . 0.0 110.465 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 88.0 tttt -91.65 -43.2 9.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.286 0.565 . . . . 0.0 109.55 173.01 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -112.28 118.48 35.39 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.39 177.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.517 ' HG1' HG12 ' A' ' 8' ' ' ILE . 8.8 t -82.69 159.19 22.67 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.088 177.115 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.469 ' OE1' HG12 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -144.9 151.65 39.01 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.779 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.466 ' O ' HG21 ' A' ' 92' ' ' VAL . 2.6 m -53.56 -48.51 69.08 Favored 'General case' 0 C--N 1.323 -0.549 0 O-C-N 123.735 0.647 . . . . 0.0 111.036 178.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.469 HG12 ' OE1' ' A' ' 87' ' ' GLU . 31.5 pt -62.77 -35.21 69.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.85 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.471 HG23 HD23 ' A' ' 101' ' ' LEU . 58.1 mt -70.28 -45.04 76.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.67 -45.72 91.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.849 178.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.576 ' O ' ' HG2' ' A' ' 96' ' ' MET . 69.5 t -58.43 -50.88 77.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.43 -43.09 98.76 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.656 -177.364 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.431 ' HB2' ' HB ' ' A' ' 99' ' ' ILE . . . -73.47 -31.22 63.64 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -176.045 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -66.04 -33.77 76.57 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.689 0.281 . . . . 0.0 110.94 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.576 ' HG2' ' O ' ' A' ' 92' ' ' VAL . 19.2 mmt -66.65 -44.5 81.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.576 0.703 . . . . 0.0 110.596 179.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.56 ' HB1' ' HA ' ' A' ' 69' ' ' LEU . . . -95.18 -0.39 53.28 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 114.878 -1.055 . . . . 0.0 112.125 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 56.52 64.58 1.64 Allowed 'General case' 0 C--O 1.235 0.31 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -172.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.505 HD11 ' HB3' ' A' ' 68' ' ' LEU . 54.9 mt -113.6 89.84 16.53 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.811 177.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.449 ' HB3' ' CB ' ' A' ' 123' ' ' ALA . 77.7 Cg_exo -50.14 113.24 0.93 Allowed 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 123.07 2.513 . . . . 0.0 112.564 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.471 HD23 HG23 ' A' ' 90' ' ' ILE . 1.7 pp -125.54 133.8 52.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.233 0.539 . . . . 0.0 110.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.734 HG21 HD11 ' A' ' 82' ' ' ILE . 5.3 m -126.48 152.51 34.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 175.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.622 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 11.9 pt-20 -99.42 119.87 38.69 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.192 0.52 . . . . 0.0 110.268 178.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.719 HG13 ' SG ' ' A' ' 5' ' ' CYS . 33.1 m -97.2 153.71 3.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.522 ' HD3' ' O ' ' A' ' 105' ' ' ARG . 3.4 tmt_? -127.62 -15.55 4.98 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.037 0.446 . . . . 0.0 110.842 -176.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.459 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 5.0 t70 -94.49 138.14 32.77 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.407 -170.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -71.73 -30.99 66.22 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.759 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.459 ' HE2' ' OD1' ' A' ' 106' ' ' ASP . 46.4 mtmt -59.94 -28.19 67.42 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.652 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.51 ' O ' HG11 ' A' ' 113' ' ' VAL . 81.6 t80 -65.41 -48.24 73.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.504 177.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -68.15 -26.83 65.97 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.009 -175.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.466 ' HA ' ' OE1' ' A' ' 111' ' ' GLU . 3.3 mm-40 -84.76 -36.55 21.67 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.756 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -67.65 -39.85 84.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.916 0.388 . . . . 0.0 110.751 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 109' ' ' PHE . 8.4 p -93.11 140.01 17.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.662 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.453 ' NZ ' ' HA ' ' A' ' 111' ' ' GLU . 43.1 mmtm -142.12 155.26 45.34 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.777 175.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.479 HG21 HD12 ' A' ' 18' ' ' LEU . 17.3 m -57.46 116.04 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.806 -176.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.73 -34.84 2.23 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.268 -0.967 . . . . 0.0 113.658 175.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -92.29 -174.6 3.78 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.438 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.12 142.87 41.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.221 0.534 . . . . 0.0 111.879 -168.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.412 HG22 ' HA ' ' A' ' 130' ' ' LEU . 9.9 p -141.17 140.65 31.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.28 174.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.1 t -108.9 119.83 59.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.862 178.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.443 HG11 HD12 ' A' ' 82' ' ' ILE . 53.3 t -114.24 114.6 47.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.113 0.482 . . . . 0.0 111.044 -177.703 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -100.46 99.67 10.32 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.449 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -76.74 -8.03 56.51 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.413 -174.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.549 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 20.4 t70 -65.26 -37.87 88.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.091 0.472 . . . . 0.0 109.95 177.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -102.29 -28.23 12.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.619 179.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.98 61.15 1.78 Allowed Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -166.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -136.24 124.28 22.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -165.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.427 HG11 HG23 ' A' ' 121' ' ' VAL . 21.2 t -123.87 113.67 38.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.712 0.291 . . . . 0.0 110.583 -175.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -107.99 114.58 28.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.379 177.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.412 ' HA ' HG22 ' A' ' 119' ' ' VAL . 44.8 tp -85.84 129.57 34.79 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 11.2 tt -126.46 113.78 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-O 122.196 0.998 . . . . 0.0 110.347 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.227 0 CA-C-N 113.91 -1.495 . . . . 0.0 109.704 -173.99 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.543 HG23 ' HG3' ' A' ' 2' ' ' LYS . 20.8 m . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.543 ' HG3' HG23 ' A' ' 1' ' ' VAL . 51.8 mttm 69.03 93.21 0.08 Allowed 'General case' 0 N--CA 1.469 0.49 0 O-C-N 123.454 0.471 . . . . 0.0 110.36 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -121.46 149.97 42.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.949 -175.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.14 134.74 41.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.096 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.538 ' SG ' HG22 ' A' ' 104' ' ' VAL . 82.9 m -128.46 175.86 8.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.049 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.609 ' HB3' ' HG2' ' A' ' 103' ' ' GLU . 50.2 ttt180 -93.87 120.63 34.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 178.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.572 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -91.29 112.69 24.7 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.976 0.417 . . . . 0.0 111.915 -175.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.426 ' N ' HD13 ' A' ' 8' ' ' ILE . 3.6 mp -81.45 -51.47 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.607 177.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.3 p -101.94 -173.67 2.4 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.342 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.613 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 65.8 mmt-85 -124.76 175.23 7.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.558 0.218 . . . . 0.0 110.497 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.64 173.05 25.77 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 12' ' ' ARG . 12.5 ptt180 -142.14 151.13 41.95 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 117.276 0.538 . . . . 0.0 110.802 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.501 ' HB3' ' HB3' ' A' ' 79' ' ' LYS . . . -140.73 138.02 33.89 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.742 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.554 ' HG3' HG22 ' A' ' 120' ' ' VAL . 28.0 tt0 -129.19 122.45 29.78 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.944 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 178.61 -160.4 26.25 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 119.93 -1.129 . . . . 0.0 113.028 176.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.539 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 27.1 mt-10 -70.36 134.19 47.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 122.635 0.374 . . . . 0.0 111.008 -177.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -91.23 125.32 35.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.012 0.434 . . . . 0.0 110.843 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.634 ' HB3' HD12 ' A' ' 53' ' ' LEU . 5.8 tp -117.82 118.49 32.17 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.9 t -102.01 127.05 55.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.208 0.528 . . . . 0.0 111.576 -173.286 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.45 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 19.2 m -126.18 108.49 11.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.647 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -86.22 8.78 19.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.748 0.309 . . . . 0.0 111.546 -174.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.67 143.68 35.81 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.157 0.503 . . . . 0.0 110.742 178.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -81.99 139.14 34.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.411 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.0 pt -127.55 155.95 39.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.763 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.408 ' C ' ' H ' ' A' ' 27' ' ' LEU . 18.6 p -91.81 2.06 56.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.205 -178.091 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 72.09 -10.12 0.92 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.34 -178.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' A' ' 25' ' ' SER . 2.9 mm? -94.94 33.03 1.55 Allowed 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 169.15 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.23 -175.85 50.93 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.301 -0.863 . . . . 0.0 112.899 -174.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.12 40.77 3.02 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 121.427 -0.416 . . . . 0.0 113.751 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 34.2 mt -79.09 112.44 17.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -57.72 129.55 42.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.129 0.49 . . . . 0.0 110.975 -176.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 44.9 pttt -82.29 -10.53 59.07 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.013 -173.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -93.71 -42.42 9.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -178.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 p -120.37 -5.2 9.88 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.94 32.39 80.8 Favored Glycine 0 C--N 1.329 0.143 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.339 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 46.7 mm -90.68 121.27 40.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.21 96.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.369 0.604 . . . . 0.0 109.946 176.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.3 mmmm -85.01 -5.99 59.34 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.565 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -69.75 139.08 53.27 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.65 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -77.23 132.94 38.97 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.282 -175.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.408 ' C ' ' H ' ' A' ' 43' ' ' ILE . 12.8 t -172.08 26.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.952 178.624 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 69.25 -39.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.8 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.408 ' H ' ' C ' ' A' ' 41' ' ' CYS . 35.9 pt -79.97 12.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.465 0.65 . . . . 0.0 110.497 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -57.05 122.91 13.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.803 177.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.8 -6.76 24.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.405 -178.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -85.65 148.44 25.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.9 0.381 . . . . 0.0 111.118 177.006 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 39.1 t -95.6 150.19 20.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 176.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.486 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.3 m -105.84 3.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.79 178.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.52 90.64 0.39 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.635 0.731 . . . . 0.0 111.497 -175.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.9 23.31 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.5 175.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.539 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 98.3 mtt180 -116.08 168.18 10.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.79 0.328 . . . . 0.0 110.518 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 52' ' ' ILE . 3.0 mp -107.93 122.92 62.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.634 HD12 ' HB3' ' A' ' 18' ' ' LEU . 4.6 mm? -96.34 138.45 33.92 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.142 0.496 . . . . 0.0 111.452 -175.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.94 119.71 61.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.067 177.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.663 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 90.7 m-85 -129.77 144.97 55.1 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.148 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 20' ' ' THR . 13.0 Cg_exo -71.37 -55.27 0.13 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.337 2.025 . . . . 0.0 111.519 175.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.698 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.361 -178.277 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 50.9 p90 . . . . . 0 N--CA 1.464 0.233 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.463 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 10.5 p -60.66 -33.58 55.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.41 -177.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 90.0 mt -68.88 -41.0 78.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.183 0.516 . . . . 0.0 110.484 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.1 tp -66.17 -39.53 89.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.949 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -60.21 -43.34 96.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.531 177.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.9 mt -65.86 -38.42 88.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.534 178.092 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.514 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 5.0 mmm180 -63.54 -42.83 98.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.233 178.099 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.418 ' HD3' ' O ' ' A' ' 73' ' ' LYS . 6.7 tmtt? -63.71 -29.21 70.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.402 0.62 . . . . 0.0 110.56 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -86.69 -12.27 48.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.117 0.485 . . . . 0.0 110.319 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 77.8 20.49 73.57 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.306 176.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.3 m -116.29 14.88 7.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.24 0.543 . . . . 0.0 110.929 -177.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -97.45 158.08 33.72 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.651 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.524 ' HB3' HD23 ' A' ' 53' ' ' LEU . 22.9 Cg_exo -65.37 165.43 22.45 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.665 2.243 . . . . 0.0 111.961 176.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 13' ' ' ALA . 54.6 mttm -80.8 -40.19 25.42 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.069 0.461 . . . . 0.0 110.245 173.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB3' ' HG2' ' A' ' 100' ' ' PRO . . . -160.36 158.34 29.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.32 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.537 HG23 ' HB2' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -130.05 127.34 63.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.157 0.504 . . . . 0.0 109.648 174.686 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.531 HG21 HG21 ' A' ' 102' ' ' VAL . 6.5 mm -106.91 116.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.235 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.663 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.0 m120 -115.27 158.65 22.05 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -177.038 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.406 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 50.4 tttm -81.69 -33.29 31.29 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 170.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . 0.439 ' HD2' ' HA ' ' A' ' 85' ' ' LYS . 28.1 tptt -153.92 148.09 25.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.249 173.284 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.0 t -140.51 -179.47 6.04 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.731 -0.213 . . . . 0.0 110.88 -175.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.79 160.15 18.26 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.437 ' O ' HG22 ' A' ' 92' ' ' VAL . 9.1 m -58.5 -45.14 89.36 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.082 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 15.2 mm -55.63 -41.56 65.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 111.193 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 27.5 mm -64.15 -45.48 96.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.361 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.79 -41.78 98.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.253 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 88' ' ' THR . 94.8 t -60.68 -44.34 96.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.053 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -68.64 -41.25 84.54 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.076 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.84 -32.65 74.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.646 0.26 . . . . 0.0 111.125 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.37 -44.07 92.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.283 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.6 mtm -75.53 -39.44 58.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.363 -177.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.514 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -79.12 0.19 29.11 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 57.23 53.08 8.08 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.362 0.601 . . . . 0.0 111.403 -177.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 21.7 mm -113.11 88.06 11.67 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.541 178.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.501 ' HG2' ' HB3' ' A' ' 80' ' ' ALA . 1.0 OUTLIER -45.64 117.44 1.76 Allowed 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.319 2.679 . . . . 0.0 112.546 -179.614 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.97 121.0 37.99 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.821 -176.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.572 HG11 ' HA ' ' A' ' 7' ' ' ALA . 34.7 m -123.84 142.64 39.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.32 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.609 ' HG2' ' HB3' ' A' ' 6' ' ' ARG . 13.3 pt-20 -100.31 129.38 46.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.204 0.526 . . . . 0.0 110.286 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.538 HG22 ' SG ' ' A' ' 5' ' ' CYS . 11.3 t -90.33 138.13 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.896 -177.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 77.7 mtt180 -89.56 -33.63 16.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.006 0.431 . . . . 0.0 110.603 177.07 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -96.6 139.56 32.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.421 0.629 . . . . 0.0 112.09 -168.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -71.93 -26.96 62.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.754 178.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.6 mttm -65.39 -17.88 64.88 Favored 'General case' 0 CA--C 1.521 -0.141 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -176.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 75.5 t80 -60.43 -46.21 90.84 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 174.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.406 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 88.1 m-85 -72.0 -28.96 63.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.098 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -66.24 -45.95 78.86 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.463 176.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.13 -47.31 20.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.227 -176.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.52 133.26 30.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 121.362 0.601 . . . . 0.0 111.605 -173.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -122.76 145.99 47.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.584 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.1 m -66.91 100.39 0.72 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 138.3 -16.65 3.39 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.451 -178.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -83.63 175.33 9.81 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.489 176.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.816 HH21 HG13 ' A' ' 131' ' ' ILE . 21.3 ttp180 -111.93 134.25 53.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.989 -178.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.1 p -124.51 138.29 54.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.201 0.524 . . . . 0.0 110.82 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.554 HG22 ' HG3' ' A' ' 14' ' ' GLU . 40.5 t -111.32 106.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.117 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.4 p -104.06 126.58 58.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.333 0.587 . . . . 0.0 110.959 -178.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.7 t30 -114.98 100.55 8.28 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.572 176.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.26 -0.42 52.28 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.8 -176.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.613 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 28.3 t70 -67.89 -39.15 83.7 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.967 175.047 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -104.8 -30.6 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.303 177.067 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.463 ' CA ' ' HB2' ' A' ' 7' ' ' ALA . . . 96.5 57.61 1.11 Allowed Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -173.059 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 50.8 t80 -138.28 124.69 20.59 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.8 p -117.35 107.21 21.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.972 0.891 . . . . 0.0 110.106 -178.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.516 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 31.2 tt0 -105.61 108.22 19.62 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.765 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 44.3 tp -84.68 124.83 31.93 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.93 176.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.816 HG13 HH21 ' A' ' 118' ' ' ARG . 23.6 mm -97.66 118.9 44.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--N 1.312 -1.033 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.31 -177.43 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.477 HG22 ' HB3' ' A' ' 130' ' ' LEU . 18.4 m . . . . . 0 N--CA 1.455 -0.199 0 CA-C-O 121.172 0.511 . . . . 0.0 111.037 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.566 ' HB3' ' CE2' ' A' ' 127' ' ' TYR . 53.6 mtmt -129.99 117.71 20.49 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.159 -178.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -115.25 164.71 13.83 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.626 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.44 135.96 53.53 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.874 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.848 ' HG ' HG21 ' A' ' 102' ' ' VAL . 6.4 p -121.74 168.7 11.52 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.96 0.41 . . . . 0.0 111.136 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.801 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 65.4 ttt180 -95.25 109.21 21.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.705 177.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.544 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -67.23 117.7 9.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.793 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.421 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 50.1 mm -101.51 -60.66 2.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.545 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.6 OUTLIER -96.69 174.44 6.82 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 172.014 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.409 ' H ' HG22 ' A' ' 9' ' ' THR . 52.2 mtt180 -126.53 167.9 14.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.942 0.401 . . . . 0.0 111.327 -176.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.82 159.96 9.38 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.711 -175.017 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.1 mtp85 -128.35 114.57 17.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.609 0.243 . . . . 0.0 110.506 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.452 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -139.21 146.27 40.3 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.056 0.455 . . . . 0.0 111.604 -175.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -133.45 148.25 51.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.334 174.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 172.34 -160.19 31.43 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.306 174.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.673 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.0 mt-10 -70.51 129.77 40.12 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 120.968 0.414 . . . . 0.0 110.843 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.489 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.01 117.3 21.49 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.006 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.504 HD13 HG21 ' A' ' 115' ' ' THR . 12.0 tp -105.71 115.4 30.18 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 176.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.413 ' HA ' ' CG2' ' A' ' 54' ' ' VAL . 11.3 p -100.4 110.8 28.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 122.049 0.928 . . . . 0.0 111.074 -172.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.47 HG21 HG13 ' A' ' 43' ' ' ILE . 10.1 m -106.0 88.92 2.92 Favored 'General case' 0 N--CA 1.44 -0.962 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.031 178.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.529 ' HG3' ' OE2' ' A' ' 22' ' ' GLU . 21.0 pttp -76.55 -1.06 25.52 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.119 176.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.529 ' OE2' ' HG3' ' A' ' 21' ' ' LYS . 8.5 mm-40 -92.43 160.68 14.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.382 178.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 9.7 p90 -112.67 104.99 13.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.336 0.588 . . . . 0.0 110.322 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.3 mp -100.52 130.24 50.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.993 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -71.54 121.76 19.28 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -72.97 87.44 1.33 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.248 0.547 . . . . 0.0 111.41 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -134.86 -68.08 0.54 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.128 176.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -142.1 177.4 21.5 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.653 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.19 -62.76 0.61 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 57.4 mt -69.67 124.43 25.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.641 0.258 . . . . 0.0 110.626 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -59.21 133.11 55.8 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.513 177.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.451 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 33.5 mmtp -67.09 -21.26 65.88 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.291 0.567 . . . . 0.0 110.098 177.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -100.01 -58.52 1.9 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.738 -172.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.481 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -87.96 -14.03 40.23 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.753 0.649 . . . . 0.0 112.753 -175.379 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.619 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 67.14 29.69 74.78 Favored Glycine 0 CA--C 1.518 0.261 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.598 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.481 HG12 ' HB ' ' A' ' 34' ' ' THR . 47.4 mm -103.84 133.02 48.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 3.9 p -80.32 105.33 9.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.607 0.717 . . . . 0.0 110.308 178.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -80.08 -19.64 46.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.094 -179.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -69.48 135.79 50.63 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.541 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 34.1 t70 -83.87 130.36 34.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.48 -175.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 22' ' ' GLU . 5.8 t 173.56 50.5 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 123.927 0.767 . . . . 0.0 109.23 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 72.42 -47.86 0.67 Allowed 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 123.509 0.724 . . . . 0.0 112.208 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.47 HG13 HG21 ' A' ' 20' ' ' THR . 33.4 mm -77.17 -10.4 13.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.063 0.459 . . . . 0.0 111.078 -176.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.541 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 61.8 tttp -52.89 124.08 13.19 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.976 -0.557 . . . . 0.0 111.663 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.56 -16.67 28.84 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.696 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -87.03 162.43 17.62 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.223 0.535 . . . . 0.0 112.019 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 33.2 p -102.43 150.42 23.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.623 179.242 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.438 HG21 HD11 ' A' ' 30' ' ' ILE . 2.8 t -108.68 -0.04 9.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.367 0.603 . . . . 0.0 110.159 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.32 91.62 0.55 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.833 -171.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.562 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 90.86 23.6 29.9 Favored Glycine 0 C--N 1.317 -0.525 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.21 172.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.673 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 97.5 mtt180 -111.09 169.32 8.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.867 0.365 . . . . 0.0 111.358 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.446 ' N ' HD12 ' A' ' 52' ' ' ILE . 2.3 mp -109.68 113.02 43.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 11.1 mp -102.54 132.45 48.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.962 0.41 . . . . 0.0 111.383 -174.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.497 HG12 ' HB ' ' A' ' 82' ' ' ILE . 10.5 m -109.41 130.95 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.672 176.278 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.567 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 92.7 m-85 -130.49 145.2 56.45 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.421 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.85 -33.63 33.11 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.254 1.97 . . . . 0.0 111.507 174.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.761 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.133 177.854 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.87 -42.17 61.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.715 0.293 . . . . 0.0 111.515 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.68 -32.47 72.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.922 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.536 ' HG ' ' HE2' ' A' ' 73' ' ' LYS . 56.8 tp -68.51 -42.83 77.99 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -59.13 -43.91 92.02 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.318 177.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.451 ' CD2' ' HA ' ' A' ' 32' ' ' LYS . 87.8 mt -64.99 -38.62 91.55 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.547 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.542 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -68.63 -38.68 80.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.388 -178.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.536 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 52.5 mttm -60.32 -34.27 73.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.212 0.529 . . . . 0.0 110.716 176.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.1 t30 -86.48 -22.65 26.31 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.819 -177.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.09 20.02 44.27 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.391 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.619 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 28.1 m -112.18 13.92 8.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.103 0.478 . . . . 0.0 110.811 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -96.0 160.12 30.73 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.562 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.74 141.24 71.34 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.187 1.925 . . . . 0.0 111.698 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.562 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 89.0 mttt -68.98 -28.11 66.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 110.52 176.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -160.86 147.85 15.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.695 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.521 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 63.9 mt -123.4 117.29 50.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 175.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.543 HG23 ' CG2' ' A' ' 104' ' ' VAL . 3.1 mm -110.57 115.22 49.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.567 ' ND2' ' HB2' ' A' ' 55' ' ' PHE . 15.6 m120 -111.54 153.36 26.35 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.272 -177.346 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.604 ' HA ' ' HB ' ' A' ' 104' ' ' VAL . 2.1 tmtp? -66.96 -45.63 77.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 174.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -142.98 120.88 11.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.238 177.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 3.7 m -86.29 150.11 24.58 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.303 -172.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -118.58 155.18 31.37 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 173.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.431 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.3 m -49.77 -51.38 39.65 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 123.31 0.644 . . . . 0.0 112.68 -173.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 61.8 mt -57.04 -41.18 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 121.078 0.466 . . . . 0.0 111.441 -176.276 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 20.4 mt -70.1 -43.31 79.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.384 -177.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.9 -43.98 86.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.539 -178.077 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 88' ' ' THR . 97.5 t -62.1 -43.03 97.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.992 0.425 . . . . 0.0 110.864 -179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.4 -43.38 99.14 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.58 -39.45 62.23 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -177.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.493 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -57.87 -46.54 84.71 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.78 -177.073 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.411 ' HE2' HG13 ' A' ' 92' ' ' VAL . 73.1 mtm -66.11 -30.73 71.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.923 0.392 . . . . 0.0 111.416 -177.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.542 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -88.46 2.2 53.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.576 -179.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 60.72 41.03 15.55 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.118 0.485 . . . . 0.0 110.884 -177.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.9 90.36 2.9 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.458 177.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.545 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.2 Cg_endo -48.33 100.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.603 2.868 . . . . 0.0 113.144 -173.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.521 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 3.4 tt -99.68 127.37 45.8 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.411 -0.813 . . . . 0.0 108.919 176.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.848 HG21 ' HG ' ' A' ' 5' ' ' CYS . 35.2 m -132.12 159.38 43.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.844 -178.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.801 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 25.3 tt0 -89.11 125.46 35.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.528 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.604 ' HB ' ' HA ' ' A' ' 84' ' ' LYS . 90.8 t -86.18 102.21 11.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.022 0.439 . . . . 0.0 110.602 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -78.99 -35.72 42.5 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.36 0.6 . . . . 0.0 109.639 176.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.607 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 17.7 t70 -89.92 101.87 14.57 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.496 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -70.17 -15.58 62.97 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.005 0.431 . . . . 0.0 111.038 -174.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.607 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 30.9 mmmt -62.1 -24.81 67.35 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.887 177.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -59.8 -38.42 81.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.819 177.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.459 ' HA ' HG11 ' A' ' 113' ' ' VAL . 62.1 m-85 -71.64 -22.7 61.65 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.883 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.76 -32.17 46.5 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.248 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -86.43 -30.85 21.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.062 -178.181 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.459 HG11 ' HA ' ' A' ' 110' ' ' PHE . 12.5 p -74.87 127.24 36.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.435 0.636 . . . . 0.0 111.825 -176.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.508 ' HE2' ' HA ' ' A' ' 114' ' ' LYS . 8.9 mmpt? -130.18 161.49 31.01 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.164 175.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.504 HG21 HD13 ' A' ' 18' ' ' LEU . 91.1 m -67.41 125.01 24.77 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.809 0.338 . . . . 0.0 110.89 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 103.79 -1.18 45.16 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.277 176.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -85.88 175.26 8.75 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.487 HH21 HD11 ' A' ' 131' ' ' ILE . 18.1 ttp85 -117.18 120.74 39.22 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.371 0.532 . . . . 0.0 110.855 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.489 HG23 ' HB2' ' A' ' 17' ' ' ALA . 76.6 t -118.89 126.65 75.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.695 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.02 110.14 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.0 p -100.4 118.08 46.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.665 0.745 . . . . 0.0 111.421 -176.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -100.73 94.03 5.87 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.004 175.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.8 1.63 42.05 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 122.03 0.919 . . . . 0.0 108.835 173.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -84.49 -1.83 56.34 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.041 -1.436 . . . . 0.0 109.531 175.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.14 -43.17 0.18 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.632 -176.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.41 52.23 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -175.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . 0.566 ' CE2' ' HB3' ' A' ' 2' ' ' LYS . 12.3 t80 -154.76 140.33 17.91 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -170.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 16.7 m -124.7 127.04 72.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.285 0.564 . . . . 0.0 111.351 -177.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -101.88 111.7 24.06 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.958 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.477 ' HB3' HG22 ' A' ' 1' ' ' VAL . 9.6 tt -108.77 129.68 55.38 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.413 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.487 HD11 HH21 ' A' ' 118' ' ' ARG . 3.8 mp -121.71 111.45 31.04 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.803 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 C--N 1.313 -1.003 0 O-C-N 124.485 1.116 . . . . 0.0 110.48 -175.204 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.563 0.697 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.44 ' HE3' ' HG3' ' A' ' 129' ' ' GLU . 55.9 mtpt -133.58 120.54 20.87 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.411 -175.189 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.401 ' HB2' ' CG2' ' A' ' 128' ' ' VAL . 92.4 m-85 -97.85 150.02 21.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.425 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -101.14 127.72 47.57 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.629 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.727 ' HG ' HG13 ' A' ' 128' ' ' VAL . 4.3 p -120.59 169.9 9.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.308 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.444 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 24.4 tpt180 -94.05 120.59 34.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.552 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.558 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -70.44 119.73 15.04 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.696 -176.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.2 mm -101.95 -47.47 11.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 174.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.49 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -111.95 -165.73 1.02 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.455 176.966 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 54.8 mtt180 -132.76 170.1 15.75 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 176.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 113.95 153.75 11.03 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.018 -178.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.537 ' HG3' ' HA ' ' A' ' 122' ' ' ASN . 1.0 OUTLIER -123.34 126.29 46.58 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 177.834 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.531 ' HB3' ' HB3' ' A' ' 79' ' ' LYS . . . -133.28 132.07 40.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.035 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.36 127.76 55.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.399 -178.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -167.98 -179.39 40.51 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.086 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.66 133.32 42.13 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 177.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.17 120.48 24.34 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.891 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.493 ' HA ' HG23 ' A' ' 115' ' ' THR . 8.0 tt -107.76 113.83 27.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.2 t -104.04 111.1 32.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.204 0.526 . . . . 0.0 111.094 -175.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.405 ' HB ' HD11 ' A' ' 43' ' ' ILE . 1.0 OUTLIER -135.58 130.7 34.88 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 174.19 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 21.5 mtpp -92.29 -83.2 0.3 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.24 -172.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 44.84 -163.8 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.58 0.705 . . . . 0.0 112.721 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -147.1 100.98 3.36 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 168.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.438 HD12 ' SG ' ' A' ' 41' ' ' CYS . 58.7 mt -112.26 132.59 60.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.914 0.387 . . . . 0.0 111.369 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.8 p -76.46 124.68 27.94 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 171.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -79.91 39.8 0.44 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.088 0.471 . . . . 0.0 111.711 -174.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.37 -30.61 42.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 173.435 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -157.41 -105.4 0.22 Allowed Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 114.816 -1.084 . . . . 0.0 111.096 178.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.85 -41.48 3.05 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.388 174.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 52.3 mt -115.18 142.12 29.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.847 0.356 . . . . 0.0 110.708 -176.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -73.78 136.3 43.59 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.766 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -83.06 -3.3 57.13 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -173.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -112.12 -52.84 2.76 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 122.169 -0.332 . . . . 0.0 111.297 -176.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.1 m -101.28 -15.91 17.13 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.645 -175.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.598 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.95 21.46 68.14 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.503 -0.855 . . . . 0.0 112.402 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 42.9 mm -89.12 132.33 34.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.4 m -64.46 114.91 2.52 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.45 0.643 . . . . 0.0 110.557 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -78.55 -11.16 59.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.89 177.157 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -94.84 149.88 20.78 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.141 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -79.97 135.16 36.33 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.106 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.438 ' SG ' HD12 ' A' ' 24' ' ' ILE . 56.6 m -148.98 -170.77 3.71 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -176.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -60.68 -52.32 65.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.835 0.35 . . . . 0.0 110.088 175.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.405 HD11 ' HB ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -116.3 51.42 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.385 0.612 . . . . 0.0 111.145 -179.738 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.435 ' HB2' ' H ' ' A' ' 41' ' ' CYS . 13.0 tmtt? -60.66 127.83 33.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.563 176.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.74 -5.69 12.69 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.136 -178.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -84.49 148.17 26.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.817 0.341 . . . . 0.0 111.099 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.6 m -93.0 113.28 25.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.513 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.598 ' HA ' ' HD3' ' A' ' 51' ' ' ARG . 26.5 m -82.16 19.97 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.79 0.329 . . . . 0.0 111.862 -175.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.14 92.1 5.62 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.174 0.511 . . . . 0.0 111.568 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.85 19.65 21.37 Favored Glycine 0 C--N 1.32 -0.337 0 C-N-CA 120.688 -0.767 . . . . 0.0 113.47 171.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.598 ' HD3' ' HA ' ' A' ' 48' ' ' VAL . 7.2 ptm180 -119.96 -179.28 3.87 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 177.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.9 mm -104.06 135.04 43.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.566 ' HB3' HG12 ' A' ' 81' ' ' ILE . 56.1 tp -106.84 125.85 51.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.127 0.489 . . . . 0.0 110.837 -179.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -107.47 112.06 38.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.53 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 19.4 t80 -132.89 142.12 43.55 Favored Pre-proline 0 C--N 1.324 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -173.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -69.98 -56.34 0.14 Allowed 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.168 1.912 . . . . 0.0 112.867 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.472 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.42 -179.163 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.0 p90 . . . . . 0 N--CA 1.461 0.106 0 CA-C-O 120.597 0.237 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.426 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 48.0 t -56.15 -56.86 10.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.306 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 92.6 mt -59.62 -40.87 88.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 -177.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.535 ' O ' ' HG3' ' A' ' 73' ' ' LYS . 62.5 tp -66.63 -51.22 58.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.725 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -56.3 -44.95 80.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.445 ' CB ' ' HB3' ' A' ' 77' ' ' ALA . 90.3 mt -67.05 -36.36 81.87 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.154 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.63 ' HG3' HD12 ' A' ' 99' ' ' ILE . 0.0 OUTLIER -76.24 -28.4 57.14 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.813 -176.41 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.535 ' HG3' ' O ' ' A' ' 69' ' ' LEU . 8.2 mtpm? -67.97 -35.18 77.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.979 0.418 . . . . 0.0 109.902 176.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -78.69 -25.24 44.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.007 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.89 21.9 32.17 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.413 178.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.598 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.7 m -115.12 12.28 7.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.895 0.378 . . . . 0.0 111.034 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.445 ' HB3' ' CB ' ' A' ' 71' ' ' LEU . . . -97.29 155.33 37.5 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.811 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.543 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 22.3 Cg_exo -64.66 146.34 88.57 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.306 2.004 . . . . 0.0 111.154 174.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 13' ' ' ALA . 93.4 mttt -62.25 -35.81 80.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.878 0.371 . . . . 0.0 111.035 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.468 ' HA ' HG21 ' A' ' 99' ' ' ILE . . . -161.48 158.34 26.42 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.64 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.566 HG12 ' HB3' ' A' ' 53' ' ' LEU . 54.5 mt -131.26 124.11 54.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.591 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.671 HG22 HG23 ' A' ' 102' ' ' VAL . 5.2 mm -103.75 116.77 48.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.53 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 22.2 m120 -114.78 156.35 25.04 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.313 0.578 . . . . 0.0 111.742 -175.428 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.489 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 82.0 tttt -84.12 -38.33 20.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.415 177.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -123.81 108.25 12.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.718 174.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 19.7 p -78.55 108.85 12.23 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.194 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.58 ' HB3' HG12 ' A' ' 90' ' ' ILE . 0.4 OUTLIER -72.69 135.39 45.38 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.011 -0.736 . . . . 0.0 109.011 177.652 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -56.03 -42.99 77.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.835 -174.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.4 mt -69.19 -32.58 54.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.879 -177.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.58 HG12 ' HB3' ' A' ' 87' ' ' GLU . 49.4 mm -67.23 -39.98 84.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.043 177.237 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.19 -43.69 92.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.13 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.78 -45.16 95.0 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.546 178.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.572 ' HA2' ' HE2' ' A' ' 96' ' ' MET . . . -67.91 -43.47 82.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.71 -178.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -61.13 -38.07 85.07 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.953 0.406 . . . . 0.0 111.004 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.24 -32.31 73.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.546 -179.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.572 ' HE2' ' HA2' ' A' ' 93' ' ' GLY . 67.7 mtm -77.38 -40.46 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.71 0.291 . . . . 0.0 111.406 -177.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 69' ' ' LEU . . . -84.91 -0.94 55.87 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.811 -176.248 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 60.11 53.95 4.32 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 122.011 0.91 . . . . 0.0 109.78 -173.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.63 HD12 ' HG3' ' A' ' 72' ' ' ARG . 44.3 mm -110.1 88.26 6.84 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.744 175.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.49 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 5.4 Cg_endo -47.53 98.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.323 2.682 . . . . 0.0 112.753 -175.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 64.0 tp -92.87 130.97 38.29 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.27 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.671 HG23 HG22 ' A' ' 82' ' ' ILE . 14.1 m -135.41 148.78 28.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.289 177.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.449 ' CD ' ' HE ' ' A' ' 105' ' ' ARG . 39.5 tt0 -100.71 121.69 42.08 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.654 -177.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.46 HG11 ' HB3' ' A' ' 5' ' ' CYS . 14.2 m -108.92 117.62 54.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.443 0.64 . . . . 0.0 111.132 176.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . 0.449 ' HE ' ' CD ' ' A' ' 103' ' ' GLU . 12.8 mmt180 -93.46 4.5 53.86 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.852 176.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -95.67 123.27 39.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.211 -171.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -72.16 -32.51 66.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.018 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -65.99 -30.09 70.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.15 -176.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.418 ' O ' HG12 ' A' ' 113' ' ' VAL . 73.6 t80 -54.77 -50.73 67.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.075 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.489 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 89.5 m-85 -69.0 -22.64 64.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.107 0.479 . . . . 0.0 111.168 -175.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -85.57 -34.05 21.57 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.473 -179.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.91 -33.5 34.14 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.485 -178.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.418 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.6 p -78.99 125.08 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.28 0.562 . . . . 0.0 110.679 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -118.16 153.63 33.51 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.702 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 18' ' ' LEU . 24.5 m -68.2 94.35 0.51 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.071 0.463 . . . . 0.0 110.214 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.55 -9.71 2.91 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.029 -176.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . 0.473 ' HB3' HD11 ' A' ' 130' ' ' LEU . 82.9 m-20 -80.85 159.39 25.07 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 176.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -103.57 113.9 27.76 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.894 0.378 . . . . 0.0 110.324 176.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 17' ' ' ALA . 6.5 p -119.92 120.71 64.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.151 0.5 . . . . 0.0 110.18 178.207 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.455 ' CG1' ' HB3' ' A' ' 129' ' ' GLU . 7.7 p -98.63 115.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.556 0.694 . . . . 0.0 109.343 175.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 7.5 p -78.57 128.78 38.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.65 -178.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . 0.537 ' HA ' ' HG3' ' A' ' 12' ' ' ARG . 49.9 t-20 -115.07 94.51 4.77 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.6 -10.37 51.68 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.264 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -75.42 -40.28 57.89 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.249 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -102.32 -14.42 16.94 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.387 -179.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.7 65.67 1.81 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.58 -178.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -152.6 144.61 23.75 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.772 0.32 . . . . 0.0 110.613 -173.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.727 HG13 ' HG ' ' A' ' 5' ' ' CYS . 4.1 m -116.7 106.59 20.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.372 0.606 . . . . 0.0 109.708 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.455 ' HB3' ' CG1' ' A' ' 120' ' ' VAL . 29.8 tt0 -93.11 108.45 20.04 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.043 -174.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.473 HD11 ' HB3' ' A' ' 117' ' ' ASP . 38.8 tp -97.46 129.69 44.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.136 -175.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 13.2 mm -124.8 120.2 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.867 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 . . . . . 0 C--N 1.313 -1.001 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.707 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.457 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 4.6 m . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.433 0.635 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.51 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 19.5 mtpp -117.64 112.84 21.06 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.979 -176.739 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.457 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 96.5 m-85 -112.32 156.03 23.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.311 0.577 . . . . 0.0 111.728 -172.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.57 133.03 48.24 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.068 175.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.4 m -119.57 -179.45 3.88 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -177.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.894 ' HA ' ' HE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -101.36 126.02 48.07 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 120.241 -0.584 . . . . 0.0 110.083 174.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.527 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -80.13 128.13 33.14 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.731 -174.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.449 ' HB ' HD12 ' A' ' 101' ' ' LEU . 49.6 mm -112.5 -49.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 174.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.574 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -100.23 172.06 7.4 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 171.433 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.7 mtp180 -127.17 177.24 6.8 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.781 -178.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.78 -158.84 20.26 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -172.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ptt180 -141.87 160.6 39.87 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 117.107 0.453 . . . . 0.0 110.477 175.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.525 ' CB ' ' HB1' ' A' ' 80' ' ' ALA . . . -145.79 159.58 42.99 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.324 -178.216 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -153.21 143.04 22.06 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.063 -177.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.12 175.35 39.56 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.883 -1.151 . . . . 0.0 112.757 175.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -73.41 136.42 44.3 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.502 ' HB3' HG22 ' A' ' 119' ' ' VAL . . . -80.79 128.05 33.21 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.211 0.529 . . . . 0.0 111.841 -175.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.468 HD11 HG22 ' A' ' 115' ' ' THR . 5.2 tp -116.12 110.44 18.86 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.389 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.61 134.84 48.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.232 0.539 . . . . 0.0 111.661 -171.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.501 HG21 ' HB3' ' A' ' 55' ' ' PHE . 2.1 t -146.3 117.62 7.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.245 174.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -82.65 -8.92 59.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.471 0.653 . . . . 0.0 109.293 176.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.407 ' OE1' ' HB3' ' A' ' 41' ' ' CYS . 1.5 tm-20 -81.19 146.13 30.65 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 174.223 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -86.07 158.9 19.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.558 -171.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.497 HD11 ' HE2' ' A' ' 44' ' ' LYS . 12.5 tt -150.24 127.51 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.679 0.752 . . . . 0.0 111.032 177.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -76.28 135.09 39.63 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.845 -177.211 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -73.06 -20.05 61.05 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.106 -175.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -65.33 -67.07 0.47 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.747 0.308 . . . . 0.0 110.501 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -114.26 34.9 4.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.663 -0.78 . . . . 0.0 111.509 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -98.34 -19.99 21.56 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.864 -0.684 . . . . 0.0 113.06 -175.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 53.6 mt -129.2 133.73 65.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 117.374 0.587 . . . . 0.0 110.75 -177.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.641 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.3 t70 -69.5 128.61 37.11 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.882 176.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -79.02 -7.13 57.84 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.558 -174.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -101.61 -57.67 2.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.994 0.426 . . . . 0.0 110.816 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -101.96 -8.3 21.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -172.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.95 21.88 78.93 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.643 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 37.7 mm -84.49 128.01 39.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 177.18 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 6.3 m -62.27 120.27 8.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.153 0.501 . . . . 0.0 110.545 175.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.641 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 21.2 mmmt -88.44 -35.21 17.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.808 -175.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.555 ' O ' ' HD3' ' A' ' 44' ' ' LYS . 31.9 tt0 -77.8 107.7 10.5 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.681 ' HA ' ' HD3' ' A' ' 44' ' ' LYS . 13.2 t70 -110.52 144.61 39.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.269 0.556 . . . . 0.0 112.354 -172.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.621 ' SG ' ' HD2' ' A' ' 44' ' ' LYS . 12.4 p -108.93 -51.08 2.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.476 173.134 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.417 ' HG3' HG22 ' A' ' 43' ' ' ILE . 12.5 pt-20 -172.36 -29.92 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.003 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.417 HG22 ' HG3' ' A' ' 42' ' ' GLU . 18.5 pt -114.86 10.95 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.741 -178.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.681 ' HD3' ' HA ' ' A' ' 40' ' ' ASP . 24.2 mttt -92.59 146.96 23.26 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.176 0.512 . . . . 0.0 110.575 -176.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.01 0.74 1.43 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.724 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 -87.58 158.39 18.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.88 0.371 . . . . 0.0 111.113 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.506 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 35.5 t -89.05 151.84 22.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.882 176.013 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 19.6 m -104.8 10.65 8.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.835 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.84 87.93 0.37 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.918 -174.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.61 -2.67 42.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.284 -0.871 . . . . 0.0 113.536 171.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.506 ' HD2' ' O ' ' A' ' 47' ' ' SER . 0.7 OUTLIER -109.13 -172.28 2.01 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 117.199 0.499 . . . . 0.0 110.856 -178.361 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.489 HG12 ' HB3' ' A' ' 80' ' ' ALA . 72.4 mt -118.44 120.61 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.327 -177.542 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.411 HD11 ' O ' ' A' ' 18' ' ' LEU . 47.4 tp -103.5 121.3 42.56 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.53 106.26 20.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.073 0.463 . . . . 0.0 110.658 -178.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.501 ' HB3' HG21 ' A' ' 20' ' ' THR . 23.6 p90 -137.25 151.79 72.26 Favored Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.851 176.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_exo -62.51 -41.52 32.13 Favored 'Trans proline' 0 CA--C 1.529 0.245 0 C-N-CA 122.458 2.105 . . . . 0.0 112.197 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.443 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.032 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.555 ' CD2' HG23 ' A' ' 67' ' ' VAL . 38.6 p90 . . . . . 0 N--CA 1.454 -0.256 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.555 HG23 ' CD2' ' A' ' 66' ' ' TYR . 76.1 t 72.99 -60.88 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 122.846 0.459 . . . . 0.0 110.467 -174.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 8.3 mp -63.41 -39.42 94.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.1 0.476 . . . . 0.0 109.846 176.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.1 tp -62.26 -40.19 95.37 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.123 175.343 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.33 -38.89 92.91 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.293 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 93.7 mt -58.13 -41.2 83.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.555 177.675 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.503 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -67.28 -34.74 78.05 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.564 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -67.12 -25.66 66.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.288 -178.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -100.27 -17.2 17.43 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.126 0.488 . . . . 0.0 110.299 177.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.96 0.17 58.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.942 176.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.5 19.03 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.54 -176.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -80.84 148.69 65.57 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.351 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.426 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 11.7 Cg_exo -68.77 154.2 71.63 Favored 'Trans proline' 0 N--CA 1.463 -0.266 0 C-N-CA 122.576 2.184 . . . . 0.0 110.96 175.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.426 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 45.1 mttp -85.06 -32.99 22.57 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.199 179.425 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.525 ' HB1' ' CB ' ' A' ' 13' ' ' ALA . . . -151.42 143.96 24.25 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.796 0.331 . . . . 0.0 111.407 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 40.3 mm -129.41 124.78 60.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 174.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.568 HG21 HG21 ' A' ' 102' ' ' VAL . 3.7 mm -118.05 116.46 51.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -120.03 165.51 14.61 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -175.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 0.0 OUTLIER -76.54 -28.81 56.46 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.669 0.747 . . . . 0.0 109.956 177.568 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.7 tttm -138.91 130.51 27.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.629 169.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 25.4 p -90.4 155.94 18.58 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 175.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -123.06 146.09 47.98 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.709 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.2 m -57.95 -50.4 73.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.231 -173.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 59.4 mt -58.79 -42.71 86.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.162 0.506 . . . . 0.0 110.663 -178.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 57.4 mt -70.11 -41.35 79.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.511 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.5 93.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.335 -179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 94.2 t -61.44 -45.48 98.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.694 178.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -66.63 -41.59 93.86 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.406 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.32 -41.88 93.53 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.69 0.281 . . . . 0.0 111.269 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.63 -29.6 69.35 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.021 0.438 . . . . 0.0 110.451 176.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 76.8 mtp -83.33 -30.31 27.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.185 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.503 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -96.04 16.68 17.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.868 -177.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.435 ' OE1' ' HD2' ' A' ' 72' ' ' ARG . 3.5 mp0 55.03 41.2 32.02 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.121 0.486 . . . . 0.0 111.297 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.415 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 48.7 mt -115.47 86.06 14.42 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.754 176.604 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.574 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 30.0 Cg_endo -65.58 109.89 1.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.309 2.006 . . . . 0.0 112.167 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.449 HD12 ' HB ' ' A' ' 8' ' ' ILE . 3.1 pp -110.31 151.27 27.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.202 0.525 . . . . 0.0 111.26 179.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.568 HG21 HG21 ' A' ' 82' ' ' ILE . 31.3 m -135.75 162.28 37.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.691 177.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -108.13 126.54 52.89 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.82 0.343 . . . . 0.0 110.98 -175.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 8.3 m -109.24 123.52 65.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.451 176.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -101.51 12.35 37.45 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.141 0.496 . . . . 0.0 110.201 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.481 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 28.6 t70 -107.62 122.73 47.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.022 -177.286 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -71.17 -29.07 64.73 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.629 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.597 ' HB2' ' HZ2' ' A' ' 108' ' ' LYS . 10.2 mtmp? -62.64 -28.72 70.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.074 -177.069 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -60.12 -48.82 80.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.029 178.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -65.79 -26.96 67.93 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.341 0.591 . . . . 0.0 110.835 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -79.73 -27.23 40.61 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.842 -179.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.69 -39.95 12.15 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.835 -177.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.503 ' HA ' HD23 ' A' ' 130' ' ' LEU . 13.6 p -69.3 134.96 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.034 0.445 . . . . 0.0 111.176 -177.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -121.32 151.59 39.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.794 -177.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.468 HG22 HD11 ' A' ' 18' ' ' LEU . 71.4 m -71.91 124.43 24.85 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.112 175.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.04 9.42 54.01 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.879 -177.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -97.97 177.14 5.53 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.476 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.6 OUTLIER -116.07 113.79 23.66 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.363 0.602 . . . . 0.0 111.613 -172.914 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.567 HG23 HD12 ' A' ' 130' ' ' LEU . 45.3 t -113.2 127.96 70.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.68 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.6 t -113.15 117.4 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 172.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 43.0 t -108.98 123.96 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.758 -174.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -106.33 94.98 5.44 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 171.015 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.02 -19.73 62.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.947 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -62.29 -37.73 86.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.098 0.475 . . . . 0.0 109.927 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -87.37 -36.87 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.041 174.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.431 ' HA2' HG12 ' A' ' 102' ' ' VAL . . . 87.15 54.15 2.65 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -167.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 72.8 t80 -137.14 134.86 36.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.383 -169.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 28.1 m -120.12 130.69 74.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.061 0.458 . . . . 0.0 110.842 -179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.51 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 38.8 tt0 -108.27 107.41 18.0 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 175.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.567 HD12 HG23 ' A' ' 119' ' ' VAL . 60.2 tp -104.76 107.62 18.67 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.928 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.476 HG12 ' NH2' ' A' ' 118' ' ' ARG . 34.5 mm -101.44 110.98 29.67 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 . . . . . 0 C--N 1.313 -1.02 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.584 -177.688 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.988 0.423 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.455 ' HG2' ' HB3' ' A' ' 129' ' ' GLU . 54.3 mttm -93.42 133.45 36.68 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.212 174.244 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.441 ' CD2' ' HD1' ' A' ' 109' ' ' PHE . 93.5 m-85 -122.13 157.97 30.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.41 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.46 117.13 32.74 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.02 -178.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.6 p -119.6 172.9 7.33 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.16 177.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -104.97 131.95 51.83 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 177.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.511 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.49 134.02 34.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.092 -173.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.476 HD12 ' HG3' ' A' ' 103' ' ' GLU . 2.5 mp -110.58 -51.41 6.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 172.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -94.36 178.01 5.76 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -122.72 174.74 6.92 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 97.87 -163.44 21.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.687 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.9 mtt180 -120.59 148.46 43.84 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 178.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.693 ' HB1' ' HB1' ' A' ' 80' ' ' ALA . . . -129.15 114.68 16.62 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 178.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.498 ' HB2' HG23 ' A' ' 120' ' ' VAL . 15.7 tm-20 -133.61 122.01 22.88 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.657 -173.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.03 -173.98 44.74 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.344 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 31.1 mp0 -71.39 138.23 48.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -95.24 123.12 38.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.885 0.374 . . . . 0.0 110.915 178.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.1 mp -104.84 127.03 52.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.113 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.761 HG11 ' HB ' ' A' ' 115' ' ' THR . 13.4 p -102.04 137.67 29.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.852 -173.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.4 m -150.14 107.86 3.68 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 175.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -96.72 65.26 2.17 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.03 -177.457 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 mm-40 -142.74 161.74 37.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.3 176.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -88.38 81.75 7.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.909 0.385 . . . . 0.0 111.6 -177.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.446 HG21 ' H ' ' A' ' 26' ' ' PHE . 4.3 mp -108.17 112.23 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.694 0 CA-C-O 121.733 0.778 . . . . 0.0 109.749 173.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.3 m -87.38 36.36 0.74 Allowed 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.009 -177.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.446 ' H ' HG21 ' A' ' 24' ' ' ILE . 56.8 m-85 63.88 -81.89 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.223 0.609 . . . . 0.0 111.106 -176.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.2 mt 58.41 -85.4 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 O-C-N 123.896 0.748 . . . . 0.0 111.598 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -158.17 24.59 0.39 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.84 -22.29 79.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.772 -176.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 39.8 mt -92.94 127.61 44.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.961 0.41 . . . . 0.0 110.338 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.44 ' HB2' ' CG ' ' A' ' 38' ' ' LYS . 16.2 t70 -67.27 119.03 11.47 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.957 176.393 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 10.2 ptpp? -83.22 0.6 44.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.645 0.259 . . . . 0.0 111.355 -173.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -85.29 -46.81 10.65 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.899 0.38 . . . . 0.0 110.544 177.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.4 p -125.56 -5.47 7.05 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.991 0.738 . . . . 0.0 112.991 -174.105 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.99 30.86 55.08 Favored Glycine 0 C--O 1.236 0.233 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.41 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 40.9 mm -99.66 123.84 52.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.608 HG23 ' HE3' ' A' ' 44' ' ' LYS . 15.3 t -71.2 104.53 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.244 176.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.44 ' CG ' ' HB2' ' A' ' 31' ' ' ASP . 6.8 mmmm -78.62 -19.99 51.41 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.523 -174.016 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -90.56 110.22 21.36 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.756 178.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.464 ' HA ' ' HB3' ' A' ' 44' ' ' LYS . 19.3 t70 -97.81 155.88 16.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.108 0.48 . . . . 0.0 110.966 -178.067 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 18.7 p -141.32 -37.93 0.42 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.322 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -141.02 -62.47 0.48 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.186 -177.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.433 HD11 HG21 ' A' ' 115' ' ' THR . 30.2 pt -133.17 17.52 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.932 -172.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.608 ' HE3' HG23 ' A' ' 37' ' ' VAL . 17.4 tptt -80.97 -173.4 4.24 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.13 0.491 . . . . 0.0 111.565 -168.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.36 -0.44 55.8 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -173.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -94.28 179.01 5.44 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.963 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 9.5 m -92.41 132.13 37.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.203 -175.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.5 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 28.7 m -106.23 -0.27 10.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.113 0.482 . . . . 0.0 110.003 172.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.86 96.54 0.19 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.546 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.513 ' C ' ' HD2' ' A' ' 51' ' ' ARG . . . 86.12 20.98 54.05 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.266 -1.333 . . . . 0.0 112.517 177.464 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.513 ' HD2' ' C ' ' A' ' 50' ' ' GLY . 4.0 mpt_? -119.01 166.15 13.23 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.719 0.295 . . . . 0.0 110.588 178.332 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.746 HG12 ' HB3' ' A' ' 80' ' ' ALA . 63.3 mt -93.63 122.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.299 -0.409 . . . . 0.0 109.943 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.485 HD12 ' HZ1' ' A' ' 44' ' ' LYS . 17.0 tp -99.33 128.0 45.4 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.572 -175.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.9 120.17 60.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.118 0.485 . . . . 0.0 111.215 -177.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . 0.426 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.9 m-85 -133.37 144.49 52.57 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 176.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 14.0 Cg_exo -69.72 -54.21 0.23 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.55 2.167 . . . . 0.0 111.074 175.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.624 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.434 178.577 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 26.4 p90 . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.277 0.56 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.608 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 9.6 p -71.23 -29.79 37.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.401 -175.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.4 mp -66.9 -41.68 86.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.78 -178.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.27 -36.0 80.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 177.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -58.94 -48.33 81.88 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.332 175.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.608 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 81.2 mt -58.4 -40.32 82.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 178.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.51 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -66.78 -42.78 85.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.082 -178.616 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -64.79 -27.97 69.25 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.682 0.277 . . . . 0.0 111.374 -179.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -90.47 -17.8 26.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.19 0.519 . . . . 0.0 110.082 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 83.58 26.8 41.21 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.349 178.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.87 11.6 7.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.152 0.501 . . . . 0.0 110.537 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.411 ' HB3' HD13 ' A' ' 99' ' ' ILE . . . -81.93 158.38 67.68 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.138 -179.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 24.3 Cg_exo -62.16 148.55 93.0 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.192 1.928 . . . . 0.0 110.99 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.495 ' HD3' ' O ' ' A' ' 14' ' ' GLU . 75.5 tttt -84.96 -21.63 29.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.511 . . . . 0.0 109.635 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.746 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -166.49 163.55 17.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.227 175.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . 0.442 HG22 ' HB3' ' A' ' 101' ' ' LEU . 7.9 tt -146.84 114.71 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.288 0.566 . . . . 0.0 110.065 174.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.616 HD11 HG22 ' A' ' 102' ' ' VAL . 7.6 mm -108.55 124.31 64.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.442 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.426 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.3 m120 -120.93 160.89 22.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.297 -173.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -77.11 -37.45 54.21 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 171.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -154.71 154.71 33.32 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 114.711 -1.132 . . . . 0.0 108.57 168.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -143.52 172.63 12.53 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.78 -178.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -107.98 168.19 9.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.597 -177.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.0 m -58.85 -52.15 66.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -173.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 pt -63.5 -30.08 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 C-N-CA 120.638 -0.425 . . . . 0.0 112.067 -174.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.1 mm -64.93 -45.41 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.498 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -64.47 -48.02 76.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.051 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 86.9 t -61.81 -46.51 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.18 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.13 -43.87 98.03 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.567 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.557 ' HB3' ' HB ' ' A' ' 99' ' ' ILE . . . -72.21 -35.93 69.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.437 0.161 . . . . 0.0 111.319 -178.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.07 -31.26 69.83 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.139 0.495 . . . . 0.0 110.73 178.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.8 mtm -82.68 -39.88 21.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.625 178.24 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.51 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -80.68 6.84 11.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.024 -178.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.472 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 47.9 mt-10 64.23 35.47 10.05 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.263 0.554 . . . . 0.0 110.971 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.557 ' HB ' ' HB3' ' A' ' 94' ' ' ALA . 54.2 mt -109.91 88.61 6.97 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.101 178.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.557 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 32.8 Cg_exo -58.53 118.04 4.86 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.67 2.247 . . . . 0.0 113.018 -176.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.556 HD23 ' HB1' ' A' ' 94' ' ' ALA . 1.7 pt? -117.34 141.64 48.07 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.251 175.14 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.616 HG22 HD11 ' A' ' 82' ' ' ILE . 31.3 m -138.04 161.56 32.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.928 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . 0.476 ' HG3' HD12 ' A' ' 8' ' ' ILE . 53.2 mt-10 -97.92 116.8 30.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.686 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.481 HG12 HG22 ' A' ' 82' ' ' ILE . 7.2 p -115.23 107.38 22.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.764 0.792 . . . . 0.0 109.187 172.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 8.3 ttm-85 -99.04 14.65 28.46 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.048 -175.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -89.18 120.01 30.18 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.044 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -67.39 -34.71 77.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.391 -175.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 108' ' ' LYS . 32.8 mmtp -69.49 -23.0 63.57 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.32 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.441 ' HD1' ' CD2' ' A' ' 3' ' ' PHE . 87.6 t80 -62.19 -51.04 69.39 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 172.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.404 ' CZ ' HG11 ' A' ' 104' ' ' VAL . 87.0 m-85 -69.7 -25.96 64.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.842 -178.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.41 ' HB2' ' HA ' ' A' ' 108' ' ' LYS . 37.1 mm-40 -74.92 -29.59 61.01 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.009 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.79 -34.03 14.74 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -176.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.407 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.7 p -85.15 138.6 18.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.173 0.511 . . . . 0.0 111.375 -175.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -124.48 167.07 14.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.972 173.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.761 ' HB ' HG11 ' A' ' 19' ' ' VAL . 9.8 t -67.55 107.58 2.55 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.725 0.774 . . . . 0.0 110.657 -178.371 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.15 -24.39 4.23 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.554 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -63.72 151.12 42.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.868 0.334 . . . . 0.0 110.28 179.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.668 HH21 HG13 ' A' ' 131' ' ' ILE . 1.1 tmm_? -96.68 120.37 36.89 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -175.04 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.443 HG23 HD12 ' A' ' 130' ' ' LEU . 46.3 t -120.68 141.2 42.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.757 -175.047 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . 0.498 HG23 ' HB2' ' A' ' 14' ' ' GLU . 9.9 p -124.38 121.1 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 121.763 0.792 . . . . 0.0 109.464 169.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.51 ' HB ' ' HB2' ' A' ' 13' ' ' ALA . 40.2 t -106.54 127.35 62.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.472 -178.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.2 t-20 -93.44 97.48 10.58 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.38 -13.83 51.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.363 -175.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -68.92 -45.11 71.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.158 0.504 . . . . 0.0 109.744 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -93.85 -43.26 8.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.086 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.38 69.22 0.82 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -172.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.7 t80 -161.31 157.62 25.74 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 -172.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -152.99 138.64 11.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.021 -179.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.455 ' HB3' ' HG2' ' A' ' 2' ' ' LYS . 2.2 pm0 -118.75 119.99 36.05 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.356 0.598 . . . . 0.0 110.458 174.142 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.443 HD12 HG23 ' A' ' 119' ' ' VAL . 54.7 tp -84.01 130.54 34.88 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.69 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.668 HG13 HH21 ' A' ' 118' ' ' ARG . 37.1 mm -101.27 120.25 50.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 CA-C-O 121.412 0.625 . . . . 0.0 109.6 177.236 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.198 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.195 -178.129 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -131.06 113.22 13.66 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.513 178.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -93.3 152.85 18.9 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.949 0.404 . . . . 0.0 111.181 -175.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.51 124.39 47.97 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.669 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 56.9 m -119.41 174.0 6.63 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.914 0.388 . . . . 0.0 110.82 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 40.7 ttt180 -92.83 111.7 23.4 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -90.84 137.83 32.06 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.569 -171.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.6 HD13 HD12 ' A' ' 101' ' ' LEU . 4.3 mp -103.87 -52.2 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 48.7 p -102.95 176.42 5.16 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.771 176.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 61.0 mtt180 -122.37 -175.35 3.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.661 0.267 . . . . 0.0 111.076 -176.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.15 171.83 27.35 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -175.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.26 139.5 35.56 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 117.282 0.541 . . . . 0.0 110.52 -178.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.576 ' HB2' ' HB3' ' A' ' 79' ' ' LYS . . . -135.46 145.49 47.23 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.076 0.465 . . . . 0.0 111.65 -174.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.21 123.05 38.73 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.083 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.89 176.4 41.93 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 119.68 -1.248 . . . . 0.0 112.528 179.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.66 137.65 39.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 177.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.562 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.46 124.81 29.24 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.814 -176.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.28 121.23 39.16 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.496 HG11 ' OG1' ' A' ' 115' ' ' THR . 8.9 p -111.4 120.12 61.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.078 0.466 . . . . 0.0 110.185 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.3 t -94.12 -6.74 44.29 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.077 0.465 . . . . 0.0 111.366 -175.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.0 tttt 68.54 -61.07 0.42 Allowed 'General case' 0 CA--C 1.539 0.54 0 CA-C-N 114.958 -1.019 . . . . 0.0 113.605 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -71.64 163.67 27.33 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -82.53 78.2 9.19 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.622 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.6 pt -106.11 135.74 43.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.961 0.41 . . . . 0.0 110.397 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.3 t -111.02 178.02 4.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.941 -178.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -87.53 29.6 0.87 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.257 0.551 . . . . 0.0 111.414 -174.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.508 HD21 HG13 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -65.39 -21.97 66.74 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 171.04 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.95 -127.61 1.44 Allowed Glycine 0 N--CA 1.444 -0.833 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.184 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.65 ' HA2' ' HB2' ' A' ' 39' ' ' GLU . . . 86.59 -43.78 3.27 Favored Glycine 0 C--O 1.221 -0.687 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.847 172.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.447 HG12 HG13 ' A' ' 37' ' ' VAL . 57.3 mt -109.05 136.94 43.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -66.07 130.03 41.85 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.88 -33.31 73.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -170.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -109.41 -35.12 6.34 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.48 -0.488 . . . . 0.0 111.887 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 m -81.47 -28.57 34.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.583 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.81 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.82 19.55 78.82 Favored Glycine 0 C--N 1.329 0.191 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.505 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.449 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.7 mm -95.87 131.06 43.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.447 HG13 HG12 ' A' ' 30' ' ' ILE . 13.9 m -71.39 107.97 2.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.814 0.816 . . . . 0.0 110.218 175.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mmmm -92.35 -10.44 38.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.047 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.65 ' HB2' ' HA2' ' A' ' 29' ' ' GLY . 9.8 tp10 -80.8 153.4 27.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.792 177.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -100.04 137.95 37.79 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.244 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 16.3 p -161.27 -56.23 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.327 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -173.29 -51.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.477 174.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -92.05 44.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.885 0.85 . . . . 0.0 110.156 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -78.76 129.88 35.14 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.409 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.52 11.3 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.797 179.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.415 ' O ' HG23 ' A' ' 37' ' ' VAL . 26.7 mt-10 -92.86 171.69 8.81 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.299 0.571 . . . . 0.0 111.973 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.449 ' HB3' HD13 ' A' ' 36' ' ' ILE . 15.6 p -105.37 151.12 24.58 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.447 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.41 HG23 HD13 ' A' ' 30' ' ' ILE . 27.2 m -102.66 18.2 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.773 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.8 95.72 2.96 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.759 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.03 21.07 28.91 Favored Glycine 0 C--N 1.315 -0.619 0 CA-C-N 115.163 -0.926 . . . . 0.0 113.472 170.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -123.6 175.0 7.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.479 HD13 ' HB2' ' A' ' 80' ' ' ALA . 50.2 mm -99.11 129.51 49.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 -174.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.584 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 3.6 mm? -110.0 130.69 55.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.098 0.475 . . . . 0.0 111.341 -176.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.436 HG21 HG23 ' A' ' 113' ' ' VAL . 52.8 t -117.9 125.7 74.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.662 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.584 ' CE1' ' HB3' ' A' ' 53' ' ' LEU . 27.3 m-85 -131.5 143.92 51.24 Favored Pre-proline 0 C--N 1.327 -0.385 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -73.15 -42.83 0.86 Allowed 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 121.855 1.704 . . . . 0.0 110.57 171.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -176.23 -177.79 45.51 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.59 130.7 4.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.902 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.3 ptmm? -74.27 139.38 44.24 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.867 0.365 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.23 -82.57 1.67 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 121.129 -0.558 . . . . 0.0 111.781 -178.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 51.0 m 58.65 31.04 20.7 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.19 0.519 . . . . 0.0 111.54 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 3.8 m -75.23 -23.45 57.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.977 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.508 HG13 HD21 ' A' ' 27' ' ' LEU . 6.0 p -145.5 158.2 12.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.444 ' HA2' HG22 ' A' ' 67' ' ' VAL . . . 153.1 -13.58 0.63 Allowed Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.47 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -65.4 -22.56 66.8 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 111.499 0.185 . . . . 0.0 111.499 -177.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -96.22 -34.19 11.73 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -177.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.444 HG22 ' HA2' ' A' ' 64' ' ' GLY . 35.3 m -69.39 -32.22 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 111.648 0.24 . . . . 0.0 111.648 -173.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.3 mt -61.0 -38.8 87.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.942 0.401 . . . . 0.0 110.932 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 59.4 tp -71.74 -41.18 68.79 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.561 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -62.62 -44.18 96.93 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.714 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 94.7 mt -62.75 -39.6 94.64 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.614 178.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.51 ' HG2' ' O ' ' A' ' 97' ' ' ALA . 11.3 tpt180 -67.65 -41.47 83.75 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.365 -175.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.33 -10.08 59.24 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 110.898 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -94.98 -16.58 22.65 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.075 0.464 . . . . 0.0 110.399 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.23 11.66 81.93 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.086 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.81 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.2 m -106.65 13.67 8.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.106 0.479 . . . . 0.0 111.011 -177.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.15 155.57 42.75 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.832 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.557 ' HB3' HD22 ' A' ' 53' ' ' LEU . 37.0 Cg_endo -66.42 147.18 82.32 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.487 2.125 . . . . 0.0 111.201 173.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.576 ' HB3' ' HB2' ' A' ' 13' ' ' ALA . 93.2 mttt -68.15 -42.16 80.52 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.867 0.365 . . . . 0.0 111.14 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HB3' ' HG2' ' A' ' 100' ' ' PRO . . . -151.4 156.54 40.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.778 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.406 ' HB ' ' CD2' ' A' ' 101' ' ' LEU . 74.5 mt -132.83 128.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.392 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.678 HG21 HG23 ' A' ' 102' ' ' VAL . 2.3 mm -112.37 128.39 69.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.344 -0.614 . . . . 0.0 109.344 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.456 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -126.31 159.55 32.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.879 -178.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.508 ' O ' ' HD3' ' A' ' 84' ' ' LYS . 2.7 tmtp? -92.91 -35.69 13.2 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 173.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -142.58 101.99 3.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.813 174.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -95.41 -179.9 4.93 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -174.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.31 150.69 43.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.944 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.447 ' O ' HG23 ' A' ' 92' ' ' VAL . 13.1 m -62.52 -37.7 87.06 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.289 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.98 -29.53 47.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.9 mt -71.83 -42.52 69.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.47 ' HB1' HG22 ' A' ' 8' ' ' ILE . . . -59.43 -42.88 92.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.263 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 88' ' ' THR . 57.1 t -62.76 -47.86 90.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.828 179.287 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.2 -43.41 99.16 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.258 178.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.488 ' HB2' ' O ' ' A' ' 99' ' ' ILE . . . -65.5 -31.08 71.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.358 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -70.09 -35.11 73.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.911 0.386 . . . . 0.0 111.252 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.1 mtm -81.61 -33.62 31.4 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 -178.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.51 ' O ' ' HG2' ' A' ' 72' ' ' ARG . . . -89.99 0.51 57.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.003 -177.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 55.15 61.63 2.84 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.829 0.823 . . . . 0.0 110.098 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.488 ' O ' ' HB2' ' A' ' 94' ' ' ALA . 69.7 mt -123.11 90.05 50.55 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 114.784 -1.098 . . . . 0.0 109.801 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.496 ' HG2' ' HB3' ' A' ' 80' ' ' ALA . 4.2 Cg_exo -40.04 109.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.348 0.541 0 C-N-CA 123.669 2.912 . . . . 0.0 112.891 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.6 HD12 HD13 ' A' ' 8' ' ' ILE . 1.1 tm? -110.59 120.0 40.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.348 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.678 HG23 HG21 ' A' ' 82' ' ' ILE . 24.7 m -130.36 144.21 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.019 0.438 . . . . 0.0 110.634 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -110.16 122.84 48.58 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.03 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.8 134.45 37.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.185 0.517 . . . . 0.0 110.687 -177.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.436 ' HD3' ' O ' ' A' ' 105' ' ' ARG . 0.7 OUTLIER -92.79 -14.8 27.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.929 -174.328 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -109.42 137.61 47.01 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.558 -0.457 . . . . 0.0 111.274 -175.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -72.78 -19.36 61.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.847 -176.172 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 19.0 mmtp -58.3 -26.6 63.21 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.448 ' O ' HG13 ' A' ' 113' ' ' VAL . 79.9 t80 -61.72 -42.81 99.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.755 0.312 . . . . 0.0 110.3 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.496 ' HA ' HG13 ' A' ' 113' ' ' VAL . 87.6 m-85 -75.16 -24.97 57.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.24 -175.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -74.33 -33.45 63.16 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.484 175.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.16 -41.05 17.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.723 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.496 HG13 ' HA ' ' A' ' 110' ' ' PHE . 11.4 p -78.27 124.37 36.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.777 0.799 . . . . 0.0 111.386 -175.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 32.0 mmtp -132.06 153.25 50.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.706 175.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 60.8 m -62.35 114.87 3.74 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 123.195 0.31 . . . . 0.0 110.932 -178.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.6 -32.13 2.17 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 119.792 -1.194 . . . . 0.0 114.395 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.93 -172.11 2.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 117.736 0.768 . . . . 0.0 111.028 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -112.27 126.04 54.82 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.278 0.561 . . . . 0.0 111.905 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 17' ' ' ALA . 65.8 t -121.52 120.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.892 176.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.522 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 60.7 t -89.29 111.83 23.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.759 177.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 41.9 t -95.54 109.02 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.565 -177.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -110.34 99.08 8.17 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.99 -9.35 53.77 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.022 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -63.81 -47.01 82.58 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 174.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -93.2 -31.18 14.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.736 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 91.92 59.08 1.35 Allowed Glycine 0 N--CA 1.452 -0.295 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 143.49 29.75 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.793 0.33 . . . . 0.0 110.643 -169.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.53 106.31 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.319 0.581 . . . . 0.0 109.962 174.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.522 ' HB2' ' HB ' ' A' ' 120' ' ' VAL . 39.8 mt-10 -96.3 108.46 20.97 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.665 -174.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.6 tp -81.3 110.05 16.39 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.6 mm -112.74 114.9 48.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -176.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 . . . . . 0 C--N 1.312 -1.041 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.157 -170.604 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.226 -0.162 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.487 ' HD3' ' OH ' ' A' ' 127' ' ' TYR . 74.2 mttt -125.54 145.67 50.01 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.529 -177.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.462 ' HB2' HG12 ' A' ' 128' ' ' VAL . 89.6 m-85 -129.48 161.92 29.3 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.398 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.15 126.65 55.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.106 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.453 ' SG ' HG21 ' A' ' 102' ' ' VAL . 5.7 p -119.71 167.74 11.75 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.209 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.552 ' HD3' ' OE2' ' A' ' 103' ' ' GLU . 36.6 ttt180 -93.96 121.95 35.96 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.981 0.42 . . . . 0.0 110.107 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.98 102.9 3.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.123 -175.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.529 HG13 HG23 ' A' ' 86' ' ' THR . 50.0 mm -95.91 -43.57 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.11 177.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.7 p -109.57 -165.0 0.97 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.134 177.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -136.43 164.49 28.03 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -177.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.05 161.62 22.77 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.932 -0.652 . . . . 0.0 111.906 -177.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -147.86 154.12 40.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.09 0.445 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.45 164.97 24.3 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.081 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -127.92 127.05 42.66 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 176.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.62 178.92 32.83 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.056 -1.069 . . . . 0.0 112.69 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -74.44 139.86 44.25 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.33 178.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG22 ' A' ' 119' ' ' VAL . . . -80.56 122.83 27.53 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.07 0.462 . . . . 0.0 111.002 -178.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.3 tt -117.61 117.14 28.59 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 174.438 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.795 HG13 ' HB ' ' A' ' 115' ' ' THR . 8.4 p -101.6 124.99 55.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.442 0.639 . . . . 0.0 110.984 -173.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 1.027 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 13.2 m -95.63 95.03 8.08 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.446 0.641 . . . . 0.0 109.875 179.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -82.25 -2.61 53.1 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.944 -177.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -103.1 130.41 50.25 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.67 -176.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -85.14 98.89 10.72 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -118.95 172.64 5.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.253 -0.43 . . . . 0.0 112.007 -170.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.4 p -79.5 122.41 26.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.175 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.556 ' O ' ' HB ' ' A' ' 63' ' ' VAL . 21.5 t80 -85.48 31.26 0.59 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.568 0.699 . . . . 0.0 109.991 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.481 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -68.89 -23.8 64.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.198 177.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 174.37 -103.84 0.19 Allowed Glycine 0 N--CA 1.444 -0.832 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.294 178.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.72 -51.42 2.31 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.548 176.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.435 HD13 ' N ' ' A' ' 30' ' ' ILE . 3.7 mp -87.47 129.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.73 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 27.5 t70 -78.55 139.96 38.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.038 0.447 . . . . 0.0 111.005 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.479 ' HA ' HD21 ' A' ' 71' ' ' LEU . 0.0 OUTLIER -64.84 -26.33 68.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.548 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.45 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 45.4 mt-10 -95.41 -46.88 6.51 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 20.7 p -102.88 -19.15 14.76 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 73.93 20.14 79.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.015 -178.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.2 mm -87.68 133.03 31.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.639 -0.28 . . . . 0.0 110.453 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.3 m -74.28 111.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.582 0.706 . . . . 0.0 110.892 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.73 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 57.2 mttt -91.67 -10.89 38.61 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.947 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -66.33 138.27 57.49 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.646 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.41 131.42 44.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.38 -172.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 13.6 p 174.55 -178.22 0.1 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.981 -1.008 . . . . 0.0 108.482 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -79.35 -9.27 59.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.274 0.559 . . . . 0.0 110.095 175.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.414 ' O ' ' HB2' ' A' ' 46' ' ' GLU . 24.3 mt -94.26 -8.83 9.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.183 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.1 tmmm? -56.85 125.83 24.23 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.358 0.599 . . . . 0.0 110.372 -178.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.25 -24.36 12.64 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.964 -176.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' ' 43' ' ' ILE . 1.1 mm-40 -71.15 162.97 28.54 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.311 0.577 . . . . 0.0 111.656 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.2 p -116.89 127.13 53.96 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.61 -178.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -87.53 1.8 5.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.207 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.25 88.04 0.3 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.923 -177.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.514 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 107.36 11.04 26.34 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.519 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 mmm-85 -106.14 156.08 18.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.44 116.58 47.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 176.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.671 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -92.94 124.85 37.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.289 0.566 . . . . 0.0 111.324 -173.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 72.6 t -117.91 107.91 23.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.173 176.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 1.027 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 43.6 p90 -135.7 153.66 77.56 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.461 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -64.07 -49.89 3.42 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 122.591 2.194 . . . . 0.0 111.997 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -176.56 170.17 42.88 Favored Glycine 0 N--CA 1.448 -0.558 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.86 42.04 2.06 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.15 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 46.5 mtpt 64.46 8.96 4.63 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.96 43.18 74.62 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.557 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.8 p -91.91 125.61 36.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.135 0.493 . . . . 0.0 110.548 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.7 p -88.68 71.2 8.8 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-O 121.54 0.686 . . . . 0.0 111.214 -171.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.748 HG11 ' H ' ' A' ' 65' ' ' SER . 7.1 p -46.67 -35.03 2.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.079 173.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 102.79 -4.57 50.0 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.203 178.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.748 ' H ' HG11 ' A' ' 63' ' ' VAL . 60.7 p 60.06 -154.56 0.37 Allowed 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 123.62 0.768 . . . . 0.0 111.36 178.147 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 72.35 -56.48 0.65 Allowed 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.782 0.833 . . . . 0.0 112.084 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.3 m -60.92 -16.84 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -173.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.21 -28.18 69.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.803 0.335 . . . . 0.0 110.699 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.0 tp -62.34 -38.48 89.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.423 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -58.22 -47.67 82.77 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.649 178.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.479 HD21 ' HA ' ' A' ' 32' ' ' LYS . 76.4 mt -56.76 -44.43 81.77 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.706 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.511 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -72.8 -41.32 65.08 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.745 -176.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -61.85 -33.3 73.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.824 0.345 . . . . 0.0 110.374 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -85.53 -19.68 30.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.126 0.489 . . . . 0.0 110.512 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 86.89 23.44 41.79 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.216 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.4 m -113.32 12.47 8.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.603 -179.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.47 ' HB1' ' HD2' ' A' ' 78' ' ' PRO . . . -90.91 162.66 32.39 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.671 ' HB3' HD13 ' A' ' 53' ' ' LEU . 43.7 Cg_endo -69.66 149.9 68.1 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.037 1.825 . . . . 0.0 111.434 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.514 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 88.4 mttt -69.47 -30.46 68.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.938 0.399 . . . . 0.0 110.75 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -163.77 155.3 16.67 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.457 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 68.5 mt -131.09 127.28 60.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.998 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.449 HG23 HG22 ' A' ' 102' ' ' VAL . 5.5 mm -117.85 120.79 65.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 13.6 m120 -120.03 164.03 16.74 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.645 0.26 . . . . 0.0 110.74 -176.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -79.07 -46.11 18.76 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 174.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.502 ' O ' ' HG3' ' A' ' 85' ' ' LYS . 44.2 pttt -125.88 112.75 16.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.762 172.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.649 ' HG1' HD22 ' A' ' 101' ' ' LEU . 5.8 t -92.47 116.3 28.87 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.41 0.624 . . . . 0.0 109.476 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -98.52 167.91 10.52 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.544 -175.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.5 m -53.98 -47.64 71.17 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -169.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.526 HG13 HG13 ' A' ' 90' ' ' ILE . 9.2 pt -55.56 -46.04 78.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 111.984 0.365 . . . . 0.0 111.984 -178.182 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.526 HG13 HG13 ' A' ' 89' ' ' ILE . 36.4 mt -76.77 -40.56 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.325 -176.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.511 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.44 -50.64 73.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.564 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 92.3 t -64.87 -42.37 94.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.791 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.35 -45.56 96.19 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.785 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.93 -33.01 63.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.552 0.215 . . . . 0.0 111.567 -178.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.8 -40.16 95.96 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.963 0.411 . . . . 0.0 111.512 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 69.7 mtm -74.04 -42.87 59.62 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.244 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.511 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -74.3 -14.78 60.95 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -177.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 71.71 59.89 0.16 Allowed 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.662 0.744 . . . . 0.0 109.934 -173.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 59.1 mt -121.96 89.32 48.23 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.481 177.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -38.29 107.56 0.06 OUTLIER 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 123.792 2.994 . . . . 0.0 113.441 -177.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.649 HD22 ' HG1' ' A' ' 86' ' ' THR . 43.6 tp -128.16 120.72 27.87 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.421 -176.259 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.453 HG21 ' SG ' ' A' ' 5' ' ' CYS . 20.6 m -135.0 166.76 27.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.195 179.366 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.552 ' OE2' ' HD3' ' A' ' 6' ' ' ARG . 9.9 pt-20 -113.59 141.16 47.52 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.066 0.46 . . . . 0.0 111.167 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 5.2 m -105.84 140.75 22.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.454 176.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -88.67 -26.27 21.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.221 -174.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -106.16 140.08 39.68 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.052 0.453 . . . . 0.0 111.372 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -71.14 -20.94 62.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.944 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.524 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 57.2 mttm -64.91 -17.97 64.8 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -60.64 -45.85 92.52 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 173.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.499 ' HA ' HG12 ' A' ' 113' ' ' VAL . 53.2 m-85 -76.12 -32.11 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.006 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.524 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.7 tt0 -57.3 -46.22 83.38 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.996 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -87.75 -24.62 23.74 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.481 -174.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.9 p -76.04 139.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.535 0.684 . . . . 0.0 111.96 -174.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -139.13 159.28 42.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.992 172.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.795 ' HB ' HG13 ' A' ' 19' ' ' VAL . 12.1 t -81.69 138.62 35.24 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.961 0.41 . . . . 0.0 110.434 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.53 -25.3 9.2 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.775 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -85.28 -171.78 3.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.608 0.242 . . . . 0.0 110.797 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 20.0 ttp180 -115.36 133.73 55.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.011 0.434 . . . . 0.0 111.447 -176.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG22 ' HB2' ' A' ' 17' ' ' ALA . 85.6 t -122.58 129.5 75.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.126 175.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.66 ' HB ' ' HB3' ' A' ' 129' ' ' GLU . 50.3 t -101.86 113.56 38.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.79 129.67 61.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.946 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -131.4 100.52 5.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.807 176.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.82 -12.22 55.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.472 -174.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.18 -7.64 58.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.025 0.44 . . . . 0.0 110.804 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -128.3 -20.99 3.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.868 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.29 59.94 2.79 Favored Glycine 0 CA--C 1.509 -0.336 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . 0.487 ' OH ' ' HD3' ' A' ' 2' ' ' LYS . 60.8 t80 -142.71 135.64 28.19 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.316 -167.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.462 HG12 ' HB2' ' A' ' 3' ' ' PHE . 6.6 p -137.76 124.81 28.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.461 0.648 . . . . 0.0 110.579 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.66 ' HB3' ' HB ' ' A' ' 120' ' ' VAL . 34.5 tt0 -115.96 122.45 45.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.413 -175.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 19.6 tp -106.63 127.53 53.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.945 0.402 . . . . 0.0 110.688 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.404 ' N ' HD13 ' A' ' 131' ' ' ILE . 3.5 mp -122.45 122.07 65.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 174.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 132' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.315 -0.91 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.618 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 C--O 1.234 0.25 0 CA-C-O 120.677 0.275 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.511 ' HG2' ' HG2' ' A' ' 129' ' ' GLU . 49.2 mttp -101.7 107.48 18.72 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 177.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -86.76 141.42 28.88 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.27 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.31 127.97 36.31 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.514 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.2 m -120.82 159.02 26.33 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.032 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.438 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 27.1 ttm180 -102.79 115.94 31.58 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 176.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.574 ' HA ' HG13 ' A' ' 102' ' ' VAL . . . -73.0 133.84 44.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.0 -173.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.535 HG13 ' HG1' ' A' ' 86' ' ' THR . 45.0 mm -106.94 -49.36 8.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 174.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 61.7 p -117.42 177.24 4.81 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.786 173.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 10' ' ' ARG . 61.5 mtt180 -101.1 169.49 8.9 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.801 0.334 . . . . 0.0 111.003 -177.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 134.68 153.54 6.89 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.124 178.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.423 HH11 ' HD3' ' A' ' 12' ' ' ARG . 45.9 ttp180 -137.84 130.17 29.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.557 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -146.27 164.22 33.02 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.937 0.398 . . . . 0.0 111.391 -175.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.03 149.12 27.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.833 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 160.36 -167.53 35.65 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.142 -1.028 . . . . 0.0 112.148 175.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 50.9 mm-40 -64.57 128.08 34.26 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.488 ' HB1' HG21 ' A' ' 119' ' ' VAL . . . -81.05 122.13 26.94 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.852 -178.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.3 tp -106.22 108.4 19.89 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 175.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.489 ' HB ' ' HB ' ' A' ' 115' ' ' THR . 43.3 t -110.59 113.52 44.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.967 0.413 . . . . 0.0 110.991 -172.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 30.2 m -105.0 110.17 22.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.922 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -86.26 26.8 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.263 0.554 . . . . 0.0 110.837 -177.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -115.44 157.51 23.86 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.76 178.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -103.4 94.61 5.58 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 pt -85.32 172.1 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.3 0.571 . . . . 0.0 111.445 -175.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.707 ' HB2' HD21 ' A' ' 27' ' ' LEU . 26.0 p -110.26 122.54 47.9 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.957 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.551 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 90.7 m-85 -81.21 64.4 5.93 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.319 0.58 . . . . 0.0 110.476 179.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.707 HD21 ' HB2' ' A' ' 25' ' ' SER . 3.5 mm? -119.74 -57.03 2.0 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.936 174.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.54 44.52 0.69 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.81 -53.15 6.55 Favored Glycine 0 C--O 1.224 -0.47 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.943 -176.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 65.7 mt -98.61 135.51 33.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.833 0.316 . . . . 0.0 110.815 -177.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -67.06 134.78 52.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.268 177.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -68.52 -25.61 65.03 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.221 0.452 . . . . 0.0 112.221 -171.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -110.77 -38.11 5.23 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.231 0.538 . . . . 0.0 111.288 -168.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.512 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -98.94 -14.97 19.31 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.585 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' A' ' 47' ' ' SER . . . 68.29 21.89 74.3 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.085 -178.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.512 HG12 ' HB ' ' A' ' 34' ' ' THR . 36.4 mm -88.44 127.07 41.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 122.18 0.192 . . . . 0.0 110.625 -177.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 47.1 t -71.62 113.92 9.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -88.62 -28.61 20.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.054 -176.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -65.58 123.01 18.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.587 ' HA ' ' HG3' ' A' ' 44' ' ' LYS . 35.2 t70 -73.26 141.11 47.23 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.968 -173.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 42.0 t -172.81 -73.65 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.071 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -156.58 -51.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.331 179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.9 pp -82.41 15.31 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.078 177.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.587 ' HG3' ' HA ' ' A' ' 40' ' ' ASP . 4.5 tmmm? -65.16 124.99 23.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.698 179.233 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 104.4 -15.29 50.3 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.368 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -91.27 159.24 16.13 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.307 0.575 . . . . 0.0 112.07 177.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.481 ' HB3' HD13 ' A' ' 36' ' ' ILE . 2.5 p -103.74 158.54 16.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.246 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.472 HG13 HD22 ' A' ' 53' ' ' LEU . 26.7 m -108.63 20.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.919 -179.511 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.03 91.93 2.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.647 -173.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.96 20.64 27.75 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.001 -0.999 . . . . 0.0 112.91 174.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -110.33 158.97 17.86 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.863 -0.198 . . . . 0.0 110.64 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.448 ' HB ' ' HA ' ' A' ' 17' ' ' ALA . 49.6 mm -95.59 104.58 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.815 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.606 HD12 ' HB3' ' A' ' 78' ' ' PRO . 9.9 mp -85.58 133.34 34.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.17 0.509 . . . . 0.0 111.688 -172.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.61 121.15 59.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.743 176.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.551 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 78.3 m-85 -128.88 144.42 52.41 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.825 0.345 . . . . 0.0 111.332 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -81.17 -11.32 12.17 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.546 2.164 . . . . 0.0 111.883 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 137.54 -158.66 24.6 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.054 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 154.96 -142.87 9.34 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -120.42 102.79 8.69 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.868 0.366 . . . . 0.0 110.597 177.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.551 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -96.47 81.73 0.76 Allowed Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.6 t -82.57 -178.29 7.02 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.071 0.463 . . . . 0.0 110.751 -176.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.1 p -66.93 -13.92 62.27 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.078 -175.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.1 t -87.55 -14.91 9.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.892 0.377 . . . . 0.0 110.774 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -77.27 -24.6 65.55 Favored Glycine 0 N--CA 1.453 -0.204 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.434 -178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.9 p -80.19 162.65 24.58 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.91 -0.171 . . . . 0.0 111.004 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 2.0 t80 75.58 -43.76 0.5 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.373 0.669 . . . . 0.0 111.899 175.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 58.9 t -58.85 -33.74 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.929 0.395 . . . . 0.0 111.323 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.424 ' HB3' HD13 ' A' ' 99' ' ' ILE . 87.1 mt -57.73 -31.37 66.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.573 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.6 tp -67.3 -33.99 76.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.105 0.478 . . . . 0.0 110.514 -178.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -66.01 -41.84 90.48 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.972 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.7 mt -57.42 -42.59 82.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.587 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -59.78 -51.04 71.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.915 -178.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 55.8 mtmt -75.39 -8.07 55.7 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.985 -174.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . 0.454 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.0 t-20 -92.42 -30.91 15.51 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.988 0.423 . . . . 0.0 109.909 175.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.09 15.41 28.34 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.091 -178.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.454 HG22 ' HB3' ' A' ' 74' ' ' ASN . 20.1 m -117.64 14.17 7.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.888 0.375 . . . . 0.0 111.185 -178.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -73.99 150.11 87.9 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.245 179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.606 ' HB3' HD12 ' A' ' 53' ' ' LEU . 7.9 Cg_exo -71.89 138.47 31.45 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.558 2.172 . . . . 0.0 110.383 171.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.557 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 85.5 mttt -63.44 -42.26 98.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.756 0.313 . . . . 0.0 111.346 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -157.92 153.57 26.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.803 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.551 HG12 ' HB2' ' A' ' 53' ' ' LEU . 52.8 mt -134.07 114.44 19.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.423 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.402 HG21 ' CG2' ' A' ' 102' ' ' VAL . 21.3 mm -100.65 124.22 54.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 34.9 m-80 -123.35 155.75 36.71 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.018 0.437 . . . . 0.0 111.228 -174.395 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 88.3 tttt -76.95 -46.98 22.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.502 174.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -116.89 120.71 39.31 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.815 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.535 ' HG1' HG13 ' A' ' 8' ' ' ILE . 9.4 t -99.51 134.77 41.91 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.721 -177.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.51 141.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.459 ' O ' HG22 ' A' ' 92' ' ' VAL . 5.5 m -66.99 -36.18 81.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.503 -175.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 87.0 mt -61.29 -43.88 97.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.976 0.417 . . . . 0.0 110.353 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.47 HD13 ' HA3' ' A' ' 60' ' ' GLY . 59.5 mt -64.4 -40.58 89.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.006 177.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.502 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.46 -46.57 88.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.527 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 88' ' ' THR . 90.1 t -58.52 -43.65 87.45 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 CA-C-O 120.975 0.417 . . . . 0.0 110.555 179.152 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.27 -41.05 69.73 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.5 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.425 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -71.05 -31.28 67.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.463 0.173 . . . . 0.0 111.412 -177.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.56 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.987 0.422 . . . . 0.0 110.971 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.7 mtm -70.29 -32.99 71.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.003 -179.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.43 3.47 49.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.797 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 56.15 43.1 27.35 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.927 0.87 . . . . 0.0 110.362 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.424 HD13 ' HB3' ' A' ' 68' ' ' LEU . 63.8 mt -109.77 89.26 7.53 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.671 177.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.99 116.0 2.9 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.893 2.395 . . . . 0.0 112.616 -176.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 91' ' ' ALA . 2.6 pt? -118.44 137.07 53.41 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.508 175.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.574 HG13 ' HA ' ' A' ' 7' ' ' ALA . 18.9 m -132.48 163.1 38.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.861 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.438 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 14.7 pt-20 -103.81 135.34 45.53 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.848 0.356 . . . . 0.0 110.094 176.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 15.8 m -116.26 130.92 70.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.102 0.477 . . . . 0.0 110.382 175.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -101.92 1.3 36.68 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.127 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -95.94 123.64 39.62 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.984 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.93 -32.79 67.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.371 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 28.6 mtpp -69.89 -23.7 63.28 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -174.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -54.44 -49.43 70.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 174.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 96.6 m-85 -74.58 -28.25 60.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.981 0.419 . . . . 0.0 110.996 -179.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -66.44 -45.25 80.45 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.599 176.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.21 -39.45 19.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.454 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.488 HG13 ' HA ' ' A' ' 110' ' ' PHE . 9.4 p -65.45 127.83 27.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-O 121.475 0.655 . . . . 0.0 110.963 -175.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -123.15 135.88 54.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.755 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.489 ' HB ' ' HB ' ' A' ' 19' ' ' VAL . 14.8 t -72.24 113.85 9.71 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-O 121.41 0.624 . . . . 0.0 109.551 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.5 -18.94 3.41 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.392 -176.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . 0.544 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 0.8 OUTLIER -99.02 -171.71 2.14 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.676 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.544 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -114.54 137.34 51.98 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.337 0.589 . . . . 0.0 112.025 -174.92 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.488 HG21 ' HB1' ' A' ' 17' ' ' ALA . 84.3 t -120.38 130.33 74.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.743 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.5 t -98.88 111.44 28.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 174.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 88.3 t -96.0 120.71 45.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.134 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -124.71 99.85 6.36 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -86.18 -11.67 51.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.126 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -67.71 -43.01 81.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.015 0.436 . . . . 0.0 110.009 178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -96.38 -23.92 16.39 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.542 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.16 62.93 1.46 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.521 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . 0.533 ' HE1' ' HG3' ' A' ' 129' ' ' GLU . 25.6 p90 -162.41 163.55 27.67 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.772 0.32 . . . . 0.0 110.168 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.26 126.36 58.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.248 175.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.533 ' HG3' ' HE1' ' A' ' 127' ' ' TYR . 39.5 mt-10 -98.56 107.92 20.49 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.095 176.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 60.7 tp -82.45 102.0 11.03 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.358 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 18.1 pt -92.37 109.94 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.455 0.645 . . . . 0.0 110.291 -175.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 . . . . . 0 C--N 1.316 -0.854 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.085 -177.165 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.525 HG11 ' HB2' ' A' ' 112' ' ' ALA . 13.9 m . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 121.261 0.553 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -130.74 114.93 15.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.739 -176.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.502 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 76.6 m-85 -128.5 164.75 22.1 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.118 0.485 . . . . 0.0 111.036 -176.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -118.49 139.43 51.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.447 174.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.617 ' HG ' HG12 ' A' ' 128' ' ' VAL . 10.3 p -120.21 171.67 8.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.258 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.7 ttt85 -93.88 118.06 30.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.971 0.415 . . . . 0.0 110.116 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.509 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -71.82 96.52 1.66 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.042 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.458 HD13 ' OE1' ' A' ' 103' ' ' GLU . 49.3 mm -82.2 -43.51 19.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.87 175.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.8 p -125.29 -164.25 1.27 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.293 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 60.7 mtt-85 -118.56 -175.28 2.85 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.705 0.288 . . . . 0.0 110.59 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.551 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 115.71 145.21 8.43 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.04 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 68.8 mtm-85 -141.38 115.2 9.11 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.24 169.38 24.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.871 0.367 . . . . 0.0 111.193 -176.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.536 ' OE1' ' HD2' ' A' ' 118' ' ' ARG . 14.2 pt-20 -135.42 146.77 48.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.87 178.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.98 -173.48 34.48 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 120.079 -1.058 . . . . 0.0 112.098 174.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.62 127.97 34.4 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.45 118.98 22.54 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.905 -177.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.8 tp -102.02 111.42 23.68 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.553 ' HA ' ' CG1' ' A' ' 54' ' ' VAL . 47.1 t -98.87 110.92 27.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.385 0.612 . . . . 0.0 110.522 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.444 HG22 HD12 ' A' ' 24' ' ' ILE . 6.8 m -110.55 132.16 54.43 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.092 -176.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -102.77 -10.02 19.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.13 0.491 . . . . 0.0 110.573 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -97.88 161.47 13.73 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -96.0 141.73 29.06 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.553 0.216 . . . . 0.0 110.468 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 20' ' ' THR . 2.5 mp -114.16 132.89 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 55.2 p -78.73 115.23 18.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.148 0.499 . . . . 0.0 110.722 -178.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.95 -6.3 32.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.333 179.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.504 HD11 ' O ' ' A' ' 27' ' ' LEU . 1.8 tm? -65.05 -30.53 71.5 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 175.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 146.55 51.81 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.48 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.16 21.17 32.64 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.161 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.488 HD11 HG23 ' A' ' 48' ' ' VAL . 53.6 mt -130.75 136.74 57.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 -179.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.568 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.1 t70 -69.46 123.79 22.18 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.268 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.597 ' HG2' ' OE1' ' A' ' 33' ' ' GLU . 0.6 OUTLIER -79.28 -12.21 59.94 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -170.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.597 ' OE1' ' HG2' ' A' ' 32' ' ' LYS . 2.4 mp0 -94.33 -41.09 9.61 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 121.137 -0.225 . . . . 0.0 111.254 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.9 p -103.06 -36.97 7.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 -177.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.79 16.45 36.2 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.816 -175.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.0 mm -91.45 128.44 43.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.498 HG22 ' HG2' ' A' ' 44' ' ' LYS . 8.4 m -62.96 142.02 17.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.021 0.439 . . . . 0.0 110.912 177.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.568 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 26.9 mmmt -96.12 -3.67 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.487 0.661 . . . . 0.0 110.823 -174.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -92.39 158.86 15.84 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.642 -175.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -92.29 139.28 30.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.371 0.605 . . . . 0.0 112.127 -176.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.511 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 48.8 t -179.22 168.7 1.52 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 172.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -68.32 -35.97 78.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.049 0.452 . . . . 0.0 110.428 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 32.3 pt -102.62 12.36 7.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.493 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.511 ' HB2' ' HB3' ' A' ' 41' ' ' CYS . 70.2 mttt -99.44 147.5 25.2 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 176.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.48 1.55 15.59 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -175.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -108.82 -179.36 3.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.802 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.6 m -91.83 133.9 35.23 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.933 -171.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.488 HG23 HD11 ' A' ' 30' ' ' ILE . 34.5 m -101.6 4.38 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.3 0.572 . . . . 0.0 110.005 174.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -67.27 100.13 0.78 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.186 -174.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.17 19.99 50.97 Favored Glycine 0 C--N 1.308 -1.001 0 CA-C-N 114.536 -1.211 . . . . 0.0 112.872 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -110.72 155.53 22.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.853 HG13 ' HB1' ' A' ' 80' ' ' ALA . 1.8 mp -84.66 105.48 13.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 175.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 32.1 tp -82.28 126.89 32.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.447 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.553 ' CG1' ' HA ' ' A' ' 19' ' ' VAL . 11.8 p -130.26 106.96 13.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.62 0.724 . . . . 0.0 111.842 177.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.416 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 38.1 p90 -136.16 151.68 73.95 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.175 170.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.91 -55.43 2.33 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.547 2.164 . . . . 0.0 112.808 -177.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 134.43 138.15 3.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.874 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -167.7 -101.79 0.15 Allowed Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.69 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 25' ' ' SER . 65.4 tttp -75.63 81.92 2.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.156 0.503 . . . . 0.0 109.807 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -161.98 88.59 0.11 Allowed Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.493 ' HA ' ' OE1' ' A' ' 87' ' ' GLU . 21.9 t -153.9 161.78 41.74 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -178.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 7.6 m 66.71 43.88 2.31 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.899 0.857 . . . . 0.0 110.382 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.593 HG21 HG12 ' A' ' 90' ' ' ILE . 5.1 t -72.26 -27.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.515 177.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 76.35 -77.46 1.39 Allowed Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.121 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.7 p 173.13 -77.1 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 O-C-N 124.092 0.525 . . . . 0.0 111.84 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -70.69 -9.5 57.3 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -170.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 62.9 t -60.63 -41.79 89.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.983 0.421 . . . . 0.0 110.648 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.417 ' O ' HD13 ' A' ' 68' ' ' LEU . 0.7 OUTLIER -73.38 -32.17 64.33 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.231 0.539 . . . . 0.0 109.871 179.282 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.6 tp -61.33 -32.49 72.38 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.2 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -54.94 -44.23 74.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.213 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 88.0 mt -61.84 -33.15 73.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.005 -178.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.545 ' HD3' ' HA ' ' A' ' 97' ' ' ALA . 8.0 ttp180 -72.16 -35.94 69.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.126 -178.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -61.37 -31.19 71.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.014 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -93.54 -25.17 17.69 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.938 0.399 . . . . 0.0 110.442 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 94.16 26.94 12.94 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.704 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.8 m -107.15 4.56 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.171 0.51 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.96 159.38 73.57 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.733 179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.49 162.38 24.45 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.491 2.127 . . . . 0.0 112.13 175.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -82.83 -28.8 29.94 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.853 ' HB1' HG13 ' A' ' 52' ' ' ILE . . . -166.77 165.22 16.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.673 175.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.68 HG23 HD21 ' A' ' 101' ' ' LEU . 8.3 tt -152.07 121.29 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.45 0.643 . . . . 0.0 110.824 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.801 HG22 HG22 ' A' ' 102' ' ' VAL . 2.7 mm -110.21 118.88 58.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -116.39 165.96 12.61 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.364 0.602 . . . . 0.0 111.758 -174.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.22 -31.49 10.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.302 176.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.9 tttm -121.28 122.41 39.83 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.577 176.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 66.5 p -127.68 158.75 36.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.967 0.413 . . . . 0.0 111.681 -175.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.552 ' HB2' HG13 ' A' ' 90' ' ' ILE . 53.8 mt-10 -123.58 157.66 33.2 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.776 173.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.512 ' O ' HG23 ' A' ' 92' ' ' VAL . 89.2 m -60.09 -44.28 94.92 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.107 178.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.9 pt -63.9 -29.89 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.453 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.593 HG12 HG21 ' A' ' 63' ' ' VAL . 64.4 mt -66.98 -42.75 89.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.99 -32.96 74.75 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.198 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 88' ' ' THR . 73.1 t -66.69 -49.87 70.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 120.929 0.395 . . . . 0.0 110.543 177.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.35 -44.11 97.35 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.13 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.09 -37.33 87.04 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 111.585 0.216 . . . . 0.0 111.585 -179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.3 -41.76 96.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.807 0.337 . . . . 0.0 111.12 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 66.5 mtm -74.64 -32.09 62.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.897 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.545 ' HA ' ' HD3' ' A' ' 72' ' ' ARG . . . -82.04 -0.61 45.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 176.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 57.32 38.39 28.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.278 0.561 . . . . 0.0 111.233 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 61.4 mt -111.08 90.93 12.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.198 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.551 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 82.5 Cg_exo -40.57 115.6 0.34 Allowed 'Trans proline' 0 C--N 1.35 0.651 0 C-N-CA 124.027 3.151 . . . . 0.0 113.872 -175.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.68 HD21 HG23 ' A' ' 81' ' ' ILE . 0.1 OUTLIER -108.94 120.67 43.22 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.584 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.801 HG22 HG22 ' A' ' 82' ' ' ILE . 5.5 m -140.5 161.84 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.784 177.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.458 ' OE1' HD13 ' A' ' 8' ' ' ILE . 46.1 mt-10 -101.21 132.99 46.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.529 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 3.4 m -96.48 139.65 18.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -99.97 -46.76 5.25 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.347 -174.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.43 ' OD1' ' HG3' ' A' ' 108' ' ' LYS . 7.1 t70 -92.8 146.51 23.59 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.218 0.532 . . . . 0.0 111.338 -174.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -71.1 -18.76 62.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.103 -0.953 . . . . 0.0 111.177 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.43 ' HG3' ' OD1' ' A' ' 106' ' ' ASP . 67.7 mttm -55.08 -33.08 62.47 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -61.31 -40.6 94.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.421 -178.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.01 -31.14 68.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.295 -176.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -77.98 -45.58 23.44 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.902 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.525 ' HB2' HG11 ' A' ' 1' ' ' VAL . . . -66.51 -37.56 85.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.179 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 12.0 p -75.15 129.28 36.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.405 0.621 . . . . 0.0 111.076 -177.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.424 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 71.1 mmtt -118.91 144.12 46.6 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.431 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.9 m -64.76 110.9 2.55 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.96 0.41 . . . . 0.0 110.631 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.89 -7.57 8.78 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.425 -178.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . 0.424 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 12.2 m-20 -87.39 171.84 10.28 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 174.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.536 ' HD2' ' OE1' ' A' ' 14' ' ' GLU . 11.7 ttp180 -115.67 121.94 44.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.824 0.345 . . . . 0.0 110.862 -178.382 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.95 130.07 66.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.187 0.518 . . . . 0.0 110.409 178.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 45.6 t -99.19 111.21 28.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.1 p -102.25 115.23 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.642 0.734 . . . . 0.0 111.754 -174.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . 0.472 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 50.1 t-20 -99.94 94.15 6.14 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 172.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.411 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -82.4 -19.67 38.64 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.108 0.48 . . . . 0.0 110.266 -178.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.78 -39.07 93.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.643 -179.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -107.46 -28.02 10.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.814 177.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.95 64.45 0.99 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.487 -0.863 . . . . 0.0 111.291 -176.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . 0.472 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 35.6 t80 -144.55 124.39 13.44 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -174.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.617 HG12 ' HG ' ' A' ' 5' ' ' CYS . 5.9 m -126.26 118.09 50.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.481 0.657 . . . . 0.0 110.997 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -121.04 123.38 42.23 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.193 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.481 ' HB3' HG22 ' A' ' 1' ' ' VAL . 17.0 tp -103.81 120.59 41.3 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.152 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.438 HD13 ' N ' ' A' ' 131' ' ' ILE . 4.0 mp -89.43 123.27 41.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.235 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--N 1.317 -0.814 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.309 -178.938 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 2' ' ' LYS . 60.6 t . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 1' ' ' VAL . 49.2 mttp 64.34 77.84 0.3 Allowed 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -170.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -98.97 136.79 38.44 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.053 0.454 . . . . 0.0 110.775 -176.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -107.27 110.64 22.72 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.708 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.879 ' SG ' HG12 ' A' ' 104' ' ' VAL . 58.2 m -119.71 -178.73 3.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.489 -174.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.465 ' HB3' ' HG3' ' A' ' 103' ' ' GLU . 17.5 tpt180 -91.3 119.86 31.7 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.996 0.427 . . . . 0.0 110.639 -171.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.546 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -93.54 140.05 30.05 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.021 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.8 mp -114.0 -45.51 4.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.751 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.424 HG21 ' H ' ' A' ' 10' ' ' ARG . 3.0 m -109.6 177.55 4.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.401 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.424 ' H ' HG21 ' A' ' 9' ' ' THR . 81.6 mtt180 -112.05 -177.97 3.3 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.539 0.209 . . . . 0.0 110.794 -175.118 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.56 172.59 22.97 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.026 -178.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -149.71 119.73 7.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.044 0.45 . . . . 0.0 110.401 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -125.44 139.25 53.8 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.534 -174.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.26 125.23 44.04 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.925 -177.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.97 -160.91 23.1 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.996 175.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.688 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.9 mt-10 -74.67 130.94 40.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 122.822 0.449 . . . . 0.0 111.036 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.36 128.91 34.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.659 177.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.2 tt -118.97 114.74 23.03 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 177.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.21 126.39 60.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.978 0.418 . . . . 0.0 111.039 -173.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.5 m -129.56 95.35 3.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 177.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -84.49 83.79 7.88 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.123 0.487 . . . . 0.0 110.117 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -160.73 161.05 32.09 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.419 -0.81 . . . . 0.0 108.856 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 87.6 m-85 -101.26 89.14 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.582 ' HB ' ' HG2' ' A' ' 39' ' ' GLU . 32.7 pt -108.66 170.88 2.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.543 -172.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.27 123.01 39.75 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.488 -177.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.404 ' HE2' ' HA3' ' A' ' 64' ' ' GLY . 44.3 t80 -78.73 -4.91 51.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.334 0.588 . . . . 0.0 109.96 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.513 ' HA ' HG21 ' A' ' 63' ' ' VAL . 4.1 pp -72.93 -16.21 61.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.147 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.52 44.46 0.72 Allowed Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.29 -84.34 0.37 Allowed Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.265 -179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.472 HD13 ' N ' ' A' ' 30' ' ' ILE . 4.1 mp -92.42 137.8 21.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 178.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -62.01 138.73 58.41 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.694 0.283 . . . . 0.0 110.351 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.532 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.8 pttp -74.5 -8.58 56.79 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -171.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.661 ' HA ' ' ND2' ' A' ' 74' ' ' ASN . 33.4 mt-10 -127.03 -44.47 1.61 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.3 p -96.92 -16.97 20.42 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -177.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.64 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.11 16.74 79.33 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.941 177.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.501 HD11 ' HB3' ' A' ' 47' ' ' SER . 35.5 mm -90.46 133.5 32.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.94 123.14 15.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.89 0.376 . . . . 0.0 110.63 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -87.24 -47.18 9.05 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.759 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.582 ' HG2' ' HB ' ' A' ' 24' ' ' ILE . 4.8 tp10 -62.06 134.76 57.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.671 179.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -93.03 160.85 14.68 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.269 0.557 . . . . 0.0 111.235 -175.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 47.9 t -178.68 -49.63 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -176.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 176.2 -45.98 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 114.642 -1.163 . . . . 0.0 109.718 174.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.78 13.25 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.936 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.2 tmmt? -65.91 128.68 36.99 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 116.74 -21.78 11.15 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.959 -176.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -87.98 156.48 19.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.982 0.42 . . . . 0.0 110.457 177.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.501 ' HB3' HD11 ' A' ' 36' ' ' ILE . 13.3 p -103.02 144.8 30.81 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.944 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.427 HG21 ' H ' ' A' ' 49' ' ' ALA . 0.0 OUTLIER -74.47 -76.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.608 175.046 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.427 ' H ' HG21 ' A' ' 48' ' ' VAL . . . 46.3 81.42 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.925 0.713 . . . . 0.0 112.925 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.09 3.78 88.79 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.64 -0.79 . . . . 0.0 113.303 177.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.688 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 52.0 mtt180 -94.6 162.28 13.86 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.411 -0.464 . . . . 0.0 110.902 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.438 HD13 ' N ' ' A' ' 52' ' ' ILE . 2.6 mp -104.99 120.18 55.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.445 ' O ' HD12 ' A' ' 81' ' ' ILE . 54.8 tp -99.06 132.85 44.08 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.483 -177.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.44 107.3 15.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.038 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.429 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 41.0 p90 -135.76 144.58 49.43 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 172.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -55.13 -55.19 3.37 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.824 2.349 . . . . 0.0 112.883 -177.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 23' ' ' TYR . . . 165.36 -161.7 35.1 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.738 -178.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . 161.56 -101.61 0.2 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.254 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.439 ' HD2' ' C ' ' A' ' 58' ' ' GLY . 14.0 mptt -125.92 98.44 5.52 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.665 0.269 . . . . 0.0 111.227 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.97 72.18 1.65 Allowed Glycine 0 N--CA 1.453 -0.198 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 176.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.431 ' O ' HG22 ' A' ' 63' ' ' VAL . 9.0 t -80.56 66.98 6.26 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 -171.102 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.56 ' HA ' HG23 ' A' ' 89' ' ' ILE . 24.4 p 53.89 16.91 1.18 Allowed 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.688 1.366 . . . . 0.0 114.688 171.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.513 HG21 ' HA ' ' A' ' 27' ' ' LEU . 74.1 t -87.37 -33.63 6.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 O-C-N 122.104 -0.373 . . . . 0.0 111.487 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.404 ' HA3' ' HE2' ' A' ' 26' ' ' PHE . . . -79.36 30.48 2.17 Favored Glycine 0 C--O 1.228 -0.27 0 C-N-CA 120.811 -0.709 . . . . 0.0 113.041 -178.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 8.1 p -90.96 -26.34 19.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.576 0.227 . . . . 0.0 111.448 -177.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -156.24 -21.61 0.1 Allowed 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 86.3 t -58.37 -32.88 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.521 ' HA ' HD11 ' A' ' 71' ' ' LEU . 10.3 mp -61.85 -28.22 69.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.512 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.493 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 61.6 tp -70.64 -39.8 73.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.905 0.383 . . . . 0.0 110.331 178.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -65.9 -32.35 73.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.911 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' A' ' 68' ' ' LEU . 97.3 mt -57.63 -39.55 77.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.488 175.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 49.2 ttp180 -71.52 -33.36 69.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.572 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -62.41 -33.8 75.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.245 0.545 . . . . 0.0 110.295 177.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . 0.661 ' ND2' ' HA ' ' A' ' 33' ' ' GLU . 92.0 m-20 -88.02 -14.33 39.31 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.906 178.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 79.19 13.56 82.75 Favored Glycine 0 N--CA 1.453 -0.205 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.541 178.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.64 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.5 m -106.79 8.68 9.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.127 0.489 . . . . 0.0 110.966 -176.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -70.7 150.45 95.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.483 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.49 147.68 52.56 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.458 2.105 . . . . 0.0 110.562 171.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.46 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 12.0 mttm -71.81 -35.53 69.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.922 0.391 . . . . 0.0 110.533 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.406 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -155.83 151.99 27.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.368 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.542 HG23 ' HB3' ' A' ' 101' ' ' LEU . 3.8 tp -129.52 120.84 51.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.905 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.696 HD12 HG21 ' A' ' 102' ' ' VAL . 4.7 mm -117.32 116.73 52.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 25.9 m120 -109.1 -179.67 3.91 Favored 'General case' 0 C--O 1.22 -0.471 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.474 ' O ' ' HB2' ' A' ' 103' ' ' GLU . 39.0 ttmt -82.55 -45.04 15.14 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -141.37 100.45 3.79 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 169.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -74.22 150.39 40.34 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -92.3 147.4 22.95 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.254 -175.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.411 ' O ' HG21 ' A' ' 92' ' ' VAL . 6.8 m -52.79 -36.93 59.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.419 -177.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.56 HG23 ' HA ' ' A' ' 62' ' ' THR . 49.5 mt -56.35 -47.54 81.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.006 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.9 mt -68.3 -38.78 79.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.378 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.92 -42.87 94.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.177 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.411 HG21 ' O ' ' A' ' 88' ' ' THR . 93.7 t -66.19 -42.95 92.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.77 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.9 -45.45 73.79 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.769 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.478 ' HB3' ' HB ' ' A' ' 99' ' ' ILE . . . -68.57 -30.06 68.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.677 0.275 . . . . 0.0 111.519 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -62.76 -25.38 68.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.408 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.0 mtm -83.17 -26.42 30.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.349 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.493 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -96.5 1.02 51.09 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.939 -178.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 1.5 mp0 59.0 47.85 11.6 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.124 0.488 . . . . 0.0 110.855 -175.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.478 ' HB ' ' HB3' ' A' ' 94' ' ' ALA . 58.1 mt -107.74 89.39 5.2 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.882 176.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.506 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 36.6 Cg_exo -55.87 116.69 3.34 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.904 2.403 . . . . 0.0 112.195 -177.175 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.542 ' HB3' HG23 ' A' ' 81' ' ' ILE . 1.8 pt? -122.71 134.7 54.45 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.44 0.638 . . . . 0.0 110.792 178.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.696 HG21 HD12 ' A' ' 82' ' ' ILE . 14.4 m -130.31 170.16 19.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.546 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 7.9 pt-20 -119.41 132.48 55.83 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.315 0.578 . . . . 0.0 111.676 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.879 HG12 ' SG ' ' A' ' 5' ' ' CYS . 17.3 m -104.47 105.04 17.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.925 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.413 ' HA ' ' HG3' ' A' ' 84' ' ' LYS . 32.6 ttp180 -99.13 27.62 4.97 Favored 'General case' 0 C--N 1.32 -0.717 0 O-C-N 121.837 -0.539 . . . . 0.0 110.614 -177.442 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -123.87 131.88 53.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.125 178.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -71.33 -26.59 62.9 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.212 -176.144 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -65.22 -24.21 67.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.167 -177.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.578 ' O ' HG11 ' A' ' 113' ' ' VAL . 80.6 t80 -65.01 -48.6 73.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -66.69 -25.42 66.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.687 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -78.85 -25.98 44.05 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 115.487 -0.778 . . . . 0.0 111.627 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -94.32 -39.69 10.36 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.032 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.578 HG11 ' O ' ' A' ' 109' ' ' PHE . 11.4 p -89.8 137.97 20.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 111.17 -176.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -137.28 157.62 46.24 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.39 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 32.6 m -64.24 110.09 2.1 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.492 -175.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.08 -17.37 3.85 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.546 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 -82.66 156.86 23.61 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.966 0.413 . . . . 0.0 111.13 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.93 119.38 30.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.079 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.38 136.87 56.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.244 0.545 . . . . 0.0 111.078 -178.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.0 110.51 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.499 173.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.432 HG13 HD13 ' A' ' 82' ' ' ILE . 66.7 t -92.82 104.44 15.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.693 179.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -107.05 98.75 8.37 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.027 -179.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.12 -9.04 58.34 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.342 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -64.27 -39.41 93.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.581 175.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -102.63 -34.46 9.06 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.863 175.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 98.31 68.2 0.91 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.474 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -166.15 166.18 17.19 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.27 121.51 42.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.349 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -120.69 117.79 28.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.317 0.579 . . . . 0.0 110.678 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.569 HD12 HG22 ' A' ' 113' ' ' VAL . 0.9 OUTLIER -109.43 147.87 32.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.143 178.101 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 46.6 mm -110.01 128.58 66.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 173.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 C--N 1.317 -0.815 0 O-C-N 123.954 0.783 . . . . 0.0 109.939 -179.448 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.514 HG21 ' HB3' ' A' ' 130' ' ' LEU . 17.1 m . . . . . 0 N--CA 1.452 -0.341 0 CA-C-O 121.303 0.573 . . . . 0.0 112.219 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.422 ' HB3' ' HE3' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -137.21 140.51 41.77 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.079 173.06 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -127.5 151.09 49.31 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.924 0.392 . . . . 0.0 111.044 -173.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.9 127.02 44.72 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.044 177.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 4.4 p -120.87 173.44 7.23 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.734 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 tpm_? -94.04 121.5 35.59 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 176.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.559 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -86.53 97.39 10.48 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.413 . . . . 0.0 111.302 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.63 -45.12 19.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 173.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.3 172.08 6.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.549 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 55.9 mtt-85 -111.04 176.83 4.87 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.283 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.51 -178.14 16.42 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.668 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -155.51 114.78 3.59 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 156.37 41.25 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -169.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tm-20 -135.85 120.92 18.82 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.041 -0.981 . . . . 0.0 108.735 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.19 162.44 35.72 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 119.717 -1.23 . . . . 0.0 113.4 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.74 140.95 56.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.535 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.94 125.79 30.58 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.969 0.414 . . . . 0.0 111.651 -176.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.495 ' HA ' HG23 ' A' ' 115' ' ' THR . 7.9 tt -111.89 110.43 20.76 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 171.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.1 t -102.7 110.17 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.091 0.472 . . . . 0.0 110.824 -175.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.445 HG22 ' CD2' ' A' ' 18' ' ' LEU . 2.0 p -99.43 112.92 25.04 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.814 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.0 pttt -92.32 0.72 57.47 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.856 0.836 . . . . 0.0 109.105 176.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -79.61 -173.39 3.75 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.54 -1.209 . . . . 0.0 109.675 174.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . 0.418 ' HB3' ' HA2' ' A' ' 58' ' ' GLY . 42.1 m-85 -121.0 93.99 4.2 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.297 0.57 . . . . 0.0 110.557 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.478 ' O ' ' HA3' ' A' ' 58' ' ' GLY . 31.8 mt -106.21 146.44 12.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.527 -176.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.567 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 33.9 t -131.74 162.27 30.87 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.453 ' HD2' HG12 ' A' ' 90' ' ' ILE . 64.0 m-85 -88.45 23.82 2.11 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.167 0.508 . . . . 0.0 111.007 -177.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.567 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 1.0 OUTLIER -74.93 -14.7 60.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.921 169.466 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.49 ' N ' HD12 ' A' ' 27' ' ' LEU . . . 139.84 57.65 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.727 -178.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.77 -42.23 6.12 Favored Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.866 -178.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.457 HG13 HG12 ' A' ' 37' ' ' VAL . 4.3 mp -93.41 146.46 6.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.668 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 20.0 t70 -70.43 138.98 51.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.825 0.345 . . . . 0.0 110.175 176.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.406 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.2 ptmt -79.77 -10.49 59.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.406 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 43.0 mt-10 -121.21 -40.45 2.59 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -176.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.0 p -92.57 -18.8 22.63 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.997 0.427 . . . . 0.0 111.384 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.452 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 76.51 11.13 85.43 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.093 -179.013 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.0 mm -86.92 132.37 32.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.457 HG12 HG13 ' A' ' 30' ' ' ILE . 11.8 m -67.87 129.49 32.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.281 0.562 . . . . 0.0 111.355 178.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.668 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 72.4 mmtt -84.64 -37.14 21.4 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 174.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -94.51 90.62 6.26 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.512 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.981 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.5 t70 -146.96 -164.47 2.0 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.007 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 45.6 t -166.87 -41.2 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 120.818 0.342 . . . . 0.0 110.469 -177.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -103.93 -48.43 3.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.505 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -111.56 15.93 8.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.891 0.377 . . . . 0.0 111.336 -173.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.981 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 38.6 ttmt -50.26 128.9 20.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.171 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.72 -7.45 12.15 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.107 -175.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.449 ' HB3' ' NH1' ' A' ' 51' ' ' ARG . 22.0 mm-40 -93.3 145.26 24.59 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 110.282 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.474 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 34.6 t -97.7 148.39 23.39 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 20.5 m -86.82 2.06 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.983 0.421 . . . . 0.0 110.706 178.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.492 ' HB3' ' HA ' ' A' ' 76' ' ' VAL . . . -67.22 92.51 0.27 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.538 -176.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.99 5.36 33.16 Favored Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.328 -0.851 . . . . 0.0 113.443 171.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.488 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 0.8 OUTLIER -123.56 178.29 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 O-C-N 122.65 -0.324 . . . . 0.0 110.461 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.491 HD12 ' HB ' ' A' ' 119' ' ' VAL . 72.2 mt -108.1 130.02 61.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.165 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.584 ' HB3' HG12 ' A' ' 81' ' ' ILE . 60.3 tp -96.1 123.93 39.91 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.706 -176.058 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 54.4 t -123.79 108.77 21.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.749 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.432 ' HB3' ' OG1' ' A' ' 20' ' ' THR . 53.4 p90 -134.58 144.56 51.36 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.104 174.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 6.2 Cg_exo -74.81 -38.82 1.53 Allowed 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 123.018 2.479 . . . . 0.0 112.027 177.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.95 -165.48 31.88 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . -170.19 -134.14 1.7 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.13 -1.034 . . . . 0.0 113.284 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -69.2 158.59 34.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.653 0.263 . . . . 0.0 110.573 -178.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -83.09 -27.14 41.69 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.046 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.442 ' O ' HD23 ' A' ' 27' ' ' LEU . 22.8 m -76.61 73.59 3.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.348 0.594 . . . . 0.0 110.305 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.49 ' HG1' HG12 ' A' ' 89' ' ' ILE . 10.7 t -83.7 42.86 0.87 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.542 0.686 . . . . 0.0 111.333 -175.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.3 t -112.41 130.58 65.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.485 0.659 . . . . 0.0 111.196 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 150.86 -76.26 0.24 Allowed Glycine 0 N--CA 1.441 -0.98 0 CA-C-N 114.88 -1.055 . . . . 0.0 111.148 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.521 ' HB2' ' HB ' ' A' ' 89' ' ' ILE . 11.8 t 52.51 -161.03 0.1 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.811 0.444 . . . . 0.0 110.959 -177.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 69.32 -31.95 0.22 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.907 0.883 . . . . 0.0 113.298 175.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.533 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 23.0 m -56.79 -31.12 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.496 HD23 HG22 ' A' ' 67' ' ' VAL . 4.0 mm? -59.13 -40.52 85.73 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 178.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.497 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.3 tp -63.58 -44.65 93.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.194 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -62.13 -45.73 92.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.267 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 92.7 mt -59.36 -40.38 86.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.589 178.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.646 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -69.12 -37.73 78.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.061 -176.172 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.492 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 32.5 mmmt -70.01 -27.34 64.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.933 0.397 . . . . 0.0 110.709 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -87.61 -21.92 25.06 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.132 0.491 . . . . 0.0 110.435 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.79 20.43 37.0 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.216 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.492 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 21.9 m -118.41 24.24 4.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.015 0.436 . . . . 0.0 110.791 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -95.44 159.34 32.91 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.801 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.463 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 62.5 Cg_endo -76.45 151.69 33.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.178 1.919 . . . . 0.0 111.392 175.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.435 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 89.6 mttt -74.8 -30.96 61.58 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.73 0.3 . . . . 0.0 111.255 -178.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.96 161.73 36.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.43 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.584 HG12 ' HB3' ' A' ' 53' ' ' LEU . 71.2 mt -139.36 129.75 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 O-C-N 123.323 0.39 . . . . 0.0 110.176 178.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.582 HG22 HG21 ' A' ' 102' ' ' VAL . 4.6 mm -117.01 125.0 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -120.21 161.79 20.48 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.735 0.302 . . . . 0.0 111.218 -176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.5 tptp -94.64 -38.0 11.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.596 0.712 . . . . 0.0 109.24 171.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -133.14 116.05 15.8 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.545 175.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.8 t -106.95 171.51 7.33 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.453 -177.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.475 ' HG3' HG21 ' A' ' 62' ' ' THR . 1.4 tm-20 -137.44 159.82 40.85 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -175.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.415 ' H ' ' CD ' ' A' ' 87' ' ' GLU . 4.3 m -52.44 -47.79 66.2 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 122.941 0.496 . . . . 0.0 111.518 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.521 ' HB ' ' HB2' ' A' ' 65' ' ' SER . 2.1 pp -62.92 -28.89 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-O 121.014 0.435 . . . . 0.0 110.86 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.453 HG12 ' HD2' ' A' ' 26' ' ' PHE . 51.1 mt -75.16 -50.91 22.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.168 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.84 -48.36 82.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.084 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.66 -43.54 98.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.0 -41.74 98.48 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.6 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.546 ' HB2' ' HB ' ' A' ' 99' ' ' ILE . . . -71.6 -40.32 69.91 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.781 0.324 . . . . 0.0 111.056 -179.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.04 -41.15 91.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.516 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.1 mtm -64.84 -31.56 72.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.542 -177.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.646 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -99.96 5.02 45.23 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.289 0.478 . . . . 0.0 112.289 -175.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 63.07 52.4 2.56 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.71 0.766 . . . . 0.0 109.861 -176.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 94' ' ' ALA . 33.3 mm -111.59 89.62 11.15 Favored Pre-proline 0 C--N 1.318 -0.788 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.168 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.435 ' HD2' ' O ' ' A' ' 79' ' ' LYS . 73.2 Cg_exo -47.89 105.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.558 0 C-N-CA 122.979 2.453 . . . . 0.0 112.324 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.553 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 9.8 tt -122.83 129.97 52.33 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.622 -177.142 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.582 HG21 HG22 ' A' ' 82' ' ' ILE . 30.2 m -134.68 164.72 33.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.823 -178.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -110.27 112.53 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.674 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 7.2 p -91.99 122.93 43.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.294 0.568 . . . . 0.0 111.113 -175.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.26 6.01 49.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.187 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 9.8 t70 -108.72 126.03 52.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.117 0.484 . . . . 0.0 111.015 -175.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -71.55 -33.64 69.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.721 -177.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.573 ' HA ' ' HE3' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -61.54 -26.98 68.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.858 -176.993 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -56.48 -49.0 75.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.817 177.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -70.3 -26.86 63.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.089 -175.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.38 -36.11 46.37 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.235 178.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -85.89 -28.2 24.52 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 10.0 p -81.26 127.06 39.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.48 0.657 . . . . 0.0 111.232 -177.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.553 ' HZ2' ' HB3' ' A' ' 114' ' ' LYS . 3.2 mmmp? -122.94 154.82 37.87 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.44 176.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 18' ' ' LEU . 36.7 m -67.87 94.62 0.47 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.065 0.46 . . . . 0.0 110.525 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.32 -29.63 0.97 Allowed Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.181 -178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -71.98 169.37 16.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 174.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 6.9 tmm_? -115.87 132.33 56.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.035 0.445 . . . . 0.0 110.903 -175.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 17' ' ' ALA . 48.2 t -110.43 139.83 32.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.023 -176.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.07 112.57 41.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 172.062 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.415 HG22 HD11 ' A' ' 52' ' ' ILE . 62.9 t -101.91 114.94 42.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.145 -174.129 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 -106.06 92.91 4.35 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.5 -6.83 56.07 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.48 . . . . 0.0 110.639 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -73.38 -36.78 66.13 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.58 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -112.49 -4.24 14.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.134 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.427 ' CA ' ' HB1' ' A' ' 7' ' ' ALA . . . 74.73 71.7 1.11 Allowed Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.251 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -158.4 144.99 17.4 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -130.8 122.93 53.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.311 0.576 . . . . 0.0 110.911 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -109.3 118.34 36.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.514 ' HB3' HG21 ' A' ' 1' ' ' VAL . 64.9 tp -93.38 115.14 27.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.015 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 22.6 mm -91.3 111.73 24.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.5 0.667 . . . . 0.0 109.691 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 . . . . . 0 C--N 1.308 -1.21 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.001 -179.224 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.461 ' HD3' ' HG2' ' A' ' 129' ' ' GLU . 87.8 mttt 63.74 96.86 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.486 0.66 . . . . 0.0 110.113 -175.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -110.34 148.0 32.82 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.066 -172.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.78 130.38 39.81 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.289 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.607 ' SG ' HG21 ' A' ' 104' ' ' VAL . 26.0 m -121.43 179.4 4.45 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.03 0.443 . . . . 0.0 111.001 -176.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.633 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 40.2 ttt180 -94.79 121.88 36.84 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.775 178.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.525 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -84.41 130.71 34.75 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.775 0.321 . . . . 0.0 111.683 -174.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.1 mp -105.32 -48.12 9.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 173.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 26.7 p -117.19 -173.89 2.49 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.957 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -120.69 -177.26 3.43 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.635 0.255 . . . . 0.0 110.649 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 110.46 152.06 13.11 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.247 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.419 HH11 ' HD2' ' A' ' 12' ' ' ARG . 16.7 mtp180 -113.16 136.9 52.21 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.684 0.278 . . . . 0.0 110.271 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -137.35 132.15 33.17 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.433 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.533 ' HG3' HG21 ' A' ' 120' ' ' VAL . 35.6 tt0 -131.11 126.2 35.13 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.947 176.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 177.6 -158.27 23.4 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.048 -1.072 . . . . 0.0 113.086 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -72.2 136.15 46.32 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 122.807 0.443 . . . . 0.0 110.723 -177.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.467 ' HB3' HG23 ' A' ' 119' ' ' VAL . . . -99.75 131.94 45.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.384 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.3 tp -118.78 120.67 38.07 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.533 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.57 117.4 47.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.645 0.736 . . . . 0.0 110.194 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.435 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 8.9 m -108.48 134.57 51.09 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.497 -176.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.49 -21.54 18.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.194 0.521 . . . . 0.0 109.717 177.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -79.06 160.34 27.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.568 -175.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 6.1 p90 -117.67 121.31 40.53 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.68 174.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.0 mp -123.02 123.75 68.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 120.826 0.346 . . . . 0.0 111.138 -174.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.3 p -76.68 127.57 33.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 169.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.872 ' HB2' HG11 ' A' ' 63' ' ' VAL . 97.1 m-85 -74.83 78.67 2.1 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.668 0.747 . . . . 0.0 111.944 -173.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.3 mt -120.06 -47.97 2.36 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 170.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.2 -142.78 3.88 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 113.848 -1.523 . . . . 0.0 110.43 172.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.59 -48.18 3.52 Favored Glycine 0 C--O 1.222 -0.598 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.445 HD13 ' N ' ' A' ' 30' ' ' ILE . 3.1 mp -111.88 131.73 62.46 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 174.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -68.01 123.93 21.99 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.936 0.398 . . . . 0.0 109.952 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 45.8 pttt -80.62 -5.09 56.4 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -172.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -103.92 -33.62 8.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.829 0.347 . . . . 0.0 111.214 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.5 p -109.68 -28.16 8.98 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.914 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.581 ' CA ' HG12 ' A' ' 76' ' ' VAL . . . 89.42 9.7 66.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.43 -177.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.503 HD11 ' HB3' ' A' ' 47' ' ' SER . 48.7 mm -84.05 124.97 40.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.571 0.224 . . . . 0.0 110.614 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 20.7 m -68.78 116.67 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.759 0.79 . . . . 0.0 110.408 175.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 10.4 mmmm -89.58 -24.56 21.68 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.434 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -65.0 132.38 49.08 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.333 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.413 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 25.8 t70 -68.03 133.4 48.96 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.069 0.461 . . . . 0.0 111.403 -177.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 23.1 p -174.22 -170.64 0.54 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.516 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -83.23 -16.92 44.56 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.484 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.1 mt -100.17 15.17 4.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 122.12 0.962 . . . . 0.0 109.32 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.413 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 82.1 tttt -62.04 134.85 57.14 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.489 -1.232 . . . . 0.0 111.45 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 98.46 -10.91 63.23 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.572 -0.74 . . . . 0.0 113.231 177.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -92.47 170.45 9.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.307 0.575 . . . . 0.0 111.732 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.503 ' HB3' HD11 ' A' ' 36' ' ' ILE . 6.2 p -110.97 142.43 43.09 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.683 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.1 9.06 8.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.417 0.627 . . . . 0.0 109.881 175.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.452 ' CB ' ' HA ' ' A' ' 76' ' ' VAL . . . -75.24 95.45 3.15 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.21 28.79 12.42 Favored Glycine 0 C--N 1.317 -0.508 0 CA-C-N 114.705 -1.134 . . . . 0.0 113.609 172.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -130.65 177.76 7.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.719 0.26 . . . . 0.0 110.675 174.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.653 HG13 ' HB2' ' A' ' 80' ' ' ALA . 2.5 mp -89.37 118.55 34.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 35.8 tp -106.4 116.6 32.21 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.15 -177.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.48 107.77 23.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.194 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.435 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 36.7 p90 -134.42 153.43 79.23 Favored Pre-proline 0 C--N 1.32 -0.714 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.843 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 -40.1 79.15 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.717 2.278 . . . . 0.0 111.982 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.39 -144.02 12.25 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 170.96 -177.02 44.18 Favored Glycine 0 N--CA 1.445 -0.764 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.778 178.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -93.26 104.66 16.82 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.57 80.73 1.37 Allowed Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.985 -0.626 . . . . 0.0 113.009 -173.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 8.0 t -128.35 129.69 46.63 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 4.3 m 66.71 17.46 10.59 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-O 121.467 0.651 . . . . 0.0 110.826 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.898 ' HB ' HD12 ' A' ' 89' ' ' ILE . 69.9 t -70.78 140.81 17.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.326 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.81 65.89 2.15 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.127 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.603 ' HB3' ' HB ' ' A' ' 89' ' ' ILE . 12.0 p -52.07 -39.71 60.1 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 122.714 0.406 . . . . 0.0 111.94 177.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -69.32 -27.52 65.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 110.967 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.424 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 47.8 t -68.41 -26.84 34.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.585 -177.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.601 HD12 ' HA3' ' A' ' 93' ' ' GLY . 94.9 mt -57.92 -32.75 68.08 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.054 178.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.498 ' HA ' ' HB3' ' A' ' 97' ' ' ALA . 57.7 tp -67.5 -46.08 73.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.322 178.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -65.21 -38.24 89.81 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.484 HD13 HD23 ' A' ' 68' ' ' LEU . 94.2 mt -58.43 -45.14 89.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.389 176.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.412 ' HD3' ' O ' ' A' ' 72' ' ' ARG . 0.2 OUTLIER -68.84 -37.91 79.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.614 -178.042 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -62.93 -33.88 76.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.024 0.44 . . . . 0.0 110.702 176.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -86.35 -18.15 32.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.623 -177.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 95.2 1.31 62.8 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.262 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.581 HG12 ' CA ' ' A' ' 35' ' ' GLY . 71.2 t -79.65 -30.36 13.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 C-N-CA 122.71 0.404 . . . . 0.0 111.585 -175.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.99 144.7 98.9 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.696 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.26 141.86 94.65 Favored 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.304 2.003 . . . . 0.0 110.926 175.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 tttt -74.81 -16.5 60.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.119 0.485 . . . . 0.0 110.005 -175.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.653 ' HB2' HG13 ' A' ' 52' ' ' ILE . . . -164.27 142.94 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.518 176.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.484 HG13 ' HG ' ' A' ' 101' ' ' LEU . 9.3 pt -128.68 120.21 51.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.366 0.603 . . . . 0.0 111.115 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.779 HG22 HG21 ' A' ' 102' ' ' VAL . 1.2 mm -113.1 116.66 53.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -123.16 161.73 23.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 112.076 -171.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -99.46 -34.45 10.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.055 174.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -125.93 131.98 52.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.867 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -130.26 174.44 9.83 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.466 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -135.82 162.45 32.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.896 0.379 . . . . 0.0 110.553 -178.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.501 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.6 m -60.19 -51.57 69.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.47 -177.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.898 HD12 ' HB ' ' A' ' 63' ' ' VAL . 9.1 pt -58.35 -32.03 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.619 -179.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.2 mm -68.7 -45.52 81.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.45 -38.43 89.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.022 178.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 88' ' ' THR . 93.0 t -62.94 -50.48 79.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.716 178.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.601 ' HA3' HD12 ' A' ' 68' ' ' LEU . . . -60.26 -43.97 97.96 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.144 178.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.59 -36.15 82.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 111.38 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -69.18 -42.79 75.38 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.33 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 58.4 mtm -73.86 -36.62 64.87 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.577 -176.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.498 ' HB3' ' HA ' ' A' ' 69' ' ' LEU . . . -89.37 -9.75 49.18 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.764 -176.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.415 ' HA ' ' OE1' ' A' ' 98' ' ' GLU . 2.8 tp10 65.91 72.54 0.4 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.824 0.821 . . . . 0.0 110.161 -175.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.442 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 60.6 mt -127.15 90.11 50.05 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 114.759 -1.109 . . . . 0.0 109.734 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 4.4 Cg_exo -39.3 110.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 123.985 3.123 . . . . 0.0 112.993 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.484 ' HG ' HG13 ' A' ' 81' ' ' ILE . 4.7 tt -119.66 123.43 43.8 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.368 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.779 HG21 HG22 ' A' ' 82' ' ' ILE . 8.6 m -128.17 139.82 50.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.238 0.542 . . . . 0.0 110.651 176.805 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.633 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 43.6 tt0 -88.92 123.14 32.99 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.54 -178.17 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.607 HG21 ' SG ' ' A' ' 5' ' ' CYS . 96.3 t -107.27 117.72 53.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.793 178.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 24.2 mtm180 -107.44 14.09 26.25 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.237 0.541 . . . . 0.0 110.06 177.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -108.62 130.74 55.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.51 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -71.92 -28.07 63.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.65 -175.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -73.39 -18.25 61.18 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -172.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -63.03 -48.31 79.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.955 0.407 . . . . 0.0 109.984 176.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -71.98 -22.71 61.4 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.364 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -72.81 -42.15 64.15 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.733 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.03 -36.86 30.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.009 -175.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.65 136.72 24.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-O 121.314 0.578 . . . . 0.0 111.091 -176.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.548 ' HB2' ' HZ2' ' A' ' 114' ' ' LYS . 9.7 mtmp? -126.18 158.77 34.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.949 176.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 50.0 m -65.16 111.46 2.95 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 172.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.92 1.67 19.16 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.351 -0.928 . . . . 0.0 113.592 176.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . 0.493 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 28.2 m-20 -85.42 177.55 7.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 117.348 0.574 . . . . 0.0 110.519 176.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.401 ' NH2' HG13 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -115.42 119.79 37.42 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.0 110.152 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 17' ' ' ALA . 36.7 t -109.34 126.52 66.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.156 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.533 HG21 ' HG3' ' A' ' 14' ' ' GLU . 14.6 t -106.96 102.24 13.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 173.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.461 HG22 HG23 ' A' ' 128' ' ' VAL . 7.3 p -108.32 131.66 58.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.279 0.562 . . . . 0.0 111.78 -176.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -116.08 103.87 10.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.467 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.83 -18.71 50.16 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.369 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.2 -30.69 70.57 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.063 0.458 . . . . 0.0 110.588 177.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -108.89 -37.06 5.95 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.44 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 97.39 56.09 1.13 Allowed Glycine 0 N--CA 1.45 -0.386 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -145.04 133.46 21.85 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -172.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.461 HG23 HG22 ' A' ' 121' ' ' VAL . 49.0 t -118.8 112.32 37.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.057 -177.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.461 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 45.8 mt-10 -106.72 108.47 20.0 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.166 177.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -106.52 147.8 28.97 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 178.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.401 HG13 ' NH2' ' A' ' 118' ' ' ARG . 42.6 mm -112.27 133.86 56.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.06 177.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.418 -177.526 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.1 p . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 121.362 0.601 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.464 ' HD3' ' HE1' ' A' ' 127' ' ' TYR . 97.5 mttt -121.18 140.16 52.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.689 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -115.77 161.71 18.35 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.327 -177.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.01 127.26 50.08 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.158 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.7 p -120.55 176.11 5.66 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.972 0.415 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.446 ' HA ' ' NE ' ' A' ' 6' ' ' ARG . 2.6 tpm_? -98.43 124.75 43.3 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 175.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.513 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.06 140.0 46.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.9 0.381 . . . . 0.0 111.82 -175.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.1 mm -112.47 -57.26 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.424 HG23 ' HA ' ' A' ' 95' ' ' ALA . 52.7 p -113.13 -164.99 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.627 174.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.497 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 7.9 mpt_? -120.08 167.58 12.06 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.017 0.437 . . . . 0.0 111.486 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.732 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 134.46 145.84 5.31 Favored Glycine 0 CA--C 1.519 0.305 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.69 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.53 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 1.1 tmm_? -139.88 114.14 9.07 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.34 170.32 17.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.636 0.255 . . . . 0.0 111.428 -175.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -110.23 165.5 11.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.393 178.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.445 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -175.43 157.31 23.78 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 173.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.839 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 52.8 mt-10 -61.44 137.37 58.24 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 174.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.733 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -78.84 109.2 12.89 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.712 0.291 . . . . 0.0 110.463 -176.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.9 tt -102.4 109.55 21.24 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 173.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.6 t -120.64 114.09 42.43 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.153 -171.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 t -127.5 118.19 23.54 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.736 174.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 30.5 ttmt -93.53 20.91 6.76 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.89 0.853 . . . . 0.0 109.118 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.552 ' HG2' ' SG ' ' A' ' 41' ' ' CYS . 5.0 mp0 -97.66 147.68 24.08 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.79 -1.096 . . . . 0.0 109.7 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -82.8 100.61 10.42 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.073 0.463 . . . . 0.0 110.317 175.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.452 ' C ' ' H ' ' A' ' 26' ' ' PHE . 27.9 mm -91.44 1.25 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.269 -176.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.8 m 68.57 -26.81 0.14 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 171.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.452 ' H ' ' C ' ' A' ' 24' ' ' ILE . 47.1 t80 75.36 -31.25 0.2 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 123.749 0.82 . . . . 0.0 112.015 175.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.512 ' HA ' HG23 ' A' ' 63' ' ' VAL . 3.1 tm? -61.72 102.25 0.25 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.042 0.448 . . . . 0.0 110.176 177.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.24 26.13 69.03 Favored Glycine 0 C--N 1.335 0.486 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.2 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.431 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -83.61 -15.32 71.18 Favored Glycine 0 C--O 1.224 -0.523 0 C-N-CA 120.867 -0.683 . . . . 0.0 113.797 -173.377 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 59.7 mt -125.8 130.57 72.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 117.492 0.646 . . . . 0.0 111.18 -177.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.495 ' HA ' ' HE2' ' A' ' 38' ' ' LYS . 12.3 t70 -65.57 130.42 43.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.966 175.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.482 ' HA ' HD21 ' A' ' 71' ' ' LEU . 21.2 pttp -84.76 -0.12 52.62 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -171.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -101.69 -53.63 2.93 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.846 0.355 . . . . 0.0 111.608 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.513 HG21 HG12 ' A' ' 36' ' ' ILE . 3.5 t -109.69 -2.68 17.28 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.253 -0.431 . . . . 0.0 112.057 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.45 43.85 91.56 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.54 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.513 HG12 HG21 ' A' ' 34' ' ' THR . 47.3 mm -110.66 131.48 61.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 53.6 t -61.0 123.44 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.806 0.336 . . . . 0.0 110.599 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.495 ' HE2' ' HA ' ' A' ' 31' ' ' ASP . 63.8 mmtt -72.08 -47.99 47.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.221 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.44 ' HB3' HG23 ' A' ' 24' ' ' ILE . 7.8 tp10 -62.13 125.48 24.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.629 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.52 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 14.1 t70 -83.11 133.23 35.07 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.329 178.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.552 ' SG ' ' HG2' ' A' ' 22' ' ' GLU . 4.0 t -170.8 39.04 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 75.63 -29.94 0.19 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 114.984 -1.007 . . . . 0.0 111.945 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 41.8 mm -84.17 -10.47 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-O 121.623 0.725 . . . . 0.0 110.45 177.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.52 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 21.8 ttpp -59.64 135.94 57.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.126 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 111.34 -14.8 27.86 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.455 -0.879 . . . . 0.0 113.036 176.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -89.47 142.39 27.71 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.008 0.432 . . . . 0.0 111.236 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.435 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 20.3 m -85.36 136.66 33.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.552 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.4 m -89.05 -6.96 10.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.195 173.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.87 94.62 0.13 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.243 -176.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.67 13.66 49.84 Favored Glycine 0 C--N 1.313 -0.749 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.668 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.839 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 95.9 mtt180 -113.46 166.26 11.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.981 0.419 . . . . 0.0 111.051 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.445 HG12 ' HA3' ' A' ' 15' ' ' GLY . 39.3 mm -95.99 122.15 47.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.169 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.453 ' HB3' HG12 ' A' ' 81' ' ' ILE . 58.5 tp -93.2 113.26 25.44 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.768 0.318 . . . . 0.0 110.36 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.6 t -102.93 108.16 23.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 176.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.677 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.0 t80 -134.37 140.27 35.3 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.195 -172.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 15.2 Cg_endo -94.13 -56.5 0.01 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.914 2.409 . . . . 0.0 113.38 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -150.18 138.75 6.9 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.309 -176.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 59' ' ' LYS . . . -110.48 -82.38 1.3 Allowed Glycine 0 N--CA 1.443 -0.864 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 58' ' ' GLY . 38.4 ttmt 174.64 -70.59 0.01 OUTLIER 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.234 0.54 . . . . 0.0 109.734 178.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 138.5 -102.57 0.37 Allowed Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.428 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.2 t 70.24 -165.52 0.16 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 122.871 0.468 . . . . 0.0 110.898 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 5.2 t -102.0 58.12 0.82 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.812 0.815 . . . . 0.0 111.032 -175.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.512 HG23 ' HA ' ' A' ' 27' ' ' LEU . 41.3 t -70.69 -44.92 76.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.353 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -5.88 72.99 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.315 -177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 56.9 p 56.43 12.76 1.11 Allowed 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 113.577 0.954 . . . . 0.0 113.577 177.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -90.31 -6.29 55.27 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 122.094 -0.379 . . . . 0.0 111.891 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.539 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 66.4 t -62.56 -51.4 72.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.676 0.274 . . . . 0.0 110.689 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.27 -39.58 93.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.956 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.49 ' O ' ' HG2' ' A' ' 73' ' ' LYS . 56.4 tp -62.82 -46.08 89.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.565 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.51 -44.71 93.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.422 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.3 mt -54.43 -41.59 69.56 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.114 0.483 . . . . 0.0 110.397 177.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.556 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -65.04 -37.08 86.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.144 -178.159 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.49 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 34.5 mmtp -69.91 -25.29 63.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.214 -177.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -93.84 -22.82 18.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.285 0.564 . . . . 0.0 110.182 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.37 15.66 37.29 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.221 178.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.47 23.68 3.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.238 0.542 . . . . 0.0 110.701 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.87 156.03 41.03 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.054 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 42.1 Cg_endo -68.14 155.92 67.68 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.4 2.067 . . . . 0.0 112.129 175.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 53.9 mmtt -68.51 -41.86 79.39 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.824 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.427 ' HB1' HG11 ' A' ' 121' ' ' VAL . . . -163.69 165.97 22.71 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.251 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.453 HG12 ' HB3' ' A' ' 53' ' ' LEU . 63.9 mt -131.87 119.34 41.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.094 0.473 . . . . 0.0 110.24 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.592 HG21 HG22 ' A' ' 102' ' ' VAL . 3.8 mm -103.83 116.88 48.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.677 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.7 m120 -111.64 164.49 12.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.949 0.404 . . . . 0.0 111.503 -175.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -69.76 -54.14 15.09 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.711 175.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.596 ' HG2' ' OE2' ' A' ' 103' ' ' GLU . 4.8 tttm -139.75 22.59 2.48 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.515 178.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 30.5 m 72.48 124.03 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.618 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.482 ' HB3' ' HB ' ' A' ' 90' ' ' ILE . 8.8 tp10 -84.13 130.54 34.84 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 172.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.6 m -57.5 -50.2 73.84 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.962 0.41 . . . . 0.0 111.66 -173.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.1 mt -68.95 -35.14 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.199 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.482 ' HB ' ' HB3' ' A' ' 87' ' ' GLU . 59.7 mt -69.23 -38.07 77.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.36 -44.77 92.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.416 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -62.26 -49.28 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.994 0.426 . . . . 0.0 110.576 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.92 -42.24 99.72 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.466 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.499 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.06 -39.17 92.88 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.704 0.287 . . . . 0.0 111.149 -179.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.424 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -63.13 -41.89 99.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.923 178.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.5 mtm -72.49 -35.96 68.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.498 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.556 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -92.36 5.96 48.68 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 56.92 50.78 11.66 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.449 0.643 . . . . 0.0 110.911 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.499 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 62.1 mt -114.29 90.3 20.09 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.816 179.539 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.732 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 91.6 Cg_exo -35.3 112.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.352 0.733 0 C-N-CA 124.071 3.181 . . . . 0.0 113.998 -176.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.15 128.75 55.64 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.836 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.592 HG22 HG21 ' A' ' 82' ' ' ILE . 16.2 m -136.55 162.18 35.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.343 178.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.596 ' OE2' ' HG2' ' A' ' 85' ' ' LYS . 32.1 tt0 -115.88 119.09 34.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.814 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.423 HG12 ' H ' ' A' ' 106' ' ' ASP . 13.5 t -99.52 128.97 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.888 0.375 . . . . 0.0 110.4 177.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.493 ' NE ' ' HA ' ' A' ' 105' ' ' ARG . 3.2 mmp_? -92.02 24.8 3.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.223 0.535 . . . . 0.0 110.42 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.423 ' H ' HG12 ' A' ' 104' ' ' VAL . 35.9 t70 -141.96 111.9 6.81 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.698 -175.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -69.84 -26.68 64.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.846 178.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -63.51 -19.95 65.2 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.527 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.589 ' O ' HG12 ' A' ' 113' ' ' VAL . 49.9 t80 -61.25 -45.1 95.9 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 170.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -68.3 -22.05 64.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.277 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -83.64 -32.75 25.5 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.049 0.452 . . . . 0.0 110.522 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.7 -44.34 28.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.185 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.589 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.9 p -83.21 123.5 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 110.149 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -130.21 152.66 49.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.048 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.733 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 21.6 m -58.4 107.49 0.5 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.042 -179.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.32 -39.04 0.55 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.331 -0.938 . . . . 0.0 113.449 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . 0.729 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 1.7 t0 -101.09 -166.96 1.36 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 117.286 0.543 . . . . 0.0 110.997 -176.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.729 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -110.03 138.54 46.27 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.33 0.586 . . . . 0.0 112.559 -173.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.527 HG22 ' HB3' ' A' ' 17' ' ' ALA . 83.7 t -119.71 122.7 69.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.551 173.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.914 ' HB ' ' HG3' ' A' ' 129' ' ' GLU . 47.1 t -100.06 112.58 33.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.427 HG11 ' HB1' ' A' ' 80' ' ' ALA . 8.9 p -86.54 133.2 30.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.561 -177.545 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . 0.636 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 44.0 t-20 -126.06 94.64 4.15 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.252 0.549 . . . . 0.0 109.767 177.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 9' ' ' THR . . . -90.16 2.66 55.09 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.418 0.627 . . . . 0.0 110.107 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.452 ' HB3' ' OD1' ' A' ' 122' ' ' ASN . 4.5 t70 -73.7 -37.1 65.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.665 175.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -114.11 -15.36 12.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.573 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.06 66.89 1.74 Allowed Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -168.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . 0.636 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 9.2 t80 -146.24 144.75 30.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.146 -0.527 . . . . 0.0 109.744 -167.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.407 HG13 ' CE1' ' A' ' 109' ' ' PHE . 60.1 t -126.87 104.87 13.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 175.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.914 ' HG3' ' HB ' ' A' ' 120' ' ' VAL . 9.0 pt-20 -97.05 108.13 20.81 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.502 0.668 . . . . 0.0 109.931 179.169 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.9 tp -85.57 127.83 34.57 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.497 -178.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 5.2 mm -116.76 111.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -178.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.403 ' HA ' ' OD2' ' A' ' 117' ' ' ASP . 12.4 mp0 . . . . . 0 C--N 1.314 -0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.447 HG23 ' HB3' ' A' ' 130' ' ' LEU . 10.8 m . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 121.464 0.649 . . . . 0.0 111.914 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.422 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 28.1 mtpp -107.78 94.21 4.96 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.143 174.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -96.77 155.62 16.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.018 0.437 . . . . 0.0 111.379 -176.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.41 126.27 52.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.702 174.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.495 ' HB3' ' O ' ' A' ' 103' ' ' GLU . 80.3 m -118.93 179.59 4.1 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.029 -177.17 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.512 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 64.4 ttp85 -92.04 116.12 28.66 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -175.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.55 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -71.65 124.39 24.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.091 -0.958 . . . . 0.0 111.786 -173.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.414 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 44.5 mm -102.81 -47.99 10.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.734 176.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.553 ' OG1' HD22 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -107.16 -171.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.379 177.558 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 10' ' ' ARG . 39.3 mtt180 -115.33 -178.7 3.44 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 173.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.97 -176.81 36.42 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.846 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -161.14 143.31 12.21 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 -178.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.51 179.07 9.46 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.29 0.567 . . . . 0.0 111.494 -175.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -125.77 160.59 29.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.533 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.564 ' HA3' HG13 ' A' ' 52' ' ' ILE . . . 179.61 155.69 15.82 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.832 171.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.515 ' HB3' ' HD3' ' A' ' 51' ' ' ARG . 28.7 tt0 -75.44 137.95 41.32 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 175.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.494 ' HB2' HG22 ' A' ' 119' ' ' VAL . . . -78.0 134.92 37.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.119 0.485 . . . . 0.0 111.825 -169.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.501 HD22 HG21 ' A' ' 43' ' ' ILE . 6.3 tt -130.29 115.41 16.91 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 174.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.545 HG13 ' OG1' ' A' ' 115' ' ' THR . 9.9 p -103.47 130.94 53.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.198 0.523 . . . . 0.0 110.831 -175.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.778 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 29.1 m -108.82 127.52 54.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.031 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -99.88 -1.01 38.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.559 -175.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -96.99 158.98 15.17 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.358 0.599 . . . . 0.0 112.188 -173.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -104.38 91.24 3.82 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 27.4 pt -122.35 16.83 5.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -169.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.446 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 59.6 p 51.8 -154.54 0.17 Allowed 'General case' 0 CA--C 1.53 0.202 0 O-C-N 123.606 0.566 . . . . 0.0 110.485 -175.492 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -143.64 18.25 1.84 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.064 0.459 . . . . 0.0 110.626 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.13 -10.05 57.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.316 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.03 130.64 1.25 Allowed Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.183 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -173.27 -47.37 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.264 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.635 HG13 HG22 ' A' ' 37' ' ' VAL . 4.1 mp -88.27 134.63 27.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.729 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 29.2 t70 -77.89 147.25 35.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.687 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 9.5 ptpp? -82.76 -14.49 54.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.135 -174.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -100.79 -47.82 4.69 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.427 -175.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.9 p -92.91 -37.09 12.44 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.778 0.323 . . . . 0.0 111.735 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.8 20.03 48.91 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.336 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.2 mm -90.24 138.3 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.287 179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.635 HG22 HG13 ' A' ' 30' ' ' ILE . 96.3 t -79.81 102.26 5.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.139 0.495 . . . . 0.0 109.755 174.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.729 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 59.3 mttt -84.32 -28.64 26.93 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.706 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -96.14 78.66 3.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.614 0.721 . . . . 0.0 110.384 178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 1.028 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 9.2 t70 -147.82 -167.78 2.89 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.936 177.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.404 ' H ' ' CG ' ' A' ' 40' ' ' ASP . 71.5 m -144.82 -23.14 0.51 Allowed 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.611 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -133.86 -47.77 0.8 Allowed 'General case' 0 C--O 1.233 0.225 0 O-C-N 122.031 -0.418 . . . . 0.0 110.796 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.501 HG21 HD22 ' A' ' 18' ' ' LEU . 23.0 mm -75.83 -17.75 15.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 109.227 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 1.028 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 54.3 tttm -44.37 118.23 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 CA-C-N 114.166 -1.379 . . . . 0.0 112.156 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 130.83 -19.13 5.02 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.807 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -93.46 156.36 16.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.056 0.455 . . . . 0.0 111.692 -177.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.0 m -95.94 138.69 33.22 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.423 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.1 m -94.2 -3.69 10.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.993 0.425 . . . . 0.0 110.808 176.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.42 89.51 0.5 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.559 0.695 . . . . 0.0 110.868 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.682 ' HA2' ' HE3' ' A' ' 79' ' ' LYS . . . 112.6 2.98 25.64 Favored Glycine 0 C--N 1.313 -0.741 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.703 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.515 ' HD3' ' HB3' ' A' ' 16' ' ' GLU . 20.2 mmt85 -105.59 156.29 18.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.556 -0.322 . . . . 0.0 110.827 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.695 HG12 ' HB1' ' A' ' 80' ' ' ALA . 29.1 mt -97.29 117.65 42.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 169.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.42 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 28.1 tp -93.56 124.57 37.64 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.957 -171.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 62.6 t -123.85 107.51 18.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.892 0.377 . . . . 0.0 110.195 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.778 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 40.9 p90 -136.01 146.09 55.21 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 177.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.97 -29.55 34.02 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.851 2.367 . . . . 0.0 111.462 175.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.71 -60.63 4.79 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.747 176.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 81.14 -65.12 4.04 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -177.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.446 ' O ' ' HA ' ' A' ' 25' ' ' SER . 59.7 mttm -104.66 128.21 52.64 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -88.28 -37.72 7.54 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.63 177.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.4 m 63.99 -177.06 0.16 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 121.149 0.5 . . . . 0.0 111.294 178.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.5 p -119.23 11.32 12.28 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.188 0.518 . . . . 0.0 111.059 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.9 t -129.92 138.53 53.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.42 ' O ' HG22 ' A' ' 67' ' ' VAL . . . 152.4 -11.44 0.65 Allowed Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.038 -178.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.32 151.37 44.24 Favored 'General case' 0 C--N 1.321 -0.637 0 O-C-N 122.703 -0.292 . . . . 0.0 111.278 178.033 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 75.25 -35.46 0.28 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 174.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.479 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 29.8 m -62.79 -24.65 36.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -175.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.2 mp -69.0 -32.16 71.51 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.664 0.269 . . . . 0.0 110.576 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.4 tp -66.43 -38.48 87.5 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -61.21 -48.85 79.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.129 175.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.479 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 67.6 mt -60.59 -41.68 95.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.674 178.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.459 ' HD3' ' O ' ' A' ' 72' ' ' ARG . 0.0 OUTLIER -72.06 -35.61 69.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.097 -176.402 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -59.75 -38.41 81.68 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.434 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -82.6 -29.66 30.02 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 109.876 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 99.14 22.27 13.51 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.561 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.47 4.9 9.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.998 0.428 . . . . 0.0 111.156 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.32 154.54 66.41 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.767 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 27.7 Cg_endo -63.63 147.33 92.86 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.148 1.899 . . . . 0.0 111.075 174.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.682 ' HE3' ' HA2' ' A' ' 50' ' ' GLY . 97.2 mttt -73.32 -27.25 61.42 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.049 0.452 . . . . 0.0 110.725 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.695 ' HB1' HG12 ' A' ' 52' ' ' ILE . . . -157.79 157.48 33.43 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.305 176.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 34.1 mt -136.57 127.39 41.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 178.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.48 HG21 HG12 ' A' ' 104' ' ' VAL . 3.6 mm -121.67 118.26 55.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.404 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 11.8 m120 -130.43 -179.84 5.5 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.147 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.419 ' O ' ' HD3' ' A' ' 84' ' ' LYS . 4.1 tmtt? -109.86 -37.91 5.51 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 171.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -103.01 114.84 29.46 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -120.67 141.26 50.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.903 0.382 . . . . 0.0 110.266 177.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.49 ' HB2' HG13 ' A' ' 90' ' ' ILE . 81.2 mm-40 -108.94 159.65 16.64 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.11 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 m -60.01 -45.34 93.06 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.83 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.437 HD12 ' N ' ' A' ' 90' ' ' ILE . 2.5 pp -64.82 -31.08 52.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.725 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.49 HG13 ' HB2' ' A' ' 87' ' ' GLU . 69.3 mt -68.38 -45.79 81.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.984 0.421 . . . . 0.0 109.99 177.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.55 -48.27 82.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.965 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.06 -45.49 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.974 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.68 -43.28 99.47 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.61 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.89 -37.15 62.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 111.576 0.213 . . . . 0.0 111.576 -177.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.45 -38.83 85.42 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.737 0.303 . . . . 0.0 111.428 -178.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 59.1 mtm -71.22 -31.03 67.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.039 0.447 . . . . 0.0 111.054 -179.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.55 -2.86 58.47 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.432 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.528 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 3.9 tp10 62.4 43.95 7.66 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-O 121.49 0.662 . . . . 0.0 110.3 -177.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 59.0 mt -107.44 88.6 4.21 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.83 175.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 24.3 Cg_exo -62.14 118.22 5.1 Favored 'Trans proline' 0 C--O 1.233 0.267 0 C-N-CA 122.918 2.412 . . . . 0.0 112.665 -174.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.553 HD22 ' OG1' ' A' ' 9' ' ' THR . 1.9 pt? -118.96 147.09 44.43 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.95 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.55 HG11 ' HA ' ' A' ' 7' ' ' ALA . 26.9 m -136.97 158.33 36.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.014 178.288 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.512 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 30.3 tt0 -94.89 119.82 34.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.491 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.48 HG12 HG21 ' A' ' 82' ' ' ILE . 20.7 m -74.25 144.32 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.135 174.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -117.55 23.47 11.73 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.76 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 10.4 t70 -144.35 127.81 16.95 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -176.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -66.56 -36.76 83.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.367 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.57 ' HZ1' ' HB2' ' A' ' 108' ' ' LYS . 10.0 mtmp? -67.9 -18.35 64.76 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.324 -175.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -58.98 -39.89 83.17 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -67.69 -29.07 68.24 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.754 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.11 -40.14 60.09 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 177.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.03 -46.55 56.65 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.703 -176.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.0 p -66.0 138.02 23.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 121.106 0.479 . . . . 0.0 111.376 -175.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -138.06 151.07 47.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.989 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.545 ' OG1' HG13 ' A' ' 19' ' ' VAL . 80.4 m -70.17 118.37 12.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.605 -0.271 . . . . 0.0 110.319 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 120.69 -12.5 10.11 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.257 177.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.82 179.33 6.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.829 0.314 . . . . 0.0 111.127 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -109.18 120.81 43.64 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 121.046 0.45 . . . . 0.0 111.344 -175.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.494 HG22 ' HB2' ' A' ' 17' ' ' ALA . 52.1 t -123.02 137.39 56.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.485 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.437 ' CG2' ' HB3' ' A' ' 129' ' ' GLU . 6.0 m -114.43 134.56 57.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.654 170.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -112.96 133.95 57.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.165 0.507 . . . . 0.0 110.644 -178.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -129.29 94.85 3.89 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 174.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.39 -16.13 35.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.185 0.516 . . . . 0.0 110.293 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.32 -40.95 73.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.252 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -100.45 -25.26 14.27 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.153 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 90.41 68.76 1.2 Allowed Glycine 0 CA--C 1.516 0.124 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.352 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -158.38 146.94 18.77 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 122.468 0.307 . . . . 0.0 110.832 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.34 125.53 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.705 173.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.437 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 41.1 tt0 -109.1 112.61 24.87 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.234 0.54 . . . . 0.0 110.722 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.447 ' HB3' HG23 ' A' ' 1' ' ' VAL . 55.7 tp -105.86 122.59 46.41 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.957 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.8 mt -115.3 120.49 64.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--N 1.31 -1.148 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.282 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 N--CA 1.454 -0.271 0 CA-C-O 120.934 0.397 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.441 ' N ' ' HD2' ' A' ' 2' ' ' LYS . 11.4 mptt -101.46 113.66 26.96 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -93.85 148.21 22.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.828 0.346 . . . . 0.0 110.764 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.06 125.86 40.0 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.665 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.8 m -120.36 175.14 6.11 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.534 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 40.9 ttm180 -101.28 121.21 41.47 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.526 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -69.83 114.05 7.65 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.765 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 mm -90.75 -66.56 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 174.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.5 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 21.2 p -96.18 -170.95 2.2 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 173.072 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.27 164.71 24.98 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.056 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.05 155.54 10.96 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.052 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 57.9 ttt180 -115.87 117.08 29.18 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.908 0.385 . . . . 0.0 110.143 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.461 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -119.01 138.18 53.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.994 0.426 . . . . 0.0 111.352 -175.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.468 ' HG3' HG22 ' A' ' 120' ' ' VAL . 20.6 tt0 -112.0 139.49 47.47 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.053 178.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.411 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -172.7 170.66 43.75 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.473 175.045 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -82.63 127.48 33.41 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 52' ' ' ILE . . . -90.2 131.58 35.96 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -169.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mp -112.75 130.52 56.04 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.148 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.484 HG13 HG13 ' A' ' 113' ' ' VAL . 48.2 t -119.47 126.16 75.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.552 -172.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.4 t -118.27 139.52 51.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 176.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -91.65 -9.39 44.16 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.239 0.542 . . . . 0.0 110.033 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -95.37 143.86 26.38 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.824 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -85.42 153.62 22.38 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.869 177.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.411 ' O ' ' HA3' ' A' ' 58' ' ' GLY . 41.0 pt -122.0 -178.99 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.197 0.523 . . . . 0.0 111.5 -175.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.3 p -111.32 124.38 52.12 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.767 -0.652 . . . . 0.0 109.641 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.713 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 1.3 m-85 -76.36 95.61 3.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.345 0.593 . . . . 0.0 110.824 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 pp -165.83 -162.57 0.57 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.708 -1.133 . . . . 0.0 109.164 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -73.34 67.12 1.53 Allowed Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.579 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.42 -23.03 10.63 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 121.21 -0.519 . . . . 0.0 112.401 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.459 HG12 HG23 ' A' ' 37' ' ' VAL . 60.3 mt -101.92 138.21 26.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 177.032 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -69.34 133.02 47.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.605 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.467 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 60.8 pttt -78.52 -16.72 57.16 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -173.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.5 mm-40 -94.73 -52.32 4.33 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -174.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.537 HG21 HG12 ' A' ' 36' ' ' ILE . 7.6 t -106.3 -2.94 21.75 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 111.795 0.294 . . . . 0.0 111.795 -176.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.558 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.24 37.8 93.22 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.226 175.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.537 HG12 HG21 ' A' ' 34' ' ' THR . 49.7 mm -104.02 128.74 57.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.459 HG23 HG12 ' A' ' 30' ' ' ILE . 21.3 t -72.29 117.75 16.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.865 0.364 . . . . 0.0 110.181 178.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -83.64 -36.27 23.96 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.266 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -64.98 132.79 50.21 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 176.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.541 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 9.0 t70 -80.38 136.83 36.45 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.287 0.565 . . . . 0.0 111.832 -170.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 79.4 m -144.55 28.04 1.33 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.033 -0.985 . . . . 0.0 109.105 177.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 70.26 -69.12 0.18 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.28 -177.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 46.6 pt -80.39 5.43 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.27 0.557 . . . . 0.0 111.203 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.541 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER -68.18 139.41 56.09 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.254 178.676 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.94 -1.29 1.72 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.635 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -102.58 159.8 15.13 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.663 0.268 . . . . 0.0 110.569 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.4 p -82.1 121.96 27.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-O 121.28 0.562 . . . . 0.0 110.041 176.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.0 m -86.71 19.26 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.438 -176.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.13 92.16 0.17 Allowed 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.706 0.765 . . . . 0.0 111.128 -176.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.499 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 84.92 24.32 45.65 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 114.735 -1.121 . . . . 0.0 112.23 177.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.442 HH11 ' HD2' ' A' ' 51' ' ' ARG . 12.5 mmt180 -98.08 163.96 12.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.627 0.251 . . . . 0.0 110.728 178.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 17' ' ' ALA . 51.0 mm -102.15 118.37 48.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 175.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.517 HD22 ' HB3' ' A' ' 78' ' ' PRO . 4.3 mm? -106.7 125.3 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.922 0.391 . . . . 0.0 111.221 -177.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.459 ' HB ' HG21 ' A' ' 19' ' ' VAL . 59.7 t -110.7 106.38 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.849 176.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -136.59 148.12 62.43 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.787 176.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.433 ' O ' ' HG2' ' A' ' 84' ' ' LYS . 32.1 Cg_exo -59.61 -45.28 26.46 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.416 2.077 . . . . 0.0 111.955 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.89 1.66 Allowed Glycine 0 N--CA 1.446 -0.666 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . 138.02 -140.71 11.41 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.173 178.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -92.46 103.21 15.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.915 0.388 . . . . 0.0 110.142 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -91.57 85.31 1.25 Allowed Glycine 0 N--CA 1.447 -0.621 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.742 -176.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.8 m -78.63 155.79 29.38 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 176.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.51 ' HA ' HG22 ' A' ' 89' ' ' ILE . 12.0 t -68.21 -20.24 64.82 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.774 0.321 . . . . 0.0 111.329 -175.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.8 p -67.2 -28.07 41.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.289 0.566 . . . . 0.0 110.462 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -87.47 11.91 64.53 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.98 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 25.4 t -83.29 -56.03 3.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.936 0.398 . . . . 0.0 110.581 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -78.31 -15.46 58.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.934 -174.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.425 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 34.4 m -66.42 -28.58 43.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.239 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 98.9 mt -62.35 -40.77 97.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.988 0.423 . . . . 0.0 110.168 178.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.7 tp -69.4 -43.12 74.1 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.266 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.498 HD21 ' C ' ' A' ' 70' ' ' ASN . 0.2 OUTLIER -57.36 -49.93 74.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.913 178.477 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.537 ' CB ' ' HB3' ' A' ' 77' ' ' ALA . 97.9 mt -63.49 -43.52 97.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.054 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.414 ' HD3' ' C ' ' A' ' 72' ' ' ARG . 0.3 OUTLIER -66.83 -38.95 87.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.708 0.289 . . . . 0.0 110.347 -177.438 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.46 ' HD2' ' O ' ' A' ' 73' ' ' LYS . 2.4 tmmm? -61.48 -32.1 72.09 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.53 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -91.37 -7.73 50.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.267 0.556 . . . . 0.0 110.143 178.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.21 16.34 72.05 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.0 174.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.558 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.9 m -108.25 7.56 9.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.776 0.322 . . . . 0.0 111.448 -177.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.537 ' HB3' ' CB ' ' A' ' 71' ' ' LEU . . . -92.45 159.95 35.79 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.501 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.517 ' HB3' HD22 ' A' ' 53' ' ' LEU . 34.7 Cg_exo -58.41 150.17 69.63 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.373 2.049 . . . . 0.0 111.12 172.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.499 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 79.0 tttt -81.49 -24.68 36.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.151 0.5 . . . . 0.0 109.828 -178.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.47 ' HB2' HD13 ' A' ' 52' ' ' ILE . . . -168.37 154.29 6.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.893 176.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.498 HG21 ' HB2' ' A' ' 53' ' ' LEU . 25.5 pt -136.25 146.1 29.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.821 0.343 . . . . 0.0 111.295 -178.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.587 HG21 HG21 ' A' ' 102' ' ' VAL . 4.7 mm -118.82 124.22 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.477 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 14.2 m120 -122.39 171.22 9.22 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -176.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.433 ' HG2' ' O ' ' A' ' 56' ' ' PRO . 63.1 pttt -96.97 -32.57 11.95 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.4 0.619 . . . . 0.0 110.321 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.406 ' NZ ' ' HA ' ' A' ' 85' ' ' LYS . 1.4 tppm? -138.02 113.15 9.24 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.665 177.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.3 m -99.03 127.68 45.01 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.782 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.68 152.12 22.01 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 16.3 m -56.64 -39.52 73.83 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.693 0.283 . . . . 0.0 110.997 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.51 HG22 ' HA ' ' A' ' 62' ' ' THR . 80.8 mt -55.38 -41.4 62.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-O 121.335 0.588 . . . . 0.0 110.686 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 25.8 mm -71.77 -41.65 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.247 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.41 81.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.227 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -60.31 -45.54 96.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.829 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.22 -48.07 85.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.52 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.28 -33.17 74.73 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.534 0.206 . . . . 0.0 111.472 -178.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.98 -45.07 90.7 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.911 0.386 . . . . 0.0 111.068 178.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.6 mtm -69.02 -33.14 73.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.138 -178.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -85.74 -7.24 58.9 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.54 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.442 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 63.2 mt-10 60.4 48.52 7.74 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.501 0.667 . . . . 0.0 110.471 -177.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.3 90.07 7.85 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.026 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.5 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 50.0 Cg_exo -52.8 115.77 2.46 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.764 2.309 . . . . 0.0 112.202 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pt? -129.77 143.85 51.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.004 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 82' ' ' ILE . 17.4 m -136.18 155.29 34.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.918 -178.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.534 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 2.6 pt-20 -102.93 137.08 41.6 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.057 0.456 . . . . 0.0 111.618 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 2.2 m -125.17 109.41 22.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.53 173.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.404 ' HD3' ' H ' ' A' ' 105' ' ' ARG . 0.0 OUTLIER -87.6 17.42 4.65 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.451 0.643 . . . . 0.0 110.156 176.789 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -95.12 123.28 38.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.058 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -71.45 -38.75 71.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.428 -176.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.53 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 62.3 mttm -70.81 -18.83 62.72 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -171.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -56.07 -49.85 72.62 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 171.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -75.72 -26.48 57.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.511 0.672 . . . . 0.0 110.231 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.53 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.3 tt0 -65.02 -44.57 88.7 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.314 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -96.84 -27.97 14.46 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.484 HG13 HG13 ' A' ' 19' ' ' VAL . 11.0 p -67.24 134.75 29.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 111.225 -175.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -110.98 157.13 20.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.421 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 8.8 t -87.41 127.97 35.21 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.483 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.57 0.4 24.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.169 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -101.78 -172.1 2.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.808 0.304 . . . . 0.0 110.871 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -103.07 127.37 50.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.368 . . . . 0.0 111.574 -172.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.501 ' HA ' ' O ' ' A' ' 129' ' ' GLU . 73.9 t -134.07 123.15 43.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.322 176.083 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.468 HG22 ' HG3' ' A' ' 14' ' ' GLU . 81.2 t -114.82 125.05 72.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.2 p -107.9 123.89 63.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.456 0.646 . . . . 0.0 111.252 -177.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -103.58 95.97 6.41 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.121 173.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.11 6.03 17.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.956 0.408 . . . . 0.0 110.979 -176.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.01 -38.99 79.56 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.264 0.554 . . . . 0.0 109.798 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -115.19 -22.84 9.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.888 175.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 92.72 66.3 1.09 Allowed Glycine 0 C--O 1.228 -0.232 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -174.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -144.29 125.11 14.24 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -169.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 24.6 m -113.33 134.29 56.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.29 0.567 . . . . 0.0 111.823 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 119' ' ' VAL . 46.3 mt-10 -96.55 107.79 20.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.17 176.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.8 tp -101.3 108.99 20.77 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 175.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.5 mm -120.13 125.72 74.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.9 0.381 . . . . 0.0 110.297 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 . . . . . 0 C--N 1.318 -0.79 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.426 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 121.443 0.64 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.693 ' HE3' ' HG2' ' A' ' 129' ' ' GLU . 52.0 mtpt -121.49 121.39 37.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.231 -0.895 . . . . 0.0 108.606 170.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.485 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 96.6 m-85 -97.17 150.11 21.25 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.99 0.424 . . . . 0.0 111.37 -173.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.76 122.15 46.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.733 177.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.466 ' SG ' HG23 ' A' ' 102' ' ' VAL . 7.1 p -120.49 171.16 8.74 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.123 -177.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.637 ' HB3' ' HB2' ' A' ' 103' ' ' GLU . 7.8 tpt180 -93.5 115.8 28.31 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 176.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.538 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -74.88 110.31 9.07 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.589 -178.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.2 mm -85.06 -55.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 172.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.6 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -100.17 174.73 6.01 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 171.925 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 43.1 mtm180 -119.56 174.7 6.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.804 0.335 . . . . 0.0 110.434 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.4 144.8 6.84 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.096 -178.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.494 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 60.1 mtm180 -119.16 131.64 55.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 177.582 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.57 145.29 23.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.519 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.06 140.92 52.5 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.158 -0.473 . . . . 0.0 109.754 177.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -170.26 175.79 44.11 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.522 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -67.08 128.15 35.28 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.482 ' HB3' HG23 ' A' ' 119' ' ' VAL . . . -80.9 125.29 29.94 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.984 -176.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.1 tt -108.39 109.07 20.28 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 175.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.439 HG22 ' HB ' ' A' ' 54' ' ' VAL . 75.1 t -103.15 128.8 55.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.948 0.404 . . . . 0.0 110.669 -174.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.414 HG21 ' HB3' ' A' ' 22' ' ' GLU . 7.2 m -123.94 108.69 12.68 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.523 -177.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -89.54 16.54 7.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.402 0.62 . . . . 0.0 110.315 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.492 ' CG ' HG23 ' A' ' 24' ' ' ILE . 6.0 tp10 -83.87 159.38 21.35 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.419 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . 0.445 ' N ' ' HG3' ' A' ' 22' ' ' GLU . 23.8 m-85 -119.69 81.48 1.73 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.28 0.562 . . . . 0.0 110.007 176.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.492 HG23 ' CG ' ' A' ' 22' ' ' GLU . 18.4 pt -107.63 168.53 3.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.827 0.822 . . . . 0.0 111.744 -176.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.55 123.17 34.0 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 114.306 -1.315 . . . . 0.0 109.063 176.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -56.29 -70.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.205 0 O-C-N 123.276 0.36 . . . . 0.0 110.483 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt 59.28 -85.42 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 O-C-N 123.791 0.682 . . . . 0.0 111.991 176.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 168.75 42.08 0.03 OUTLIER Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.0 -7.91 84.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.255 -174.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.441 HG13 HG11 ' A' ' 37' ' ' VAL . 4.1 mp -79.83 119.49 29.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 176.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.09 127.8 33.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.106 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.445 ' HE3' ' OD1' ' A' ' 70' ' ' ASN . 0.0 OUTLIER -74.64 -10.2 59.31 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -172.749 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -97.81 -35.98 10.35 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.749 0.309 . . . . 0.0 111.34 -176.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.6 p -105.53 -36.42 7.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.342 -0.39 . . . . 0.0 112.013 -178.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.93 15.41 59.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.634 -175.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 49.2 mm -95.44 138.35 21.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.441 HG11 HG13 ' A' ' 30' ' ' ILE . 15.3 m -72.49 116.21 14.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.371 0.605 . . . . 0.0 110.762 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -88.75 -9.41 51.98 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.382 -178.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -90.29 151.16 21.62 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.429 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 10.5 t70 -76.9 134.69 38.89 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.316 -171.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 7.6 p -167.32 173.38 8.94 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.427 ' HG3' ' N ' ' A' ' 43' ' ' ILE . 5.3 pt-20 -62.08 -36.26 81.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 -178.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.427 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 15.1 pt -105.38 43.54 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 122.053 0.93 . . . . 0.0 110.144 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.429 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 86.4 tttt -67.47 121.53 16.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.778 -179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.71 -2.48 29.0 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.886 -178.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -79.54 155.7 28.09 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.937 0.398 . . . . 0.0 111.052 177.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.1 p -102.8 136.49 42.52 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.326 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.1 m -98.11 -1.36 10.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.905 0.383 . . . . 0.0 110.957 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.31 95.03 0.29 Allowed 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.802 -176.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.08 17.6 39.89 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.196 175.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.5 mmt180 -109.64 150.83 27.66 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.484 HD13 HG23 ' A' ' 121' ' ' VAL . 65.8 mt -96.19 105.26 16.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 177.188 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.567 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -80.61 116.6 20.72 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.373 0.606 . . . . 0.0 111.332 -174.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.439 ' HB ' HG22 ' A' ' 19' ' ' VAL . 61.6 t -114.13 106.94 21.66 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.657 175.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -134.86 148.32 66.56 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.126 176.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.27 -41.5 21.14 Favored 'Trans proline' 0 C--O 1.236 0.388 0 C-N-CA 122.53 2.153 . . . . 0.0 112.319 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 167.14 -149.1 14.16 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.114 -0.565 . . . . 0.0 111.936 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 169.48 -140.03 5.9 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.265 -179.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -91.94 139.31 30.78 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.841 0.353 . . . . 0.0 110.912 179.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.476 ' HA2' ' HG3' ' A' ' 87' ' ' GLU . . . -99.16 88.09 0.81 Allowed Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.807 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.7 t -95.78 152.96 18.0 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.985 0.422 . . . . 0.0 110.701 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.1 t -84.49 49.14 1.63 Allowed 'General case' 0 CA--C 1.539 0.522 0 CA-C-O 121.531 0.682 . . . . 0.0 110.618 -176.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.449 ' HB ' HG22 ' A' ' 89' ' ' ILE . 46.9 t -48.06 -49.09 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 114.982 -1.008 . . . . 0.0 112.658 -176.59 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.62 16.72 38.53 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.944 -176.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 90.3 p 60.2 -152.47 0.39 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.179 0.592 . . . . 0.0 111.631 173.068 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.463 ' HB2' ' O ' ' A' ' 65' ' ' SER . 58.1 m-85 76.07 -42.9 0.46 Allowed 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.713 0.805 . . . . 0.0 112.721 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.44 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 17.4 m -52.3 -36.9 21.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -175.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.404 HD21 ' HB1' ' A' ' 94' ' ' ALA . 5.3 mp -68.85 -34.87 76.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.001 0.429 . . . . 0.0 111.075 -178.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.494 HD13 ' HA ' ' A' ' 97' ' ' ALA . 66.1 tp -70.63 -40.06 73.32 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.044 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.445 ' OD1' ' HE3' ' A' ' 32' ' ' LYS . 12.7 t-20 -56.2 -41.88 76.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.776 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 80.6 mt -62.59 -41.47 98.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.34 -179.33 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.55 ' NH1' ' HB3' ' A' ' 98' ' ' GLU . 15.2 ttp180 -74.2 -25.06 59.46 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.856 -0.337 . . . . 0.0 111.09 -174.323 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -73.72 -26.09 60.53 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.825 -0.35 . . . . 0.0 111.282 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -92.56 -27.95 17.05 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.898 176.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.87 22.79 7.43 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.476 -0.869 . . . . 0.0 112.522 177.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.413 HG22 ' HA ' ' A' ' 32' ' ' LYS . 30.4 m -114.27 21.05 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.122 0.487 . . . . 0.0 110.882 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.4 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -92.02 155.52 43.01 Favored Pre-proline 0 C--O 1.237 0.431 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.428 -177.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.567 ' HB3' HD13 ' A' ' 53' ' ' LEU . 15.7 Cg_exo -69.69 158.9 55.43 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.997 2.465 . . . . 0.0 112.021 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -69.76 -44.69 69.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.057 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.98 164.24 25.78 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.204 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.696 ' HB ' ' HB3' ' A' ' 101' ' ' LEU . 37.5 mm -127.0 124.64 65.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.428 -178.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.1 mm -119.19 116.27 50.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.422 ' O ' HG12 ' A' ' 104' ' ' VAL . 13.6 m120 -126.26 157.38 38.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.692 0.282 . . . . 0.0 111.031 -175.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 23.5 ttmm -68.89 -52.07 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 173.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.1 tptm -155.6 109.99 2.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.172 171.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.7 t -91.62 167.03 12.5 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.314 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.476 ' HG3' ' HA2' ' A' ' 60' ' ' GLY . 2.9 mm-40 -83.56 152.08 25.05 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.934 0.397 . . . . 0.0 110.854 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 m -58.87 -34.02 71.14 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.148 -178.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.449 HG22 ' HB ' ' A' ' 63' ' ' VAL . 3.0 mp -61.22 -39.99 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.098 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 50.0 mt -77.15 -42.4 31.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.413 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.509 ' HA ' HD22 ' A' ' 101' ' ' LEU . . . -55.59 -48.76 74.32 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.586 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -71.79 -39.06 67.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.524 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.95 -41.52 99.66 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.601 -178.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.408 ' HB2' ' O ' ' A' ' 99' ' ' ILE . . . -74.56 -31.16 62.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.555 0.217 . . . . 0.0 110.809 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.402 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -61.28 -38.54 87.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.01 0.433 . . . . 0.0 110.112 175.39 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 84.2 mtp -66.22 -42.45 88.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.685 177.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.494 ' HA ' HD13 ' A' ' 69' ' ' LEU . . . -80.94 -4.29 54.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.964 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.55 ' HB3' ' NH1' ' A' ' 72' ' ' ARG . 37.7 tt0 60.24 37.75 20.34 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.85 0.833 . . . . 0.0 109.852 -177.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.408 ' O ' ' HB2' ' A' ' 94' ' ' ALA . 60.1 mt -105.11 89.18 2.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.931 175.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.6 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 12.1 Cg_endo -53.47 117.07 3.42 Favored 'Trans proline' 0 C--O 1.234 0.302 0 C-N-CA 123.17 2.58 . . . . 0.0 113.845 -170.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.696 ' HB3' ' HB ' ' A' ' 81' ' ' ILE . 2.3 pp -117.56 148.11 42.19 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.504 171.183 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.538 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.0 m -136.34 163.92 32.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.083 -175.533 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.637 ' HB2' ' HB3' ' A' ' 6' ' ' ARG . 43.8 mt-10 -97.08 113.91 25.51 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.875 175.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 7.2 p -110.74 112.7 41.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.653 0.74 . . . . 0.0 109.86 174.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 105' ' ' ARG . 52.4 mtt180 -95.81 28.38 3.1 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.992 -173.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.415 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 22.8 t70 -118.07 121.33 40.31 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.625 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -72.6 -33.86 66.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.968 -178.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 49.5 mmtm -60.6 -35.88 77.2 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 -176.305 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.491 ' O ' HG13 ' A' ' 113' ' ' VAL . 44.7 t80 -51.8 -46.04 64.09 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.857 177.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -70.18 -22.63 62.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.195 0.522 . . . . 0.0 111.17 -174.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' HE2' ' A' ' 114' ' ' LYS . 11.5 mm-40 -88.51 -28.19 20.95 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.191 176.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.61 -44.31 64.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.803 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.491 HG13 ' O ' ' A' ' 109' ' ' PHE . 11.9 p -91.93 133.18 34.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.172 0.51 . . . . 0.0 111.151 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.473 ' HE2' ' O ' ' A' ' 111' ' ' GLU . 74.7 mmtt -128.93 160.87 31.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 10.8 t -63.35 125.44 24.17 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.162 0.506 . . . . 0.0 110.37 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.35 -16.36 11.67 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.855 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -91.24 175.28 6.99 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 118' ' ' ARG . 1.3 tmm_? -116.24 129.76 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.135 0.493 . . . . 0.0 111.352 -174.18 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' A' ' 17' ' ' ALA . 86.6 t -116.41 140.41 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.209 178.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 48.6 t -104.94 108.21 24.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 172.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.484 HG23 HD13 ' A' ' 52' ' ' ILE . 96.1 t -92.77 119.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.148 0.499 . . . . 0.0 111.264 -175.227 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . 0.494 ' HA ' ' HG2' ' A' ' 12' ' ' ARG . 55.9 t-20 -115.74 93.81 4.42 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -94.36 -0.61 54.78 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 110.378 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -80.72 -40.25 25.63 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.399 177.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -98.75 -28.07 13.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.849 176.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.43 59.66 1.14 Allowed Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.27 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -148.59 146.33 28.2 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.917 0.389 . . . . 0.0 110.451 -174.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 54.8 t -119.71 108.85 24.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.761 177.136 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.693 ' HG2' ' HE3' ' A' ' 2' ' ' LYS . 39.1 mt-10 -99.81 107.9 20.05 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.961 0.41 . . . . 0.0 110.251 179.434 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 47.6 tp -93.35 132.66 37.37 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.209 178.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.8 mt -119.22 114.98 46.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.575 0.702 . . . . 0.0 109.5 175.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--N 1.312 -1.052 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.889 179.664 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 45.0 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 121.997 0.903 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mtmm -108.21 122.69 47.44 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.164 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -89.64 136.18 33.18 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 176.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.63 114.99 26.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.678 -176.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' HB ' ' A' ' 104' ' ' VAL . 11.7 m -120.33 163.08 18.37 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.38 178.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 45.3 ttt180 -93.74 124.83 38.01 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 120.344 -0.542 . . . . 0.0 109.854 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.491 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -95.71 137.95 34.05 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.69 -172.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.404 ' N ' HD13 ' A' ' 8' ' ' ILE . 4.4 mp -103.18 -48.55 10.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 174.122 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.3 p -102.1 169.57 8.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.378 174.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.417 ' HB3' ' OD1' ' A' ' 124' ' ' ASP . 71.8 mtt85 -125.44 -174.75 3.14 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.928 0.394 . . . . 0.0 111.761 -176.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.35 175.85 23.39 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.401 ' N ' ' HD3' ' A' ' 12' ' ' ARG . 0.0 OUTLIER -147.4 149.38 32.63 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 178.472 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.31 156.19 35.06 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.975 0.417 . . . . 0.0 111.099 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -124.28 132.82 53.59 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.694 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.09 175.33 39.43 Favored Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.051 177.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -72.3 133.21 44.89 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 176.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.491 ' HB2' HG21 ' A' ' 119' ' ' VAL . . . -79.77 121.54 25.49 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.017 0.436 . . . . 0.0 110.808 -177.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.986 HD21 HG21 ' A' ' 43' ' ' ILE . 7.3 tt -113.23 113.59 25.53 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 53.1 t -102.99 109.94 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.105 0.479 . . . . 0.0 110.759 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.727 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 20.9 m -87.37 116.75 25.68 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.348 176.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.893 ' HD3' ' HG3' ' A' ' 42' ' ' GLU . 8.8 mptt -73.37 -25.77 60.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.377 -176.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.448 ' HG3' ' HB3' ' A' ' 41' ' ' CYS . 22.0 mm-40 -91.36 152.97 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -91.14 90.88 8.0 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.956 178.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 pt -86.03 145.39 7.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.135 -178.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 58' ' ' GLY . 7.2 m -91.75 150.19 21.23 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.552 -173.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.778 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 74.9 m-85 -86.11 15.17 5.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.905 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 63' ' ' VAL . 33.7 mt -73.53 -8.45 55.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.179 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 126.48 70.5 0.18 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.245 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -106.74 -25.63 6.16 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.786 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.465 HD11 ' N ' ' A' ' 30' ' ' ILE . 4.2 mp -92.21 133.74 32.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 -177.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.414 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 13.2 t70 -69.68 135.11 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.996 0.426 . . . . 0.0 110.293 175.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.435 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 49.9 pttt -73.38 -14.02 61.2 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -171.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -106.65 -44.53 4.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.996 0.427 . . . . 0.0 111.771 -174.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 36' ' ' ILE . 34.6 p -97.48 -26.88 14.67 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.11 -174.195 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.64 8.5 84.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.559 -175.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.451 HG12 ' HB ' ' A' ' 34' ' ' THR . 34.0 mm -82.56 133.48 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.367 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.443 HG11 HG13 ' A' ' 30' ' ' ILE . 5.5 m -77.39 131.73 34.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.312 0.577 . . . . 0.0 110.974 176.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.414 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 75.1 mmtt -95.39 -14.92 23.41 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.691 177.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -129.01 85.12 2.29 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.674 -176.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.1 t70 -148.14 -162.79 1.63 Allowed 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.597 -178.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.485 ' H ' ' CG ' ' A' ' 40' ' ' ASP . 44.9 t -155.3 -32.47 0.1 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.553 -175.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.893 ' HG3' ' HD3' ' A' ' 21' ' ' LYS . 17.6 mm-40 -109.53 -47.26 3.4 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -177.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.986 HG21 HD21 ' A' ' 18' ' ' LEU . 40.8 pt -101.28 10.08 8.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.351 0.596 . . . . 0.0 109.919 -177.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 79.0 tttt -54.57 114.0 1.51 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.604 177.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 114.18 -14.19 21.24 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.374 -176.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -103.71 169.24 8.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.748 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.404 ' HB2' HD13 ' A' ' 36' ' ' ILE . 40.8 t -109.62 152.28 25.75 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.553 -179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.8 m -103.9 3.54 10.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.848 177.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.0 85.48 1.0 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.394 -176.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 116.18 8.26 13.42 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.516 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -114.46 158.83 21.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.0 mt -93.11 117.5 36.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 37.0 tp -90.32 111.16 22.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.579 -173.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 19' ' ' VAL . 61.3 t -119.0 105.95 18.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.413 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.727 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 19.1 p90 -137.48 163.61 47.4 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.596 ' HD2' ' HB2' ' A' ' 55' ' ' PHE . 10.0 Cg_endo -52.56 -54.92 4.33 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.858 2.372 . . . . 0.0 112.707 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 118.0 145.83 8.0 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.431 ' O ' ' HA ' ' A' ' 25' ' ' SER . . . 177.78 125.72 0.93 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.932 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt 55.04 90.71 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 174.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.778 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -102.06 -57.04 0.82 Allowed Glycine 0 N--CA 1.447 -0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 175.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 12.3 t 65.24 -172.26 0.18 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.937 0.495 . . . . 0.0 111.004 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.533 ' HA ' HG22 ' A' ' 89' ' ' ILE . 6.6 m -69.49 -25.01 63.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -178.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 27' ' ' LEU . 7.7 p -69.86 -37.35 72.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.971 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.439 ' HA3' ' HB3' ' A' ' 26' ' ' PHE . . . -82.25 59.72 4.88 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.89 -178.134 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.1 p -140.87 -70.5 0.37 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.858 0.361 . . . . 0.0 110.952 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -69.55 -16.32 63.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.765 -177.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.533 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 93.4 t -58.13 -45.34 88.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.895 0.379 . . . . 0.0 110.164 176.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -61.7 -38.94 89.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.593 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 54.4 tp -66.86 -40.29 87.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.878 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -69.55 -40.94 76.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.96 0.41 . . . . 0.0 110.492 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 91.6 mt -62.63 -37.44 86.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.239 176.434 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -63.87 -37.56 87.86 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.216 -178.178 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -69.1 -29.47 67.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.833 0.349 . . . . 0.0 110.749 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -89.41 -14.37 35.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.34 0.59 . . . . 0.0 110.055 -177.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 85.92 10.45 75.49 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.531 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.74 14.01 5.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 -178.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -81.4 154.5 71.67 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.35 176.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.16 159.14 54.16 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.334 2.023 . . . . 0.0 111.775 176.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -71.33 -31.36 67.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.907 0.384 . . . . 0.0 110.717 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -168.25 164.12 13.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.217 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 66.4 mt -137.33 118.62 17.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.257 -0.429 . . . . 0.0 109.978 179.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 10.1 mm -114.9 118.09 57.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 177.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -119.01 158.28 26.1 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.506 -174.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 1.5 tmtp? -83.96 -45.19 13.41 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 174.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -141.81 113.07 7.55 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.069 -0.969 . . . . 0.0 108.878 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.6 t -123.57 -176.92 3.57 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.582 -176.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -115.86 150.7 36.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.265 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.452 ' O ' HG22 ' A' ' 92' ' ' VAL . 2.8 m -61.92 -37.89 86.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.677 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.533 HG22 ' HA ' ' A' ' 62' ' ' THR . 51.0 mt -61.08 -39.22 81.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.968 0.414 . . . . 0.0 110.793 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.624 HD13 ' HA3' ' A' ' 60' ' ' GLY . 60.4 mt -62.86 -42.13 95.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.055 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.568 ' HA ' HD22 ' A' ' 101' ' ' LEU . . . -61.72 -38.4 87.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.89 178.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.477 HG11 ' HE1' ' A' ' 96' ' ' MET . 58.3 t -63.87 -43.49 97.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.536 177.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.72 -40.11 97.18 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.13 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 99' ' ' ILE . . . -65.29 -32.67 74.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.748 0.308 . . . . 0.0 111.055 177.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.01 -25.03 67.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 178.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.477 ' HE1' HG11 ' A' ' 92' ' ' VAL . 45.2 mtt -79.37 -43.87 22.62 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.708 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.485 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -83.49 -0.74 51.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.134 -174.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 64.1 38.53 8.34 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.129 0.49 . . . . 0.0 110.769 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.448 ' O ' ' HB2' ' A' ' 94' ' ' ALA . 69.0 mt -109.41 90.07 8.02 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 17.7 Cg_endo -58.16 125.01 17.22 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.899 2.399 . . . . 0.0 112.68 -178.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.568 HD22 ' HA ' ' A' ' 91' ' ' ALA . 2.2 pp -127.35 147.52 50.26 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.17 0.509 . . . . 0.0 111.16 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.491 HG11 ' HA ' ' A' ' 7' ' ' ALA . 27.4 m -134.56 156.2 39.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.05 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.448 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 42.9 mt-10 -95.92 119.46 34.46 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.583 176.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 4.5 p -114.45 116.42 52.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.257 0.551 . . . . 0.0 110.176 176.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -91.53 -29.34 17.02 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.783 -177.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -69.39 117.88 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -177.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -68.64 -21.28 64.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.762 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.4 mttm -62.16 -19.97 63.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.442 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.554 ' O ' HG12 ' A' ' 113' ' ' VAL . 46.9 t80 -65.52 -51.97 56.03 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 173.197 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -69.7 -26.49 64.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.491 0.662 . . . . 0.0 110.412 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -70.38 -37.35 74.52 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.543 176.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.45 -54.64 5.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.1 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 109' ' ' PHE . 9.9 p -69.96 138.9 21.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.254 0.549 . . . . 0.0 110.601 -177.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 55.9 mttp -135.04 151.43 50.78 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.956 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.528 HG23 ' HA ' ' A' ' 18' ' ' LEU . 16.2 m -58.16 113.33 1.87 Allowed 'General case' 0 C--N 1.324 -0.519 0 O-C-N 123.353 0.408 . . . . 0.0 110.397 178.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 106.18 31.73 3.99 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.949 -179.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -132.55 173.72 11.02 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 171.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -97.52 122.51 40.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.022 0.439 . . . . 0.0 111.797 -172.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.491 HG21 ' HB2' ' A' ' 17' ' ' ALA . 83.4 t -117.83 124.18 72.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.065 174.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.4 t -107.17 105.05 18.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 174.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.9 p -92.86 132.31 37.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.555 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -127.23 93.51 3.76 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 176.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.05 -13.34 56.0 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.607 -171.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.417 ' OD1' ' HB3' ' A' ' 10' ' ' ARG . 48.3 m-20 -61.57 -34.77 76.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.909 0.385 . . . . 0.0 109.977 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.401 ' HB3' ' CE1' ' A' ' 127' ' ' TYR . 32.1 tt0 -106.5 -27.74 10.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.1 178.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 93.07 70.13 1.13 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.969 175.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . 0.401 ' CE1' ' HB3' ' A' ' 125' ' ' GLU . 46.1 p90 -170.31 162.13 8.42 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.21 179.147 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.45 HG23 ' CE1' ' A' ' 109' ' ' PHE . 15.0 m -124.61 132.11 71.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.507 178.212 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -105.42 117.77 34.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.743 179.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.8 tp -94.2 125.4 38.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 177.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.4 mm -108.13 111.45 35.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--N 1.312 -1.034 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.436 -173.627 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.855 0.36 . . . . 0.0 111.162 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -121.5 111.67 17.55 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.572 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 90.1 m-85 -92.59 149.46 21.34 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.725 0.297 . . . . 0.0 110.77 -177.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 117.66 34.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.809 176.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.517 ' HB3' HG23 ' A' ' 104' ' ' VAL . 4.5 p -120.35 169.14 10.57 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.166 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 44.2 ttp180 -94.69 128.38 41.33 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.581 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -95.12 127.62 41.32 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.979 0.419 . . . . 0.0 111.458 -174.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.4 mm -101.31 -55.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.549 177.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.618 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -95.42 173.68 7.4 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.553 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -121.25 168.18 11.9 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.402 -175.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.68 -174.41 16.54 Favored Glycine 0 N--CA 1.452 -0.256 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.77 154.7 46.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 117.618 0.709 . . . . 0.0 111.147 176.526 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.479 ' HB2' ' HB3' ' A' ' 79' ' ' LYS . . . -138.61 139.51 38.59 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.959 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 123.92 30.82 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.77 -179.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.95 -166.34 37.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 119.585 -1.293 . . . . 0.0 113.39 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -73.19 135.16 44.58 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 122.598 0.359 . . . . 0.0 110.797 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.72 124.95 32.1 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.929 0.395 . . . . 0.0 111.046 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.536 ' HA ' HG22 ' A' ' 115' ' ' THR . 6.5 tt -108.78 110.71 22.16 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.657 ' HA ' ' HB ' ' A' ' 54' ' ' VAL . 47.0 t -104.58 125.7 59.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.269 0.557 . . . . 0.0 112.425 -168.538 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.439 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 17.5 p -137.22 144.98 43.1 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.614 174.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.541 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 15.8 ptpt -128.89 20.14 5.98 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.193 0.52 . . . . 0.0 111.031 175.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -80.57 125.3 29.82 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.192 173.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -77.83 109.46 11.87 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.212 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.74 ' HB ' ' HZ ' ' A' ' 55' ' ' PHE . 43.8 mt -124.45 -7.62 6.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 110.256 -174.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.531 ' HA ' ' CA ' ' A' ' 58' ' ' GLY . 22.0 p 48.94 23.25 0.67 Allowed 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 113.596 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.453 ' CD1' HD13 ' A' ' 90' ' ' ILE . 36.9 m-85 64.51 18.34 11.31 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 178.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.2 27.26 0.81 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.176 0.512 . . . . 0.0 109.878 173.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -94.01 -128.39 5.1 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.488 -176.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 177.39 93.38 0.09 OUTLIER Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.416 -177.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.437 HG12 HG22 ' A' ' 37' ' ' VAL . 54.5 mt -92.82 126.67 45.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 170.212 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -62.92 124.31 20.75 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.695 0.283 . . . . 0.0 110.701 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.525 ' HA ' HD23 ' A' ' 71' ' ' LEU . 20.7 pttp -85.08 3.97 36.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -173.368 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -101.47 -36.99 8.62 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.94 0.4 . . . . 0.0 110.818 177.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.2 p -113.22 -19.1 11.93 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.645 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.13 25.01 62.61 Favored Glycine 0 N--CA 1.453 -0.176 0 C-N-CA 120.989 -0.624 . . . . 0.0 111.963 -177.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.3 mm -102.3 127.99 55.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.706 0.289 . . . . 0.0 110.416 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.437 HG22 HG12 ' A' ' 30' ' ' ILE . 21.8 t -67.0 111.46 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.854 0.359 . . . . 0.0 110.198 177.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -87.24 -27.96 22.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.467 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -67.76 129.78 40.97 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.492 178.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -74.09 133.84 42.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.293 0.568 . . . . 0.0 110.811 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 3.5 p -160.78 35.17 0.15 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.18 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 32.7 mm-40 72.38 -51.64 0.7 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.77 -174.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -88.55 42.36 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.308 0.575 . . . . 0.0 110.896 178.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.3 tttm -73.22 127.39 32.49 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.27 -2.2 29.66 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.166 -176.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -77.37 150.6 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.228 0.537 . . . . 0.0 111.939 178.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 36.0 t -101.36 131.93 47.17 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.782 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.487 ' HB ' ' HG3' ' A' ' 78' ' ' PRO . 31.2 m -105.53 4.72 10.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.964 0.411 . . . . 0.0 110.877 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.76 92.17 1.99 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.55 0.69 . . . . 0.0 111.242 -174.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 105.65 12.07 27.3 Favored Glycine 0 C--N 1.315 -0.595 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.635 176.245 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -110.46 175.3 5.48 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 54.1 mt -110.19 121.24 62.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.513 ' HB3' HG21 ' A' ' 81' ' ' ILE . 54.4 tp -91.46 120.26 32.13 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.746 -174.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.657 ' HB ' ' HA ' ' A' ' 19' ' ' VAL . 67.5 t -101.99 107.97 22.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.777 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 51.4 t80 -133.99 143.3 46.77 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -173.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.541 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 23.8 Cg_endo -62.95 -36.92 57.31 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 121.955 1.77 . . . . 0.0 111.505 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.16 -154.94 16.53 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.287 176.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.531 ' CA ' ' HA ' ' A' ' 25' ' ' SER . . . -132.05 -143.64 5.18 Favored Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 177.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 30.9 ttmt -173.54 -64.58 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -106.71 75.41 0.22 Allowed Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 110.594 -1.003 . . . . 0.0 110.594 172.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.426 ' HB2' ' HG3' ' A' ' 87' ' ' GLU . 50.9 m -104.23 178.35 4.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.397 0.618 . . . . 0.0 112.011 -173.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 85.5 m -154.77 -40.13 0.09 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.091 176.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.9 t -89.06 141.35 14.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.502 174.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 136.4 -7.22 3.98 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.742 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.512 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 12.8 p -90.09 -73.22 0.53 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.001 0.429 . . . . 0.0 111.747 -178.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -66.51 -27.87 68.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.63 -173.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.469 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 26.8 m -67.15 -31.99 55.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.025 -178.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.42 -36.78 77.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.932 0.396 . . . . 0.0 110.357 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.4 tp -66.15 -39.9 90.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.764 176.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -60.05 -48.61 81.0 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.587 176.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.525 HD23 ' HA ' ' A' ' 32' ' ' LYS . 96.3 mt -57.45 -47.62 81.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.964 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.435 ' HB2' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -66.07 -37.39 85.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -177.393 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.8 mmtt -61.4 -30.2 70.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.5 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . 0.523 ' HB3' HG23 ' A' ' 76' ' ' VAL . 21.6 t-20 -89.64 -22.78 22.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.195 0.522 . . . . 0.0 109.877 178.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.27 16.49 55.5 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.385 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.645 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 32.2 m -106.94 13.81 8.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.084 0.469 . . . . 0.0 110.821 -176.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.88 49.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.935 -179.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.487 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 13.1 Cg_exo -68.33 143.12 57.1 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.195 1.93 . . . . 0.0 110.185 170.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.479 ' HB3' ' HB2' ' A' ' 13' ' ' ALA . 94.8 mttt -61.58 -33.92 74.71 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.165 0.507 . . . . 0.0 110.618 -179.335 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.62 155.25 34.36 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.438 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.513 HG21 ' HB3' ' A' ' 53' ' ' LEU . 16.1 pt -124.65 114.76 42.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.082 175.308 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.731 HG22 HG22 ' A' ' 102' ' ' VAL . 4.4 mm -102.86 116.78 47.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.777 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -115.1 175.96 5.27 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.822 0.344 . . . . 0.0 111.154 -173.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -101.37 -40.81 6.92 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 171.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -125.15 114.41 18.98 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.502 177.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.1 t -81.15 154.99 26.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.042 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.426 ' HG3' ' HB2' ' A' ' 61' ' ' SER . 1.0 OUTLIER -126.29 142.38 51.55 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.497 ' O ' HG22 ' A' ' 92' ' ' VAL . 18.1 m -56.26 -50.02 72.56 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 123.536 0.522 . . . . 0.0 112.033 -174.483 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 72.1 mt -65.24 -44.96 95.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 121.054 0.454 . . . . 0.0 110.702 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.453 HD13 ' CD1' ' A' ' 26' ' ' PHE . 63.9 mt -63.98 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.693 -179.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.4 -41.58 94.18 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.502 HG13 ' HE2' ' A' ' 96' ' ' MET . 98.9 t -61.86 -44.56 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.54 178.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.512 ' HA3' ' HA ' ' A' ' 65' ' ' SER . . . -62.6 -44.76 97.08 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.358 179.39 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.427 ' HB3' HD23 ' A' ' 101' ' ' LEU . . . -67.02 -30.96 71.19 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.594 0.235 . . . . 0.0 111.131 179.296 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.72 -38.11 88.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.541 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.502 ' HE2' HG13 ' A' ' 92' ' ' VAL . 61.0 mtt -64.26 -45.92 86.01 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.516 0.674 . . . . 0.0 109.91 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.435 ' HB1' ' HB2' ' A' ' 72' ' ' ARG . . . -80.14 -1.65 41.19 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 114.992 -1.004 . . . . 0.0 111.697 -175.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 58.9 43.17 18.45 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 121.25 0.548 . . . . 0.0 110.569 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.2 mm -104.18 91.08 3.51 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.751 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.618 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 9.3 Cg_endo -49.96 100.41 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.558 2.838 . . . . 0.0 112.667 -176.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.427 HD23 ' HB3' ' A' ' 94' ' ' ALA . 1.5 pp -102.43 137.0 41.25 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.235 0.54 . . . . 0.0 109.994 179.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.731 HG22 HG22 ' A' ' 82' ' ' ILE . 35.1 m -135.17 159.23 41.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 8.3 pt-20 -121.06 135.57 55.17 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.365 0.602 . . . . 0.0 111.838 -178.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.572 HG13 ' HB2' ' A' ' 109' ' ' PHE . 32.4 t -115.9 105.04 17.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 170.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -84.16 35.85 0.55 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.95 -170.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -138.55 145.12 40.28 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.679 176.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -71.22 -23.93 62.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.171 -176.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -60.28 -29.24 68.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.582 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.572 ' HB2' HG13 ' A' ' 104' ' ' VAL . 84.6 t80 -61.25 -46.46 90.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.985 0.422 . . . . 0.0 110.312 177.416 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -71.97 -22.61 61.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.243 -175.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.8 mm-40 -79.04 -36.62 40.71 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.346 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.67 -42.44 22.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.87 -176.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.505 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.0 p -79.86 138.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.014 0.435 . . . . 0.0 110.345 -177.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.3 mttp -122.77 151.61 41.45 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.045 -177.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.536 HG22 ' HA ' ' A' ' 18' ' ' LEU . 33.1 m -71.56 95.76 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.101 0.476 . . . . 0.0 109.921 176.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.2 1.95 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.268 -177.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -77.78 166.98 22.27 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.4 177.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.714 HH21 HG13 ' A' ' 131' ' ' ILE . 2.2 tmm_? -107.67 122.87 47.59 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.372 0.606 . . . . 0.0 109.863 -176.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 91.3 t -119.57 139.33 47.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.262 -175.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.9 t -117.05 111.82 36.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.319 171.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.491 HG22 HD12 ' A' ' 82' ' ' ILE . 55.1 t -107.56 117.53 53.45 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.285 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . 0.719 HD22 ' HB2' ' A' ' 124' ' ' ASP . 9.8 t30 -109.97 118.02 35.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 177.013 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -101.15 8.01 42.91 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.37 -174.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.719 ' HB2' HD22 ' A' ' 122' ' ' ASN . 53.5 m-20 -64.99 -41.43 95.43 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 176.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -117.9 -33.43 4.48 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 173.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 108.93 91.84 2.19 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.195 172.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 25.6 p90 -159.66 153.35 22.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.949 0.404 . . . . 0.0 110.322 174.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.572 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 84.9 t -116.15 111.21 34.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.831 178.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -92.62 108.37 19.92 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 59.2 tp -94.6 114.07 25.98 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.908 -176.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.714 HG13 HH21 ' A' ' 118' ' ' ARG . 33.5 mm -111.58 116.95 53.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.364 174.346 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.876 -179.299 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.234 0.238 0 CA-C-O 120.963 0.411 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -126.98 140.78 52.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.937 -174.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -133.59 149.09 51.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.437 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.79 131.72 45.59 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.649 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.0 m -122.09 169.09 11.2 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.321 176.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -96.2 134.59 39.1 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 174.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.23 96.6 4.59 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.922 0.391 . . . . 0.0 111.473 -174.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.482 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 43.8 mm -82.81 -49.37 16.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 174.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.545 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -109.22 176.19 5.18 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 172.604 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -126.23 178.13 6.0 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.48 -0.193 . . . . 0.0 110.48 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.442 ' H ' ' HB2' ' A' ' 124' ' ' ASP . . . 97.19 -162.39 21.79 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -174.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -156.41 148.01 22.68 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.695 0.283 . . . . 0.0 110.496 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -149.66 151.56 33.94 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -137.82 127.77 25.65 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.958 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.64 172.14 39.47 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.324 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -70.38 128.87 37.69 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.463 ' HB2' HG21 ' A' ' 119' ' ' VAL . . . -80.92 141.69 34.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.267 0.556 . . . . 0.0 111.712 -175.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.5 tt -121.24 114.09 20.88 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 177.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.0 t -102.79 110.84 30.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.196 0.522 . . . . 0.0 111.674 -173.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.436 ' O ' HG21 ' A' ' 20' ' ' THR . 9.7 t -152.36 95.63 2.06 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 172.346 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -67.77 -72.2 0.18 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.154 -174.257 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.82 ' HG2' ' HB3' ' A' ' 41' ' ' CYS . 0.3 OUTLIER 51.15 -163.52 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 O-C-N 123.469 0.48 . . . . 0.0 111.794 178.368 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 13.3 p90 -158.59 44.49 0.29 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.443 0.639 . . . . 0.0 110.045 176.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.5 pt -73.29 177.84 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.721 -177.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.86 ' HA ' ' HB2' ' A' ' 59' ' ' LYS . 40.1 t -88.22 128.52 35.46 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.338 -178.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.595 ' O ' ' HB ' ' A' ' 63' ' ' VAL . 23.3 t80 -82.91 91.19 7.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -124.97 -77.49 0.59 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.033 177.002 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.45 59.17 0.41 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.6 15.65 45.26 Favored Glycine 0 C--O 1.226 -0.387 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 -177.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.424 HD11 HG21 ' A' ' 48' ' ' VAL . 58.2 mt -134.31 134.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.653 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 15.2 t70 -66.26 135.59 54.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.679 0.276 . . . . 0.0 110.357 178.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -81.21 -7.45 59.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -173.012 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -117.65 -30.43 5.47 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.555 HG22 HG12 ' A' ' 36' ' ' ILE . 7.8 t -123.16 -4.88 8.41 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 120.104 -0.638 . . . . 0.0 112.519 179.247 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 70.35 27.95 72.0 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.87 -0.681 . . . . 0.0 113.446 176.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.555 HG12 HG22 ' A' ' 34' ' ' THR . 42.5 mm -87.97 129.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 176.447 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.89 128.69 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.019 0.438 . . . . 0.0 111.032 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.653 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 74.3 mmtt -87.67 -41.43 13.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.669 -179.123 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -89.97 122.19 32.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.87 -172.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.609 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 21.7 t70 -74.35 133.51 42.52 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.359 0.599 . . . . 0.0 111.087 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.82 ' HB3' ' HG2' ' A' ' 22' ' ' GLU . 59.0 m -123.11 -28.09 4.09 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.896 178.354 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 175.52 -62.25 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 pt -114.79 71.02 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.295 179.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.609 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 13.3 tmtt? -93.74 140.76 29.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.698 -178.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 136.62 -8.1 3.95 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.915 175.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -103.89 173.02 6.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.239 0.542 . . . . 0.0 111.58 -175.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 m -93.36 137.7 32.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.653 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.424 HG21 HD11 ' A' ' 30' ' ' ILE . 29.7 m -100.76 2.7 10.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.972 0.415 . . . . 0.0 110.399 174.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.32 94.76 0.17 Allowed 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.861 -177.151 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.482 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 97.43 14.04 42.69 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 114.756 -1.111 . . . . 0.0 112.634 176.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 82.4 mtt180 -104.69 164.85 11.46 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.669 0.271 . . . . 0.0 110.574 176.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.464 HD11 ' HB3' ' A' ' 80' ' ' ALA . 51.5 mm -95.93 111.46 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.077 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.491 ' HB3' HG23 ' A' ' 81' ' ' ILE . 18.3 tp -101.7 125.86 48.45 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -173.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.4 t -113.75 128.61 70.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.958 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -131.99 145.87 59.27 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.46 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.83 -50.31 0.1 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.624 2.216 . . . . 0.0 112.002 175.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 154.8 86.62 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.424 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.442 -177.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -93.21 -138.52 8.84 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.993 -175.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.86 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 23.4 mtpp -94.18 113.41 25.34 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.85 -44.18 92.49 Favored Glycine 0 C--N 1.329 0.14 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.126 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.8 m 57.43 23.26 8.83 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 173.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.484 ' HA ' ' CD1' ' A' ' 89' ' ' ILE . 4.5 m 60.77 30.45 19.69 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.887 176.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.595 ' HB ' ' O ' ' A' ' 26' ' ' PHE . 92.2 t -122.7 149.77 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 151.76 -47.17 0.58 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.997 -0.62 . . . . 0.0 111.869 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.2 p -70.71 142.55 51.48 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 122.964 -0.139 . . . . 0.0 110.881 -179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 85.7 m-85 74.11 -52.8 0.69 Allowed 'General case' 0 N--CA 1.471 0.597 0 O-C-N 123.985 0.803 . . . . 0.0 112.498 175.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.77 -39.14 76.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.7 mt -65.07 -34.83 79.35 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.716 0.293 . . . . 0.0 110.847 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.3 tp -65.06 -44.71 88.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.405 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -64.26 -41.49 96.91 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.409 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.57 -38.39 86.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.798 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.451 ' CG ' HD11 ' A' ' 99' ' ' ILE . 2.7 tmt_? -72.04 -39.48 69.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.528 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -64.16 -30.94 71.97 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.278 0.561 . . . . 0.0 110.336 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -84.86 -22.91 29.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.0 178.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.49 23.79 38.64 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.747 176.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.05 -0.26 9.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.057 0.456 . . . . 0.0 111.269 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.14 162.59 40.05 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.685 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 31.5 Cg_exo -59.03 147.8 88.44 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.229 1.953 . . . . 0.0 111.099 172.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.482 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 80.3 tttt -73.72 -26.15 60.56 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.05 0.452 . . . . 0.0 110.43 -175.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.464 ' HB3' HD11 ' A' ' 52' ' ' ILE . . . -166.71 150.19 6.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.753 176.232 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.491 HG23 ' HB3' ' A' ' 53' ' ' LEU . 15.7 pt -126.69 123.31 62.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.922 0.391 . . . . 0.0 110.564 178.381 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.671 HG21 HG21 ' A' ' 102' ' ' VAL . 5.4 mm -111.01 120.56 61.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.264 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 12.4 m120 -129.96 167.15 18.67 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -176.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -104.68 -38.83 6.57 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.4 tttp -128.58 103.43 7.1 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.218 174.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.9 t -112.0 156.8 21.57 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 175.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -79.46 145.93 33.01 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -56.87 -34.01 67.42 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.182 0.515 . . . . 0.0 110.986 -176.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.484 ' CD1' ' HA ' ' A' ' 62' ' ' THR . 54.8 mt -64.45 -41.15 91.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.822 178.317 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.9 mt -71.83 -42.17 69.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.542 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.61 -47.11 80.35 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.304 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.412 ' O ' ' HG3' ' A' ' 96' ' ' MET . 90.1 t -68.22 -42.25 84.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.615 179.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.97 99.15 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.352 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.54 -40.06 92.46 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.785 0.326 . . . . 0.0 110.833 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.412 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -63.64 -37.18 86.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.941 179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.412 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 89.4 mtp -68.39 -37.73 80.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.683 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.14 -1.28 57.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.342 -175.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 62.36 47.32 5.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.414 0.626 . . . . 0.0 110.467 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.458 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 44.2 mm -107.29 90.55 5.82 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.587 175.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.545 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.3 Cg_endo -48.48 96.51 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.421 2.747 . . . . 0.0 113.277 -175.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.482 ' O ' ' HB ' ' A' ' 8' ' ' ILE . 5.8 tt -102.29 126.0 49.16 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.721 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.671 HG21 HG21 ' A' ' 82' ' ' ILE . 11.0 m -127.71 150.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.257 176.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.529 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 6.5 tm-20 -97.8 114.9 27.04 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.507 -177.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.476 HG13 HG22 ' A' ' 82' ' ' ILE . 14.4 m -71.57 134.12 30.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.333 0.587 . . . . 0.0 111.832 -177.123 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.552 ' HD3' ' O ' ' A' ' 105' ' ' ARG . 1.0 OUTLIER -84.94 -33.95 22.57 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.363 -179.548 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -112.5 140.36 47.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.185 -172.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.34 -20.67 62.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.315 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mmtt -57.54 -24.15 54.46 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.905 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -60.65 -46.23 91.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.691 0.281 . . . . 0.0 110.508 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -65.07 -31.46 72.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.544 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -79.69 -30.91 41.23 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.976 -178.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.38 -33.01 17.02 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.371 -175.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 14.8 p -64.1 134.82 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.083 0.468 . . . . 0.0 110.841 -177.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -116.89 139.57 50.47 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.886 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.4 m -71.34 99.92 2.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.216 175.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.73 -31.6 2.92 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.666 179.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -85.47 161.27 19.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.861 0.362 . . . . 0.0 111.616 -177.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.853 HH21 HG13 ' A' ' 131' ' ' ILE . 18.0 ttp180 -89.17 127.37 35.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.248 0.547 . . . . 0.0 111.61 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.463 HG21 ' HB2' ' A' ' 17' ' ' ALA . 96.2 t -108.13 120.91 60.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.742 175.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.84 101.63 12.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 176.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 3.2 p -102.18 114.88 42.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 121.381 0.61 . . . . 0.0 110.907 -178.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -101.94 93.64 5.38 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 175.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.29 -26.68 62.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.374 -173.147 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.442 ' HB2' ' H ' ' A' ' 11' ' ' GLY . 25.8 t70 -63.38 -22.6 66.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.234 -177.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -120.11 -1.44 10.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.719 0.295 . . . . 0.0 110.708 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.18 62.66 5.42 Favored Glycine 0 C--N 1.332 0.356 0 CA-C-N 116.053 -0.521 . . . . 0.0 112.376 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -152.13 141.8 21.84 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.37 -0.488 . . . . 0.0 110.308 -177.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.5 m -122.97 136.28 60.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.199 0.524 . . . . 0.0 111.441 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -120.73 114.66 21.98 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.379 177.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 42.0 tp -90.49 125.18 35.51 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.853 HG13 HH21 ' A' ' 118' ' ' ARG . 19.3 mm -101.36 111.61 31.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.309 -1.181 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.441 -175.828 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.414 ' HB3' ' HE2' ' A' ' 2' ' ' LYS . 14.3 ptpt -145.18 148.87 34.04 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.815 0.341 . . . . 0.0 111.215 -177.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -136.44 152.95 51.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.734 -0.667 . . . . 0.0 109.977 179.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.79 114.09 25.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.209 175.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.719 ' SG ' HG13 ' A' ' 104' ' ' VAL . 83.9 m -120.24 176.93 5.22 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.215 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.9 tpm_? -94.73 119.84 34.0 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.119 -172.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 102' ' ' VAL . . . -86.69 142.55 28.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.174 -179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.517 HG12 ' HG1' ' A' ' 86' ' ' THR . 3.2 mp -105.97 -54.65 6.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.3 p -98.4 161.31 13.75 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 170.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.549 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 46.0 mtm180 -123.73 -175.85 3.32 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 119.574 -0.85 . . . . 0.0 112.681 -174.674 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.85 -164.89 14.07 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 -169.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.5 ttp180 -148.76 143.47 26.41 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 117.542 0.671 . . . . 0.0 109.789 177.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.569 ' HB1' ' HB1' ' A' ' 80' ' ' ALA . . . -154.52 152.15 29.74 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.716 0.293 . . . . 0.0 110.96 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.81 161.21 41.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.494 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 147.85 -160.54 28.35 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.155 -1.022 . . . . 0.0 112.453 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -64.4 124.09 20.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.986 0.422 . . . . 0.0 110.444 177.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.84 117.22 21.3 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.254 179.37 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.479 HD12 HG21 ' A' ' 115' ' ' THR . 13.4 tp -96.54 108.82 21.46 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.42 112.73 40.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.319 0.58 . . . . 0.0 110.96 -174.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -116.45 101.15 8.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.308 176.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -73.59 -12.09 60.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.401 -175.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -71.84 130.12 40.29 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.051 0.453 . . . . 0.0 110.154 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -78.53 69.92 4.8 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.407 0.622 . . . . 0.0 111.338 -177.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -82.14 152.63 4.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.226 176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -116.58 174.73 5.91 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.326 -173.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.489 ' O ' ' HB3' ' A' ' 27' ' ' LEU . 85.3 m-85 -82.97 -163.34 0.71 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.89 -0.596 . . . . 0.0 109.987 175.623 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.496 HD12 HG21 ' A' ' 63' ' ' VAL . 64.9 tp 72.24 14.91 5.46 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.996 0.903 . . . . 0.0 109.831 -176.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.82 44.8 0.12 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.817 177.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.63 -72.51 1.21 Allowed Glycine 0 N--CA 1.452 -0.285 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 174.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.455 HD11 ' N ' ' A' ' 30' ' ' ILE . 4.0 mp -85.84 133.31 29.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 170.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.494 ' HB2' ' HG2' ' A' ' 38' ' ' LYS . 29.0 t70 -72.74 146.08 46.66 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.309 0.576 . . . . 0.0 111.475 -175.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.508 ' HG2' ' HG3' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -82.94 -11.68 57.96 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.958 -173.102 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.508 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 31.0 mt-10 -110.29 -41.32 4.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.636 0.255 . . . . 0.0 111.48 -174.383 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 42.4 p -100.86 -23.01 14.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -177.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.484 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.3 16.84 80.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.521 -175.347 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.3 mm -99.58 143.78 13.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.5 t -67.98 115.14 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.67 0.271 . . . . 0.0 110.395 177.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.494 ' HG2' ' HB2' ' A' ' 31' ' ' ASP . 30.3 mmtp -81.83 -26.67 34.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.65 146.5 53.77 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.86 -178.496 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -77.28 136.92 38.53 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.546 -177.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 53.1 t -165.22 167.66 17.81 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -177.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -63.8 -36.18 83.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.322 0.582 . . . . 0.0 109.464 175.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.637 ' O ' ' HG2' ' A' ' 46' ' ' GLU . 13.6 pt -108.19 53.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.327 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.742 ' HZ2' ' HB3' ' A' ' 44' ' ' LYS . 0.0 OUTLIER -77.94 132.95 38.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 177.89 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.78 8.51 34.48 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.602 179.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.637 ' HG2' ' O ' ' A' ' 43' ' ' ILE . 32.2 mm-40 -63.53 146.97 52.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.227 0.537 . . . . 0.0 110.888 178.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.0 m -106.34 107.58 18.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.179 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.2 m -82.26 0.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.941 -175.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.23 89.15 0.45 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.298 0.571 . . . . 0.0 111.452 -175.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.91 8.58 29.65 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.401 -0.818 . . . . 0.0 113.003 174.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.6 mpt_? -103.78 172.44 6.8 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.753 0.311 . . . . 0.0 111.057 -179.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 50.1 mm -99.92 104.09 15.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 171.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 81' ' ' ILE . 45.3 tp -85.71 113.7 22.11 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.342 -170.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -119.66 106.89 19.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.108 0.48 . . . . 0.0 110.496 178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.415 ' HD1' ' HG ' ' A' ' 53' ' ' LEU . 34.2 p90 -136.97 149.86 67.84 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.82 176.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -63.79 -49.6 3.97 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.106 1.871 . . . . 0.0 110.464 172.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.88 139.83 2.13 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.41 -0.814 . . . . 0.0 113.061 175.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.34 5.31 60.73 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.472 177.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 69.1 -85.47 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.231 0.612 . . . . 0.0 111.102 -178.156 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.1 -113.98 1.32 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.067 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 19.6 t -151.72 53.85 0.83 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.963 0.411 . . . . 0.0 110.813 -175.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.548 ' HA ' HG21 ' A' ' 89' ' ' ILE . 19.8 m 73.57 -19.38 0.34 Allowed 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 173.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.496 HG21 HD12 ' A' ' 27' ' ' LEU . 4.3 t -82.52 36.66 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.835 0.826 . . . . 0.0 111.064 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.43 ' HA3' HD12 ' A' ' 89' ' ' ILE . . . -92.98 -14.11 55.37 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.44 177.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.9 p -84.21 166.01 17.91 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 122.875 -0.191 . . . . 0.0 110.927 -178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 74.37 -44.57 0.56 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.555 0.742 . . . . 0.0 112.216 178.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.496 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 46.8 t -54.31 -45.56 68.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.755 0.312 . . . . 0.0 111.564 -177.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.505 ' HB3' HD11 ' A' ' 99' ' ' ILE . 84.3 mt -61.28 -36.28 79.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.632 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.56 ' HA ' ' HB1' ' A' ' 97' ' ' ALA . 60.4 tp -69.74 -39.76 76.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.17 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -59.44 -48.79 80.28 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.876 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 85.2 mt -57.55 -41.08 80.26 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.778 -0.647 . . . . 0.0 111.437 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.552 ' HG3' ' HB2' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -71.71 -40.23 69.61 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.306 -178.31 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.481 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 68.3 mttm -62.61 -34.85 77.86 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.248 0.547 . . . . 0.0 109.981 175.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . 0.515 ' HB3' HG21 ' A' ' 76' ' ' VAL . 37.8 t-20 -72.23 -34.0 67.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.008 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.27 6.98 57.45 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.087 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.515 HG21 ' HB3' ' A' ' 74' ' ' ASN . 28.8 m -103.41 10.07 8.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.025 0.441 . . . . 0.0 111.228 -176.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.33 147.12 49.31 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.133 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.77 160.18 49.42 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.683 176.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.536 ' HB3' ' HB3' ' A' ' 13' ' ' ALA . 96.6 mttt -69.29 -38.16 78.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.96 0.409 . . . . 0.0 110.251 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.569 ' HB1' ' HB1' ' A' ' 13' ' ' ALA . . . -148.71 158.83 44.42 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.477 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 73.9 mt -132.98 119.58 37.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.88 178.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.734 HD11 HG21 ' A' ' 102' ' ' VAL . 9.1 mm -114.2 120.17 63.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.48 172.62 7.21 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.753 0.311 . . . . 0.0 110.465 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.501 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 88.0 tttt -91.65 -43.2 9.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.286 0.565 . . . . 0.0 109.55 173.01 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -112.28 118.48 35.39 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.39 177.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.517 ' HG1' HG12 ' A' ' 8' ' ' ILE . 8.8 t -82.69 159.19 22.67 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.088 177.115 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.469 ' OE1' HG12 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -144.9 151.65 39.01 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.779 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.466 ' O ' HG21 ' A' ' 92' ' ' VAL . 2.6 m -53.56 -48.51 69.08 Favored 'General case' 0 C--N 1.323 -0.549 0 O-C-N 123.735 0.647 . . . . 0.0 111.036 178.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.548 HG21 ' HA ' ' A' ' 62' ' ' THR . 31.5 pt -62.77 -35.21 69.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.85 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.471 HG23 HD23 ' A' ' 101' ' ' LEU . 58.1 mt -70.28 -45.04 76.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.67 -45.72 91.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.849 178.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.576 ' O ' ' HG2' ' A' ' 96' ' ' MET . 69.5 t -58.43 -50.88 77.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.43 -43.09 98.76 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.656 -177.364 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.431 ' HB2' ' HB ' ' A' ' 99' ' ' ILE . . . -73.47 -31.22 63.64 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -176.045 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -66.04 -33.77 76.57 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.689 0.281 . . . . 0.0 110.94 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.576 ' HG2' ' O ' ' A' ' 92' ' ' VAL . 19.2 mmt -66.65 -44.5 81.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.576 0.703 . . . . 0.0 110.596 179.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.56 ' HB1' ' HA ' ' A' ' 69' ' ' LEU . . . -95.18 -0.39 53.28 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 114.878 -1.055 . . . . 0.0 112.125 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 56.52 64.58 1.64 Allowed 'General case' 0 C--O 1.235 0.31 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -172.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.505 HD11 ' HB3' ' A' ' 68' ' ' LEU . 54.9 mt -113.6 89.84 16.53 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.811 177.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.449 ' HB3' ' CB ' ' A' ' 123' ' ' ALA . 77.7 Cg_exo -50.14 113.24 0.93 Allowed 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 123.07 2.513 . . . . 0.0 112.564 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.471 HD23 HG23 ' A' ' 90' ' ' ILE . 1.7 pp -125.54 133.8 52.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.233 0.539 . . . . 0.0 110.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.734 HG21 HD11 ' A' ' 82' ' ' ILE . 5.3 m -126.48 152.51 34.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 175.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.622 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 11.9 pt-20 -99.42 119.87 38.69 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.192 0.52 . . . . 0.0 110.268 178.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.719 HG13 ' SG ' ' A' ' 5' ' ' CYS . 33.1 m -97.2 153.71 3.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.522 ' HD3' ' O ' ' A' ' 105' ' ' ARG . 3.4 tmt_? -127.62 -15.55 4.98 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.037 0.446 . . . . 0.0 110.842 -176.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.459 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 5.0 t70 -94.49 138.14 32.77 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.407 -170.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -71.73 -30.99 66.22 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.759 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' HE2' ' OD1' ' A' ' 106' ' ' ASP . 46.4 mtmt -59.94 -28.19 67.42 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.652 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.51 ' O ' HG11 ' A' ' 113' ' ' VAL . 81.6 t80 -65.41 -48.24 73.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.504 177.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -68.15 -26.83 65.97 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.009 -175.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.466 ' HA ' ' OE1' ' A' ' 111' ' ' GLU . 3.3 mm-40 -84.76 -36.55 21.67 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.756 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -67.65 -39.85 84.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.916 0.388 . . . . 0.0 110.751 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 109' ' ' PHE . 8.4 p -93.11 140.01 17.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.662 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.453 ' NZ ' ' HA ' ' A' ' 111' ' ' GLU . 43.1 mmtm -142.12 155.26 45.34 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.777 175.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.479 HG21 HD12 ' A' ' 18' ' ' LEU . 17.3 m -57.46 116.04 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.806 -176.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.73 -34.84 2.23 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.268 -0.967 . . . . 0.0 113.658 175.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -92.29 -174.6 3.78 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.438 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.12 142.87 41.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.221 0.534 . . . . 0.0 111.879 -168.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.412 HG22 ' HA ' ' A' ' 130' ' ' LEU . 9.9 p -141.17 140.65 31.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.28 174.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.1 t -108.9 119.83 59.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.862 178.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.443 HG11 HD12 ' A' ' 82' ' ' ILE . 53.3 t -114.24 114.6 47.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.113 0.482 . . . . 0.0 111.044 -177.703 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -100.46 99.67 10.32 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.449 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -76.74 -8.03 56.51 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.413 -174.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.549 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 20.4 t70 -65.26 -37.87 88.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.091 0.472 . . . . 0.0 109.95 177.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -102.29 -28.23 12.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.619 179.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.98 61.15 1.78 Allowed Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -166.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -136.24 124.28 22.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -165.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.427 HG11 HG23 ' A' ' 121' ' ' VAL . 21.2 t -123.87 113.67 38.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.712 0.291 . . . . 0.0 110.583 -175.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -107.99 114.58 28.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.379 177.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.412 ' HA ' HG22 ' A' ' 119' ' ' VAL . 44.8 tp -85.84 129.57 34.79 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 11.2 tt -126.46 113.78 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-O 122.196 0.998 . . . . 0.0 110.347 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.227 0 CA-C-N 113.91 -1.495 . . . . 0.0 109.704 -173.99 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.543 HG23 ' HG3' ' A' ' 2' ' ' LYS . 20.8 m . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.543 ' HG3' HG23 ' A' ' 1' ' ' VAL . 51.8 mttm 69.03 93.21 0.08 Allowed 'General case' 0 N--CA 1.469 0.49 0 O-C-N 123.454 0.471 . . . . 0.0 110.36 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -121.46 149.97 42.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.949 -175.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.14 134.74 41.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.096 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.538 ' SG ' HG22 ' A' ' 104' ' ' VAL . 82.9 m -128.46 175.86 8.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.049 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.609 ' HB3' ' HG2' ' A' ' 103' ' ' GLU . 50.2 ttt180 -93.87 120.63 34.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 178.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.572 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -91.29 112.69 24.7 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.976 0.417 . . . . 0.0 111.915 -175.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.426 ' N ' HD13 ' A' ' 8' ' ' ILE . 3.6 mp -81.45 -51.47 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.607 177.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.3 p -101.94 -173.67 2.4 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.342 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.613 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 65.8 mmt-85 -124.76 175.23 7.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.558 0.218 . . . . 0.0 110.497 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.64 173.05 25.77 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 12' ' ' ARG . 12.5 ptt180 -142.14 151.13 41.95 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 117.276 0.538 . . . . 0.0 110.802 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.501 ' HB3' ' HB3' ' A' ' 79' ' ' LYS . . . -140.73 138.02 33.89 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.742 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.554 ' HG3' HG22 ' A' ' 120' ' ' VAL . 28.0 tt0 -129.19 122.45 29.78 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.944 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 178.61 -160.4 26.25 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 119.93 -1.129 . . . . 0.0 113.028 176.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.539 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 27.1 mt-10 -70.36 134.19 47.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 122.635 0.374 . . . . 0.0 111.008 -177.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -91.23 125.32 35.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.012 0.434 . . . . 0.0 110.843 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.634 ' HB3' HD12 ' A' ' 53' ' ' LEU . 5.8 tp -117.82 118.49 32.17 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.9 t -102.01 127.05 55.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.208 0.528 . . . . 0.0 111.576 -173.286 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.45 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 19.2 m -126.18 108.49 11.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.647 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -86.22 8.78 19.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.748 0.309 . . . . 0.0 111.546 -174.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.67 143.68 35.81 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.157 0.503 . . . . 0.0 110.742 178.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -81.99 139.14 34.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.411 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.0 pt -127.55 155.95 39.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.763 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.408 ' C ' ' H ' ' A' ' 27' ' ' LEU . 18.6 p -91.81 2.06 56.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.205 -178.091 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 72.09 -10.12 0.92 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.34 -178.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 63' ' ' VAL . 2.9 mm? -94.94 33.03 1.55 Allowed 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 169.15 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.23 -175.85 50.93 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.301 -0.863 . . . . 0.0 112.899 -174.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.12 40.77 3.02 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 121.427 -0.416 . . . . 0.0 113.751 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 34.2 mt -79.09 112.44 17.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -57.72 129.55 42.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.129 0.49 . . . . 0.0 110.975 -176.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 44.9 pttt -82.29 -10.53 59.07 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.013 -173.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -93.71 -42.42 9.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -178.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 p -120.37 -5.2 9.88 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.94 32.39 80.8 Favored Glycine 0 C--N 1.329 0.143 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.339 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 46.7 mm -90.68 121.27 40.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.21 96.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.369 0.604 . . . . 0.0 109.946 176.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.3 mmmm -85.01 -5.99 59.34 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.565 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -69.75 139.08 53.27 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.65 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -77.23 132.94 38.97 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.282 -175.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.408 ' C ' ' H ' ' A' ' 43' ' ' ILE . 12.8 t -172.08 26.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.952 178.624 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 69.25 -39.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.8 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.408 ' H ' ' C ' ' A' ' 41' ' ' CYS . 35.9 pt -79.97 12.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.465 0.65 . . . . 0.0 110.497 174.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -57.05 122.91 13.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.803 177.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.8 -6.76 24.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.405 -178.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -85.65 148.44 25.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.9 0.381 . . . . 0.0 111.118 177.006 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 39.1 t -95.6 150.19 20.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 176.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.486 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.3 m -105.84 3.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.79 178.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.52 90.64 0.39 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.635 0.731 . . . . 0.0 111.497 -175.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.9 23.31 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.5 175.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.539 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 98.3 mtt180 -116.08 168.18 10.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.79 0.328 . . . . 0.0 110.518 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 52' ' ' ILE . 3.0 mp -107.93 122.92 62.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.634 HD12 ' HB3' ' A' ' 18' ' ' LEU . 4.6 mm? -96.34 138.45 33.92 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.142 0.496 . . . . 0.0 111.452 -175.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.94 119.71 61.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.067 177.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.663 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 90.7 m-85 -129.77 144.97 55.1 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.148 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 20' ' ' THR . 13.0 Cg_exo -71.37 -55.27 0.13 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.337 2.025 . . . . 0.0 111.519 175.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -135.94 108.77 0.7 Allowed Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.361 -178.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -82.34 129.74 9.25 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 175.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 33.3 ttpt -134.9 165.23 25.8 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -175.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 125.25 94.32 0.99 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -178.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.526 ' HA ' HG13 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -107.19 17.23 23.19 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.743 0.782 . . . . 0.0 109.607 -177.318 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 12.9 t -135.36 18.23 3.38 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.992 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.562 ' HA ' HD23 ' A' ' 27' ' ' LEU . 28.1 t -70.07 -49.75 53.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.233 -176.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 109.86 -24.04 20.18 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 -175.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.438 ' HB3' ' CA ' ' A' ' 93' ' ' GLY . 20.3 m 74.46 -33.31 0.25 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.761 0.825 . . . . 0.0 112.992 173.608 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.96 -23.19 65.13 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 -177.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.463 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 10.5 p -60.66 -33.58 55.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.41 -177.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 90.0 mt -68.88 -41.0 78.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.183 0.516 . . . . 0.0 110.484 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.1 tp -66.17 -39.53 89.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.949 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -60.21 -43.34 96.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.531 177.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.9 mt -65.86 -38.42 88.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.534 178.092 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.514 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 5.0 mmm180 -63.54 -42.83 98.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.233 178.099 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.418 ' HD3' ' O ' ' A' ' 73' ' ' LYS . 6.7 tmtt? -63.71 -29.21 70.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.402 0.62 . . . . 0.0 110.56 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -86.69 -12.27 48.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.117 0.485 . . . . 0.0 110.319 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 77.8 20.49 73.57 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.306 176.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.3 m -116.29 14.88 7.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.24 0.543 . . . . 0.0 110.929 -177.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -97.45 158.08 33.72 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.651 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.524 ' HB3' HD23 ' A' ' 53' ' ' LEU . 22.9 Cg_exo -65.37 165.43 22.45 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.665 2.243 . . . . 0.0 111.961 176.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 13' ' ' ALA . 54.6 mttm -80.8 -40.19 25.42 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.069 0.461 . . . . 0.0 110.245 173.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB3' ' HG2' ' A' ' 100' ' ' PRO . . . -160.36 158.34 29.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.32 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.537 HG23 ' HB2' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -130.05 127.34 63.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.157 0.504 . . . . 0.0 109.648 174.686 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.531 HG21 HG21 ' A' ' 102' ' ' VAL . 6.5 mm -106.91 116.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.235 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.663 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.0 m120 -115.27 158.65 22.05 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -177.038 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.406 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 50.4 tttm -81.69 -33.29 31.29 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 170.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.439 ' HD2' ' HA ' ' A' ' 85' ' ' LYS . 28.1 tptt -153.92 148.09 25.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.249 173.284 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.0 t -140.51 -179.47 6.04 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.731 -0.213 . . . . 0.0 110.88 -175.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.79 160.15 18.26 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.437 ' O ' HG22 ' A' ' 92' ' ' VAL . 9.1 m -58.5 -45.14 89.36 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.082 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.526 HG13 ' HA ' ' A' ' 61' ' ' SER . 15.2 mm -55.63 -41.56 65.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 111.193 178.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 27.5 mm -64.15 -45.48 96.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.361 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.79 -41.78 98.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.253 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 88' ' ' THR . 94.8 t -60.68 -44.34 96.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.053 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.438 ' CA ' ' HB3' ' A' ' 65' ' ' SER . . . -68.64 -41.25 84.54 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.076 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.84 -32.65 74.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.646 0.26 . . . . 0.0 111.125 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.37 -44.07 92.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.283 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.6 mtm -75.53 -39.44 58.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.363 -177.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.514 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -79.12 0.19 29.11 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 57.23 53.08 8.08 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.362 0.601 . . . . 0.0 111.403 -177.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 21.7 mm -113.11 88.06 11.67 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.541 178.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.501 ' HG2' ' HB3' ' A' ' 80' ' ' ALA . 1.0 OUTLIER -45.64 117.44 1.76 Allowed 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.319 2.679 . . . . 0.0 112.546 -179.614 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.97 121.0 37.99 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.821 -176.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.572 HG11 ' HA ' ' A' ' 7' ' ' ALA . 34.7 m -123.84 142.64 39.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.32 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.609 ' HG2' ' HB3' ' A' ' 6' ' ' ARG . 13.3 pt-20 -100.31 129.38 46.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.204 0.526 . . . . 0.0 110.286 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.538 HG22 ' SG ' ' A' ' 5' ' ' CYS . 11.3 t -90.33 138.13 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.896 -177.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 77.7 mtt180 -89.56 -33.63 16.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.006 0.431 . . . . 0.0 110.603 177.07 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -96.6 139.56 32.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.421 0.629 . . . . 0.0 112.09 -168.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -71.93 -26.96 62.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.754 178.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.6 mttm -65.39 -17.88 64.88 Favored 'General case' 0 CA--C 1.521 -0.141 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -176.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 75.5 t80 -60.43 -46.21 90.84 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 174.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.406 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 88.1 m-85 -72.0 -28.96 63.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.098 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -66.24 -45.95 78.86 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.463 176.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.13 -47.31 20.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.227 -176.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.52 133.26 30.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 121.362 0.601 . . . . 0.0 111.605 -173.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -122.76 145.99 47.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.584 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.1 m -66.91 100.39 0.72 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 138.3 -16.65 3.39 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.451 -178.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -83.63 175.33 9.81 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.489 176.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.816 HH21 HG13 ' A' ' 131' ' ' ILE . 21.3 ttp180 -111.93 134.25 53.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.989 -178.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.1 p -124.51 138.29 54.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.201 0.524 . . . . 0.0 110.82 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.554 HG22 ' HG3' ' A' ' 14' ' ' GLU . 40.5 t -111.32 106.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.117 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.4 p -104.06 126.58 58.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.333 0.587 . . . . 0.0 110.959 -178.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.7 t30 -114.98 100.55 8.28 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.572 176.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.26 -0.42 52.28 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.8 -176.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.613 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 28.3 t70 -67.89 -39.15 83.7 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.967 175.047 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -104.8 -30.6 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.303 177.067 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.463 ' CA ' ' HB2' ' A' ' 7' ' ' ALA . . . 96.5 57.61 1.11 Allowed Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -173.059 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 50.8 t80 -138.28 124.69 20.59 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.8 p -117.35 107.21 21.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.972 0.891 . . . . 0.0 110.106 -178.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.516 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 31.2 tt0 -105.61 108.22 19.62 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.765 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 44.3 tp -84.68 124.83 31.93 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.93 176.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.816 HG13 HH21 ' A' ' 118' ' ' ARG . 23.6 mm -97.66 118.9 44.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--N 1.312 -1.033 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.31 -177.43 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.477 HG22 ' HB3' ' A' ' 130' ' ' LEU . 18.4 m . . . . . 0 N--CA 1.455 -0.199 0 CA-C-O 121.172 0.511 . . . . 0.0 111.037 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.566 ' HB3' ' CE2' ' A' ' 127' ' ' TYR . 53.6 mtmt -129.99 117.71 20.49 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.159 -178.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -115.25 164.71 13.83 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.626 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.44 135.96 53.53 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.874 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.848 ' HG ' HG21 ' A' ' 102' ' ' VAL . 6.4 p -121.74 168.7 11.52 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.96 0.41 . . . . 0.0 111.136 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.801 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 65.4 ttt180 -95.25 109.21 21.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.705 177.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.544 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -67.23 117.7 9.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.793 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.421 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 50.1 mm -101.51 -60.66 2.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.545 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.6 OUTLIER -96.69 174.44 6.82 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 172.014 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.409 ' H ' HG22 ' A' ' 9' ' ' THR . 52.2 mtt180 -126.53 167.9 14.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.942 0.401 . . . . 0.0 111.327 -176.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.82 159.96 9.38 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.711 -175.017 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.1 mtp85 -128.35 114.57 17.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.609 0.243 . . . . 0.0 110.506 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.452 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -139.21 146.27 40.3 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.056 0.455 . . . . 0.0 111.604 -175.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -133.45 148.25 51.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.334 174.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 172.34 -160.19 31.43 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.306 174.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.673 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.0 mt-10 -70.51 129.77 40.12 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 120.968 0.414 . . . . 0.0 110.843 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.489 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.01 117.3 21.49 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.006 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.504 HD13 HG21 ' A' ' 115' ' ' THR . 12.0 tp -105.71 115.4 30.18 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 176.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.413 ' HA ' ' CG2' ' A' ' 54' ' ' VAL . 11.3 p -100.4 110.8 28.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 122.049 0.928 . . . . 0.0 111.074 -172.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.47 HG21 HG13 ' A' ' 43' ' ' ILE . 10.1 m -106.0 88.92 2.92 Favored 'General case' 0 N--CA 1.44 -0.962 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.031 178.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.529 ' HG3' ' OE2' ' A' ' 22' ' ' GLU . 21.0 pttp -76.55 -1.06 25.52 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.119 176.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.529 ' OE2' ' HG3' ' A' ' 21' ' ' LYS . 8.5 mm-40 -92.43 160.68 14.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.382 178.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 9.7 p90 -112.67 104.99 13.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.336 0.588 . . . . 0.0 110.322 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.3 mp -100.52 130.24 50.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.993 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.477 ' HB2' ' OG ' ' A' ' 61' ' ' SER . 32.7 p -71.54 121.76 19.28 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 175.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.458 ' HE2' ' HA3' ' A' ' 58' ' ' GLY . 97.3 m-85 -72.97 87.44 1.33 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.248 0.547 . . . . 0.0 111.41 -174.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -134.86 -68.08 0.54 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.128 176.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -142.1 177.4 21.5 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.653 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.19 -62.76 0.61 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 57.4 mt -69.67 124.43 25.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.641 0.258 . . . . 0.0 110.626 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -59.21 133.11 55.8 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.513 177.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.451 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 33.5 mmtp -67.09 -21.26 65.88 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.291 0.567 . . . . 0.0 110.098 177.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -100.01 -58.52 1.9 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.738 -172.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.481 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -87.96 -14.03 40.23 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.753 0.649 . . . . 0.0 112.753 -175.379 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.619 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 67.14 29.69 74.78 Favored Glycine 0 CA--C 1.518 0.261 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.598 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.481 HG12 ' HB ' ' A' ' 34' ' ' THR . 47.4 mm -103.84 133.02 48.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 3.9 p -80.32 105.33 9.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.607 0.717 . . . . 0.0 110.308 178.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -80.08 -19.64 46.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.094 -179.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -69.48 135.79 50.63 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.541 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 34.1 t70 -83.87 130.36 34.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.48 -175.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 22' ' ' GLU . 5.8 t 173.56 50.5 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 123.927 0.767 . . . . 0.0 109.23 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 72.42 -47.86 0.67 Allowed 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 123.509 0.724 . . . . 0.0 112.208 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.47 HG13 HG21 ' A' ' 20' ' ' THR . 33.4 mm -77.17 -10.4 13.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.063 0.459 . . . . 0.0 111.078 -176.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.541 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 61.8 tttp -52.89 124.08 13.19 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.976 -0.557 . . . . 0.0 111.663 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.56 -16.67 28.84 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.696 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -87.03 162.43 17.62 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.223 0.535 . . . . 0.0 112.019 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 33.2 p -102.43 150.42 23.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.623 179.242 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.438 HG21 HD11 ' A' ' 30' ' ' ILE . 2.8 t -108.68 -0.04 9.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.367 0.603 . . . . 0.0 110.159 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.32 91.62 0.55 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.833 -171.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.562 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 90.86 23.6 29.9 Favored Glycine 0 C--N 1.317 -0.525 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.21 172.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.673 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 97.5 mtt180 -111.09 169.32 8.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.867 0.365 . . . . 0.0 111.358 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.446 ' N ' HD12 ' A' ' 52' ' ' ILE . 2.3 mp -109.68 113.02 43.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 11.1 mp -102.54 132.45 48.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.962 0.41 . . . . 0.0 111.383 -174.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.497 HG12 ' HB ' ' A' ' 82' ' ' ILE . 10.5 m -109.41 130.95 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.672 176.278 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.567 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 92.7 m-85 -130.49 145.2 56.45 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.421 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.85 -33.63 33.11 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.254 1.97 . . . . 0.0 111.507 174.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -177.47 -87.41 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.133 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.458 ' HA3' ' HE2' ' A' ' 26' ' ' PHE . . . 118.12 148.15 8.51 Favored Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -176.055 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -93.99 148.93 21.69 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.933 0.397 . . . . 0.0 110.802 -178.102 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.31 84.64 0.84 Allowed Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.534 -0.757 . . . . 0.0 113.001 -174.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.477 ' OG ' ' HB2' ' A' ' 25' ' ' SER . 25.0 m -95.9 144.73 25.98 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 171.149 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.9 t -93.97 64.42 3.37 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 122.571 1.177 . . . . 0.0 111.035 -171.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.749 HG13 ' H ' ' A' ' 65' ' ' SER . 12.5 p -60.28 -26.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.851 174.104 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.62 -1.43 68.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.525 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.749 ' H ' HG13 ' A' ' 63' ' ' VAL . 21.4 m 66.43 -165.51 0.22 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 122.622 0.369 . . . . 0.0 110.654 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 72.24 -30.07 0.21 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.514 0.726 . . . . 0.0 112.412 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.442 ' H ' ' C ' ' A' ' 65' ' ' SER . 98.3 t -54.87 -42.17 61.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.715 0.293 . . . . 0.0 111.515 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.68 -32.47 72.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.922 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.536 ' HG ' ' HE2' ' A' ' 73' ' ' LYS . 56.8 tp -68.51 -42.83 77.99 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -59.13 -43.91 92.02 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.318 177.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.451 ' CD2' ' HA ' ' A' ' 32' ' ' LYS . 87.8 mt -64.99 -38.62 91.55 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.547 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.542 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -68.63 -38.68 80.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.388 -178.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.536 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 52.5 mttm -60.32 -34.27 73.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.212 0.529 . . . . 0.0 110.716 176.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.1 t30 -86.48 -22.65 26.31 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.819 -177.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.09 20.02 44.27 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.391 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.619 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 28.1 m -112.18 13.92 8.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.103 0.478 . . . . 0.0 110.811 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -96.0 160.12 30.73 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.562 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.74 141.24 71.34 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.187 1.925 . . . . 0.0 111.698 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.562 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 89.0 mttt -68.98 -28.11 66.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 110.52 176.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -160.86 147.85 15.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.695 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.521 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 63.9 mt -123.4 117.29 50.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 175.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.543 HG23 ' CG2' ' A' ' 104' ' ' VAL . 3.1 mm -110.57 115.22 49.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.567 ' ND2' ' HB2' ' A' ' 55' ' ' PHE . 15.6 m120 -111.54 153.36 26.35 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.272 -177.346 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.604 ' HA ' ' HB ' ' A' ' 104' ' ' VAL . 2.1 tmtp? -66.96 -45.63 77.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 174.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -142.98 120.88 11.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.238 177.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 3.7 m -86.29 150.11 24.58 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.303 -172.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -118.58 155.18 31.37 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 173.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.431 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.3 m -49.77 -51.38 39.65 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 123.31 0.644 . . . . 0.0 112.68 -173.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 61.8 mt -57.04 -41.18 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 121.078 0.466 . . . . 0.0 111.441 -176.276 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 20.4 mt -70.1 -43.31 79.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.384 -177.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.9 -43.98 86.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.539 -178.077 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 88' ' ' THR . 97.5 t -62.1 -43.03 97.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.992 0.425 . . . . 0.0 110.864 -179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.4 -43.38 99.14 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.58 -39.45 62.23 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -177.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.493 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -57.87 -46.54 84.71 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.78 -177.073 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.411 ' HE2' HG13 ' A' ' 92' ' ' VAL . 73.1 mtm -66.11 -30.73 71.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.923 0.392 . . . . 0.0 111.416 -177.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.542 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -88.46 2.2 53.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.576 -179.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 60.72 41.03 15.55 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.118 0.485 . . . . 0.0 110.884 -177.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.9 90.36 2.9 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.458 177.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.545 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.2 Cg_endo -48.33 100.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.603 2.868 . . . . 0.0 113.144 -173.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.521 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 3.4 tt -99.68 127.37 45.8 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.411 -0.813 . . . . 0.0 108.919 176.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.848 HG21 ' HG ' ' A' ' 5' ' ' CYS . 35.2 m -132.12 159.38 43.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.844 -178.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.801 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 25.3 tt0 -89.11 125.46 35.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.528 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.604 ' HB ' ' HA ' ' A' ' 84' ' ' LYS . 90.8 t -86.18 102.21 11.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.022 0.439 . . . . 0.0 110.602 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -78.99 -35.72 42.5 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.36 0.6 . . . . 0.0 109.639 176.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.607 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 17.7 t70 -89.92 101.87 14.57 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.496 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -70.17 -15.58 62.97 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.005 0.431 . . . . 0.0 111.038 -174.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.607 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 30.9 mmmt -62.1 -24.81 67.35 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.887 177.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -59.8 -38.42 81.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.819 177.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.459 ' HA ' HG11 ' A' ' 113' ' ' VAL . 62.1 m-85 -71.64 -22.7 61.65 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.883 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.76 -32.17 46.5 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.248 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -86.43 -30.85 21.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.062 -178.181 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.459 HG11 ' HA ' ' A' ' 110' ' ' PHE . 12.5 p -74.87 127.24 36.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.435 0.636 . . . . 0.0 111.825 -176.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.508 ' HE2' ' HA ' ' A' ' 114' ' ' LYS . 8.9 mmpt? -130.18 161.49 31.01 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.164 175.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.504 HG21 HD13 ' A' ' 18' ' ' LEU . 91.1 m -67.41 125.01 24.77 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.809 0.338 . . . . 0.0 110.89 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 103.79 -1.18 45.16 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.277 176.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -85.88 175.26 8.75 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.487 HH21 HD11 ' A' ' 131' ' ' ILE . 18.1 ttp85 -117.18 120.74 39.22 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.371 0.532 . . . . 0.0 110.855 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.489 HG23 ' HB2' ' A' ' 17' ' ' ALA . 76.6 t -118.89 126.65 75.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.695 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.02 110.14 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.0 p -100.4 118.08 46.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.665 0.745 . . . . 0.0 111.421 -176.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -100.73 94.03 5.87 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.004 175.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.8 1.63 42.05 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 122.03 0.919 . . . . 0.0 108.835 173.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -84.49 -1.83 56.34 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.041 -1.436 . . . . 0.0 109.531 175.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.14 -43.17 0.18 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.632 -176.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.41 52.23 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -175.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . 0.566 ' CE2' ' HB3' ' A' ' 2' ' ' LYS . 12.3 t80 -154.76 140.33 17.91 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -170.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 16.7 m -124.7 127.04 72.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.285 0.564 . . . . 0.0 111.351 -177.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -101.88 111.7 24.06 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.958 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.477 ' HB3' HG22 ' A' ' 1' ' ' VAL . 9.6 tt -108.77 129.68 55.38 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.413 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.487 HD11 HH21 ' A' ' 118' ' ' ARG . 3.8 mp -121.71 111.45 31.04 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.803 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 C--N 1.313 -1.003 0 O-C-N 124.485 1.116 . . . . 0.0 110.48 -175.204 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.563 0.697 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.44 ' HE3' ' HG3' ' A' ' 129' ' ' GLU . 55.9 mtpt -133.58 120.54 20.87 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.411 -175.189 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.401 ' HB2' ' CG2' ' A' ' 128' ' ' VAL . 92.4 m-85 -97.85 150.02 21.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.425 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -101.14 127.72 47.57 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.629 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.727 ' HG ' HG13 ' A' ' 128' ' ' VAL . 4.3 p -120.59 169.9 9.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.308 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.444 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 24.4 tpt180 -94.05 120.59 34.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.552 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.558 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -70.44 119.73 15.04 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.696 -176.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.2 mm -101.95 -47.47 11.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 174.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.49 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -111.95 -165.73 1.02 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.455 176.966 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 54.8 mtt180 -132.76 170.1 15.75 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 176.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 113.95 153.75 11.03 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.018 -178.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.537 ' HG3' ' HA ' ' A' ' 122' ' ' ASN . 1.0 OUTLIER -123.34 126.29 46.58 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 177.834 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.531 ' HB3' ' HB3' ' A' ' 79' ' ' LYS . . . -133.28 132.07 40.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.035 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.36 127.76 55.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.399 -178.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -167.98 -179.39 40.51 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.086 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.66 133.32 42.13 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 177.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.17 120.48 24.34 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.891 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.493 ' HA ' HG23 ' A' ' 115' ' ' THR . 8.0 tt -107.76 113.83 27.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.2 t -104.04 111.1 32.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.204 0.526 . . . . 0.0 111.094 -175.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.405 ' HB ' HD11 ' A' ' 43' ' ' ILE . 1.0 OUTLIER -135.58 130.7 34.88 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 174.19 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 21.5 mtpp -92.29 -83.2 0.3 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.24 -172.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 44.84 -163.8 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.58 0.705 . . . . 0.0 112.721 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -147.1 100.98 3.36 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 168.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.438 HD12 ' SG ' ' A' ' 41' ' ' CYS . 58.7 mt -112.26 132.59 60.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.914 0.387 . . . . 0.0 111.369 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.8 p -76.46 124.68 27.94 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 171.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -79.91 39.8 0.44 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.088 0.471 . . . . 0.0 111.711 -174.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.37 -30.61 42.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 173.435 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -157.41 -105.4 0.22 Allowed Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 114.816 -1.084 . . . . 0.0 111.096 178.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.85 -41.48 3.05 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.388 174.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 52.3 mt -115.18 142.12 29.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.847 0.356 . . . . 0.0 110.708 -176.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -73.78 136.3 43.59 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.766 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -83.06 -3.3 57.13 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -173.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -112.12 -52.84 2.76 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 122.169 -0.332 . . . . 0.0 111.297 -176.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.1 m -101.28 -15.91 17.13 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.645 -175.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.598 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.95 21.46 68.14 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.503 -0.855 . . . . 0.0 112.402 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 42.9 mm -89.12 132.33 34.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.4 m -64.46 114.91 2.52 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.45 0.643 . . . . 0.0 110.557 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -78.55 -11.16 59.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.89 177.157 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -94.84 149.88 20.78 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.141 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -79.97 135.16 36.33 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.106 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.438 ' SG ' HD12 ' A' ' 24' ' ' ILE . 56.6 m -148.98 -170.77 3.71 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -176.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -60.68 -52.32 65.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.835 0.35 . . . . 0.0 110.088 175.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.405 HD11 ' HB ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -116.3 51.42 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.385 0.612 . . . . 0.0 111.145 -179.738 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.435 ' HB2' ' H ' ' A' ' 41' ' ' CYS . 13.0 tmtt? -60.66 127.83 33.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.563 176.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.74 -5.69 12.69 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.136 -178.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -84.49 148.17 26.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.817 0.341 . . . . 0.0 111.099 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.6 m -93.0 113.28 25.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.513 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.598 ' HA ' ' HD3' ' A' ' 51' ' ' ARG . 26.5 m -82.16 19.97 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.79 0.329 . . . . 0.0 111.862 -175.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.14 92.1 5.62 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.174 0.511 . . . . 0.0 111.568 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.85 19.65 21.37 Favored Glycine 0 C--N 1.32 -0.337 0 C-N-CA 120.688 -0.767 . . . . 0.0 113.47 171.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.598 ' HD3' ' HA ' ' A' ' 48' ' ' VAL . 7.2 ptm180 -119.96 -179.28 3.87 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 177.677 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.9 mm -104.06 135.04 43.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.566 ' HB3' HG12 ' A' ' 81' ' ' ILE . 56.1 tp -106.84 125.85 51.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.127 0.489 . . . . 0.0 110.837 -179.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -107.47 112.06 38.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.53 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 19.4 t80 -132.89 142.12 43.55 Favored Pre-proline 0 C--N 1.324 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -173.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -69.98 -56.34 0.14 Allowed 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.168 1.912 . . . . 0.0 112.867 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 179.21 146.67 6.82 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.42 -179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.0 161.73 32.62 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.406 ' HB2' ' HE2' ' A' ' 59' ' ' LYS . 30.8 mtmm -106.46 142.52 35.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.185 0.493 . . . . 0.0 111.267 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -121.13 45.28 1.24 Allowed Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 172.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.9 m -51.12 104.32 0.08 Allowed 'General case' 0 C--O 1.235 0.315 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -172.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.547 ' H ' HD13 ' A' ' 89' ' ' ILE . 2.5 m 55.63 33.83 22.01 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.538 175.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.802 HG11 ' H ' ' A' ' 65' ' ' SER . 11.6 p -76.56 -24.86 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.324 0.583 . . . . 0.0 110.173 176.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 103.91 -11.59 52.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.894 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.802 ' H ' HG11 ' A' ' 63' ' ' VAL . 19.7 m 65.7 12.26 8.15 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.897 0.479 . . . . 0.0 111.828 176.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -76.67 -18.36 58.6 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.09 -177.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.426 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 48.0 t -56.15 -56.86 10.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.306 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 92.6 mt -59.62 -40.87 88.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 -177.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.535 ' O ' ' HG3' ' A' ' 73' ' ' LYS . 62.5 tp -66.63 -51.22 58.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.725 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -56.3 -44.95 80.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.445 ' CB ' ' HB3' ' A' ' 77' ' ' ALA . 90.3 mt -67.05 -36.36 81.87 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.154 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.63 ' HG3' HD12 ' A' ' 99' ' ' ILE . 0.0 OUTLIER -76.24 -28.4 57.14 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.813 -176.41 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.535 ' HG3' ' O ' ' A' ' 69' ' ' LEU . 8.2 mtpm? -67.97 -35.18 77.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.979 0.418 . . . . 0.0 109.902 176.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -78.69 -25.24 44.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.007 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.89 21.9 32.17 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.413 178.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.598 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.7 m -115.12 12.28 7.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.895 0.378 . . . . 0.0 111.034 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.445 ' HB3' ' CB ' ' A' ' 71' ' ' LEU . . . -97.29 155.33 37.5 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.811 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.543 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 22.3 Cg_exo -64.66 146.34 88.57 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.306 2.004 . . . . 0.0 111.154 174.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 13' ' ' ALA . 93.4 mttt -62.25 -35.81 80.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.878 0.371 . . . . 0.0 111.035 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.468 ' HA ' HG21 ' A' ' 99' ' ' ILE . . . -161.48 158.34 26.42 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.64 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.566 HG12 ' HB3' ' A' ' 53' ' ' LEU . 54.5 mt -131.26 124.11 54.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.591 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.671 HG22 HG23 ' A' ' 102' ' ' VAL . 5.2 mm -103.75 116.77 48.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.53 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 22.2 m120 -114.78 156.35 25.04 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.313 0.578 . . . . 0.0 111.742 -175.428 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.489 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 82.0 tttt -84.12 -38.33 20.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.415 177.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -123.81 108.25 12.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.718 174.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 19.7 p -78.55 108.85 12.23 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.194 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.58 ' HB3' HG12 ' A' ' 90' ' ' ILE . 0.4 OUTLIER -72.69 135.39 45.38 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.011 -0.736 . . . . 0.0 109.011 177.652 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -56.03 -42.99 77.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.835 -174.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.547 HD13 ' H ' ' A' ' 62' ' ' THR . 60.4 mt -69.19 -32.58 54.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.879 -177.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.58 HG12 ' HB3' ' A' ' 87' ' ' GLU . 49.4 mm -67.23 -39.98 84.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.043 177.237 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.19 -43.69 92.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.13 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.78 -45.16 95.0 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.546 178.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.572 ' HA2' ' HE2' ' A' ' 96' ' ' MET . . . -67.91 -43.47 82.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.71 -178.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -61.13 -38.07 85.07 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.953 0.406 . . . . 0.0 111.004 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.24 -32.31 73.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.546 -179.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.572 ' HE2' ' HA2' ' A' ' 93' ' ' GLY . 67.7 mtm -77.38 -40.46 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.71 0.291 . . . . 0.0 111.406 -177.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 69' ' ' LEU . . . -84.91 -0.94 55.87 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.811 -176.248 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 60.11 53.95 4.32 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 122.011 0.91 . . . . 0.0 109.78 -173.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.63 HD12 ' HG3' ' A' ' 72' ' ' ARG . 44.3 mm -110.1 88.26 6.84 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.744 175.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.49 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 5.4 Cg_endo -47.53 98.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.323 2.682 . . . . 0.0 112.753 -175.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 64.0 tp -92.87 130.97 38.29 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.27 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.671 HG23 HG22 ' A' ' 82' ' ' ILE . 14.1 m -135.41 148.78 28.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.289 177.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.449 ' CD ' ' HE ' ' A' ' 105' ' ' ARG . 39.5 tt0 -100.71 121.69 42.08 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.654 -177.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.46 HG11 ' HB3' ' A' ' 5' ' ' CYS . 14.2 m -108.92 117.62 54.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.443 0.64 . . . . 0.0 111.132 176.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . 0.449 ' HE ' ' CD ' ' A' ' 103' ' ' GLU . 12.8 mmt180 -93.46 4.5 53.86 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.852 176.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -95.67 123.27 39.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.211 -171.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -72.16 -32.51 66.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.018 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -65.99 -30.09 70.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.15 -176.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.418 ' O ' HG12 ' A' ' 113' ' ' VAL . 73.6 t80 -54.77 -50.73 67.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.075 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.489 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 89.5 m-85 -69.0 -22.64 64.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.107 0.479 . . . . 0.0 111.168 -175.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -85.57 -34.05 21.57 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.473 -179.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.91 -33.5 34.14 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.485 -178.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.418 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.6 p -78.99 125.08 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.28 0.562 . . . . 0.0 110.679 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -118.16 153.63 33.51 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.702 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 18' ' ' LEU . 24.5 m -68.2 94.35 0.51 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.071 0.463 . . . . 0.0 110.214 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.55 -9.71 2.91 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.029 -176.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . 0.473 ' HB3' HD11 ' A' ' 130' ' ' LEU . 82.9 m-20 -80.85 159.39 25.07 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 176.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -103.57 113.9 27.76 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.894 0.378 . . . . 0.0 110.324 176.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.479 HG11 ' HB3' ' A' ' 17' ' ' ALA . 6.5 p -119.92 120.71 64.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.151 0.5 . . . . 0.0 110.18 178.207 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.455 ' CG1' ' HB3' ' A' ' 129' ' ' GLU . 7.7 p -98.63 115.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.556 0.694 . . . . 0.0 109.343 175.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 7.5 p -78.57 128.78 38.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.65 -178.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . 0.537 ' HA ' ' HG3' ' A' ' 12' ' ' ARG . 49.9 t-20 -115.07 94.51 4.77 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.6 -10.37 51.68 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.264 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -75.42 -40.28 57.89 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.249 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -102.32 -14.42 16.94 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.387 -179.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.7 65.67 1.81 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.58 -178.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -152.6 144.61 23.75 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.772 0.32 . . . . 0.0 110.613 -173.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.727 HG13 ' HG ' ' A' ' 5' ' ' CYS . 4.1 m -116.7 106.59 20.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.372 0.606 . . . . 0.0 109.708 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.455 ' HB3' ' CG1' ' A' ' 120' ' ' VAL . 29.8 tt0 -93.11 108.45 20.04 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.043 -174.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.473 HD11 ' HB3' ' A' ' 117' ' ' ASP . 38.8 tp -97.46 129.69 44.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.136 -175.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 13.2 mm -124.8 120.2 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.867 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 . . . . . 0 C--N 1.313 -1.001 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.707 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.457 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 4.6 m . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.433 0.635 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.51 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 19.5 mtpp -117.64 112.84 21.06 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.979 -176.739 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.457 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 96.5 m-85 -112.32 156.03 23.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.311 0.577 . . . . 0.0 111.728 -172.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.57 133.03 48.24 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.068 175.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.4 m -119.57 -179.45 3.88 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -177.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.894 ' HA ' ' HE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -101.36 126.02 48.07 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 120.241 -0.584 . . . . 0.0 110.083 174.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.527 ' HA ' HG11 ' A' ' 102' ' ' VAL . . . -80.13 128.13 33.14 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.731 -174.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.449 ' HB ' HD12 ' A' ' 101' ' ' LEU . 49.6 mm -112.5 -49.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 174.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.574 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -100.23 172.06 7.4 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 171.433 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.7 mtp180 -127.17 177.24 6.8 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.781 -178.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.78 -158.84 20.26 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -172.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ptt180 -141.87 160.6 39.87 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 117.107 0.453 . . . . 0.0 110.477 175.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.525 ' CB ' ' HB1' ' A' ' 80' ' ' ALA . . . -145.79 159.58 42.99 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.324 -178.216 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -153.21 143.04 22.06 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.063 -177.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.12 175.35 39.56 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.883 -1.151 . . . . 0.0 112.757 175.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -73.41 136.42 44.3 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.502 ' HB3' HG22 ' A' ' 119' ' ' VAL . . . -80.79 128.05 33.21 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.211 0.529 . . . . 0.0 111.841 -175.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.468 HD11 HG22 ' A' ' 115' ' ' THR . 5.2 tp -116.12 110.44 18.86 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.389 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.61 134.84 48.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.232 0.539 . . . . 0.0 111.661 -171.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.501 HG21 ' HB3' ' A' ' 55' ' ' PHE . 2.1 t -146.3 117.62 7.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.245 174.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -82.65 -8.92 59.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.471 0.653 . . . . 0.0 109.293 176.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.407 ' OE1' ' HB3' ' A' ' 41' ' ' CYS . 1.5 tm-20 -81.19 146.13 30.65 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 174.223 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -86.07 158.9 19.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.558 -171.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.497 HD11 ' HE2' ' A' ' 44' ' ' LYS . 12.5 tt -150.24 127.51 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.679 0.752 . . . . 0.0 111.032 177.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.632 ' HA ' ' O ' ' A' ' 58' ' ' GLY . 0.9 OUTLIER -76.28 135.09 39.63 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.845 -177.211 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.462 ' HB2' HG13 ' A' ' 63' ' ' VAL . 81.5 m-85 -73.06 -20.05 61.05 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.106 -175.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -65.33 -67.07 0.47 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.747 0.308 . . . . 0.0 110.501 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -114.26 34.9 4.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.663 -0.78 . . . . 0.0 111.509 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -98.34 -19.99 21.56 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.864 -0.684 . . . . 0.0 113.06 -175.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 53.6 mt -129.2 133.73 65.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 117.374 0.587 . . . . 0.0 110.75 -177.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.641 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.3 t70 -69.5 128.61 37.11 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.882 176.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -79.02 -7.13 57.84 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.558 -174.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -101.61 -57.67 2.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.994 0.426 . . . . 0.0 110.816 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -101.96 -8.3 21.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -172.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.95 21.88 78.93 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.643 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 37.7 mm -84.49 128.01 39.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 177.18 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 6.3 m -62.27 120.27 8.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.153 0.501 . . . . 0.0 110.545 175.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.641 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 21.2 mmmt -88.44 -35.21 17.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.808 -175.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.555 ' O ' ' HD3' ' A' ' 44' ' ' LYS . 31.9 tt0 -77.8 107.7 10.5 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.681 ' HA ' ' HD3' ' A' ' 44' ' ' LYS . 13.2 t70 -110.52 144.61 39.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.269 0.556 . . . . 0.0 112.354 -172.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.621 ' SG ' ' HD2' ' A' ' 44' ' ' LYS . 12.4 p -108.93 -51.08 2.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.476 173.134 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.417 ' HG3' HG22 ' A' ' 43' ' ' ILE . 12.5 pt-20 -172.36 -29.92 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.003 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.417 HG22 ' HG3' ' A' ' 42' ' ' GLU . 18.5 pt -114.86 10.95 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.741 -178.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.681 ' HD3' ' HA ' ' A' ' 40' ' ' ASP . 24.2 mttt -92.59 146.96 23.26 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.176 0.512 . . . . 0.0 110.575 -176.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.01 0.74 1.43 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.724 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 -87.58 158.39 18.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.88 0.371 . . . . 0.0 111.113 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.506 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 35.5 t -89.05 151.84 22.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.882 176.013 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 19.6 m -104.8 10.65 8.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.835 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.84 87.93 0.37 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.918 -174.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.61 -2.67 42.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.284 -0.871 . . . . 0.0 113.536 171.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.506 ' HD2' ' O ' ' A' ' 47' ' ' SER . 0.7 OUTLIER -109.13 -172.28 2.01 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 117.199 0.499 . . . . 0.0 110.856 -178.361 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.489 HG12 ' HB3' ' A' ' 80' ' ' ALA . 72.4 mt -118.44 120.61 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.327 -177.542 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.411 HD11 ' O ' ' A' ' 18' ' ' LEU . 47.4 tp -103.5 121.3 42.56 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.53 106.26 20.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.073 0.463 . . . . 0.0 110.658 -178.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.501 ' HB3' HG21 ' A' ' 20' ' ' THR . 23.6 p90 -137.25 151.79 72.26 Favored Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.851 176.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_exo -62.51 -41.52 32.13 Favored 'Trans proline' 0 CA--C 1.529 0.245 0 C-N-CA 122.458 2.105 . . . . 0.0 112.197 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.74 -159.01 32.12 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.632 ' O ' ' HA ' ' A' ' 25' ' ' SER . . . 169.05 72.39 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.189 -1.005 . . . . 0.0 113.336 178.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 95.4 mttt 69.33 127.77 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.755 0.788 . . . . 0.0 112.545 172.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.0 74.88 1.81 Allowed Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.24 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.606 ' HB2' HG11 ' A' ' 63' ' ' VAL . 14.9 m -84.41 176.12 8.89 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.826 0.346 . . . . 0.0 110.854 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.2 t -76.73 37.29 0.18 Allowed 'General case' 0 CA--C 1.539 0.522 0 CA-C-O 121.381 0.61 . . . . 0.0 111.261 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.606 HG11 ' HB2' ' A' ' 61' ' ' SER . 7.9 p -127.23 149.34 32.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.239 -175.324 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.28 -49.98 0.58 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.794 -0.717 . . . . 0.0 111.731 -179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.524 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 13.5 m -67.33 -52.15 43.73 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.123 0.487 . . . . 0.0 110.069 177.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.555 ' CD2' HG23 ' A' ' 67' ' ' VAL . 38.6 p90 -94.87 179.91 5.07 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.555 HG23 ' CD2' ' A' ' 66' ' ' TYR . 76.1 t 72.99 -60.88 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 122.846 0.459 . . . . 0.0 110.467 -174.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 8.3 mp -63.41 -39.42 94.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.1 0.476 . . . . 0.0 109.846 176.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.1 tp -62.26 -40.19 95.37 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.123 175.343 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.33 -38.89 92.91 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.293 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 93.7 mt -58.13 -41.2 83.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.555 177.675 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.503 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -67.28 -34.74 78.05 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.564 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -67.12 -25.66 66.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.288 -178.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -100.27 -17.2 17.43 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.126 0.488 . . . . 0.0 110.299 177.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.96 0.17 58.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.942 176.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.5 19.03 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.54 -176.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -80.84 148.69 65.57 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.351 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.426 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 11.7 Cg_exo -68.77 154.2 71.63 Favored 'Trans proline' 0 N--CA 1.463 -0.266 0 C-N-CA 122.576 2.184 . . . . 0.0 110.96 175.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.426 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 45.1 mttp -85.06 -32.99 22.57 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.199 179.425 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.525 ' HB1' ' CB ' ' A' ' 13' ' ' ALA . . . -151.42 143.96 24.25 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.796 0.331 . . . . 0.0 111.407 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 40.3 mm -129.41 124.78 60.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 174.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.568 HG21 HG21 ' A' ' 102' ' ' VAL . 3.7 mm -118.05 116.46 51.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -120.03 165.51 14.61 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -175.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 0.0 OUTLIER -76.54 -28.81 56.46 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.669 0.747 . . . . 0.0 109.956 177.568 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.7 tttm -138.91 130.51 27.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.629 169.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 25.4 p -90.4 155.94 18.58 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 175.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -123.06 146.09 47.98 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.709 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.2 m -57.95 -50.4 73.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.231 -173.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 59.4 mt -58.79 -42.71 86.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.162 0.506 . . . . 0.0 110.663 -178.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 57.4 mt -70.11 -41.35 79.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.511 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.5 93.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.335 -179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 94.2 t -61.44 -45.48 98.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.694 178.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.524 ' CA ' ' HA ' ' A' ' 65' ' ' SER . . . -66.63 -41.59 93.86 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.406 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.32 -41.88 93.53 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.69 0.281 . . . . 0.0 111.269 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.63 -29.6 69.35 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.021 0.438 . . . . 0.0 110.451 176.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 76.8 mtp -83.33 -30.31 27.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.185 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.503 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -96.04 16.68 17.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.868 -177.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.435 ' OE1' ' HD2' ' A' ' 72' ' ' ARG . 3.5 mp0 55.03 41.2 32.02 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.121 0.486 . . . . 0.0 111.297 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.415 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 48.7 mt -115.47 86.06 14.42 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.754 176.604 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.574 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 30.0 Cg_endo -65.58 109.89 1.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.309 2.006 . . . . 0.0 112.167 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.449 HD12 ' HB ' ' A' ' 8' ' ' ILE . 3.1 pp -110.31 151.27 27.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.202 0.525 . . . . 0.0 111.26 179.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.568 HG21 HG21 ' A' ' 82' ' ' ILE . 31.3 m -135.75 162.28 37.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.691 177.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -108.13 126.54 52.89 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.82 0.343 . . . . 0.0 110.98 -175.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 8.3 m -109.24 123.52 65.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.451 176.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -101.51 12.35 37.45 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.141 0.496 . . . . 0.0 110.201 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.481 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 28.6 t70 -107.62 122.73 47.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.022 -177.286 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -71.17 -29.07 64.73 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.629 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.597 ' HB2' ' HZ2' ' A' ' 108' ' ' LYS . 10.2 mtmp? -62.64 -28.72 70.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.074 -177.069 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -60.12 -48.82 80.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.029 178.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -65.79 -26.96 67.93 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.341 0.591 . . . . 0.0 110.835 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -79.73 -27.23 40.61 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.842 -179.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.69 -39.95 12.15 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.835 -177.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.503 ' HA ' HD23 ' A' ' 130' ' ' LEU . 13.6 p -69.3 134.96 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.034 0.445 . . . . 0.0 111.176 -177.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -121.32 151.59 39.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.794 -177.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.468 HG22 HD11 ' A' ' 18' ' ' LEU . 71.4 m -71.91 124.43 24.85 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.112 175.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.04 9.42 54.01 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.879 -177.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -97.97 177.14 5.53 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.476 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.6 OUTLIER -116.07 113.79 23.66 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.363 0.602 . . . . 0.0 111.613 -172.914 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.567 HG23 HD12 ' A' ' 130' ' ' LEU . 45.3 t -113.2 127.96 70.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.68 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.6 t -113.15 117.4 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 172.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 43.0 t -108.98 123.96 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.758 -174.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -106.33 94.98 5.44 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 171.015 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.02 -19.73 62.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.947 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -62.29 -37.73 86.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.098 0.475 . . . . 0.0 109.927 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -87.37 -36.87 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.041 174.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.431 ' HA2' HG12 ' A' ' 102' ' ' VAL . . . 87.15 54.15 2.65 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -167.073 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 72.8 t80 -137.14 134.86 36.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.383 -169.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 28.1 m -120.12 130.69 74.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.061 0.458 . . . . 0.0 110.842 -179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.51 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 38.8 tt0 -108.27 107.41 18.0 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 175.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.567 HD12 HG23 ' A' ' 119' ' ' VAL . 60.2 tp -104.76 107.62 18.67 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.928 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.476 HG12 ' NH2' ' A' ' 118' ' ' ARG . 34.5 mm -101.44 110.98 29.67 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 . . . . . 0 C--N 1.313 -1.02 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.584 -177.688 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.988 0.423 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.455 ' HG2' ' HB3' ' A' ' 129' ' ' GLU . 54.3 mttm -93.42 133.45 36.68 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.212 174.244 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.441 ' CD2' ' HD1' ' A' ' 109' ' ' PHE . 93.5 m-85 -122.13 157.97 30.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.41 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.46 117.13 32.74 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.02 -178.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.6 p -119.6 172.9 7.33 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.16 177.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -104.97 131.95 51.83 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 177.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.511 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.49 134.02 34.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.092 -173.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.476 HD12 ' HG3' ' A' ' 103' ' ' GLU . 2.5 mp -110.58 -51.41 6.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 172.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -94.36 178.01 5.76 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -122.72 174.74 6.92 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 97.87 -163.44 21.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.687 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.9 mtt180 -120.59 148.46 43.84 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 178.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.693 ' HB1' ' HB1' ' A' ' 80' ' ' ALA . . . -129.15 114.68 16.62 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 178.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.498 ' HB2' HG23 ' A' ' 120' ' ' VAL . 15.7 tm-20 -133.61 122.01 22.88 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.657 -173.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.03 -173.98 44.74 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.344 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 31.1 mp0 -71.39 138.23 48.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -95.24 123.12 38.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.885 0.374 . . . . 0.0 110.915 178.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.1 mp -104.84 127.03 52.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.113 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.761 HG11 ' HB ' ' A' ' 115' ' ' THR . 13.4 p -102.04 137.67 29.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.852 -173.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.4 m -150.14 107.86 3.68 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 175.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -96.72 65.26 2.17 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.03 -177.457 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 mm-40 -142.74 161.74 37.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.3 176.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -88.38 81.75 7.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.909 0.385 . . . . 0.0 111.6 -177.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.446 HG21 ' H ' ' A' ' 26' ' ' PHE . 4.3 mp -108.17 112.23 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.694 0 CA-C-O 121.733 0.778 . . . . 0.0 109.749 173.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.3 m -87.38 36.36 0.74 Allowed 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.009 -177.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.446 ' H ' HG21 ' A' ' 24' ' ' ILE . 56.8 m-85 63.88 -81.89 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.223 0.609 . . . . 0.0 111.106 -176.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.2 mt 58.41 -85.4 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 O-C-N 123.896 0.748 . . . . 0.0 111.598 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -158.17 24.59 0.39 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.84 -22.29 79.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.772 -176.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 39.8 mt -92.94 127.61 44.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.961 0.41 . . . . 0.0 110.338 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.44 ' HB2' ' CG ' ' A' ' 38' ' ' LYS . 16.2 t70 -67.27 119.03 11.47 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.957 176.393 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 10.2 ptpp? -83.22 0.6 44.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.645 0.259 . . . . 0.0 111.355 -173.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -85.29 -46.81 10.65 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.899 0.38 . . . . 0.0 110.544 177.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.4 p -125.56 -5.47 7.05 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.991 0.738 . . . . 0.0 112.991 -174.105 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.99 30.86 55.08 Favored Glycine 0 C--O 1.236 0.233 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.41 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 40.9 mm -99.66 123.84 52.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.608 HG23 ' HE3' ' A' ' 44' ' ' LYS . 15.3 t -71.2 104.53 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.244 176.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.44 ' CG ' ' HB2' ' A' ' 31' ' ' ASP . 6.8 mmmm -78.62 -19.99 51.41 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.523 -174.016 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -90.56 110.22 21.36 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.756 178.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.464 ' HA ' ' HB3' ' A' ' 44' ' ' LYS . 19.3 t70 -97.81 155.88 16.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.108 0.48 . . . . 0.0 110.966 -178.067 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 18.7 p -141.32 -37.93 0.42 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.322 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -141.02 -62.47 0.48 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.186 -177.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.433 HD11 HG21 ' A' ' 115' ' ' THR . 30.2 pt -133.17 17.52 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.932 -172.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.608 ' HE3' HG23 ' A' ' 37' ' ' VAL . 17.4 tptt -80.97 -173.4 4.24 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.13 0.491 . . . . 0.0 111.565 -168.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.36 -0.44 55.8 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -173.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -94.28 179.01 5.44 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.963 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 9.5 m -92.41 132.13 37.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.203 -175.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.5 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 28.7 m -106.23 -0.27 10.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.113 0.482 . . . . 0.0 110.003 172.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.86 96.54 0.19 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.546 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.513 ' C ' ' HD2' ' A' ' 51' ' ' ARG . . . 86.12 20.98 54.05 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.266 -1.333 . . . . 0.0 112.517 177.464 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.513 ' HD2' ' C ' ' A' ' 50' ' ' GLY . 4.0 mpt_? -119.01 166.15 13.23 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.719 0.295 . . . . 0.0 110.588 178.332 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.746 HG12 ' HB3' ' A' ' 80' ' ' ALA . 63.3 mt -93.63 122.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.299 -0.409 . . . . 0.0 109.943 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.485 HD12 ' HZ1' ' A' ' 44' ' ' LYS . 17.0 tp -99.33 128.0 45.4 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.572 -175.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.9 120.17 60.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.118 0.485 . . . . 0.0 111.215 -177.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . 0.426 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.9 m-85 -133.37 144.49 52.57 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 176.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 14.0 Cg_exo -69.72 -54.21 0.23 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.55 2.167 . . . . 0.0 111.074 175.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -165.65 67.87 0.2 Allowed Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.434 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -61.51 -29.38 71.59 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.934 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.515 ' HG2' ' N ' ' A' ' 60' ' ' GLY . 41.2 ttmt 70.62 166.04 0.29 Allowed 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 123.022 0.529 . . . . 0.0 111.073 178.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.515 ' N ' ' HG2' ' A' ' 59' ' ' LYS . . . -126.81 96.28 0.45 Allowed Glycine 0 N--CA 1.443 -0.865 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 175.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 27.3 m -96.37 95.13 7.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.534 0.207 . . . . 0.0 111.242 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 4.3 m 58.58 45.51 16.09 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-O 121.381 0.61 . . . . 0.0 111.317 175.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.571 ' HB ' HD11 ' A' ' 89' ' ' ILE . 51.8 t -80.79 -36.4 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.345 -177.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 84.51 -27.02 4.86 Favored Glycine 0 CA--C 1.516 0.15 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.032 -177.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.447 ' HA ' HD11 ' A' ' 68' ' ' LEU . 27.6 m 70.14 1.73 3.66 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.358 0.663 . . . . 0.0 112.399 174.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 26.4 p90 -70.81 -29.91 66.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.277 0.56 . . . . 0.0 110.24 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.608 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 9.6 p -71.23 -29.79 37.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.401 -175.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.447 HD11 ' HA ' ' A' ' 65' ' ' SER . 6.4 mp -66.9 -41.68 86.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.78 -178.74 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.27 -36.0 80.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 177.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -58.94 -48.33 81.88 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.332 175.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.608 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 81.2 mt -58.4 -40.32 82.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 178.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.51 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -66.78 -42.78 85.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.082 -178.616 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -64.79 -27.97 69.25 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.682 0.277 . . . . 0.0 111.374 -179.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -90.47 -17.8 26.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.19 0.519 . . . . 0.0 110.082 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 83.58 26.8 41.21 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.349 178.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.87 11.6 7.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.152 0.501 . . . . 0.0 110.537 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.411 ' HB3' HD13 ' A' ' 99' ' ' ILE . . . -81.93 158.38 67.68 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.138 -179.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 24.3 Cg_exo -62.16 148.55 93.0 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.192 1.928 . . . . 0.0 110.99 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.495 ' HD3' ' O ' ' A' ' 14' ' ' GLU . 75.5 tttt -84.96 -21.63 29.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.511 . . . . 0.0 109.635 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.746 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -166.49 163.55 17.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.227 175.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . 0.442 HG22 ' HB3' ' A' ' 101' ' ' LEU . 7.9 tt -146.84 114.71 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.288 0.566 . . . . 0.0 110.065 174.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.616 HD11 HG22 ' A' ' 102' ' ' VAL . 7.6 mm -108.55 124.31 64.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.442 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.426 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.3 m120 -120.93 160.89 22.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.297 -173.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -77.11 -37.45 54.21 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 171.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -154.71 154.71 33.32 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 114.711 -1.132 . . . . 0.0 108.57 168.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -143.52 172.63 12.53 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.78 -178.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.515 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 57.7 mm-40 -107.98 168.19 9.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.597 -177.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.0 m -58.85 -52.15 66.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -173.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.571 HD11 ' HB ' ' A' ' 63' ' ' VAL . 36.1 pt -63.5 -30.08 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 C-N-CA 120.638 -0.425 . . . . 0.0 112.067 -174.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.1 mm -64.93 -45.41 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.498 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -64.47 -48.02 76.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.051 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 86.9 t -61.81 -46.51 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.18 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.445 ' HA3' ' HB3' ' A' ' 65' ' ' SER . . . -63.13 -43.87 98.03 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.567 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.557 ' HB3' ' HB ' ' A' ' 99' ' ' ILE . . . -72.21 -35.93 69.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.437 0.161 . . . . 0.0 111.319 -178.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.07 -31.26 69.83 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.139 0.495 . . . . 0.0 110.73 178.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.8 mtm -82.68 -39.88 21.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.625 178.24 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.51 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -80.68 6.84 11.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.024 -178.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.472 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 47.9 mt-10 64.23 35.47 10.05 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.263 0.554 . . . . 0.0 110.971 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.557 ' HB ' ' HB3' ' A' ' 94' ' ' ALA . 54.2 mt -109.91 88.61 6.97 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.101 178.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.557 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 32.8 Cg_exo -58.53 118.04 4.86 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.67 2.247 . . . . 0.0 113.018 -176.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.556 HD23 ' HB1' ' A' ' 94' ' ' ALA . 1.7 pt? -117.34 141.64 48.07 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.251 175.14 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.616 HG22 HD11 ' A' ' 82' ' ' ILE . 31.3 m -138.04 161.56 32.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.928 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . 0.476 ' HG3' HD12 ' A' ' 8' ' ' ILE . 53.2 mt-10 -97.92 116.8 30.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.686 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.481 HG12 HG22 ' A' ' 82' ' ' ILE . 7.2 p -115.23 107.38 22.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.764 0.792 . . . . 0.0 109.187 172.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 8.3 ttm-85 -99.04 14.65 28.46 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.048 -175.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -89.18 120.01 30.18 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.044 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -67.39 -34.71 77.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.391 -175.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 108' ' ' LYS . 32.8 mmtp -69.49 -23.0 63.57 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.32 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.441 ' HD1' ' CD2' ' A' ' 3' ' ' PHE . 87.6 t80 -62.19 -51.04 69.39 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 172.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.404 ' CZ ' HG11 ' A' ' 104' ' ' VAL . 87.0 m-85 -69.7 -25.96 64.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.842 -178.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.41 ' HB2' ' HA ' ' A' ' 108' ' ' LYS . 37.1 mm-40 -74.92 -29.59 61.01 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.009 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.79 -34.03 14.74 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -176.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.407 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.7 p -85.15 138.6 18.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.173 0.511 . . . . 0.0 111.375 -175.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -124.48 167.07 14.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.972 173.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.761 ' HB ' HG11 ' A' ' 19' ' ' VAL . 9.8 t -67.55 107.58 2.55 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.725 0.774 . . . . 0.0 110.657 -178.371 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.15 -24.39 4.23 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.554 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -63.72 151.12 42.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.868 0.334 . . . . 0.0 110.28 179.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.668 HH21 HG13 ' A' ' 131' ' ' ILE . 1.1 tmm_? -96.68 120.37 36.89 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -175.04 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.443 HG23 HD12 ' A' ' 130' ' ' LEU . 46.3 t -120.68 141.2 42.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.757 -175.047 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.498 HG23 ' HB2' ' A' ' 14' ' ' GLU . 9.9 p -124.38 121.1 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 121.763 0.792 . . . . 0.0 109.464 169.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.51 ' HB ' ' HB2' ' A' ' 13' ' ' ALA . 40.2 t -106.54 127.35 62.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.472 -178.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.2 t-20 -93.44 97.48 10.58 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.38 -13.83 51.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.363 -175.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -68.92 -45.11 71.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.158 0.504 . . . . 0.0 109.744 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -93.85 -43.26 8.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.086 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.38 69.22 0.82 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -172.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.7 t80 -161.31 157.62 25.74 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 -172.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -152.99 138.64 11.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.021 -179.032 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.455 ' HB3' ' HG2' ' A' ' 2' ' ' LYS . 2.2 pm0 -118.75 119.99 36.05 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.356 0.598 . . . . 0.0 110.458 174.142 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.443 HD12 HG23 ' A' ' 119' ' ' VAL . 54.7 tp -84.01 130.54 34.88 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.69 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.668 HG13 HH21 ' A' ' 118' ' ' ARG . 37.1 mm -101.27 120.25 50.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 CA-C-O 121.412 0.625 . . . . 0.0 109.6 177.236 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.198 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.195 -178.129 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -131.06 113.22 13.66 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.513 178.602 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -93.3 152.85 18.9 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.949 0.404 . . . . 0.0 111.181 -175.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.51 124.39 47.97 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.669 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 56.9 m -119.41 174.0 6.63 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.914 0.388 . . . . 0.0 110.82 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 40.7 ttt180 -92.83 111.7 23.4 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -90.84 137.83 32.06 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.569 -171.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.609 HD13 HD12 ' A' ' 101' ' ' LEU . 4.3 mp -103.87 -52.2 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 48.7 p -102.95 176.42 5.16 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.771 176.077 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 61.0 mtt180 -122.37 -175.35 3.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.661 0.267 . . . . 0.0 111.076 -176.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.15 171.83 27.35 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -175.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.4 HH21 ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -140.26 139.5 35.56 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 117.282 0.541 . . . . 0.0 110.52 -178.631 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.613 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -135.46 145.49 47.23 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.076 0.465 . . . . 0.0 111.65 -174.561 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.21 123.05 38.73 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.083 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.89 176.4 41.93 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 119.68 -1.248 . . . . 0.0 112.528 179.202 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.66 137.65 39.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 177.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.46 124.81 29.24 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.814 -176.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.404 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.8 tt -119.28 121.23 39.16 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' OG1' ' A' ' 115' ' ' THR . 8.9 p -111.4 120.12 61.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.078 0.466 . . . . 0.0 110.185 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.3 t -94.12 -6.74 44.29 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.077 0.465 . . . . 0.0 111.366 -175.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.0 tttt 68.54 -61.07 0.42 Allowed 'General case' 0 CA--C 1.539 0.54 0 CA-C-N 114.958 -1.019 . . . . 0.0 113.605 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -71.64 163.67 27.33 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -82.53 78.2 9.19 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.622 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.6 pt -106.11 135.74 43.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.961 0.41 . . . . 0.0 110.397 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.3 t -111.02 178.02 4.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.941 -178.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.41 ' HZ ' HD13 ' A' ' 81' ' ' ILE . 77.7 m-85 -87.53 29.6 0.87 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.257 0.551 . . . . 0.0 111.414 -174.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.39 -21.97 66.74 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 171.04 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.95 -127.61 1.44 Allowed Glycine 0 N--CA 1.444 -0.833 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.184 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.688 ' HA2' ' HB2' ' A' ' 39' ' ' GLU . . . 86.59 -43.78 3.27 Favored Glycine 0 C--O 1.221 -0.687 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.847 172.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.461 HG12 HG12 ' A' ' 37' ' ' VAL . 57.3 mt -109.05 136.94 43.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -66.07 130.03 41.85 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.88 -33.31 73.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -170.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -109.41 -35.12 6.34 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.48 -0.488 . . . . 0.0 111.887 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 m -81.47 -28.57 34.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.583 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.832 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.82 19.55 78.82 Favored Glycine 0 C--N 1.329 0.191 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.505 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.456 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.7 mm -95.87 131.06 43.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.461 HG12 HG12 ' A' ' 30' ' ' ILE . 13.9 m -71.39 107.97 2.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.814 0.816 . . . . 0.0 110.218 175.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mmmm -92.35 -10.44 38.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.047 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.688 ' HB2' ' HA2' ' A' ' 29' ' ' GLY . 9.8 tp10 -80.8 153.4 27.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.792 177.152 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -100.04 137.95 37.79 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.244 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 16.3 p -161.27 -56.23 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.327 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -173.29 -51.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.477 174.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -92.05 44.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.885 0.85 . . . . 0.0 110.156 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -78.76 129.88 35.14 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.409 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.52 11.3 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.797 179.396 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.424 ' O ' HG22 ' A' ' 37' ' ' VAL . 26.7 mt-10 -92.86 171.69 8.81 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.299 0.571 . . . . 0.0 111.973 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.456 ' HB3' HD13 ' A' ' 36' ' ' ILE . 15.6 p -105.37 151.12 24.58 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.447 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 30' ' ' ILE . 27.2 m -102.66 18.2 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.773 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.8 95.72 2.96 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.759 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.03 21.07 28.91 Favored Glycine 0 C--N 1.315 -0.619 0 CA-C-N 115.163 -0.926 . . . . 0.0 113.472 170.251 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -123.6 175.0 7.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 80' ' ' ALA . 50.2 mm -99.11 129.51 49.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 -174.621 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.594 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 3.6 mm? -110.0 130.69 55.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.098 0.475 . . . . 0.0 111.341 -176.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.457 HG21 HG21 ' A' ' 113' ' ' VAL . 52.8 t -117.9 125.7 74.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.662 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.594 ' CE1' ' HB3' ' A' ' 53' ' ' LEU . 27.3 m-85 -131.5 143.92 51.24 Favored Pre-proline 0 C--N 1.327 -0.385 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -73.15 -42.83 0.86 Allowed 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 121.855 1.704 . . . . 0.0 110.57 171.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.824 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.222 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 . . . . . 0 C--O 1.233 0.226 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.39 -32.22 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 111.648 0.24 . . . . 0.0 111.648 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.3 mt -61.0 -38.8 87.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.942 0.401 . . . . 0.0 110.932 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 59.4 tp -71.74 -41.18 68.79 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.561 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -62.62 -44.18 96.93 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.714 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 94.7 mt -62.75 -39.6 94.64 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.614 178.131 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.516 ' HG2' ' O ' ' A' ' 97' ' ' ALA . 11.3 tpt180 -67.65 -41.47 83.75 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.365 -175.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.33 -10.08 59.24 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 110.898 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -94.98 -16.58 22.65 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.075 0.464 . . . . 0.0 110.399 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.23 11.66 81.93 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.086 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.832 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.2 m -106.65 13.67 8.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.106 0.479 . . . . 0.0 111.011 -177.281 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.15 155.57 42.75 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.832 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.594 ' HB3' HD23 ' A' ' 53' ' ' LEU . 37.0 Cg_endo -66.42 147.18 82.32 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.487 2.125 . . . . 0.0 111.201 173.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.613 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.2 mttt -68.15 -42.16 80.52 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.867 0.365 . . . . 0.0 111.14 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.534 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -151.4 156.54 40.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.778 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.41 HD13 ' HZ ' ' A' ' 26' ' ' PHE . 74.5 mt -132.83 128.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.392 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.713 HG23 HG23 ' A' ' 102' ' ' VAL . 2.3 mm -112.37 128.39 69.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.344 -0.614 . . . . 0.0 109.344 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 89.2 m-20 -126.31 159.55 32.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.879 -178.004 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.517 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 2.7 tmtp? -92.91 -35.69 13.2 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 173.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -142.58 101.99 3.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.813 174.174 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -95.41 -179.9 4.93 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -174.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.31 150.69 43.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.944 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 92' ' ' VAL . 13.1 m -62.52 -37.7 87.06 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.289 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.98 -29.53 47.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.9 mt -71.83 -42.52 69.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB1' HG21 ' A' ' 8' ' ' ILE . . . -59.43 -42.88 92.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.263 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 88' ' ' THR . 57.1 t -62.76 -47.86 90.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.828 179.287 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.2 -43.41 99.16 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.258 178.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.49 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.5 -31.08 71.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.358 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -70.09 -35.11 73.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.911 0.386 . . . . 0.0 111.252 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.1 mtm -81.61 -33.62 31.4 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 -178.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.516 ' O ' ' HG2' ' A' ' 72' ' ' ARG . . . -89.99 0.51 57.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.003 -177.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 55.15 61.63 2.84 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.829 0.823 . . . . 0.0 110.098 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.49 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.7 mt -123.11 90.05 50.55 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 114.784 -1.098 . . . . 0.0 109.801 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 4.2 Cg_exo -40.04 109.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.348 0.541 0 C-N-CA 123.669 2.912 . . . . 0.0 112.891 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.609 HD12 HD13 ' A' ' 8' ' ' ILE . 1.1 tm? -110.59 120.0 40.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.348 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.713 HG23 HG23 ' A' ' 82' ' ' ILE . 24.7 m -130.36 144.21 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.019 0.438 . . . . 0.0 110.634 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -110.16 122.84 48.58 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.03 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.456 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.3 p -98.8 134.45 37.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.185 0.517 . . . . 0.0 110.687 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 0.7 OUTLIER -92.79 -14.8 27.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.929 -174.328 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 104' ' ' VAL . 5.6 t70 -109.42 137.61 47.01 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.558 -0.457 . . . . 0.0 111.274 -175.376 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -72.78 -19.36 61.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.847 -176.172 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 19.0 mmtp -58.3 -26.6 63.21 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.461 ' O ' HG12 ' A' ' 113' ' ' VAL . 79.9 t80 -61.72 -42.81 99.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.755 0.312 . . . . 0.0 110.3 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.51 ' HA ' HG12 ' A' ' 113' ' ' VAL . 87.6 m-85 -75.16 -24.97 57.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.24 -175.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -74.33 -33.45 63.16 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.484 175.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.16 -41.05 17.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.723 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.4 p -78.27 124.37 36.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.777 0.799 . . . . 0.0 111.386 -175.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 114' ' ' LYS . 32.0 mmtp -132.06 153.25 50.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.706 175.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 60.8 m -62.35 114.87 3.74 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 123.195 0.31 . . . . 0.0 110.932 -178.283 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.6 -32.13 2.17 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 119.792 -1.194 . . . . 0.0 114.395 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.93 -172.11 2.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 117.736 0.768 . . . . 0.0 111.028 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -112.27 126.04 54.82 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.278 0.561 . . . . 0.0 111.905 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.449 HG23 ' HB2' ' A' ' 17' ' ' ALA . 65.8 t -121.52 120.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.892 176.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 60.7 t -89.29 111.83 23.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.759 177.178 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 41.9 t -95.54 109.02 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.565 -177.466 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -110.34 99.08 8.17 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.99 -9.35 53.77 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.022 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' HH21 ' A' ' 12' ' ' ARG . 18.5 m-20 -63.81 -47.01 82.58 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 174.2 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -93.2 -31.18 14.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.736 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 91.92 59.08 1.35 Allowed Glycine 0 N--CA 1.452 -0.295 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 143.49 29.75 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.793 0.33 . . . . 0.0 110.643 -169.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.53 106.31 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.319 0.581 . . . . 0.0 109.962 174.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 120' ' ' VAL . 39.8 mt-10 -96.3 108.46 20.97 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.665 -174.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.6 tp -81.3 110.05 16.39 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.6 mm -112.74 114.9 48.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -176.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 . . . . . 0 C--N 1.312 -1.041 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.157 -170.604 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.226 -0.162 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.507 ' HD3' ' OH ' ' A' ' 127' ' ' TYR . 74.2 mttt -125.54 145.67 50.01 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.529 -177.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.479 ' HB2' HG13 ' A' ' 128' ' ' VAL . 89.6 m-85 -129.48 161.92 29.3 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.398 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.15 126.65 55.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.106 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.43 ' SG ' HG21 ' A' ' 102' ' ' VAL . 5.7 p -119.71 167.74 11.75 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.209 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.567 ' HD3' ' OE2' ' A' ' 103' ' ' GLU . 36.6 ttt180 -93.96 121.95 35.96 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.981 0.42 . . . . 0.0 110.107 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.98 102.9 3.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.123 -175.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.556 HG13 HG21 ' A' ' 86' ' ' THR . 50.0 mm -95.91 -43.57 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.11 177.181 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.7 p -109.57 -165.0 0.97 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.134 177.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -136.43 164.49 28.03 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -177.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.05 161.62 22.77 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.932 -0.652 . . . . 0.0 111.906 -177.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -147.86 154.12 40.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.09 0.445 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.45 164.97 24.3 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.081 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -127.92 127.05 42.66 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 176.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.62 178.92 32.83 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.056 -1.069 . . . . 0.0 112.69 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -74.44 139.86 44.25 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.33 178.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.586 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.56 122.83 27.53 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.07 0.462 . . . . 0.0 111.002 -178.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.3 tt -117.61 117.14 28.59 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 174.438 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.822 HG12 ' HB ' ' A' ' 115' ' ' THR . 8.4 p -101.6 124.99 55.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.442 0.639 . . . . 0.0 110.984 -173.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . 1.037 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 13.2 m -95.63 95.03 8.08 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.446 0.641 . . . . 0.0 109.875 179.638 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -82.25 -2.61 53.1 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.944 -177.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -103.1 130.41 50.25 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.67 -176.33 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -85.14 98.89 10.72 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -118.95 172.64 5.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.253 -0.43 . . . . 0.0 112.007 -170.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.4 p -79.5 122.41 26.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.175 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -85.48 31.26 0.59 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.568 0.699 . . . . 0.0 109.991 -177.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -68.89 -23.8 64.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.198 177.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 174.37 -103.84 0.19 Allowed Glycine 0 N--CA 1.444 -0.832 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.294 178.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.72 -51.42 2.31 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.548 176.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.436 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.7 mp -87.47 129.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.75 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 27.5 t70 -78.55 139.96 38.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.038 0.447 . . . . 0.0 111.005 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.492 ' HA ' HD23 ' A' ' 71' ' ' LEU . 0.0 OUTLIER -64.84 -26.33 68.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.548 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 45.4 mt-10 -95.41 -46.88 6.51 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.215 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 36' ' ' ILE . 20.7 p -102.88 -19.15 14.76 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -174.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 73.93 20.14 79.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.015 -178.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.412 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.2 mm -87.68 133.03 31.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.639 -0.28 . . . . 0.0 110.453 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.3 m -74.28 111.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.582 0.706 . . . . 0.0 110.892 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.75 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 57.2 mttt -91.67 -10.89 38.61 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.947 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -66.33 138.27 57.49 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.646 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.41 131.42 44.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.38 -172.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 13.6 p 174.55 -178.22 0.1 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.981 -1.008 . . . . 0.0 108.482 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -79.35 -9.27 59.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.274 0.559 . . . . 0.0 110.095 175.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.417 ' O ' ' HB2' ' A' ' 46' ' ' GLU . 24.3 mt -94.26 -8.83 9.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.183 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.1 tmmm? -56.85 125.83 24.23 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.358 0.599 . . . . 0.0 110.372 -178.074 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.25 -24.36 12.64 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.964 -176.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 43' ' ' ILE . 1.1 mm-40 -71.15 162.97 28.54 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.311 0.577 . . . . 0.0 111.656 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.412 ' HB3' HD13 ' A' ' 36' ' ' ILE . 18.2 p -116.89 127.13 53.96 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.61 -178.431 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.414 HG21 HG12 ' A' ' 30' ' ' ILE . 33.4 m -87.53 1.8 5.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.207 -178.448 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.436 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.25 88.04 0.3 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.923 -177.553 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.53 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 107.36 11.04 26.34 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.519 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 mmm-85 -106.14 156.08 18.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.44 116.58 47.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 176.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.713 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -92.94 124.85 37.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.289 0.566 . . . . 0.0 111.324 -173.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 72.6 t -117.91 107.91 23.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.173 176.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 1.037 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 43.6 p90 -135.7 153.66 77.56 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.461 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -64.07 -49.89 3.42 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 122.591 2.194 . . . . 0.0 111.997 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.558 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 -179.666 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 . . . . . 0 N--CA 1.474 0.762 0 N-CA-C 112.084 0.402 . . . . 0.0 112.084 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.3 m -60.92 -16.84 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -173.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.21 -28.18 69.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.803 0.335 . . . . 0.0 110.699 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.0 tp -62.34 -38.48 89.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.423 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -58.22 -47.67 82.77 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.649 178.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.492 HD23 ' HA ' ' A' ' 32' ' ' LYS . 76.4 mt -56.76 -44.43 81.77 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.706 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -72.8 -41.32 65.08 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.745 -176.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -61.85 -33.3 73.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.824 0.345 . . . . 0.0 110.374 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -85.53 -19.68 30.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.126 0.489 . . . . 0.0 110.512 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 86.89 23.44 41.79 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.216 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.523 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.4 m -113.32 12.47 8.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.603 -179.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.467 ' HB1' ' HD2' ' A' ' 78' ' ' PRO . . . -90.91 162.66 32.39 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.713 ' HB3' HD13 ' A' ' 53' ' ' LEU . 43.7 Cg_endo -69.66 149.9 68.1 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.037 1.825 . . . . 0.0 111.434 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.53 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 88.4 mttt -69.47 -30.46 68.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.938 0.399 . . . . 0.0 110.75 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -163.77 155.3 16.67 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.457 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 68.5 mt -131.09 127.28 60.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.998 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.453 HG23 HG23 ' A' ' 102' ' ' VAL . 5.5 mm -117.85 120.79 65.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 13.6 m120 -120.03 164.03 16.74 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.645 0.26 . . . . 0.0 110.74 -176.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -79.07 -46.11 18.76 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 174.651 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 85' ' ' LYS . 44.2 pttt -125.88 112.75 16.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.762 172.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.556 HG21 HG13 ' A' ' 8' ' ' ILE . 5.8 t -92.47 116.3 28.87 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.41 0.624 . . . . 0.0 109.476 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -98.52 167.91 10.52 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.544 -175.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.5 m -53.98 -47.64 71.17 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -169.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 90' ' ' ILE . 9.2 pt -55.56 -46.04 78.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 111.984 0.365 . . . . 0.0 111.984 -178.182 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 89' ' ' ILE . 36.4 mt -76.77 -40.56 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.325 -176.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.528 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.44 -50.64 73.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.564 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 92.3 t -64.87 -42.37 94.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.791 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.35 -45.56 96.19 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.785 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -73.93 -33.01 63.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.552 0.215 . . . . 0.0 111.567 -178.089 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.8 -40.16 95.96 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.963 0.411 . . . . 0.0 111.512 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 69.7 mtm -74.04 -42.87 59.62 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.244 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -74.3 -14.78 60.95 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -177.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 71.71 59.89 0.16 Allowed 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.662 0.744 . . . . 0.0 109.934 -173.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.1 mt -121.96 89.32 48.23 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.481 177.15 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -38.29 107.56 0.06 OUTLIER 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 123.792 2.994 . . . . 0.0 113.441 -177.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 43.6 tp -128.16 120.72 27.87 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.421 -176.259 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.453 HG23 HG23 ' A' ' 82' ' ' ILE . 20.6 m -135.0 166.76 27.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.195 179.366 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.567 ' OE2' ' HD3' ' A' ' 6' ' ' ARG . 9.9 pt-20 -113.59 141.16 47.52 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.066 0.46 . . . . 0.0 111.167 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 5.2 m -105.84 140.75 22.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.454 176.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -88.67 -26.27 21.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.221 -174.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -106.16 140.08 39.68 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.052 0.453 . . . . 0.0 111.372 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -71.14 -20.94 62.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.944 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.553 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 57.2 mttm -64.91 -17.97 64.8 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -60.64 -45.85 92.52 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 173.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.56 ' HA ' HG12 ' A' ' 113' ' ' VAL . 53.2 m-85 -76.12 -32.11 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.006 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.553 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.7 tt0 -57.3 -46.22 83.38 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.996 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -87.75 -24.62 23.74 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.481 -174.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.9 p -76.04 139.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.535 0.684 . . . . 0.0 111.96 -174.023 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -139.13 159.28 42.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.992 172.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.822 ' HB ' HG12 ' A' ' 19' ' ' VAL . 12.1 t -81.69 138.62 35.24 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.961 0.41 . . . . 0.0 110.434 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.53 -25.3 9.2 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.775 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -85.28 -171.78 3.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.608 0.242 . . . . 0.0 110.797 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 20.0 ttp180 -115.36 133.73 55.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.011 0.434 . . . . 0.0 111.447 -176.254 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.586 HG23 ' HB2' ' A' ' 17' ' ' ALA . 85.6 t -122.58 129.5 75.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.126 175.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.681 ' HB ' ' HB3' ' A' ' 129' ' ' GLU . 50.3 t -101.86 113.56 38.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.79 129.67 61.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.946 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -131.4 100.52 5.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.807 176.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.82 -12.22 55.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.472 -174.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.18 -7.64 58.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.025 0.44 . . . . 0.0 110.804 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -128.3 -20.99 3.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.868 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.29 59.94 2.79 Favored Glycine 0 CA--C 1.509 -0.336 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.507 ' OH ' ' HD3' ' A' ' 2' ' ' LYS . 60.8 t80 -142.71 135.64 28.19 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.316 -167.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.479 HG13 ' HB2' ' A' ' 3' ' ' PHE . 6.6 p -137.76 124.81 28.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.461 0.648 . . . . 0.0 110.579 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.681 ' HB3' ' HB ' ' A' ' 120' ' ' VAL . 34.5 tt0 -115.96 122.45 45.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.413 -175.665 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 19.6 tp -106.63 127.53 53.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.945 0.402 . . . . 0.0 110.688 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 131' ' ' ILE . 3.5 mp -122.45 122.07 65.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 174.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.465 ' H ' ' CD ' ' A' ' 132' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.315 -0.91 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.618 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 C--O 1.234 0.25 0 CA-C-O 120.677 0.275 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.513 ' HG2' ' HG2' ' A' ' 129' ' ' GLU . 49.2 mttp -101.7 107.48 18.72 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 177.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -86.76 141.42 28.88 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.27 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.31 127.97 36.31 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.514 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.2 m -120.82 159.02 26.33 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.032 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.444 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 27.1 ttm180 -102.79 115.94 31.58 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 176.279 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.709 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.0 133.84 44.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.0 -173.67 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.0 mm -106.94 -49.36 8.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 174.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.425 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 61.7 p -117.42 177.24 4.81 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.786 173.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 10' ' ' ARG . 61.5 mtt180 -101.1 169.49 8.9 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.801 0.334 . . . . 0.0 111.003 -177.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 134.68 153.54 6.89 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.124 178.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -137.84 130.17 29.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.577 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -146.27 164.22 33.02 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.937 0.398 . . . . 0.0 111.391 -175.19 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.03 149.12 27.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.833 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 160.36 -167.53 35.65 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.142 -1.028 . . . . 0.0 112.148 175.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 50.9 mm-40 -64.57 128.08 34.26 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.535 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.05 122.13 26.94 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.852 -178.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.3 tp -106.22 108.4 19.89 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 175.168 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.517 ' HB ' ' HB ' ' A' ' 115' ' ' THR . 43.3 t -110.59 113.52 44.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.967 0.413 . . . . 0.0 110.991 -172.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 22' ' ' GLU . 30.2 m -105.0 110.17 22.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.922 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -86.26 26.8 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.263 0.554 . . . . 0.0 110.837 -177.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' THR . 8.0 tp10 -115.44 157.51 23.86 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.76 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -103.4 94.61 5.58 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 pt -85.32 172.1 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.3 0.571 . . . . 0.0 111.445 -175.507 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.729 ' HB2' HD23 ' A' ' 27' ' ' LEU . 26.0 p -110.26 122.54 47.9 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.957 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -81.21 64.4 5.93 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.319 0.58 . . . . 0.0 110.476 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.729 HD23 ' HB2' ' A' ' 25' ' ' SER . 3.5 mm? -119.74 -57.03 2.0 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.936 174.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.54 44.52 0.69 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.81 -53.15 6.55 Favored Glycine 0 C--O 1.224 -0.47 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.943 -176.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 65.7 mt -98.61 135.51 33.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.833 0.316 . . . . 0.0 110.815 -177.026 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.418 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 13.1 t70 -67.06 134.78 52.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.268 177.091 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -68.52 -25.61 65.03 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.221 0.452 . . . . 0.0 112.221 -171.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -110.77 -38.11 5.23 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.231 0.538 . . . . 0.0 111.288 -168.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.551 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -98.94 -14.97 19.31 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.585 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 47' ' ' SER . . . 68.29 21.89 74.3 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.085 -178.386 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.551 HG12 ' HB ' ' A' ' 34' ' ' THR . 36.4 mm -88.44 127.07 41.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 122.18 0.192 . . . . 0.0 110.625 -177.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 47.1 t -71.62 113.92 9.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -88.62 -28.61 20.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.054 -176.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -65.58 123.01 18.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.588 ' HA ' ' HG3' ' A' ' 44' ' ' LYS . 35.2 t70 -73.26 141.11 47.23 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.968 -173.221 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 42.0 t -172.81 -73.65 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.071 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -156.58 -51.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.331 179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.407 HG13 ' H ' ' A' ' 43' ' ' ILE . 1.9 pp -82.41 15.31 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.078 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.588 ' HG3' ' HA ' ' A' ' 40' ' ' ASP . 4.5 tmmm? -65.16 124.99 23.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.698 179.233 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 104.4 -15.29 50.3 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.368 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -91.27 159.24 16.13 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.307 0.575 . . . . 0.0 112.07 177.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.505 ' HB3' HD13 ' A' ' 36' ' ' ILE . 2.5 p -103.74 158.54 16.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.246 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.509 HG11 HD21 ' A' ' 53' ' ' LEU . 26.7 m -108.63 20.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.919 -179.511 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.03 91.93 2.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.647 -173.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.96 20.64 27.75 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.001 -0.999 . . . . 0.0 112.91 174.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -110.33 158.97 17.86 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.863 -0.198 . . . . 0.0 110.64 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.46 ' HB ' ' HA ' ' A' ' 17' ' ' ALA . 49.6 mm -95.59 104.58 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.815 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.623 HD13 ' HB3' ' A' ' 78' ' ' PRO . 9.9 mp -85.58 133.34 34.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.17 0.509 . . . . 0.0 111.688 -172.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.61 121.15 59.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.743 176.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.554 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 78.3 m-85 -128.88 144.42 52.41 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.825 0.345 . . . . 0.0 111.332 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -81.17 -11.32 12.17 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.546 2.164 . . . . 0.0 111.883 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.909 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.054 179.857 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 2.0 t80 . . . . . 0 N--CA 1.47 0.565 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 58.9 t -58.85 -33.74 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.929 0.395 . . . . 0.0 111.323 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.433 ' HB3' HD12 ' A' ' 99' ' ' ILE . 87.1 mt -57.73 -31.37 66.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.573 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.6 tp -67.3 -33.99 76.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.105 0.478 . . . . 0.0 110.514 -178.377 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -66.01 -41.84 90.48 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.972 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.7 mt -57.42 -42.59 82.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.587 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.403 ' N ' ' HB2' ' A' ' 77' ' ' ALA . 34.4 ttt180 -59.78 -51.04 71.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.915 -178.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 55.8 mtmt -75.39 -8.07 55.7 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.985 -174.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.481 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.0 t-20 -92.42 -30.91 15.51 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.988 0.423 . . . . 0.0 109.909 175.033 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.09 15.41 28.34 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.091 -178.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.481 HG22 ' HB3' ' A' ' 74' ' ' ASN . 20.1 m -117.64 14.17 7.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.888 0.375 . . . . 0.0 111.185 -178.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.403 ' HB2' ' N ' ' A' ' 72' ' ' ARG . . . -73.99 150.11 87.9 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.245 179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.623 ' HB3' HD13 ' A' ' 53' ' ' LEU . 7.9 Cg_exo -71.89 138.47 31.45 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.558 2.172 . . . . 0.0 110.383 171.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.577 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 85.5 mttt -63.44 -42.26 98.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.756 0.313 . . . . 0.0 111.346 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -157.92 153.57 26.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.803 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.575 HG12 ' HB2' ' A' ' 53' ' ' LEU . 52.8 mt -134.07 114.44 19.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.423 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.414 HG23 ' CG2' ' A' ' 102' ' ' VAL . 21.3 mm -100.65 124.22 54.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.554 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 16.8 m120 -123.35 155.75 36.71 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.018 0.437 . . . . 0.0 111.228 -174.395 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.524 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 88.3 tttt -76.95 -46.98 22.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.502 174.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -116.89 120.71 39.31 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.815 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.4 t -99.51 134.77 41.91 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.721 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.51 141.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.464 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.5 m -66.99 -36.18 81.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.503 -175.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 87.0 mt -61.29 -43.88 97.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.976 0.417 . . . . 0.0 110.353 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.5 mt -64.4 -40.58 89.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.006 177.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.479 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -59.46 -46.57 88.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.527 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 88' ' ' THR . 90.1 t -58.52 -43.65 87.45 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 CA-C-O 120.975 0.417 . . . . 0.0 110.555 179.152 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.27 -41.05 69.73 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.5 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -71.05 -31.28 67.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.463 0.173 . . . . 0.0 111.412 -177.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.56 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.987 0.422 . . . . 0.0 110.971 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.7 mtm -70.29 -32.99 71.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.003 -179.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.43 3.47 49.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.797 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 56.15 43.1 27.35 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.927 0.87 . . . . 0.0 110.362 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 68' ' ' LEU . 63.8 mt -109.77 89.26 7.53 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.671 177.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.425 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 19.1 Cg_endo -56.99 116.0 2.9 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.893 2.395 . . . . 0.0 112.616 -176.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.48 ' H ' HD23 ' A' ' 101' ' ' LEU . 2.6 pt? -118.44 137.07 53.41 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.508 175.359 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 7' ' ' ALA . 18.9 m -132.48 163.1 38.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.861 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.444 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 14.7 pt-20 -103.81 135.34 45.53 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.848 0.356 . . . . 0.0 110.094 176.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 15.8 m -116.26 130.92 70.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.102 0.477 . . . . 0.0 110.382 175.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -101.92 1.3 36.68 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.127 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -95.94 123.64 39.62 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.984 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.93 -32.79 67.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.371 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 28.6 mtpp -69.89 -23.7 63.28 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -174.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -54.44 -49.43 70.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 174.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.524 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 96.6 m-85 -74.58 -28.25 60.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.981 0.419 . . . . 0.0 110.996 -179.032 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 43.2 tt0 -66.44 -45.25 80.45 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.599 176.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.21 -39.45 19.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.454 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.4 p -65.45 127.83 27.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-O 121.475 0.655 . . . . 0.0 110.963 -175.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -123.15 135.88 54.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.755 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.517 ' HB ' ' HB ' ' A' ' 19' ' ' VAL . 14.8 t -72.24 113.85 9.71 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-O 121.41 0.624 . . . . 0.0 109.551 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.5 -18.94 3.41 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.392 -176.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ASP . . . . . 0.553 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 0.8 OUTLIER -99.02 -171.71 2.14 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.676 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.553 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -114.54 137.34 51.98 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.337 0.589 . . . . 0.0 112.025 -174.92 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 17' ' ' ALA . 84.3 t -120.38 130.33 74.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.743 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.5 t -98.88 111.44 28.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 174.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 88.3 t -96.0 120.71 45.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.134 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -124.71 99.85 6.36 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -86.18 -11.67 51.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.126 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -67.71 -43.01 81.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.015 0.436 . . . . 0.0 110.009 178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -96.38 -23.92 16.39 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.542 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.16 62.93 1.46 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.521 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.528 ' CE1' ' HG3' ' A' ' 129' ' ' GLU . 25.6 p90 -162.41 163.55 27.67 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.772 0.32 . . . . 0.0 110.168 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.26 126.36 58.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.248 175.529 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.528 ' HG3' ' CE1' ' A' ' 127' ' ' TYR . 39.5 mt-10 -98.56 107.92 20.49 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.095 176.454 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 60.7 tp -82.45 102.0 11.03 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.358 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 18.1 pt -92.37 109.94 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.455 0.645 . . . . 0.0 110.291 -175.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 . . . . . 0 C--N 1.316 -0.854 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.085 -177.165 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.508 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 13.9 m . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 121.261 0.553 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -130.74 114.93 15.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.739 -176.06 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.508 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 76.6 m-85 -128.5 164.75 22.1 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.118 0.485 . . . . 0.0 111.036 -176.526 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -118.49 139.43 51.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.447 174.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 10.3 p -120.21 171.67 8.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.258 -178.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.7 ttt85 -93.88 118.06 30.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.971 0.415 . . . . 0.0 110.116 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.53 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.82 96.52 1.66 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.042 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.468 HD11 ' OE1' ' A' ' 103' ' ' GLU . 49.3 mm -82.2 -43.51 19.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.87 175.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.8 p -125.29 -164.25 1.27 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.293 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 60.7 mtt-85 -118.56 -175.28 2.85 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.705 0.288 . . . . 0.0 110.59 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.564 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 115.71 145.21 8.43 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.04 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 68.8 mtm-85 -141.38 115.2 9.11 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.24 169.38 24.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.871 0.367 . . . . 0.0 111.193 -176.379 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.553 ' OE1' ' HD2' ' A' ' 118' ' ' ARG . 14.2 pt-20 -135.42 146.77 48.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.87 178.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.98 -173.48 34.48 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 120.079 -1.058 . . . . 0.0 112.098 174.119 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.62 127.97 34.4 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.45 118.98 22.54 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.905 -177.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.8 tp -102.02 111.42 23.68 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.563 ' HA ' ' CG1' ' A' ' 54' ' ' VAL . 47.1 t -98.87 110.92 27.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.385 0.612 . . . . 0.0 110.522 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.468 HG21 HD11 ' A' ' 24' ' ' ILE . 6.8 m -110.55 132.16 54.43 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.092 -176.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -102.77 -10.02 19.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.13 0.491 . . . . 0.0 110.573 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -97.88 161.47 13.73 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -96.0 141.73 29.06 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.553 0.216 . . . . 0.0 110.468 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 20' ' ' THR . 2.5 mp -114.16 132.89 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 55.2 p -78.73 115.23 18.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.148 0.499 . . . . 0.0 110.722 -178.479 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.95 -6.3 32.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.333 179.199 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.05 -30.53 71.5 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 175.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 146.55 51.81 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.48 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.16 21.17 32.64 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.161 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.511 HD13 HG21 ' A' ' 48' ' ' VAL . 53.6 mt -130.75 136.74 57.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 -179.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.592 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.1 t70 -69.46 123.79 22.18 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.268 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.608 ' HG2' ' OE1' ' A' ' 33' ' ' GLU . 0.6 OUTLIER -79.28 -12.21 59.94 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -170.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.608 ' OE1' ' HG2' ' A' ' 32' ' ' LYS . 2.4 mp0 -94.33 -41.09 9.61 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 121.137 -0.225 . . . . 0.0 111.254 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.9 p -103.06 -36.97 7.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 -177.027 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.79 16.45 36.2 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.816 -175.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.0 mm -91.45 128.44 43.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 44' ' ' LYS . 8.4 m -62.96 142.02 17.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.021 0.439 . . . . 0.0 110.912 177.035 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.592 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 26.9 mmmt -96.12 -3.67 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.487 0.661 . . . . 0.0 110.823 -174.681 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -92.39 158.86 15.84 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.642 -175.384 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -92.29 139.28 30.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.371 0.605 . . . . 0.0 112.127 -176.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 48.8 t -179.22 168.7 1.52 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 172.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -68.32 -35.97 78.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.049 0.452 . . . . 0.0 110.428 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 32.3 pt -102.62 12.36 7.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.493 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.52 ' HB2' ' HB3' ' A' ' 41' ' ' CYS . 70.2 mttt -99.44 147.5 25.2 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 176.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.408 ' H ' ' CG2' ' A' ' 37' ' ' VAL . . . 118.48 1.55 15.59 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -175.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -108.82 -179.36 3.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.802 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.6 m -91.83 133.9 35.23 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.933 -171.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.511 HG21 HD13 ' A' ' 30' ' ' ILE . 34.5 m -101.6 4.38 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.3 0.572 . . . . 0.0 110.005 174.245 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -67.27 100.13 0.78 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.186 -174.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.17 19.99 50.97 Favored Glycine 0 C--N 1.308 -1.001 0 CA-C-N 114.536 -1.211 . . . . 0.0 112.872 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -110.72 155.53 22.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.87 HG13 ' HB3' ' A' ' 80' ' ' ALA . 1.8 mp -84.66 105.48 13.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 175.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 32.1 tp -82.28 126.89 32.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.447 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.563 ' CG1' ' HA ' ' A' ' 19' ' ' VAL . 11.8 p -130.26 106.96 13.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.62 0.724 . . . . 0.0 111.842 177.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.441 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 38.1 p90 -136.16 151.68 73.95 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.175 170.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.91 -55.43 2.33 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.547 2.164 . . . . 0.0 112.808 -177.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.53 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.874 -178.436 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 28.1 p90 . . . . . 0 CA--C 1.53 0.199 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 62.9 t -60.63 -41.79 89.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.983 0.421 . . . . 0.0 110.648 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.428 HD13 ' O ' ' A' ' 68' ' ' LEU . 0.7 OUTLIER -73.38 -32.17 64.33 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.231 0.539 . . . . 0.0 109.871 179.282 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.6 tp -61.33 -32.49 72.38 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.2 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -54.94 -44.23 74.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.213 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 88.0 mt -61.84 -33.15 73.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.005 -178.179 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.558 ' HD3' ' HA ' ' A' ' 97' ' ' ALA . 8.0 ttp180 -72.16 -35.94 69.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.126 -178.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -61.37 -31.19 71.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.014 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -93.54 -25.17 17.69 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.938 0.399 . . . . 0.0 110.442 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 94.16 26.94 12.94 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.704 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.8 m -107.15 4.56 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.171 0.51 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.96 159.38 73.57 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.733 179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.49 162.38 24.45 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.491 2.127 . . . . 0.0 112.13 175.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -82.83 -28.8 29.94 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.614 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.87 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -166.77 165.22 16.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.673 175.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.694 HG23 HD22 ' A' ' 101' ' ' LEU . 8.3 tt -152.07 121.29 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.45 0.643 . . . . 0.0 110.824 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.821 HG23 HG23 ' A' ' 102' ' ' VAL . 2.7 mm -110.21 118.88 58.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -116.39 165.96 12.61 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.364 0.602 . . . . 0.0 111.758 -174.196 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.22 -31.49 10.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.302 176.598 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.9 tttm -121.28 122.41 39.83 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.577 176.793 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 66.5 p -127.68 158.75 36.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.967 0.413 . . . . 0.0 111.681 -175.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.552 ' HB2' HG13 ' A' ' 90' ' ' ILE . 53.8 mt-10 -123.58 157.66 33.2 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.776 173.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.524 ' O ' HG23 ' A' ' 92' ' ' VAL . 89.2 m -60.09 -44.28 94.92 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.107 178.343 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.9 pt -63.9 -29.89 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.453 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.552 HG13 ' HB2' ' A' ' 87' ' ' GLU . 64.4 mt -66.98 -42.75 89.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.788 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.99 -32.96 74.75 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.198 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 88' ' ' THR . 73.1 t -66.69 -49.87 70.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 120.929 0.395 . . . . 0.0 110.543 177.079 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.35 -44.11 97.35 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.13 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.409 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -64.09 -37.33 87.04 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 111.585 0.216 . . . . 0.0 111.585 -179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.3 -41.76 96.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.807 0.337 . . . . 0.0 111.12 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 66.5 mtm -74.64 -32.09 62.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.897 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.558 ' HA ' ' HD3' ' A' ' 72' ' ' ARG . . . -82.04 -0.61 45.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 176.577 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 57.32 38.39 28.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.278 0.561 . . . . 0.0 111.233 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.409 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 61.4 mt -111.08 90.93 12.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.198 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.564 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 82.5 Cg_exo -40.57 115.6 0.34 Allowed 'Trans proline' 0 C--N 1.35 0.651 0 C-N-CA 124.027 3.151 . . . . 0.0 113.872 -175.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.694 HD22 HG23 ' A' ' 81' ' ' ILE . 0.1 OUTLIER -108.94 120.67 43.22 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.584 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.821 HG23 HG23 ' A' ' 82' ' ' ILE . 5.5 m -140.5 161.84 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.784 177.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.468 ' OE1' HD11 ' A' ' 8' ' ' ILE . 46.1 mt-10 -101.21 132.99 46.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.529 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.425 HG13 ' CG2' ' A' ' 82' ' ' ILE . 3.4 m -96.48 139.65 18.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 167.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -99.97 -46.76 5.25 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.347 -174.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.419 ' OD1' ' HG3' ' A' ' 108' ' ' LYS . 7.1 t70 -92.8 146.51 23.59 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.218 0.532 . . . . 0.0 111.338 -174.139 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -71.1 -18.76 62.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.103 -0.953 . . . . 0.0 111.177 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HG3' ' OD1' ' A' ' 106' ' ' ASP . 67.7 mttm -55.08 -33.08 62.47 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -61.31 -40.6 94.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.421 -178.379 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.01 -31.14 68.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.295 -176.598 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -77.98 -45.58 23.44 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.902 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.482 ' HB1' HG11 ' A' ' 1' ' ' VAL . . . -66.51 -37.56 85.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.179 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 12.0 p -75.15 129.28 36.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.405 0.621 . . . . 0.0 111.076 -177.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.425 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 71.1 mmtt -118.91 144.12 46.6 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.431 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.9 m -64.76 110.9 2.55 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.96 0.41 . . . . 0.0 110.631 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.89 -7.57 8.78 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.425 -178.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ASP . . . . . 0.425 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 12.2 m-20 -87.39 171.84 10.28 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 174.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.553 ' HD2' ' OE1' ' A' ' 14' ' ' GLU . 11.7 ttp180 -115.67 121.94 44.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.824 0.345 . . . . 0.0 110.862 -178.382 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.95 130.07 66.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.187 0.518 . . . . 0.0 110.409 178.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 45.6 t -99.19 111.21 28.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.1 p -102.25 115.23 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.642 0.734 . . . . 0.0 111.754 -174.155 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ASN . . . . . 0.482 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 50.1 t-20 -99.94 94.15 6.14 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 172.239 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.423 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -82.4 -19.67 38.64 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.108 0.48 . . . . 0.0 110.266 -178.619 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.78 -39.07 93.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.643 -179.034 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -107.46 -28.02 10.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.814 177.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.95 64.45 0.99 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.487 -0.863 . . . . 0.0 111.291 -176.016 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.482 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 35.6 t80 -144.55 124.39 13.44 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -174.589 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.425 HG23 ' HB2' ' A' ' 3' ' ' PHE . 5.9 m -126.26 118.09 50.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.481 0.657 . . . . 0.0 110.997 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -121.04 123.38 42.23 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.193 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.496 ' HB3' HG23 ' A' ' 1' ' ' VAL . 17.0 tp -103.81 120.59 41.3 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.152 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.44 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -89.43 123.27 41.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.235 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--N 1.317 -0.814 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.309 -178.938 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 2' ' ' LYS . 60.6 t . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 1' ' ' VAL . 49.2 mttp 64.34 77.84 0.3 Allowed 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -170.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -98.97 136.79 38.44 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.053 0.454 . . . . 0.0 110.775 -176.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -107.27 110.64 22.72 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.708 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.887 ' SG ' HG12 ' A' ' 104' ' ' VAL . 58.2 m -119.71 -178.73 3.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.489 -174.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.501 ' HB3' ' HG3' ' A' ' 103' ' ' GLU . 17.5 tpt180 -91.3 119.86 31.7 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.996 0.427 . . . . 0.0 110.639 -171.071 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -93.54 140.05 30.05 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.021 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.402 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.8 mp -114.0 -45.51 4.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.751 177.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 10' ' ' ARG . 3.0 m -109.6 177.55 4.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.401 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' THR . 81.6 mtt180 -112.05 -177.97 3.3 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.539 0.209 . . . . 0.0 110.794 -175.118 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 106.56 172.59 22.97 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.026 -178.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 7.3 ptm180 -149.71 119.73 7.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.044 0.45 . . . . 0.0 110.401 178.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.474 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -125.44 139.25 53.8 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.534 -174.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.26 125.23 44.04 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.925 -177.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.97 -160.91 23.1 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.996 175.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.717 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.9 mt-10 -74.67 130.94 40.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 122.822 0.449 . . . . 0.0 111.036 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.36 128.91 34.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.659 177.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.2 tt -118.97 114.74 23.03 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 177.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.21 126.39 60.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.978 0.418 . . . . 0.0 111.039 -173.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.5 m -129.56 95.35 3.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 177.05 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -84.49 83.79 7.88 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.123 0.487 . . . . 0.0 110.117 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -160.73 161.05 32.09 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.419 -0.81 . . . . 0.0 108.856 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 87.6 m-85 -101.26 89.14 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.596 ' HB ' ' HG2' ' A' ' 39' ' ' GLU . 32.7 pt -108.66 170.88 2.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.543 -172.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.27 123.01 39.75 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.488 -177.144 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.73 -4.91 51.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.334 0.588 . . . . 0.0 109.96 -178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.1 pp -72.93 -16.21 61.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.147 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.52 44.46 0.72 Allowed Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.29 -84.34 0.37 Allowed Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.265 -179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.461 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.1 mp -92.42 137.8 21.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 178.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -62.01 138.73 58.41 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.694 0.283 . . . . 0.0 110.351 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.541 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.8 pttp -74.5 -8.58 56.79 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -171.269 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.541 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 33.4 mt-10 -127.03 -44.47 1.61 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.3 p -96.92 -16.97 20.42 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -177.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.66 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.11 16.74 79.33 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.941 177.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.544 HD13 ' HB3' ' A' ' 47' ' ' SER . 35.5 mm -90.46 133.5 32.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.94 123.14 15.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.89 0.376 . . . . 0.0 110.63 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -87.24 -47.18 9.05 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.759 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.596 ' HG2' ' HB ' ' A' ' 24' ' ' ILE . 4.8 tp10 -62.06 134.76 57.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.671 179.588 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -93.03 160.85 14.68 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.269 0.557 . . . . 0.0 111.235 -175.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 47.9 t -178.68 -49.63 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -176.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 176.2 -45.98 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 114.642 -1.163 . . . . 0.0 109.718 174.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.78 13.25 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.936 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.2 tmmt? -65.91 128.68 36.99 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 116.74 -21.78 11.15 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.959 -176.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -87.98 156.48 19.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.982 0.42 . . . . 0.0 110.457 177.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.544 ' HB3' HD13 ' A' ' 36' ' ' ILE . 13.3 p -103.02 144.8 30.81 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.944 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.444 HG23 ' H ' ' A' ' 49' ' ' ALA . 0.0 OUTLIER -74.47 -76.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.608 175.046 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.444 ' H ' HG23 ' A' ' 48' ' ' VAL . . . 46.3 81.42 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.925 0.713 . . . . 0.0 112.925 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.09 3.78 88.79 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.64 -0.79 . . . . 0.0 113.303 177.148 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.717 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 52.0 mtt180 -94.6 162.28 13.86 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.411 -0.464 . . . . 0.0 110.902 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.453 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.6 mp -104.99 120.18 55.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 81' ' ' ILE . 54.8 tp -99.06 132.85 44.08 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.483 -177.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.44 107.3 15.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.038 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 41.0 p90 -135.76 144.58 49.43 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 172.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -55.13 -55.19 3.37 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.824 2.349 . . . . 0.0 112.883 -177.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.414 ' O ' ' HA ' ' A' ' 23' ' ' TYR . . . . . . . . 0 N--CA 1.449 -0.484 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.738 -178.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.463 0.187 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 86.3 t -58.37 -32.88 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.524 ' HA ' HD12 ' A' ' 71' ' ' LEU . 10.3 mp -61.85 -28.22 69.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.512 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 61.6 tp -70.64 -39.8 73.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.905 0.383 . . . . 0.0 110.331 178.36 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -65.9 -32.35 73.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.911 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.524 HD12 ' HA ' ' A' ' 68' ' ' LEU . 97.3 mt -57.63 -39.55 77.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.488 175.256 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 49.2 ttp180 -71.52 -33.36 69.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.572 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -62.41 -33.8 75.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.245 0.545 . . . . 0.0 110.295 177.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.529 ' OD1' ' HA ' ' A' ' 33' ' ' GLU . 12.6 m120 -88.02 -14.33 39.31 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.906 178.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 79.19 13.56 82.75 Favored Glycine 0 N--CA 1.453 -0.205 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.541 178.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.66 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.5 m -106.79 8.68 9.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.127 0.489 . . . . 0.0 110.966 -176.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -70.7 150.45 95.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.483 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.49 147.68 52.56 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.458 2.105 . . . . 0.0 110.562 171.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.474 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 12.0 mttm -71.81 -35.53 69.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.922 0.391 . . . . 0.0 110.533 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.453 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -155.83 151.99 27.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.368 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.545 HG23 ' HB3' ' A' ' 101' ' ' LEU . 3.8 tp -129.52 120.84 51.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.905 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.711 HD12 HG22 ' A' ' 102' ' ' VAL . 4.7 mm -117.32 116.73 52.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.299 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.443 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 25.9 m120 -109.1 -179.67 3.91 Favored 'General case' 0 C--O 1.22 -0.471 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 103' ' ' GLU . 39.0 ttmt -82.55 -45.04 15.14 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -141.37 100.45 3.79 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 169.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -74.22 150.39 40.34 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -92.3 147.4 22.95 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.254 -175.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.8 m -52.79 -36.93 59.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.419 -177.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 49.5 mt -56.35 -47.54 81.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.006 178.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.9 mt -68.3 -38.78 79.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.378 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.92 -42.87 94.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.177 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 88' ' ' THR . 93.7 t -66.19 -42.95 92.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.77 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.9 -45.45 73.79 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.769 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.489 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -68.57 -30.06 68.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.677 0.275 . . . . 0.0 111.519 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -62.76 -25.38 68.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.408 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.0 mtm -83.17 -26.42 30.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.349 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.578 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -96.5 1.02 51.09 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.939 -178.458 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.521 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 1.5 mp0 59.0 47.85 11.6 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.124 0.488 . . . . 0.0 110.855 -175.46 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.489 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 58.1 mt -107.74 89.39 5.2 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.882 176.256 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 36.6 Cg_exo -55.87 116.69 3.34 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.904 2.403 . . . . 0.0 112.195 -177.175 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.545 ' HB3' HG23 ' A' ' 81' ' ' ILE . 1.8 pt? -122.71 134.7 54.45 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.44 0.638 . . . . 0.0 110.792 178.371 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.711 HG22 HD12 ' A' ' 82' ' ' ILE . 14.4 m -130.31 170.16 19.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.562 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 7.9 pt-20 -119.41 132.48 55.83 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.315 0.578 . . . . 0.0 111.676 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.887 HG12 ' SG ' ' A' ' 5' ' ' CYS . 17.3 m -104.47 105.04 17.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.925 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.436 ' HA ' ' HG3' ' A' ' 84' ' ' LYS . 32.6 ttp180 -99.13 27.62 4.97 Favored 'General case' 0 C--N 1.32 -0.717 0 O-C-N 121.837 -0.539 . . . . 0.0 110.614 -177.442 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -123.87 131.88 53.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.125 178.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -71.33 -26.59 62.9 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.212 -176.144 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -65.22 -24.21 67.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.167 -177.406 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.592 ' O ' HG12 ' A' ' 113' ' ' VAL . 80.6 t80 -65.01 -48.6 73.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -66.69 -25.42 66.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.687 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -78.85 -25.98 44.05 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 115.487 -0.778 . . . . 0.0 111.627 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -94.32 -39.69 10.36 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.032 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.4 p -89.8 137.97 20.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 111.17 -176.207 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -137.28 157.62 46.24 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.39 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 18' ' ' LEU . 32.6 m -64.24 110.09 2.1 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.492 -175.579 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.08 -17.37 3.85 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.546 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 -82.66 156.86 23.61 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.966 0.413 . . . . 0.0 111.13 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.0 OUTLIER -89.93 119.38 30.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.079 179.835 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.38 136.87 56.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.244 0.545 . . . . 0.0 111.078 -178.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.0 110.51 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.499 173.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.446 HG11 HD11 ' A' ' 82' ' ' ILE . 66.7 t -92.82 104.44 15.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.693 179.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -107.05 98.75 8.37 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.027 -179.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.12 -9.04 58.34 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.342 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -64.27 -39.41 93.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.581 175.431 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -102.63 -34.46 9.06 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.863 175.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 98.31 68.2 0.91 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.474 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -166.15 166.18 17.19 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.27 121.51 42.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.349 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -120.69 117.79 28.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.317 0.579 . . . . 0.0 110.678 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.588 HD13 HG23 ' A' ' 113' ' ' VAL . 0.9 OUTLIER -109.43 147.87 32.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.143 178.101 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.404 HG12 ' NH2' ' A' ' 118' ' ' ARG . 46.6 mm -110.01 128.58 66.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 C--N 1.317 -0.815 0 O-C-N 123.954 0.783 . . . . 0.0 109.939 -179.448 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.532 HG23 ' HB3' ' A' ' 130' ' ' LEU . 17.1 m . . . . . 0 N--CA 1.452 -0.341 0 CA-C-O 121.303 0.573 . . . . 0.0 112.219 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.423 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -137.21 140.51 41.77 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.079 173.06 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -127.5 151.09 49.31 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.924 0.392 . . . . 0.0 111.044 -173.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.9 127.02 44.72 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.044 177.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 4.4 p -120.87 173.44 7.23 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.734 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 tpm_? -94.04 121.5 35.59 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 176.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.591 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -86.53 97.39 10.48 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.413 . . . . 0.0 111.302 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.63 -45.12 19.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 173.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.3 172.08 6.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.549 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 55.9 mtt-85 -111.04 176.83 4.87 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.283 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.51 -178.14 16.42 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.668 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -155.51 114.78 3.59 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 156.37 41.25 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -169.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tm-20 -135.85 120.92 18.82 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.041 -0.981 . . . . 0.0 108.735 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.19 162.44 35.72 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 119.717 -1.23 . . . . 0.0 113.4 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.74 140.95 56.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.608 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.94 125.79 30.58 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.969 0.414 . . . . 0.0 111.651 -176.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.51 ' HA ' HG23 ' A' ' 115' ' ' THR . 7.9 tt -111.89 110.43 20.76 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 171.287 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.1 t -102.7 110.17 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.091 0.472 . . . . 0.0 110.824 -175.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.455 HG23 ' CD2' ' A' ' 18' ' ' LEU . 2.0 p -99.43 112.92 25.04 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.814 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.42 ' HG2' ' H ' ' A' ' 21' ' ' LYS . 44.0 pttt -92.32 0.72 57.47 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.856 0.836 . . . . 0.0 109.105 176.528 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -79.61 -173.39 3.75 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.54 -1.209 . . . . 0.0 109.675 174.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -121.0 93.99 4.2 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.297 0.57 . . . . 0.0 110.557 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.8 mt -106.21 146.44 12.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.527 -176.195 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.542 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 33.9 t -131.74 162.27 30.87 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.461 ' HD2' HG12 ' A' ' 90' ' ' ILE . 64.0 m-85 -88.45 23.82 2.11 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.167 0.508 . . . . 0.0 111.007 -177.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.542 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 1.0 OUTLIER -74.93 -14.7 60.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.921 169.466 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.524 ' N ' HD12 ' A' ' 27' ' ' LEU . . . 139.84 57.65 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.727 -178.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.77 -42.23 6.12 Favored Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.866 -178.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.509 HG13 HG12 ' A' ' 37' ' ' VAL . 4.3 mp -93.41 146.46 6.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.311 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 20.0 t70 -70.43 138.98 51.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.825 0.345 . . . . 0.0 110.175 176.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.2 ptmt -79.77 -10.49 59.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.44 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.439 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 43.0 mt-10 -121.21 -40.45 2.59 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -176.115 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.0 p -92.57 -18.8 22.63 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.997 0.427 . . . . 0.0 111.384 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.475 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 76.51 11.13 85.43 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.093 -179.013 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.0 mm -86.92 132.37 32.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.509 HG12 HG13 ' A' ' 30' ' ' ILE . 11.8 m -67.87 129.49 32.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.281 0.562 . . . . 0.0 111.355 178.625 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 72.4 mmtt -84.64 -37.14 21.4 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 174.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -94.51 90.62 6.26 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.512 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.975 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.5 t70 -146.96 -164.47 2.0 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.007 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 45.6 t -166.87 -41.2 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 120.818 0.342 . . . . 0.0 110.469 -177.145 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -103.93 -48.43 3.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.505 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -111.56 15.93 8.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.891 0.377 . . . . 0.0 111.336 -173.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.975 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 38.6 ttmt -50.26 128.9 20.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.171 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.72 -7.45 12.15 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.107 -175.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.45 ' HB3' ' NH1' ' A' ' 51' ' ' ARG . 22.0 mm-40 -93.3 145.26 24.59 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 110.282 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 34.6 t -97.7 148.39 23.39 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.404 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 20.5 m -86.82 2.06 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.983 0.421 . . . . 0.0 110.706 178.517 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -67.22 92.51 0.27 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.538 -176.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.99 5.36 33.16 Favored Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.328 -0.851 . . . . 0.0 113.443 171.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.502 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 0.8 OUTLIER -123.56 178.29 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 O-C-N 122.65 -0.324 . . . . 0.0 110.461 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.506 HD12 ' HB ' ' A' ' 119' ' ' VAL . 72.2 mt -108.1 130.02 61.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.165 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.598 ' HB3' HG12 ' A' ' 81' ' ' ILE . 60.3 tp -96.1 123.93 39.91 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.706 -176.058 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 54.4 t -123.79 108.77 21.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.749 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.448 ' HB3' ' OG1' ' A' ' 20' ' ' THR . 53.4 p90 -134.58 144.56 51.36 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.104 174.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 6.2 Cg_exo -74.81 -38.82 1.53 Allowed 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 123.018 2.479 . . . . 0.0 112.027 177.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.609 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.787 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.473 0.687 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.545 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 23.0 m -56.79 -31.12 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.518 HD22 HG23 ' A' ' 67' ' ' VAL . 4.0 mm? -59.13 -40.52 85.73 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 178.279 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.545 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.3 tp -63.58 -44.65 93.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.194 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -62.13 -45.73 92.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.267 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.545 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 92.7 mt -59.36 -40.38 86.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.589 178.597 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.653 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -69.12 -37.73 78.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.061 -176.172 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.506 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 32.5 mmmt -70.01 -27.34 64.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.933 0.397 . . . . 0.0 110.709 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -87.61 -21.92 25.06 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.132 0.491 . . . . 0.0 110.435 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.79 20.43 37.0 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.216 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.617 ' HA ' ' HB2' ' A' ' 49' ' ' ALA . 21.9 m -118.41 24.24 4.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.015 0.436 . . . . 0.0 110.791 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -95.44 159.34 32.91 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.801 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 62.5 Cg_endo -76.45 151.69 33.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.178 1.919 . . . . 0.0 111.392 175.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.444 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 89.6 mttt -74.8 -30.96 61.58 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.73 0.3 . . . . 0.0 111.255 -178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.96 161.73 36.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.43 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.598 HG12 ' HB3' ' A' ' 53' ' ' LEU . 71.2 mt -139.36 129.75 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 O-C-N 123.323 0.39 . . . . 0.0 110.176 178.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.601 HG23 HG23 ' A' ' 102' ' ' VAL . 4.6 mm -117.01 125.0 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -120.21 161.79 20.48 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.735 0.302 . . . . 0.0 111.218 -176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.5 tptp -94.64 -38.0 11.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.596 0.712 . . . . 0.0 109.24 171.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -133.14 116.05 15.8 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.545 175.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.8 t -106.95 171.51 7.33 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.453 -177.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.405 ' CD ' ' H ' ' A' ' 88' ' ' THR . 1.4 tm-20 -137.44 159.82 40.85 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -175.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.405 ' H ' ' CD ' ' A' ' 87' ' ' GLU . 4.3 m -52.44 -47.79 66.2 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 122.941 0.496 . . . . 0.0 111.518 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.1 pp -62.92 -28.89 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-O 121.014 0.435 . . . . 0.0 110.86 -178.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.461 HG12 ' HD2' ' A' ' 26' ' ' PHE . 51.1 mt -75.16 -50.91 22.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.168 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.84 -48.36 82.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.084 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.66 -43.54 98.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.0 -41.74 98.48 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.6 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -71.6 -40.32 69.91 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.781 0.324 . . . . 0.0 111.056 -179.5 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.04 -41.15 91.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.516 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.1 mtm -64.84 -31.56 72.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.542 -177.478 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.653 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -99.96 5.02 45.23 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.289 0.478 . . . . 0.0 112.289 -175.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 63.07 52.4 2.56 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.71 0.766 . . . . 0.0 109.861 -176.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.513 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 33.3 mm -111.59 89.62 11.15 Favored Pre-proline 0 C--N 1.318 -0.788 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.168 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 79' ' ' LYS . 73.2 Cg_exo -47.89 105.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.558 0 C-N-CA 122.979 2.453 . . . . 0.0 112.324 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 9.8 tt -122.83 129.97 52.33 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.622 -177.142 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.601 HG23 HG23 ' A' ' 82' ' ' ILE . 30.2 m -134.68 164.72 33.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.823 -178.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -110.27 112.53 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.674 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.483 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.2 p -91.99 122.93 43.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.294 0.568 . . . . 0.0 111.113 -175.485 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.26 6.01 49.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.187 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.484 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 9.8 t70 -108.72 126.03 52.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.117 0.484 . . . . 0.0 111.015 -175.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -71.55 -33.64 69.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.721 -177.142 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.574 ' HE3' ' HA ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -61.54 -26.98 68.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.858 -176.993 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -56.48 -49.0 75.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.817 177.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -70.3 -26.86 63.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.089 -175.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.38 -36.11 46.37 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.235 178.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -85.89 -28.2 24.52 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 10.0 p -81.26 127.06 39.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.48 0.657 . . . . 0.0 111.232 -177.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -122.94 154.82 37.87 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.44 176.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 18' ' ' LEU . 36.7 m -67.87 94.62 0.47 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.065 0.46 . . . . 0.0 110.525 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.32 -29.63 0.97 Allowed Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.181 -178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -71.98 169.37 16.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 174.593 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 6.9 tmm_? -115.87 132.33 56.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.035 0.445 . . . . 0.0 110.903 -175.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 17' ' ' ALA . 48.2 t -110.43 139.83 32.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.023 -176.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.07 112.57 41.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 172.062 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.418 HG23 HD13 ' A' ' 52' ' ' ILE . 62.9 t -101.91 114.94 42.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.145 -174.129 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 -106.06 92.91 4.35 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.5 -6.83 56.07 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.48 . . . . 0.0 110.639 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -73.38 -36.78 66.13 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.58 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -112.49 -4.24 14.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.134 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.431 ' CA ' ' HB2' ' A' ' 7' ' ' ALA . . . 74.73 71.7 1.11 Allowed Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.251 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -158.4 144.99 17.4 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.247 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -130.8 122.93 53.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.311 0.576 . . . . 0.0 110.911 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -109.3 118.34 36.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.532 ' HB3' HG23 ' A' ' 1' ' ' VAL . 64.9 tp -93.38 115.14 27.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.015 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 22.6 mm -91.3 111.73 24.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.5 0.667 . . . . 0.0 109.691 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 . . . . . 0 C--N 1.308 -1.21 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.001 -179.224 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.444 ' HD3' ' HG2' ' A' ' 129' ' ' GLU . 87.8 mttt 63.74 96.86 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.486 0.66 . . . . 0.0 110.113 -175.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -110.34 148.0 32.82 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.066 -172.355 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.78 130.38 39.81 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.289 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.614 ' SG ' HG22 ' A' ' 104' ' ' VAL . 26.0 m -121.43 179.4 4.45 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.03 0.443 . . . . 0.0 111.001 -176.467 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.646 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 40.2 ttt180 -94.79 121.88 36.84 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.775 178.844 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.541 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.41 130.71 34.75 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.775 0.321 . . . . 0.0 111.683 -174.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.1 mp -105.32 -48.12 9.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 173.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 26.7 p -117.19 -173.89 2.49 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.957 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -120.69 -177.26 3.43 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.635 0.255 . . . . 0.0 110.649 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 110.46 152.06 13.11 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.247 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.435 HH11 ' HD2' ' A' ' 12' ' ' ARG . 16.7 mtp180 -113.16 136.9 52.21 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.684 0.278 . . . . 0.0 110.271 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -137.35 132.15 33.17 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.433 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.541 ' HG3' HG22 ' A' ' 120' ' ' VAL . 35.6 tt0 -131.11 126.2 35.13 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.947 176.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 177.6 -158.27 23.4 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.048 -1.072 . . . . 0.0 113.086 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -72.2 136.15 46.32 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 122.807 0.443 . . . . 0.0 110.723 -177.555 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.528 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -99.75 131.94 45.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.384 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.3 tp -118.78 120.67 38.07 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.533 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.57 117.4 47.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.645 0.736 . . . . 0.0 110.194 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 8.9 m -108.48 134.57 51.09 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.497 -176.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.49 -21.54 18.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.194 0.521 . . . . 0.0 109.717 177.538 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.414 ' H ' HG22 ' A' ' 20' ' ' THR . 13.4 mm-40 -79.06 160.34 27.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.568 -175.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 6.1 p90 -117.67 121.31 40.53 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.68 174.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.0 mp -123.02 123.75 68.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 120.826 0.346 . . . . 0.0 111.138 -174.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.3 p -76.68 127.57 33.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 169.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -74.83 78.67 2.1 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.668 0.747 . . . . 0.0 111.944 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.3 mt -120.06 -47.97 2.36 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 170.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.2 -142.78 3.88 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 113.848 -1.523 . . . . 0.0 110.43 172.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.59 -48.18 3.52 Favored Glycine 0 C--O 1.222 -0.598 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.448 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.1 mp -111.88 131.73 62.46 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 174.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -68.01 123.93 21.99 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.936 0.398 . . . . 0.0 109.952 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 45.8 pttt -80.62 -5.09 56.4 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -172.365 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -103.92 -33.62 8.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.829 0.347 . . . . 0.0 111.214 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.5 p -109.68 -28.16 8.98 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.914 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.591 ' CA ' HG13 ' A' ' 76' ' ' VAL . . . 89.42 9.7 66.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.43 -177.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.538 HD13 ' HB3' ' A' ' 47' ' ' SER . 48.7 mm -84.05 124.97 40.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.571 0.224 . . . . 0.0 110.614 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 20.7 m -68.78 116.67 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.759 0.79 . . . . 0.0 110.408 175.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 10.4 mmmm -89.58 -24.56 21.68 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.434 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -65.0 132.38 49.08 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.333 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 25.8 t70 -68.03 133.4 48.96 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.069 0.461 . . . . 0.0 111.403 -177.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 23.1 p -174.22 -170.64 0.54 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.516 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -83.23 -16.92 44.56 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.484 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.1 mt -100.17 15.17 4.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 122.12 0.962 . . . . 0.0 109.32 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.402 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 82.1 tttt -62.04 134.85 57.14 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.489 -1.232 . . . . 0.0 111.45 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 98.46 -10.91 63.23 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.572 -0.74 . . . . 0.0 113.231 177.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -92.47 170.45 9.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.307 0.575 . . . . 0.0 111.732 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.538 ' HB3' HD13 ' A' ' 36' ' ' ILE . 6.2 p -110.97 142.43 43.09 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.683 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.1 9.06 8.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.417 0.627 . . . . 0.0 109.881 175.465 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 76' ' ' VAL . . . -75.24 95.45 3.15 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.21 28.79 12.42 Favored Glycine 0 C--N 1.317 -0.508 0 CA-C-N 114.705 -1.134 . . . . 0.0 113.609 172.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -130.65 177.76 7.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.719 0.26 . . . . 0.0 110.675 174.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.69 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.5 mp -89.37 118.55 34.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.403 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 35.8 tp -106.4 116.6 32.21 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.15 -177.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.48 107.77 23.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.194 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.455 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 36.7 p90 -134.42 153.43 79.23 Favored Pre-proline 0 C--N 1.32 -0.714 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.843 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 -40.1 79.15 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.717 2.278 . . . . 0.0 111.982 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.776 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.25 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.932 0.396 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.437 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 47.8 t -68.41 -26.84 34.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.585 -177.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.611 HD12 ' HA3' ' A' ' 93' ' ' GLY . 94.9 mt -57.92 -32.75 68.08 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.054 178.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.556 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.7 tp -67.5 -46.08 73.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.322 178.4 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -65.21 -38.24 89.81 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.501 HD12 HD23 ' A' ' 68' ' ' LEU . 94.2 mt -58.43 -45.14 89.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.389 176.242 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.413 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.2 OUTLIER -68.84 -37.91 79.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.614 -178.042 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -62.93 -33.88 76.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.024 0.44 . . . . 0.0 110.702 176.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -86.35 -18.15 32.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.623 -177.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 95.2 1.31 62.8 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.262 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.591 HG13 ' CA ' ' A' ' 35' ' ' GLY . 71.2 t -79.65 -30.36 13.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 C-N-CA 122.71 0.404 . . . . 0.0 111.585 -175.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.99 144.7 98.9 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.696 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.26 141.86 94.65 Favored 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.304 2.003 . . . . 0.0 110.926 175.008 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 tttt -74.81 -16.5 60.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.119 0.485 . . . . 0.0 110.005 -175.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.69 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -164.27 142.94 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.518 176.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.494 HG13 ' HG ' ' A' ' 101' ' ' LEU . 9.3 pt -128.68 120.21 51.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.366 0.603 . . . . 0.0 111.115 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG23 ' A' ' 102' ' ' VAL . 1.2 mm -113.1 116.66 53.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -123.16 161.73 23.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 112.076 -171.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -99.46 -34.45 10.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.055 174.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -125.93 131.98 52.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.867 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -130.26 174.44 9.83 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.466 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -135.82 162.45 32.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.896 0.379 . . . . 0.0 110.553 -178.206 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.503 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.6 m -60.19 -51.57 69.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.47 -177.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.1 pt -58.35 -32.03 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.619 -179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.2 mm -68.7 -45.52 81.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.45 -38.43 89.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.022 178.17 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 88' ' ' THR . 93.0 t -62.94 -50.48 79.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.716 178.328 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.611 ' HA3' HD12 ' A' ' 68' ' ' LEU . . . -60.26 -43.97 97.96 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.144 178.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.59 -36.15 82.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 111.38 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -69.18 -42.79 75.38 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.33 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 58.4 mtm -73.86 -36.62 64.87 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.577 -176.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.37 -9.75 49.18 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.764 -176.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.443 ' OE1' ' HA ' ' A' ' 98' ' ' GLU . 2.8 tp10 65.91 72.54 0.4 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.824 0.821 . . . . 0.0 110.161 -175.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.428 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 60.6 mt -127.15 90.11 50.05 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 114.759 -1.109 . . . . 0.0 109.734 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 4.4 Cg_exo -39.3 110.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 123.985 3.123 . . . . 0.0 112.993 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.494 ' HG ' HG13 ' A' ' 81' ' ' ILE . 4.7 tt -119.66 123.43 43.8 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.368 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 82' ' ' ILE . 8.6 m -128.17 139.82 50.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.238 0.542 . . . . 0.0 110.651 176.805 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 43.6 tt0 -88.92 123.14 32.99 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.54 -178.17 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.614 HG22 ' SG ' ' A' ' 5' ' ' CYS . 96.3 t -107.27 117.72 53.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.793 178.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 24.2 mtm180 -107.44 14.09 26.25 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.237 0.541 . . . . 0.0 110.06 177.191 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -108.62 130.74 55.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.51 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -71.92 -28.07 63.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.65 -175.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -73.39 -18.25 61.18 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -172.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -63.03 -48.31 79.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.955 0.407 . . . . 0.0 109.984 176.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.408 ' HA ' HG12 ' A' ' 113' ' ' VAL . 88.3 m-85 -71.98 -22.71 61.4 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.364 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -72.81 -42.15 64.15 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.733 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.03 -36.86 30.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.009 -175.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.408 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.5 p -75.65 136.72 24.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-O 121.314 0.578 . . . . 0.0 111.091 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.489 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 9.7 mtmp? -126.18 158.77 34.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.949 176.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 50.0 m -65.16 111.46 2.95 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 172.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.92 1.67 19.16 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.351 -0.928 . . . . 0.0 113.592 176.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ASP . . . . . 0.489 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 28.2 m-20 -85.42 177.55 7.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 117.348 0.574 . . . . 0.0 110.519 176.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.419 ' NH2' HG13 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -115.42 119.79 37.42 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.0 110.152 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.528 HG23 ' HB2' ' A' ' 17' ' ' ALA . 36.7 t -109.34 126.52 66.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.156 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.541 HG22 ' HG3' ' A' ' 14' ' ' GLU . 14.6 t -106.96 102.24 13.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 173.036 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.478 HG23 HG22 ' A' ' 128' ' ' VAL . 7.3 p -108.32 131.66 58.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.279 0.562 . . . . 0.0 111.78 -176.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -116.08 103.87 10.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.467 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.83 -18.71 50.16 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.369 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.2 -30.69 70.57 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.063 0.458 . . . . 0.0 110.588 177.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -108.89 -37.06 5.95 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.44 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 97.39 56.09 1.13 Allowed Glycine 0 N--CA 1.45 -0.386 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -145.04 133.46 21.85 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -172.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 121' ' ' VAL . 49.0 t -118.8 112.32 37.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.057 -177.372 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.444 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 45.8 mt-10 -106.72 108.47 20.0 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.166 177.554 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.426 HD23 ' H ' ' A' ' 130' ' ' LEU . 2.0 pt? -106.52 147.8 28.97 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.419 HG13 ' NH2' ' A' ' 118' ' ' ARG . 42.6 mm -112.27 133.86 56.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.06 177.82 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.418 -177.526 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.1 p . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 121.362 0.601 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.468 ' HD3' ' HE1' ' A' ' 127' ' ' TYR . 97.5 mttt -121.18 140.16 52.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.689 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -115.77 161.71 18.35 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.327 -177.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.01 127.26 50.08 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.158 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.7 p -120.55 176.11 5.66 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.972 0.415 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.473 ' NE ' ' HA ' ' A' ' 6' ' ' ARG . 2.6 tpm_? -98.43 124.75 43.3 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 175.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.06 140.0 46.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.9 0.381 . . . . 0.0 111.82 -175.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 49.1 mm -112.47 -57.26 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.123 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 ' HA ' ' A' ' 95' ' ' ALA . 52.7 p -113.13 -164.99 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.627 174.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.501 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 7.9 mpt_? -120.08 167.58 12.06 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.017 0.437 . . . . 0.0 111.486 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.748 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 134.46 145.84 5.31 Favored Glycine 0 CA--C 1.519 0.305 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.69 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.559 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 1.1 tmm_? -139.88 114.14 9.07 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.203 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.34 170.32 17.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.636 0.255 . . . . 0.0 111.428 -175.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -110.23 165.5 11.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.393 178.385 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.438 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -175.43 157.31 23.78 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 173.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.849 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 52.8 mt-10 -61.44 137.37 58.24 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 174.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -78.84 109.2 12.89 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.712 0.291 . . . . 0.0 110.463 -176.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.9 tt -102.4 109.55 21.24 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 173.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.6 t -120.64 114.09 42.43 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.153 -171.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 t -127.5 118.19 23.54 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.736 174.559 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.409 ' HE2' ' HB3' ' A' ' 110' ' ' PHE . 30.5 ttmt -93.53 20.91 6.76 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.89 0.853 . . . . 0.0 109.118 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.572 ' HG2' ' SG ' ' A' ' 41' ' ' CYS . 5.0 mp0 -97.66 147.68 24.08 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.79 -1.096 . . . . 0.0 109.7 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -82.8 100.61 10.42 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.073 0.463 . . . . 0.0 110.317 175.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.448 HG23 ' HB3' ' A' ' 39' ' ' GLU . 27.9 mm -91.44 1.25 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.269 -176.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.8 m 68.57 -26.81 0.14 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 171.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 24' ' ' ILE . 47.1 t80 75.36 -31.25 0.2 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 123.749 0.82 . . . . 0.0 112.015 175.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -61.72 102.25 0.25 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.042 0.448 . . . . 0.0 110.176 177.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.24 26.13 69.03 Favored Glycine 0 C--N 1.335 0.486 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.2 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -83.61 -15.32 71.18 Favored Glycine 0 C--O 1.224 -0.523 0 C-N-CA 120.867 -0.683 . . . . 0.0 113.797 -173.377 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 59.7 mt -125.8 130.57 72.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 117.492 0.646 . . . . 0.0 111.18 -177.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.506 ' HA ' ' HE2' ' A' ' 38' ' ' LYS . 12.3 t70 -65.57 130.42 43.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.966 175.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.555 ' HA ' HD21 ' A' ' 71' ' ' LEU . 21.2 pttp -84.76 -0.12 52.62 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -171.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -101.69 -53.63 2.93 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.846 0.355 . . . . 0.0 111.608 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.518 HG23 HG12 ' A' ' 36' ' ' ILE . 3.5 t -109.69 -2.68 17.28 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.253 -0.431 . . . . 0.0 112.057 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.45 43.85 91.56 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.54 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.518 HG12 HG23 ' A' ' 34' ' ' THR . 47.3 mm -110.66 131.48 61.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 53.6 t -61.0 123.44 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.806 0.336 . . . . 0.0 110.599 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.506 ' HE2' ' HA ' ' A' ' 31' ' ' ASP . 63.8 mmtt -72.08 -47.99 47.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.221 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 24' ' ' ILE . 7.8 tp10 -62.13 125.48 24.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.629 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.548 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 14.1 t70 -83.11 133.23 35.07 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.329 178.043 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.572 ' SG ' ' HG2' ' A' ' 22' ' ' GLU . 4.0 t -170.8 39.04 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 75.63 -29.94 0.19 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 114.984 -1.007 . . . . 0.0 111.945 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 41.8 mm -84.17 -10.47 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-O 121.623 0.725 . . . . 0.0 110.45 177.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.548 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 21.8 ttpp -59.64 135.94 57.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.126 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 111.34 -14.8 27.86 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.455 -0.879 . . . . 0.0 113.036 176.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -89.47 142.39 27.71 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.008 0.432 . . . . 0.0 111.236 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.443 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 20.3 m -85.36 136.66 33.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.552 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.4 m -89.05 -6.96 10.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.195 173.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.87 94.62 0.13 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.243 -176.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.67 13.66 49.84 Favored Glycine 0 C--N 1.313 -0.749 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.668 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.849 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 95.9 mtt180 -113.46 166.26 11.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.981 0.419 . . . . 0.0 111.051 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.438 HG12 ' HA3' ' A' ' 15' ' ' GLY . 39.3 mm -95.99 122.15 47.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.169 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HB3' HG12 ' A' ' 81' ' ' ILE . 58.5 tp -93.2 113.26 25.44 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.768 0.318 . . . . 0.0 110.36 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.6 t -102.93 108.16 23.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 176.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.685 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.0 t80 -134.37 140.27 35.3 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.195 -172.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 15.2 Cg_endo -94.13 -56.5 0.01 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.914 2.409 . . . . 0.0 113.38 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.643 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.309 -176.887 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 . . . . . 0 N--CA 1.46 0.069 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.55 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 66.4 t -62.56 -51.4 72.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.676 0.274 . . . . 0.0 110.689 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.27 -39.58 93.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.956 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.501 ' O ' ' HG2' ' A' ' 73' ' ' LYS . 56.4 tp -62.82 -46.08 89.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.565 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.51 -44.71 93.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.422 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.555 HD21 ' HA ' ' A' ' 32' ' ' LYS . 97.3 mt -54.43 -41.59 69.56 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.114 0.483 . . . . 0.0 110.397 177.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -65.04 -37.08 86.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.144 -178.159 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.501 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 34.5 mmtp -69.91 -25.29 63.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.214 -177.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -93.84 -22.82 18.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.285 0.564 . . . . 0.0 110.182 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.37 15.66 37.29 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.221 178.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.47 23.68 3.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.238 0.542 . . . . 0.0 110.701 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.87 156.03 41.03 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.054 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 42.1 Cg_endo -68.14 155.92 67.68 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.4 2.067 . . . . 0.0 112.129 175.537 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 53.9 mmtt -68.51 -41.86 79.39 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.824 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.444 ' HB2' HG11 ' A' ' 121' ' ' VAL . . . -163.69 165.97 22.71 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.251 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.482 HG12 ' HB3' ' A' ' 53' ' ' LEU . 63.9 mt -131.87 119.34 41.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.094 0.473 . . . . 0.0 110.24 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.631 HG23 HG23 ' A' ' 102' ' ' VAL . 3.8 mm -103.83 116.88 48.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.7 m120 -111.64 164.49 12.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.949 0.404 . . . . 0.0 111.503 -175.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -69.76 -54.14 15.09 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.711 175.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.614 ' HG2' ' OE2' ' A' ' 103' ' ' GLU . 4.8 tttm -139.75 22.59 2.48 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.515 178.18 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 30.5 m 72.48 124.03 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.618 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.491 ' HB3' ' HB ' ' A' ' 90' ' ' ILE . 8.8 tp10 -84.13 130.54 34.84 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 172.018 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.6 m -57.5 -50.2 73.84 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.962 0.41 . . . . 0.0 111.66 -173.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.1 mt -68.95 -35.14 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.199 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 87' ' ' GLU . 59.7 mt -69.23 -38.07 77.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.36 -44.77 92.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.416 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -62.26 -49.28 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.994 0.426 . . . . 0.0 110.576 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.92 -42.24 99.72 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.466 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.06 -39.17 92.88 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.704 0.287 . . . . 0.0 111.149 -179.789 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.439 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -63.13 -41.89 99.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.923 178.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.5 mtm -72.49 -35.96 68.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.498 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.567 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -92.36 5.96 48.68 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.567 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 56.92 50.78 11.66 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.449 0.643 . . . . 0.0 110.911 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 62.1 mt -114.29 90.3 20.09 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.816 179.539 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.748 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 91.6 Cg_exo -35.3 112.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.352 0.733 0 C-N-CA 124.071 3.181 . . . . 0.0 113.998 -176.071 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.409 HD13 ' N ' ' A' ' 102' ' ' VAL . 0.5 OUTLIER -110.15 128.75 55.64 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.836 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.631 HG23 HG23 ' A' ' 82' ' ' ILE . 16.2 m -136.55 162.18 35.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.343 178.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.614 ' OE2' ' HG2' ' A' ' 85' ' ' LYS . 32.1 tt0 -115.88 119.09 34.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.814 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 106' ' ' ASP . 13.5 t -99.52 128.97 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.888 0.375 . . . . 0.0 110.4 177.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 105' ' ' ARG . 3.2 mmp_? -92.02 24.8 3.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.223 0.535 . . . . 0.0 110.42 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.497 ' H ' HG12 ' A' ' 104' ' ' VAL . 35.9 t70 -141.96 111.9 6.81 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.698 -175.021 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -69.84 -26.68 64.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.846 178.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.4 ' HD3' ' HA ' ' A' ' 108' ' ' LYS . 68.8 mmtt -63.51 -19.95 65.2 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.527 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.599 ' O ' HG12 ' A' ' 113' ' ' VAL . 49.9 t80 -61.25 -45.1 95.9 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 170.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.409 ' HB3' ' HE2' ' A' ' 21' ' ' LYS . 87.4 m-85 -68.3 -22.05 64.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.277 -177.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -83.64 -32.75 25.5 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.049 0.452 . . . . 0.0 110.522 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.7 -44.34 28.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.185 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.599 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.9 p -83.21 123.5 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 110.149 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -130.21 152.66 49.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.048 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.742 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 21.6 m -58.4 107.49 0.5 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.042 -179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.32 -39.04 0.55 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.331 -0.938 . . . . 0.0 113.449 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ASP . . . . . 0.741 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 1.7 t0 -101.09 -166.96 1.36 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 117.286 0.543 . . . . 0.0 110.997 -176.762 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.741 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -110.03 138.54 46.27 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.33 0.586 . . . . 0.0 112.559 -173.987 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.624 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.7 t -119.71 122.7 69.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.551 173.675 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.932 ' HB ' ' HG3' ' A' ' 129' ' ' GLU . 47.1 t -100.06 112.58 33.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.444 HG11 ' HB2' ' A' ' 80' ' ' ALA . 8.9 p -86.54 133.2 30.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.561 -177.545 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ASN . . . . . 0.665 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 44.0 t-20 -126.06 94.64 4.15 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.252 0.549 . . . . 0.0 109.767 177.069 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.437 ' HB1' ' O ' ' A' ' 9' ' ' THR . . . -90.16 2.66 55.09 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.418 0.627 . . . . 0.0 110.107 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.455 ' HB3' ' OD1' ' A' ' 122' ' ' ASN . 4.5 t70 -73.7 -37.1 65.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.665 175.327 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -114.11 -15.36 12.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.573 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.06 66.89 1.74 Allowed Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -168.075 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.665 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 9.2 t80 -146.24 144.75 30.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.146 -0.527 . . . . 0.0 109.744 -167.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 109' ' ' PHE . 60.1 t -126.87 104.87 13.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 175.65 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.932 ' HG3' ' HB ' ' A' ' 120' ' ' VAL . 9.0 pt-20 -97.05 108.13 20.81 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.502 0.668 . . . . 0.0 109.931 179.169 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.9 tp -85.57 127.83 34.57 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.497 -178.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 5.2 mm -116.76 111.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -178.169 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.414 ' HA ' ' OD2' ' A' ' 117' ' ' ASP . 12.4 mp0 . . . . . 0 C--N 1.314 -0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.464 HG23 ' HB3' ' A' ' 130' ' ' LEU . 10.8 m . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 121.464 0.649 . . . . 0.0 111.914 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.432 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 28.1 mtpp -107.78 94.21 4.96 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.143 174.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -96.77 155.62 16.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.018 0.437 . . . . 0.0 111.379 -176.145 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.41 126.27 52.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.702 174.642 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 103' ' ' GLU . 80.3 m -118.93 179.59 4.1 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.029 -177.17 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 64.4 ttp85 -92.04 116.12 28.66 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -175.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.659 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.65 124.39 24.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.091 -0.958 . . . . 0.0 111.786 -173.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 44.5 mm -102.81 -47.99 10.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.734 176.554 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.564 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -107.16 -171.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.379 177.558 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 10' ' ' ARG . 39.3 mtt180 -115.33 -178.7 3.44 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 173.294 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.97 -176.81 36.42 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.846 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -161.14 143.31 12.21 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 -178.177 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.51 179.07 9.46 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.29 0.567 . . . . 0.0 111.494 -175.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -125.77 160.59 29.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.533 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.57 ' HA3' HG13 ' A' ' 52' ' ' ILE . . . 179.61 155.69 15.82 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.832 171.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.527 ' HB3' ' HD3' ' A' ' 51' ' ' ARG . 28.7 tt0 -75.44 137.95 41.32 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 175.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.515 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -78.0 134.92 37.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.119 0.485 . . . . 0.0 111.825 -169.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.506 HD21 HG21 ' A' ' 43' ' ' ILE . 6.3 tt -130.29 115.41 16.91 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 174.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.549 HG12 ' OG1' ' A' ' 115' ' ' THR . 9.9 p -103.47 130.94 53.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.198 0.523 . . . . 0.0 110.831 -175.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.8 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 29.1 m -108.82 127.52 54.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.031 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -99.88 -1.01 38.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.559 -175.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.453 ' H ' HG22 ' A' ' 20' ' ' THR . 53.4 mm-40 -96.99 158.98 15.17 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.358 0.599 . . . . 0.0 112.188 -173.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -104.38 91.24 3.82 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 27.4 pt -122.35 16.83 5.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -169.426 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 59.6 p 51.8 -154.54 0.17 Allowed 'General case' 0 CA--C 1.53 0.202 0 O-C-N 123.606 0.566 . . . . 0.0 110.485 -175.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.411 ' HE2' HD11 ' A' ' 68' ' ' LEU . 9.6 t80 -143.64 18.25 1.84 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.064 0.459 . . . . 0.0 110.626 179.239 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.13 -10.05 57.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.316 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.03 130.64 1.25 Allowed Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.183 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.435 ' HA2' ' HB3' ' A' ' 39' ' ' GLU . . . -173.27 -47.37 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.264 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.674 HG13 HG22 ' A' ' 37' ' ' VAL . 4.1 mp -88.27 134.63 27.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.744 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 29.2 t70 -77.89 147.25 35.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.687 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 9.5 ptpp? -82.76 -14.49 54.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.135 -174.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -100.79 -47.82 4.69 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.427 -175.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.9 p -92.91 -37.09 12.44 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.778 0.323 . . . . 0.0 111.735 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.8 20.03 48.91 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.336 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.2 mm -90.24 138.3 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.287 179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.674 HG22 HG13 ' A' ' 30' ' ' ILE . 96.3 t -79.81 102.26 5.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.139 0.495 . . . . 0.0 109.755 174.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.744 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 59.3 mttt -84.32 -28.64 26.93 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.706 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.435 ' HB3' ' HA2' ' A' ' 29' ' ' GLY . 9.4 tp10 -96.14 78.66 3.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.614 0.721 . . . . 0.0 110.384 178.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 1.027 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 9.2 t70 -147.82 -167.78 2.89 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.936 177.385 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 71.5 m -144.82 -23.14 0.51 Allowed 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -133.86 -47.77 0.8 Allowed 'General case' 0 C--O 1.233 0.225 0 O-C-N 122.031 -0.418 . . . . 0.0 110.796 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.506 HG21 HD21 ' A' ' 18' ' ' LEU . 23.0 mm -75.83 -17.75 15.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 109.227 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 1.027 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 54.3 tttm -44.37 118.23 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 CA-C-N 114.166 -1.379 . . . . 0.0 112.156 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 130.83 -19.13 5.02 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.807 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -93.46 156.36 16.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.056 0.455 . . . . 0.0 111.692 -177.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.0 m -95.94 138.69 33.22 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.423 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.1 m -94.2 -3.69 10.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.993 0.425 . . . . 0.0 110.808 176.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.42 89.51 0.5 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.559 0.695 . . . . 0.0 110.868 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.7 ' HA2' ' HE3' ' A' ' 79' ' ' LYS . . . 112.6 2.98 25.64 Favored Glycine 0 C--N 1.313 -0.741 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.703 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.527 ' HD3' ' HB3' ' A' ' 16' ' ' GLU . 20.2 mmt85 -105.59 156.29 18.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.556 -0.322 . . . . 0.0 110.827 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.706 HG12 ' HB3' ' A' ' 80' ' ' ALA . 29.1 mt -97.29 117.65 42.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 169.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.43 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 28.1 tp -93.56 124.57 37.64 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.957 -171.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 62.6 t -123.85 107.51 18.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.892 0.377 . . . . 0.0 110.195 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.8 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 40.9 p90 -136.01 146.09 55.21 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 177.881 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.97 -29.55 34.02 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.851 2.367 . . . . 0.0 111.462 175.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.747 176.778 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 . . . . . 0 N--CA 1.471 0.619 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.487 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 29.8 m -62.79 -24.65 36.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -175.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.411 HD11 ' HE2' ' A' ' 26' ' ' PHE . 6.2 mp -69.0 -32.16 71.51 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.664 0.269 . . . . 0.0 110.576 178.171 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.414 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.4 tp -66.43 -38.48 87.5 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -61.21 -48.85 79.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.129 175.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.487 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 67.6 mt -60.59 -41.68 95.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.674 178.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.0 OUTLIER -72.06 -35.61 69.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.097 -176.402 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -59.75 -38.41 81.68 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.434 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -82.6 -29.66 30.02 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 109.876 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 99.14 22.27 13.51 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.561 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.47 4.9 9.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.998 0.428 . . . . 0.0 111.156 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.32 154.54 66.41 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.767 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 27.7 Cg_endo -63.63 147.33 92.86 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.148 1.899 . . . . 0.0 111.075 174.379 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.7 ' HE3' ' HA2' ' A' ' 50' ' ' GLY . 97.2 mttt -73.32 -27.25 61.42 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.049 0.452 . . . . 0.0 110.725 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.706 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -157.79 157.48 33.43 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.305 176.067 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.466 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 34.1 mt -136.57 127.39 41.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 178.113 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.527 HG22 HG13 ' A' ' 104' ' ' VAL . 3.6 mm -121.67 118.26 55.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 11.8 m120 -130.43 -179.84 5.5 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.147 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.434 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 4.1 tmtt? -109.86 -37.91 5.51 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 171.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -103.01 114.84 29.46 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -120.67 141.26 50.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.903 0.382 . . . . 0.0 110.266 177.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.49 ' HB2' HG13 ' A' ' 90' ' ' ILE . 81.2 mm-40 -108.94 159.65 16.64 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.11 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 m -60.01 -45.34 93.06 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.83 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.444 HD12 ' N ' ' A' ' 90' ' ' ILE . 2.5 pp -64.82 -31.08 52.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.725 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.49 HG13 ' HB2' ' A' ' 87' ' ' GLU . 69.3 mt -68.38 -45.79 81.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.984 0.421 . . . . 0.0 109.99 177.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.55 -48.27 82.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.965 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.06 -45.49 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.974 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.68 -43.28 99.47 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.61 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -74.89 -37.15 62.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 111.576 0.213 . . . . 0.0 111.576 -177.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.45 -38.83 85.42 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.737 0.303 . . . . 0.0 111.428 -178.091 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 59.1 mtm -71.22 -31.03 67.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.039 0.447 . . . . 0.0 111.054 -179.161 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.414 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.55 -2.86 58.47 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.432 -179.396 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.543 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 3.9 tp10 62.4 43.95 7.66 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-O 121.49 0.662 . . . . 0.0 110.3 -177.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.0 mt -107.44 88.6 4.21 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.83 175.645 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 24.3 Cg_exo -62.14 118.22 5.1 Favored 'Trans proline' 0 C--O 1.233 0.267 0 C-N-CA 122.918 2.412 . . . . 0.0 112.665 -174.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.564 HD23 ' OG1' ' A' ' 9' ' ' THR . 1.9 pt? -118.96 147.09 44.43 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.95 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.659 HG12 ' HA ' ' A' ' 7' ' ' ALA . 26.9 m -136.97 158.33 36.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.014 178.288 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.539 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 30.3 tt0 -94.89 119.82 34.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.491 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.527 HG13 HG22 ' A' ' 82' ' ' ILE . 20.7 m -74.25 144.32 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.135 174.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -117.55 23.47 11.73 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.76 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.481 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 10.4 t70 -144.35 127.81 16.95 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -176.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -66.56 -36.76 83.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.367 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.481 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 10.0 mtmp? -67.9 -18.35 64.76 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.324 -175.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -58.98 -39.89 83.17 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -67.69 -29.07 68.24 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.754 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.11 -40.14 60.09 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 177.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.03 -46.55 56.65 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.703 -176.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.0 p -66.0 138.02 23.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 121.106 0.479 . . . . 0.0 111.376 -175.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -138.06 151.07 47.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.989 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.549 ' OG1' HG12 ' A' ' 19' ' ' VAL . 80.4 m -70.17 118.37 12.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.605 -0.271 . . . . 0.0 110.319 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 120.69 -12.5 10.11 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.257 177.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.82 179.33 6.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.829 0.314 . . . . 0.0 111.127 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -109.18 120.81 43.64 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 121.046 0.45 . . . . 0.0 111.344 -175.003 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 17' ' ' ALA . 52.1 t -123.02 137.39 56.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.485 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.449 ' CG2' ' HB3' ' A' ' 129' ' ' GLU . 6.0 m -114.43 134.56 57.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.654 170.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.402 HG11 ' CB ' ' A' ' 80' ' ' ALA . 11.2 p -112.96 133.95 57.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.165 0.507 . . . . 0.0 110.644 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -129.29 94.85 3.89 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 174.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.39 -16.13 35.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.185 0.516 . . . . 0.0 110.293 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.32 -40.95 73.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.252 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -100.45 -25.26 14.27 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.153 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 90.41 68.76 1.2 Allowed Glycine 0 CA--C 1.516 0.124 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.352 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -158.38 146.94 18.77 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 122.468 0.307 . . . . 0.0 110.832 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.34 125.53 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.705 173.033 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.449 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 41.1 tt0 -109.1 112.61 24.87 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.234 0.54 . . . . 0.0 110.722 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.464 ' HB3' HG23 ' A' ' 1' ' ' VAL . 55.7 tp -105.86 122.59 46.41 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.957 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.8 mt -115.3 120.49 64.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--N 1.31 -1.148 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.282 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 N--CA 1.454 -0.271 0 CA-C-O 120.934 0.397 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.452 ' HD2' ' N ' ' A' ' 2' ' ' LYS . 11.4 mptt -101.46 113.66 26.96 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -93.85 148.21 22.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.828 0.346 . . . . 0.0 110.764 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.06 125.86 40.0 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.665 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.8 m -120.36 175.14 6.11 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.55 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 40.9 ttm180 -101.28 121.21 41.47 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -69.83 114.05 7.65 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.765 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 mm -90.75 -66.56 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 174.039 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.551 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 21.2 p -96.18 -170.95 2.2 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 173.072 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.27 164.71 24.98 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.056 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.05 155.54 10.96 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.052 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 57.9 ttt180 -115.87 117.08 29.18 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.908 0.385 . . . . 0.0 110.143 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.424 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -119.01 138.18 53.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.994 0.426 . . . . 0.0 111.352 -175.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.493 ' HG3' HG22 ' A' ' 120' ' ' VAL . 20.6 tt0 -112.0 139.49 47.47 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.053 178.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.405 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -172.7 170.66 43.75 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.473 175.045 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -82.63 127.48 33.41 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 52' ' ' ILE . . . -90.2 131.58 35.96 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -169.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mp -112.75 130.52 56.04 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.148 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.487 HG11 HG13 ' A' ' 113' ' ' VAL . 48.2 t -119.47 126.16 75.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.552 -172.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.4 t -118.27 139.52 51.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 176.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -91.65 -9.39 44.16 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.239 0.542 . . . . 0.0 110.033 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -95.37 143.86 26.38 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.824 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -85.42 153.62 22.38 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.869 177.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.0 pt -122.0 -178.99 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.197 0.523 . . . . 0.0 111.5 -175.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.3 p -111.32 124.38 52.12 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.767 -0.652 . . . . 0.0 109.641 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.36 95.61 3.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.345 0.593 . . . . 0.0 110.824 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 pp -165.83 -162.57 0.57 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.708 -1.133 . . . . 0.0 109.164 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -73.34 67.12 1.53 Allowed Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.579 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.42 -23.03 10.63 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 121.21 -0.519 . . . . 0.0 112.401 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 37' ' ' VAL . 60.3 mt -101.92 138.21 26.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 177.032 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -69.34 133.02 47.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.605 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 60.8 pttt -78.52 -16.72 57.16 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -173.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.5 mm-40 -94.73 -52.32 4.33 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -174.361 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.581 HG23 HG12 ' A' ' 36' ' ' ILE . 7.6 t -106.3 -2.94 21.75 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 111.795 0.294 . . . . 0.0 111.795 -176.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.58 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.24 37.8 93.22 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.226 175.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.581 HG12 HG23 ' A' ' 34' ' ' THR . 49.7 mm -104.02 128.74 57.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.458 HG22 HG12 ' A' ' 30' ' ' ILE . 21.3 t -72.29 117.75 16.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.865 0.364 . . . . 0.0 110.181 178.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -83.64 -36.27 23.96 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.266 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -64.98 132.79 50.21 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 176.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.534 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 9.0 t70 -80.38 136.83 36.45 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.287 0.565 . . . . 0.0 111.832 -170.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.454 ' H ' ' HB3' ' A' ' 44' ' ' LYS . 79.4 m -144.55 28.04 1.33 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.033 -0.985 . . . . 0.0 109.105 177.061 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 70.26 -69.12 0.18 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.28 -177.046 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 46.6 pt -80.39 5.43 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.27 0.557 . . . . 0.0 111.203 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.534 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER -68.18 139.41 56.09 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.254 178.676 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.94 -1.29 1.72 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.635 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -102.58 159.8 15.13 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.663 0.268 . . . . 0.0 110.569 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.4 p -82.1 121.96 27.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-O 121.28 0.562 . . . . 0.0 110.041 176.286 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.0 m -86.71 19.26 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.438 -176.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.13 92.16 0.17 Allowed 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.706 0.765 . . . . 0.0 111.128 -176.455 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.51 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 84.92 24.32 45.65 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 114.735 -1.121 . . . . 0.0 112.23 177.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.452 HH11 ' HD2' ' A' ' 51' ' ' ARG . 12.5 mmt180 -98.08 163.96 12.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.627 0.251 . . . . 0.0 110.728 178.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.483 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.0 mm -102.15 118.37 48.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 175.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.538 ' HB2' HG22 ' A' ' 81' ' ' ILE . 4.3 mm? -106.7 125.3 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.922 0.391 . . . . 0.0 111.221 -177.762 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.477 ' HB ' HG22 ' A' ' 19' ' ' VAL . 59.7 t -110.7 106.38 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.849 176.208 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -136.59 148.12 62.43 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.787 176.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.451 ' O ' ' HG2' ' A' ' 84' ' ' LYS . 32.1 Cg_exo -59.61 -45.28 26.46 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.416 2.077 . . . . 0.0 111.955 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.666 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -178.834 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.1 p90 . . . . . 0 C--O 1.231 0.097 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.44 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 34.4 m -66.42 -28.58 43.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.239 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 98.9 mt -62.35 -40.77 97.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.988 0.423 . . . . 0.0 110.168 178.486 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.7 tp -69.4 -43.12 74.1 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.266 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 46.8 t-20 -57.36 -49.93 74.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.913 178.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.564 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 97.9 mt -63.49 -43.52 97.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.054 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.415 ' C ' ' HD3' ' A' ' 72' ' ' ARG . 0.3 OUTLIER -66.83 -38.95 87.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.708 0.289 . . . . 0.0 110.347 -177.438 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.452 ' HD2' ' O ' ' A' ' 73' ' ' LYS . 2.4 tmmm? -61.48 -32.1 72.09 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.53 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -91.37 -7.73 50.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.267 0.556 . . . . 0.0 110.143 178.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.21 16.34 72.05 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.0 174.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.58 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.9 m -108.25 7.56 9.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.776 0.322 . . . . 0.0 111.448 -177.16 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.564 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -92.45 159.95 35.79 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.501 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.528 ' HB3' HD23 ' A' ' 53' ' ' LEU . 34.7 Cg_exo -58.41 150.17 69.63 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.373 2.049 . . . . 0.0 111.12 172.198 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.51 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 79.0 tttt -81.49 -24.68 36.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.151 0.5 . . . . 0.0 109.828 -178.368 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.483 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -168.37 154.29 6.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.893 176.548 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.538 HG22 ' HB2' ' A' ' 53' ' ' LEU . 25.5 pt -136.25 146.1 29.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.821 0.343 . . . . 0.0 111.295 -178.441 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.605 HG23 HG23 ' A' ' 102' ' ' VAL . 4.7 mm -118.82 124.22 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 14.2 m120 -122.39 171.22 9.22 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -176.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.451 ' HG2' ' O ' ' A' ' 56' ' ' PRO . 63.1 pttt -96.97 -32.57 11.95 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.4 0.619 . . . . 0.0 110.321 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.412 ' NZ ' ' HA ' ' A' ' 85' ' ' LYS . 1.4 tppm? -138.02 113.15 9.24 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.665 177.361 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.3 m -99.03 127.68 45.01 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.782 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.68 152.12 22.01 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 16.3 m -56.64 -39.52 73.83 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.693 0.283 . . . . 0.0 110.997 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 80.8 mt -55.38 -41.4 62.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-O 121.335 0.588 . . . . 0.0 110.686 177.027 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 25.8 mm -71.77 -41.65 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.247 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.41 81.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.227 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -60.31 -45.54 96.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.829 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.22 -48.07 85.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.52 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.28 -33.17 74.73 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.534 0.206 . . . . 0.0 111.472 -178.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.98 -45.07 90.7 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.911 0.386 . . . . 0.0 111.068 178.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.6 mtm -69.02 -33.14 73.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.138 -178.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -85.74 -7.24 58.9 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.54 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.461 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 63.2 mt-10 60.4 48.52 7.74 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.501 0.667 . . . . 0.0 110.471 -177.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.3 90.07 7.85 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.026 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.551 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 50.0 Cg_exo -52.8 115.77 2.46 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.764 2.309 . . . . 0.0 112.202 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pt? -129.77 143.85 51.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.004 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.605 HG23 HG23 ' A' ' 82' ' ' ILE . 17.4 m -136.18 155.29 34.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.918 -178.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.55 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 2.6 pt-20 -102.93 137.08 41.6 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.057 0.456 . . . . 0.0 111.618 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 2.2 m -125.17 109.41 22.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.53 173.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.451 ' H ' ' HD3' ' A' ' 105' ' ' ARG . 0.0 OUTLIER -87.6 17.42 4.65 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.451 0.643 . . . . 0.0 110.156 176.789 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -95.12 123.28 38.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.058 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -71.45 -38.75 71.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.428 -176.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.566 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 62.3 mttm -70.81 -18.83 62.72 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -171.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -56.07 -49.85 72.62 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 171.025 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -75.72 -26.48 57.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.511 0.672 . . . . 0.0 110.231 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.3 tt0 -65.02 -44.57 88.7 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.314 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -96.84 -27.97 14.46 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.487 HG13 HG11 ' A' ' 19' ' ' VAL . 11.0 p -67.24 134.75 29.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 111.225 -175.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -110.98 157.13 20.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.421 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.443 ' HB ' ' H ' ' A' ' 19' ' ' VAL . 8.8 t -87.41 127.97 35.21 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.483 179.352 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.57 0.4 24.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.169 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -101.78 -172.1 2.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.808 0.304 . . . . 0.0 110.871 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 118' ' ' ARG . 2.0 ttp180 -103.07 127.37 50.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.368 . . . . 0.0 111.574 -172.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 129' ' ' GLU . 73.9 t -134.07 123.15 43.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.322 176.083 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.493 HG22 ' HG3' ' A' ' 14' ' ' GLU . 81.2 t -114.82 125.05 72.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.624 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 6.2 p -107.9 123.89 63.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.456 0.646 . . . . 0.0 111.252 -177.19 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -103.58 95.97 6.41 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.121 173.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.11 6.03 17.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.956 0.408 . . . . 0.0 110.979 -176.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.01 -38.99 79.56 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.264 0.554 . . . . 0.0 109.798 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -115.19 -22.84 9.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.888 175.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 92.72 66.3 1.09 Allowed Glycine 0 C--O 1.228 -0.232 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -174.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -144.29 125.11 14.24 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -169.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 24.6 m -113.33 134.29 56.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.29 0.567 . . . . 0.0 111.823 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.503 ' O ' ' HA ' ' A' ' 119' ' ' VAL . 46.3 mt-10 -96.55 107.79 20.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.17 176.273 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.8 tp -101.3 108.99 20.77 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 175.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.5 mm -120.13 125.72 74.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.9 0.381 . . . . 0.0 110.297 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 . . . . . 0 C--N 1.318 -0.79 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.426 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 121.443 0.64 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.707 ' HE3' ' HG2' ' A' ' 129' ' ' GLU . 52.0 mtpt -121.49 121.39 37.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.231 -0.895 . . . . 0.0 108.606 170.624 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.51 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 96.6 m-85 -97.17 150.11 21.25 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.99 0.424 . . . . 0.0 111.37 -173.607 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.76 122.15 46.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.733 177.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.462 ' SG ' HG21 ' A' ' 102' ' ' VAL . 7.1 p -120.49 171.16 8.74 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.123 -177.525 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.653 ' HB3' ' HB2' ' A' ' 103' ' ' GLU . 7.8 tpt180 -93.5 115.8 28.31 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 176.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.604 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -74.88 110.31 9.07 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.589 -178.415 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.2 mm -85.06 -55.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 172.397 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.586 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -100.17 174.73 6.01 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 171.925 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 10' ' ' ARG . 43.1 mtm180 -119.56 174.7 6.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.804 0.335 . . . . 0.0 110.434 175.169 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.4 144.8 6.84 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.096 -178.189 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.527 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 60.1 mtm180 -119.16 131.64 55.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 177.582 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.57 145.29 23.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.519 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.06 140.92 52.5 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.158 -0.473 . . . . 0.0 109.754 177.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -170.26 175.79 44.11 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.522 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -67.08 128.15 35.28 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.9 125.29 29.94 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.984 -176.58 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 tt -108.39 109.07 20.28 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 175.288 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.455 HG22 ' HB ' ' A' ' 54' ' ' VAL . 75.1 t -103.15 128.8 55.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.948 0.404 . . . . 0.0 110.669 -174.194 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 22' ' ' GLU . 7.2 m -123.94 108.69 12.68 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.523 -177.321 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -89.54 16.54 7.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.402 0.62 . . . . 0.0 110.315 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.508 ' CG ' HG23 ' A' ' 24' ' ' ILE . 6.0 tp10 -83.87 159.38 21.35 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.419 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TYR . . . . . 0.438 ' N ' ' HG3' ' A' ' 22' ' ' GLU . 23.8 m-85 -119.69 81.48 1.73 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.28 0.562 . . . . 0.0 110.007 176.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.508 HG23 ' CG ' ' A' ' 22' ' ' GLU . 18.4 pt -107.63 168.53 3.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.827 0.822 . . . . 0.0 111.744 -176.486 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.55 123.17 34.0 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 114.306 -1.315 . . . . 0.0 109.063 176.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -56.29 -70.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.205 0 O-C-N 123.276 0.36 . . . . 0.0 110.483 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt 59.28 -85.42 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 O-C-N 123.791 0.682 . . . . 0.0 111.991 176.526 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 168.75 42.08 0.03 OUTLIER Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.0 -7.91 84.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.255 -174.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.453 HG13 HG12 ' A' ' 37' ' ' VAL . 4.1 mp -79.83 119.49 29.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 176.056 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.09 127.8 33.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.106 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.463 ' HE3' ' OD1' ' A' ' 70' ' ' ASN . 0.0 OUTLIER -74.64 -10.2 59.31 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -172.749 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -97.81 -35.98 10.35 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.749 0.309 . . . . 0.0 111.34 -176.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.6 p -105.53 -36.42 7.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.342 -0.39 . . . . 0.0 112.013 -178.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.93 15.41 59.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.634 -175.102 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 49.2 mm -95.44 138.35 21.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.453 HG12 HG13 ' A' ' 30' ' ' ILE . 15.3 m -72.49 116.21 14.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.371 0.605 . . . . 0.0 110.762 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -88.75 -9.41 51.98 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.382 -178.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -90.29 151.16 21.62 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.431 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 10.5 t70 -76.9 134.69 38.89 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.316 -171.837 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 7.6 p -167.32 173.38 8.94 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 43' ' ' ILE . 5.3 pt-20 -62.08 -36.26 81.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 -178.777 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.436 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 15.1 pt -105.38 43.54 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 122.053 0.93 . . . . 0.0 110.144 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.431 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 86.4 tttt -67.47 121.53 16.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.778 -179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.71 -2.48 29.0 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.886 -178.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -79.54 155.7 28.09 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.937 0.398 . . . . 0.0 111.052 177.419 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.1 p -102.8 136.49 42.52 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.326 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.1 m -98.11 -1.36 10.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.905 0.383 . . . . 0.0 110.957 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.31 95.03 0.29 Allowed 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.802 -176.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.08 17.6 39.89 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.196 175.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.5 mmt180 -109.64 150.83 27.66 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.562 HD13 HG23 ' A' ' 121' ' ' VAL . 65.8 mt -96.19 105.26 16.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 177.188 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.593 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -80.61 116.6 20.72 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.373 0.606 . . . . 0.0 111.332 -174.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.455 ' HB ' HG22 ' A' ' 19' ' ' VAL . 61.6 t -114.13 106.94 21.66 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.657 175.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -134.86 148.32 66.56 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.126 176.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.27 -41.5 21.14 Favored 'Trans proline' 0 C--O 1.236 0.388 0 C-N-CA 122.53 2.153 . . . . 0.0 112.319 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 C-N-CA 121.114 -0.565 . . . . 0.0 111.936 -179.236 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.1 m-85 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.45 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 17.4 m -52.3 -36.9 21.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -175.198 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.45 HD22 ' HB2' ' A' ' 94' ' ' ALA . 5.3 mp -68.85 -34.87 76.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.001 0.429 . . . . 0.0 111.075 -178.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.499 HD13 ' HA ' ' A' ' 97' ' ' ALA . 66.1 tp -70.63 -40.06 73.32 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.044 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.463 ' OD1' ' HE3' ' A' ' 32' ' ' LYS . 12.7 t-20 -56.2 -41.88 76.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.776 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.45 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 80.6 mt -62.59 -41.47 98.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.34 -179.33 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.563 ' NH1' ' HB3' ' A' ' 98' ' ' GLU . 15.2 ttp180 -74.2 -25.06 59.46 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.856 -0.337 . . . . 0.0 111.09 -174.323 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -73.72 -26.09 60.53 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.825 -0.35 . . . . 0.0 111.282 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -92.56 -27.95 17.05 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.898 176.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.87 22.79 7.43 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.476 -0.869 . . . . 0.0 112.522 177.102 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.434 HG21 ' HA ' ' A' ' 32' ' ' LYS . 30.4 m -114.27 21.05 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.122 0.487 . . . . 0.0 110.882 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -92.02 155.52 43.01 Favored Pre-proline 0 C--O 1.237 0.431 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.428 -177.143 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.593 ' HB3' HD13 ' A' ' 53' ' ' LEU . 15.7 Cg_exo -69.69 158.9 55.43 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.997 2.465 . . . . 0.0 112.021 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -69.76 -44.69 69.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.057 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.98 164.24 25.78 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.204 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 37.5 mm -127.0 124.64 65.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.428 -178.824 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.1 mm -119.19 116.27 50.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.331 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' HG12 ' A' ' 104' ' ' VAL . 13.6 m120 -126.26 157.38 38.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.692 0.282 . . . . 0.0 111.031 -175.028 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 23.5 ttmm -68.89 -52.07 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 173.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.1 tptm -155.6 109.99 2.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.172 171.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.7 t -91.62 167.03 12.5 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.314 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -83.56 152.08 25.05 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.934 0.397 . . . . 0.0 110.854 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 m -58.87 -34.02 71.14 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.148 -178.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.424 HD12 ' N ' ' A' ' 89' ' ' ILE . 3.0 mp -61.22 -39.99 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.098 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 50.0 mt -77.15 -42.4 31.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.413 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.574 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -55.59 -48.76 74.32 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.586 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -71.79 -39.06 67.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.524 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.95 -41.52 99.66 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.601 -178.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.45 ' HB2' HD22 ' A' ' 68' ' ' LEU . . . -74.56 -31.16 62.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.555 0.217 . . . . 0.0 110.809 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -61.28 -38.54 87.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.01 0.433 . . . . 0.0 110.112 175.39 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 84.2 mtp -66.22 -42.45 88.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.685 177.201 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.499 ' HA ' HD13 ' A' ' 69' ' ' LEU . . . -80.94 -4.29 54.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.964 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.563 ' HB3' ' NH1' ' A' ' 72' ' ' ARG . 37.7 tt0 60.24 37.75 20.34 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.85 0.833 . . . . 0.0 109.852 -177.317 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.447 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 60.1 mt -105.11 89.18 2.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.931 175.376 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.586 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 12.1 Cg_endo -53.47 117.07 3.42 Favored 'Trans proline' 0 C--O 1.234 0.302 0 C-N-CA 123.17 2.58 . . . . 0.0 113.845 -170.853 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.707 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pp -117.56 148.11 42.19 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.504 171.183 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.0 m -136.34 163.92 32.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.083 -175.533 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.653 ' HB2' ' HB3' ' A' ' 6' ' ' ARG . 43.8 mt-10 -97.08 113.91 25.51 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.875 175.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 7.2 p -110.74 112.7 41.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.653 0.74 . . . . 0.0 109.86 174.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 105' ' ' ARG . 52.4 mtt180 -95.81 28.38 3.1 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.992 -173.817 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 22.8 t70 -118.07 121.33 40.31 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.625 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -72.6 -33.86 66.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.968 -178.594 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.416 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 49.5 mmtm -60.6 -35.88 77.2 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 -176.305 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.502 ' O ' HG12 ' A' ' 113' ' ' VAL . 44.7 t80 -51.8 -46.04 64.09 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.857 177.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -70.18 -22.63 62.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.195 0.522 . . . . 0.0 111.17 -174.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.481 ' O ' ' HE2' ' A' ' 114' ' ' LYS . 11.5 mm-40 -88.51 -28.19 20.95 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.191 176.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.61 -44.31 64.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.803 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.9 p -91.93 133.18 34.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.172 0.51 . . . . 0.0 111.151 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.481 ' HE2' ' O ' ' A' ' 111' ' ' GLU . 74.7 mmtt -128.93 160.87 31.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 10.8 t -63.35 125.44 24.17 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.162 0.506 . . . . 0.0 110.37 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.35 -16.36 11.67 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.855 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -91.24 175.28 6.99 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.42 HH11 ' HD3' ' A' ' 118' ' ' ARG . 1.3 tmm_? -116.24 129.76 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.135 0.493 . . . . 0.0 111.352 -174.18 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 86.6 t -116.41 140.41 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.209 178.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.563 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 48.6 t -104.94 108.21 24.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 172.283 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.562 HG23 HD13 ' A' ' 52' ' ' ILE . 96.1 t -92.77 119.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.148 0.499 . . . . 0.0 111.264 -175.227 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ASN . . . . . 0.527 ' HA ' ' HG2' ' A' ' 12' ' ' ARG . 55.9 t-20 -115.74 93.81 4.42 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -94.36 -0.61 54.78 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 110.378 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -80.72 -40.25 25.63 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.399 177.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -98.75 -28.07 13.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.849 176.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.43 59.66 1.14 Allowed Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.27 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -148.59 146.33 28.2 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.917 0.389 . . . . 0.0 110.451 -174.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.51 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 54.8 t -119.71 108.85 24.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.761 177.136 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.707 ' HG2' ' HE3' ' A' ' 2' ' ' LYS . 39.1 mt-10 -99.81 107.9 20.05 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.961 0.41 . . . . 0.0 110.251 179.434 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 47.6 tp -93.35 132.66 37.37 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.209 178.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.8 mt -119.22 114.98 46.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.575 0.702 . . . . 0.0 109.5 175.429 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--N 1.312 -1.052 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.889 179.664 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 45.0 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 121.997 0.903 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mtmm -108.21 122.69 47.44 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.164 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -89.64 136.18 33.18 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 176.266 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.63 114.99 26.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.678 -176.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HB ' ' A' ' 104' ' ' VAL . 11.7 m -120.33 163.08 18.37 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.38 178.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 45.3 ttt180 -93.74 124.83 38.01 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 120.344 -0.542 . . . . 0.0 109.854 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.483 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.71 137.95 34.05 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.69 -172.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 4.4 mp -103.18 -48.55 10.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 174.122 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.3 p -102.1 169.57 8.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.378 174.003 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.427 ' HB3' ' OD1' ' A' ' 124' ' ' ASP . 71.8 mtt85 -125.44 -174.75 3.14 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.928 0.394 . . . . 0.0 111.761 -176.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.35 175.85 23.39 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.4 149.38 32.63 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.31 156.19 35.06 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.975 0.417 . . . . 0.0 111.099 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -124.28 132.82 53.59 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.694 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.09 175.33 39.43 Favored Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.051 177.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -72.3 133.21 44.89 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 176.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -79.77 121.54 25.49 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.017 0.436 . . . . 0.0 110.808 -177.183 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.986 HD21 HG21 ' A' ' 43' ' ' ILE . 7.3 tt -113.23 113.59 25.53 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.495 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 53.1 t -102.99 109.94 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.105 0.479 . . . . 0.0 110.759 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.745 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 20.9 m -87.37 116.75 25.68 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.348 176.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.901 ' HD3' ' HG3' ' A' ' 42' ' ' GLU . 8.8 mptt -73.37 -25.77 60.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.377 -176.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.482 ' HG3' ' HB3' ' A' ' 41' ' ' CYS . 22.0 mm-40 -91.36 152.97 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -91.14 90.88 8.0 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.956 178.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 pt -86.03 145.39 7.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.135 -178.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.442 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 7.2 m -91.75 150.19 21.23 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.552 -173.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.432 ' CZ ' ' HZ ' ' A' ' 55' ' ' PHE . 74.9 m-85 -86.11 15.17 5.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.905 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.442 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 33.7 mt -73.53 -8.45 55.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.179 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 126.48 70.5 0.18 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.245 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -106.74 -25.63 6.16 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.786 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 37' ' ' VAL . 4.2 mp -92.21 133.74 32.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 -177.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 13.2 t70 -69.68 135.11 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.996 0.426 . . . . 0.0 110.293 175.252 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 49.9 pttt -73.38 -14.02 61.2 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -171.651 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -106.65 -44.53 4.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.996 0.427 . . . . 0.0 111.771 -174.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.466 ' HB ' HG12 ' A' ' 36' ' ' ILE . 34.6 p -97.48 -26.88 14.67 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.11 -174.195 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.64 8.5 84.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.559 -175.509 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.466 HG12 ' HB ' ' A' ' 34' ' ' THR . 34.0 mm -82.56 133.48 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.367 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.49 HG12 HG13 ' A' ' 30' ' ' ILE . 5.5 m -77.39 131.73 34.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.312 0.577 . . . . 0.0 110.974 176.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.449 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 75.1 mmtt -95.39 -14.92 23.41 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.691 177.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -129.01 85.12 2.29 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.674 -176.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.577 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.1 t70 -148.14 -162.79 1.63 Allowed 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.597 -178.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.482 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 44.9 t -155.3 -32.47 0.1 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.553 -175.746 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.901 ' HG3' ' HD3' ' A' ' 21' ' ' LYS . 17.6 mm-40 -109.53 -47.26 3.4 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -177.372 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.986 HG21 HD21 ' A' ' 18' ' ' LEU . 40.8 pt -101.28 10.08 8.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.351 0.596 . . . . 0.0 109.919 -177.558 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.577 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 79.0 tttt -54.57 114.0 1.51 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.604 177.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 114.18 -14.19 21.24 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.374 -176.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -103.71 169.24 8.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.748 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.408 ' HB2' HD13 ' A' ' 36' ' ' ILE . 40.8 t -109.62 152.28 25.75 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.553 -179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.8 m -103.9 3.54 10.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.848 177.426 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.0 85.48 1.0 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.394 -176.162 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 116.18 8.26 13.42 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.516 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -114.46 158.83 21.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.0 mt -93.11 117.5 36.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 37.0 tp -90.32 111.16 22.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.579 -173.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 19' ' ' VAL . 61.3 t -119.0 105.95 18.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.413 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.745 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 19.1 p90 -137.48 163.61 47.4 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.397 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.603 ' HD2' ' HB2' ' A' ' 55' ' ' PHE . 10.0 Cg_endo -52.56 -54.92 4.33 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.858 2.372 . . . . 0.0 112.707 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.202 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.012 -179.818 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 . . . . . 0 C--O 1.232 0.158 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.543 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 93.4 t -58.13 -45.34 88.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.895 0.379 . . . . 0.0 110.164 176.38 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -61.7 -38.94 89.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.593 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 54.4 tp -66.86 -40.29 87.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.878 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -69.55 -40.94 76.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.96 0.41 . . . . 0.0 110.492 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.543 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 91.6 mt -62.63 -37.44 86.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.239 176.434 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -63.87 -37.56 87.86 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.216 -178.178 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -69.1 -29.47 67.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.833 0.349 . . . . 0.0 110.749 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.411 ' HB3' HG22 ' A' ' 76' ' ' VAL . 62.1 t30 -89.41 -14.37 35.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.34 0.59 . . . . 0.0 110.055 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 85.92 10.45 75.49 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.531 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.411 HG22 ' HB3' ' A' ' 74' ' ' ASN . 27.3 m -100.74 14.01 5.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -81.4 154.5 71.67 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.35 176.08 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.16 159.14 54.16 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.334 2.023 . . . . 0.0 111.775 176.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -71.33 -31.36 67.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.907 0.384 . . . . 0.0 110.717 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -168.25 164.12 13.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.217 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 66.4 mt -137.33 118.62 17.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.257 -0.429 . . . . 0.0 109.978 179.375 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.4 HG23 ' CG2' ' A' ' 102' ' ' VAL . 10.1 mm -114.9 118.09 57.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 177.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -119.01 158.28 26.1 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.506 -174.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.576 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 1.5 tmtp? -83.96 -45.19 13.41 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 174.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -141.81 113.07 7.55 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.069 -0.969 . . . . 0.0 108.878 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.6 t -123.57 -176.92 3.57 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.582 -176.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.454 ' H ' HD12 ' A' ' 90' ' ' ILE . 77.9 mt-10 -115.86 150.7 36.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.265 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.8 m -61.92 -37.89 86.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.677 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 51.0 mt -61.08 -39.22 81.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.968 0.414 . . . . 0.0 110.793 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.454 HD12 ' H ' ' A' ' 87' ' ' GLU . 60.4 mt -62.86 -42.13 95.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.055 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.583 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -61.72 -38.4 87.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.89 178.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 88' ' ' THR . 58.3 t -63.87 -43.49 97.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.536 177.22 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.72 -40.11 97.18 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.13 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.29 -32.67 74.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.748 0.308 . . . . 0.0 111.055 177.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.01 -25.03 67.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 178.004 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.417 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 45.2 mtt -79.37 -43.87 22.62 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.708 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.5 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -83.49 -0.74 51.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.134 -174.765 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 64.1 38.53 8.34 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.129 0.49 . . . . 0.0 110.769 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.47 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.0 mt -109.41 90.07 8.02 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 17.7 Cg_endo -58.16 125.01 17.22 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.899 2.399 . . . . 0.0 112.68 -178.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.583 HD21 ' HA ' ' A' ' 91' ' ' ALA . 2.2 pp -127.35 147.52 50.26 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.17 0.509 . . . . 0.0 111.16 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 7' ' ' ALA . 27.4 m -134.56 156.2 39.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.05 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.451 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 42.9 mt-10 -95.92 119.46 34.46 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.583 176.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.576 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 4.5 p -114.45 116.42 52.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.257 0.551 . . . . 0.0 110.176 176.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -91.53 -29.34 17.02 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.783 -177.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -69.39 117.88 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -177.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -68.64 -21.28 64.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.762 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 31.4 mttm -62.16 -19.97 63.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.442 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 113' ' ' VAL . 46.9 t80 -65.52 -51.97 56.03 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 173.197 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -69.7 -26.49 64.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.491 0.662 . . . . 0.0 110.412 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.408 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 39.1 tt0 -70.38 -37.35 74.52 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.543 176.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.45 -54.64 5.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.1 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 109' ' ' PHE . 9.9 p -69.96 138.9 21.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.254 0.549 . . . . 0.0 110.601 -177.445 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 55.9 mttp -135.04 151.43 50.78 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.956 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.553 HG23 ' HA ' ' A' ' 18' ' ' LEU . 16.2 m -58.16 113.33 1.87 Allowed 'General case' 0 C--N 1.324 -0.519 0 O-C-N 123.353 0.408 . . . . 0.0 110.397 178.047 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 106.18 31.73 3.99 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.949 -179.187 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -132.55 173.72 11.02 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 171.258 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB ' ' A' ' 131' ' ' ILE . 10.1 ttm180 -97.52 122.51 40.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.022 0.439 . . . . 0.0 111.797 -172.211 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.4 t -117.83 124.18 72.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.065 174.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.4 t -107.17 105.05 18.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 174.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.9 p -92.86 132.31 37.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.555 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -127.23 93.51 3.76 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 176.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.05 -13.34 56.0 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.607 -171.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.427 ' OD1' ' HB3' ' A' ' 10' ' ' ARG . 48.3 m-20 -61.57 -34.77 76.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.909 0.385 . . . . 0.0 109.977 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.412 ' HB3' ' CE1' ' A' ' 127' ' ' TYR . 32.1 tt0 -106.5 -27.74 10.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.1 178.513 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 93.07 70.13 1.13 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.969 175.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.412 ' CE1' ' HB3' ' A' ' 125' ' ' GLU . 46.1 p90 -170.31 162.13 8.42 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.21 179.147 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.451 HG21 ' CE1' ' A' ' 109' ' ' PHE . 15.0 m -124.61 132.11 71.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.507 178.212 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -105.42 117.77 34.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.743 179.156 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.8 tp -94.2 125.4 38.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 177.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.422 ' HB ' ' HD2' ' A' ' 118' ' ' ARG . 31.4 mm -108.13 111.45 35.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--N 1.312 -1.034 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.436 -173.627 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.855 0.36 . . . . 0.0 111.162 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -121.5 111.67 17.55 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.589 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 90.1 m-85 -92.59 149.46 21.34 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.725 0.297 . . . . 0.0 110.77 -177.219 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 117.66 34.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.809 176.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.553 ' HB3' HG22 ' A' ' 104' ' ' VAL . 4.5 p -120.35 169.14 10.57 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.166 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 44.2 ttp180 -94.69 128.38 41.33 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.596 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.12 127.62 41.32 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.979 0.419 . . . . 0.0 111.458 -174.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.4 mm -101.31 -55.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.549 177.044 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.679 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -95.42 173.68 7.4 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.553 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.417 ' H ' HG22 ' A' ' 9' ' ' THR . 25.3 mmt180 -121.25 168.18 11.9 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.402 -175.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.68 -174.41 16.54 Favored Glycine 0 N--CA 1.452 -0.256 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.329 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.77 154.7 46.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 117.618 0.709 . . . . 0.0 111.147 176.526 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.465 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -138.61 139.51 38.59 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.959 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 123.92 30.82 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.77 -179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.95 -166.34 37.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 119.585 -1.293 . . . . 0.0 113.39 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -73.19 135.16 44.58 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 122.598 0.359 . . . . 0.0 110.797 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.72 124.95 32.1 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.929 0.395 . . . . 0.0 111.046 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.572 ' HA ' HG23 ' A' ' 115' ' ' THR . 6.5 tt -108.78 110.71 22.16 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.035 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.669 ' HA ' ' HB ' ' A' ' 54' ' ' VAL . 47.0 t -104.58 125.7 59.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.269 0.557 . . . . 0.0 112.425 -168.538 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.461 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 17.5 p -137.22 144.98 43.1 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.614 174.535 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.523 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 15.8 ptpt -128.89 20.14 5.98 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.193 0.52 . . . . 0.0 111.031 175.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -80.57 125.3 29.82 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.192 173.253 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -77.83 109.46 11.87 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.212 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.75 ' HB ' ' HZ ' ' A' ' 55' ' ' PHE . 43.8 mt -124.45 -7.62 6.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 110.256 -174.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.0 p 48.94 23.25 0.67 Allowed 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 113.596 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.455 ' CD1' HD13 ' A' ' 90' ' ' ILE . 36.9 m-85 64.51 18.34 11.31 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 178.573 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.2 27.26 0.81 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.176 0.512 . . . . 0.0 109.878 173.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' HA2' ' HG2' ' A' ' 39' ' ' GLU . . . -94.01 -128.39 5.1 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.488 -176.451 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 177.39 93.38 0.09 OUTLIER Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.416 -177.143 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.435 HG12 HG22 ' A' ' 37' ' ' VAL . 54.5 mt -92.82 126.67 45.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 170.212 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -62.92 124.31 20.75 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.695 0.283 . . . . 0.0 110.701 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.549 ' HA ' HD23 ' A' ' 71' ' ' LEU . 20.7 pttp -85.08 3.97 36.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -173.368 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -101.47 -36.99 8.62 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.94 0.4 . . . . 0.0 110.818 177.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.2 p -113.22 -19.1 11.93 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.667 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.13 25.01 62.61 Favored Glycine 0 N--CA 1.453 -0.176 0 C-N-CA 120.989 -0.624 . . . . 0.0 111.963 -177.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.3 mm -102.3 127.99 55.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.706 0.289 . . . . 0.0 110.416 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 30' ' ' ILE . 21.8 t -67.0 111.46 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.854 0.359 . . . . 0.0 110.198 177.607 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -87.24 -27.96 22.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.467 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' HA2' ' A' ' 28' ' ' GLY . 7.7 tp10 -67.76 129.78 40.97 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.492 178.068 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -74.09 133.84 42.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.293 0.568 . . . . 0.0 110.811 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 3.5 p -160.78 35.17 0.15 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.18 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 32.7 mm-40 72.38 -51.64 0.7 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.77 -174.546 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -88.55 42.36 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.308 0.575 . . . . 0.0 110.896 178.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.3 tttm -73.22 127.39 32.49 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.27 -2.2 29.66 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.166 -176.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -77.37 150.6 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.228 0.537 . . . . 0.0 111.939 178.252 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 36.0 t -101.36 131.93 47.17 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.782 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.498 ' HB ' ' HG3' ' A' ' 78' ' ' PRO . 31.2 m -105.53 4.72 10.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.964 0.411 . . . . 0.0 110.877 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.76 92.17 1.99 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.55 0.69 . . . . 0.0 111.242 -174.179 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 105.65 12.07 27.3 Favored Glycine 0 C--N 1.315 -0.595 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.635 176.245 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -110.46 175.3 5.48 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 54.1 mt -110.19 121.24 62.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.562 ' HB3' HG22 ' A' ' 81' ' ' ILE . 54.4 tp -91.46 120.26 32.13 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.746 -174.411 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.669 ' HB ' ' HA ' ' A' ' 19' ' ' VAL . 67.5 t -101.99 107.97 22.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.785 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 51.4 t80 -133.99 143.3 46.77 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -173.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.523 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 23.8 Cg_endo -62.95 -36.92 57.31 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 121.955 1.77 . . . . 0.0 111.505 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.025 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.287 176.932 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.605 0.241 . . . . 0.0 111.63 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.482 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 26.8 m -67.15 -31.99 55.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.025 -178.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.42 -36.78 77.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.932 0.396 . . . . 0.0 110.357 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.441 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.4 tp -66.15 -39.9 90.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.764 176.625 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -60.05 -48.61 81.0 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.587 176.687 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.549 HD23 ' HA ' ' A' ' 32' ' ' LYS . 96.3 mt -57.45 -47.62 81.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.964 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.41 ' HB2' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -66.07 -37.39 85.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -177.393 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.8 mmtt -61.4 -30.2 70.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.5 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.574 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.6 t-20 -89.64 -22.78 22.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.195 0.522 . . . . 0.0 109.877 178.552 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.27 16.49 55.5 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.385 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.667 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 32.2 m -106.94 13.81 8.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.084 0.469 . . . . 0.0 110.821 -176.683 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.88 49.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.935 -179.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.498 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 13.1 Cg_exo -68.33 143.12 57.1 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.195 1.93 . . . . 0.0 110.185 170.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.465 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 94.8 mttt -61.58 -33.92 74.71 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.165 0.507 . . . . 0.0 110.618 -179.335 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.62 155.25 34.36 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.438 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.562 HG22 ' HB3' ' A' ' 53' ' ' LEU . 16.1 pt -124.65 114.76 42.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.082 175.308 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.752 HG23 HG23 ' A' ' 102' ' ' VAL . 4.4 mm -102.86 116.78 47.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.785 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 89.8 m-20 -115.1 175.96 5.27 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.822 0.344 . . . . 0.0 111.154 -173.476 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -101.37 -40.81 6.92 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 171.368 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 85' ' ' LYS . 68.4 mmtt -125.15 114.41 18.98 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.502 177.449 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.1 t -81.15 154.99 26.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.042 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.29 142.38 51.55 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.511 ' O ' HG23 ' A' ' 92' ' ' VAL . 18.1 m -56.26 -50.02 72.56 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 123.536 0.522 . . . . 0.0 112.033 -174.483 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 72.1 mt -65.24 -44.96 95.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 121.054 0.454 . . . . 0.0 110.702 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.455 HD13 ' CD1' ' A' ' 26' ' ' PHE . 63.9 mt -63.98 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.693 -179.265 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.4 -41.58 94.18 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 88' ' ' THR . 98.9 t -61.86 -44.56 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.54 178.222 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.6 -44.76 97.08 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.358 179.39 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.421 ' HB3' HD23 ' A' ' 101' ' ' LEU . . . -67.02 -30.96 71.19 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.594 0.235 . . . . 0.0 111.131 179.296 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.72 -38.11 88.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.541 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.435 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 61.0 mtt -64.26 -45.92 86.01 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.516 0.674 . . . . 0.0 109.91 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -80.14 -1.65 41.19 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 114.992 -1.004 . . . . 0.0 111.697 -175.535 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 58.9 43.17 18.45 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 121.25 0.548 . . . . 0.0 110.569 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.2 mm -104.18 91.08 3.51 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.751 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.679 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 9.3 Cg_endo -49.96 100.41 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.558 2.838 . . . . 0.0 112.667 -176.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 94' ' ' ALA . 1.5 pp -102.43 137.0 41.25 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.235 0.54 . . . . 0.0 109.994 179.653 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.752 HG23 HG23 ' A' ' 82' ' ' ILE . 35.1 m -135.17 159.23 41.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 8.3 pt-20 -121.06 135.57 55.17 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.365 0.602 . . . . 0.0 111.838 -178.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.571 HG11 ' HB2' ' A' ' 109' ' ' PHE . 32.4 t -115.9 105.04 17.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 170.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 105' ' ' ARG . 14.1 ptt180 -84.16 35.85 0.55 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.95 -170.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -138.55 145.12 40.28 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.679 176.757 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -71.22 -23.93 62.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.171 -176.732 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -60.28 -29.24 68.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.582 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.571 ' HB2' HG11 ' A' ' 104' ' ' VAL . 84.6 t80 -61.25 -46.46 90.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.985 0.422 . . . . 0.0 110.312 177.416 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -71.97 -22.61 61.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.243 -175.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.8 mm-40 -79.04 -36.62 40.71 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.346 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.67 -42.44 22.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.87 -176.351 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.0 p -79.86 138.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.014 0.435 . . . . 0.0 110.345 -177.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.3 mttp -122.77 151.61 41.45 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.045 -177.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.572 HG23 ' HA ' ' A' ' 18' ' ' LEU . 33.1 m -71.56 95.76 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.101 0.476 . . . . 0.0 109.921 176.643 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.2 1.95 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.268 -177.429 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -77.78 166.98 22.27 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.4 177.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.748 HH21 HG13 ' A' ' 131' ' ' ILE . 2.2 tmm_? -107.67 122.87 47.59 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.372 0.606 . . . . 0.0 109.863 -176.769 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.412 HG23 ' HB2' ' A' ' 17' ' ' ALA . 91.3 t -119.57 139.33 47.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.262 -175.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.9 t -117.05 111.82 36.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.319 171.044 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.525 HG21 HD11 ' A' ' 82' ' ' ILE . 55.1 t -107.56 117.53 53.45 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.285 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ASN . . . . . 0.744 HD21 ' HB2' ' A' ' 124' ' ' ASP . 9.8 t30 -109.97 118.02 35.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 177.013 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -101.15 8.01 42.91 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.37 -174.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.744 ' HB2' HD21 ' A' ' 122' ' ' ASN . 53.5 m-20 -64.99 -41.43 95.43 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 176.116 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -117.9 -33.43 4.48 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 173.436 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 108.93 91.84 2.19 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.195 172.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.404 ' HE1' ' HB2' ' A' ' 129' ' ' GLU . 25.6 p90 -159.66 153.35 22.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.949 0.404 . . . . 0.0 110.322 174.211 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.589 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 84.9 t -116.15 111.21 34.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.831 178.798 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HB2' ' HE1' ' A' ' 127' ' ' TYR . 26.3 tt0 -92.62 108.37 19.92 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.248 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 59.2 tp -94.6 114.07 25.98 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.908 -176.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.748 HG13 HH21 ' A' ' 118' ' ' ARG . 33.5 mm -111.58 116.95 53.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.364 174.346 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.876 -179.299 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.234 0.238 0 CA-C-O 120.963 0.411 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -126.98 140.78 52.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.937 -174.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -133.59 149.09 51.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.437 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.79 131.72 45.59 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.649 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.0 m -122.09 169.09 11.2 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.321 176.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -96.2 134.59 39.1 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 174.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.23 96.6 4.59 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.922 0.391 . . . . 0.0 111.473 -174.762 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.494 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 43.8 mm -82.81 -49.37 16.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 174.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.581 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -109.22 176.19 5.18 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 172.604 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.471 ' H ' HG22 ' A' ' 9' ' ' THR . 63.9 mtt180 -126.23 178.13 6.0 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.48 -0.193 . . . . 0.0 110.48 -179.11 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 124' ' ' ASP . . . 97.19 -162.39 21.79 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -174.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -156.41 148.01 22.68 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.695 0.283 . . . . 0.0 110.496 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.407 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -149.66 151.56 33.94 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -137.82 127.77 25.65 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.958 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.64 172.14 39.47 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.324 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -70.38 128.87 37.69 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.005 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.539 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.92 141.69 34.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.267 0.556 . . . . 0.0 111.712 -175.793 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.5 tt -121.24 114.09 20.88 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 177.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.0 t -102.79 110.84 30.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.196 0.522 . . . . 0.0 111.674 -173.627 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 20' ' ' THR . 9.7 t -152.36 95.63 2.06 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 172.346 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 0.1 OUTLIER -67.77 -72.2 0.18 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.154 -174.257 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.832 ' HG2' ' HB3' ' A' ' 41' ' ' CYS . 0.3 OUTLIER 51.15 -163.52 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 O-C-N 123.469 0.48 . . . . 0.0 111.794 178.368 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 13.3 p90 -158.59 44.49 0.29 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.443 0.639 . . . . 0.0 110.045 176.522 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.5 pt -73.29 177.84 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.721 -177.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.1 t -88.22 128.52 35.46 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.338 -178.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -82.91 91.19 7.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -124.97 -77.49 0.59 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.033 177.002 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.45 59.17 0.41 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.6 15.65 45.26 Favored Glycine 0 C--O 1.226 -0.387 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 -177.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.443 HD13 HG21 ' A' ' 48' ' ' VAL . 58.2 mt -134.31 134.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 15.2 t70 -66.26 135.59 54.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.679 0.276 . . . . 0.0 110.357 178.124 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -81.21 -7.45 59.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -173.012 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -117.65 -30.43 5.47 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.619 HG23 HG12 ' A' ' 36' ' ' ILE . 7.8 t -123.16 -4.88 8.41 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 120.104 -0.638 . . . . 0.0 112.519 179.247 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 70.35 27.95 72.0 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.87 -0.681 . . . . 0.0 113.446 176.202 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.619 HG12 HG23 ' A' ' 34' ' ' THR . 42.5 mm -87.97 129.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 176.447 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.89 128.69 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.019 0.438 . . . . 0.0 111.032 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 74.3 mmtt -87.67 -41.43 13.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.669 -179.123 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -89.97 122.19 32.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.87 -172.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.623 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 21.7 t70 -74.35 133.51 42.52 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.359 0.599 . . . . 0.0 111.087 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.832 ' HB3' ' HG2' ' A' ' 22' ' ' GLU . 59.0 m -123.11 -28.09 4.09 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.896 178.354 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 175.52 -62.25 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 pt -114.79 71.02 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.295 179.328 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.623 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 13.3 tmtt? -93.74 140.76 29.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.698 -178.19 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 136.62 -8.1 3.95 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.915 175.221 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -103.89 173.02 6.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.239 0.542 . . . . 0.0 111.58 -175.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 m -93.36 137.7 32.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.653 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.443 HG21 HD13 ' A' ' 30' ' ' ILE . 29.7 m -100.76 2.7 10.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.972 0.415 . . . . 0.0 110.399 174.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.32 94.76 0.17 Allowed 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.861 -177.151 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.482 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 97.43 14.04 42.69 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 114.756 -1.111 . . . . 0.0 112.634 176.297 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 82.4 mtt180 -104.69 164.85 11.46 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.669 0.271 . . . . 0.0 110.574 176.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.505 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.5 mm -95.93 111.46 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.077 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' HG22 ' A' ' 81' ' ' ILE . 18.3 tp -101.7 125.86 48.45 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -173.064 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.4 t -113.75 128.61 70.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.958 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -131.99 145.87 59.27 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.46 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 60.2 Cg_endo -76.83 -50.31 0.1 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.624 2.216 . . . . 0.0 112.002 175.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.424 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.442 -177.83 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 85.7 m-85 . . . . . 0 N--CA 1.471 0.597 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.77 -39.14 76.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.7 mt -65.07 -34.83 79.35 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.716 0.293 . . . . 0.0 110.847 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.3 tp -65.06 -44.71 88.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.405 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -64.26 -41.49 96.91 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.409 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.57 -38.39 86.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.798 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.468 ' CG ' HD11 ' A' ' 99' ' ' ILE . 2.7 tmt_? -72.04 -39.48 69.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.528 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -64.16 -30.94 71.97 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.278 0.561 . . . . 0.0 110.336 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -84.86 -22.91 29.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.0 178.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.49 23.79 38.64 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.747 176.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.05 -0.26 9.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.057 0.456 . . . . 0.0 111.269 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.14 162.59 40.05 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.685 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.03 147.8 88.44 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.229 1.953 . . . . 0.0 111.099 172.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.482 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 80.3 tttt -73.72 -26.15 60.56 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.05 0.452 . . . . 0.0 110.43 -175.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -166.71 150.19 6.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.753 176.232 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.511 HG22 ' HB3' ' A' ' 53' ' ' LEU . 15.7 pt -126.69 123.31 62.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.922 0.391 . . . . 0.0 110.564 178.381 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.694 HG23 HG23 ' A' ' 102' ' ' VAL . 5.4 mm -111.01 120.56 61.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.264 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.553 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 12.4 m120 -129.96 167.15 18.67 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -176.083 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -104.68 -38.83 6.57 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.4 tttp -128.58 103.43 7.1 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.218 174.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.9 t -112.0 156.8 21.57 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 175.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -79.46 145.93 33.01 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -56.87 -34.01 67.42 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.182 0.515 . . . . 0.0 110.986 -176.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 54.8 mt -64.45 -41.15 91.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.822 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.9 mt -71.83 -42.17 69.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.542 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.61 -47.11 80.35 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.304 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.408 ' O ' ' HG3' ' A' ' 96' ' ' MET . 90.1 t -68.22 -42.25 84.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.615 179.112 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.97 99.15 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.352 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.54 -40.06 92.46 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.785 0.326 . . . . 0.0 110.833 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.506 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -63.64 -37.18 86.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.941 179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.408 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 89.4 mtp -68.39 -37.73 80.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.683 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.14 -1.28 57.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.342 -175.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 62.36 47.32 5.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.414 0.626 . . . . 0.0 110.467 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.468 HD11 ' CG ' ' A' ' 72' ' ' ARG . 44.2 mm -107.29 90.55 5.82 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.587 175.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.3 Cg_endo -48.48 96.51 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.421 2.747 . . . . 0.0 113.277 -175.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.494 ' O ' ' HB ' ' A' ' 8' ' ' ILE . 5.8 tt -102.29 126.0 49.16 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.721 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.694 HG23 HG23 ' A' ' 82' ' ' ILE . 11.0 m -127.71 150.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.257 176.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.553 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 6.5 tm-20 -97.8 114.9 27.04 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.507 -177.371 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 82' ' ' ILE . 14.4 m -71.57 134.12 30.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.333 0.587 . . . . 0.0 111.832 -177.123 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.559 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 1.0 OUTLIER -84.94 -33.95 22.57 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.363 -179.548 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -112.5 140.36 47.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.185 -172.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.34 -20.67 62.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.315 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mmtt -57.54 -24.15 54.46 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.905 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.412 ' CD2' HG11 ' A' ' 104' ' ' VAL . 92.7 t80 -60.65 -46.23 91.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.691 0.281 . . . . 0.0 110.508 178.049 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -65.07 -31.46 72.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.544 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -79.69 -30.91 41.23 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.976 -178.065 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.38 -33.01 17.02 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.371 -175.311 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 14.8 p -64.1 134.82 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.083 0.468 . . . . 0.0 110.841 -177.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -116.89 139.57 50.47 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.886 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.4 m -71.34 99.92 2.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.216 175.34 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.73 -31.6 2.92 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.666 179.343 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -85.47 161.27 19.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.861 0.362 . . . . 0.0 111.616 -177.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.864 HH21 HG13 ' A' ' 131' ' ' ILE . 18.0 ttp180 -89.17 127.37 35.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.248 0.547 . . . . 0.0 111.61 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.539 HG23 ' HB2' ' A' ' 17' ' ' ALA . 96.2 t -108.13 120.91 60.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.742 175.302 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.84 101.63 12.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 176.633 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 3.2 p -102.18 114.88 42.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 121.381 0.61 . . . . 0.0 110.907 -178.031 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -101.94 93.64 5.38 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 175.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.29 -26.68 62.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.374 -173.147 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.501 ' HB2' ' H ' ' A' ' 11' ' ' GLY . 25.8 t70 -63.38 -22.6 66.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.234 -177.53 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -120.11 -1.44 10.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.719 0.295 . . . . 0.0 110.708 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.18 62.66 5.42 Favored Glycine 0 C--N 1.332 0.356 0 CA-C-N 116.053 -0.521 . . . . 0.0 112.376 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -152.13 141.8 21.84 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.37 -0.488 . . . . 0.0 110.308 -177.445 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.5 m -122.97 136.28 60.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.199 0.524 . . . . 0.0 111.441 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -120.73 114.66 21.98 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.379 177.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 42.0 tp -90.49 125.18 35.51 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.864 HG13 HH21 ' A' ' 118' ' ' ARG . 19.3 mm -101.36 111.61 31.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.309 -1.181 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.441 -175.828 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.413 ' HB3' ' HE2' ' A' ' 2' ' ' LYS . 14.3 ptpt -145.18 148.87 34.04 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.815 0.341 . . . . 0.0 111.215 -177.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -136.44 152.95 51.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.734 -0.667 . . . . 0.0 109.977 179.124 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.79 114.09 25.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.209 175.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.725 ' SG ' HG12 ' A' ' 104' ' ' VAL . 83.9 m -120.24 176.93 5.22 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.215 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.9 tpm_? -94.73 119.84 34.0 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.119 -172.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 102' ' ' VAL . . . -86.69 142.55 28.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.174 -179.786 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.2 mp -105.97 -54.65 6.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.3 p -98.4 161.31 13.75 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 170.247 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.573 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 46.0 mtm180 -123.73 -175.85 3.32 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 119.574 -0.85 . . . . 0.0 112.681 -174.674 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.85 -164.89 14.07 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 -169.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.5 ttp180 -148.76 143.47 26.41 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 117.542 0.671 . . . . 0.0 109.789 177.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.567 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -154.52 152.15 29.74 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.716 0.293 . . . . 0.0 110.96 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.414 ' O ' ' HD2' ' A' ' 79' ' ' LYS . 0.1 OUTLIER -147.81 161.21 41.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.494 178.84 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 147.85 -160.54 28.35 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.155 -1.022 . . . . 0.0 112.453 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -64.4 124.09 20.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.986 0.422 . . . . 0.0 110.444 177.341 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.84 117.22 21.3 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.254 179.37 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.505 HD12 HG23 ' A' ' 115' ' ' THR . 13.4 tp -96.54 108.82 21.46 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.538 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.42 112.73 40.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.319 0.58 . . . . 0.0 110.96 -174.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -116.45 101.15 8.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.308 176.302 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -73.59 -12.09 60.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.401 -175.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -71.84 130.12 40.29 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.051 0.453 . . . . 0.0 110.154 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -78.53 69.92 4.8 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.407 0.622 . . . . 0.0 111.338 -177.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -82.14 152.63 4.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.226 176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -116.58 174.73 5.91 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.326 -173.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.493 ' O ' ' HB3' ' A' ' 27' ' ' LEU . 85.3 m-85 -82.97 -163.34 0.71 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.89 -0.596 . . . . 0.0 109.987 175.623 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.5 ' HG ' ' O ' ' A' ' 27' ' ' LEU . 64.9 tp 72.24 14.91 5.46 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.996 0.903 . . . . 0.0 109.831 -176.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.82 44.8 0.12 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.817 177.042 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.63 -72.51 1.21 Allowed Glycine 0 N--CA 1.452 -0.285 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 174.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.0 mp -85.84 133.31 29.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 170.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.527 ' HB2' ' HG2' ' A' ' 38' ' ' LYS . 29.0 t70 -72.74 146.08 46.66 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.309 0.576 . . . . 0.0 111.475 -175.618 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HG2' ' HG3' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -82.94 -11.68 57.96 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.958 -173.102 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.538 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 31.0 mt-10 -110.29 -41.32 4.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.636 0.255 . . . . 0.0 111.48 -174.383 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 42.4 p -100.86 -23.01 14.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -177.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.504 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.3 16.84 80.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.521 -175.347 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.3 mm -99.58 143.78 13.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.5 t -67.98 115.14 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.67 0.271 . . . . 0.0 110.395 177.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.527 ' HG2' ' HB2' ' A' ' 31' ' ' ASP . 30.3 mmtp -81.83 -26.67 34.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.65 146.5 53.77 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.86 -178.496 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -77.28 136.92 38.53 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.546 -177.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 53.1 t -165.22 167.66 17.81 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -177.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -63.8 -36.18 83.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.322 0.582 . . . . 0.0 109.464 175.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.649 ' O ' ' HG2' ' A' ' 46' ' ' GLU . 13.6 pt -108.19 53.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.327 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.607 ' NZ ' ' HB3' ' A' ' 44' ' ' LYS . 0.0 OUTLIER -77.94 132.95 38.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 177.89 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.78 8.51 34.48 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.602 179.11 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.649 ' HG2' ' O ' ' A' ' 43' ' ' ILE . 32.2 mm-40 -63.53 146.97 52.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.227 0.537 . . . . 0.0 110.888 178.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.0 m -106.34 107.58 18.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.179 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.2 m -82.26 0.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.941 -175.037 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.23 89.15 0.45 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.298 0.571 . . . . 0.0 111.452 -175.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.91 8.58 29.65 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.401 -0.818 . . . . 0.0 113.003 174.501 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.6 mpt_? -103.78 172.44 6.8 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.753 0.311 . . . . 0.0 111.057 -179.261 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 50.1 mm -99.92 104.09 15.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 171.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 45.3 tp -85.71 113.7 22.11 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.342 -170.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -119.66 106.89 19.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.108 0.48 . . . . 0.0 110.496 178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.424 ' HD1' ' HG ' ' A' ' 53' ' ' LEU . 34.2 p90 -136.97 149.86 67.84 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.82 176.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -63.79 -49.6 3.97 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.106 1.871 . . . . 0.0 110.464 172.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.52 0 CA-C-N 115.41 -0.814 . . . . 0.0 113.061 175.624 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 . . . . . 0 N--CA 1.472 0.643 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.508 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 46.8 t -54.31 -45.56 68.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.755 0.312 . . . . 0.0 111.564 -177.538 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HB3' HD12 ' A' ' 99' ' ' ILE . 84.3 mt -61.28 -36.28 79.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.632 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.71 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 60.4 tp -69.74 -39.76 76.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.17 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -59.44 -48.79 80.28 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.876 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 85.2 mt -57.55 -41.08 80.26 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.778 -0.647 . . . . 0.0 111.437 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -71.71 -40.23 69.61 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.306 -178.31 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.475 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 68.3 mttm -62.61 -34.85 77.86 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.248 0.547 . . . . 0.0 109.981 175.082 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.521 ' HB3' HG22 ' A' ' 76' ' ' VAL . 37.8 t-20 -72.23 -34.0 67.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.008 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.27 6.98 57.45 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.087 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.521 HG22 ' HB3' ' A' ' 74' ' ' ASN . 28.8 m -103.41 10.07 8.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.025 0.441 . . . . 0.0 111.228 -176.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.33 147.12 49.31 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.133 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.77 160.18 49.42 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.683 176.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.528 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 96.6 mttt -69.29 -38.16 78.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.96 0.409 . . . . 0.0 110.251 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 13' ' ' ALA . . . -148.71 158.83 44.42 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.477 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 73.9 mt -132.98 119.58 37.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.88 178.576 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.753 HD12 HG22 ' A' ' 102' ' ' VAL . 9.1 mm -114.2 120.17 63.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.169 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -117.48 172.62 7.21 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.753 0.311 . . . . 0.0 110.465 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 88.0 tttt -91.65 -43.2 9.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.286 0.565 . . . . 0.0 109.55 173.01 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -112.28 118.48 35.39 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.39 177.214 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.8 t -82.69 159.19 22.67 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.088 177.115 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.473 ' OE1' HG12 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -144.9 151.65 39.01 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.779 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.484 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.6 m -53.56 -48.51 69.08 Favored 'General case' 0 C--N 1.323 -0.549 0 O-C-N 123.735 0.647 . . . . 0.0 111.036 178.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.473 HG12 ' OE1' ' A' ' 87' ' ' GLU . 31.5 pt -62.77 -35.21 69.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.85 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.486 HG22 HD22 ' A' ' 101' ' ' LEU . 58.1 mt -70.28 -45.04 76.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.781 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.67 -45.72 91.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.849 178.504 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.59 ' O ' ' HG2' ' A' ' 96' ' ' MET . 69.5 t -58.43 -50.88 77.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.43 -43.09 98.76 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.656 -177.364 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.47 -31.22 63.64 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -176.045 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -66.04 -33.77 76.57 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.689 0.281 . . . . 0.0 110.94 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.59 ' HG2' ' O ' ' A' ' 92' ' ' VAL . 19.2 mmt -66.65 -44.5 81.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.576 0.703 . . . . 0.0 110.596 179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.722 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -95.18 -0.39 53.28 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 114.878 -1.055 . . . . 0.0 112.125 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 56.52 64.58 1.64 Allowed 'General case' 0 C--O 1.235 0.31 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -172.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.534 HD12 ' HB3' ' A' ' 68' ' ' LEU . 54.9 mt -113.6 89.84 16.53 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.811 177.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.458 ' HB3' ' CB ' ' A' ' 123' ' ' ALA . 77.7 Cg_exo -50.14 113.24 0.93 Allowed 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 123.07 2.513 . . . . 0.0 112.564 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.486 HD22 HG22 ' A' ' 90' ' ' ILE . 1.7 pp -125.54 133.8 52.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.233 0.539 . . . . 0.0 110.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.753 HG22 HD12 ' A' ' 82' ' ' ILE . 5.3 m -126.48 152.51 34.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 175.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.634 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 11.9 pt-20 -99.42 119.87 38.69 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.192 0.52 . . . . 0.0 110.268 178.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.725 HG12 ' SG ' ' A' ' 5' ' ' CYS . 33.1 m -97.2 153.71 3.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.499 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 3.4 tmt_? -127.62 -15.55 4.98 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.037 0.446 . . . . 0.0 110.842 -176.318 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.475 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 5.0 t70 -94.49 138.14 32.77 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.407 -170.78 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -71.73 -30.99 66.22 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.759 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.475 ' HE2' ' OD1' ' A' ' 106' ' ' ASP . 46.4 mtmt -59.94 -28.19 67.42 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.652 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.524 ' O ' HG12 ' A' ' 113' ' ' VAL . 81.6 t80 -65.41 -48.24 73.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.504 177.379 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -68.15 -26.83 65.97 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.009 -175.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 114' ' ' LYS . 3.3 mm-40 -84.76 -36.55 21.67 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.756 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -67.65 -39.85 84.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.916 0.388 . . . . 0.0 110.751 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 109' ' ' PHE . 8.4 p -93.11 140.01 17.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.662 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.476 ' NZ ' ' HA ' ' A' ' 111' ' ' GLU . 43.1 mmtm -142.12 155.26 45.34 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.777 175.174 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.505 HG23 HD12 ' A' ' 18' ' ' LEU . 17.3 m -57.46 116.04 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.806 -176.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.73 -34.84 2.23 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.268 -0.967 . . . . 0.0 113.658 175.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -92.29 -174.6 3.78 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.438 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.12 142.87 41.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.221 0.534 . . . . 0.0 111.879 -168.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' A' ' 130' ' ' LEU . 9.9 p -141.17 140.65 31.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.28 174.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.1 t -108.9 119.83 59.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.862 178.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.455 HG22 HG13 ' A' ' 128' ' ' VAL . 53.3 t -114.24 114.6 47.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.113 0.482 . . . . 0.0 111.044 -177.703 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -100.46 99.67 10.32 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -76.74 -8.03 56.51 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.413 -174.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.573 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 20.4 t70 -65.26 -37.87 88.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.091 0.472 . . . . 0.0 109.95 177.137 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -102.29 -28.23 12.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.619 179.133 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.98 61.15 1.78 Allowed Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -166.135 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -136.24 124.28 22.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -165.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 121' ' ' VAL . 21.2 t -123.87 113.67 38.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.712 0.291 . . . . 0.0 110.583 -175.025 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -107.99 114.58 28.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.379 177.381 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' A' ' 119' ' ' VAL . 44.8 tp -85.84 129.57 34.79 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.145 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 11.2 tt -126.46 113.78 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-O 122.196 0.998 . . . . 0.0 110.347 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.227 0 CA-C-N 113.91 -1.495 . . . . 0.0 109.704 -173.99 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.551 HG23 ' HG3' ' A' ' 2' ' ' LYS . 20.8 m . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.551 ' HG3' HG23 ' A' ' 1' ' ' VAL . 51.8 mttm 69.03 93.21 0.08 Allowed 'General case' 0 N--CA 1.469 0.49 0 O-C-N 123.454 0.471 . . . . 0.0 110.36 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -121.46 149.97 42.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.949 -175.11 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.14 134.74 41.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.096 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 104' ' ' VAL . 82.9 m -128.46 175.86 8.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.049 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.63 ' HB3' ' HG2' ' A' ' 103' ' ' GLU . 50.2 ttt180 -93.87 120.63 34.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 178.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.566 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -91.29 112.69 24.7 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.976 0.417 . . . . 0.0 111.915 -175.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.6 mp -81.45 -51.47 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.607 177.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.3 p -101.94 -173.67 2.4 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.342 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.648 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 65.8 mmt-85 -124.76 175.23 7.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.558 0.218 . . . . 0.0 110.497 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.64 173.05 25.77 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 12' ' ' ARG . 12.5 ptt180 -142.14 151.13 41.95 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 117.276 0.538 . . . . 0.0 110.802 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.524 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -140.73 138.02 33.89 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.742 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.565 ' HG3' HG22 ' A' ' 120' ' ' VAL . 28.0 tt0 -129.19 122.45 29.78 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.944 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 178.61 -160.4 26.25 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 119.93 -1.129 . . . . 0.0 113.028 176.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.533 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 27.1 mt-10 -70.36 134.19 47.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 122.635 0.374 . . . . 0.0 111.008 -177.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -91.23 125.32 35.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.012 0.434 . . . . 0.0 110.843 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.641 ' HB3' HD13 ' A' ' 53' ' ' LEU . 5.8 tp -117.82 118.49 32.17 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.9 t -102.01 127.05 55.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.208 0.528 . . . . 0.0 111.576 -173.286 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.475 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 19.2 m -126.18 108.49 11.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.647 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -86.22 8.78 19.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.748 0.309 . . . . 0.0 111.546 -174.32 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.67 143.68 35.81 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.157 0.503 . . . . 0.0 110.742 178.454 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -81.99 139.14 34.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.411 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.0 pt -127.55 155.95 39.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.763 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 18.6 p -91.81 2.06 56.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.205 -178.091 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 72.09 -10.12 0.92 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.34 -178.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -94.94 33.03 1.55 Allowed 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 169.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.23 -175.85 50.93 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.301 -0.863 . . . . 0.0 112.899 -174.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.12 40.77 3.02 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 121.427 -0.416 . . . . 0.0 113.751 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 34.2 mt -79.09 112.44 17.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.419 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 24.2 t70 -57.72 129.55 42.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.129 0.49 . . . . 0.0 110.975 -176.03 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.421 ' H ' ' HG2' ' A' ' 32' ' ' LYS . 44.9 pttt -82.29 -10.53 59.07 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.013 -173.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -93.71 -42.42 9.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -178.311 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 p -120.37 -5.2 9.88 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.414 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.94 32.39 80.8 Favored Glycine 0 C--N 1.329 0.143 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.339 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 46.7 mm -90.68 121.27 40.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.391 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.21 96.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.369 0.604 . . . . 0.0 109.946 176.044 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.3 mmmm -85.01 -5.99 59.34 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.565 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -69.75 139.08 53.27 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.65 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -77.23 132.94 38.97 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.282 -175.167 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 12.8 t -172.08 26.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.952 178.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 69.25 -39.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.8 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 35.9 pt -79.97 12.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.465 0.65 . . . . 0.0 110.497 174.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -57.05 122.91 13.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.803 177.431 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.8 -6.76 24.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.405 -178.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -85.65 148.44 25.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.9 0.381 . . . . 0.0 111.118 177.006 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 39.1 t -95.6 150.19 20.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 176.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.3 m -105.84 3.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.79 178.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.411 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.52 90.64 0.39 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.635 0.731 . . . . 0.0 111.497 -175.078 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.9 23.31 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.5 175.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.533 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 98.3 mtt180 -116.08 168.18 10.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.79 0.328 . . . . 0.0 110.518 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.44 HD12 ' N ' ' A' ' 52' ' ' ILE . 3.0 mp -107.93 122.92 62.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.641 HD13 ' HB3' ' A' ' 18' ' ' LEU . 4.6 mm? -96.34 138.45 33.92 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.142 0.496 . . . . 0.0 111.452 -175.388 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.94 119.71 61.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.067 177.001 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.671 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 90.7 m-85 -129.77 144.97 55.1 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.148 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 20' ' ' THR . 13.0 Cg_exo -71.37 -55.27 0.13 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.337 2.025 . . . . 0.0 111.519 175.537 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.698 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.361 -178.277 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 50.9 p90 . . . . . 0 N--CA 1.464 0.233 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.475 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 10.5 p -60.66 -33.58 55.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.41 -177.603 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 90.0 mt -68.88 -41.0 78.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.183 0.516 . . . . 0.0 110.484 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.1 tp -66.17 -39.53 89.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.949 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -60.21 -43.34 96.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.531 177.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.9 mt -65.86 -38.42 88.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.534 178.092 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.548 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 5.0 mmm180 -63.54 -42.83 98.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.233 178.099 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 73' ' ' LYS . 6.7 tmtt? -63.71 -29.21 70.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.402 0.62 . . . . 0.0 110.56 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -86.69 -12.27 48.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.117 0.485 . . . . 0.0 110.319 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 77.8 20.49 73.57 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.306 176.683 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.414 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.3 m -116.29 14.88 7.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.24 0.543 . . . . 0.0 110.929 -177.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -97.45 158.08 33.72 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.651 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.557 ' HB3' HD23 ' A' ' 53' ' ' LEU . 22.9 Cg_exo -65.37 165.43 22.45 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.665 2.243 . . . . 0.0 111.961 176.174 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.524 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 54.6 mttm -80.8 -40.19 25.42 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.069 0.461 . . . . 0.0 110.245 173.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.585 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -160.36 158.34 29.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.32 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.56 HG22 ' HB2' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -130.05 127.34 63.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.157 0.504 . . . . 0.0 109.648 174.686 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.555 HG23 HG23 ' A' ' 102' ' ' VAL . 6.5 mm -106.91 116.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.235 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.671 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 72.2 m-20 -115.27 158.65 22.05 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -177.038 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 50.4 tttm -81.69 -33.29 31.29 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 170.712 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' ' HA ' ' A' ' 85' ' ' LYS . 28.1 tptt -153.92 148.09 25.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.249 173.284 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.412 ' HB ' HD21 ' A' ' 83' ' ' ASN . 11.0 t -140.51 -179.47 6.04 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.731 -0.213 . . . . 0.0 110.88 -175.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.79 160.15 18.26 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 92' ' ' VAL . 9.1 m -58.5 -45.14 89.36 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.082 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 15.2 mm -55.63 -41.56 65.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 111.193 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 27.5 mm -64.15 -45.48 96.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.361 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.79 -41.78 98.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.253 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 88' ' ' THR . 94.8 t -60.68 -44.34 96.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.053 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -68.64 -41.25 84.54 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.076 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.84 -32.65 74.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.646 0.26 . . . . 0.0 111.125 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.37 -44.07 92.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.283 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.6 mtm -75.53 -39.44 58.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.363 -177.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.548 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -79.12 0.19 29.11 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 57.23 53.08 8.08 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.362 0.601 . . . . 0.0 111.403 -177.555 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 21.7 mm -113.11 88.06 11.67 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.541 178.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.585 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 1.0 OUTLIER -45.64 117.44 1.76 Allowed 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.319 2.679 . . . . 0.0 112.546 -179.614 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.97 121.0 37.99 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.821 -176.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.566 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.7 m -123.84 142.64 39.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.32 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.63 ' HG2' ' HB3' ' A' ' 6' ' ' ARG . 13.3 pt-20 -100.31 129.38 46.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.204 0.526 . . . . 0.0 110.286 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.546 HG22 ' SG ' ' A' ' 5' ' ' CYS . 11.3 t -90.33 138.13 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.896 -177.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 77.7 mtt180 -89.56 -33.63 16.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.006 0.431 . . . . 0.0 110.603 177.07 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -96.6 139.56 32.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.421 0.629 . . . . 0.0 112.09 -168.373 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -71.93 -26.96 62.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.754 178.753 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.6 mttm -65.39 -17.88 64.88 Favored 'General case' 0 CA--C 1.521 -0.141 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -176.124 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 75.5 t80 -60.43 -46.21 90.84 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 174.513 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 88.1 m-85 -72.0 -28.96 63.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.098 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -66.24 -45.95 78.86 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.463 176.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.13 -47.31 20.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.227 -176.076 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.52 133.26 30.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 121.362 0.601 . . . . 0.0 111.605 -173.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -122.76 145.99 47.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.584 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.1 m -66.91 100.39 0.72 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.472 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 138.3 -16.65 3.39 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.451 -178.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -83.63 175.33 9.81 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.489 176.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.84 HH21 HG13 ' A' ' 131' ' ' ILE . 21.3 ttp180 -111.93 134.25 53.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.989 -178.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.1 p -124.51 138.29 54.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.201 0.524 . . . . 0.0 110.82 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.565 HG22 ' HG3' ' A' ' 14' ' ' GLU . 40.5 t -111.32 106.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.117 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.4 p -104.06 126.58 58.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.333 0.587 . . . . 0.0 110.959 -178.465 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.7 t30 -114.98 100.55 8.28 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.572 176.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.26 -0.42 52.28 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.8 -176.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.648 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 28.3 t70 -67.89 -39.15 83.7 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.967 175.047 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -104.8 -30.6 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.303 177.067 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.48 ' HA2' ' HB2' ' A' ' 7' ' ' ALA . . . 96.5 57.61 1.11 Allowed Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -173.059 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 50.8 t80 -138.28 124.69 20.59 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 128' ' ' VAL . 10.8 p -117.35 107.21 21.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.972 0.891 . . . . 0.0 110.106 -178.174 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.536 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 31.2 tt0 -105.61 108.22 19.62 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.765 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 44.3 tp -84.68 124.83 31.93 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.93 176.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.84 HG13 HH21 ' A' ' 118' ' ' ARG . 23.6 mm -97.66 118.9 44.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--N 1.312 -1.033 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.31 -177.43 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.509 HG23 ' HB3' ' A' ' 130' ' ' LEU . 18.4 m . . . . . 0 N--CA 1.455 -0.199 0 CA-C-O 121.172 0.511 . . . . 0.0 111.037 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.576 ' HB3' ' CE2' ' A' ' 127' ' ' TYR . 53.6 mtmt -129.99 117.71 20.49 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.159 -178.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -115.25 164.71 13.83 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.626 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.44 135.96 53.53 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.874 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' HG21 ' A' ' 102' ' ' VAL . 6.4 p -121.74 168.7 11.52 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.96 0.41 . . . . 0.0 111.136 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.807 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 65.4 ttt180 -95.25 109.21 21.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.705 177.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.636 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -67.23 117.7 9.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.793 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.431 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 50.1 mm -101.51 -60.66 2.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.059 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.596 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.6 OUTLIER -96.69 174.44 6.82 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 172.014 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 9' ' ' THR . 52.2 mtt180 -126.53 167.9 14.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.942 0.401 . . . . 0.0 111.327 -176.663 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.82 159.96 9.38 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.711 -175.017 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.1 mtp85 -128.35 114.57 17.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.609 0.243 . . . . 0.0 110.506 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.468 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -139.21 146.27 40.3 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.056 0.455 . . . . 0.0 111.604 -175.06 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -133.45 148.25 51.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.334 174.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 172.34 -160.19 31.43 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.306 174.263 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.681 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.0 mt-10 -70.51 129.77 40.12 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 120.968 0.414 . . . . 0.0 110.843 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.566 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.01 117.3 21.49 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.006 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.536 HD12 HG23 ' A' ' 115' ' ' THR . 12.0 tp -105.71 115.4 30.18 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 176.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.425 ' HA ' ' CG2' ' A' ' 54' ' ' VAL . 11.3 p -100.4 110.8 28.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 122.049 0.928 . . . . 0.0 111.074 -172.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.465 HG23 HG13 ' A' ' 43' ' ' ILE . 10.1 m -106.0 88.92 2.92 Favored 'General case' 0 N--CA 1.44 -0.962 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.031 178.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' ' OE2' ' A' ' 22' ' ' GLU . 21.0 pttp -76.55 -1.06 25.52 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.119 176.692 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.539 ' OE2' ' HG3' ' A' ' 21' ' ' LYS . 8.5 mm-40 -92.43 160.68 14.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.382 178.428 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 9.7 p90 -112.67 104.99 13.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.336 0.588 . . . . 0.0 110.322 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.3 mp -100.52 130.24 50.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.993 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -71.54 121.76 19.28 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -72.97 87.44 1.33 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.248 0.547 . . . . 0.0 111.41 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.425 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.3 tm? -134.86 -68.08 0.54 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.128 176.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -142.1 177.4 21.5 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.653 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.19 -62.76 0.61 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.521 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 57.4 mt -69.67 124.43 25.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.641 0.258 . . . . 0.0 110.626 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -59.21 133.11 55.8 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.513 177.548 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.459 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 33.5 mmtp -67.09 -21.26 65.88 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.291 0.567 . . . . 0.0 110.098 177.081 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -100.01 -58.52 1.9 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.738 -172.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.508 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -87.96 -14.03 40.23 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.753 0.649 . . . . 0.0 112.753 -175.379 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.641 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 67.14 29.69 74.78 Favored Glycine 0 CA--C 1.518 0.261 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.598 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.508 HG12 ' HB ' ' A' ' 34' ' ' THR . 47.4 mm -103.84 133.02 48.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.446 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 3.9 p -80.32 105.33 9.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.607 0.717 . . . . 0.0 110.308 178.181 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -80.08 -19.64 46.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.094 -179.229 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -69.48 135.79 50.63 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.567 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 34.1 t70 -83.87 130.36 34.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.48 -175.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 22' ' ' GLU . 5.8 t 173.56 50.5 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 123.927 0.767 . . . . 0.0 109.23 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 72.42 -47.86 0.67 Allowed 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 123.509 0.724 . . . . 0.0 112.208 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.465 HG13 HG23 ' A' ' 20' ' ' THR . 33.4 mm -77.17 -10.4 13.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.063 0.459 . . . . 0.0 111.078 -176.597 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.567 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 61.8 tttp -52.89 124.08 13.19 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.976 -0.557 . . . . 0.0 111.663 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.56 -16.67 28.84 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.696 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -87.03 162.43 17.62 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.223 0.535 . . . . 0.0 112.019 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 33.2 p -102.43 150.42 23.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.623 179.242 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.447 HG21 HD13 ' A' ' 30' ' ' ILE . 2.8 t -108.68 -0.04 9.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.367 0.603 . . . . 0.0 110.159 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.32 91.62 0.55 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.833 -171.219 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.589 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 90.86 23.6 29.9 Favored Glycine 0 C--N 1.317 -0.525 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.21 172.568 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.681 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 97.5 mtt180 -111.09 169.32 8.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.867 0.365 . . . . 0.0 111.358 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.438 HD12 ' N ' ' A' ' 52' ' ' ILE . 2.3 mp -109.68 113.02 43.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 11.1 mp -102.54 132.45 48.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.962 0.41 . . . . 0.0 111.383 -174.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.529 HG12 ' HB ' ' A' ' 82' ' ' ILE . 10.5 m -109.41 130.95 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.672 176.278 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.589 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 92.7 m-85 -130.49 145.2 56.45 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.421 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.85 -33.63 33.11 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.254 1.97 . . . . 0.0 111.507 174.09 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.761 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.133 177.854 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.87 -42.17 61.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.715 0.293 . . . . 0.0 111.515 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.68 -32.47 72.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.922 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.547 ' HG ' ' HE2' ' A' ' 73' ' ' LYS . 56.8 tp -68.51 -42.83 77.99 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -59.13 -43.91 92.02 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.318 177.105 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.459 ' CD2' ' HA ' ' A' ' 32' ' ' LYS . 87.8 mt -64.99 -38.62 91.55 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.547 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -68.63 -38.68 80.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.388 -178.248 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.547 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 52.5 mttm -60.32 -34.27 73.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.212 0.529 . . . . 0.0 110.716 176.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.1 t30 -86.48 -22.65 26.31 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.819 -177.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.09 20.02 44.27 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.391 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.641 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 28.1 m -112.18 13.92 8.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.103 0.478 . . . . 0.0 110.811 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -96.0 160.12 30.73 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.562 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.74 141.24 71.34 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.187 1.925 . . . . 0.0 111.698 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.589 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 89.0 mttt -68.98 -28.11 66.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 110.52 176.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -160.86 147.85 15.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.695 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 63.9 mt -123.4 117.29 50.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 175.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.544 HG22 ' CG2' ' A' ' 104' ' ' VAL . 3.1 mm -110.57 115.22 49.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.589 ' ND2' ' HB2' ' A' ' 55' ' ' PHE . 15.6 m120 -111.54 153.36 26.35 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.272 -177.346 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.63 ' HA ' ' HB ' ' A' ' 104' ' ' VAL . 2.1 tmtp? -66.96 -45.63 77.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 174.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -142.98 120.88 11.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.238 177.065 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 3.7 m -86.29 150.11 24.58 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.303 -172.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -118.58 155.18 31.37 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 173.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.3 m -49.77 -51.38 39.65 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 123.31 0.644 . . . . 0.0 112.68 -173.231 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 61.8 mt -57.04 -41.18 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 121.078 0.466 . . . . 0.0 111.441 -176.276 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 20.4 mt -70.1 -43.31 79.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.384 -177.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.9 -43.98 86.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.539 -178.077 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 88' ' ' THR . 97.5 t -62.1 -43.03 97.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.992 0.425 . . . . 0.0 110.864 -179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.4 -43.38 99.14 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.58 -39.45 62.23 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -177.495 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.442 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -57.87 -46.54 84.71 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.78 -177.073 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.1 mtm -66.11 -30.73 71.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.923 0.392 . . . . 0.0 111.416 -177.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.546 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -88.46 2.2 53.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.576 -179.691 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 60.72 41.03 15.55 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.118 0.485 . . . . 0.0 110.884 -177.369 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.9 90.36 2.9 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.458 177.36 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.2 Cg_endo -48.33 100.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.603 2.868 . . . . 0.0 113.144 -173.606 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 3.4 tt -99.68 127.37 45.8 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.411 -0.813 . . . . 0.0 108.919 176.584 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 7' ' ' ALA . 35.2 m -132.12 159.38 43.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.844 -178.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.807 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 25.3 tt0 -89.11 125.46 35.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.528 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.63 ' HB ' ' HA ' ' A' ' 84' ' ' LYS . 90.8 t -86.18 102.21 11.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.022 0.439 . . . . 0.0 110.602 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -78.99 -35.72 42.5 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.36 0.6 . . . . 0.0 109.639 176.71 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.612 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 17.7 t70 -89.92 101.87 14.57 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.496 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -70.17 -15.58 62.97 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.005 0.431 . . . . 0.0 111.038 -174.417 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.612 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 30.9 mmmt -62.1 -24.81 67.35 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.887 177.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -59.8 -38.42 81.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.819 177.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.477 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.1 m-85 -71.64 -22.7 61.65 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.883 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.76 -32.17 46.5 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.248 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -86.43 -30.85 21.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.062 -178.181 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.477 HG12 ' HA ' ' A' ' 110' ' ' PHE . 12.5 p -74.87 127.24 36.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.435 0.636 . . . . 0.0 111.825 -176.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.546 ' HE2' ' HA ' ' A' ' 114' ' ' LYS . 8.9 mmpt? -130.18 161.49 31.01 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.164 175.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.536 HG23 HD12 ' A' ' 18' ' ' LEU . 91.1 m -67.41 125.01 24.77 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.809 0.338 . . . . 0.0 110.89 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 103.79 -1.18 45.16 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.277 176.493 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -85.88 175.26 8.75 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.497 HH21 HD13 ' A' ' 131' ' ' ILE . 18.1 ttp85 -117.18 120.74 39.22 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.371 0.532 . . . . 0.0 110.855 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.566 HG23 ' HB2' ' A' ' 17' ' ' ALA . 76.6 t -118.89 126.65 75.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.695 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.02 110.14 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.0 p -100.4 118.08 46.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.665 0.745 . . . . 0.0 111.421 -176.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -100.73 94.03 5.87 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.004 175.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.8 1.63 42.05 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 122.03 0.919 . . . . 0.0 108.835 173.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -84.49 -1.83 56.34 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.041 -1.436 . . . . 0.0 109.531 175.759 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.14 -43.17 0.18 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.632 -176.428 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.41 52.23 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -175.499 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.576 ' CE2' ' HB3' ' A' ' 2' ' ' LYS . 12.3 t80 -154.76 140.33 17.91 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -170.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 16.7 m -124.7 127.04 72.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.285 0.564 . . . . 0.0 111.351 -177.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -101.88 111.7 24.06 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.958 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.509 ' HB3' HG23 ' A' ' 1' ' ' VAL . 9.6 tt -108.77 129.68 55.38 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.413 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.497 HD13 HH21 ' A' ' 118' ' ' ARG . 3.8 mp -121.71 111.45 31.04 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.803 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.493 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 C--N 1.313 -1.003 0 O-C-N 124.485 1.116 . . . . 0.0 110.48 -175.204 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.563 0.697 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.427 ' HE3' ' HG3' ' A' ' 129' ' ' GLU . 55.9 mtpt -133.58 120.54 20.87 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.411 -175.189 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.416 ' HB2' ' CG2' ' A' ' 128' ' ' VAL . 92.4 m-85 -97.85 150.02 21.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.425 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -101.14 127.72 47.57 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.629 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.508 ' HB3' HG12 ' A' ' 104' ' ' VAL . 4.3 p -120.59 169.9 9.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.308 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.472 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 24.4 tpt180 -94.05 120.59 34.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.552 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.58 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -70.44 119.73 15.04 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.696 -176.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.2 mm -101.95 -47.47 11.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 174.636 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.535 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -111.95 -165.73 1.02 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.455 176.966 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 10' ' ' ARG . 54.8 mtt180 -132.76 170.1 15.75 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 176.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 113.95 153.75 11.03 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.018 -178.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.57 ' HG3' ' HA ' ' A' ' 122' ' ' ASN . 1.0 OUTLIER -123.34 126.29 46.58 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 177.834 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.555 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -133.28 132.07 40.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.035 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.36 127.76 55.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.399 -178.382 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -167.98 -179.39 40.51 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.086 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.66 133.32 42.13 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 177.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.527 ' HB2' HG12 ' A' ' 119' ' ' VAL . . . -80.17 120.48 24.34 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.891 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HA ' HG23 ' A' ' 115' ' ' THR . 8.0 tt -107.76 113.83 27.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.641 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.2 t -104.04 111.1 32.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.204 0.526 . . . . 0.0 111.094 -175.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.58 130.7 34.88 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 174.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 21.5 mtpp -92.29 -83.2 0.3 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.24 -172.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 44.84 -163.8 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.58 0.705 . . . . 0.0 112.721 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -147.1 100.98 3.36 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 168.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.445 HD11 ' SG ' ' A' ' 41' ' ' CYS . 58.7 mt -112.26 132.59 60.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.914 0.387 . . . . 0.0 111.369 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.8 p -76.46 124.68 27.94 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 171.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -79.91 39.8 0.44 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.088 0.471 . . . . 0.0 111.711 -174.633 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.37 -30.61 42.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 173.435 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -157.41 -105.4 0.22 Allowed Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 114.816 -1.084 . . . . 0.0 111.096 178.189 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.85 -41.48 3.05 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.388 174.42 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 52.3 mt -115.18 142.12 29.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.847 0.356 . . . . 0.0 110.708 -176.531 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -73.78 136.3 43.59 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.766 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -83.06 -3.3 57.13 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -173.139 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -112.12 -52.84 2.76 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 122.169 -0.332 . . . . 0.0 111.297 -176.485 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.1 m -101.28 -15.91 17.13 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.645 -175.026 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.62 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.95 21.46 68.14 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.503 -0.855 . . . . 0.0 112.402 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 42.9 mm -89.12 132.33 34.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.4 m -64.46 114.91 2.52 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.45 0.643 . . . . 0.0 110.557 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -78.55 -11.16 59.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.89 177.157 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -94.84 149.88 20.78 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.141 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -79.97 135.16 36.33 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.106 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.497 ' H ' ' HB2' ' A' ' 44' ' ' LYS . 56.6 m -148.98 -170.77 3.71 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -176.193 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -60.68 -52.32 65.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.835 0.35 . . . . 0.0 110.088 175.567 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.3 51.42 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.385 0.612 . . . . 0.0 111.145 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.497 ' HB2' ' H ' ' A' ' 41' ' ' CYS . 13.0 tmtt? -60.66 127.83 33.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.563 176.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.74 -5.69 12.69 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.136 -178.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -84.49 148.17 26.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.817 0.341 . . . . 0.0 111.099 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.6 m -93.0 113.28 25.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.513 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.627 ' HA ' ' HD3' ' A' ' 51' ' ' ARG . 26.5 m -82.16 19.97 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.79 0.329 . . . . 0.0 111.862 -175.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.419 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -80.14 92.1 5.62 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.174 0.511 . . . . 0.0 111.568 -174.205 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.85 19.65 21.37 Favored Glycine 0 C--N 1.32 -0.337 0 C-N-CA 120.688 -0.767 . . . . 0.0 113.47 171.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.627 ' HD3' ' HA ' ' A' ' 48' ' ' VAL . 7.2 ptm180 -119.96 -179.28 3.87 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 177.677 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.9 mm -104.06 135.04 43.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.587 ' HB3' HG12 ' A' ' 81' ' ' ILE . 56.1 tp -106.84 125.85 51.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.127 0.489 . . . . 0.0 110.837 -179.136 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -107.47 112.06 38.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.535 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 19.4 t80 -132.89 142.12 43.55 Favored Pre-proline 0 C--N 1.324 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -173.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -69.98 -56.34 0.14 Allowed 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.168 1.912 . . . . 0.0 112.867 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.472 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.42 -179.163 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.0 p90 . . . . . 0 N--CA 1.461 0.106 0 CA-C-O 120.597 0.237 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.434 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 48.0 t -56.15 -56.86 10.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.306 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 92.6 mt -59.62 -40.87 88.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 -177.555 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.533 ' O ' ' HG3' ' A' ' 73' ' ' LYS . 62.5 tp -66.63 -51.22 58.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.725 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -56.3 -44.95 80.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 90.3 mt -67.05 -36.36 81.87 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.154 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.645 ' HG3' HD11 ' A' ' 99' ' ' ILE . 0.0 OUTLIER -76.24 -28.4 57.14 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.813 -176.41 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.533 ' HG3' ' O ' ' A' ' 69' ' ' LEU . 8.2 mtpm? -67.97 -35.18 77.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.979 0.418 . . . . 0.0 109.902 176.379 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -78.69 -25.24 44.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.007 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.89 21.9 32.17 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.413 178.25 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.62 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.7 m -115.12 12.28 7.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.895 0.378 . . . . 0.0 111.034 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.458 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -97.29 155.33 37.5 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.811 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.542 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 22.3 Cg_exo -64.66 146.34 88.57 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.306 2.004 . . . . 0.0 111.154 174.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.555 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.4 mttt -62.25 -35.81 80.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.878 0.371 . . . . 0.0 111.035 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.518 ' HA ' HG23 ' A' ' 99' ' ' ILE . . . -161.48 158.34 26.42 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.64 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.587 HG12 ' HB3' ' A' ' 53' ' ' LEU . 54.5 mt -131.26 124.11 54.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.591 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.693 HG23 HG23 ' A' ' 102' ' ' VAL . 5.2 mm -103.75 116.77 48.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 22.2 m120 -114.78 156.35 25.04 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.313 0.578 . . . . 0.0 111.742 -175.428 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 82.0 tttt -84.12 -38.33 20.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.415 177.328 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -123.81 108.25 12.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.718 174.72 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 19.7 p -78.55 108.85 12.23 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.194 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.618 ' HB3' HG12 ' A' ' 90' ' ' ILE . 0.4 OUTLIER -72.69 135.39 45.38 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.011 -0.736 . . . . 0.0 109.011 177.652 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -56.03 -42.99 77.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.835 -174.485 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.4 mt -69.19 -32.58 54.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.879 -177.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.618 HG12 ' HB3' ' A' ' 87' ' ' GLU . 49.4 mm -67.23 -39.98 84.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.043 177.237 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.19 -43.69 92.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.13 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.78 -45.16 95.0 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.546 178.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.91 -43.47 82.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.71 -178.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.406 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -61.13 -38.07 85.07 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.953 0.406 . . . . 0.0 111.004 -179.051 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.24 -32.31 73.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.546 -179.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.45 ' HB2' ' HE3' ' A' ' 96' ' ' MET . 67.7 mtm -77.38 -40.46 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.71 0.291 . . . . 0.0 111.406 -177.179 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.506 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -84.91 -0.94 55.87 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.811 -176.248 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 60.11 53.95 4.32 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 122.011 0.91 . . . . 0.0 109.78 -173.471 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.645 HD11 ' HG3' ' A' ' 72' ' ' ARG . 44.3 mm -110.1 88.26 6.84 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.744 175.528 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 5.4 Cg_endo -47.53 98.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.323 2.682 . . . . 0.0 112.753 -175.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 64.0 tp -92.87 130.97 38.29 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.27 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.693 HG23 HG23 ' A' ' 82' ' ' ILE . 14.1 m -135.41 148.78 28.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.289 177.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.485 ' CD ' ' HE ' ' A' ' 105' ' ' ARG . 39.5 tt0 -100.71 121.69 42.08 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.654 -177.515 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 5' ' ' CYS . 14.2 m -108.92 117.62 54.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.443 0.64 . . . . 0.0 111.132 176.176 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ARG . . . . . 0.485 ' HE ' ' CD ' ' A' ' 103' ' ' GLU . 12.8 mmt180 -93.46 4.5 53.86 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.852 176.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 20.9 t70 -95.67 123.27 39.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.211 -171.739 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -72.16 -32.51 66.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.018 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 14.2 mptt -65.99 -30.09 70.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.15 -176.766 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 113' ' ' VAL . 73.6 t80 -54.77 -50.73 67.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.075 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.493 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 89.5 m-85 -69.0 -22.64 64.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.107 0.479 . . . . 0.0 111.168 -175.111 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -85.57 -34.05 21.57 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.473 -179.366 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.91 -33.5 34.14 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.485 -178.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.6 p -78.99 125.08 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.28 0.562 . . . . 0.0 110.679 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -118.16 153.63 33.51 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.702 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 18' ' ' LEU . 24.5 m -68.2 94.35 0.51 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.071 0.463 . . . . 0.0 110.214 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.55 -9.71 2.91 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.029 -176.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ASP . . . . . 0.479 ' HB3' HD11 ' A' ' 130' ' ' LEU . 82.9 m-20 -80.85 159.39 25.07 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 176.528 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -103.57 113.9 27.76 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.894 0.378 . . . . 0.0 110.324 176.401 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.527 HG12 ' HB2' ' A' ' 17' ' ' ALA . 6.5 p -119.92 120.71 64.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.151 0.5 . . . . 0.0 110.18 178.207 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 129' ' ' GLU . 7.7 p -98.63 115.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.556 0.694 . . . . 0.0 109.343 175.706 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 7.5 p -78.57 128.78 38.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.65 -178.008 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ASN . . . . . 0.57 ' HA ' ' HG3' ' A' ' 12' ' ' ARG . 49.9 t-20 -115.07 94.51 4.77 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.344 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.6 -10.37 51.68 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.264 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -75.42 -40.28 57.89 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.249 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -102.32 -14.42 16.94 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.387 -179.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.7 65.67 1.81 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.58 -178.285 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -152.6 144.61 23.75 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.772 0.32 . . . . 0.0 110.613 -173.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 3' ' ' PHE . 4.1 m -116.7 106.59 20.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.372 0.606 . . . . 0.0 109.708 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HB3' HG13 ' A' ' 120' ' ' VAL . 29.8 tt0 -93.11 108.45 20.04 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.043 -174.601 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.479 HD11 ' HB3' ' A' ' 117' ' ' ASP . 38.8 tp -97.46 129.69 44.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.136 -175.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 13.2 mm -124.8 120.2 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.867 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 . . . . . 0 C--N 1.313 -1.001 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.707 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.466 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 4.6 m . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.433 0.635 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.53 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 19.5 mtpp -117.64 112.84 21.06 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.979 -176.739 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.466 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 96.5 m-85 -112.32 156.03 23.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.311 0.577 . . . . 0.0 111.728 -172.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.57 133.03 48.24 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.068 175.138 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.4 m -119.57 -179.45 3.88 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -177.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.929 ' HA ' ' HE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -101.36 126.02 48.07 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 120.241 -0.584 . . . . 0.0 110.083 174.989 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.565 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -80.13 128.13 33.14 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.731 -174.576 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.462 ' HB ' HD12 ' A' ' 101' ' ' LEU . 49.6 mm -112.5 -49.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 174.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.582 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -100.23 172.06 7.4 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 171.433 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.7 mtp180 -127.17 177.24 6.8 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.781 -178.267 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.78 -158.84 20.26 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -172.727 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ptt180 -141.87 160.6 39.87 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 117.107 0.453 . . . . 0.0 110.477 175.418 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.523 ' CB ' ' HB2' ' A' ' 80' ' ' ALA . . . -145.79 159.58 42.99 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.324 -178.216 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -153.21 143.04 22.06 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.063 -177.273 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.12 175.35 39.56 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.883 -1.151 . . . . 0.0 112.757 175.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -73.41 136.42 44.3 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.564 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.79 128.05 33.21 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.211 0.529 . . . . 0.0 111.841 -175.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.479 HD12 HG23 ' A' ' 115' ' ' THR . 5.2 tp -116.12 110.44 18.86 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.389 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.61 134.84 48.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.232 0.539 . . . . 0.0 111.661 -171.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.538 HG23 ' HB3' ' A' ' 55' ' ' PHE . 2.1 t -146.3 117.62 7.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.245 174.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.433 ' HA ' ' HD2' ' A' ' 21' ' ' LYS . 19.7 tptm -82.65 -8.92 59.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.471 0.653 . . . . 0.0 109.293 176.689 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' HB3' ' A' ' 41' ' ' CYS . 1.5 tm-20 -81.19 146.13 30.65 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 174.223 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -86.07 158.9 19.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.558 -171.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.499 HD12 ' HE2' ' A' ' 44' ' ' LYS . 12.5 tt -150.24 127.51 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.679 0.752 . . . . 0.0 111.032 177.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -76.28 135.09 39.63 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.845 -177.211 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -73.06 -20.05 61.05 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.106 -175.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -65.33 -67.07 0.47 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.747 0.308 . . . . 0.0 110.501 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -114.26 34.9 4.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.663 -0.78 . . . . 0.0 111.509 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -98.34 -19.99 21.56 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.864 -0.684 . . . . 0.0 113.06 -175.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 53.6 mt -129.2 133.73 65.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 117.374 0.587 . . . . 0.0 110.75 -177.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.3 t70 -69.5 128.61 37.11 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.882 176.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -79.02 -7.13 57.84 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.558 -174.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -101.61 -57.67 2.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.994 0.426 . . . . 0.0 110.816 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -101.96 -8.3 21.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -172.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.95 21.88 78.93 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.643 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 37.7 mm -84.49 128.01 39.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 177.18 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 6.3 m -62.27 120.27 8.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.153 0.501 . . . . 0.0 110.545 175.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 21.2 mmmt -88.44 -35.21 17.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.808 -175.079 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.549 ' O ' ' HD3' ' A' ' 44' ' ' LYS . 31.9 tt0 -77.8 107.7 10.5 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.722 ' HA ' ' HD3' ' A' ' 44' ' ' LYS . 13.2 t70 -110.52 144.61 39.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.269 0.556 . . . . 0.0 112.354 -172.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.63 ' SG ' ' HD2' ' A' ' 44' ' ' LYS . 12.4 p -108.93 -51.08 2.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.476 173.134 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.435 ' HG3' HG23 ' A' ' 43' ' ' ILE . 12.5 pt-20 -172.36 -29.92 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.003 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.435 HG23 ' HG3' ' A' ' 42' ' ' GLU . 18.5 pt -114.86 10.95 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.741 -178.173 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.722 ' HD3' ' HA ' ' A' ' 40' ' ' ASP . 24.2 mttt -92.59 146.96 23.26 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.176 0.512 . . . . 0.0 110.575 -176.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.01 0.74 1.43 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.724 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 -87.58 158.39 18.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.88 0.371 . . . . 0.0 111.113 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.509 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 35.5 t -89.05 151.84 22.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.882 176.013 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 19.6 m -104.8 10.65 8.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.835 178.009 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.84 87.93 0.37 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.918 -174.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.61 -2.67 42.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.284 -0.871 . . . . 0.0 113.536 171.512 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 47' ' ' SER . 0.7 OUTLIER -109.13 -172.28 2.01 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 117.199 0.499 . . . . 0.0 110.856 -178.361 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.528 HG12 ' HB3' ' A' ' 80' ' ' ALA . 72.4 mt -118.44 120.61 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.327 -177.542 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.42 HD12 ' O ' ' A' ' 18' ' ' LEU . 47.4 tp -103.5 121.3 42.56 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.53 106.26 20.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.073 0.463 . . . . 0.0 110.658 -178.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.538 ' HB3' HG23 ' A' ' 20' ' ' THR . 23.6 p90 -137.25 151.79 72.26 Favored Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.851 176.156 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_exo -62.51 -41.52 32.13 Favored 'Trans proline' 0 CA--C 1.529 0.245 0 C-N-CA 122.458 2.105 . . . . 0.0 112.197 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.443 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.032 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.562 ' CD2' HG23 ' A' ' 67' ' ' VAL . 38.6 p90 . . . . . 0 N--CA 1.454 -0.256 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.562 HG23 ' CD2' ' A' ' 66' ' ' TYR . 76.1 t 72.99 -60.88 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 122.846 0.459 . . . . 0.0 110.467 -174.03 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 8.3 mp -63.41 -39.42 94.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.1 0.476 . . . . 0.0 109.846 176.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.405 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 56.1 tp -62.26 -40.19 95.37 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.123 175.343 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.33 -38.89 92.91 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.293 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.502 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 93.7 mt -58.13 -41.2 83.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.555 177.675 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -67.28 -34.74 78.05 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.564 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -67.12 -25.66 66.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.288 -178.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -100.27 -17.2 17.43 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.126 0.488 . . . . 0.0 110.299 177.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.96 0.17 58.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.942 176.585 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.5 19.03 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.54 -176.342 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.411 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -80.84 148.69 65.57 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.351 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 77' ' ' ALA . 11.7 Cg_exo -68.77 154.2 71.63 Favored 'Trans proline' 0 N--CA 1.463 -0.266 0 C-N-CA 122.576 2.184 . . . . 0.0 110.96 175.468 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.419 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 45.1 mttp -85.06 -32.99 22.57 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.199 179.425 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.528 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -151.42 143.96 24.25 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.796 0.331 . . . . 0.0 111.407 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 40.3 mm -129.41 124.78 60.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 174.505 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.588 HG23 HG23 ' A' ' 102' ' ' VAL . 3.7 mm -118.05 116.46 51.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -120.03 165.51 14.61 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -175.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.656 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 0.0 OUTLIER -76.54 -28.81 56.46 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.669 0.747 . . . . 0.0 109.956 177.568 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.7 tttm -138.91 130.51 27.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.629 169.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 25.4 p -90.4 155.94 18.58 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 175.048 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -123.06 146.09 47.98 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.709 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 92' ' ' VAL . 21.2 m -57.95 -50.4 73.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.231 -173.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 59.4 mt -58.79 -42.71 86.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.162 0.506 . . . . 0.0 110.663 -178.367 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 57.4 mt -70.11 -41.35 79.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.511 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.5 93.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.335 -179.349 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 88' ' ' THR . 94.2 t -61.44 -45.48 98.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.694 178.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -66.63 -41.59 93.86 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.406 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.32 -41.88 93.53 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.69 0.281 . . . . 0.0 111.269 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.63 -29.6 69.35 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.021 0.438 . . . . 0.0 110.451 176.636 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 76.8 mtp -83.33 -30.31 27.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.185 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -96.04 16.68 17.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.868 -177.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.458 ' OE1' ' HD2' ' A' ' 72' ' ' ARG . 3.5 mp0 55.03 41.2 32.02 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.121 0.486 . . . . 0.0 111.297 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.466 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 48.7 mt -115.47 86.06 14.42 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.754 176.604 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 30.0 Cg_endo -65.58 109.89 1.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.309 2.006 . . . . 0.0 112.167 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.462 HD12 ' HB ' ' A' ' 8' ' ' ILE . 3.1 pp -110.31 151.27 27.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.202 0.525 . . . . 0.0 111.26 179.527 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.588 HG23 HG23 ' A' ' 82' ' ' ILE . 31.3 m -135.75 162.28 37.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.691 177.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -108.13 126.54 52.89 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.82 0.343 . . . . 0.0 110.98 -175.251 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.656 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 8.3 m -109.24 123.52 65.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.451 176.181 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -101.51 12.35 37.45 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.141 0.496 . . . . 0.0 110.201 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 28.6 t70 -107.62 122.73 47.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.022 -177.286 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -71.17 -29.07 64.73 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.629 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 10.2 mtmp? -62.64 -28.72 70.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.074 -177.069 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -60.12 -48.82 80.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.029 178.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -65.79 -26.96 67.93 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.341 0.591 . . . . 0.0 110.835 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -79.73 -27.23 40.61 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.842 -179.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.69 -39.95 12.15 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.835 -177.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.532 ' HA ' HD21 ' A' ' 130' ' ' LEU . 13.6 p -69.3 134.96 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.034 0.445 . . . . 0.0 111.176 -177.186 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -121.32 151.59 39.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.794 -177.23 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.479 HG23 HD12 ' A' ' 18' ' ' LEU . 71.4 m -71.91 124.43 24.85 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.112 175.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.04 9.42 54.01 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.879 -177.182 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -97.97 177.14 5.53 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.496 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.6 OUTLIER -116.07 113.79 23.66 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.363 0.602 . . . . 0.0 111.613 -172.914 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 17' ' ' ALA . 45.3 t -113.2 127.96 70.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.68 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.6 t -113.15 117.4 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 172.049 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.431 HG22 HG12 ' A' ' 128' ' ' VAL . 43.0 t -108.98 123.96 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -106.33 94.98 5.44 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 171.015 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.02 -19.73 62.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.947 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -62.29 -37.73 86.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.098 0.475 . . . . 0.0 109.927 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -87.37 -36.87 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.041 174.165 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.408 ' HA2' HG11 ' A' ' 102' ' ' VAL . . . 87.15 54.15 2.65 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -167.073 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' TYR . . . . . 0.409 ' OH ' ' HB3' ' A' ' 2' ' ' LYS . 72.8 t80 -137.14 134.86 36.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.383 -169.427 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.431 HG12 HG22 ' A' ' 121' ' ' VAL . 28.1 m -120.12 130.69 74.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.061 0.458 . . . . 0.0 110.842 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.53 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 38.8 tt0 -108.27 107.41 18.0 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 175.457 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 119' ' ' VAL . 60.2 tp -104.76 107.62 18.67 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.928 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.496 HG12 ' NH2' ' A' ' 118' ' ' ARG . 34.5 mm -101.44 110.98 29.67 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 . . . . . 0 C--N 1.313 -1.02 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.584 -177.688 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.988 0.423 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.487 ' HG2' ' HB3' ' A' ' 129' ' ' GLU . 54.3 mttm -93.42 133.45 36.68 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.212 174.244 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.442 ' CD2' ' HD1' ' A' ' 109' ' ' PHE . 93.5 m-85 -122.13 157.97 30.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.41 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.46 117.13 32.74 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.02 -178.127 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.6 p -119.6 172.9 7.33 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.16 177.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -104.97 131.95 51.83 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 177.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.618 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.49 134.02 34.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.092 -173.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.494 HD11 ' HG3' ' A' ' 103' ' ' GLU . 2.5 mp -110.58 -51.41 6.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 172.761 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.574 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -94.36 178.01 5.76 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.968 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -122.72 174.74 6.92 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 97.87 -163.44 21.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.687 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 58.9 mtt180 -120.59 148.46 43.84 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 178.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.657 ' HB1' ' HB2' ' A' ' 80' ' ' ALA . . . -129.15 114.68 16.62 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 178.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 79' ' ' LYS . 15.7 tm-20 -133.61 122.01 22.88 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.657 -173.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.03 -173.98 44.74 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.344 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 31.1 mp0 -71.39 138.23 48.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -95.24 123.12 38.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.885 0.374 . . . . 0.0 110.915 178.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.1 mp -104.84 127.03 52.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.113 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.784 HG12 ' HB ' ' A' ' 115' ' ' THR . 13.4 p -102.04 137.67 29.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.852 -173.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.4 m -150.14 107.86 3.68 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 175.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -96.72 65.26 2.17 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.03 -177.457 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 mm-40 -142.74 161.74 37.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.3 176.157 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -88.38 81.75 7.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.909 0.385 . . . . 0.0 111.6 -177.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.518 HG22 ' H ' ' A' ' 26' ' ' PHE . 4.3 mp -108.17 112.23 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.694 0 CA-C-O 121.733 0.778 . . . . 0.0 109.749 173.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.3 m -87.38 36.36 0.74 Allowed 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.009 -177.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.518 ' H ' HG22 ' A' ' 24' ' ' ILE . 56.8 m-85 63.88 -81.89 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.223 0.609 . . . . 0.0 111.106 -176.228 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.2 mt 58.41 -85.4 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 O-C-N 123.896 0.748 . . . . 0.0 111.598 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -158.17 24.59 0.39 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.135 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.84 -22.29 79.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.772 -176.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 39.8 mt -92.94 127.61 44.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.961 0.41 . . . . 0.0 110.338 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 38' ' ' LYS . 16.2 t70 -67.27 119.03 11.47 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.957 176.393 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 10.2 ptpp? -83.22 0.6 44.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.645 0.259 . . . . 0.0 111.355 -173.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -85.29 -46.81 10.65 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.899 0.38 . . . . 0.0 110.544 177.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.4 p -125.56 -5.47 7.05 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.991 0.738 . . . . 0.0 112.991 -174.105 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.99 30.86 55.08 Favored Glycine 0 C--O 1.236 0.233 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.41 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 40.9 mm -99.66 123.84 52.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.641 HG21 ' HE3' ' A' ' 44' ' ' LYS . 15.3 t -71.2 104.53 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.244 176.731 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.453 ' CG ' ' HB2' ' A' ' 31' ' ' ASP . 6.8 mmmm -78.62 -19.99 51.41 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.523 -174.016 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -90.56 110.22 21.36 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.756 178.032 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.491 ' HA ' ' HB3' ' A' ' 44' ' ' LYS . 19.3 t70 -97.81 155.88 16.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.108 0.48 . . . . 0.0 110.966 -178.067 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 18.7 p -141.32 -37.93 0.42 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.322 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -141.02 -62.47 0.48 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.186 -177.227 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.441 HD12 HG21 ' A' ' 115' ' ' THR . 30.2 pt -133.17 17.52 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.932 -172.683 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.641 ' HE3' HG21 ' A' ' 37' ' ' VAL . 17.4 tptt -80.97 -173.4 4.24 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.13 0.491 . . . . 0.0 111.565 -168.57 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.36 -0.44 55.8 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -173.147 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -94.28 179.01 5.44 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.963 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 9.5 m -92.41 132.13 37.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.203 -175.034 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 28.7 m -106.23 -0.27 10.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.113 0.482 . . . . 0.0 110.003 172.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.86 96.54 0.19 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.546 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.522 ' C ' ' HD2' ' A' ' 51' ' ' ARG . . . 86.12 20.98 54.05 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.266 -1.333 . . . . 0.0 112.517 177.464 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.522 ' HD2' ' C ' ' A' ' 50' ' ' GLY . 4.0 mpt_? -119.01 166.15 13.23 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.719 0.295 . . . . 0.0 110.588 178.332 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.783 HG12 ' HB3' ' A' ' 80' ' ' ALA . 63.3 mt -93.63 122.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.299 -0.409 . . . . 0.0 109.943 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.427 HD21 ' HE2' ' A' ' 55' ' ' PHE . 17.0 tp -99.33 128.0 45.4 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.572 -175.488 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.9 120.17 60.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.118 0.485 . . . . 0.0 111.215 -177.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PHE . . . . . 0.428 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.9 m-85 -133.37 144.49 52.57 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 176.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 14.0 Cg_exo -69.72 -54.21 0.23 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.55 2.167 . . . . 0.0 111.074 175.032 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.624 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.434 178.577 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 26.4 p90 . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.277 0.56 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.622 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 9.6 p -71.23 -29.79 37.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.401 -175.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.4 mp -66.9 -41.68 86.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.78 -178.74 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.27 -36.0 80.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 177.738 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -58.94 -48.33 81.88 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.332 175.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.622 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 81.2 mt -58.4 -40.32 82.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 178.765 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.521 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -66.78 -42.78 85.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.082 -178.616 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -64.79 -27.97 69.25 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.682 0.277 . . . . 0.0 111.374 -179.234 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -90.47 -17.8 26.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.19 0.519 . . . . 0.0 110.082 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 83.58 26.8 41.21 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.349 178.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.87 11.6 7.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.152 0.501 . . . . 0.0 110.537 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.439 ' HB1' HD11 ' A' ' 99' ' ' ILE . . . -81.93 158.38 67.68 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.138 -179.303 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 24.3 Cg_exo -62.16 148.55 93.0 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.192 1.928 . . . . 0.0 110.99 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.506 ' HD3' ' O ' ' A' ' 14' ' ' GLU . 75.5 tttt -84.96 -21.63 29.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.511 . . . . 0.0 109.635 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.783 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -166.49 163.55 17.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.227 175.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.458 HG23 ' HB3' ' A' ' 101' ' ' LEU . 7.9 tt -146.84 114.71 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.288 0.566 . . . . 0.0 110.065 174.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.63 HD12 HG22 ' A' ' 102' ' ' VAL . 7.6 mm -108.55 124.31 64.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.442 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.3 m120 -120.93 160.89 22.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.297 -173.065 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 79.7 tttt -77.11 -37.45 54.21 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 171.783 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -154.71 154.71 33.32 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 114.711 -1.132 . . . . 0.0 108.57 168.703 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -143.52 172.63 12.53 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.78 -178.242 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -107.98 168.19 9.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.597 -177.377 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.0 m -58.85 -52.15 66.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -173.075 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 pt -63.5 -30.08 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 C-N-CA 120.638 -0.425 . . . . 0.0 112.067 -174.43 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.1 mm -64.93 -45.41 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -64.47 -48.02 76.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.051 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 86.9 t -61.81 -46.51 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.18 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.13 -43.87 98.03 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.567 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.558 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -72.21 -35.93 69.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.437 0.161 . . . . 0.0 111.319 -178.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.07 -31.26 69.83 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.139 0.495 . . . . 0.0 110.73 178.051 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.8 mtm -82.68 -39.88 21.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.625 178.24 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.521 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -80.68 6.84 11.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.024 -178.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 47.9 mt-10 64.23 35.47 10.05 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.263 0.554 . . . . 0.0 110.971 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.53 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 54.2 mt -109.91 88.61 6.97 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.101 178.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 32.8 Cg_exo -58.53 118.04 4.86 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.67 2.247 . . . . 0.0 113.018 -176.248 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.58 HD21 ' HA ' ' A' ' 91' ' ' ALA . 1.7 pt? -117.34 141.64 48.07 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.251 175.14 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.63 HG22 HD12 ' A' ' 82' ' ' ILE . 31.3 m -138.04 161.56 32.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.928 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.494 ' HG3' HD11 ' A' ' 8' ' ' ILE . 53.2 mt-10 -97.92 116.8 30.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.686 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.592 HG12 HG22 ' A' ' 82' ' ' ILE . 7.2 p -115.23 107.38 22.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.764 0.792 . . . . 0.0 109.187 172.143 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 8.3 ttm-85 -99.04 14.65 28.46 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.048 -175.215 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -89.18 120.01 30.18 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.044 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -67.39 -34.71 77.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.391 -175.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 111' ' ' GLU . 32.8 mmtp -69.49 -23.0 63.57 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.32 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.442 ' HD1' ' CD2' ' A' ' 3' ' ' PHE . 87.6 t80 -62.19 -51.04 69.39 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 172.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.402 ' CZ ' HG13 ' A' ' 104' ' ' VAL . 87.0 m-85 -69.7 -25.96 64.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.842 -178.243 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.439 ' HB2' ' HA ' ' A' ' 108' ' ' LYS . 37.1 mm-40 -74.92 -29.59 61.01 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.009 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.79 -34.03 14.74 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -176.811 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.7 p -85.15 138.6 18.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.173 0.511 . . . . 0.0 111.375 -175.508 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -124.48 167.07 14.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.972 173.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.784 ' HB ' HG12 ' A' ' 19' ' ' VAL . 9.8 t -67.55 107.58 2.55 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.725 0.774 . . . . 0.0 110.657 -178.371 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.15 -24.39 4.23 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.554 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -63.72 151.12 42.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.868 0.334 . . . . 0.0 110.28 179.156 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.691 HH21 HG13 ' A' ' 131' ' ' ILE . 1.1 tmm_? -96.68 120.37 36.89 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -175.04 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.448 HG22 HD12 ' A' ' 130' ' ' LEU . 46.3 t -120.68 141.2 42.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.757 -175.047 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' VAL . . . . . 0.486 HG23 ' HB2' ' A' ' 14' ' ' GLU . 9.9 p -124.38 121.1 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 121.763 0.792 . . . . 0.0 109.464 169.652 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 13' ' ' ALA . 40.2 t -106.54 127.35 62.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.472 -178.01 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.2 t-20 -93.44 97.48 10.58 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.38 -13.83 51.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.363 -175.047 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -68.92 -45.11 71.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.158 0.504 . . . . 0.0 109.744 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -93.85 -43.26 8.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.086 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.38 69.22 0.82 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -172.32 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.7 t80 -161.31 157.62 25.74 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 -172.128 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -152.99 138.64 11.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.021 -179.032 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HG2' ' A' ' 2' ' ' LYS . 2.2 pm0 -118.75 119.99 36.05 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.356 0.598 . . . . 0.0 110.458 174.142 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.448 HD12 HG22 ' A' ' 119' ' ' VAL . 54.7 tp -84.01 130.54 34.88 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.69 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.691 HG13 HH21 ' A' ' 118' ' ' ARG . 37.1 mm -101.27 120.25 50.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 CA-C-O 121.412 0.625 . . . . 0.0 109.6 177.236 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.198 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.195 -178.129 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -131.06 113.22 13.66 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.513 178.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -93.3 152.85 18.9 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.949 0.404 . . . . 0.0 111.181 -175.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.51 124.39 47.97 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.669 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 56.9 m -119.41 174.0 6.63 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.914 0.388 . . . . 0.0 110.82 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 40.7 ttt180 -92.83 111.7 23.4 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -90.84 137.83 32.06 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.569 -171.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.609 HD13 HD12 ' A' ' 101' ' ' LEU . 4.3 mp -103.87 -52.2 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 48.7 p -102.95 176.42 5.16 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.771 176.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 61.0 mtt180 -122.37 -175.35 3.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.661 0.267 . . . . 0.0 111.076 -176.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.15 171.83 27.35 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -175.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.4 HH21 ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -140.26 139.5 35.56 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 117.282 0.541 . . . . 0.0 110.52 -178.631 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.613 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -135.46 145.49 47.23 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.076 0.465 . . . . 0.0 111.65 -174.561 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.21 123.05 38.73 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.083 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.89 176.4 41.93 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 119.68 -1.248 . . . . 0.0 112.528 179.202 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.66 137.65 39.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 177.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.46 124.81 29.24 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.814 -176.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.404 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.8 tt -119.28 121.23 39.16 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' OG1' ' A' ' 115' ' ' THR . 8.9 p -111.4 120.12 61.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.078 0.466 . . . . 0.0 110.185 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.3 t -94.12 -6.74 44.29 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.077 0.465 . . . . 0.0 111.366 -175.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.0 tttt 68.54 -61.07 0.42 Allowed 'General case' 0 CA--C 1.539 0.54 0 CA-C-N 114.958 -1.019 . . . . 0.0 113.605 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -71.64 163.67 27.33 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -82.53 78.2 9.19 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.622 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.6 pt -106.11 135.74 43.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.961 0.41 . . . . 0.0 110.397 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.3 t -111.02 178.02 4.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.941 -178.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.41 ' HZ ' HD13 ' A' ' 81' ' ' ILE . 77.7 m-85 -87.53 29.6 0.87 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.257 0.551 . . . . 0.0 111.414 -174.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.556 HD22 HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -65.39 -21.97 66.74 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 171.04 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.95 -127.61 1.44 Allowed Glycine 0 N--CA 1.444 -0.833 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.184 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.688 ' HA2' ' HB2' ' A' ' 39' ' ' GLU . . . 86.59 -43.78 3.27 Favored Glycine 0 C--O 1.221 -0.687 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.847 172.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.461 HG12 HG12 ' A' ' 37' ' ' VAL . 57.3 mt -109.05 136.94 43.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -66.07 130.03 41.85 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.88 -33.31 73.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -170.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -109.41 -35.12 6.34 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.48 -0.488 . . . . 0.0 111.887 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 m -81.47 -28.57 34.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.583 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.832 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.82 19.55 78.82 Favored Glycine 0 C--N 1.329 0.191 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.505 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.456 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.7 mm -95.87 131.06 43.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.461 HG12 HG12 ' A' ' 30' ' ' ILE . 13.9 m -71.39 107.97 2.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.814 0.816 . . . . 0.0 110.218 175.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mmmm -92.35 -10.44 38.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.047 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.688 ' HB2' ' HA2' ' A' ' 29' ' ' GLY . 9.8 tp10 -80.8 153.4 27.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.792 177.152 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -100.04 137.95 37.79 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.244 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 16.3 p -161.27 -56.23 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.327 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -173.29 -51.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.477 174.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -92.05 44.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.885 0.85 . . . . 0.0 110.156 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -78.76 129.88 35.14 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.409 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.52 11.3 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.797 179.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.424 ' O ' HG22 ' A' ' 37' ' ' VAL . 26.7 mt-10 -92.86 171.69 8.81 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.299 0.571 . . . . 0.0 111.973 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.456 ' HB3' HD13 ' A' ' 36' ' ' ILE . 15.6 p -105.37 151.12 24.58 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.447 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 30' ' ' ILE . 27.2 m -102.66 18.2 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.773 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.8 95.72 2.96 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.759 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.03 21.07 28.91 Favored Glycine 0 C--N 1.315 -0.619 0 CA-C-N 115.163 -0.926 . . . . 0.0 113.472 170.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -123.6 175.0 7.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 80' ' ' ALA . 50.2 mm -99.11 129.51 49.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 -174.621 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.594 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 3.6 mm? -110.0 130.69 55.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.098 0.475 . . . . 0.0 111.341 -176.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.457 HG21 HG21 ' A' ' 113' ' ' VAL . 52.8 t -117.9 125.7 74.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.662 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.594 ' CE1' ' HB3' ' A' ' 53' ' ' LEU . 27.3 m-85 -131.5 143.92 51.24 Favored Pre-proline 0 C--N 1.327 -0.385 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -73.15 -42.83 0.86 Allowed 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 121.855 1.704 . . . . 0.0 110.57 171.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -176.23 -177.79 45.51 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.59 130.7 4.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.902 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.3 ptmm? -74.27 139.38 44.24 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.867 0.365 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.23 -82.57 1.67 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 121.129 -0.558 . . . . 0.0 111.781 -178.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 51.0 m 58.65 31.04 20.7 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.19 0.519 . . . . 0.0 111.54 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 3.8 m -75.23 -23.45 57.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.977 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.556 HG12 HD22 ' A' ' 27' ' ' LEU . 6.0 p -145.5 158.2 12.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.443 ' HA2' HG22 ' A' ' 67' ' ' VAL . . . 153.1 -13.58 0.63 Allowed Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.47 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -65.4 -22.56 66.8 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 111.499 0.185 . . . . 0.0 111.499 -177.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -96.22 -34.19 11.73 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -177.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.443 HG22 ' HA2' ' A' ' 64' ' ' GLY . 35.3 m -69.39 -32.22 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 111.648 0.24 . . . . 0.0 111.648 -173.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.3 mt -61.0 -38.8 87.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.942 0.401 . . . . 0.0 110.932 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 59.4 tp -71.74 -41.18 68.79 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.561 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -62.62 -44.18 96.93 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.714 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 94.7 mt -62.75 -39.6 94.64 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.614 178.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.516 ' HG2' ' O ' ' A' ' 97' ' ' ALA . 11.3 tpt180 -67.65 -41.47 83.75 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.365 -175.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.33 -10.08 59.24 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 110.898 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -94.98 -16.58 22.65 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.075 0.464 . . . . 0.0 110.399 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.23 11.66 81.93 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.086 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.832 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.2 m -106.65 13.67 8.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.106 0.479 . . . . 0.0 111.011 -177.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.15 155.57 42.75 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.832 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.594 ' HB3' HD23 ' A' ' 53' ' ' LEU . 37.0 Cg_endo -66.42 147.18 82.32 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.487 2.125 . . . . 0.0 111.201 173.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.613 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.2 mttt -68.15 -42.16 80.52 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.867 0.365 . . . . 0.0 111.14 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.534 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -151.4 156.54 40.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.778 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.41 HD13 ' HZ ' ' A' ' 26' ' ' PHE . 74.5 mt -132.83 128.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.392 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.713 HG23 HG23 ' A' ' 102' ' ' VAL . 2.3 mm -112.37 128.39 69.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.344 -0.614 . . . . 0.0 109.344 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 89.2 m-20 -126.31 159.55 32.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.879 -178.004 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.517 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 2.7 tmtp? -92.91 -35.69 13.2 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 173.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -142.58 101.99 3.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.813 174.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -95.41 -179.9 4.93 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -174.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.31 150.69 43.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.944 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 92' ' ' VAL . 13.1 m -62.52 -37.7 87.06 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.289 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.98 -29.53 47.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.9 mt -71.83 -42.52 69.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB1' HG21 ' A' ' 8' ' ' ILE . . . -59.43 -42.88 92.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.263 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 88' ' ' THR . 57.1 t -62.76 -47.86 90.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.828 179.287 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.2 -43.41 99.16 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.258 178.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.49 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.5 -31.08 71.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.358 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -70.09 -35.11 73.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.911 0.386 . . . . 0.0 111.252 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.1 mtm -81.61 -33.62 31.4 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 -178.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.516 ' O ' ' HG2' ' A' ' 72' ' ' ARG . . . -89.99 0.51 57.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.003 -177.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 55.15 61.63 2.84 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.829 0.823 . . . . 0.0 110.098 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.49 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.7 mt -123.11 90.05 50.55 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 114.784 -1.098 . . . . 0.0 109.801 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 4.2 Cg_exo -40.04 109.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.348 0.541 0 C-N-CA 123.669 2.912 . . . . 0.0 112.891 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.609 HD12 HD13 ' A' ' 8' ' ' ILE . 1.1 tm? -110.59 120.0 40.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.348 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.713 HG23 HG23 ' A' ' 82' ' ' ILE . 24.7 m -130.36 144.21 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.019 0.438 . . . . 0.0 110.634 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -110.16 122.84 48.58 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.03 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.456 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.3 p -98.8 134.45 37.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.185 0.517 . . . . 0.0 110.687 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 0.7 OUTLIER -92.79 -14.8 27.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.929 -174.328 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 104' ' ' VAL . 5.6 t70 -109.42 137.61 47.01 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.558 -0.457 . . . . 0.0 111.274 -175.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -72.78 -19.36 61.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.847 -176.172 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 19.0 mmtp -58.3 -26.6 63.21 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.461 ' O ' HG12 ' A' ' 113' ' ' VAL . 79.9 t80 -61.72 -42.81 99.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.755 0.312 . . . . 0.0 110.3 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.51 ' HA ' HG12 ' A' ' 113' ' ' VAL . 87.6 m-85 -75.16 -24.97 57.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.24 -175.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -74.33 -33.45 63.16 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.484 175.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.16 -41.05 17.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.723 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.4 p -78.27 124.37 36.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.777 0.799 . . . . 0.0 111.386 -175.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 114' ' ' LYS . 32.0 mmtp -132.06 153.25 50.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.706 175.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 60.8 m -62.35 114.87 3.74 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 123.195 0.31 . . . . 0.0 110.932 -178.283 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.6 -32.13 2.17 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 119.792 -1.194 . . . . 0.0 114.395 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.93 -172.11 2.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 117.736 0.768 . . . . 0.0 111.028 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -112.27 126.04 54.82 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.278 0.561 . . . . 0.0 111.905 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.449 HG23 ' HB2' ' A' ' 17' ' ' ALA . 65.8 t -121.52 120.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.892 176.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 60.7 t -89.29 111.83 23.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.759 177.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 41.9 t -95.54 109.02 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.565 -177.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -110.34 99.08 8.17 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.99 -9.35 53.77 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.022 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' HH21 ' A' ' 12' ' ' ARG . 18.5 m-20 -63.81 -47.01 82.58 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 174.2 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -93.2 -31.18 14.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.736 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 91.92 59.08 1.35 Allowed Glycine 0 N--CA 1.452 -0.295 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 143.49 29.75 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.793 0.33 . . . . 0.0 110.643 -169.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.53 106.31 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.319 0.581 . . . . 0.0 109.962 174.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 120' ' ' VAL . 39.8 mt-10 -96.3 108.46 20.97 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.665 -174.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.6 tp -81.3 110.05 16.39 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.6 mm -112.74 114.9 48.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -176.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 . . . . . 0 C--N 1.312 -1.041 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.157 -170.604 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.226 -0.162 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.507 ' HD3' ' OH ' ' A' ' 127' ' ' TYR . 74.2 mttt -125.54 145.67 50.01 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.529 -177.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.479 ' HB2' HG13 ' A' ' 128' ' ' VAL . 89.6 m-85 -129.48 161.92 29.3 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.398 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.15 126.65 55.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.106 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.43 ' SG ' HG21 ' A' ' 102' ' ' VAL . 5.7 p -119.71 167.74 11.75 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.209 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.567 ' HD3' ' OE2' ' A' ' 103' ' ' GLU . 36.6 ttt180 -93.96 121.95 35.96 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.981 0.42 . . . . 0.0 110.107 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.98 102.9 3.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.123 -175.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.556 HG13 HG21 ' A' ' 86' ' ' THR . 50.0 mm -95.91 -43.57 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.11 177.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.7 p -109.57 -165.0 0.97 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.134 177.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -136.43 164.49 28.03 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -177.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.05 161.62 22.77 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.932 -0.652 . . . . 0.0 111.906 -177.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -147.86 154.12 40.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.09 0.445 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.45 164.97 24.3 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.081 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -127.92 127.05 42.66 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 176.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.62 178.92 32.83 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.056 -1.069 . . . . 0.0 112.69 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -74.44 139.86 44.25 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.33 178.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.586 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.56 122.83 27.53 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.07 0.462 . . . . 0.0 111.002 -178.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.3 tt -117.61 117.14 28.59 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 174.438 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.822 HG12 ' HB ' ' A' ' 115' ' ' THR . 8.4 p -101.6 124.99 55.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.442 0.639 . . . . 0.0 110.984 -173.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . 1.037 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 13.2 m -95.63 95.03 8.08 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.446 0.641 . . . . 0.0 109.875 179.638 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -82.25 -2.61 53.1 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.944 -177.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -103.1 130.41 50.25 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.67 -176.33 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -85.14 98.89 10.72 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -118.95 172.64 5.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.253 -0.43 . . . . 0.0 112.007 -170.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.4 p -79.5 122.41 26.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.175 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.564 ' O ' ' HB ' ' A' ' 63' ' ' VAL . 21.5 t80 -85.48 31.26 0.59 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.568 0.699 . . . . 0.0 109.991 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -68.89 -23.8 64.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.198 177.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 174.37 -103.84 0.19 Allowed Glycine 0 N--CA 1.444 -0.832 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.294 178.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.72 -51.42 2.31 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.548 176.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.436 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.7 mp -87.47 129.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.75 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 27.5 t70 -78.55 139.96 38.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.038 0.447 . . . . 0.0 111.005 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.492 ' HA ' HD23 ' A' ' 71' ' ' LEU . 0.0 OUTLIER -64.84 -26.33 68.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.548 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 45.4 mt-10 -95.41 -46.88 6.51 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 36' ' ' ILE . 20.7 p -102.88 -19.15 14.76 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -174.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 73.93 20.14 79.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.015 -178.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.412 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.2 mm -87.68 133.03 31.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.639 -0.28 . . . . 0.0 110.453 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.3 m -74.28 111.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.582 0.706 . . . . 0.0 110.892 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.75 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 57.2 mttt -91.67 -10.89 38.61 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.947 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -66.33 138.27 57.49 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.646 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.41 131.42 44.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.38 -172.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 13.6 p 174.55 -178.22 0.1 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.981 -1.008 . . . . 0.0 108.482 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -79.35 -9.27 59.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.274 0.559 . . . . 0.0 110.095 175.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.417 ' O ' ' HB2' ' A' ' 46' ' ' GLU . 24.3 mt -94.26 -8.83 9.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.183 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.1 tmmm? -56.85 125.83 24.23 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.358 0.599 . . . . 0.0 110.372 -178.074 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.25 -24.36 12.64 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.964 -176.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 43' ' ' ILE . 1.1 mm-40 -71.15 162.97 28.54 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.311 0.577 . . . . 0.0 111.656 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.412 ' HB3' HD13 ' A' ' 36' ' ' ILE . 18.2 p -116.89 127.13 53.96 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.61 -178.431 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.414 HG21 HG12 ' A' ' 30' ' ' ILE . 33.4 m -87.53 1.8 5.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.207 -178.448 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.436 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.25 88.04 0.3 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.923 -177.553 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.53 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 107.36 11.04 26.34 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.519 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 mmm-85 -106.14 156.08 18.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.44 116.58 47.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 176.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.713 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -92.94 124.85 37.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.289 0.566 . . . . 0.0 111.324 -173.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 72.6 t -117.91 107.91 23.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.173 176.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 1.037 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 43.6 p90 -135.7 153.66 77.56 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.461 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -64.07 -49.89 3.42 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 122.591 2.194 . . . . 0.0 111.997 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -176.56 170.17 42.88 Favored Glycine 0 N--CA 1.448 -0.558 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.86 42.04 2.06 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.15 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 46.5 mtpt 64.46 8.96 4.63 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.96 43.18 74.62 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.557 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.8 p -91.91 125.61 36.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.135 0.493 . . . . 0.0 110.548 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.7 p -88.68 71.2 8.8 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-O 121.54 0.686 . . . . 0.0 111.214 -171.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.823 HG13 ' H ' ' A' ' 65' ' ' SER . 7.1 p -46.67 -35.03 2.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.079 173.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 102.79 -4.57 50.0 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.203 178.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.823 ' H ' HG13 ' A' ' 63' ' ' VAL . 60.7 p 60.06 -154.56 0.37 Allowed 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 123.62 0.768 . . . . 0.0 111.36 178.147 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 72.35 -56.48 0.65 Allowed 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.782 0.833 . . . . 0.0 112.084 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.3 m -60.92 -16.84 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -173.335 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.21 -28.18 69.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.803 0.335 . . . . 0.0 110.699 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.0 tp -62.34 -38.48 89.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.423 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -58.22 -47.67 82.77 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.649 178.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.492 HD23 ' HA ' ' A' ' 32' ' ' LYS . 76.4 mt -56.76 -44.43 81.77 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.706 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -72.8 -41.32 65.08 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.745 -176.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -61.85 -33.3 73.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.824 0.345 . . . . 0.0 110.374 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -85.53 -19.68 30.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.126 0.489 . . . . 0.0 110.512 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 86.89 23.44 41.79 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.216 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.523 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.4 m -113.32 12.47 8.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.603 -179.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.467 ' HB1' ' HD2' ' A' ' 78' ' ' PRO . . . -90.91 162.66 32.39 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.713 ' HB3' HD13 ' A' ' 53' ' ' LEU . 43.7 Cg_endo -69.66 149.9 68.1 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.037 1.825 . . . . 0.0 111.434 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.53 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 88.4 mttt -69.47 -30.46 68.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.938 0.399 . . . . 0.0 110.75 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -163.77 155.3 16.67 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.457 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 68.5 mt -131.09 127.28 60.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.998 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.453 HG23 HG23 ' A' ' 102' ' ' VAL . 5.5 mm -117.85 120.79 65.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 13.6 m120 -120.03 164.03 16.74 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.645 0.26 . . . . 0.0 110.74 -176.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -79.07 -46.11 18.76 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 174.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 85' ' ' LYS . 44.2 pttt -125.88 112.75 16.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.762 172.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.556 HG21 HG13 ' A' ' 8' ' ' ILE . 5.8 t -92.47 116.3 28.87 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.41 0.624 . . . . 0.0 109.476 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -98.52 167.91 10.52 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.544 -175.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.5 m -53.98 -47.64 71.17 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -169.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 90' ' ' ILE . 9.2 pt -55.56 -46.04 78.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 111.984 0.365 . . . . 0.0 111.984 -178.182 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 89' ' ' ILE . 36.4 mt -76.77 -40.56 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.325 -176.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.528 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.44 -50.64 73.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.564 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 92.3 t -64.87 -42.37 94.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.791 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.35 -45.56 96.19 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.785 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -73.93 -33.01 63.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.552 0.215 . . . . 0.0 111.567 -178.089 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.8 -40.16 95.96 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.963 0.411 . . . . 0.0 111.512 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 69.7 mtm -74.04 -42.87 59.62 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.244 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -74.3 -14.78 60.95 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -177.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 71.71 59.89 0.16 Allowed 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.662 0.744 . . . . 0.0 109.934 -173.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.1 mt -121.96 89.32 48.23 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.481 177.15 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -38.29 107.56 0.06 OUTLIER 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 123.792 2.994 . . . . 0.0 113.441 -177.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 43.6 tp -128.16 120.72 27.87 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.421 -176.259 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.453 HG23 HG23 ' A' ' 82' ' ' ILE . 20.6 m -135.0 166.76 27.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.195 179.366 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.567 ' OE2' ' HD3' ' A' ' 6' ' ' ARG . 9.9 pt-20 -113.59 141.16 47.52 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.066 0.46 . . . . 0.0 111.167 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 5.2 m -105.84 140.75 22.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.454 176.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -88.67 -26.27 21.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.221 -174.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -106.16 140.08 39.68 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.052 0.453 . . . . 0.0 111.372 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -71.14 -20.94 62.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.944 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.553 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 57.2 mttm -64.91 -17.97 64.8 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -60.64 -45.85 92.52 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 173.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.56 ' HA ' HG12 ' A' ' 113' ' ' VAL . 53.2 m-85 -76.12 -32.11 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.006 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.553 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.7 tt0 -57.3 -46.22 83.38 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.996 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -87.75 -24.62 23.74 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.481 -174.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.9 p -76.04 139.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.535 0.684 . . . . 0.0 111.96 -174.023 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -139.13 159.28 42.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.992 172.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.822 ' HB ' HG12 ' A' ' 19' ' ' VAL . 12.1 t -81.69 138.62 35.24 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.961 0.41 . . . . 0.0 110.434 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.53 -25.3 9.2 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.775 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -85.28 -171.78 3.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.608 0.242 . . . . 0.0 110.797 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 20.0 ttp180 -115.36 133.73 55.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.011 0.434 . . . . 0.0 111.447 -176.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.586 HG23 ' HB2' ' A' ' 17' ' ' ALA . 85.6 t -122.58 129.5 75.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.126 175.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.681 ' HB ' ' HB3' ' A' ' 129' ' ' GLU . 50.3 t -101.86 113.56 38.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.79 129.67 61.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.946 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -131.4 100.52 5.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.807 176.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.82 -12.22 55.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.472 -174.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.18 -7.64 58.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.025 0.44 . . . . 0.0 110.804 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -128.3 -20.99 3.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.868 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.29 59.94 2.79 Favored Glycine 0 CA--C 1.509 -0.336 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.507 ' OH ' ' HD3' ' A' ' 2' ' ' LYS . 60.8 t80 -142.71 135.64 28.19 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.316 -167.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.479 HG13 ' HB2' ' A' ' 3' ' ' PHE . 6.6 p -137.76 124.81 28.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.461 0.648 . . . . 0.0 110.579 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.681 ' HB3' ' HB ' ' A' ' 120' ' ' VAL . 34.5 tt0 -115.96 122.45 45.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.413 -175.665 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 19.6 tp -106.63 127.53 53.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.945 0.402 . . . . 0.0 110.688 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 131' ' ' ILE . 3.5 mp -122.45 122.07 65.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 174.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.465 ' H ' ' CD ' ' A' ' 132' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.315 -0.91 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.618 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 C--O 1.234 0.25 0 CA-C-O 120.677 0.275 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.513 ' HG2' ' HG2' ' A' ' 129' ' ' GLU . 49.2 mttp -101.7 107.48 18.72 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 177.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -86.76 141.42 28.88 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.27 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.31 127.97 36.31 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.514 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.2 m -120.82 159.02 26.33 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.032 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.444 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 27.1 ttm180 -102.79 115.94 31.58 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 176.279 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.709 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.0 133.84 44.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.0 -173.67 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.0 mm -106.94 -49.36 8.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 174.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.425 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 61.7 p -117.42 177.24 4.81 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.786 173.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 10' ' ' ARG . 61.5 mtt180 -101.1 169.49 8.9 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.801 0.334 . . . . 0.0 111.003 -177.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 134.68 153.54 6.89 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.124 178.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -137.84 130.17 29.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.577 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -146.27 164.22 33.02 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.937 0.398 . . . . 0.0 111.391 -175.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.03 149.12 27.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.833 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 160.36 -167.53 35.65 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.142 -1.028 . . . . 0.0 112.148 175.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 50.9 mm-40 -64.57 128.08 34.26 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.535 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.05 122.13 26.94 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.852 -178.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.3 tp -106.22 108.4 19.89 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 175.168 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.517 ' HB ' ' HB ' ' A' ' 115' ' ' THR . 43.3 t -110.59 113.52 44.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.967 0.413 . . . . 0.0 110.991 -172.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 22' ' ' GLU . 30.2 m -105.0 110.17 22.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.922 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -86.26 26.8 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.263 0.554 . . . . 0.0 110.837 -177.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' THR . 8.0 tp10 -115.44 157.51 23.86 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.76 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -103.4 94.61 5.58 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 pt -85.32 172.1 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.3 0.571 . . . . 0.0 111.445 -175.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.729 ' HB2' HD23 ' A' ' 27' ' ' LEU . 26.0 p -110.26 122.54 47.9 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.957 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.551 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 90.7 m-85 -81.21 64.4 5.93 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.319 0.58 . . . . 0.0 110.476 179.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.729 HD23 ' HB2' ' A' ' 25' ' ' SER . 3.5 mm? -119.74 -57.03 2.0 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.936 174.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.54 44.52 0.69 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.81 -53.15 6.55 Favored Glycine 0 C--O 1.224 -0.47 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.943 -176.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 65.7 mt -98.61 135.51 33.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.833 0.316 . . . . 0.0 110.815 -177.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.418 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 13.1 t70 -67.06 134.78 52.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.268 177.091 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -68.52 -25.61 65.03 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.221 0.452 . . . . 0.0 112.221 -171.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -110.77 -38.11 5.23 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.231 0.538 . . . . 0.0 111.288 -168.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.551 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -98.94 -14.97 19.31 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.585 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 47' ' ' SER . . . 68.29 21.89 74.3 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.085 -178.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.551 HG12 ' HB ' ' A' ' 34' ' ' THR . 36.4 mm -88.44 127.07 41.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 122.18 0.192 . . . . 0.0 110.625 -177.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 47.1 t -71.62 113.92 9.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -88.62 -28.61 20.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.054 -176.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -65.58 123.01 18.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.588 ' HA ' ' HG3' ' A' ' 44' ' ' LYS . 35.2 t70 -73.26 141.11 47.23 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.968 -173.221 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 42.0 t -172.81 -73.65 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.071 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -156.58 -51.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.331 179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.407 HG13 ' H ' ' A' ' 43' ' ' ILE . 1.9 pp -82.41 15.31 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.078 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.588 ' HG3' ' HA ' ' A' ' 40' ' ' ASP . 4.5 tmmm? -65.16 124.99 23.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.698 179.233 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 104.4 -15.29 50.3 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.368 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -91.27 159.24 16.13 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.307 0.575 . . . . 0.0 112.07 177.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.505 ' HB3' HD13 ' A' ' 36' ' ' ILE . 2.5 p -103.74 158.54 16.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.246 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.509 HG11 HD21 ' A' ' 53' ' ' LEU . 26.7 m -108.63 20.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.919 -179.511 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.03 91.93 2.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.647 -173.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.96 20.64 27.75 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.001 -0.999 . . . . 0.0 112.91 174.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -110.33 158.97 17.86 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.863 -0.198 . . . . 0.0 110.64 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.46 ' HB ' ' HA ' ' A' ' 17' ' ' ALA . 49.6 mm -95.59 104.58 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.815 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.623 HD13 ' HB3' ' A' ' 78' ' ' PRO . 9.9 mp -85.58 133.34 34.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.17 0.509 . . . . 0.0 111.688 -172.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.61 121.15 59.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.743 176.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.554 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 78.3 m-85 -128.88 144.42 52.41 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.825 0.345 . . . . 0.0 111.332 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -81.17 -11.32 12.17 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.546 2.164 . . . . 0.0 111.883 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 137.54 -158.66 24.6 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.054 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 154.96 -142.87 9.34 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -120.42 102.79 8.69 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.868 0.366 . . . . 0.0 110.597 177.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.551 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -96.47 81.73 0.76 Allowed Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.6 t -82.57 -178.29 7.02 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.071 0.463 . . . . 0.0 110.751 -176.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.1 p -66.93 -13.92 62.27 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.078 -175.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.1 t -87.55 -14.91 9.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.892 0.377 . . . . 0.0 110.774 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 26' ' ' PHE . . . -77.27 -24.6 65.55 Favored Glycine 0 N--CA 1.453 -0.204 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.434 -178.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.9 p -80.19 162.65 24.58 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.91 -0.171 . . . . 0.0 111.004 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 2.0 t80 75.58 -43.76 0.5 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.373 0.669 . . . . 0.0 111.899 175.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 58.9 t -58.85 -33.74 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.929 0.395 . . . . 0.0 111.323 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.433 ' HB3' HD12 ' A' ' 99' ' ' ILE . 87.1 mt -57.73 -31.37 66.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.573 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.6 tp -67.3 -33.99 76.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.105 0.478 . . . . 0.0 110.514 -178.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -66.01 -41.84 90.48 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.972 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.7 mt -57.42 -42.59 82.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.587 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.403 ' N ' ' HB2' ' A' ' 77' ' ' ALA . 34.4 ttt180 -59.78 -51.04 71.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.915 -178.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 55.8 mtmt -75.39 -8.07 55.7 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.985 -174.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.481 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.0 t-20 -92.42 -30.91 15.51 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.988 0.423 . . . . 0.0 109.909 175.033 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.09 15.41 28.34 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.091 -178.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.481 HG22 ' HB3' ' A' ' 74' ' ' ASN . 20.1 m -117.64 14.17 7.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.888 0.375 . . . . 0.0 111.185 -178.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.403 ' HB2' ' N ' ' A' ' 72' ' ' ARG . . . -73.99 150.11 87.9 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.245 179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.623 ' HB3' HD13 ' A' ' 53' ' ' LEU . 7.9 Cg_exo -71.89 138.47 31.45 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.558 2.172 . . . . 0.0 110.383 171.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.577 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 85.5 mttt -63.44 -42.26 98.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.756 0.313 . . . . 0.0 111.346 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -157.92 153.57 26.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.803 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.575 HG12 ' HB2' ' A' ' 53' ' ' LEU . 52.8 mt -134.07 114.44 19.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.423 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.414 HG23 ' CG2' ' A' ' 102' ' ' VAL . 21.3 mm -100.65 124.22 54.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.554 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 16.8 m120 -123.35 155.75 36.71 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.018 0.437 . . . . 0.0 111.228 -174.395 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.524 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 88.3 tttt -76.95 -46.98 22.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.502 174.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -116.89 120.71 39.31 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.815 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.4 t -99.51 134.77 41.91 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.721 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.51 141.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.464 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.5 m -66.99 -36.18 81.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.503 -175.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 87.0 mt -61.29 -43.88 97.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.976 0.417 . . . . 0.0 110.353 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.493 HD11 ' HA3' ' A' ' 60' ' ' GLY . 59.5 mt -64.4 -40.58 89.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.006 177.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.479 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -59.46 -46.57 88.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.527 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 88' ' ' THR . 90.1 t -58.52 -43.65 87.45 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 CA-C-O 120.975 0.417 . . . . 0.0 110.555 179.152 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.27 -41.05 69.73 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.5 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -71.05 -31.28 67.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.463 0.173 . . . . 0.0 111.412 -177.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.56 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.987 0.422 . . . . 0.0 110.971 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.7 mtm -70.29 -32.99 71.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.003 -179.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.43 3.47 49.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.797 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 56.15 43.1 27.35 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.927 0.87 . . . . 0.0 110.362 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 68' ' ' LEU . 63.8 mt -109.77 89.26 7.53 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.671 177.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.425 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 19.1 Cg_endo -56.99 116.0 2.9 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.893 2.395 . . . . 0.0 112.616 -176.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.48 ' H ' HD23 ' A' ' 101' ' ' LEU . 2.6 pt? -118.44 137.07 53.41 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.508 175.359 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 7' ' ' ALA . 18.9 m -132.48 163.1 38.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.861 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.444 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 14.7 pt-20 -103.81 135.34 45.53 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.848 0.356 . . . . 0.0 110.094 176.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 15.8 m -116.26 130.92 70.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.102 0.477 . . . . 0.0 110.382 175.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -101.92 1.3 36.68 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.127 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -95.94 123.64 39.62 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.984 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.93 -32.79 67.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.371 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 28.6 mtpp -69.89 -23.7 63.28 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -174.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -54.44 -49.43 70.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 174.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.524 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 96.6 m-85 -74.58 -28.25 60.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.981 0.419 . . . . 0.0 110.996 -179.032 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 43.2 tt0 -66.44 -45.25 80.45 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.599 176.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.21 -39.45 19.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.454 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.4 p -65.45 127.83 27.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-O 121.475 0.655 . . . . 0.0 110.963 -175.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -123.15 135.88 54.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.755 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.517 ' HB ' ' HB ' ' A' ' 19' ' ' VAL . 14.8 t -72.24 113.85 9.71 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-O 121.41 0.624 . . . . 0.0 109.551 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.5 -18.94 3.41 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.392 -176.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ASP . . . . . 0.553 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 0.8 OUTLIER -99.02 -171.71 2.14 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.676 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.553 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -114.54 137.34 51.98 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.337 0.589 . . . . 0.0 112.025 -174.92 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 17' ' ' ALA . 84.3 t -120.38 130.33 74.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.743 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.5 t -98.88 111.44 28.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 174.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 88.3 t -96.0 120.71 45.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.134 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -124.71 99.85 6.36 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -86.18 -11.67 51.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.126 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -67.71 -43.01 81.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.015 0.436 . . . . 0.0 110.009 178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -96.38 -23.92 16.39 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.542 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.16 62.93 1.46 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.521 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.528 ' CE1' ' HG3' ' A' ' 129' ' ' GLU . 25.6 p90 -162.41 163.55 27.67 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.772 0.32 . . . . 0.0 110.168 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.26 126.36 58.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.248 175.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.528 ' HG3' ' CE1' ' A' ' 127' ' ' TYR . 39.5 mt-10 -98.56 107.92 20.49 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.095 176.454 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 60.7 tp -82.45 102.0 11.03 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.358 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 18.1 pt -92.37 109.94 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.455 0.645 . . . . 0.0 110.291 -175.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 . . . . . 0 C--N 1.316 -0.854 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.085 -177.165 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.508 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 13.9 m . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 121.261 0.553 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -130.74 114.93 15.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.739 -176.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.508 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 76.6 m-85 -128.5 164.75 22.1 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.118 0.485 . . . . 0.0 111.036 -176.526 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -118.49 139.43 51.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.447 174.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 10.3 p -120.21 171.67 8.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.258 -178.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.7 ttt85 -93.88 118.06 30.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.971 0.415 . . . . 0.0 110.116 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.53 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.82 96.52 1.66 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.042 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.468 HD11 ' OE1' ' A' ' 103' ' ' GLU . 49.3 mm -82.2 -43.51 19.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.87 175.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.8 p -125.29 -164.25 1.27 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.293 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 60.7 mtt-85 -118.56 -175.28 2.85 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.705 0.288 . . . . 0.0 110.59 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.564 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 115.71 145.21 8.43 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.04 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 68.8 mtm-85 -141.38 115.2 9.11 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.24 169.38 24.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.871 0.367 . . . . 0.0 111.193 -176.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.553 ' OE1' ' HD2' ' A' ' 118' ' ' ARG . 14.2 pt-20 -135.42 146.77 48.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.87 178.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.98 -173.48 34.48 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 120.079 -1.058 . . . . 0.0 112.098 174.119 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.62 127.97 34.4 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.45 118.98 22.54 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.905 -177.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.8 tp -102.02 111.42 23.68 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.563 ' HA ' ' CG1' ' A' ' 54' ' ' VAL . 47.1 t -98.87 110.92 27.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.385 0.612 . . . . 0.0 110.522 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.468 HG21 HD11 ' A' ' 24' ' ' ILE . 6.8 m -110.55 132.16 54.43 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.092 -176.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -102.77 -10.02 19.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.13 0.491 . . . . 0.0 110.573 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -97.88 161.47 13.73 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -96.0 141.73 29.06 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.553 0.216 . . . . 0.0 110.468 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 20' ' ' THR . 2.5 mp -114.16 132.89 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.517 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 55.2 p -78.73 115.23 18.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.148 0.499 . . . . 0.0 110.722 -178.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.95 -6.3 32.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.333 179.199 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.05 -30.53 71.5 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 175.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 146.55 51.81 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.48 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.16 21.17 32.64 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.161 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.511 HD13 HG21 ' A' ' 48' ' ' VAL . 53.6 mt -130.75 136.74 57.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 -179.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.592 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.1 t70 -69.46 123.79 22.18 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.268 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.608 ' HG2' ' OE1' ' A' ' 33' ' ' GLU . 0.6 OUTLIER -79.28 -12.21 59.94 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -170.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.608 ' OE1' ' HG2' ' A' ' 32' ' ' LYS . 2.4 mp0 -94.33 -41.09 9.61 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 121.137 -0.225 . . . . 0.0 111.254 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.9 p -103.06 -36.97 7.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 -177.027 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.79 16.45 36.2 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.816 -175.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.0 mm -91.45 128.44 43.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 44' ' ' LYS . 8.4 m -62.96 142.02 17.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.021 0.439 . . . . 0.0 110.912 177.035 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.592 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 26.9 mmmt -96.12 -3.67 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.487 0.661 . . . . 0.0 110.823 -174.681 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -92.39 158.86 15.84 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.642 -175.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -92.29 139.28 30.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.371 0.605 . . . . 0.0 112.127 -176.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 48.8 t -179.22 168.7 1.52 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 172.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -68.32 -35.97 78.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.049 0.452 . . . . 0.0 110.428 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 32.3 pt -102.62 12.36 7.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.493 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.52 ' HB2' ' HB3' ' A' ' 41' ' ' CYS . 70.2 mttt -99.44 147.5 25.2 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 176.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.408 ' H ' ' CG2' ' A' ' 37' ' ' VAL . . . 118.48 1.55 15.59 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -175.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -108.82 -179.36 3.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.802 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.6 m -91.83 133.9 35.23 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.933 -171.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.511 HG21 HD13 ' A' ' 30' ' ' ILE . 34.5 m -101.6 4.38 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.3 0.572 . . . . 0.0 110.005 174.245 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -67.27 100.13 0.78 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.186 -174.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.17 19.99 50.97 Favored Glycine 0 C--N 1.308 -1.001 0 CA-C-N 114.536 -1.211 . . . . 0.0 112.872 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -110.72 155.53 22.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.87 HG13 ' HB3' ' A' ' 80' ' ' ALA . 1.8 mp -84.66 105.48 13.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 175.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 32.1 tp -82.28 126.89 32.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.447 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.563 ' CG1' ' HA ' ' A' ' 19' ' ' VAL . 11.8 p -130.26 106.96 13.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.62 0.724 . . . . 0.0 111.842 177.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.441 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 38.1 p90 -136.16 151.68 73.95 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.175 170.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.91 -55.43 2.33 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.547 2.164 . . . . 0.0 112.808 -177.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 134.43 138.15 3.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.874 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -167.7 -101.79 0.15 Allowed Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.69 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.517 ' O ' ' HA ' ' A' ' 25' ' ' SER . 65.4 tttp -75.63 81.92 2.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.156 0.503 . . . . 0.0 109.807 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -161.98 88.59 0.11 Allowed Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.508 ' HA ' ' OE1' ' A' ' 87' ' ' GLU . 21.9 t -153.9 161.78 41.74 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -178.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 7.6 m 66.71 43.88 2.31 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.899 0.857 . . . . 0.0 110.382 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.625 HG21 HG12 ' A' ' 90' ' ' ILE . 5.1 t -72.26 -27.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.515 177.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 76.35 -77.46 1.39 Allowed Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.121 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.7 p 173.13 -77.1 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 O-C-N 124.092 0.525 . . . . 0.0 111.84 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -70.69 -9.5 57.3 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -170.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 62.9 t -60.63 -41.79 89.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.983 0.421 . . . . 0.0 110.648 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.428 HD13 ' O ' ' A' ' 68' ' ' LEU . 0.7 OUTLIER -73.38 -32.17 64.33 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.231 0.539 . . . . 0.0 109.871 179.282 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.6 tp -61.33 -32.49 72.38 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.2 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -54.94 -44.23 74.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.213 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 88.0 mt -61.84 -33.15 73.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.005 -178.179 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.558 ' HD3' ' HA ' ' A' ' 97' ' ' ALA . 8.0 ttp180 -72.16 -35.94 69.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.126 -178.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -61.37 -31.19 71.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.014 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -93.54 -25.17 17.69 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.938 0.399 . . . . 0.0 110.442 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 94.16 26.94 12.94 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.704 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.8 m -107.15 4.56 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.171 0.51 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.96 159.38 73.57 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.733 179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.49 162.38 24.45 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.491 2.127 . . . . 0.0 112.13 175.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -82.83 -28.8 29.94 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.87 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -166.77 165.22 16.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.673 175.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.694 HG23 HD22 ' A' ' 101' ' ' LEU . 8.3 tt -152.07 121.29 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.45 0.643 . . . . 0.0 110.824 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.821 HG23 HG23 ' A' ' 102' ' ' VAL . 2.7 mm -110.21 118.88 58.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -116.39 165.96 12.61 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.364 0.602 . . . . 0.0 111.758 -174.196 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.22 -31.49 10.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.302 176.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.9 tttm -121.28 122.41 39.83 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.577 176.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 66.5 p -127.68 158.75 36.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.967 0.413 . . . . 0.0 111.681 -175.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.552 ' HB2' HG13 ' A' ' 90' ' ' ILE . 53.8 mt-10 -123.58 157.66 33.2 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.776 173.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.524 ' O ' HG23 ' A' ' 92' ' ' VAL . 89.2 m -60.09 -44.28 94.92 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.107 178.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.9 pt -63.9 -29.89 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.453 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.625 HG12 HG21 ' A' ' 63' ' ' VAL . 64.4 mt -66.98 -42.75 89.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.788 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.99 -32.96 74.75 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.198 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 88' ' ' THR . 73.1 t -66.69 -49.87 70.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 120.929 0.395 . . . . 0.0 110.543 177.079 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.35 -44.11 97.35 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.13 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.409 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -64.09 -37.33 87.04 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 111.585 0.216 . . . . 0.0 111.585 -179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.3 -41.76 96.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.807 0.337 . . . . 0.0 111.12 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 66.5 mtm -74.64 -32.09 62.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.897 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.558 ' HA ' ' HD3' ' A' ' 72' ' ' ARG . . . -82.04 -0.61 45.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 176.577 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 57.32 38.39 28.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.278 0.561 . . . . 0.0 111.233 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.409 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 61.4 mt -111.08 90.93 12.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.198 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.564 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 82.5 Cg_exo -40.57 115.6 0.34 Allowed 'Trans proline' 0 C--N 1.35 0.651 0 C-N-CA 124.027 3.151 . . . . 0.0 113.872 -175.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.694 HD22 HG23 ' A' ' 81' ' ' ILE . 0.1 OUTLIER -108.94 120.67 43.22 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.584 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.821 HG23 HG23 ' A' ' 82' ' ' ILE . 5.5 m -140.5 161.84 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.784 177.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.468 ' OE1' HD11 ' A' ' 8' ' ' ILE . 46.1 mt-10 -101.21 132.99 46.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.529 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.425 HG13 ' CG2' ' A' ' 82' ' ' ILE . 3.4 m -96.48 139.65 18.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 167.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -99.97 -46.76 5.25 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.347 -174.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.419 ' OD1' ' HG3' ' A' ' 108' ' ' LYS . 7.1 t70 -92.8 146.51 23.59 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.218 0.532 . . . . 0.0 111.338 -174.139 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -71.1 -18.76 62.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.103 -0.953 . . . . 0.0 111.177 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HG3' ' OD1' ' A' ' 106' ' ' ASP . 67.7 mttm -55.08 -33.08 62.47 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -61.31 -40.6 94.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.421 -178.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.01 -31.14 68.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.295 -176.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -77.98 -45.58 23.44 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.902 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.482 ' HB1' HG11 ' A' ' 1' ' ' VAL . . . -66.51 -37.56 85.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.179 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 12.0 p -75.15 129.28 36.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.405 0.621 . . . . 0.0 111.076 -177.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.425 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 71.1 mmtt -118.91 144.12 46.6 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.431 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.9 m -64.76 110.9 2.55 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.96 0.41 . . . . 0.0 110.631 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.89 -7.57 8.78 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.425 -178.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ASP . . . . . 0.425 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 12.2 m-20 -87.39 171.84 10.28 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 174.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.553 ' HD2' ' OE1' ' A' ' 14' ' ' GLU . 11.7 ttp180 -115.67 121.94 44.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.824 0.345 . . . . 0.0 110.862 -178.382 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.95 130.07 66.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.187 0.518 . . . . 0.0 110.409 178.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 45.6 t -99.19 111.21 28.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.1 p -102.25 115.23 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.642 0.734 . . . . 0.0 111.754 -174.155 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ASN . . . . . 0.482 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 50.1 t-20 -99.94 94.15 6.14 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 172.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.423 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -82.4 -19.67 38.64 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.108 0.48 . . . . 0.0 110.266 -178.619 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.78 -39.07 93.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.643 -179.034 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -107.46 -28.02 10.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.814 177.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.95 64.45 0.99 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.487 -0.863 . . . . 0.0 111.291 -176.016 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.482 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 35.6 t80 -144.55 124.39 13.44 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -174.589 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.425 HG23 ' HB2' ' A' ' 3' ' ' PHE . 5.9 m -126.26 118.09 50.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.481 0.657 . . . . 0.0 110.997 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -121.04 123.38 42.23 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.193 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.496 ' HB3' HG23 ' A' ' 1' ' ' VAL . 17.0 tp -103.81 120.59 41.3 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.152 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.44 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -89.43 123.27 41.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.235 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--N 1.317 -0.814 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.309 -178.938 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 2' ' ' LYS . 60.6 t . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 1' ' ' VAL . 49.2 mttp 64.34 77.84 0.3 Allowed 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -170.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -98.97 136.79 38.44 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.053 0.454 . . . . 0.0 110.775 -176.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -107.27 110.64 22.72 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.708 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.887 ' SG ' HG12 ' A' ' 104' ' ' VAL . 58.2 m -119.71 -178.73 3.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.489 -174.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.501 ' HB3' ' HG3' ' A' ' 103' ' ' GLU . 17.5 tpt180 -91.3 119.86 31.7 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.996 0.427 . . . . 0.0 110.639 -171.071 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -93.54 140.05 30.05 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.021 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.402 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.8 mp -114.0 -45.51 4.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.751 177.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 10' ' ' ARG . 3.0 m -109.6 177.55 4.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.401 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' THR . 81.6 mtt180 -112.05 -177.97 3.3 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.539 0.209 . . . . 0.0 110.794 -175.118 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 106.56 172.59 22.97 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.026 -178.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 7.3 ptm180 -149.71 119.73 7.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.044 0.45 . . . . 0.0 110.401 178.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.474 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -125.44 139.25 53.8 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.534 -174.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.26 125.23 44.04 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.925 -177.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.97 -160.91 23.1 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.996 175.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.717 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.9 mt-10 -74.67 130.94 40.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 122.822 0.449 . . . . 0.0 111.036 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.36 128.91 34.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.659 177.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.2 tt -118.97 114.74 23.03 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 177.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.21 126.39 60.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.978 0.418 . . . . 0.0 111.039 -173.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.5 m -129.56 95.35 3.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 177.05 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -84.49 83.79 7.88 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.123 0.487 . . . . 0.0 110.117 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -160.73 161.05 32.09 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.419 -0.81 . . . . 0.0 108.856 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 87.6 m-85 -101.26 89.14 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.596 ' HB ' ' HG2' ' A' ' 39' ' ' GLU . 32.7 pt -108.66 170.88 2.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.543 -172.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.27 123.01 39.75 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.488 -177.144 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.421 ' HE2' ' HA3' ' A' ' 64' ' ' GLY . 44.3 t80 -78.73 -4.91 51.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.334 0.588 . . . . 0.0 109.96 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.547 ' HA ' HG21 ' A' ' 63' ' ' VAL . 4.1 pp -72.93 -16.21 61.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.147 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.52 44.46 0.72 Allowed Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.29 -84.34 0.37 Allowed Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.265 -179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.461 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.1 mp -92.42 137.8 21.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 178.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -62.01 138.73 58.41 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.694 0.283 . . . . 0.0 110.351 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.541 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.8 pttp -74.5 -8.58 56.79 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -171.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.541 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 33.4 mt-10 -127.03 -44.47 1.61 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.3 p -96.92 -16.97 20.42 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -177.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.66 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.11 16.74 79.33 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.941 177.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.544 HD13 ' HB3' ' A' ' 47' ' ' SER . 35.5 mm -90.46 133.5 32.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.94 123.14 15.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.89 0.376 . . . . 0.0 110.63 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -87.24 -47.18 9.05 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.759 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.596 ' HG2' ' HB ' ' A' ' 24' ' ' ILE . 4.8 tp10 -62.06 134.76 57.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.671 179.588 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -93.03 160.85 14.68 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.269 0.557 . . . . 0.0 111.235 -175.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 47.9 t -178.68 -49.63 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -176.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 176.2 -45.98 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 114.642 -1.163 . . . . 0.0 109.718 174.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.78 13.25 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.936 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.2 tmmt? -65.91 128.68 36.99 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 116.74 -21.78 11.15 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.959 -176.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -87.98 156.48 19.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.982 0.42 . . . . 0.0 110.457 177.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.544 ' HB3' HD13 ' A' ' 36' ' ' ILE . 13.3 p -103.02 144.8 30.81 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.944 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.444 HG23 ' H ' ' A' ' 49' ' ' ALA . 0.0 OUTLIER -74.47 -76.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.608 175.046 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.444 ' H ' HG23 ' A' ' 48' ' ' VAL . . . 46.3 81.42 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.925 0.713 . . . . 0.0 112.925 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.09 3.78 88.79 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.64 -0.79 . . . . 0.0 113.303 177.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.717 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 52.0 mtt180 -94.6 162.28 13.86 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.411 -0.464 . . . . 0.0 110.902 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.453 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.6 mp -104.99 120.18 55.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 81' ' ' ILE . 54.8 tp -99.06 132.85 44.08 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.483 -177.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.44 107.3 15.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.038 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 41.0 p90 -135.76 144.58 49.43 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 172.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -55.13 -55.19 3.37 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.824 2.349 . . . . 0.0 112.883 -177.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.414 ' O ' ' HA ' ' A' ' 23' ' ' TYR . . . 165.36 -161.7 35.1 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.738 -178.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . 161.56 -101.61 0.2 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.254 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.45 ' HD2' ' C ' ' A' ' 58' ' ' GLY . 14.0 mptt -125.92 98.44 5.52 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.665 0.269 . . . . 0.0 111.227 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.97 72.18 1.65 Allowed Glycine 0 N--CA 1.453 -0.198 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 176.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.459 ' HB3' ' HB3' ' A' ' 27' ' ' LEU . 9.0 t -80.56 66.98 6.26 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 -171.102 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.587 ' HA ' HG21 ' A' ' 89' ' ' ILE . 24.4 p 53.89 16.91 1.18 Allowed 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.688 1.366 . . . . 0.0 114.688 171.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.547 HG21 ' HA ' ' A' ' 27' ' ' LEU . 74.1 t -87.37 -33.63 6.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 O-C-N 122.104 -0.373 . . . . 0.0 111.487 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.421 ' HA3' ' HE2' ' A' ' 26' ' ' PHE . . . -79.36 30.48 2.17 Favored Glycine 0 C--O 1.228 -0.27 0 C-N-CA 120.811 -0.709 . . . . 0.0 113.041 -178.062 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 8.1 p -90.96 -26.34 19.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.576 0.227 . . . . 0.0 111.448 -177.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -156.24 -21.61 0.1 Allowed 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 86.3 t -58.37 -32.88 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.524 ' HA ' HD12 ' A' ' 71' ' ' LEU . 10.3 mp -61.85 -28.22 69.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.512 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 61.6 tp -70.64 -39.8 73.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.905 0.383 . . . . 0.0 110.331 178.36 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -65.9 -32.35 73.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.911 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.524 HD12 ' HA ' ' A' ' 68' ' ' LEU . 97.3 mt -57.63 -39.55 77.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.488 175.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 49.2 ttp180 -71.52 -33.36 69.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.572 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -62.41 -33.8 75.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.245 0.545 . . . . 0.0 110.295 177.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.529 ' OD1' ' HA ' ' A' ' 33' ' ' GLU . 12.6 m120 -88.02 -14.33 39.31 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.906 178.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 79.19 13.56 82.75 Favored Glycine 0 N--CA 1.453 -0.205 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.541 178.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.66 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.5 m -106.79 8.68 9.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.127 0.489 . . . . 0.0 110.966 -176.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -70.7 150.45 95.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.483 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.49 147.68 52.56 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.458 2.105 . . . . 0.0 110.562 171.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.474 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 12.0 mttm -71.81 -35.53 69.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.922 0.391 . . . . 0.0 110.533 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.453 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -155.83 151.99 27.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.368 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.545 HG23 ' HB3' ' A' ' 101' ' ' LEU . 3.8 tp -129.52 120.84 51.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.905 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.711 HD12 HG22 ' A' ' 102' ' ' VAL . 4.7 mm -117.32 116.73 52.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.299 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.443 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 25.9 m120 -109.1 -179.67 3.91 Favored 'General case' 0 C--O 1.22 -0.471 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 103' ' ' GLU . 39.0 ttmt -82.55 -45.04 15.14 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -141.37 100.45 3.79 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 169.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -74.22 150.39 40.34 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -92.3 147.4 22.95 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.254 -175.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.8 m -52.79 -36.93 59.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.419 -177.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.587 HG21 ' HA ' ' A' ' 62' ' ' THR . 49.5 mt -56.35 -47.54 81.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.006 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.9 mt -68.3 -38.78 79.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.378 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.92 -42.87 94.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.177 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 88' ' ' THR . 93.7 t -66.19 -42.95 92.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.77 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.9 -45.45 73.79 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.769 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.489 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -68.57 -30.06 68.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.677 0.275 . . . . 0.0 111.519 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -62.76 -25.38 68.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.408 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.0 mtm -83.17 -26.42 30.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.349 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.578 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -96.5 1.02 51.09 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.939 -178.458 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.521 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 1.5 mp0 59.0 47.85 11.6 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.124 0.488 . . . . 0.0 110.855 -175.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.489 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 58.1 mt -107.74 89.39 5.2 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.882 176.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 36.6 Cg_exo -55.87 116.69 3.34 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.904 2.403 . . . . 0.0 112.195 -177.175 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.545 ' HB3' HG23 ' A' ' 81' ' ' ILE . 1.8 pt? -122.71 134.7 54.45 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.44 0.638 . . . . 0.0 110.792 178.371 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.711 HG22 HD12 ' A' ' 82' ' ' ILE . 14.4 m -130.31 170.16 19.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.562 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 7.9 pt-20 -119.41 132.48 55.83 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.315 0.578 . . . . 0.0 111.676 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.887 HG12 ' SG ' ' A' ' 5' ' ' CYS . 17.3 m -104.47 105.04 17.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.925 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.436 ' HA ' ' HG3' ' A' ' 84' ' ' LYS . 32.6 ttp180 -99.13 27.62 4.97 Favored 'General case' 0 C--N 1.32 -0.717 0 O-C-N 121.837 -0.539 . . . . 0.0 110.614 -177.442 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -123.87 131.88 53.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.125 178.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -71.33 -26.59 62.9 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.212 -176.144 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -65.22 -24.21 67.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.167 -177.406 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.592 ' O ' HG12 ' A' ' 113' ' ' VAL . 80.6 t80 -65.01 -48.6 73.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -66.69 -25.42 66.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.687 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -78.85 -25.98 44.05 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 115.487 -0.778 . . . . 0.0 111.627 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -94.32 -39.69 10.36 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.032 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.4 p -89.8 137.97 20.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 111.17 -176.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -137.28 157.62 46.24 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.39 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 18' ' ' LEU . 32.6 m -64.24 110.09 2.1 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.492 -175.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.08 -17.37 3.85 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.546 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 -82.66 156.86 23.61 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.966 0.413 . . . . 0.0 111.13 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.0 OUTLIER -89.93 119.38 30.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.079 179.835 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.38 136.87 56.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.244 0.545 . . . . 0.0 111.078 -178.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.0 110.51 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.499 173.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.446 HG11 HD11 ' A' ' 82' ' ' ILE . 66.7 t -92.82 104.44 15.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.693 179.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -107.05 98.75 8.37 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.027 -179.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.12 -9.04 58.34 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.342 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -64.27 -39.41 93.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.581 175.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -102.63 -34.46 9.06 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.863 175.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 98.31 68.2 0.91 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.474 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -166.15 166.18 17.19 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.27 121.51 42.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.349 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -120.69 117.79 28.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.317 0.579 . . . . 0.0 110.678 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.588 HD13 HG23 ' A' ' 113' ' ' VAL . 0.9 OUTLIER -109.43 147.87 32.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.143 178.101 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.404 HG12 ' NH2' ' A' ' 118' ' ' ARG . 46.6 mm -110.01 128.58 66.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 C--N 1.317 -0.815 0 O-C-N 123.954 0.783 . . . . 0.0 109.939 -179.448 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.532 HG23 ' HB3' ' A' ' 130' ' ' LEU . 17.1 m . . . . . 0 N--CA 1.452 -0.341 0 CA-C-O 121.303 0.573 . . . . 0.0 112.219 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.423 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -137.21 140.51 41.77 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.079 173.06 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -127.5 151.09 49.31 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.924 0.392 . . . . 0.0 111.044 -173.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.9 127.02 44.72 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.044 177.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 4.4 p -120.87 173.44 7.23 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.734 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 tpm_? -94.04 121.5 35.59 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 176.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.591 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -86.53 97.39 10.48 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.413 . . . . 0.0 111.302 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.63 -45.12 19.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 173.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.3 172.08 6.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.549 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 55.9 mtt-85 -111.04 176.83 4.87 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.283 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.51 -178.14 16.42 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.668 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -155.51 114.78 3.59 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 156.37 41.25 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -169.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tm-20 -135.85 120.92 18.82 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.041 -0.981 . . . . 0.0 108.735 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.19 162.44 35.72 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 119.717 -1.23 . . . . 0.0 113.4 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.74 140.95 56.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.608 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.94 125.79 30.58 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.969 0.414 . . . . 0.0 111.651 -176.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.51 ' HA ' HG23 ' A' ' 115' ' ' THR . 7.9 tt -111.89 110.43 20.76 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 171.287 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.1 t -102.7 110.17 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.091 0.472 . . . . 0.0 110.824 -175.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.455 HG23 ' CD2' ' A' ' 18' ' ' LEU . 2.0 p -99.43 112.92 25.04 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.814 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.42 ' HG2' ' H ' ' A' ' 21' ' ' LYS . 44.0 pttt -92.32 0.72 57.47 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.856 0.836 . . . . 0.0 109.105 176.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -79.61 -173.39 3.75 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.54 -1.209 . . . . 0.0 109.675 174.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TYR . . . . . 0.415 ' HB3' ' HA2' ' A' ' 58' ' ' GLY . 42.1 m-85 -121.0 93.99 4.2 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.297 0.57 . . . . 0.0 110.557 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.486 ' O ' ' HA3' ' A' ' 58' ' ' GLY . 31.8 mt -106.21 146.44 12.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.527 -176.195 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.542 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 33.9 t -131.74 162.27 30.87 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.461 ' HD2' HG12 ' A' ' 90' ' ' ILE . 64.0 m-85 -88.45 23.82 2.11 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.167 0.508 . . . . 0.0 111.007 -177.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.542 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 1.0 OUTLIER -74.93 -14.7 60.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.921 169.466 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.524 ' N ' HD12 ' A' ' 27' ' ' LEU . . . 139.84 57.65 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.727 -178.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.77 -42.23 6.12 Favored Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.866 -178.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.509 HG13 HG12 ' A' ' 37' ' ' VAL . 4.3 mp -93.41 146.46 6.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.311 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 20.0 t70 -70.43 138.98 51.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.825 0.345 . . . . 0.0 110.175 176.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.2 ptmt -79.77 -10.49 59.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.44 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.439 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 43.0 mt-10 -121.21 -40.45 2.59 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -176.115 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.0 p -92.57 -18.8 22.63 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.997 0.427 . . . . 0.0 111.384 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.475 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 76.51 11.13 85.43 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.093 -179.013 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.0 mm -86.92 132.37 32.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.509 HG12 HG13 ' A' ' 30' ' ' ILE . 11.8 m -67.87 129.49 32.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.281 0.562 . . . . 0.0 111.355 178.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 72.4 mmtt -84.64 -37.14 21.4 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 174.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -94.51 90.62 6.26 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.512 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.975 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.5 t70 -146.96 -164.47 2.0 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.007 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 45.6 t -166.87 -41.2 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 120.818 0.342 . . . . 0.0 110.469 -177.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -103.93 -48.43 3.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.505 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -111.56 15.93 8.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.891 0.377 . . . . 0.0 111.336 -173.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.975 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 38.6 ttmt -50.26 128.9 20.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.171 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.72 -7.45 12.15 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.107 -175.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.45 ' HB3' ' NH1' ' A' ' 51' ' ' ARG . 22.0 mm-40 -93.3 145.26 24.59 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 110.282 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 34.6 t -97.7 148.39 23.39 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.404 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 20.5 m -86.82 2.06 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.983 0.421 . . . . 0.0 110.706 178.517 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -67.22 92.51 0.27 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.538 -176.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.99 5.36 33.16 Favored Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.328 -0.851 . . . . 0.0 113.443 171.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.502 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 0.8 OUTLIER -123.56 178.29 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 O-C-N 122.65 -0.324 . . . . 0.0 110.461 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.506 HD12 ' HB ' ' A' ' 119' ' ' VAL . 72.2 mt -108.1 130.02 61.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.165 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.598 ' HB3' HG12 ' A' ' 81' ' ' ILE . 60.3 tp -96.1 123.93 39.91 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.706 -176.058 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 54.4 t -123.79 108.77 21.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.749 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.448 ' HB3' ' OG1' ' A' ' 20' ' ' THR . 53.4 p90 -134.58 144.56 51.36 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.104 174.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 6.2 Cg_exo -74.81 -38.82 1.53 Allowed 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 123.018 2.479 . . . . 0.0 112.027 177.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.95 -165.48 31.88 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.486 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . -170.19 -134.14 1.7 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.13 -1.034 . . . . 0.0 113.284 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -69.2 158.59 34.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.653 0.263 . . . . 0.0 110.573 -178.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -83.09 -27.14 41.69 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.046 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.449 ' O ' HD23 ' A' ' 27' ' ' LEU . 22.8 m -76.61 73.59 3.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.348 0.594 . . . . 0.0 110.305 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.498 HG21 ' HG3' ' A' ' 87' ' ' GLU . 10.7 t -83.7 42.86 0.87 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.542 0.686 . . . . 0.0 111.333 -175.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.3 t -112.41 130.58 65.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.485 0.659 . . . . 0.0 111.196 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 150.86 -76.26 0.24 Allowed Glycine 0 N--CA 1.441 -0.98 0 CA-C-N 114.88 -1.055 . . . . 0.0 111.148 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.541 ' HB2' ' HB ' ' A' ' 89' ' ' ILE . 11.8 t 52.51 -161.03 0.1 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.811 0.444 . . . . 0.0 110.959 -177.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 69.32 -31.95 0.22 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.907 0.883 . . . . 0.0 113.298 175.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.545 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 23.0 m -56.79 -31.12 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.518 HD22 HG23 ' A' ' 67' ' ' VAL . 4.0 mm? -59.13 -40.52 85.73 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 178.279 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.545 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.3 tp -63.58 -44.65 93.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.194 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -62.13 -45.73 92.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.267 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.545 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 92.7 mt -59.36 -40.38 86.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.589 178.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.653 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -69.12 -37.73 78.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.061 -176.172 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.506 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 32.5 mmmt -70.01 -27.34 64.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.933 0.397 . . . . 0.0 110.709 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -87.61 -21.92 25.06 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.132 0.491 . . . . 0.0 110.435 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.79 20.43 37.0 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.216 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.617 ' HA ' ' HB2' ' A' ' 49' ' ' ALA . 21.9 m -118.41 24.24 4.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.015 0.436 . . . . 0.0 110.791 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -95.44 159.34 32.91 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.801 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 62.5 Cg_endo -76.45 151.69 33.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.178 1.919 . . . . 0.0 111.392 175.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.444 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 89.6 mttt -74.8 -30.96 61.58 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.73 0.3 . . . . 0.0 111.255 -178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.96 161.73 36.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.43 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.598 HG12 ' HB3' ' A' ' 53' ' ' LEU . 71.2 mt -139.36 129.75 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 O-C-N 123.323 0.39 . . . . 0.0 110.176 178.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.601 HG23 HG23 ' A' ' 102' ' ' VAL . 4.6 mm -117.01 125.0 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -120.21 161.79 20.48 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.735 0.302 . . . . 0.0 111.218 -176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.5 tptp -94.64 -38.0 11.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.596 0.712 . . . . 0.0 109.24 171.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -133.14 116.05 15.8 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.545 175.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.8 t -106.95 171.51 7.33 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.453 -177.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.498 ' HG3' HG21 ' A' ' 62' ' ' THR . 1.4 tm-20 -137.44 159.82 40.85 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -175.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.405 ' H ' ' CD ' ' A' ' 87' ' ' GLU . 4.3 m -52.44 -47.79 66.2 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 122.941 0.496 . . . . 0.0 111.518 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 65' ' ' SER . 2.1 pp -62.92 -28.89 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-O 121.014 0.435 . . . . 0.0 110.86 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.461 HG12 ' HD2' ' A' ' 26' ' ' PHE . 51.1 mt -75.16 -50.91 22.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.168 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.84 -48.36 82.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.084 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.66 -43.54 98.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.0 -41.74 98.48 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.6 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -71.6 -40.32 69.91 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.781 0.324 . . . . 0.0 111.056 -179.5 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.04 -41.15 91.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.516 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.1 mtm -64.84 -31.56 72.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.542 -177.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.653 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -99.96 5.02 45.23 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.289 0.478 . . . . 0.0 112.289 -175.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 63.07 52.4 2.56 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.71 0.766 . . . . 0.0 109.861 -176.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.513 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 33.3 mm -111.59 89.62 11.15 Favored Pre-proline 0 C--N 1.318 -0.788 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.168 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 79' ' ' LYS . 73.2 Cg_exo -47.89 105.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.558 0 C-N-CA 122.979 2.453 . . . . 0.0 112.324 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 9.8 tt -122.83 129.97 52.33 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.622 -177.142 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.601 HG23 HG23 ' A' ' 82' ' ' ILE . 30.2 m -134.68 164.72 33.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.823 -178.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -110.27 112.53 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.674 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.483 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.2 p -91.99 122.93 43.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.294 0.568 . . . . 0.0 111.113 -175.485 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.26 6.01 49.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.187 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.484 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 9.8 t70 -108.72 126.03 52.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.117 0.484 . . . . 0.0 111.015 -175.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -71.55 -33.64 69.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.721 -177.142 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.574 ' HE3' ' HA ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -61.54 -26.98 68.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.858 -176.993 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -56.48 -49.0 75.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.817 177.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -70.3 -26.86 63.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.089 -175.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.38 -36.11 46.37 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.235 178.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -85.89 -28.2 24.52 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 10.0 p -81.26 127.06 39.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.48 0.657 . . . . 0.0 111.232 -177.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -122.94 154.82 37.87 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.44 176.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 18' ' ' LEU . 36.7 m -67.87 94.62 0.47 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.065 0.46 . . . . 0.0 110.525 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.32 -29.63 0.97 Allowed Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.181 -178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -71.98 169.37 16.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 174.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 6.9 tmm_? -115.87 132.33 56.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.035 0.445 . . . . 0.0 110.903 -175.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 17' ' ' ALA . 48.2 t -110.43 139.83 32.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.023 -176.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.07 112.57 41.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 172.062 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.418 HG23 HD13 ' A' ' 52' ' ' ILE . 62.9 t -101.91 114.94 42.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.145 -174.129 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 -106.06 92.91 4.35 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.5 -6.83 56.07 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.48 . . . . 0.0 110.639 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -73.38 -36.78 66.13 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.58 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -112.49 -4.24 14.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.134 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.431 ' CA ' ' HB2' ' A' ' 7' ' ' ALA . . . 74.73 71.7 1.11 Allowed Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.251 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -158.4 144.99 17.4 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.247 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -130.8 122.93 53.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.311 0.576 . . . . 0.0 110.911 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -109.3 118.34 36.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.532 ' HB3' HG23 ' A' ' 1' ' ' VAL . 64.9 tp -93.38 115.14 27.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.015 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 22.6 mm -91.3 111.73 24.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.5 0.667 . . . . 0.0 109.691 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 . . . . . 0 C--N 1.308 -1.21 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.001 -179.224 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.444 ' HD3' ' HG2' ' A' ' 129' ' ' GLU . 87.8 mttt 63.74 96.86 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.486 0.66 . . . . 0.0 110.113 -175.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -110.34 148.0 32.82 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.066 -172.355 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.78 130.38 39.81 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.289 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.614 ' SG ' HG22 ' A' ' 104' ' ' VAL . 26.0 m -121.43 179.4 4.45 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.03 0.443 . . . . 0.0 111.001 -176.467 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.646 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 40.2 ttt180 -94.79 121.88 36.84 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.775 178.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.541 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.41 130.71 34.75 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.775 0.321 . . . . 0.0 111.683 -174.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.1 mp -105.32 -48.12 9.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 173.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 26.7 p -117.19 -173.89 2.49 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.957 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -120.69 -177.26 3.43 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.635 0.255 . . . . 0.0 110.649 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 110.46 152.06 13.11 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.247 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.435 HH11 ' HD2' ' A' ' 12' ' ' ARG . 16.7 mtp180 -113.16 136.9 52.21 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.684 0.278 . . . . 0.0 110.271 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -137.35 132.15 33.17 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.433 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.541 ' HG3' HG22 ' A' ' 120' ' ' VAL . 35.6 tt0 -131.11 126.2 35.13 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.947 176.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 177.6 -158.27 23.4 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.048 -1.072 . . . . 0.0 113.086 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -72.2 136.15 46.32 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 122.807 0.443 . . . . 0.0 110.723 -177.555 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.528 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -99.75 131.94 45.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.384 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.3 tp -118.78 120.67 38.07 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.533 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.57 117.4 47.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.645 0.736 . . . . 0.0 110.194 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 8.9 m -108.48 134.57 51.09 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.497 -176.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.49 -21.54 18.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.194 0.521 . . . . 0.0 109.717 177.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.414 ' H ' HG22 ' A' ' 20' ' ' THR . 13.4 mm-40 -79.06 160.34 27.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.568 -175.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 6.1 p90 -117.67 121.31 40.53 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.68 174.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.0 mp -123.02 123.75 68.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 120.826 0.346 . . . . 0.0 111.138 -174.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.3 p -76.68 127.57 33.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 169.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.882 ' HB2' HG13 ' A' ' 63' ' ' VAL . 97.1 m-85 -74.83 78.67 2.1 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.668 0.747 . . . . 0.0 111.944 -173.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.3 mt -120.06 -47.97 2.36 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 170.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.2 -142.78 3.88 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 113.848 -1.523 . . . . 0.0 110.43 172.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.59 -48.18 3.52 Favored Glycine 0 C--O 1.222 -0.598 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.448 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.1 mp -111.88 131.73 62.46 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 174.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -68.01 123.93 21.99 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.936 0.398 . . . . 0.0 109.952 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 45.8 pttt -80.62 -5.09 56.4 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -172.365 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -103.92 -33.62 8.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.829 0.347 . . . . 0.0 111.214 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.5 p -109.68 -28.16 8.98 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.914 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.591 ' CA ' HG13 ' A' ' 76' ' ' VAL . . . 89.42 9.7 66.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.43 -177.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.538 HD13 ' HB3' ' A' ' 47' ' ' SER . 48.7 mm -84.05 124.97 40.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.571 0.224 . . . . 0.0 110.614 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 20.7 m -68.78 116.67 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.759 0.79 . . . . 0.0 110.408 175.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 10.4 mmmm -89.58 -24.56 21.68 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.434 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -65.0 132.38 49.08 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.333 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 25.8 t70 -68.03 133.4 48.96 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.069 0.461 . . . . 0.0 111.403 -177.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 23.1 p -174.22 -170.64 0.54 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.516 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -83.23 -16.92 44.56 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.484 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.1 mt -100.17 15.17 4.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 122.12 0.962 . . . . 0.0 109.32 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.402 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 82.1 tttt -62.04 134.85 57.14 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.489 -1.232 . . . . 0.0 111.45 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 98.46 -10.91 63.23 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.572 -0.74 . . . . 0.0 113.231 177.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -92.47 170.45 9.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.307 0.575 . . . . 0.0 111.732 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.538 ' HB3' HD13 ' A' ' 36' ' ' ILE . 6.2 p -110.97 142.43 43.09 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.683 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.1 9.06 8.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.417 0.627 . . . . 0.0 109.881 175.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 76' ' ' VAL . . . -75.24 95.45 3.15 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.21 28.79 12.42 Favored Glycine 0 C--N 1.317 -0.508 0 CA-C-N 114.705 -1.134 . . . . 0.0 113.609 172.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -130.65 177.76 7.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.719 0.26 . . . . 0.0 110.675 174.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.69 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.5 mp -89.37 118.55 34.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.403 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 35.8 tp -106.4 116.6 32.21 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.15 -177.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.48 107.77 23.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.194 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.455 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 36.7 p90 -134.42 153.43 79.23 Favored Pre-proline 0 C--N 1.32 -0.714 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.843 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 -40.1 79.15 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.717 2.278 . . . . 0.0 111.982 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.39 -144.02 12.25 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 170.96 -177.02 44.18 Favored Glycine 0 N--CA 1.445 -0.764 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.778 178.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -93.26 104.66 16.82 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.57 80.73 1.37 Allowed Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.985 -0.626 . . . . 0.0 113.009 -173.34 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 8.0 t -128.35 129.69 46.63 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 4.3 m 66.71 17.46 10.59 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-O 121.467 0.651 . . . . 0.0 110.826 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.904 ' HB ' HD12 ' A' ' 89' ' ' ILE . 69.9 t -70.78 140.81 17.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.326 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.81 65.89 2.15 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.127 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.614 ' HB3' ' HB ' ' A' ' 89' ' ' ILE . 12.0 p -52.07 -39.71 60.1 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 122.714 0.406 . . . . 0.0 111.94 177.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -69.32 -27.52 65.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 110.967 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.437 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 47.8 t -68.41 -26.84 34.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.585 -177.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.611 HD12 ' HA3' ' A' ' 93' ' ' GLY . 94.9 mt -57.92 -32.75 68.08 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.054 178.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.556 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.7 tp -67.5 -46.08 73.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.322 178.4 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -65.21 -38.24 89.81 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.501 HD12 HD23 ' A' ' 68' ' ' LEU . 94.2 mt -58.43 -45.14 89.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.389 176.242 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.413 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.2 OUTLIER -68.84 -37.91 79.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.614 -178.042 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -62.93 -33.88 76.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.024 0.44 . . . . 0.0 110.702 176.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -86.35 -18.15 32.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.623 -177.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 95.2 1.31 62.8 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.262 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.591 HG13 ' CA ' ' A' ' 35' ' ' GLY . 71.2 t -79.65 -30.36 13.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 C-N-CA 122.71 0.404 . . . . 0.0 111.585 -175.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.99 144.7 98.9 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.696 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.26 141.86 94.65 Favored 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.304 2.003 . . . . 0.0 110.926 175.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 tttt -74.81 -16.5 60.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.119 0.485 . . . . 0.0 110.005 -175.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.69 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -164.27 142.94 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.518 176.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.494 HG13 ' HG ' ' A' ' 101' ' ' LEU . 9.3 pt -128.68 120.21 51.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.366 0.603 . . . . 0.0 111.115 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG23 ' A' ' 102' ' ' VAL . 1.2 mm -113.1 116.66 53.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -123.16 161.73 23.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 112.076 -171.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -99.46 -34.45 10.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.055 174.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -125.93 131.98 52.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.867 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -130.26 174.44 9.83 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.466 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -135.82 162.45 32.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.896 0.379 . . . . 0.0 110.553 -178.206 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.503 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.6 m -60.19 -51.57 69.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.47 -177.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.904 HD12 ' HB ' ' A' ' 63' ' ' VAL . 9.1 pt -58.35 -32.03 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.619 -179.549 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.2 mm -68.7 -45.52 81.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.45 -38.43 89.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.022 178.17 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 88' ' ' THR . 93.0 t -62.94 -50.48 79.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.716 178.328 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.611 ' HA3' HD12 ' A' ' 68' ' ' LEU . . . -60.26 -43.97 97.96 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.144 178.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.59 -36.15 82.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 111.38 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -69.18 -42.79 75.38 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.33 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 58.4 mtm -73.86 -36.62 64.87 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.577 -176.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.37 -9.75 49.18 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.764 -176.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.443 ' OE1' ' HA ' ' A' ' 98' ' ' GLU . 2.8 tp10 65.91 72.54 0.4 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.824 0.821 . . . . 0.0 110.161 -175.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.428 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 60.6 mt -127.15 90.11 50.05 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 114.759 -1.109 . . . . 0.0 109.734 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 4.4 Cg_exo -39.3 110.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 123.985 3.123 . . . . 0.0 112.993 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.494 ' HG ' HG13 ' A' ' 81' ' ' ILE . 4.7 tt -119.66 123.43 43.8 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.368 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 82' ' ' ILE . 8.6 m -128.17 139.82 50.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.238 0.542 . . . . 0.0 110.651 176.805 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 43.6 tt0 -88.92 123.14 32.99 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.54 -178.17 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.614 HG22 ' SG ' ' A' ' 5' ' ' CYS . 96.3 t -107.27 117.72 53.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.793 178.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 24.2 mtm180 -107.44 14.09 26.25 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.237 0.541 . . . . 0.0 110.06 177.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -108.62 130.74 55.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.51 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -71.92 -28.07 63.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.65 -175.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -73.39 -18.25 61.18 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -172.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -63.03 -48.31 79.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.955 0.407 . . . . 0.0 109.984 176.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.408 ' HA ' HG12 ' A' ' 113' ' ' VAL . 88.3 m-85 -71.98 -22.71 61.4 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.364 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -72.81 -42.15 64.15 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.733 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.03 -36.86 30.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.009 -175.177 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.408 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.5 p -75.65 136.72 24.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-O 121.314 0.578 . . . . 0.0 111.091 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.489 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 9.7 mtmp? -126.18 158.77 34.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.949 176.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 50.0 m -65.16 111.46 2.95 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 172.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.92 1.67 19.16 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.351 -0.928 . . . . 0.0 113.592 176.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ASP . . . . . 0.489 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 28.2 m-20 -85.42 177.55 7.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 117.348 0.574 . . . . 0.0 110.519 176.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.419 ' NH2' HG13 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -115.42 119.79 37.42 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.0 110.152 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.528 HG23 ' HB2' ' A' ' 17' ' ' ALA . 36.7 t -109.34 126.52 66.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.156 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.541 HG22 ' HG3' ' A' ' 14' ' ' GLU . 14.6 t -106.96 102.24 13.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 173.036 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.478 HG23 HG22 ' A' ' 128' ' ' VAL . 7.3 p -108.32 131.66 58.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.279 0.562 . . . . 0.0 111.78 -176.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -116.08 103.87 10.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.467 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.83 -18.71 50.16 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.369 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.2 -30.69 70.57 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.063 0.458 . . . . 0.0 110.588 177.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -108.89 -37.06 5.95 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.44 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 97.39 56.09 1.13 Allowed Glycine 0 N--CA 1.45 -0.386 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -145.04 133.46 21.85 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -172.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 121' ' ' VAL . 49.0 t -118.8 112.32 37.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.057 -177.372 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.444 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 45.8 mt-10 -106.72 108.47 20.0 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.166 177.554 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.426 HD23 ' H ' ' A' ' 130' ' ' LEU . 2.0 pt? -106.52 147.8 28.97 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.419 HG13 ' NH2' ' A' ' 118' ' ' ARG . 42.6 mm -112.27 133.86 56.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.06 177.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.418 -177.526 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.1 p . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 121.362 0.601 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.468 ' HD3' ' HE1' ' A' ' 127' ' ' TYR . 97.5 mttt -121.18 140.16 52.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.689 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -115.77 161.71 18.35 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.327 -177.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.01 127.26 50.08 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.158 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.7 p -120.55 176.11 5.66 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.972 0.415 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.473 ' NE ' ' HA ' ' A' ' 6' ' ' ARG . 2.6 tpm_? -98.43 124.75 43.3 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 175.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.06 140.0 46.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.9 0.381 . . . . 0.0 111.82 -175.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 49.1 mm -112.47 -57.26 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.123 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 ' HA ' ' A' ' 95' ' ' ALA . 52.7 p -113.13 -164.99 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.627 174.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.501 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 7.9 mpt_? -120.08 167.58 12.06 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.017 0.437 . . . . 0.0 111.486 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.748 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 134.46 145.84 5.31 Favored Glycine 0 CA--C 1.519 0.305 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.69 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.559 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 1.1 tmm_? -139.88 114.14 9.07 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.203 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.34 170.32 17.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.636 0.255 . . . . 0.0 111.428 -175.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -110.23 165.5 11.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.393 178.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.438 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -175.43 157.31 23.78 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 173.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.849 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 52.8 mt-10 -61.44 137.37 58.24 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 174.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -78.84 109.2 12.89 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.712 0.291 . . . . 0.0 110.463 -176.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.9 tt -102.4 109.55 21.24 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 173.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.6 t -120.64 114.09 42.43 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.153 -171.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 t -127.5 118.19 23.54 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.736 174.559 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.409 ' HE2' ' HB3' ' A' ' 110' ' ' PHE . 30.5 ttmt -93.53 20.91 6.76 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.89 0.853 . . . . 0.0 109.118 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.572 ' HG2' ' SG ' ' A' ' 41' ' ' CYS . 5.0 mp0 -97.66 147.68 24.08 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.79 -1.096 . . . . 0.0 109.7 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -82.8 100.61 10.42 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.073 0.463 . . . . 0.0 110.317 175.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.448 HG23 ' HB3' ' A' ' 39' ' ' GLU . 27.9 mm -91.44 1.25 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.269 -176.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.8 m 68.57 -26.81 0.14 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 171.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 24' ' ' ILE . 47.1 t80 75.36 -31.25 0.2 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 123.749 0.82 . . . . 0.0 112.015 175.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.552 ' HA ' HG22 ' A' ' 63' ' ' VAL . 3.1 tm? -61.72 102.25 0.25 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.042 0.448 . . . . 0.0 110.176 177.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.24 26.13 69.03 Favored Glycine 0 C--N 1.335 0.486 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.2 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -83.61 -15.32 71.18 Favored Glycine 0 C--O 1.224 -0.523 0 C-N-CA 120.867 -0.683 . . . . 0.0 113.797 -173.377 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 59.7 mt -125.8 130.57 72.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 117.492 0.646 . . . . 0.0 111.18 -177.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.506 ' HA ' ' HE2' ' A' ' 38' ' ' LYS . 12.3 t70 -65.57 130.42 43.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.966 175.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.555 ' HA ' HD21 ' A' ' 71' ' ' LEU . 21.2 pttp -84.76 -0.12 52.62 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -171.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -101.69 -53.63 2.93 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.846 0.355 . . . . 0.0 111.608 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.518 HG23 HG12 ' A' ' 36' ' ' ILE . 3.5 t -109.69 -2.68 17.28 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.253 -0.431 . . . . 0.0 112.057 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.45 43.85 91.56 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.54 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.518 HG12 HG23 ' A' ' 34' ' ' THR . 47.3 mm -110.66 131.48 61.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 53.6 t -61.0 123.44 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.806 0.336 . . . . 0.0 110.599 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.506 ' HE2' ' HA ' ' A' ' 31' ' ' ASP . 63.8 mmtt -72.08 -47.99 47.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.221 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 24' ' ' ILE . 7.8 tp10 -62.13 125.48 24.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.629 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.548 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 14.1 t70 -83.11 133.23 35.07 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.329 178.043 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.572 ' SG ' ' HG2' ' A' ' 22' ' ' GLU . 4.0 t -170.8 39.04 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 75.63 -29.94 0.19 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 114.984 -1.007 . . . . 0.0 111.945 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 41.8 mm -84.17 -10.47 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-O 121.623 0.725 . . . . 0.0 110.45 177.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.548 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 21.8 ttpp -59.64 135.94 57.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.126 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 111.34 -14.8 27.86 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.455 -0.879 . . . . 0.0 113.036 176.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -89.47 142.39 27.71 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.008 0.432 . . . . 0.0 111.236 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.443 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 20.3 m -85.36 136.66 33.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.552 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.4 m -89.05 -6.96 10.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.195 173.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.87 94.62 0.13 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.243 -176.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.67 13.66 49.84 Favored Glycine 0 C--N 1.313 -0.749 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.668 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.849 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 95.9 mtt180 -113.46 166.26 11.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.981 0.419 . . . . 0.0 111.051 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.438 HG12 ' HA3' ' A' ' 15' ' ' GLY . 39.3 mm -95.99 122.15 47.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.169 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HB3' HG12 ' A' ' 81' ' ' ILE . 58.5 tp -93.2 113.26 25.44 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.768 0.318 . . . . 0.0 110.36 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.6 t -102.93 108.16 23.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 176.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.685 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.0 t80 -134.37 140.27 35.3 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.195 -172.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 15.2 Cg_endo -94.13 -56.5 0.01 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.914 2.409 . . . . 0.0 113.38 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -150.18 138.75 6.9 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.309 -176.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 59' ' ' LYS . . . -110.48 -82.38 1.3 Allowed Glycine 0 N--CA 1.443 -0.864 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 58' ' ' GLY . 38.4 ttmt 174.64 -70.59 0.01 OUTLIER 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.234 0.54 . . . . 0.0 109.734 178.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 138.5 -102.57 0.37 Allowed Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.428 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.2 t 70.24 -165.52 0.16 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 122.871 0.468 . . . . 0.0 110.898 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 5.2 t -102.0 58.12 0.82 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.812 0.815 . . . . 0.0 111.032 -175.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.552 HG22 ' HA ' ' A' ' 27' ' ' LEU . 41.3 t -70.69 -44.92 76.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.353 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -5.88 72.99 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.315 -177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 56.9 p 56.43 12.76 1.11 Allowed 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 113.577 0.954 . . . . 0.0 113.577 177.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -90.31 -6.29 55.27 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 122.094 -0.379 . . . . 0.0 111.891 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.55 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 66.4 t -62.56 -51.4 72.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.676 0.274 . . . . 0.0 110.689 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.27 -39.58 93.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.956 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.501 ' O ' ' HG2' ' A' ' 73' ' ' LYS . 56.4 tp -62.82 -46.08 89.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.565 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.51 -44.71 93.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.422 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.555 HD21 ' HA ' ' A' ' 32' ' ' LYS . 97.3 mt -54.43 -41.59 69.56 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.114 0.483 . . . . 0.0 110.397 177.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -65.04 -37.08 86.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.144 -178.159 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.501 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 34.5 mmtp -69.91 -25.29 63.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.214 -177.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -93.84 -22.82 18.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.285 0.564 . . . . 0.0 110.182 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.37 15.66 37.29 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.221 178.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.47 23.68 3.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.238 0.542 . . . . 0.0 110.701 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.87 156.03 41.03 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.054 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 42.1 Cg_endo -68.14 155.92 67.68 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.4 2.067 . . . . 0.0 112.129 175.537 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 53.9 mmtt -68.51 -41.86 79.39 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.824 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.444 ' HB2' HG11 ' A' ' 121' ' ' VAL . . . -163.69 165.97 22.71 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.251 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.482 HG12 ' HB3' ' A' ' 53' ' ' LEU . 63.9 mt -131.87 119.34 41.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.094 0.473 . . . . 0.0 110.24 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.631 HG23 HG23 ' A' ' 102' ' ' VAL . 3.8 mm -103.83 116.88 48.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.7 m120 -111.64 164.49 12.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.949 0.404 . . . . 0.0 111.503 -175.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -69.76 -54.14 15.09 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.711 175.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.614 ' HG2' ' OE2' ' A' ' 103' ' ' GLU . 4.8 tttm -139.75 22.59 2.48 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.515 178.18 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 30.5 m 72.48 124.03 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.618 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.491 ' HB3' ' HB ' ' A' ' 90' ' ' ILE . 8.8 tp10 -84.13 130.54 34.84 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 172.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.6 m -57.5 -50.2 73.84 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.962 0.41 . . . . 0.0 111.66 -173.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.1 mt -68.95 -35.14 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.199 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 87' ' ' GLU . 59.7 mt -69.23 -38.07 77.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.36 -44.77 92.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.416 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -62.26 -49.28 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.994 0.426 . . . . 0.0 110.576 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.92 -42.24 99.72 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.466 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.06 -39.17 92.88 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.704 0.287 . . . . 0.0 111.149 -179.789 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.439 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -63.13 -41.89 99.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.923 178.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.5 mtm -72.49 -35.96 68.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.498 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.567 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -92.36 5.96 48.68 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 56.92 50.78 11.66 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.449 0.643 . . . . 0.0 110.911 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 62.1 mt -114.29 90.3 20.09 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.816 179.539 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.748 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 91.6 Cg_exo -35.3 112.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.352 0.733 0 C-N-CA 124.071 3.181 . . . . 0.0 113.998 -176.071 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.409 HD13 ' N ' ' A' ' 102' ' ' VAL . 0.5 OUTLIER -110.15 128.75 55.64 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.836 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.631 HG23 HG23 ' A' ' 82' ' ' ILE . 16.2 m -136.55 162.18 35.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.343 178.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.614 ' OE2' ' HG2' ' A' ' 85' ' ' LYS . 32.1 tt0 -115.88 119.09 34.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.814 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 106' ' ' ASP . 13.5 t -99.52 128.97 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.888 0.375 . . . . 0.0 110.4 177.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 105' ' ' ARG . 3.2 mmp_? -92.02 24.8 3.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.223 0.535 . . . . 0.0 110.42 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.497 ' H ' HG12 ' A' ' 104' ' ' VAL . 35.9 t70 -141.96 111.9 6.81 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.698 -175.021 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -69.84 -26.68 64.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.846 178.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.4 ' HD3' ' HA ' ' A' ' 108' ' ' LYS . 68.8 mmtt -63.51 -19.95 65.2 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.527 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.599 ' O ' HG12 ' A' ' 113' ' ' VAL . 49.9 t80 -61.25 -45.1 95.9 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 170.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.409 ' HB3' ' HE2' ' A' ' 21' ' ' LYS . 87.4 m-85 -68.3 -22.05 64.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.277 -177.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -83.64 -32.75 25.5 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.049 0.452 . . . . 0.0 110.522 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.7 -44.34 28.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.185 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.599 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.9 p -83.21 123.5 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 110.149 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -130.21 152.66 49.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.048 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.742 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 21.6 m -58.4 107.49 0.5 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.042 -179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.32 -39.04 0.55 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.331 -0.938 . . . . 0.0 113.449 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ASP . . . . . 0.741 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 1.7 t0 -101.09 -166.96 1.36 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 117.286 0.543 . . . . 0.0 110.997 -176.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.741 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -110.03 138.54 46.27 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.33 0.586 . . . . 0.0 112.559 -173.987 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.624 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.7 t -119.71 122.7 69.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.551 173.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.932 ' HB ' ' HG3' ' A' ' 129' ' ' GLU . 47.1 t -100.06 112.58 33.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.444 HG11 ' HB2' ' A' ' 80' ' ' ALA . 8.9 p -86.54 133.2 30.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.561 -177.545 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ASN . . . . . 0.665 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 44.0 t-20 -126.06 94.64 4.15 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.252 0.549 . . . . 0.0 109.767 177.069 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.437 ' HB1' ' O ' ' A' ' 9' ' ' THR . . . -90.16 2.66 55.09 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.418 0.627 . . . . 0.0 110.107 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.455 ' HB3' ' OD1' ' A' ' 122' ' ' ASN . 4.5 t70 -73.7 -37.1 65.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.665 175.327 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -114.11 -15.36 12.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.573 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.06 66.89 1.74 Allowed Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -168.075 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.665 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 9.2 t80 -146.24 144.75 30.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.146 -0.527 . . . . 0.0 109.744 -167.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 109' ' ' PHE . 60.1 t -126.87 104.87 13.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 175.65 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.932 ' HG3' ' HB ' ' A' ' 120' ' ' VAL . 9.0 pt-20 -97.05 108.13 20.81 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.502 0.668 . . . . 0.0 109.931 179.169 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.9 tp -85.57 127.83 34.57 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.497 -178.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 5.2 mm -116.76 111.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -178.169 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.414 ' HA ' ' OD2' ' A' ' 117' ' ' ASP . 12.4 mp0 . . . . . 0 C--N 1.314 -0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.464 HG23 ' HB3' ' A' ' 130' ' ' LEU . 10.8 m . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 121.464 0.649 . . . . 0.0 111.914 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.432 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 28.1 mtpp -107.78 94.21 4.96 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.143 174.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -96.77 155.62 16.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.018 0.437 . . . . 0.0 111.379 -176.145 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.41 126.27 52.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.702 174.642 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 103' ' ' GLU . 80.3 m -118.93 179.59 4.1 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.029 -177.17 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 64.4 ttp85 -92.04 116.12 28.66 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -175.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.659 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.65 124.39 24.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.091 -0.958 . . . . 0.0 111.786 -173.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 44.5 mm -102.81 -47.99 10.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.734 176.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.564 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -107.16 -171.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.379 177.558 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 10' ' ' ARG . 39.3 mtt180 -115.33 -178.7 3.44 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 173.294 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.97 -176.81 36.42 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.846 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -161.14 143.31 12.21 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 -178.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.51 179.07 9.46 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.29 0.567 . . . . 0.0 111.494 -175.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -125.77 160.59 29.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.533 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.57 ' HA3' HG13 ' A' ' 52' ' ' ILE . . . 179.61 155.69 15.82 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.832 171.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.527 ' HB3' ' HD3' ' A' ' 51' ' ' ARG . 28.7 tt0 -75.44 137.95 41.32 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 175.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.515 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -78.0 134.92 37.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.119 0.485 . . . . 0.0 111.825 -169.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.506 HD21 HG21 ' A' ' 43' ' ' ILE . 6.3 tt -130.29 115.41 16.91 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 174.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.549 HG12 ' OG1' ' A' ' 115' ' ' THR . 9.9 p -103.47 130.94 53.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.198 0.523 . . . . 0.0 110.831 -175.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.8 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 29.1 m -108.82 127.52 54.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.031 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -99.88 -1.01 38.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.559 -175.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.453 ' H ' HG22 ' A' ' 20' ' ' THR . 53.4 mm-40 -96.99 158.98 15.17 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.358 0.599 . . . . 0.0 112.188 -173.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -104.38 91.24 3.82 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 27.4 pt -122.35 16.83 5.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -169.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.469 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 59.6 p 51.8 -154.54 0.17 Allowed 'General case' 0 CA--C 1.53 0.202 0 O-C-N 123.606 0.566 . . . . 0.0 110.485 -175.492 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.411 ' HE2' HD11 ' A' ' 68' ' ' LEU . 9.6 t80 -143.64 18.25 1.84 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.064 0.459 . . . . 0.0 110.626 179.239 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.13 -10.05 57.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.316 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.03 130.64 1.25 Allowed Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.183 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.435 ' HA2' ' HB3' ' A' ' 39' ' ' GLU . . . -173.27 -47.37 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.264 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.674 HG13 HG22 ' A' ' 37' ' ' VAL . 4.1 mp -88.27 134.63 27.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.744 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 29.2 t70 -77.89 147.25 35.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.687 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 9.5 ptpp? -82.76 -14.49 54.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.135 -174.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -100.79 -47.82 4.69 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.427 -175.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.9 p -92.91 -37.09 12.44 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.778 0.323 . . . . 0.0 111.735 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.8 20.03 48.91 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.336 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.2 mm -90.24 138.3 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.287 179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.674 HG22 HG13 ' A' ' 30' ' ' ILE . 96.3 t -79.81 102.26 5.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.139 0.495 . . . . 0.0 109.755 174.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.744 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 59.3 mttt -84.32 -28.64 26.93 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.706 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.435 ' HB3' ' HA2' ' A' ' 29' ' ' GLY . 9.4 tp10 -96.14 78.66 3.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.614 0.721 . . . . 0.0 110.384 178.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 1.027 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 9.2 t70 -147.82 -167.78 2.89 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.936 177.385 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 71.5 m -144.82 -23.14 0.51 Allowed 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -133.86 -47.77 0.8 Allowed 'General case' 0 C--O 1.233 0.225 0 O-C-N 122.031 -0.418 . . . . 0.0 110.796 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.506 HG21 HD21 ' A' ' 18' ' ' LEU . 23.0 mm -75.83 -17.75 15.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 109.227 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 1.027 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 54.3 tttm -44.37 118.23 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 CA-C-N 114.166 -1.379 . . . . 0.0 112.156 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 130.83 -19.13 5.02 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.807 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -93.46 156.36 16.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.056 0.455 . . . . 0.0 111.692 -177.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.0 m -95.94 138.69 33.22 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.423 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.1 m -94.2 -3.69 10.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.993 0.425 . . . . 0.0 110.808 176.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.42 89.51 0.5 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.559 0.695 . . . . 0.0 110.868 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.7 ' HA2' ' HE3' ' A' ' 79' ' ' LYS . . . 112.6 2.98 25.64 Favored Glycine 0 C--N 1.313 -0.741 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.703 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.527 ' HD3' ' HB3' ' A' ' 16' ' ' GLU . 20.2 mmt85 -105.59 156.29 18.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.556 -0.322 . . . . 0.0 110.827 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.706 HG12 ' HB3' ' A' ' 80' ' ' ALA . 29.1 mt -97.29 117.65 42.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 169.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.43 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 28.1 tp -93.56 124.57 37.64 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.957 -171.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 62.6 t -123.85 107.51 18.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.892 0.377 . . . . 0.0 110.195 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.8 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 40.9 p90 -136.01 146.09 55.21 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 177.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.97 -29.55 34.02 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.851 2.367 . . . . 0.0 111.462 175.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.71 -60.63 4.79 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.747 176.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 81.14 -65.12 4.04 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -177.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 25' ' ' SER . 59.7 mttm -104.66 128.21 52.64 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -88.28 -37.72 7.54 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.63 177.372 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.4 m 63.99 -177.06 0.16 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 121.149 0.5 . . . . 0.0 111.294 178.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.5 p -119.23 11.32 12.28 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.188 0.518 . . . . 0.0 111.059 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.9 t -129.92 138.53 53.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.429 ' O ' HG22 ' A' ' 67' ' ' VAL . . . 152.4 -11.44 0.65 Allowed Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.038 -178.173 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 0.8 OUTLIER -71.32 151.37 44.24 Favored 'General case' 0 C--N 1.321 -0.637 0 O-C-N 122.703 -0.292 . . . . 0.0 111.278 178.033 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.408 ' HB2' ' O ' ' A' ' 65' ' ' SER . 44.9 m-85 75.25 -35.46 0.28 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 174.506 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.487 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 29.8 m -62.79 -24.65 36.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -175.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.411 HD11 ' HE2' ' A' ' 26' ' ' PHE . 6.2 mp -69.0 -32.16 71.51 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.664 0.269 . . . . 0.0 110.576 178.171 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.414 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.4 tp -66.43 -38.48 87.5 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -61.21 -48.85 79.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.129 175.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.487 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 67.6 mt -60.59 -41.68 95.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.674 178.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.0 OUTLIER -72.06 -35.61 69.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.097 -176.402 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -59.75 -38.41 81.68 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.434 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -82.6 -29.66 30.02 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 109.876 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 99.14 22.27 13.51 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.561 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.47 4.9 9.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.998 0.428 . . . . 0.0 111.156 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.32 154.54 66.41 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.767 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 27.7 Cg_endo -63.63 147.33 92.86 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.148 1.899 . . . . 0.0 111.075 174.379 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.7 ' HE3' ' HA2' ' A' ' 50' ' ' GLY . 97.2 mttt -73.32 -27.25 61.42 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.049 0.452 . . . . 0.0 110.725 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.706 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -157.79 157.48 33.43 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.305 176.067 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.466 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 34.1 mt -136.57 127.39 41.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 178.113 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.527 HG22 HG13 ' A' ' 104' ' ' VAL . 3.6 mm -121.67 118.26 55.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 11.8 m120 -130.43 -179.84 5.5 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.147 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.434 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 4.1 tmtt? -109.86 -37.91 5.51 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 171.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -103.01 114.84 29.46 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -120.67 141.26 50.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.903 0.382 . . . . 0.0 110.266 177.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.49 ' HB2' HG13 ' A' ' 90' ' ' ILE . 81.2 mm-40 -108.94 159.65 16.64 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.11 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 m -60.01 -45.34 93.06 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.83 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.444 HD12 ' N ' ' A' ' 90' ' ' ILE . 2.5 pp -64.82 -31.08 52.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.725 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.49 HG13 ' HB2' ' A' ' 87' ' ' GLU . 69.3 mt -68.38 -45.79 81.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.984 0.421 . . . . 0.0 109.99 177.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.55 -48.27 82.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.965 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.06 -45.49 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.974 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.68 -43.28 99.47 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.61 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -74.89 -37.15 62.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 111.576 0.213 . . . . 0.0 111.576 -177.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.45 -38.83 85.42 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.737 0.303 . . . . 0.0 111.428 -178.091 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 59.1 mtm -71.22 -31.03 67.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.039 0.447 . . . . 0.0 111.054 -179.161 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.414 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.55 -2.86 58.47 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.432 -179.396 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.543 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 3.9 tp10 62.4 43.95 7.66 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-O 121.49 0.662 . . . . 0.0 110.3 -177.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.0 mt -107.44 88.6 4.21 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.83 175.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 24.3 Cg_exo -62.14 118.22 5.1 Favored 'Trans proline' 0 C--O 1.233 0.267 0 C-N-CA 122.918 2.412 . . . . 0.0 112.665 -174.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.564 HD23 ' OG1' ' A' ' 9' ' ' THR . 1.9 pt? -118.96 147.09 44.43 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.95 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.659 HG12 ' HA ' ' A' ' 7' ' ' ALA . 26.9 m -136.97 158.33 36.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.014 178.288 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.539 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 30.3 tt0 -94.89 119.82 34.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.491 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.527 HG13 HG22 ' A' ' 82' ' ' ILE . 20.7 m -74.25 144.32 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.135 174.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -117.55 23.47 11.73 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.76 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.481 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 10.4 t70 -144.35 127.81 16.95 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -176.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -66.56 -36.76 83.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.367 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.481 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 10.0 mtmp? -67.9 -18.35 64.76 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.324 -175.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -58.98 -39.89 83.17 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -67.69 -29.07 68.24 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.754 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.11 -40.14 60.09 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 177.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.03 -46.55 56.65 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.703 -176.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.0 p -66.0 138.02 23.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 121.106 0.479 . . . . 0.0 111.376 -175.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -138.06 151.07 47.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.989 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.549 ' OG1' HG12 ' A' ' 19' ' ' VAL . 80.4 m -70.17 118.37 12.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.605 -0.271 . . . . 0.0 110.319 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 120.69 -12.5 10.11 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.257 177.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.82 179.33 6.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.829 0.314 . . . . 0.0 111.127 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -109.18 120.81 43.64 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 121.046 0.45 . . . . 0.0 111.344 -175.003 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 17' ' ' ALA . 52.1 t -123.02 137.39 56.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.485 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.449 ' CG2' ' HB3' ' A' ' 129' ' ' GLU . 6.0 m -114.43 134.56 57.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.654 170.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.402 HG11 ' CB ' ' A' ' 80' ' ' ALA . 11.2 p -112.96 133.95 57.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.165 0.507 . . . . 0.0 110.644 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -129.29 94.85 3.89 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 174.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.39 -16.13 35.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.185 0.516 . . . . 0.0 110.293 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.32 -40.95 73.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.252 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -100.45 -25.26 14.27 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.153 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 90.41 68.76 1.2 Allowed Glycine 0 CA--C 1.516 0.124 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.352 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -158.38 146.94 18.77 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 122.468 0.307 . . . . 0.0 110.832 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.34 125.53 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.705 173.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.449 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 41.1 tt0 -109.1 112.61 24.87 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.234 0.54 . . . . 0.0 110.722 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.464 ' HB3' HG23 ' A' ' 1' ' ' VAL . 55.7 tp -105.86 122.59 46.41 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.957 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.8 mt -115.3 120.49 64.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--N 1.31 -1.148 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.282 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 N--CA 1.454 -0.271 0 CA-C-O 120.934 0.397 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.452 ' HD2' ' N ' ' A' ' 2' ' ' LYS . 11.4 mptt -101.46 113.66 26.96 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -93.85 148.21 22.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.828 0.346 . . . . 0.0 110.764 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.06 125.86 40.0 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.665 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.8 m -120.36 175.14 6.11 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.55 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 40.9 ttm180 -101.28 121.21 41.47 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -69.83 114.05 7.65 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.765 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 mm -90.75 -66.56 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 174.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.551 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 21.2 p -96.18 -170.95 2.2 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 173.072 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.27 164.71 24.98 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.056 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.05 155.54 10.96 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.052 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 57.9 ttt180 -115.87 117.08 29.18 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.908 0.385 . . . . 0.0 110.143 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.424 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -119.01 138.18 53.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.994 0.426 . . . . 0.0 111.352 -175.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.493 ' HG3' HG22 ' A' ' 120' ' ' VAL . 20.6 tt0 -112.0 139.49 47.47 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.053 178.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.405 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -172.7 170.66 43.75 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.473 175.045 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -82.63 127.48 33.41 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 52' ' ' ILE . . . -90.2 131.58 35.96 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -169.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mp -112.75 130.52 56.04 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.148 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.487 HG11 HG13 ' A' ' 113' ' ' VAL . 48.2 t -119.47 126.16 75.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.552 -172.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.4 t -118.27 139.52 51.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 176.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -91.65 -9.39 44.16 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.239 0.542 . . . . 0.0 110.033 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -95.37 143.86 26.38 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.824 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -85.42 153.62 22.38 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.869 177.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.418 ' O ' ' HA3' ' A' ' 58' ' ' GLY . 41.0 pt -122.0 -178.99 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.197 0.523 . . . . 0.0 111.5 -175.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.3 p -111.32 124.38 52.12 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.767 -0.652 . . . . 0.0 109.641 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.736 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 1.3 m-85 -76.36 95.61 3.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.345 0.593 . . . . 0.0 110.824 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 pp -165.83 -162.57 0.57 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.708 -1.133 . . . . 0.0 109.164 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -73.34 67.12 1.53 Allowed Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.579 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.42 -23.03 10.63 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 121.21 -0.519 . . . . 0.0 112.401 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 37' ' ' VAL . 60.3 mt -101.92 138.21 26.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 177.032 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -69.34 133.02 47.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.605 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 60.8 pttt -78.52 -16.72 57.16 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -173.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.5 mm-40 -94.73 -52.32 4.33 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -174.361 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.581 HG23 HG12 ' A' ' 36' ' ' ILE . 7.6 t -106.3 -2.94 21.75 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 111.795 0.294 . . . . 0.0 111.795 -176.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.58 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.24 37.8 93.22 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.226 175.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.581 HG12 HG23 ' A' ' 34' ' ' THR . 49.7 mm -104.02 128.74 57.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.458 HG22 HG12 ' A' ' 30' ' ' ILE . 21.3 t -72.29 117.75 16.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.865 0.364 . . . . 0.0 110.181 178.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -83.64 -36.27 23.96 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.266 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -64.98 132.79 50.21 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 176.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.534 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 9.0 t70 -80.38 136.83 36.45 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.287 0.565 . . . . 0.0 111.832 -170.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.454 ' H ' ' HB3' ' A' ' 44' ' ' LYS . 79.4 m -144.55 28.04 1.33 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.033 -0.985 . . . . 0.0 109.105 177.061 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 70.26 -69.12 0.18 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.28 -177.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 46.6 pt -80.39 5.43 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.27 0.557 . . . . 0.0 111.203 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.534 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER -68.18 139.41 56.09 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.254 178.676 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.94 -1.29 1.72 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.635 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -102.58 159.8 15.13 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.663 0.268 . . . . 0.0 110.569 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.4 p -82.1 121.96 27.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-O 121.28 0.562 . . . . 0.0 110.041 176.286 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.0 m -86.71 19.26 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.438 -176.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.13 92.16 0.17 Allowed 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.706 0.765 . . . . 0.0 111.128 -176.455 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.51 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 84.92 24.32 45.65 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 114.735 -1.121 . . . . 0.0 112.23 177.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.452 HH11 ' HD2' ' A' ' 51' ' ' ARG . 12.5 mmt180 -98.08 163.96 12.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.627 0.251 . . . . 0.0 110.728 178.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.483 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.0 mm -102.15 118.37 48.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 175.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.538 ' HB2' HG22 ' A' ' 81' ' ' ILE . 4.3 mm? -106.7 125.3 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.922 0.391 . . . . 0.0 111.221 -177.762 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.477 ' HB ' HG22 ' A' ' 19' ' ' VAL . 59.7 t -110.7 106.38 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.849 176.208 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -136.59 148.12 62.43 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.787 176.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.451 ' O ' ' HG2' ' A' ' 84' ' ' LYS . 32.1 Cg_exo -59.61 -45.28 26.46 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.416 2.077 . . . . 0.0 111.955 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.89 1.66 Allowed Glycine 0 N--CA 1.446 -0.666 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . 138.02 -140.71 11.41 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.173 178.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -92.46 103.21 15.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.915 0.388 . . . . 0.0 110.142 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.736 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -91.57 85.31 1.25 Allowed Glycine 0 N--CA 1.447 -0.621 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.742 -176.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.8 m -78.63 155.79 29.38 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 176.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.587 ' HA ' HG21 ' A' ' 89' ' ' ILE . 12.0 t -68.21 -20.24 64.82 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.774 0.321 . . . . 0.0 111.329 -175.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.8 p -67.2 -28.07 41.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.289 0.566 . . . . 0.0 110.462 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -87.47 11.91 64.53 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.98 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 25.4 t -83.29 -56.03 3.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.936 0.398 . . . . 0.0 110.581 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -78.31 -15.46 58.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.934 -174.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.44 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 34.4 m -66.42 -28.58 43.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.239 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 98.9 mt -62.35 -40.77 97.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.988 0.423 . . . . 0.0 110.168 178.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.7 tp -69.4 -43.12 74.1 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.266 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 46.8 t-20 -57.36 -49.93 74.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.913 178.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.564 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 97.9 mt -63.49 -43.52 97.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.054 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.415 ' C ' ' HD3' ' A' ' 72' ' ' ARG . 0.3 OUTLIER -66.83 -38.95 87.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.708 0.289 . . . . 0.0 110.347 -177.438 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.452 ' HD2' ' O ' ' A' ' 73' ' ' LYS . 2.4 tmmm? -61.48 -32.1 72.09 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.53 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -91.37 -7.73 50.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.267 0.556 . . . . 0.0 110.143 178.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.21 16.34 72.05 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.0 174.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.58 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.9 m -108.25 7.56 9.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.776 0.322 . . . . 0.0 111.448 -177.16 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.564 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -92.45 159.95 35.79 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.501 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.528 ' HB3' HD23 ' A' ' 53' ' ' LEU . 34.7 Cg_exo -58.41 150.17 69.63 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.373 2.049 . . . . 0.0 111.12 172.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.51 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 79.0 tttt -81.49 -24.68 36.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.151 0.5 . . . . 0.0 109.828 -178.368 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.483 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -168.37 154.29 6.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.893 176.548 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.538 HG22 ' HB2' ' A' ' 53' ' ' LEU . 25.5 pt -136.25 146.1 29.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.821 0.343 . . . . 0.0 111.295 -178.441 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.605 HG23 HG23 ' A' ' 102' ' ' VAL . 4.7 mm -118.82 124.22 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 14.2 m120 -122.39 171.22 9.22 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -176.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.451 ' HG2' ' O ' ' A' ' 56' ' ' PRO . 63.1 pttt -96.97 -32.57 11.95 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.4 0.619 . . . . 0.0 110.321 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.412 ' NZ ' ' HA ' ' A' ' 85' ' ' LYS . 1.4 tppm? -138.02 113.15 9.24 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.665 177.361 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.3 m -99.03 127.68 45.01 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.782 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.68 152.12 22.01 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 16.3 m -56.64 -39.52 73.83 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.693 0.283 . . . . 0.0 110.997 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.587 HG21 ' HA ' ' A' ' 62' ' ' THR . 80.8 mt -55.38 -41.4 62.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-O 121.335 0.588 . . . . 0.0 110.686 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 25.8 mm -71.77 -41.65 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.247 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.41 81.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.227 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -60.31 -45.54 96.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.829 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.22 -48.07 85.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.52 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.28 -33.17 74.73 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.534 0.206 . . . . 0.0 111.472 -178.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.98 -45.07 90.7 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.911 0.386 . . . . 0.0 111.068 178.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.6 mtm -69.02 -33.14 73.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.138 -178.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -85.74 -7.24 58.9 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.54 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.461 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 63.2 mt-10 60.4 48.52 7.74 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.501 0.667 . . . . 0.0 110.471 -177.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.3 90.07 7.85 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.026 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.551 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 50.0 Cg_exo -52.8 115.77 2.46 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.764 2.309 . . . . 0.0 112.202 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pt? -129.77 143.85 51.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.004 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.605 HG23 HG23 ' A' ' 82' ' ' ILE . 17.4 m -136.18 155.29 34.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.918 -178.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.55 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 2.6 pt-20 -102.93 137.08 41.6 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.057 0.456 . . . . 0.0 111.618 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 2.2 m -125.17 109.41 22.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.53 173.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.451 ' H ' ' HD3' ' A' ' 105' ' ' ARG . 0.0 OUTLIER -87.6 17.42 4.65 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.451 0.643 . . . . 0.0 110.156 176.789 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -95.12 123.28 38.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.058 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -71.45 -38.75 71.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.428 -176.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.566 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 62.3 mttm -70.81 -18.83 62.72 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -171.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -56.07 -49.85 72.62 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 171.025 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -75.72 -26.48 57.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.511 0.672 . . . . 0.0 110.231 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.3 tt0 -65.02 -44.57 88.7 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.314 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -96.84 -27.97 14.46 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.487 HG13 HG11 ' A' ' 19' ' ' VAL . 11.0 p -67.24 134.75 29.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 111.225 -175.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -110.98 157.13 20.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.421 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.443 ' HB ' ' H ' ' A' ' 19' ' ' VAL . 8.8 t -87.41 127.97 35.21 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.483 179.352 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.57 0.4 24.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.169 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -101.78 -172.1 2.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.808 0.304 . . . . 0.0 110.871 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 118' ' ' ARG . 2.0 ttp180 -103.07 127.37 50.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.368 . . . . 0.0 111.574 -172.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 129' ' ' GLU . 73.9 t -134.07 123.15 43.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.322 176.083 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.493 HG22 ' HG3' ' A' ' 14' ' ' GLU . 81.2 t -114.82 125.05 72.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.624 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 6.2 p -107.9 123.89 63.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.456 0.646 . . . . 0.0 111.252 -177.19 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -103.58 95.97 6.41 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.121 173.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.11 6.03 17.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.956 0.408 . . . . 0.0 110.979 -176.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.01 -38.99 79.56 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.264 0.554 . . . . 0.0 109.798 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -115.19 -22.84 9.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.888 175.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 92.72 66.3 1.09 Allowed Glycine 0 C--O 1.228 -0.232 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -174.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -144.29 125.11 14.24 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -169.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 24.6 m -113.33 134.29 56.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.29 0.567 . . . . 0.0 111.823 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.503 ' O ' ' HA ' ' A' ' 119' ' ' VAL . 46.3 mt-10 -96.55 107.79 20.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.17 176.273 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.8 tp -101.3 108.99 20.77 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 175.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.5 mm -120.13 125.72 74.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.9 0.381 . . . . 0.0 110.297 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 . . . . . 0 C--N 1.318 -0.79 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.426 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 121.443 0.64 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.707 ' HE3' ' HG2' ' A' ' 129' ' ' GLU . 52.0 mtpt -121.49 121.39 37.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.231 -0.895 . . . . 0.0 108.606 170.624 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.51 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 96.6 m-85 -97.17 150.11 21.25 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.99 0.424 . . . . 0.0 111.37 -173.607 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.76 122.15 46.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.733 177.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.462 ' SG ' HG21 ' A' ' 102' ' ' VAL . 7.1 p -120.49 171.16 8.74 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.123 -177.525 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.653 ' HB3' ' HB2' ' A' ' 103' ' ' GLU . 7.8 tpt180 -93.5 115.8 28.31 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 176.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.604 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -74.88 110.31 9.07 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.589 -178.415 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.2 mm -85.06 -55.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 172.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.586 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -100.17 174.73 6.01 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 171.925 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 10' ' ' ARG . 43.1 mtm180 -119.56 174.7 6.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.804 0.335 . . . . 0.0 110.434 175.169 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.4 144.8 6.84 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.096 -178.189 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.527 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 60.1 mtm180 -119.16 131.64 55.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 177.582 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.57 145.29 23.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.519 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.06 140.92 52.5 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.158 -0.473 . . . . 0.0 109.754 177.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -170.26 175.79 44.11 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.522 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -67.08 128.15 35.28 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.9 125.29 29.94 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.984 -176.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 tt -108.39 109.07 20.28 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 175.288 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.455 HG22 ' HB ' ' A' ' 54' ' ' VAL . 75.1 t -103.15 128.8 55.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.948 0.404 . . . . 0.0 110.669 -174.194 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 22' ' ' GLU . 7.2 m -123.94 108.69 12.68 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.523 -177.321 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -89.54 16.54 7.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.402 0.62 . . . . 0.0 110.315 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.508 ' CG ' HG23 ' A' ' 24' ' ' ILE . 6.0 tp10 -83.87 159.38 21.35 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.419 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TYR . . . . . 0.438 ' N ' ' HG3' ' A' ' 22' ' ' GLU . 23.8 m-85 -119.69 81.48 1.73 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.28 0.562 . . . . 0.0 110.007 176.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.508 HG23 ' CG ' ' A' ' 22' ' ' GLU . 18.4 pt -107.63 168.53 3.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.827 0.822 . . . . 0.0 111.744 -176.486 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.55 123.17 34.0 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 114.306 -1.315 . . . . 0.0 109.063 176.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -56.29 -70.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.205 0 O-C-N 123.276 0.36 . . . . 0.0 110.483 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt 59.28 -85.42 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 O-C-N 123.791 0.682 . . . . 0.0 111.991 176.526 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 168.75 42.08 0.03 OUTLIER Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.0 -7.91 84.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.255 -174.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.453 HG13 HG12 ' A' ' 37' ' ' VAL . 4.1 mp -79.83 119.49 29.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 176.056 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.09 127.8 33.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.106 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.463 ' HE3' ' OD1' ' A' ' 70' ' ' ASN . 0.0 OUTLIER -74.64 -10.2 59.31 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -172.749 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -97.81 -35.98 10.35 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.749 0.309 . . . . 0.0 111.34 -176.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.6 p -105.53 -36.42 7.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.342 -0.39 . . . . 0.0 112.013 -178.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.93 15.41 59.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.634 -175.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 49.2 mm -95.44 138.35 21.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.453 HG12 HG13 ' A' ' 30' ' ' ILE . 15.3 m -72.49 116.21 14.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.371 0.605 . . . . 0.0 110.762 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -88.75 -9.41 51.98 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.382 -178.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -90.29 151.16 21.62 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.431 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 10.5 t70 -76.9 134.69 38.89 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.316 -171.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 7.6 p -167.32 173.38 8.94 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 43' ' ' ILE . 5.3 pt-20 -62.08 -36.26 81.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 -178.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.436 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 15.1 pt -105.38 43.54 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 122.053 0.93 . . . . 0.0 110.144 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.431 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 86.4 tttt -67.47 121.53 16.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.778 -179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.71 -2.48 29.0 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.886 -178.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -79.54 155.7 28.09 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.937 0.398 . . . . 0.0 111.052 177.419 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.1 p -102.8 136.49 42.52 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.326 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.1 m -98.11 -1.36 10.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.905 0.383 . . . . 0.0 110.957 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.31 95.03 0.29 Allowed 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.802 -176.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.08 17.6 39.89 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.196 175.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.5 mmt180 -109.64 150.83 27.66 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.562 HD13 HG23 ' A' ' 121' ' ' VAL . 65.8 mt -96.19 105.26 16.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 177.188 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.593 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -80.61 116.6 20.72 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.373 0.606 . . . . 0.0 111.332 -174.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.455 ' HB ' HG22 ' A' ' 19' ' ' VAL . 61.6 t -114.13 106.94 21.66 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.657 175.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -134.86 148.32 66.56 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.126 176.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.27 -41.5 21.14 Favored 'Trans proline' 0 C--O 1.236 0.388 0 C-N-CA 122.53 2.153 . . . . 0.0 112.319 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 167.14 -149.1 14.16 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.114 -0.565 . . . . 0.0 111.936 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 169.48 -140.03 5.9 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.265 -179.36 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -91.94 139.31 30.78 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.841 0.353 . . . . 0.0 110.912 179.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.508 ' HA2' ' HG3' ' A' ' 87' ' ' GLU . . . -99.16 88.09 0.81 Allowed Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.807 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.7 t -95.78 152.96 18.0 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.985 0.422 . . . . 0.0 110.701 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.1 t -84.49 49.14 1.63 Allowed 'General case' 0 CA--C 1.539 0.522 0 CA-C-O 121.531 0.682 . . . . 0.0 110.618 -176.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HB ' HG21 ' A' ' 89' ' ' ILE . 46.9 t -48.06 -49.09 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 114.982 -1.008 . . . . 0.0 112.658 -176.59 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.62 16.72 38.53 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.944 -176.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 90.3 p 60.2 -152.47 0.39 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.179 0.592 . . . . 0.0 111.631 173.068 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.464 ' HB2' ' O ' ' A' ' 65' ' ' SER . 58.1 m-85 76.07 -42.9 0.46 Allowed 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.713 0.805 . . . . 0.0 112.721 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.45 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 17.4 m -52.3 -36.9 21.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -175.198 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.45 HD22 ' HB2' ' A' ' 94' ' ' ALA . 5.3 mp -68.85 -34.87 76.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.001 0.429 . . . . 0.0 111.075 -178.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.499 HD13 ' HA ' ' A' ' 97' ' ' ALA . 66.1 tp -70.63 -40.06 73.32 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.044 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.463 ' OD1' ' HE3' ' A' ' 32' ' ' LYS . 12.7 t-20 -56.2 -41.88 76.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.776 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.45 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 80.6 mt -62.59 -41.47 98.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.34 -179.33 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.563 ' NH1' ' HB3' ' A' ' 98' ' ' GLU . 15.2 ttp180 -74.2 -25.06 59.46 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.856 -0.337 . . . . 0.0 111.09 -174.323 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -73.72 -26.09 60.53 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.825 -0.35 . . . . 0.0 111.282 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 16.2 t-20 -92.56 -27.95 17.05 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.898 176.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.87 22.79 7.43 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.476 -0.869 . . . . 0.0 112.522 177.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.434 HG21 ' HA ' ' A' ' 32' ' ' LYS . 30.4 m -114.27 21.05 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.122 0.487 . . . . 0.0 110.882 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -92.02 155.52 43.01 Favored Pre-proline 0 C--O 1.237 0.431 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.428 -177.143 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.593 ' HB3' HD13 ' A' ' 53' ' ' LEU . 15.7 Cg_exo -69.69 158.9 55.43 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.997 2.465 . . . . 0.0 112.021 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -69.76 -44.69 69.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.057 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.98 164.24 25.78 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.204 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 37.5 mm -127.0 124.64 65.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.428 -178.824 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.1 mm -119.19 116.27 50.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.331 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' HG12 ' A' ' 104' ' ' VAL . 13.6 m120 -126.26 157.38 38.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.692 0.282 . . . . 0.0 111.031 -175.028 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 23.5 ttmm -68.89 -52.07 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 173.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.1 tptm -155.6 109.99 2.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.172 171.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.7 t -91.62 167.03 12.5 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.314 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.508 ' HG3' ' HA2' ' A' ' 60' ' ' GLY . 2.9 mm-40 -83.56 152.08 25.05 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.934 0.397 . . . . 0.0 110.854 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 m -58.87 -34.02 71.14 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.148 -178.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.462 HG21 ' HB ' ' A' ' 63' ' ' VAL . 3.0 mp -61.22 -39.99 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.098 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 50.0 mt -77.15 -42.4 31.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.413 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.574 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -55.59 -48.76 74.32 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.586 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -71.79 -39.06 67.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.524 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.95 -41.52 99.66 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.601 -178.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.45 ' HB2' HD22 ' A' ' 68' ' ' LEU . . . -74.56 -31.16 62.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.555 0.217 . . . . 0.0 110.809 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -61.28 -38.54 87.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.01 0.433 . . . . 0.0 110.112 175.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 84.2 mtp -66.22 -42.45 88.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.685 177.201 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.499 ' HA ' HD13 ' A' ' 69' ' ' LEU . . . -80.94 -4.29 54.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.964 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.563 ' HB3' ' NH1' ' A' ' 72' ' ' ARG . 37.7 tt0 60.24 37.75 20.34 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.85 0.833 . . . . 0.0 109.852 -177.317 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.447 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 60.1 mt -105.11 89.18 2.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.931 175.376 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.586 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 12.1 Cg_endo -53.47 117.07 3.42 Favored 'Trans proline' 0 C--O 1.234 0.302 0 C-N-CA 123.17 2.58 . . . . 0.0 113.845 -170.853 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.707 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pp -117.56 148.11 42.19 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.504 171.183 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.0 m -136.34 163.92 32.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.083 -175.533 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.653 ' HB2' ' HB3' ' A' ' 6' ' ' ARG . 43.8 mt-10 -97.08 113.91 25.51 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.875 175.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 7.2 p -110.74 112.7 41.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.653 0.74 . . . . 0.0 109.86 174.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 105' ' ' ARG . 52.4 mtt180 -95.81 28.38 3.1 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.992 -173.817 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 22.8 t70 -118.07 121.33 40.31 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.625 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -72.6 -33.86 66.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.968 -178.594 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.416 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 49.5 mmtm -60.6 -35.88 77.2 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 -176.305 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.502 ' O ' HG12 ' A' ' 113' ' ' VAL . 44.7 t80 -51.8 -46.04 64.09 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.857 177.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -70.18 -22.63 62.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.195 0.522 . . . . 0.0 111.17 -174.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.481 ' O ' ' HE2' ' A' ' 114' ' ' LYS . 11.5 mm-40 -88.51 -28.19 20.95 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.191 176.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.61 -44.31 64.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.803 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.9 p -91.93 133.18 34.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.172 0.51 . . . . 0.0 111.151 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.481 ' HE2' ' O ' ' A' ' 111' ' ' GLU . 74.7 mmtt -128.93 160.87 31.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 10.8 t -63.35 125.44 24.17 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.162 0.506 . . . . 0.0 110.37 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.35 -16.36 11.67 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.855 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -91.24 175.28 6.99 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.42 HH11 ' HD3' ' A' ' 118' ' ' ARG . 1.3 tmm_? -116.24 129.76 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.135 0.493 . . . . 0.0 111.352 -174.18 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 86.6 t -116.41 140.41 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.209 178.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.563 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 48.6 t -104.94 108.21 24.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 172.283 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.562 HG23 HD13 ' A' ' 52' ' ' ILE . 96.1 t -92.77 119.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.148 0.499 . . . . 0.0 111.264 -175.227 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ASN . . . . . 0.527 ' HA ' ' HG2' ' A' ' 12' ' ' ARG . 55.9 t-20 -115.74 93.81 4.42 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -94.36 -0.61 54.78 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 110.378 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -80.72 -40.25 25.63 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.399 177.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -98.75 -28.07 13.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.849 176.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.43 59.66 1.14 Allowed Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.27 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -148.59 146.33 28.2 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.917 0.389 . . . . 0.0 110.451 -174.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.51 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 54.8 t -119.71 108.85 24.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.761 177.136 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.707 ' HG2' ' HE3' ' A' ' 2' ' ' LYS . 39.1 mt-10 -99.81 107.9 20.05 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.961 0.41 . . . . 0.0 110.251 179.434 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 47.6 tp -93.35 132.66 37.37 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.209 178.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.8 mt -119.22 114.98 46.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.575 0.702 . . . . 0.0 109.5 175.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--N 1.312 -1.052 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.889 179.664 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 45.0 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 121.997 0.903 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mtmm -108.21 122.69 47.44 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.164 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -89.64 136.18 33.18 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 176.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.63 114.99 26.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.678 -176.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HB ' ' A' ' 104' ' ' VAL . 11.7 m -120.33 163.08 18.37 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.38 178.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 45.3 ttt180 -93.74 124.83 38.01 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 120.344 -0.542 . . . . 0.0 109.854 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.483 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.71 137.95 34.05 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.69 -172.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 4.4 mp -103.18 -48.55 10.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 174.122 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.3 p -102.1 169.57 8.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.378 174.003 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' HB3' ' OD1' ' A' ' 124' ' ' ASP . 71.8 mtt85 -125.44 -174.75 3.14 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.928 0.394 . . . . 0.0 111.761 -176.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.35 175.85 23.39 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.4 149.38 32.63 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.31 156.19 35.06 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.975 0.417 . . . . 0.0 111.099 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -124.28 132.82 53.59 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.694 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.09 175.33 39.43 Favored Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.051 177.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -72.3 133.21 44.89 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 176.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -79.77 121.54 25.49 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.017 0.436 . . . . 0.0 110.808 -177.183 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.986 HD21 HG21 ' A' ' 43' ' ' ILE . 7.3 tt -113.23 113.59 25.53 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.495 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 53.1 t -102.99 109.94 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.105 0.479 . . . . 0.0 110.759 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.745 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 20.9 m -87.37 116.75 25.68 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.348 176.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.901 ' HD3' ' HG3' ' A' ' 42' ' ' GLU . 8.8 mptt -73.37 -25.77 60.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.377 -176.351 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.482 ' HG3' ' HB3' ' A' ' 41' ' ' CYS . 22.0 mm-40 -91.36 152.97 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -91.14 90.88 8.0 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.956 178.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 pt -86.03 145.39 7.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.135 -178.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.442 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 7.2 m -91.75 150.19 21.23 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.552 -173.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.795 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 74.9 m-85 -86.11 15.17 5.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.905 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 63' ' ' VAL . 33.7 mt -73.53 -8.45 55.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.179 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 126.48 70.5 0.18 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.245 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -106.74 -25.63 6.16 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.786 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 37' ' ' VAL . 4.2 mp -92.21 133.74 32.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 -177.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 13.2 t70 -69.68 135.11 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.996 0.426 . . . . 0.0 110.293 175.252 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 49.9 pttt -73.38 -14.02 61.2 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -171.651 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -106.65 -44.53 4.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.996 0.427 . . . . 0.0 111.771 -174.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.466 ' HB ' HG12 ' A' ' 36' ' ' ILE . 34.6 p -97.48 -26.88 14.67 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.11 -174.195 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.64 8.5 84.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.559 -175.509 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.466 HG12 ' HB ' ' A' ' 34' ' ' THR . 34.0 mm -82.56 133.48 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.367 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.49 HG12 HG13 ' A' ' 30' ' ' ILE . 5.5 m -77.39 131.73 34.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.312 0.577 . . . . 0.0 110.974 176.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.449 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 75.1 mmtt -95.39 -14.92 23.41 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.691 177.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -129.01 85.12 2.29 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.674 -176.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.577 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.1 t70 -148.14 -162.79 1.63 Allowed 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.597 -178.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.482 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 44.9 t -155.3 -32.47 0.1 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.553 -175.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.901 ' HG3' ' HD3' ' A' ' 21' ' ' LYS . 17.6 mm-40 -109.53 -47.26 3.4 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -177.372 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.986 HG21 HD21 ' A' ' 18' ' ' LEU . 40.8 pt -101.28 10.08 8.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.351 0.596 . . . . 0.0 109.919 -177.558 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.577 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 79.0 tttt -54.57 114.0 1.51 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.604 177.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 114.18 -14.19 21.24 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.374 -176.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -103.71 169.24 8.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.748 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.408 ' HB2' HD13 ' A' ' 36' ' ' ILE . 40.8 t -109.62 152.28 25.75 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.553 -179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.8 m -103.9 3.54 10.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.848 177.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.0 85.48 1.0 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.394 -176.162 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 116.18 8.26 13.42 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.516 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -114.46 158.83 21.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.0 mt -93.11 117.5 36.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 37.0 tp -90.32 111.16 22.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.579 -173.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 19' ' ' VAL . 61.3 t -119.0 105.95 18.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.413 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.745 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 19.1 p90 -137.48 163.61 47.4 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.397 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.603 ' HD2' ' HB2' ' A' ' 55' ' ' PHE . 10.0 Cg_endo -52.56 -54.92 4.33 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.858 2.372 . . . . 0.0 112.707 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 118.0 145.83 8.0 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 25' ' ' SER . . . 177.78 125.72 0.93 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.932 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt 55.04 90.71 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 174.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.795 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -102.06 -57.04 0.82 Allowed Glycine 0 N--CA 1.447 -0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 175.272 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 12.3 t 65.24 -172.26 0.18 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.937 0.495 . . . . 0.0 111.004 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.563 ' HA ' HG21 ' A' ' 89' ' ' ILE . 6.6 m -69.49 -25.01 63.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -178.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 27' ' ' LEU . 7.7 p -69.86 -37.35 72.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.971 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.477 ' HA3' ' HB3' ' A' ' 26' ' ' PHE . . . -82.25 59.72 4.88 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.89 -178.134 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.416 ' HB3' HG22 ' A' ' 89' ' ' ILE . 38.1 p -140.87 -70.5 0.37 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.858 0.361 . . . . 0.0 110.952 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -69.55 -16.32 63.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.765 -177.127 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.543 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 93.4 t -58.13 -45.34 88.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.895 0.379 . . . . 0.0 110.164 176.38 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -61.7 -38.94 89.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.593 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 54.4 tp -66.86 -40.29 87.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.878 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -69.55 -40.94 76.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.96 0.41 . . . . 0.0 110.492 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.543 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 91.6 mt -62.63 -37.44 86.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.239 176.434 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -63.87 -37.56 87.86 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.216 -178.178 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -69.1 -29.47 67.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.833 0.349 . . . . 0.0 110.749 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.411 ' HB3' HG22 ' A' ' 76' ' ' VAL . 62.1 t30 -89.41 -14.37 35.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.34 0.59 . . . . 0.0 110.055 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 85.92 10.45 75.49 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.531 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.411 HG22 ' HB3' ' A' ' 74' ' ' ASN . 27.3 m -100.74 14.01 5.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -81.4 154.5 71.67 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.35 176.08 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.16 159.14 54.16 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.334 2.023 . . . . 0.0 111.775 176.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -71.33 -31.36 67.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.907 0.384 . . . . 0.0 110.717 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -168.25 164.12 13.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.217 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 66.4 mt -137.33 118.62 17.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.257 -0.429 . . . . 0.0 109.978 179.375 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.4 HG23 ' CG2' ' A' ' 102' ' ' VAL . 10.1 mm -114.9 118.09 57.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 177.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -119.01 158.28 26.1 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.506 -174.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.576 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 1.5 tmtp? -83.96 -45.19 13.41 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 174.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -141.81 113.07 7.55 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.069 -0.969 . . . . 0.0 108.878 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.6 t -123.57 -176.92 3.57 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.582 -176.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.454 ' H ' HD12 ' A' ' 90' ' ' ILE . 77.9 mt-10 -115.86 150.7 36.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.265 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.8 m -61.92 -37.89 86.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.677 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.563 HG21 ' HA ' ' A' ' 62' ' ' THR . 51.0 mt -61.08 -39.22 81.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.968 0.414 . . . . 0.0 110.793 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.648 HD11 ' HA3' ' A' ' 60' ' ' GLY . 60.4 mt -62.86 -42.13 95.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.055 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.583 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -61.72 -38.4 87.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.89 178.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 88' ' ' THR . 58.3 t -63.87 -43.49 97.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.536 177.22 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.72 -40.11 97.18 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.13 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.29 -32.67 74.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.748 0.308 . . . . 0.0 111.055 177.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.01 -25.03 67.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 178.004 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.417 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 45.2 mtt -79.37 -43.87 22.62 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.708 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.5 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -83.49 -0.74 51.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.134 -174.765 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 64.1 38.53 8.34 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.129 0.49 . . . . 0.0 110.769 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.47 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.0 mt -109.41 90.07 8.02 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 17.7 Cg_endo -58.16 125.01 17.22 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.899 2.399 . . . . 0.0 112.68 -178.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.583 HD21 ' HA ' ' A' ' 91' ' ' ALA . 2.2 pp -127.35 147.52 50.26 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.17 0.509 . . . . 0.0 111.16 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 7' ' ' ALA . 27.4 m -134.56 156.2 39.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.05 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.451 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 42.9 mt-10 -95.92 119.46 34.46 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.583 176.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.576 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 4.5 p -114.45 116.42 52.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.257 0.551 . . . . 0.0 110.176 176.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -91.53 -29.34 17.02 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.783 -177.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -69.39 117.88 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -177.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -68.64 -21.28 64.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.762 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 31.4 mttm -62.16 -19.97 63.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.442 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 113' ' ' VAL . 46.9 t80 -65.52 -51.97 56.03 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 173.197 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -69.7 -26.49 64.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.491 0.662 . . . . 0.0 110.412 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.408 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 39.1 tt0 -70.38 -37.35 74.52 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.543 176.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.45 -54.64 5.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.1 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 109' ' ' PHE . 9.9 p -69.96 138.9 21.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.254 0.549 . . . . 0.0 110.601 -177.445 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 55.9 mttp -135.04 151.43 50.78 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.956 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.553 HG23 ' HA ' ' A' ' 18' ' ' LEU . 16.2 m -58.16 113.33 1.87 Allowed 'General case' 0 C--N 1.324 -0.519 0 O-C-N 123.353 0.408 . . . . 0.0 110.397 178.047 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 106.18 31.73 3.99 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.949 -179.187 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -132.55 173.72 11.02 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 171.258 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB ' ' A' ' 131' ' ' ILE . 10.1 ttm180 -97.52 122.51 40.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.022 0.439 . . . . 0.0 111.797 -172.211 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.4 t -117.83 124.18 72.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.065 174.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.4 t -107.17 105.05 18.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 174.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.9 p -92.86 132.31 37.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.555 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -127.23 93.51 3.76 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 176.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.05 -13.34 56.0 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.607 -171.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.427 ' OD1' ' HB3' ' A' ' 10' ' ' ARG . 48.3 m-20 -61.57 -34.77 76.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.909 0.385 . . . . 0.0 109.977 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.412 ' HB3' ' CE1' ' A' ' 127' ' ' TYR . 32.1 tt0 -106.5 -27.74 10.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.1 178.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 93.07 70.13 1.13 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.969 175.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.412 ' CE1' ' HB3' ' A' ' 125' ' ' GLU . 46.1 p90 -170.31 162.13 8.42 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.21 179.147 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.451 HG21 ' CE1' ' A' ' 109' ' ' PHE . 15.0 m -124.61 132.11 71.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.507 178.212 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -105.42 117.77 34.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.743 179.156 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.8 tp -94.2 125.4 38.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 177.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.422 ' HB ' ' HD2' ' A' ' 118' ' ' ARG . 31.4 mm -108.13 111.45 35.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--N 1.312 -1.034 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.436 -173.627 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.855 0.36 . . . . 0.0 111.162 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -121.5 111.67 17.55 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.589 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 90.1 m-85 -92.59 149.46 21.34 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.725 0.297 . . . . 0.0 110.77 -177.219 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 117.66 34.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.809 176.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.553 ' HB3' HG22 ' A' ' 104' ' ' VAL . 4.5 p -120.35 169.14 10.57 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.166 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 44.2 ttp180 -94.69 128.38 41.33 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.596 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.12 127.62 41.32 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.979 0.419 . . . . 0.0 111.458 -174.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.4 mm -101.31 -55.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.549 177.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.679 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -95.42 173.68 7.4 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.553 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.417 ' H ' HG22 ' A' ' 9' ' ' THR . 25.3 mmt180 -121.25 168.18 11.9 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.402 -175.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.68 -174.41 16.54 Favored Glycine 0 N--CA 1.452 -0.256 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.329 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.77 154.7 46.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 117.618 0.709 . . . . 0.0 111.147 176.526 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.465 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -138.61 139.51 38.59 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.959 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 123.92 30.82 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.77 -179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.95 -166.34 37.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 119.585 -1.293 . . . . 0.0 113.39 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -73.19 135.16 44.58 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 122.598 0.359 . . . . 0.0 110.797 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.72 124.95 32.1 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.929 0.395 . . . . 0.0 111.046 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.572 ' HA ' HG23 ' A' ' 115' ' ' THR . 6.5 tt -108.78 110.71 22.16 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.035 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.669 ' HA ' ' HB ' ' A' ' 54' ' ' VAL . 47.0 t -104.58 125.7 59.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.269 0.557 . . . . 0.0 112.425 -168.538 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.461 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 17.5 p -137.22 144.98 43.1 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.614 174.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.523 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 15.8 ptpt -128.89 20.14 5.98 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.193 0.52 . . . . 0.0 111.031 175.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -80.57 125.3 29.82 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.192 173.253 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -77.83 109.46 11.87 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.212 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.75 ' HB ' ' HZ ' ' A' ' 55' ' ' PHE . 43.8 mt -124.45 -7.62 6.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 110.256 -174.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.516 ' HA ' ' CA ' ' A' ' 58' ' ' GLY . 22.0 p 48.94 23.25 0.67 Allowed 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 113.596 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.455 ' CD1' HD13 ' A' ' 90' ' ' ILE . 36.9 m-85 64.51 18.34 11.31 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 178.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.2 27.26 0.81 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.176 0.512 . . . . 0.0 109.878 173.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' HA2' ' HG2' ' A' ' 39' ' ' GLU . . . -94.01 -128.39 5.1 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.488 -176.451 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 177.39 93.38 0.09 OUTLIER Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.416 -177.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.435 HG12 HG22 ' A' ' 37' ' ' VAL . 54.5 mt -92.82 126.67 45.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 170.212 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -62.92 124.31 20.75 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.695 0.283 . . . . 0.0 110.701 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.549 ' HA ' HD23 ' A' ' 71' ' ' LEU . 20.7 pttp -85.08 3.97 36.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -173.368 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -101.47 -36.99 8.62 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.94 0.4 . . . . 0.0 110.818 177.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.2 p -113.22 -19.1 11.93 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.667 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.13 25.01 62.61 Favored Glycine 0 N--CA 1.453 -0.176 0 C-N-CA 120.989 -0.624 . . . . 0.0 111.963 -177.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.3 mm -102.3 127.99 55.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.706 0.289 . . . . 0.0 110.416 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 30' ' ' ILE . 21.8 t -67.0 111.46 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.854 0.359 . . . . 0.0 110.198 177.607 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -87.24 -27.96 22.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.467 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' HA2' ' A' ' 28' ' ' GLY . 7.7 tp10 -67.76 129.78 40.97 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.492 178.068 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -74.09 133.84 42.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.293 0.568 . . . . 0.0 110.811 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 3.5 p -160.78 35.17 0.15 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.18 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 32.7 mm-40 72.38 -51.64 0.7 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.77 -174.546 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -88.55 42.36 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.308 0.575 . . . . 0.0 110.896 178.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.3 tttm -73.22 127.39 32.49 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.27 -2.2 29.66 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.166 -176.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -77.37 150.6 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.228 0.537 . . . . 0.0 111.939 178.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 36.0 t -101.36 131.93 47.17 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.782 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.498 ' HB ' ' HG3' ' A' ' 78' ' ' PRO . 31.2 m -105.53 4.72 10.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.964 0.411 . . . . 0.0 110.877 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.76 92.17 1.99 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.55 0.69 . . . . 0.0 111.242 -174.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 105.65 12.07 27.3 Favored Glycine 0 C--N 1.315 -0.595 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.635 176.245 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -110.46 175.3 5.48 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 54.1 mt -110.19 121.24 62.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.562 ' HB3' HG22 ' A' ' 81' ' ' ILE . 54.4 tp -91.46 120.26 32.13 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.746 -174.411 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.669 ' HB ' ' HA ' ' A' ' 19' ' ' VAL . 67.5 t -101.99 107.97 22.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.785 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 51.4 t80 -133.99 143.3 46.77 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -173.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.523 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 23.8 Cg_endo -62.95 -36.92 57.31 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 121.955 1.77 . . . . 0.0 111.505 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.16 -154.94 16.53 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.287 176.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.516 ' CA ' ' HA ' ' A' ' 25' ' ' SER . . . -132.05 -143.64 5.18 Favored Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 177.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 30.9 ttmt -173.54 -64.58 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -106.71 75.41 0.22 Allowed Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 110.594 -1.003 . . . . 0.0 110.594 172.442 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.411 ' HB2' ' HG3' ' A' ' 87' ' ' GLU . 50.9 m -104.23 178.35 4.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.397 0.618 . . . . 0.0 112.011 -173.222 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 85.5 m -154.77 -40.13 0.09 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.091 176.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.9 t -89.06 141.35 14.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.502 174.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 136.4 -7.22 3.98 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.742 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.533 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 12.8 p -90.09 -73.22 0.53 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.001 0.429 . . . . 0.0 111.747 -178.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -66.51 -27.87 68.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.63 -173.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.482 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 26.8 m -67.15 -31.99 55.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.025 -178.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.42 -36.78 77.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.932 0.396 . . . . 0.0 110.357 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.441 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.4 tp -66.15 -39.9 90.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.764 176.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -60.05 -48.61 81.0 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.587 176.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.549 HD23 ' HA ' ' A' ' 32' ' ' LYS . 96.3 mt -57.45 -47.62 81.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.964 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.41 ' HB2' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -66.07 -37.39 85.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -177.393 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.8 mmtt -61.4 -30.2 70.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.5 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.574 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.6 t-20 -89.64 -22.78 22.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.195 0.522 . . . . 0.0 109.877 178.552 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.27 16.49 55.5 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.385 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.667 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 32.2 m -106.94 13.81 8.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.084 0.469 . . . . 0.0 110.821 -176.683 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.88 49.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.935 -179.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.498 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 13.1 Cg_exo -68.33 143.12 57.1 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.195 1.93 . . . . 0.0 110.185 170.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.465 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 94.8 mttt -61.58 -33.92 74.71 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.165 0.507 . . . . 0.0 110.618 -179.335 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.62 155.25 34.36 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.438 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.562 HG22 ' HB3' ' A' ' 53' ' ' LEU . 16.1 pt -124.65 114.76 42.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.082 175.308 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.752 HG23 HG23 ' A' ' 102' ' ' VAL . 4.4 mm -102.86 116.78 47.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.785 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 89.8 m-20 -115.1 175.96 5.27 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.822 0.344 . . . . 0.0 111.154 -173.476 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -101.37 -40.81 6.92 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 171.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 85' ' ' LYS . 68.4 mmtt -125.15 114.41 18.98 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.502 177.449 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.1 t -81.15 154.99 26.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.042 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.411 ' HG3' ' HB2' ' A' ' 61' ' ' SER . 1.0 OUTLIER -126.29 142.38 51.55 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.511 ' O ' HG23 ' A' ' 92' ' ' VAL . 18.1 m -56.26 -50.02 72.56 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 123.536 0.522 . . . . 0.0 112.033 -174.483 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.406 HG22 ' HB3' ' A' ' 65' ' ' SER . 72.1 mt -65.24 -44.96 95.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 121.054 0.454 . . . . 0.0 110.702 -176.239 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.455 HD13 ' CD1' ' A' ' 26' ' ' PHE . 63.9 mt -63.98 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.693 -179.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.4 -41.58 94.18 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 88' ' ' THR . 98.9 t -61.86 -44.56 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.54 178.222 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.533 ' HA3' ' HA ' ' A' ' 65' ' ' SER . . . -62.6 -44.76 97.08 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.358 179.39 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.421 ' HB3' HD23 ' A' ' 101' ' ' LEU . . . -67.02 -30.96 71.19 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.594 0.235 . . . . 0.0 111.131 179.296 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.72 -38.11 88.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.541 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.435 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 61.0 mtt -64.26 -45.92 86.01 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.516 0.674 . . . . 0.0 109.91 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -80.14 -1.65 41.19 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 114.992 -1.004 . . . . 0.0 111.697 -175.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 58.9 43.17 18.45 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 121.25 0.548 . . . . 0.0 110.569 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.2 mm -104.18 91.08 3.51 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.751 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.679 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 9.3 Cg_endo -49.96 100.41 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.558 2.838 . . . . 0.0 112.667 -176.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 94' ' ' ALA . 1.5 pp -102.43 137.0 41.25 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.235 0.54 . . . . 0.0 109.994 179.653 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.752 HG23 HG23 ' A' ' 82' ' ' ILE . 35.1 m -135.17 159.23 41.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 8.3 pt-20 -121.06 135.57 55.17 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.365 0.602 . . . . 0.0 111.838 -178.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.571 HG11 ' HB2' ' A' ' 109' ' ' PHE . 32.4 t -115.9 105.04 17.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 170.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 105' ' ' ARG . 14.1 ptt180 -84.16 35.85 0.55 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.95 -170.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -138.55 145.12 40.28 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.679 176.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -71.22 -23.93 62.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.171 -176.732 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -60.28 -29.24 68.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.582 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.571 ' HB2' HG11 ' A' ' 104' ' ' VAL . 84.6 t80 -61.25 -46.46 90.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.985 0.422 . . . . 0.0 110.312 177.416 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -71.97 -22.61 61.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.243 -175.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.8 mm-40 -79.04 -36.62 40.71 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.346 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.67 -42.44 22.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.87 -176.351 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.0 p -79.86 138.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.014 0.435 . . . . 0.0 110.345 -177.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.3 mttp -122.77 151.61 41.45 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.045 -177.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.572 HG23 ' HA ' ' A' ' 18' ' ' LEU . 33.1 m -71.56 95.76 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.101 0.476 . . . . 0.0 109.921 176.643 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.2 1.95 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.268 -177.429 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -77.78 166.98 22.27 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.4 177.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.748 HH21 HG13 ' A' ' 131' ' ' ILE . 2.2 tmm_? -107.67 122.87 47.59 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.372 0.606 . . . . 0.0 109.863 -176.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.412 HG23 ' HB2' ' A' ' 17' ' ' ALA . 91.3 t -119.57 139.33 47.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.262 -175.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.9 t -117.05 111.82 36.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.319 171.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.525 HG21 HD11 ' A' ' 82' ' ' ILE . 55.1 t -107.56 117.53 53.45 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.285 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ASN . . . . . 0.744 HD21 ' HB2' ' A' ' 124' ' ' ASP . 9.8 t30 -109.97 118.02 35.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 177.013 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -101.15 8.01 42.91 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.37 -174.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.744 ' HB2' HD21 ' A' ' 122' ' ' ASN . 53.5 m-20 -64.99 -41.43 95.43 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 176.116 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -117.9 -33.43 4.48 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 173.436 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 108.93 91.84 2.19 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.195 172.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.404 ' HE1' ' HB2' ' A' ' 129' ' ' GLU . 25.6 p90 -159.66 153.35 22.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.949 0.404 . . . . 0.0 110.322 174.211 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.589 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 84.9 t -116.15 111.21 34.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.831 178.798 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HB2' ' HE1' ' A' ' 127' ' ' TYR . 26.3 tt0 -92.62 108.37 19.92 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.248 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 59.2 tp -94.6 114.07 25.98 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.908 -176.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.748 HG13 HH21 ' A' ' 118' ' ' ARG . 33.5 mm -111.58 116.95 53.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.364 174.346 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.876 -179.299 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.234 0.238 0 CA-C-O 120.963 0.411 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -126.98 140.78 52.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.937 -174.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -133.59 149.09 51.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.437 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.79 131.72 45.59 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.649 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.0 m -122.09 169.09 11.2 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.321 176.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -96.2 134.59 39.1 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 174.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.23 96.6 4.59 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.922 0.391 . . . . 0.0 111.473 -174.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.494 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 43.8 mm -82.81 -49.37 16.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 174.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.581 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -109.22 176.19 5.18 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 172.604 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.471 ' H ' HG22 ' A' ' 9' ' ' THR . 63.9 mtt180 -126.23 178.13 6.0 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.48 -0.193 . . . . 0.0 110.48 -179.11 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 124' ' ' ASP . . . 97.19 -162.39 21.79 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -174.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -156.41 148.01 22.68 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.695 0.283 . . . . 0.0 110.496 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.407 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -149.66 151.56 33.94 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -137.82 127.77 25.65 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.958 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.64 172.14 39.47 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.324 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -70.38 128.87 37.69 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.005 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.539 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.92 141.69 34.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.267 0.556 . . . . 0.0 111.712 -175.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.5 tt -121.24 114.09 20.88 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 177.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.0 t -102.79 110.84 30.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.196 0.522 . . . . 0.0 111.674 -173.627 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 20' ' ' THR . 9.7 t -152.36 95.63 2.06 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 172.346 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 0.1 OUTLIER -67.77 -72.2 0.18 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.154 -174.257 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.832 ' HG2' ' HB3' ' A' ' 41' ' ' CYS . 0.3 OUTLIER 51.15 -163.52 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 O-C-N 123.469 0.48 . . . . 0.0 111.794 178.368 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 13.3 p90 -158.59 44.49 0.29 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.443 0.639 . . . . 0.0 110.045 176.522 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.5 pt -73.29 177.84 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.721 -177.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.877 ' HA ' ' HB2' ' A' ' 59' ' ' LYS . 40.1 t -88.22 128.52 35.46 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.338 -178.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.595 ' O ' ' HB ' ' A' ' 63' ' ' VAL . 23.3 t80 -82.91 91.19 7.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -124.97 -77.49 0.59 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.033 177.002 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.45 59.17 0.41 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.6 15.65 45.26 Favored Glycine 0 C--O 1.226 -0.387 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 -177.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.443 HD13 HG21 ' A' ' 48' ' ' VAL . 58.2 mt -134.31 134.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 15.2 t70 -66.26 135.59 54.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.679 0.276 . . . . 0.0 110.357 178.124 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -81.21 -7.45 59.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -173.012 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -117.65 -30.43 5.47 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.619 HG23 HG12 ' A' ' 36' ' ' ILE . 7.8 t -123.16 -4.88 8.41 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 120.104 -0.638 . . . . 0.0 112.519 179.247 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 70.35 27.95 72.0 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.87 -0.681 . . . . 0.0 113.446 176.202 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.619 HG12 HG23 ' A' ' 34' ' ' THR . 42.5 mm -87.97 129.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 176.447 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.89 128.69 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.019 0.438 . . . . 0.0 111.032 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 74.3 mmtt -87.67 -41.43 13.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.669 -179.123 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -89.97 122.19 32.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.87 -172.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.623 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 21.7 t70 -74.35 133.51 42.52 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.359 0.599 . . . . 0.0 111.087 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.832 ' HB3' ' HG2' ' A' ' 22' ' ' GLU . 59.0 m -123.11 -28.09 4.09 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.896 178.354 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 175.52 -62.25 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 pt -114.79 71.02 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.295 179.328 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.623 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 13.3 tmtt? -93.74 140.76 29.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.698 -178.19 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 136.62 -8.1 3.95 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.915 175.221 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -103.89 173.02 6.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.239 0.542 . . . . 0.0 111.58 -175.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 m -93.36 137.7 32.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.653 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.443 HG21 HD13 ' A' ' 30' ' ' ILE . 29.7 m -100.76 2.7 10.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.972 0.415 . . . . 0.0 110.399 174.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.32 94.76 0.17 Allowed 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.861 -177.151 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.482 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 97.43 14.04 42.69 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 114.756 -1.111 . . . . 0.0 112.634 176.297 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 82.4 mtt180 -104.69 164.85 11.46 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.669 0.271 . . . . 0.0 110.574 176.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.505 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.5 mm -95.93 111.46 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.077 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' HG22 ' A' ' 81' ' ' ILE . 18.3 tp -101.7 125.86 48.45 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -173.064 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.4 t -113.75 128.61 70.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.958 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -131.99 145.87 59.27 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.46 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 60.2 Cg_endo -76.83 -50.31 0.1 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.624 2.216 . . . . 0.0 112.002 175.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 154.8 86.62 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.424 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.442 -177.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -93.21 -138.52 8.84 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.993 -175.052 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.877 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 23.4 mtpp -94.18 113.41 25.34 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.85 -44.18 92.49 Favored Glycine 0 C--N 1.329 0.14 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.126 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.8 m 57.43 23.26 8.83 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 173.485 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.494 ' HA ' ' CD1' ' A' ' 89' ' ' ILE . 4.5 m 60.77 30.45 19.69 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.887 176.291 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.595 ' HB ' ' O ' ' A' ' 26' ' ' PHE . 92.2 t -122.7 149.77 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.482 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 151.76 -47.17 0.58 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.997 -0.62 . . . . 0.0 111.869 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.2 p -70.71 142.55 51.48 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 122.964 -0.139 . . . . 0.0 110.881 -179.248 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 85.7 m-85 74.11 -52.8 0.69 Allowed 'General case' 0 N--CA 1.471 0.597 0 O-C-N 123.985 0.803 . . . . 0.0 112.498 175.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.77 -39.14 76.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.7 mt -65.07 -34.83 79.35 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.716 0.293 . . . . 0.0 110.847 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.3 tp -65.06 -44.71 88.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.405 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -64.26 -41.49 96.91 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.409 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.57 -38.39 86.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.798 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.468 ' CG ' HD11 ' A' ' 99' ' ' ILE . 2.7 tmt_? -72.04 -39.48 69.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.528 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -64.16 -30.94 71.97 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.278 0.561 . . . . 0.0 110.336 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -84.86 -22.91 29.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.0 178.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.49 23.79 38.64 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.747 176.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.05 -0.26 9.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.057 0.456 . . . . 0.0 111.269 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.14 162.59 40.05 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.685 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.03 147.8 88.44 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.229 1.953 . . . . 0.0 111.099 172.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.482 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 80.3 tttt -73.72 -26.15 60.56 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.05 0.452 . . . . 0.0 110.43 -175.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -166.71 150.19 6.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.753 176.232 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.511 HG22 ' HB3' ' A' ' 53' ' ' LEU . 15.7 pt -126.69 123.31 62.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.922 0.391 . . . . 0.0 110.564 178.381 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.694 HG23 HG23 ' A' ' 102' ' ' VAL . 5.4 mm -111.01 120.56 61.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.264 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.553 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 12.4 m120 -129.96 167.15 18.67 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -176.083 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -104.68 -38.83 6.57 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.4 tttp -128.58 103.43 7.1 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.218 174.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.9 t -112.0 156.8 21.57 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 175.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -79.46 145.93 33.01 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -56.87 -34.01 67.42 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.182 0.515 . . . . 0.0 110.986 -176.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.494 ' CD1' ' HA ' ' A' ' 62' ' ' THR . 54.8 mt -64.45 -41.15 91.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.822 178.317 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.9 mt -71.83 -42.17 69.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.542 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.61 -47.11 80.35 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.304 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.408 ' O ' ' HG3' ' A' ' 96' ' ' MET . 90.1 t -68.22 -42.25 84.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.615 179.112 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.97 99.15 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.352 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.54 -40.06 92.46 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.785 0.326 . . . . 0.0 110.833 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.506 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -63.64 -37.18 86.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.941 179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.408 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 89.4 mtp -68.39 -37.73 80.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.683 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.14 -1.28 57.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.342 -175.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 62.36 47.32 5.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.414 0.626 . . . . 0.0 110.467 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.468 HD11 ' CG ' ' A' ' 72' ' ' ARG . 44.2 mm -107.29 90.55 5.82 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.587 175.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.3 Cg_endo -48.48 96.51 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.421 2.747 . . . . 0.0 113.277 -175.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.494 ' O ' ' HB ' ' A' ' 8' ' ' ILE . 5.8 tt -102.29 126.0 49.16 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.721 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.694 HG23 HG23 ' A' ' 82' ' ' ILE . 11.0 m -127.71 150.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.257 176.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.553 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 6.5 tm-20 -97.8 114.9 27.04 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.507 -177.371 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 82' ' ' ILE . 14.4 m -71.57 134.12 30.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.333 0.587 . . . . 0.0 111.832 -177.123 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.559 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 1.0 OUTLIER -84.94 -33.95 22.57 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.363 -179.548 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -112.5 140.36 47.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.185 -172.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.34 -20.67 62.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.315 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mmtt -57.54 -24.15 54.46 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.905 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.412 ' CD2' HG11 ' A' ' 104' ' ' VAL . 92.7 t80 -60.65 -46.23 91.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.691 0.281 . . . . 0.0 110.508 178.049 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -65.07 -31.46 72.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.544 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -79.69 -30.91 41.23 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.976 -178.065 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.38 -33.01 17.02 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.371 -175.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 14.8 p -64.1 134.82 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.083 0.468 . . . . 0.0 110.841 -177.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -116.89 139.57 50.47 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.886 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.4 m -71.34 99.92 2.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.216 175.34 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.73 -31.6 2.92 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.666 179.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -85.47 161.27 19.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.861 0.362 . . . . 0.0 111.616 -177.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.864 HH21 HG13 ' A' ' 131' ' ' ILE . 18.0 ttp180 -89.17 127.37 35.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.248 0.547 . . . . 0.0 111.61 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.539 HG23 ' HB2' ' A' ' 17' ' ' ALA . 96.2 t -108.13 120.91 60.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.742 175.302 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.84 101.63 12.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 176.633 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 3.2 p -102.18 114.88 42.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 121.381 0.61 . . . . 0.0 110.907 -178.031 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -101.94 93.64 5.38 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 175.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.29 -26.68 62.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.374 -173.147 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.501 ' HB2' ' H ' ' A' ' 11' ' ' GLY . 25.8 t70 -63.38 -22.6 66.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.234 -177.53 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -120.11 -1.44 10.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.719 0.295 . . . . 0.0 110.708 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.18 62.66 5.42 Favored Glycine 0 C--N 1.332 0.356 0 CA-C-N 116.053 -0.521 . . . . 0.0 112.376 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -152.13 141.8 21.84 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.37 -0.488 . . . . 0.0 110.308 -177.445 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.5 m -122.97 136.28 60.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.199 0.524 . . . . 0.0 111.441 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -120.73 114.66 21.98 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.379 177.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 42.0 tp -90.49 125.18 35.51 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.864 HG13 HH21 ' A' ' 118' ' ' ARG . 19.3 mm -101.36 111.61 31.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.309 -1.181 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.441 -175.828 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.413 ' HB3' ' HE2' ' A' ' 2' ' ' LYS . 14.3 ptpt -145.18 148.87 34.04 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.815 0.341 . . . . 0.0 111.215 -177.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -136.44 152.95 51.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.734 -0.667 . . . . 0.0 109.977 179.124 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.79 114.09 25.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.209 175.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.725 ' SG ' HG12 ' A' ' 104' ' ' VAL . 83.9 m -120.24 176.93 5.22 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.215 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.9 tpm_? -94.73 119.84 34.0 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.119 -172.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 102' ' ' VAL . . . -86.69 142.55 28.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.174 -179.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.2 mp -105.97 -54.65 6.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.3 p -98.4 161.31 13.75 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 170.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.573 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 46.0 mtm180 -123.73 -175.85 3.32 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 119.574 -0.85 . . . . 0.0 112.681 -174.674 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.85 -164.89 14.07 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 -169.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.5 ttp180 -148.76 143.47 26.41 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 117.542 0.671 . . . . 0.0 109.789 177.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.567 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -154.52 152.15 29.74 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.716 0.293 . . . . 0.0 110.96 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.414 ' O ' ' HD2' ' A' ' 79' ' ' LYS . 0.1 OUTLIER -147.81 161.21 41.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.494 178.84 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 147.85 -160.54 28.35 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.155 -1.022 . . . . 0.0 112.453 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -64.4 124.09 20.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.986 0.422 . . . . 0.0 110.444 177.341 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.84 117.22 21.3 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.254 179.37 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.505 HD12 HG23 ' A' ' 115' ' ' THR . 13.4 tp -96.54 108.82 21.46 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.538 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.42 112.73 40.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.319 0.58 . . . . 0.0 110.96 -174.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -116.45 101.15 8.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.308 176.302 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -73.59 -12.09 60.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.401 -175.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -71.84 130.12 40.29 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.051 0.453 . . . . 0.0 110.154 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -78.53 69.92 4.8 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.407 0.622 . . . . 0.0 111.338 -177.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -82.14 152.63 4.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.226 176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -116.58 174.73 5.91 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.326 -173.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.493 ' O ' ' HB3' ' A' ' 27' ' ' LEU . 85.3 m-85 -82.97 -163.34 0.71 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.89 -0.596 . . . . 0.0 109.987 175.623 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.522 HD13 HG21 ' A' ' 63' ' ' VAL . 64.9 tp 72.24 14.91 5.46 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.996 0.903 . . . . 0.0 109.831 -176.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.82 44.8 0.12 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.817 177.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.63 -72.51 1.21 Allowed Glycine 0 N--CA 1.452 -0.285 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 174.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.0 mp -85.84 133.31 29.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 170.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.527 ' HB2' ' HG2' ' A' ' 38' ' ' LYS . 29.0 t70 -72.74 146.08 46.66 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.309 0.576 . . . . 0.0 111.475 -175.618 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HG2' ' HG3' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -82.94 -11.68 57.96 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.958 -173.102 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.538 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 31.0 mt-10 -110.29 -41.32 4.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.636 0.255 . . . . 0.0 111.48 -174.383 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 42.4 p -100.86 -23.01 14.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -177.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.504 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.3 16.84 80.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.521 -175.347 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.3 mm -99.58 143.78 13.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.5 t -67.98 115.14 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.67 0.271 . . . . 0.0 110.395 177.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.527 ' HG2' ' HB2' ' A' ' 31' ' ' ASP . 30.3 mmtp -81.83 -26.67 34.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.65 146.5 53.77 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.86 -178.496 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -77.28 136.92 38.53 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.546 -177.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 53.1 t -165.22 167.66 17.81 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -177.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -63.8 -36.18 83.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.322 0.582 . . . . 0.0 109.464 175.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.649 ' O ' ' HG2' ' A' ' 46' ' ' GLU . 13.6 pt -108.19 53.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.327 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.607 ' NZ ' ' HB3' ' A' ' 44' ' ' LYS . 0.0 OUTLIER -77.94 132.95 38.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 177.89 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.78 8.51 34.48 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.602 179.11 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.649 ' HG2' ' O ' ' A' ' 43' ' ' ILE . 32.2 mm-40 -63.53 146.97 52.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.227 0.537 . . . . 0.0 110.888 178.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.0 m -106.34 107.58 18.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.179 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.2 m -82.26 0.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.941 -175.037 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.23 89.15 0.45 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.298 0.571 . . . . 0.0 111.452 -175.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.91 8.58 29.65 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.401 -0.818 . . . . 0.0 113.003 174.501 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.6 mpt_? -103.78 172.44 6.8 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.753 0.311 . . . . 0.0 111.057 -179.261 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 50.1 mm -99.92 104.09 15.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 171.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 45.3 tp -85.71 113.7 22.11 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.342 -170.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -119.66 106.89 19.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.108 0.48 . . . . 0.0 110.496 178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.424 ' HD1' ' HG ' ' A' ' 53' ' ' LEU . 34.2 p90 -136.97 149.86 67.84 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.82 176.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -63.79 -49.6 3.97 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.106 1.871 . . . . 0.0 110.464 172.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.88 139.83 2.13 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.41 -0.814 . . . . 0.0 113.061 175.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.34 5.31 60.73 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.472 177.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 69.1 -85.47 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.231 0.612 . . . . 0.0 111.102 -178.156 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.1 -113.98 1.32 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.067 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 19.6 t -151.72 53.85 0.83 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.963 0.411 . . . . 0.0 110.813 -175.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.61 ' HA ' HG21 ' A' ' 89' ' ' ILE . 19.8 m 73.57 -19.38 0.34 Allowed 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 173.128 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.522 HG21 HD13 ' A' ' 27' ' ' LEU . 4.3 t -82.52 36.66 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.835 0.826 . . . . 0.0 111.064 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.414 ' HA3' HD12 ' A' ' 89' ' ' ILE . . . -92.98 -14.11 55.37 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.44 177.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.9 p -84.21 166.01 17.91 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 122.875 -0.191 . . . . 0.0 110.927 -178.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 74.37 -44.57 0.56 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.555 0.742 . . . . 0.0 112.216 178.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.508 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 46.8 t -54.31 -45.56 68.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.755 0.312 . . . . 0.0 111.564 -177.538 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HB3' HD12 ' A' ' 99' ' ' ILE . 84.3 mt -61.28 -36.28 79.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.632 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.71 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 60.4 tp -69.74 -39.76 76.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.17 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -59.44 -48.79 80.28 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.876 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 85.2 mt -57.55 -41.08 80.26 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.778 -0.647 . . . . 0.0 111.437 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -71.71 -40.23 69.61 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.306 -178.31 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.475 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 68.3 mttm -62.61 -34.85 77.86 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.248 0.547 . . . . 0.0 109.981 175.082 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.521 ' HB3' HG22 ' A' ' 76' ' ' VAL . 37.8 t-20 -72.23 -34.0 67.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.008 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.27 6.98 57.45 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.087 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.521 HG22 ' HB3' ' A' ' 74' ' ' ASN . 28.8 m -103.41 10.07 8.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.025 0.441 . . . . 0.0 111.228 -176.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.33 147.12 49.31 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.133 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.77 160.18 49.42 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.683 176.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.528 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 96.6 mttt -69.29 -38.16 78.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.96 0.409 . . . . 0.0 110.251 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 13' ' ' ALA . . . -148.71 158.83 44.42 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.477 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 73.9 mt -132.98 119.58 37.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.88 178.576 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.753 HD12 HG22 ' A' ' 102' ' ' VAL . 9.1 mm -114.2 120.17 63.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -117.48 172.62 7.21 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.753 0.311 . . . . 0.0 110.465 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 88.0 tttt -91.65 -43.2 9.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.286 0.565 . . . . 0.0 109.55 173.01 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -112.28 118.48 35.39 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.39 177.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.8 t -82.69 159.19 22.67 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.088 177.115 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.473 ' OE1' HG12 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -144.9 151.65 39.01 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.779 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.484 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.6 m -53.56 -48.51 69.08 Favored 'General case' 0 C--N 1.323 -0.549 0 O-C-N 123.735 0.647 . . . . 0.0 111.036 178.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.61 HG21 ' HA ' ' A' ' 62' ' ' THR . 31.5 pt -62.77 -35.21 69.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.85 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.486 HG22 HD22 ' A' ' 101' ' ' LEU . 58.1 mt -70.28 -45.04 76.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.781 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.67 -45.72 91.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.849 178.504 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.59 ' O ' ' HG2' ' A' ' 96' ' ' MET . 69.5 t -58.43 -50.88 77.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.43 -43.09 98.76 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.656 -177.364 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.47 -31.22 63.64 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -176.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -66.04 -33.77 76.57 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.689 0.281 . . . . 0.0 110.94 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.59 ' HG2' ' O ' ' A' ' 92' ' ' VAL . 19.2 mmt -66.65 -44.5 81.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.576 0.703 . . . . 0.0 110.596 179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.722 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -95.18 -0.39 53.28 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 114.878 -1.055 . . . . 0.0 112.125 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 56.52 64.58 1.64 Allowed 'General case' 0 C--O 1.235 0.31 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -172.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.534 HD12 ' HB3' ' A' ' 68' ' ' LEU . 54.9 mt -113.6 89.84 16.53 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.811 177.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.458 ' HB3' ' CB ' ' A' ' 123' ' ' ALA . 77.7 Cg_exo -50.14 113.24 0.93 Allowed 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 123.07 2.513 . . . . 0.0 112.564 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.486 HD22 HG22 ' A' ' 90' ' ' ILE . 1.7 pp -125.54 133.8 52.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.233 0.539 . . . . 0.0 110.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.753 HG22 HD12 ' A' ' 82' ' ' ILE . 5.3 m -126.48 152.51 34.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 175.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.634 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 11.9 pt-20 -99.42 119.87 38.69 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.192 0.52 . . . . 0.0 110.268 178.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.725 HG12 ' SG ' ' A' ' 5' ' ' CYS . 33.1 m -97.2 153.71 3.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.499 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 3.4 tmt_? -127.62 -15.55 4.98 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.037 0.446 . . . . 0.0 110.842 -176.318 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.475 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 5.0 t70 -94.49 138.14 32.77 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.407 -170.78 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -71.73 -30.99 66.22 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.759 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.475 ' HE2' ' OD1' ' A' ' 106' ' ' ASP . 46.4 mtmt -59.94 -28.19 67.42 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.652 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.524 ' O ' HG12 ' A' ' 113' ' ' VAL . 81.6 t80 -65.41 -48.24 73.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.504 177.379 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -68.15 -26.83 65.97 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.009 -175.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 114' ' ' LYS . 3.3 mm-40 -84.76 -36.55 21.67 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.756 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -67.65 -39.85 84.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.916 0.388 . . . . 0.0 110.751 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 109' ' ' PHE . 8.4 p -93.11 140.01 17.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.662 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.476 ' NZ ' ' HA ' ' A' ' 111' ' ' GLU . 43.1 mmtm -142.12 155.26 45.34 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.777 175.174 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.505 HG23 HD12 ' A' ' 18' ' ' LEU . 17.3 m -57.46 116.04 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.806 -176.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.73 -34.84 2.23 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.268 -0.967 . . . . 0.0 113.658 175.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -92.29 -174.6 3.78 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.438 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.12 142.87 41.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.221 0.534 . . . . 0.0 111.879 -168.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' A' ' 130' ' ' LEU . 9.9 p -141.17 140.65 31.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.28 174.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.1 t -108.9 119.83 59.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.862 178.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.455 HG22 HG13 ' A' ' 128' ' ' VAL . 53.3 t -114.24 114.6 47.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.113 0.482 . . . . 0.0 111.044 -177.703 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -100.46 99.67 10.32 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -76.74 -8.03 56.51 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.413 -174.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.573 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 20.4 t70 -65.26 -37.87 88.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.091 0.472 . . . . 0.0 109.95 177.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -102.29 -28.23 12.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.619 179.133 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.98 61.15 1.78 Allowed Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -166.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -136.24 124.28 22.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -165.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 121' ' ' VAL . 21.2 t -123.87 113.67 38.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.712 0.291 . . . . 0.0 110.583 -175.025 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -107.99 114.58 28.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.379 177.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' A' ' 119' ' ' VAL . 44.8 tp -85.84 129.57 34.79 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.145 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 11.2 tt -126.46 113.78 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-O 122.196 0.998 . . . . 0.0 110.347 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.227 0 CA-C-N 113.91 -1.495 . . . . 0.0 109.704 -173.99 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.551 HG23 ' HG3' ' A' ' 2' ' ' LYS . 20.8 m . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.551 ' HG3' HG23 ' A' ' 1' ' ' VAL . 51.8 mttm 69.03 93.21 0.08 Allowed 'General case' 0 N--CA 1.469 0.49 0 O-C-N 123.454 0.471 . . . . 0.0 110.36 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -121.46 149.97 42.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.949 -175.11 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.14 134.74 41.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.096 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 104' ' ' VAL . 82.9 m -128.46 175.86 8.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.049 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.63 ' HB3' ' HG2' ' A' ' 103' ' ' GLU . 50.2 ttt180 -93.87 120.63 34.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 178.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.566 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -91.29 112.69 24.7 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.976 0.417 . . . . 0.0 111.915 -175.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.6 mp -81.45 -51.47 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.607 177.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.3 p -101.94 -173.67 2.4 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.342 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.648 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 65.8 mmt-85 -124.76 175.23 7.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.558 0.218 . . . . 0.0 110.497 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.64 173.05 25.77 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 12' ' ' ARG . 12.5 ptt180 -142.14 151.13 41.95 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 117.276 0.538 . . . . 0.0 110.802 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.524 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -140.73 138.02 33.89 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.742 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.565 ' HG3' HG22 ' A' ' 120' ' ' VAL . 28.0 tt0 -129.19 122.45 29.78 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.944 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 178.61 -160.4 26.25 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 119.93 -1.129 . . . . 0.0 113.028 176.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.533 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 27.1 mt-10 -70.36 134.19 47.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 122.635 0.374 . . . . 0.0 111.008 -177.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -91.23 125.32 35.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.012 0.434 . . . . 0.0 110.843 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.641 ' HB3' HD13 ' A' ' 53' ' ' LEU . 5.8 tp -117.82 118.49 32.17 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.9 t -102.01 127.05 55.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.208 0.528 . . . . 0.0 111.576 -173.286 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.475 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 19.2 m -126.18 108.49 11.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.647 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -86.22 8.78 19.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.748 0.309 . . . . 0.0 111.546 -174.32 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.67 143.68 35.81 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.157 0.503 . . . . 0.0 110.742 178.454 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -81.99 139.14 34.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.411 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.0 pt -127.55 155.95 39.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.763 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 18.6 p -91.81 2.06 56.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.205 -178.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 72.09 -10.12 0.92 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.34 -178.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.558 HD21 ' HA ' ' A' ' 63' ' ' VAL . 2.9 mm? -94.94 33.03 1.55 Allowed 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 169.15 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.23 -175.85 50.93 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.301 -0.863 . . . . 0.0 112.899 -174.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.12 40.77 3.02 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 121.427 -0.416 . . . . 0.0 113.751 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 34.2 mt -79.09 112.44 17.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.419 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 24.2 t70 -57.72 129.55 42.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.129 0.49 . . . . 0.0 110.975 -176.03 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.421 ' H ' ' HG2' ' A' ' 32' ' ' LYS . 44.9 pttt -82.29 -10.53 59.07 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.013 -173.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -93.71 -42.42 9.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -178.311 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 p -120.37 -5.2 9.88 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.414 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.94 32.39 80.8 Favored Glycine 0 C--N 1.329 0.143 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.339 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 46.7 mm -90.68 121.27 40.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.391 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.21 96.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.369 0.604 . . . . 0.0 109.946 176.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.3 mmmm -85.01 -5.99 59.34 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.565 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -69.75 139.08 53.27 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.65 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -77.23 132.94 38.97 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.282 -175.167 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 12.8 t -172.08 26.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.952 178.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 69.25 -39.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.8 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 35.9 pt -79.97 12.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.465 0.65 . . . . 0.0 110.497 174.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -57.05 122.91 13.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.803 177.431 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.8 -6.76 24.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.405 -178.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -85.65 148.44 25.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.9 0.381 . . . . 0.0 111.118 177.006 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 39.1 t -95.6 150.19 20.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 176.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.3 m -105.84 3.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.79 178.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.411 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.52 90.64 0.39 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.635 0.731 . . . . 0.0 111.497 -175.078 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.9 23.31 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.5 175.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.533 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 98.3 mtt180 -116.08 168.18 10.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.79 0.328 . . . . 0.0 110.518 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.44 HD12 ' N ' ' A' ' 52' ' ' ILE . 3.0 mp -107.93 122.92 62.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.641 HD13 ' HB3' ' A' ' 18' ' ' LEU . 4.6 mm? -96.34 138.45 33.92 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.142 0.496 . . . . 0.0 111.452 -175.388 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.94 119.71 61.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.067 177.001 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.671 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 90.7 m-85 -129.77 144.97 55.1 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.148 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 20' ' ' THR . 13.0 Cg_exo -71.37 -55.27 0.13 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.337 2.025 . . . . 0.0 111.519 175.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -135.94 108.77 0.7 Allowed Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.361 -178.277 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -82.34 129.74 9.25 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 175.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 33.3 ttpt -134.9 165.23 25.8 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -175.305 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 125.25 94.32 0.99 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -178.046 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.577 ' HA ' HG13 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -107.19 17.23 23.19 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.743 0.782 . . . . 0.0 109.607 -177.318 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 12.9 t -135.36 18.23 3.38 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.992 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.558 ' HA ' HD21 ' A' ' 27' ' ' LEU . 28.1 t -70.07 -49.75 53.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.233 -176.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 109.86 -24.04 20.18 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 -175.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.442 ' HB3' ' CA ' ' A' ' 93' ' ' GLY . 20.3 m 74.46 -33.31 0.25 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.761 0.825 . . . . 0.0 112.992 173.608 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.96 -23.19 65.13 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 -177.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.475 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 10.5 p -60.66 -33.58 55.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.41 -177.603 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 90.0 mt -68.88 -41.0 78.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.183 0.516 . . . . 0.0 110.484 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.1 tp -66.17 -39.53 89.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.949 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -60.21 -43.34 96.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.531 177.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.9 mt -65.86 -38.42 88.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.534 178.092 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.548 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 5.0 mmm180 -63.54 -42.83 98.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.233 178.099 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 73' ' ' LYS . 6.7 tmtt? -63.71 -29.21 70.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.402 0.62 . . . . 0.0 110.56 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -86.69 -12.27 48.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.117 0.485 . . . . 0.0 110.319 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 77.8 20.49 73.57 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.306 176.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.414 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.3 m -116.29 14.88 7.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.24 0.543 . . . . 0.0 110.929 -177.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -97.45 158.08 33.72 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.651 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.557 ' HB3' HD23 ' A' ' 53' ' ' LEU . 22.9 Cg_exo -65.37 165.43 22.45 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.665 2.243 . . . . 0.0 111.961 176.174 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.524 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 54.6 mttm -80.8 -40.19 25.42 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.069 0.461 . . . . 0.0 110.245 173.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.585 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -160.36 158.34 29.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.32 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.56 HG22 ' HB2' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -130.05 127.34 63.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.157 0.504 . . . . 0.0 109.648 174.686 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.555 HG23 HG23 ' A' ' 102' ' ' VAL . 6.5 mm -106.91 116.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.235 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.671 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 72.2 m-20 -115.27 158.65 22.05 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -177.038 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 50.4 tttm -81.69 -33.29 31.29 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 170.712 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' ' HA ' ' A' ' 85' ' ' LYS . 28.1 tptt -153.92 148.09 25.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.249 173.284 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.412 ' HB ' HD21 ' A' ' 83' ' ' ASN . 11.0 t -140.51 -179.47 6.04 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.731 -0.213 . . . . 0.0 110.88 -175.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.79 160.15 18.26 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 92' ' ' VAL . 9.1 m -58.5 -45.14 89.36 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.082 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.577 HG13 ' HA ' ' A' ' 61' ' ' SER . 15.2 mm -55.63 -41.56 65.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 111.193 178.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 27.5 mm -64.15 -45.48 96.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.361 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.79 -41.78 98.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.253 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 88' ' ' THR . 94.8 t -60.68 -44.34 96.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.053 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.442 ' CA ' ' HB3' ' A' ' 65' ' ' SER . . . -68.64 -41.25 84.54 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.076 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.84 -32.65 74.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.646 0.26 . . . . 0.0 111.125 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.37 -44.07 92.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.283 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.6 mtm -75.53 -39.44 58.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.363 -177.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.548 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -79.12 0.19 29.11 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 57.23 53.08 8.08 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.362 0.601 . . . . 0.0 111.403 -177.555 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 21.7 mm -113.11 88.06 11.67 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.541 178.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.585 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 1.0 OUTLIER -45.64 117.44 1.76 Allowed 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.319 2.679 . . . . 0.0 112.546 -179.614 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.97 121.0 37.99 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.821 -176.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.566 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.7 m -123.84 142.64 39.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.32 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.63 ' HG2' ' HB3' ' A' ' 6' ' ' ARG . 13.3 pt-20 -100.31 129.38 46.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.204 0.526 . . . . 0.0 110.286 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.546 HG22 ' SG ' ' A' ' 5' ' ' CYS . 11.3 t -90.33 138.13 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.896 -177.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 77.7 mtt180 -89.56 -33.63 16.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.006 0.431 . . . . 0.0 110.603 177.07 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -96.6 139.56 32.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.421 0.629 . . . . 0.0 112.09 -168.373 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -71.93 -26.96 62.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.754 178.753 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.6 mttm -65.39 -17.88 64.88 Favored 'General case' 0 CA--C 1.521 -0.141 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -176.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 75.5 t80 -60.43 -46.21 90.84 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 174.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 88.1 m-85 -72.0 -28.96 63.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.098 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -66.24 -45.95 78.86 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.463 176.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.13 -47.31 20.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.227 -176.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.52 133.26 30.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 121.362 0.601 . . . . 0.0 111.605 -173.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -122.76 145.99 47.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.584 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.1 m -66.91 100.39 0.72 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.472 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 138.3 -16.65 3.39 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.451 -178.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -83.63 175.33 9.81 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.489 176.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.84 HH21 HG13 ' A' ' 131' ' ' ILE . 21.3 ttp180 -111.93 134.25 53.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.989 -178.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.1 p -124.51 138.29 54.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.201 0.524 . . . . 0.0 110.82 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.565 HG22 ' HG3' ' A' ' 14' ' ' GLU . 40.5 t -111.32 106.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.117 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.4 p -104.06 126.58 58.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.333 0.587 . . . . 0.0 110.959 -178.465 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.7 t30 -114.98 100.55 8.28 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.572 176.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.26 -0.42 52.28 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.8 -176.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.648 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 28.3 t70 -67.89 -39.15 83.7 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.967 175.047 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -104.8 -30.6 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.303 177.067 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.48 ' HA2' ' HB2' ' A' ' 7' ' ' ALA . . . 96.5 57.61 1.11 Allowed Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -173.059 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 50.8 t80 -138.28 124.69 20.59 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 128' ' ' VAL . 10.8 p -117.35 107.21 21.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.972 0.891 . . . . 0.0 110.106 -178.174 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.536 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 31.2 tt0 -105.61 108.22 19.62 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.765 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 44.3 tp -84.68 124.83 31.93 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.93 176.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.84 HG13 HH21 ' A' ' 118' ' ' ARG . 23.6 mm -97.66 118.9 44.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--N 1.312 -1.033 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.31 -177.43 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.509 HG23 ' HB3' ' A' ' 130' ' ' LEU . 18.4 m . . . . . 0 N--CA 1.455 -0.199 0 CA-C-O 121.172 0.511 . . . . 0.0 111.037 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.576 ' HB3' ' CE2' ' A' ' 127' ' ' TYR . 53.6 mtmt -129.99 117.71 20.49 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.159 -178.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -115.25 164.71 13.83 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.626 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.44 135.96 53.53 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.874 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' HG21 ' A' ' 102' ' ' VAL . 6.4 p -121.74 168.7 11.52 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.96 0.41 . . . . 0.0 111.136 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.807 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 65.4 ttt180 -95.25 109.21 21.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.705 177.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.636 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -67.23 117.7 9.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.793 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.431 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 50.1 mm -101.51 -60.66 2.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.059 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.596 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.6 OUTLIER -96.69 174.44 6.82 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 172.014 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 9' ' ' THR . 52.2 mtt180 -126.53 167.9 14.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.942 0.401 . . . . 0.0 111.327 -176.663 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.82 159.96 9.38 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.711 -175.017 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.1 mtp85 -128.35 114.57 17.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.609 0.243 . . . . 0.0 110.506 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.468 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -139.21 146.27 40.3 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.056 0.455 . . . . 0.0 111.604 -175.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -133.45 148.25 51.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.334 174.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 172.34 -160.19 31.43 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.306 174.263 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.681 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.0 mt-10 -70.51 129.77 40.12 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 120.968 0.414 . . . . 0.0 110.843 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.566 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.01 117.3 21.49 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.006 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.536 HD12 HG23 ' A' ' 115' ' ' THR . 12.0 tp -105.71 115.4 30.18 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 176.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.425 ' HA ' ' CG2' ' A' ' 54' ' ' VAL . 11.3 p -100.4 110.8 28.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 122.049 0.928 . . . . 0.0 111.074 -172.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.465 HG23 HG13 ' A' ' 43' ' ' ILE . 10.1 m -106.0 88.92 2.92 Favored 'General case' 0 N--CA 1.44 -0.962 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.031 178.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' ' OE2' ' A' ' 22' ' ' GLU . 21.0 pttp -76.55 -1.06 25.52 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.119 176.692 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.539 ' OE2' ' HG3' ' A' ' 21' ' ' LYS . 8.5 mm-40 -92.43 160.68 14.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.382 178.428 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 9.7 p90 -112.67 104.99 13.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.336 0.588 . . . . 0.0 110.322 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.3 mp -100.52 130.24 50.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.993 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.488 ' HB2' ' OG ' ' A' ' 61' ' ' SER . 32.7 p -71.54 121.76 19.28 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 175.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.473 ' HE2' ' HA3' ' A' ' 58' ' ' GLY . 97.3 m-85 -72.97 87.44 1.33 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.248 0.547 . . . . 0.0 111.41 -174.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.425 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.3 tm? -134.86 -68.08 0.54 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.128 176.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -142.1 177.4 21.5 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.653 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.19 -62.76 0.61 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.521 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 57.4 mt -69.67 124.43 25.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.641 0.258 . . . . 0.0 110.626 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -59.21 133.11 55.8 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.513 177.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.459 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 33.5 mmtp -67.09 -21.26 65.88 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.291 0.567 . . . . 0.0 110.098 177.081 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -100.01 -58.52 1.9 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.738 -172.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.508 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -87.96 -14.03 40.23 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.753 0.649 . . . . 0.0 112.753 -175.379 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.641 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 67.14 29.69 74.78 Favored Glycine 0 CA--C 1.518 0.261 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.598 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.508 HG12 ' HB ' ' A' ' 34' ' ' THR . 47.4 mm -103.84 133.02 48.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.446 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 3.9 p -80.32 105.33 9.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.607 0.717 . . . . 0.0 110.308 178.181 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -80.08 -19.64 46.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.094 -179.229 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -69.48 135.79 50.63 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.567 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 34.1 t70 -83.87 130.36 34.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.48 -175.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 22' ' ' GLU . 5.8 t 173.56 50.5 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 123.927 0.767 . . . . 0.0 109.23 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 72.42 -47.86 0.67 Allowed 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 123.509 0.724 . . . . 0.0 112.208 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.465 HG13 HG23 ' A' ' 20' ' ' THR . 33.4 mm -77.17 -10.4 13.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.063 0.459 . . . . 0.0 111.078 -176.597 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.567 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 61.8 tttp -52.89 124.08 13.19 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.976 -0.557 . . . . 0.0 111.663 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.56 -16.67 28.84 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.696 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -87.03 162.43 17.62 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.223 0.535 . . . . 0.0 112.019 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 33.2 p -102.43 150.42 23.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.623 179.242 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.447 HG21 HD13 ' A' ' 30' ' ' ILE . 2.8 t -108.68 -0.04 9.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.367 0.603 . . . . 0.0 110.159 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.32 91.62 0.55 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.833 -171.219 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.589 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 90.86 23.6 29.9 Favored Glycine 0 C--N 1.317 -0.525 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.21 172.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.681 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 97.5 mtt180 -111.09 169.32 8.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.867 0.365 . . . . 0.0 111.358 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.438 HD12 ' N ' ' A' ' 52' ' ' ILE . 2.3 mp -109.68 113.02 43.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 11.1 mp -102.54 132.45 48.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.962 0.41 . . . . 0.0 111.383 -174.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.529 HG12 ' HB ' ' A' ' 82' ' ' ILE . 10.5 m -109.41 130.95 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.672 176.278 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.589 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 92.7 m-85 -130.49 145.2 56.45 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.421 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.85 -33.63 33.11 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.254 1.97 . . . . 0.0 111.507 174.09 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -177.47 -87.41 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.133 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' HA3' ' HE2' ' A' ' 26' ' ' PHE . . . 118.12 148.15 8.51 Favored Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -176.055 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -93.99 148.93 21.69 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.933 0.397 . . . . 0.0 110.802 -178.102 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.31 84.64 0.84 Allowed Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.534 -0.757 . . . . 0.0 113.001 -174.641 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.488 ' OG ' ' HB2' ' A' ' 25' ' ' SER . 25.0 m -95.9 144.73 25.98 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 171.149 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 62' ' ' THR . 9.9 t -93.97 64.42 3.37 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 122.571 1.177 . . . . 0.0 111.035 -171.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.83 HG13 ' H ' ' A' ' 65' ' ' SER . 12.5 p -60.28 -26.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.851 174.104 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.62 -1.43 68.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.525 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.83 ' H ' HG13 ' A' ' 63' ' ' VAL . 21.4 m 66.43 -165.51 0.22 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 122.622 0.369 . . . . 0.0 110.654 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 72.24 -30.07 0.21 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.514 0.726 . . . . 0.0 112.412 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 65' ' ' SER . 98.3 t -54.87 -42.17 61.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.715 0.293 . . . . 0.0 111.515 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.68 -32.47 72.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.922 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.547 ' HG ' ' HE2' ' A' ' 73' ' ' LYS . 56.8 tp -68.51 -42.83 77.99 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -59.13 -43.91 92.02 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.318 177.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.459 ' CD2' ' HA ' ' A' ' 32' ' ' LYS . 87.8 mt -64.99 -38.62 91.55 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.547 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -68.63 -38.68 80.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.388 -178.248 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.547 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 52.5 mttm -60.32 -34.27 73.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.212 0.529 . . . . 0.0 110.716 176.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.1 t30 -86.48 -22.65 26.31 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.819 -177.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.09 20.02 44.27 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.391 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.641 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 28.1 m -112.18 13.92 8.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.103 0.478 . . . . 0.0 110.811 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -96.0 160.12 30.73 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.562 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.74 141.24 71.34 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.187 1.925 . . . . 0.0 111.698 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.589 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 89.0 mttt -68.98 -28.11 66.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 110.52 176.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -160.86 147.85 15.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.695 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 63.9 mt -123.4 117.29 50.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 175.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.544 HG22 ' CG2' ' A' ' 104' ' ' VAL . 3.1 mm -110.57 115.22 49.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.589 ' ND2' ' HB2' ' A' ' 55' ' ' PHE . 15.6 m120 -111.54 153.36 26.35 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.272 -177.346 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.63 ' HA ' ' HB ' ' A' ' 104' ' ' VAL . 2.1 tmtp? -66.96 -45.63 77.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 174.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -142.98 120.88 11.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.238 177.065 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 3.7 m -86.29 150.11 24.58 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.303 -172.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -118.58 155.18 31.37 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 173.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.3 m -49.77 -51.38 39.65 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 123.31 0.644 . . . . 0.0 112.68 -173.231 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 61.8 mt -57.04 -41.18 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 121.078 0.466 . . . . 0.0 111.441 -176.276 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 20.4 mt -70.1 -43.31 79.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.384 -177.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.9 -43.98 86.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.539 -178.077 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 88' ' ' THR . 97.5 t -62.1 -43.03 97.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.992 0.425 . . . . 0.0 110.864 -179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.4 -43.38 99.14 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.58 -39.45 62.23 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -177.495 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.442 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -57.87 -46.54 84.71 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.78 -177.073 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.1 mtm -66.11 -30.73 71.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.923 0.392 . . . . 0.0 111.416 -177.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.546 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -88.46 2.2 53.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.576 -179.691 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 60.72 41.03 15.55 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.118 0.485 . . . . 0.0 110.884 -177.369 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.9 90.36 2.9 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.458 177.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.2 Cg_endo -48.33 100.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.603 2.868 . . . . 0.0 113.144 -173.606 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 3.4 tt -99.68 127.37 45.8 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.411 -0.813 . . . . 0.0 108.919 176.584 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 7' ' ' ALA . 35.2 m -132.12 159.38 43.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.844 -178.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.807 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 25.3 tt0 -89.11 125.46 35.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.528 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.63 ' HB ' ' HA ' ' A' ' 84' ' ' LYS . 90.8 t -86.18 102.21 11.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.022 0.439 . . . . 0.0 110.602 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -78.99 -35.72 42.5 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.36 0.6 . . . . 0.0 109.639 176.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.612 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 17.7 t70 -89.92 101.87 14.57 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.496 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -70.17 -15.58 62.97 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.005 0.431 . . . . 0.0 111.038 -174.417 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.612 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 30.9 mmmt -62.1 -24.81 67.35 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.887 177.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -59.8 -38.42 81.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.819 177.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.477 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.1 m-85 -71.64 -22.7 61.65 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.883 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.76 -32.17 46.5 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.248 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -86.43 -30.85 21.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.062 -178.181 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.477 HG12 ' HA ' ' A' ' 110' ' ' PHE . 12.5 p -74.87 127.24 36.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.435 0.636 . . . . 0.0 111.825 -176.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.546 ' HE2' ' HA ' ' A' ' 114' ' ' LYS . 8.9 mmpt? -130.18 161.49 31.01 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.164 175.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.536 HG23 HD12 ' A' ' 18' ' ' LEU . 91.1 m -67.41 125.01 24.77 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.809 0.338 . . . . 0.0 110.89 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 103.79 -1.18 45.16 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.277 176.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -85.88 175.26 8.75 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.497 HH21 HD13 ' A' ' 131' ' ' ILE . 18.1 ttp85 -117.18 120.74 39.22 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.371 0.532 . . . . 0.0 110.855 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.566 HG23 ' HB2' ' A' ' 17' ' ' ALA . 76.6 t -118.89 126.65 75.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.695 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.02 110.14 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.0 p -100.4 118.08 46.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.665 0.745 . . . . 0.0 111.421 -176.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -100.73 94.03 5.87 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.004 175.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.8 1.63 42.05 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 122.03 0.919 . . . . 0.0 108.835 173.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -84.49 -1.83 56.34 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.041 -1.436 . . . . 0.0 109.531 175.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.14 -43.17 0.18 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.632 -176.428 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.41 52.23 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -175.499 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.576 ' CE2' ' HB3' ' A' ' 2' ' ' LYS . 12.3 t80 -154.76 140.33 17.91 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -170.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 16.7 m -124.7 127.04 72.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.285 0.564 . . . . 0.0 111.351 -177.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -101.88 111.7 24.06 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.958 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.509 ' HB3' HG23 ' A' ' 1' ' ' VAL . 9.6 tt -108.77 129.68 55.38 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.413 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.497 HD13 HH21 ' A' ' 118' ' ' ARG . 3.8 mp -121.71 111.45 31.04 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.803 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.493 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 C--N 1.313 -1.003 0 O-C-N 124.485 1.116 . . . . 0.0 110.48 -175.204 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.563 0.697 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.427 ' HE3' ' HG3' ' A' ' 129' ' ' GLU . 55.9 mtpt -133.58 120.54 20.87 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.411 -175.189 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.416 ' HB2' ' CG2' ' A' ' 128' ' ' VAL . 92.4 m-85 -97.85 150.02 21.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.425 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -101.14 127.72 47.57 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.629 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.508 ' HB3' HG12 ' A' ' 104' ' ' VAL . 4.3 p -120.59 169.9 9.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.308 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.472 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 24.4 tpt180 -94.05 120.59 34.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.552 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.58 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -70.44 119.73 15.04 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.696 -176.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.2 mm -101.95 -47.47 11.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 174.636 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.535 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -111.95 -165.73 1.02 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.455 176.966 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 10' ' ' ARG . 54.8 mtt180 -132.76 170.1 15.75 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 176.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 113.95 153.75 11.03 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.018 -178.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.57 ' HG3' ' HA ' ' A' ' 122' ' ' ASN . 1.0 OUTLIER -123.34 126.29 46.58 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 177.834 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.555 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -133.28 132.07 40.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.035 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.36 127.76 55.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.399 -178.382 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -167.98 -179.39 40.51 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.086 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.66 133.32 42.13 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 177.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.527 ' HB2' HG12 ' A' ' 119' ' ' VAL . . . -80.17 120.48 24.34 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.891 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HA ' HG23 ' A' ' 115' ' ' THR . 8.0 tt -107.76 113.83 27.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.2 t -104.04 111.1 32.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.204 0.526 . . . . 0.0 111.094 -175.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.58 130.7 34.88 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 174.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 21.5 mtpp -92.29 -83.2 0.3 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.24 -172.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 44.84 -163.8 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.58 0.705 . . . . 0.0 112.721 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -147.1 100.98 3.36 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 168.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.445 HD11 ' SG ' ' A' ' 41' ' ' CYS . 58.7 mt -112.26 132.59 60.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.914 0.387 . . . . 0.0 111.369 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.8 p -76.46 124.68 27.94 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 171.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -79.91 39.8 0.44 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.088 0.471 . . . . 0.0 111.711 -174.633 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.37 -30.61 42.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 173.435 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -157.41 -105.4 0.22 Allowed Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 114.816 -1.084 . . . . 0.0 111.096 178.189 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.85 -41.48 3.05 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.388 174.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 52.3 mt -115.18 142.12 29.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.847 0.356 . . . . 0.0 110.708 -176.531 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -73.78 136.3 43.59 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.766 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -83.06 -3.3 57.13 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -173.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -112.12 -52.84 2.76 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 122.169 -0.332 . . . . 0.0 111.297 -176.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.1 m -101.28 -15.91 17.13 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.645 -175.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.62 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.95 21.46 68.14 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.503 -0.855 . . . . 0.0 112.402 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 42.9 mm -89.12 132.33 34.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.4 m -64.46 114.91 2.52 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.45 0.643 . . . . 0.0 110.557 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -78.55 -11.16 59.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.89 177.157 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -94.84 149.88 20.78 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.141 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -79.97 135.16 36.33 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.106 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.497 ' H ' ' HB2' ' A' ' 44' ' ' LYS . 56.6 m -148.98 -170.77 3.71 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -176.193 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -60.68 -52.32 65.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.835 0.35 . . . . 0.0 110.088 175.567 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.3 51.42 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.385 0.612 . . . . 0.0 111.145 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.497 ' HB2' ' H ' ' A' ' 41' ' ' CYS . 13.0 tmtt? -60.66 127.83 33.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.563 176.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.74 -5.69 12.69 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.136 -178.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -84.49 148.17 26.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.817 0.341 . . . . 0.0 111.099 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.6 m -93.0 113.28 25.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.513 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.627 ' HA ' ' HD3' ' A' ' 51' ' ' ARG . 26.5 m -82.16 19.97 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.79 0.329 . . . . 0.0 111.862 -175.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.419 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -80.14 92.1 5.62 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.174 0.511 . . . . 0.0 111.568 -174.205 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.85 19.65 21.37 Favored Glycine 0 C--N 1.32 -0.337 0 C-N-CA 120.688 -0.767 . . . . 0.0 113.47 171.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.627 ' HD3' ' HA ' ' A' ' 48' ' ' VAL . 7.2 ptm180 -119.96 -179.28 3.87 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 177.677 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.9 mm -104.06 135.04 43.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.587 ' HB3' HG12 ' A' ' 81' ' ' ILE . 56.1 tp -106.84 125.85 51.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.127 0.489 . . . . 0.0 110.837 -179.136 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -107.47 112.06 38.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.535 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 19.4 t80 -132.89 142.12 43.55 Favored Pre-proline 0 C--N 1.324 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -173.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -69.98 -56.34 0.14 Allowed 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.168 1.912 . . . . 0.0 112.867 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 179.21 146.67 6.82 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.42 -179.163 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.0 161.73 32.62 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.169 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.404 ' HB2' ' HE2' ' A' ' 59' ' ' LYS . 30.8 mtmm -106.46 142.52 35.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.185 0.493 . . . . 0.0 111.267 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -121.13 45.28 1.24 Allowed Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 172.688 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.9 m -51.12 104.32 0.08 Allowed 'General case' 0 C--O 1.235 0.315 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -172.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.583 ' H ' HD13 ' A' ' 89' ' ' ILE . 2.5 m 55.63 33.83 22.01 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.538 175.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.874 HG13 ' H ' ' A' ' 65' ' ' SER . 11.6 p -76.56 -24.86 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.324 0.583 . . . . 0.0 110.173 176.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 103.91 -11.59 52.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.894 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.874 ' H ' HG13 ' A' ' 63' ' ' VAL . 19.7 m 65.7 12.26 8.15 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.897 0.479 . . . . 0.0 111.828 176.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -76.67 -18.36 58.6 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.09 -177.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.434 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 48.0 t -56.15 -56.86 10.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.306 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 92.6 mt -59.62 -40.87 88.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 -177.555 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.533 ' O ' ' HG3' ' A' ' 73' ' ' LYS . 62.5 tp -66.63 -51.22 58.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.725 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -56.3 -44.95 80.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 90.3 mt -67.05 -36.36 81.87 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.154 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.645 ' HG3' HD11 ' A' ' 99' ' ' ILE . 0.0 OUTLIER -76.24 -28.4 57.14 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.813 -176.41 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.533 ' HG3' ' O ' ' A' ' 69' ' ' LEU . 8.2 mtpm? -67.97 -35.18 77.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.979 0.418 . . . . 0.0 109.902 176.379 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -78.69 -25.24 44.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.007 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.89 21.9 32.17 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.413 178.25 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.62 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.7 m -115.12 12.28 7.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.895 0.378 . . . . 0.0 111.034 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.458 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -97.29 155.33 37.5 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.811 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.542 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 22.3 Cg_exo -64.66 146.34 88.57 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.306 2.004 . . . . 0.0 111.154 174.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.555 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.4 mttt -62.25 -35.81 80.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.878 0.371 . . . . 0.0 111.035 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.518 ' HA ' HG23 ' A' ' 99' ' ' ILE . . . -161.48 158.34 26.42 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.64 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.587 HG12 ' HB3' ' A' ' 53' ' ' LEU . 54.5 mt -131.26 124.11 54.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.591 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.693 HG23 HG23 ' A' ' 102' ' ' VAL . 5.2 mm -103.75 116.77 48.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 22.2 m120 -114.78 156.35 25.04 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.313 0.578 . . . . 0.0 111.742 -175.428 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 82.0 tttt -84.12 -38.33 20.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.415 177.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -123.81 108.25 12.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.718 174.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 19.7 p -78.55 108.85 12.23 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.194 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.618 ' HB3' HG12 ' A' ' 90' ' ' ILE . 0.4 OUTLIER -72.69 135.39 45.38 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.011 -0.736 . . . . 0.0 109.011 177.652 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -56.03 -42.99 77.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.835 -174.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.583 HD13 ' H ' ' A' ' 62' ' ' THR . 60.4 mt -69.19 -32.58 54.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.879 -177.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.618 HG12 ' HB3' ' A' ' 87' ' ' GLU . 49.4 mm -67.23 -39.98 84.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.043 177.237 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.19 -43.69 92.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.13 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.78 -45.16 95.0 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.546 178.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.554 ' CA ' ' HB3' ' A' ' 65' ' ' SER . . . -67.91 -43.47 82.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.71 -178.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.406 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -61.13 -38.07 85.07 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.953 0.406 . . . . 0.0 111.004 -179.051 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.24 -32.31 73.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.546 -179.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.45 ' HB2' ' HE3' ' A' ' 96' ' ' MET . 67.7 mtm -77.38 -40.46 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.71 0.291 . . . . 0.0 111.406 -177.179 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.506 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -84.91 -0.94 55.87 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.811 -176.248 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 60.11 53.95 4.32 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 122.011 0.91 . . . . 0.0 109.78 -173.471 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.645 HD11 ' HG3' ' A' ' 72' ' ' ARG . 44.3 mm -110.1 88.26 6.84 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.744 175.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 5.4 Cg_endo -47.53 98.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.323 2.682 . . . . 0.0 112.753 -175.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 64.0 tp -92.87 130.97 38.29 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.27 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.693 HG23 HG23 ' A' ' 82' ' ' ILE . 14.1 m -135.41 148.78 28.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.289 177.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.485 ' CD ' ' HE ' ' A' ' 105' ' ' ARG . 39.5 tt0 -100.71 121.69 42.08 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.654 -177.515 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 5' ' ' CYS . 14.2 m -108.92 117.62 54.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.443 0.64 . . . . 0.0 111.132 176.176 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ARG . . . . . 0.485 ' HE ' ' CD ' ' A' ' 103' ' ' GLU . 12.8 mmt180 -93.46 4.5 53.86 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.852 176.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 20.9 t70 -95.67 123.27 39.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.211 -171.739 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -72.16 -32.51 66.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.018 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 14.2 mptt -65.99 -30.09 70.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.15 -176.766 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 113' ' ' VAL . 73.6 t80 -54.77 -50.73 67.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.075 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.493 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 89.5 m-85 -69.0 -22.64 64.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.107 0.479 . . . . 0.0 111.168 -175.111 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -85.57 -34.05 21.57 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.473 -179.366 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.91 -33.5 34.14 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.485 -178.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.6 p -78.99 125.08 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.28 0.562 . . . . 0.0 110.679 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -118.16 153.63 33.51 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.702 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 18' ' ' LEU . 24.5 m -68.2 94.35 0.51 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.071 0.463 . . . . 0.0 110.214 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.55 -9.71 2.91 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.029 -176.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ASP . . . . . 0.479 ' HB3' HD11 ' A' ' 130' ' ' LEU . 82.9 m-20 -80.85 159.39 25.07 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 176.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -103.57 113.9 27.76 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.894 0.378 . . . . 0.0 110.324 176.401 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.527 HG12 ' HB2' ' A' ' 17' ' ' ALA . 6.5 p -119.92 120.71 64.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.151 0.5 . . . . 0.0 110.18 178.207 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 129' ' ' GLU . 7.7 p -98.63 115.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.556 0.694 . . . . 0.0 109.343 175.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 7.5 p -78.57 128.78 38.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.65 -178.008 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ASN . . . . . 0.57 ' HA ' ' HG3' ' A' ' 12' ' ' ARG . 49.9 t-20 -115.07 94.51 4.77 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.6 -10.37 51.68 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.264 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -75.42 -40.28 57.89 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.249 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -102.32 -14.42 16.94 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.387 -179.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.7 65.67 1.81 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.58 -178.285 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -152.6 144.61 23.75 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.772 0.32 . . . . 0.0 110.613 -173.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 3' ' ' PHE . 4.1 m -116.7 106.59 20.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.372 0.606 . . . . 0.0 109.708 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HB3' HG13 ' A' ' 120' ' ' VAL . 29.8 tt0 -93.11 108.45 20.04 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.043 -174.601 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.479 HD11 ' HB3' ' A' ' 117' ' ' ASP . 38.8 tp -97.46 129.69 44.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.136 -175.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 13.2 mm -124.8 120.2 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.867 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 . . . . . 0 C--N 1.313 -1.001 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.707 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.466 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 4.6 m . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.433 0.635 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.53 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 19.5 mtpp -117.64 112.84 21.06 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.979 -176.739 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.466 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 96.5 m-85 -112.32 156.03 23.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.311 0.577 . . . . 0.0 111.728 -172.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.57 133.03 48.24 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.068 175.138 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.4 m -119.57 -179.45 3.88 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -177.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.929 ' HA ' ' HE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -101.36 126.02 48.07 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 120.241 -0.584 . . . . 0.0 110.083 174.989 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.565 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -80.13 128.13 33.14 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.731 -174.576 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.462 ' HB ' HD12 ' A' ' 101' ' ' LEU . 49.6 mm -112.5 -49.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 174.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.582 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -100.23 172.06 7.4 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 171.433 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.7 mtp180 -127.17 177.24 6.8 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.781 -178.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.78 -158.84 20.26 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -172.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ptt180 -141.87 160.6 39.87 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 117.107 0.453 . . . . 0.0 110.477 175.418 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.523 ' CB ' ' HB2' ' A' ' 80' ' ' ALA . . . -145.79 159.58 42.99 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.324 -178.216 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -153.21 143.04 22.06 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.063 -177.273 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.12 175.35 39.56 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.883 -1.151 . . . . 0.0 112.757 175.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -73.41 136.42 44.3 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.564 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.79 128.05 33.21 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.211 0.529 . . . . 0.0 111.841 -175.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.479 HD12 HG23 ' A' ' 115' ' ' THR . 5.2 tp -116.12 110.44 18.86 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.389 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.61 134.84 48.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.232 0.539 . . . . 0.0 111.661 -171.397 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.538 HG23 ' HB3' ' A' ' 55' ' ' PHE . 2.1 t -146.3 117.62 7.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.245 174.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.433 ' HA ' ' HD2' ' A' ' 21' ' ' LYS . 19.7 tptm -82.65 -8.92 59.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.471 0.653 . . . . 0.0 109.293 176.689 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' HB3' ' A' ' 41' ' ' CYS . 1.5 tm-20 -81.19 146.13 30.65 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 174.223 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -86.07 158.9 19.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.558 -171.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.499 HD12 ' HE2' ' A' ' 44' ' ' LYS . 12.5 tt -150.24 127.51 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.679 0.752 . . . . 0.0 111.032 177.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.632 ' HA ' ' O ' ' A' ' 58' ' ' GLY . 0.9 OUTLIER -76.28 135.09 39.63 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.845 -177.211 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.49 ' HB2' HG13 ' A' ' 63' ' ' VAL . 81.5 m-85 -73.06 -20.05 61.05 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.106 -175.148 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -65.33 -67.07 0.47 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.747 0.308 . . . . 0.0 110.501 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -114.26 34.9 4.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.663 -0.78 . . . . 0.0 111.509 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -98.34 -19.99 21.56 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.864 -0.684 . . . . 0.0 113.06 -175.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 53.6 mt -129.2 133.73 65.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 117.374 0.587 . . . . 0.0 110.75 -177.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.3 t70 -69.5 128.61 37.11 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.882 176.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -79.02 -7.13 57.84 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.558 -174.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -101.61 -57.67 2.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.994 0.426 . . . . 0.0 110.816 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -101.96 -8.3 21.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -172.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.95 21.88 78.93 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.643 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 37.7 mm -84.49 128.01 39.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 177.18 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 6.3 m -62.27 120.27 8.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.153 0.501 . . . . 0.0 110.545 175.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 21.2 mmmt -88.44 -35.21 17.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.808 -175.079 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.549 ' O ' ' HD3' ' A' ' 44' ' ' LYS . 31.9 tt0 -77.8 107.7 10.5 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.722 ' HA ' ' HD3' ' A' ' 44' ' ' LYS . 13.2 t70 -110.52 144.61 39.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.269 0.556 . . . . 0.0 112.354 -172.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.63 ' SG ' ' HD2' ' A' ' 44' ' ' LYS . 12.4 p -108.93 -51.08 2.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.476 173.134 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.435 ' HG3' HG23 ' A' ' 43' ' ' ILE . 12.5 pt-20 -172.36 -29.92 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.003 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.435 HG23 ' HG3' ' A' ' 42' ' ' GLU . 18.5 pt -114.86 10.95 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.741 -178.173 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.722 ' HD3' ' HA ' ' A' ' 40' ' ' ASP . 24.2 mttt -92.59 146.96 23.26 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.176 0.512 . . . . 0.0 110.575 -176.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.01 0.74 1.43 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.724 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 -87.58 158.39 18.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.88 0.371 . . . . 0.0 111.113 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.509 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 35.5 t -89.05 151.84 22.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.882 176.013 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 19.6 m -104.8 10.65 8.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.835 178.009 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.84 87.93 0.37 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.918 -174.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.61 -2.67 42.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.284 -0.871 . . . . 0.0 113.536 171.512 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 47' ' ' SER . 0.7 OUTLIER -109.13 -172.28 2.01 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 117.199 0.499 . . . . 0.0 110.856 -178.361 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.528 HG12 ' HB3' ' A' ' 80' ' ' ALA . 72.4 mt -118.44 120.61 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.327 -177.542 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.42 HD12 ' O ' ' A' ' 18' ' ' LEU . 47.4 tp -103.5 121.3 42.56 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.53 106.26 20.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.073 0.463 . . . . 0.0 110.658 -178.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.538 ' HB3' HG23 ' A' ' 20' ' ' THR . 23.6 p90 -137.25 151.79 72.26 Favored Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.851 176.156 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_exo -62.51 -41.52 32.13 Favored 'Trans proline' 0 CA--C 1.529 0.245 0 C-N-CA 122.458 2.105 . . . . 0.0 112.197 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.74 -159.01 32.12 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.632 ' O ' ' HA ' ' A' ' 25' ' ' SER . . . 169.05 72.39 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.189 -1.005 . . . . 0.0 113.336 178.438 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 95.4 mttt 69.33 127.77 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.755 0.788 . . . . 0.0 112.545 172.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.0 74.88 1.81 Allowed Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.24 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.631 ' HB2' HG12 ' A' ' 63' ' ' VAL . 14.9 m -84.41 176.12 8.89 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.826 0.346 . . . . 0.0 110.854 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.2 t -76.73 37.29 0.18 Allowed 'General case' 0 CA--C 1.539 0.522 0 CA-C-O 121.381 0.61 . . . . 0.0 111.261 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.631 HG12 ' HB2' ' A' ' 61' ' ' SER . 7.9 p -127.23 149.34 32.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.239 -175.324 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.28 -49.98 0.58 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.794 -0.717 . . . . 0.0 111.731 -179.174 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.536 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 13.5 m -67.33 -52.15 43.73 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.123 0.487 . . . . 0.0 110.069 177.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.562 ' CD2' HG23 ' A' ' 67' ' ' VAL . 38.6 p90 -94.87 179.91 5.07 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.562 HG23 ' CD2' ' A' ' 66' ' ' TYR . 76.1 t 72.99 -60.88 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 122.846 0.459 . . . . 0.0 110.467 -174.03 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 8.3 mp -63.41 -39.42 94.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.1 0.476 . . . . 0.0 109.846 176.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.405 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 56.1 tp -62.26 -40.19 95.37 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.123 175.343 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.33 -38.89 92.91 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.293 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.502 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 93.7 mt -58.13 -41.2 83.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.555 177.675 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -67.28 -34.74 78.05 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.564 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -67.12 -25.66 66.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.288 -178.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -100.27 -17.2 17.43 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.126 0.488 . . . . 0.0 110.299 177.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.96 0.17 58.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.942 176.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.5 19.03 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.54 -176.342 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.411 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -80.84 148.69 65.57 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.351 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 77' ' ' ALA . 11.7 Cg_exo -68.77 154.2 71.63 Favored 'Trans proline' 0 N--CA 1.463 -0.266 0 C-N-CA 122.576 2.184 . . . . 0.0 110.96 175.468 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.419 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 45.1 mttp -85.06 -32.99 22.57 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.199 179.425 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.528 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -151.42 143.96 24.25 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.796 0.331 . . . . 0.0 111.407 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 40.3 mm -129.41 124.78 60.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 174.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.588 HG23 HG23 ' A' ' 102' ' ' VAL . 3.7 mm -118.05 116.46 51.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -120.03 165.51 14.61 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -175.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.656 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 0.0 OUTLIER -76.54 -28.81 56.46 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.669 0.747 . . . . 0.0 109.956 177.568 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.7 tttm -138.91 130.51 27.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.629 169.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 25.4 p -90.4 155.94 18.58 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 175.048 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -123.06 146.09 47.98 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.709 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 92' ' ' VAL . 21.2 m -57.95 -50.4 73.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.231 -173.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 59.4 mt -58.79 -42.71 86.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.162 0.506 . . . . 0.0 110.663 -178.367 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 57.4 mt -70.11 -41.35 79.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.511 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.5 93.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.335 -179.349 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 88' ' ' THR . 94.2 t -61.44 -45.48 98.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.694 178.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.536 ' CA ' ' HA ' ' A' ' 65' ' ' SER . . . -66.63 -41.59 93.86 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.406 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.32 -41.88 93.53 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.69 0.281 . . . . 0.0 111.269 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.63 -29.6 69.35 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.021 0.438 . . . . 0.0 110.451 176.636 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 76.8 mtp -83.33 -30.31 27.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.185 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -96.04 16.68 17.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.868 -177.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.458 ' OE1' ' HD2' ' A' ' 72' ' ' ARG . 3.5 mp0 55.03 41.2 32.02 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.121 0.486 . . . . 0.0 111.297 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.466 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 48.7 mt -115.47 86.06 14.42 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.754 176.604 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 30.0 Cg_endo -65.58 109.89 1.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.309 2.006 . . . . 0.0 112.167 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.462 HD12 ' HB ' ' A' ' 8' ' ' ILE . 3.1 pp -110.31 151.27 27.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.202 0.525 . . . . 0.0 111.26 179.527 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.588 HG23 HG23 ' A' ' 82' ' ' ILE . 31.3 m -135.75 162.28 37.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.691 177.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -108.13 126.54 52.89 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.82 0.343 . . . . 0.0 110.98 -175.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.656 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 8.3 m -109.24 123.52 65.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.451 176.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -101.51 12.35 37.45 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.141 0.496 . . . . 0.0 110.201 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 28.6 t70 -107.62 122.73 47.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.022 -177.286 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -71.17 -29.07 64.73 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.629 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 10.2 mtmp? -62.64 -28.72 70.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.074 -177.069 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -60.12 -48.82 80.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.029 178.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -65.79 -26.96 67.93 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.341 0.591 . . . . 0.0 110.835 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -79.73 -27.23 40.61 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.842 -179.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.69 -39.95 12.15 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.835 -177.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.532 ' HA ' HD21 ' A' ' 130' ' ' LEU . 13.6 p -69.3 134.96 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.034 0.445 . . . . 0.0 111.176 -177.186 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -121.32 151.59 39.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.794 -177.23 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.479 HG23 HD12 ' A' ' 18' ' ' LEU . 71.4 m -71.91 124.43 24.85 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.112 175.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.04 9.42 54.01 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.879 -177.182 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -97.97 177.14 5.53 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.496 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.6 OUTLIER -116.07 113.79 23.66 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.363 0.602 . . . . 0.0 111.613 -172.914 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 17' ' ' ALA . 45.3 t -113.2 127.96 70.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.68 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.6 t -113.15 117.4 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 172.049 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.431 HG22 HG12 ' A' ' 128' ' ' VAL . 43.0 t -108.98 123.96 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -106.33 94.98 5.44 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 171.015 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.02 -19.73 62.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.947 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -62.29 -37.73 86.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.098 0.475 . . . . 0.0 109.927 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -87.37 -36.87 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.041 174.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.408 ' HA2' HG11 ' A' ' 102' ' ' VAL . . . 87.15 54.15 2.65 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -167.073 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' TYR . . . . . 0.409 ' OH ' ' HB3' ' A' ' 2' ' ' LYS . 72.8 t80 -137.14 134.86 36.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.383 -169.427 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.431 HG12 HG22 ' A' ' 121' ' ' VAL . 28.1 m -120.12 130.69 74.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.061 0.458 . . . . 0.0 110.842 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.53 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 38.8 tt0 -108.27 107.41 18.0 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 175.457 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 119' ' ' VAL . 60.2 tp -104.76 107.62 18.67 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.928 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.496 HG12 ' NH2' ' A' ' 118' ' ' ARG . 34.5 mm -101.44 110.98 29.67 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 . . . . . 0 C--N 1.313 -1.02 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.584 -177.688 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.988 0.423 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.487 ' HG2' ' HB3' ' A' ' 129' ' ' GLU . 54.3 mttm -93.42 133.45 36.68 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.212 174.244 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.442 ' CD2' ' HD1' ' A' ' 109' ' ' PHE . 93.5 m-85 -122.13 157.97 30.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.41 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.46 117.13 32.74 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.02 -178.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.6 p -119.6 172.9 7.33 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.16 177.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -104.97 131.95 51.83 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 177.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.618 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.49 134.02 34.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.092 -173.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.494 HD11 ' HG3' ' A' ' 103' ' ' GLU . 2.5 mp -110.58 -51.41 6.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 172.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.574 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -94.36 178.01 5.76 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.968 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -122.72 174.74 6.92 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 97.87 -163.44 21.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.687 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 58.9 mtt180 -120.59 148.46 43.84 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 178.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.657 ' HB1' ' HB2' ' A' ' 80' ' ' ALA . . . -129.15 114.68 16.62 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 178.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 79' ' ' LYS . 15.7 tm-20 -133.61 122.01 22.88 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.657 -173.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.03 -173.98 44.74 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.344 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 31.1 mp0 -71.39 138.23 48.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -95.24 123.12 38.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.885 0.374 . . . . 0.0 110.915 178.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.1 mp -104.84 127.03 52.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.113 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.784 HG12 ' HB ' ' A' ' 115' ' ' THR . 13.4 p -102.04 137.67 29.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.852 -173.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.4 m -150.14 107.86 3.68 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 175.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -96.72 65.26 2.17 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.03 -177.457 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 mm-40 -142.74 161.74 37.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.3 176.157 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -88.38 81.75 7.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.909 0.385 . . . . 0.0 111.6 -177.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.518 HG22 ' H ' ' A' ' 26' ' ' PHE . 4.3 mp -108.17 112.23 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.694 0 CA-C-O 121.733 0.778 . . . . 0.0 109.749 173.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.3 m -87.38 36.36 0.74 Allowed 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.009 -177.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.518 ' H ' HG22 ' A' ' 24' ' ' ILE . 56.8 m-85 63.88 -81.89 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.223 0.609 . . . . 0.0 111.106 -176.228 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.2 mt 58.41 -85.4 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 O-C-N 123.896 0.748 . . . . 0.0 111.598 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -158.17 24.59 0.39 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.84 -22.29 79.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.772 -176.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 39.8 mt -92.94 127.61 44.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.961 0.41 . . . . 0.0 110.338 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 38' ' ' LYS . 16.2 t70 -67.27 119.03 11.47 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.957 176.393 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 10.2 ptpp? -83.22 0.6 44.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.645 0.259 . . . . 0.0 111.355 -173.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -85.29 -46.81 10.65 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.899 0.38 . . . . 0.0 110.544 177.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.4 p -125.56 -5.47 7.05 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.991 0.738 . . . . 0.0 112.991 -174.105 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.99 30.86 55.08 Favored Glycine 0 C--O 1.236 0.233 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.41 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 40.9 mm -99.66 123.84 52.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.641 HG21 ' HE3' ' A' ' 44' ' ' LYS . 15.3 t -71.2 104.53 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.244 176.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.453 ' CG ' ' HB2' ' A' ' 31' ' ' ASP . 6.8 mmmm -78.62 -19.99 51.41 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.523 -174.016 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -90.56 110.22 21.36 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.756 178.032 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.491 ' HA ' ' HB3' ' A' ' 44' ' ' LYS . 19.3 t70 -97.81 155.88 16.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.108 0.48 . . . . 0.0 110.966 -178.067 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 18.7 p -141.32 -37.93 0.42 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.322 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -141.02 -62.47 0.48 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.186 -177.227 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.441 HD12 HG21 ' A' ' 115' ' ' THR . 30.2 pt -133.17 17.52 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.932 -172.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.641 ' HE3' HG21 ' A' ' 37' ' ' VAL . 17.4 tptt -80.97 -173.4 4.24 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.13 0.491 . . . . 0.0 111.565 -168.57 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.36 -0.44 55.8 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -173.147 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -94.28 179.01 5.44 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.963 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 9.5 m -92.41 132.13 37.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.203 -175.034 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 28.7 m -106.23 -0.27 10.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.113 0.482 . . . . 0.0 110.003 172.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.86 96.54 0.19 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.546 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.522 ' C ' ' HD2' ' A' ' 51' ' ' ARG . . . 86.12 20.98 54.05 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.266 -1.333 . . . . 0.0 112.517 177.464 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.522 ' HD2' ' C ' ' A' ' 50' ' ' GLY . 4.0 mpt_? -119.01 166.15 13.23 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.719 0.295 . . . . 0.0 110.588 178.332 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.783 HG12 ' HB3' ' A' ' 80' ' ' ALA . 63.3 mt -93.63 122.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.299 -0.409 . . . . 0.0 109.943 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.427 HD21 ' HE2' ' A' ' 55' ' ' PHE . 17.0 tp -99.33 128.0 45.4 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.572 -175.488 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.9 120.17 60.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.118 0.485 . . . . 0.0 111.215 -177.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PHE . . . . . 0.428 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.9 m-85 -133.37 144.49 52.57 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 176.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 14.0 Cg_exo -69.72 -54.21 0.23 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.55 2.167 . . . . 0.0 111.074 175.032 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -165.65 67.87 0.2 Allowed Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.434 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -61.51 -29.38 71.59 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.934 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.554 ' HG3' ' HG3' ' A' ' 87' ' ' GLU . 41.2 ttmt 70.62 166.04 0.29 Allowed 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 123.022 0.529 . . . . 0.0 111.073 178.214 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.526 ' N ' ' HG2' ' A' ' 59' ' ' LYS . . . -126.81 96.28 0.45 Allowed Glycine 0 N--CA 1.443 -0.865 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 175.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 27.3 m -96.37 95.13 7.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.534 0.207 . . . . 0.0 111.242 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 4.3 m 58.58 45.51 16.09 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-O 121.381 0.61 . . . . 0.0 111.317 175.399 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' HD12 ' A' ' 89' ' ' ILE . 51.8 t -80.79 -36.4 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.345 -177.563 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 84.51 -27.02 4.86 Favored Glycine 0 CA--C 1.516 0.15 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.032 -177.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.464 ' HB3' ' HA3' ' A' ' 93' ' ' GLY . 27.6 m 70.14 1.73 3.66 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.358 0.663 . . . . 0.0 112.399 174.425 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 26.4 p90 -70.81 -29.91 66.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.277 0.56 . . . . 0.0 110.24 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.622 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 9.6 p -71.23 -29.79 37.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.401 -175.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.463 HD13 ' HA ' ' A' ' 65' ' ' SER . 6.4 mp -66.9 -41.68 86.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.78 -178.74 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.27 -36.0 80.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 177.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -58.94 -48.33 81.88 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.332 175.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.622 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 81.2 mt -58.4 -40.32 82.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 178.765 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.521 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -66.78 -42.78 85.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.082 -178.616 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -64.79 -27.97 69.25 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.682 0.277 . . . . 0.0 111.374 -179.234 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -90.47 -17.8 26.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.19 0.519 . . . . 0.0 110.082 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 83.58 26.8 41.21 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.349 178.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.87 11.6 7.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.152 0.501 . . . . 0.0 110.537 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.439 ' HB1' HD11 ' A' ' 99' ' ' ILE . . . -81.93 158.38 67.68 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.138 -179.303 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 24.3 Cg_exo -62.16 148.55 93.0 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.192 1.928 . . . . 0.0 110.99 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.506 ' HD3' ' O ' ' A' ' 14' ' ' GLU . 75.5 tttt -84.96 -21.63 29.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.511 . . . . 0.0 109.635 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.783 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -166.49 163.55 17.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.227 175.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.458 HG23 ' HB3' ' A' ' 101' ' ' LEU . 7.9 tt -146.84 114.71 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.288 0.566 . . . . 0.0 110.065 174.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.63 HD12 HG22 ' A' ' 102' ' ' VAL . 7.6 mm -108.55 124.31 64.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.442 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.3 m120 -120.93 160.89 22.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.297 -173.065 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 79.7 tttt -77.11 -37.45 54.21 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 171.783 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -154.71 154.71 33.32 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 114.711 -1.132 . . . . 0.0 108.57 168.703 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -143.52 172.63 12.53 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.78 -178.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.554 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 57.7 mm-40 -107.98 168.19 9.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.597 -177.377 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.0 m -58.85 -52.15 66.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -173.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.585 HD12 ' HB ' ' A' ' 63' ' ' VAL . 36.1 pt -63.5 -30.08 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 C-N-CA 120.638 -0.425 . . . . 0.0 112.067 -174.43 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.1 mm -64.93 -45.41 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -64.47 -48.02 76.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.051 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 86.9 t -61.81 -46.51 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.18 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.464 ' HA3' ' HB3' ' A' ' 65' ' ' SER . . . -63.13 -43.87 98.03 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.567 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.558 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -72.21 -35.93 69.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.437 0.161 . . . . 0.0 111.319 -178.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.07 -31.26 69.83 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.139 0.495 . . . . 0.0 110.73 178.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.8 mtm -82.68 -39.88 21.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.625 178.24 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.521 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -80.68 6.84 11.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.024 -178.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 47.9 mt-10 64.23 35.47 10.05 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.263 0.554 . . . . 0.0 110.971 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.53 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 54.2 mt -109.91 88.61 6.97 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.101 178.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 32.8 Cg_exo -58.53 118.04 4.86 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.67 2.247 . . . . 0.0 113.018 -176.248 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.58 HD21 ' HA ' ' A' ' 91' ' ' ALA . 1.7 pt? -117.34 141.64 48.07 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.251 175.14 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.63 HG22 HD12 ' A' ' 82' ' ' ILE . 31.3 m -138.04 161.56 32.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.928 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.494 ' HG3' HD11 ' A' ' 8' ' ' ILE . 53.2 mt-10 -97.92 116.8 30.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.686 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.592 HG12 HG22 ' A' ' 82' ' ' ILE . 7.2 p -115.23 107.38 22.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.764 0.792 . . . . 0.0 109.187 172.143 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 8.3 ttm-85 -99.04 14.65 28.46 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.048 -175.215 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -89.18 120.01 30.18 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.044 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -67.39 -34.71 77.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.391 -175.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 111' ' ' GLU . 32.8 mmtp -69.49 -23.0 63.57 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.32 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.442 ' HD1' ' CD2' ' A' ' 3' ' ' PHE . 87.6 t80 -62.19 -51.04 69.39 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 172.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.402 ' CZ ' HG13 ' A' ' 104' ' ' VAL . 87.0 m-85 -69.7 -25.96 64.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.842 -178.243 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.439 ' HB2' ' HA ' ' A' ' 108' ' ' LYS . 37.1 mm-40 -74.92 -29.59 61.01 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.009 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.79 -34.03 14.74 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -176.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.7 p -85.15 138.6 18.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.173 0.511 . . . . 0.0 111.375 -175.508 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -124.48 167.07 14.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.972 173.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.784 ' HB ' HG12 ' A' ' 19' ' ' VAL . 9.8 t -67.55 107.58 2.55 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.725 0.774 . . . . 0.0 110.657 -178.371 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.15 -24.39 4.23 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.554 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -63.72 151.12 42.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.868 0.334 . . . . 0.0 110.28 179.156 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.691 HH21 HG13 ' A' ' 131' ' ' ILE . 1.1 tmm_? -96.68 120.37 36.89 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -175.04 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.448 HG22 HD12 ' A' ' 130' ' ' LEU . 46.3 t -120.68 141.2 42.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.757 -175.047 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.486 HG23 ' HB2' ' A' ' 14' ' ' GLU . 9.9 p -124.38 121.1 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 121.763 0.792 . . . . 0.0 109.464 169.652 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 13' ' ' ALA . 40.2 t -106.54 127.35 62.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.472 -178.01 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.2 t-20 -93.44 97.48 10.58 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.38 -13.83 51.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.363 -175.047 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -68.92 -45.11 71.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.158 0.504 . . . . 0.0 109.744 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -93.85 -43.26 8.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.086 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.38 69.22 0.82 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -172.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.7 t80 -161.31 157.62 25.74 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 -172.128 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -152.99 138.64 11.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.021 -179.032 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HG2' ' A' ' 2' ' ' LYS . 2.2 pm0 -118.75 119.99 36.05 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.356 0.598 . . . . 0.0 110.458 174.142 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.448 HD12 HG22 ' A' ' 119' ' ' VAL . 54.7 tp -84.01 130.54 34.88 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.69 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.691 HG13 HH21 ' A' ' 118' ' ' ARG . 37.1 mm -101.27 120.25 50.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 CA-C-O 121.412 0.625 . . . . 0.0 109.6 177.236 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.198 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.195 -178.129 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -131.06 113.22 13.66 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.513 178.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -93.3 152.85 18.9 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.949 0.404 . . . . 0.0 111.181 -175.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.51 124.39 47.97 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.669 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 56.9 m -119.41 174.0 6.63 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.914 0.388 . . . . 0.0 110.82 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 40.7 ttt180 -92.83 111.7 23.4 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -90.84 137.83 32.06 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.569 -171.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.609 HD13 HD12 ' A' ' 101' ' ' LEU . 4.3 mp -103.87 -52.2 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 48.7 p -102.95 176.42 5.16 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.771 176.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 61.0 mtt180 -122.37 -175.35 3.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.661 0.267 . . . . 0.0 111.076 -176.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.15 171.83 27.35 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -175.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.4 HH21 ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -140.26 139.5 35.56 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 117.282 0.541 . . . . 0.0 110.52 -178.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.613 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -135.46 145.49 47.23 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.076 0.465 . . . . 0.0 111.65 -174.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.21 123.05 38.73 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.083 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.89 176.4 41.93 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 119.68 -1.248 . . . . 0.0 112.528 179.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.66 137.65 39.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 177.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.46 124.81 29.24 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.814 -176.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.404 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.8 tt -119.28 121.23 39.16 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' OG1' ' A' ' 115' ' ' THR . 8.9 p -111.4 120.12 61.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.078 0.466 . . . . 0.0 110.185 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.3 t -94.12 -6.74 44.29 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.077 0.465 . . . . 0.0 111.366 -175.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.0 tttt 68.54 -61.07 0.42 Allowed 'General case' 0 CA--C 1.539 0.54 0 CA-C-N 114.958 -1.019 . . . . 0.0 113.605 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -71.64 163.67 27.33 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -82.53 78.2 9.19 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.622 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.6 pt -106.11 135.74 43.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.961 0.41 . . . . 0.0 110.397 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.3 t -111.02 178.02 4.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.941 -178.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.41 ' HZ ' HD13 ' A' ' 81' ' ' ILE . 77.7 m-85 -87.53 29.6 0.87 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.257 0.551 . . . . 0.0 111.414 -174.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.39 -21.97 66.74 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 171.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.95 -127.61 1.44 Allowed Glycine 0 N--CA 1.444 -0.833 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.184 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.688 ' HA2' ' HB2' ' A' ' 39' ' ' GLU . . . 86.59 -43.78 3.27 Favored Glycine 0 C--O 1.221 -0.687 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.847 172.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.461 HG12 HG12 ' A' ' 37' ' ' VAL . 57.3 mt -109.05 136.94 43.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -66.07 130.03 41.85 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.88 -33.31 73.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -170.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -109.41 -35.12 6.34 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.48 -0.488 . . . . 0.0 111.887 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 m -81.47 -28.57 34.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.583 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.832 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.82 19.55 78.82 Favored Glycine 0 C--N 1.329 0.191 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.505 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.456 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.7 mm -95.87 131.06 43.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.461 HG12 HG12 ' A' ' 30' ' ' ILE . 13.9 m -71.39 107.97 2.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.814 0.816 . . . . 0.0 110.218 175.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mmmm -92.35 -10.44 38.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.047 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.688 ' HB2' ' HA2' ' A' ' 29' ' ' GLY . 9.8 tp10 -80.8 153.4 27.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.792 177.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -100.04 137.95 37.79 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.244 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 16.3 p -161.27 -56.23 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.327 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -173.29 -51.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.477 174.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -92.05 44.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.885 0.85 . . . . 0.0 110.156 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -78.76 129.88 35.14 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.409 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.52 11.3 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.797 179.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.424 ' O ' HG22 ' A' ' 37' ' ' VAL . 26.7 mt-10 -92.86 171.69 8.81 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.299 0.571 . . . . 0.0 111.973 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.456 ' HB3' HD13 ' A' ' 36' ' ' ILE . 15.6 p -105.37 151.12 24.58 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.447 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 30' ' ' ILE . 27.2 m -102.66 18.2 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.773 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.8 95.72 2.96 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.759 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.03 21.07 28.91 Favored Glycine 0 C--N 1.315 -0.619 0 CA-C-N 115.163 -0.926 . . . . 0.0 113.472 170.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -123.6 175.0 7.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 80' ' ' ALA . 50.2 mm -99.11 129.51 49.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 -174.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.594 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 3.6 mm? -110.0 130.69 55.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.098 0.475 . . . . 0.0 111.341 -176.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.457 HG21 HG21 ' A' ' 113' ' ' VAL . 52.8 t -117.9 125.7 74.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.662 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.594 ' CE1' ' HB3' ' A' ' 53' ' ' LEU . 27.3 m-85 -131.5 143.92 51.24 Favored Pre-proline 0 C--N 1.327 -0.385 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -73.15 -42.83 0.86 Allowed 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 121.855 1.704 . . . . 0.0 110.57 171.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.824 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.222 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 . . . . . 0 C--O 1.233 0.226 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.39 -32.22 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 111.648 0.24 . . . . 0.0 111.648 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.3 mt -61.0 -38.8 87.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.942 0.401 . . . . 0.0 110.932 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 59.4 tp -71.74 -41.18 68.79 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.561 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -62.62 -44.18 96.93 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.714 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 94.7 mt -62.75 -39.6 94.64 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.614 178.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.516 ' HG2' ' O ' ' A' ' 97' ' ' ALA . 11.3 tpt180 -67.65 -41.47 83.75 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.365 -175.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.33 -10.08 59.24 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 110.898 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -94.98 -16.58 22.65 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.075 0.464 . . . . 0.0 110.399 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.23 11.66 81.93 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.086 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.832 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.2 m -106.65 13.67 8.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.106 0.479 . . . . 0.0 111.011 -177.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.15 155.57 42.75 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.832 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.594 ' HB3' HD23 ' A' ' 53' ' ' LEU . 37.0 Cg_endo -66.42 147.18 82.32 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.487 2.125 . . . . 0.0 111.201 173.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.613 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.2 mttt -68.15 -42.16 80.52 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.867 0.365 . . . . 0.0 111.14 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.534 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -151.4 156.54 40.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.778 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.41 HD13 ' HZ ' ' A' ' 26' ' ' PHE . 74.5 mt -132.83 128.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.392 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.713 HG23 HG23 ' A' ' 102' ' ' VAL . 2.3 mm -112.37 128.39 69.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.344 -0.614 . . . . 0.0 109.344 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -126.31 159.55 32.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.879 -178.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.517 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 2.7 tmtp? -92.91 -35.69 13.2 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 173.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -142.58 101.99 3.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.813 174.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -95.41 -179.9 4.93 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -174.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.31 150.69 43.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.944 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 92' ' ' VAL . 13.1 m -62.52 -37.7 87.06 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.289 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.98 -29.53 47.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.9 mt -71.83 -42.52 69.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB1' HG21 ' A' ' 8' ' ' ILE . . . -59.43 -42.88 92.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.263 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 88' ' ' THR . 57.1 t -62.76 -47.86 90.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.828 179.287 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.2 -43.41 99.16 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.258 178.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.49 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.5 -31.08 71.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.358 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -70.09 -35.11 73.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.911 0.386 . . . . 0.0 111.252 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.1 mtm -81.61 -33.62 31.4 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 -178.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.516 ' O ' ' HG2' ' A' ' 72' ' ' ARG . . . -89.99 0.51 57.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.003 -177.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 55.15 61.63 2.84 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.829 0.823 . . . . 0.0 110.098 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.49 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.7 mt -123.11 90.05 50.55 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 114.784 -1.098 . . . . 0.0 109.801 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 4.2 Cg_exo -40.04 109.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.348 0.541 0 C-N-CA 123.669 2.912 . . . . 0.0 112.891 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.609 HD12 HD13 ' A' ' 8' ' ' ILE . 1.1 tm? -110.59 120.0 40.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.348 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.713 HG23 HG23 ' A' ' 82' ' ' ILE . 24.7 m -130.36 144.21 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.019 0.438 . . . . 0.0 110.634 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -110.16 122.84 48.58 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.03 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.456 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.3 p -98.8 134.45 37.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.185 0.517 . . . . 0.0 110.687 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 0.7 OUTLIER -92.79 -14.8 27.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.929 -174.328 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 104' ' ' VAL . 5.6 t70 -109.42 137.61 47.01 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.558 -0.457 . . . . 0.0 111.274 -175.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -72.78 -19.36 61.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.847 -176.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 19.0 mmtp -58.3 -26.6 63.21 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.461 ' O ' HG12 ' A' ' 113' ' ' VAL . 79.9 t80 -61.72 -42.81 99.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.755 0.312 . . . . 0.0 110.3 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.51 ' HA ' HG12 ' A' ' 113' ' ' VAL . 87.6 m-85 -75.16 -24.97 57.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.24 -175.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -74.33 -33.45 63.16 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.484 175.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.16 -41.05 17.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.723 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.4 p -78.27 124.37 36.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.777 0.799 . . . . 0.0 111.386 -175.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 114' ' ' LYS . 32.0 mmtp -132.06 153.25 50.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.706 175.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 60.8 m -62.35 114.87 3.74 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 123.195 0.31 . . . . 0.0 110.932 -178.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.6 -32.13 2.17 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 119.792 -1.194 . . . . 0.0 114.395 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.93 -172.11 2.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 117.736 0.768 . . . . 0.0 111.028 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -112.27 126.04 54.82 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.278 0.561 . . . . 0.0 111.905 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.449 HG23 ' HB2' ' A' ' 17' ' ' ALA . 65.8 t -121.52 120.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.892 176.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 60.7 t -89.29 111.83 23.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.759 177.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 41.9 t -95.54 109.02 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.565 -177.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -110.34 99.08 8.17 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.99 -9.35 53.77 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.022 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' HH21 ' A' ' 12' ' ' ARG . 18.5 m-20 -63.81 -47.01 82.58 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 174.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -93.2 -31.18 14.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.736 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 91.92 59.08 1.35 Allowed Glycine 0 N--CA 1.452 -0.295 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 143.49 29.75 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.793 0.33 . . . . 0.0 110.643 -169.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.53 106.31 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.319 0.581 . . . . 0.0 109.962 174.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 120' ' ' VAL . 39.8 mt-10 -96.3 108.46 20.97 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.665 -174.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.6 tp -81.3 110.05 16.39 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.6 mm -112.74 114.9 48.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -176.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 . . . . . 0 C--N 1.312 -1.041 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.157 -170.604 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.226 -0.162 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.507 ' HD3' ' OH ' ' A' ' 127' ' ' TYR . 74.2 mttt -125.54 145.67 50.01 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.529 -177.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.479 ' HB2' HG13 ' A' ' 128' ' ' VAL . 89.6 m-85 -129.48 161.92 29.3 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.398 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.15 126.65 55.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.106 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.43 ' SG ' HG21 ' A' ' 102' ' ' VAL . 5.7 p -119.71 167.74 11.75 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.209 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.567 ' HD3' ' OE2' ' A' ' 103' ' ' GLU . 36.6 ttt180 -93.96 121.95 35.96 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.981 0.42 . . . . 0.0 110.107 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.98 102.9 3.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.123 -175.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.556 HG13 HG21 ' A' ' 86' ' ' THR . 50.0 mm -95.91 -43.57 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.11 177.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.7 p -109.57 -165.0 0.97 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.134 177.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -136.43 164.49 28.03 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -177.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.05 161.62 22.77 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.932 -0.652 . . . . 0.0 111.906 -177.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -147.86 154.12 40.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.09 0.445 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.45 164.97 24.3 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.081 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -127.92 127.05 42.66 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 176.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.62 178.92 32.83 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.056 -1.069 . . . . 0.0 112.69 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -74.44 139.86 44.25 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.33 178.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.586 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.56 122.83 27.53 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.07 0.462 . . . . 0.0 111.002 -178.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.3 tt -117.61 117.14 28.59 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 174.438 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.822 HG12 ' HB ' ' A' ' 115' ' ' THR . 8.4 p -101.6 124.99 55.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.442 0.639 . . . . 0.0 110.984 -173.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 1.037 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 13.2 m -95.63 95.03 8.08 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.446 0.641 . . . . 0.0 109.875 179.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -82.25 -2.61 53.1 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.944 -177.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -103.1 130.41 50.25 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.67 -176.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -85.14 98.89 10.72 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -118.95 172.64 5.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.253 -0.43 . . . . 0.0 112.007 -170.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.4 p -79.5 122.41 26.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.175 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -85.48 31.26 0.59 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.568 0.699 . . . . 0.0 109.991 -177.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -68.89 -23.8 64.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.198 177.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 174.37 -103.84 0.19 Allowed Glycine 0 N--CA 1.444 -0.832 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.294 178.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.72 -51.42 2.31 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.548 176.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.436 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.7 mp -87.47 129.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.75 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 27.5 t70 -78.55 139.96 38.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.038 0.447 . . . . 0.0 111.005 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.492 ' HA ' HD23 ' A' ' 71' ' ' LEU . 0.0 OUTLIER -64.84 -26.33 68.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.548 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 45.4 mt-10 -95.41 -46.88 6.51 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 36' ' ' ILE . 20.7 p -102.88 -19.15 14.76 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -174.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 73.93 20.14 79.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.015 -178.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.412 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.2 mm -87.68 133.03 31.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.639 -0.28 . . . . 0.0 110.453 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.3 m -74.28 111.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.582 0.706 . . . . 0.0 110.892 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.75 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 57.2 mttt -91.67 -10.89 38.61 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.947 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -66.33 138.27 57.49 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.646 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.41 131.42 44.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.38 -172.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 13.6 p 174.55 -178.22 0.1 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.981 -1.008 . . . . 0.0 108.482 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -79.35 -9.27 59.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.274 0.559 . . . . 0.0 110.095 175.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.417 ' O ' ' HB2' ' A' ' 46' ' ' GLU . 24.3 mt -94.26 -8.83 9.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.183 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.1 tmmm? -56.85 125.83 24.23 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.358 0.599 . . . . 0.0 110.372 -178.074 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.25 -24.36 12.64 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.964 -176.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 43' ' ' ILE . 1.1 mm-40 -71.15 162.97 28.54 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.311 0.577 . . . . 0.0 111.656 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.412 ' HB3' HD13 ' A' ' 36' ' ' ILE . 18.2 p -116.89 127.13 53.96 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.61 -178.431 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.414 HG21 HG12 ' A' ' 30' ' ' ILE . 33.4 m -87.53 1.8 5.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.207 -178.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.436 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.25 88.04 0.3 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.923 -177.553 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.53 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 107.36 11.04 26.34 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.519 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 mmm-85 -106.14 156.08 18.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.44 116.58 47.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 176.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.713 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -92.94 124.85 37.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.289 0.566 . . . . 0.0 111.324 -173.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 72.6 t -117.91 107.91 23.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.173 176.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 1.037 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 43.6 p90 -135.7 153.66 77.56 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.461 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -64.07 -49.89 3.42 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 122.591 2.194 . . . . 0.0 111.997 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.558 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 -179.666 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 . . . . . 0 N--CA 1.474 0.762 0 N-CA-C 112.084 0.402 . . . . 0.0 112.084 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.3 m -60.92 -16.84 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -173.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.21 -28.18 69.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.803 0.335 . . . . 0.0 110.699 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.0 tp -62.34 -38.48 89.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.423 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -58.22 -47.67 82.77 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.649 178.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.492 HD23 ' HA ' ' A' ' 32' ' ' LYS . 76.4 mt -56.76 -44.43 81.77 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.706 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -72.8 -41.32 65.08 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.745 -176.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -61.85 -33.3 73.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.824 0.345 . . . . 0.0 110.374 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -85.53 -19.68 30.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.126 0.489 . . . . 0.0 110.512 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 86.89 23.44 41.79 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.216 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.523 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.4 m -113.32 12.47 8.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.603 -179.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.467 ' HB1' ' HD2' ' A' ' 78' ' ' PRO . . . -90.91 162.66 32.39 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.713 ' HB3' HD13 ' A' ' 53' ' ' LEU . 43.7 Cg_endo -69.66 149.9 68.1 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.037 1.825 . . . . 0.0 111.434 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.53 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 88.4 mttt -69.47 -30.46 68.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.938 0.399 . . . . 0.0 110.75 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -163.77 155.3 16.67 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.457 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 68.5 mt -131.09 127.28 60.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.998 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.453 HG23 HG23 ' A' ' 102' ' ' VAL . 5.5 mm -117.85 120.79 65.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 13.6 m120 -120.03 164.03 16.74 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.645 0.26 . . . . 0.0 110.74 -176.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -79.07 -46.11 18.76 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 174.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 85' ' ' LYS . 44.2 pttt -125.88 112.75 16.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.762 172.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.556 HG21 HG13 ' A' ' 8' ' ' ILE . 5.8 t -92.47 116.3 28.87 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.41 0.624 . . . . 0.0 109.476 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -98.52 167.91 10.52 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.544 -175.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.5 m -53.98 -47.64 71.17 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -169.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 90' ' ' ILE . 9.2 pt -55.56 -46.04 78.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 111.984 0.365 . . . . 0.0 111.984 -178.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 89' ' ' ILE . 36.4 mt -76.77 -40.56 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.325 -176.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.528 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.44 -50.64 73.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.564 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 92.3 t -64.87 -42.37 94.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.791 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.35 -45.56 96.19 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.785 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -73.93 -33.01 63.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.552 0.215 . . . . 0.0 111.567 -178.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.8 -40.16 95.96 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.963 0.411 . . . . 0.0 111.512 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 69.7 mtm -74.04 -42.87 59.62 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.244 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -74.3 -14.78 60.95 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -177.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 71.71 59.89 0.16 Allowed 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.662 0.744 . . . . 0.0 109.934 -173.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.1 mt -121.96 89.32 48.23 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.481 177.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -38.29 107.56 0.06 OUTLIER 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 123.792 2.994 . . . . 0.0 113.441 -177.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 43.6 tp -128.16 120.72 27.87 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.421 -176.259 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.453 HG23 HG23 ' A' ' 82' ' ' ILE . 20.6 m -135.0 166.76 27.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.195 179.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.567 ' OE2' ' HD3' ' A' ' 6' ' ' ARG . 9.9 pt-20 -113.59 141.16 47.52 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.066 0.46 . . . . 0.0 111.167 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 5.2 m -105.84 140.75 22.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.454 176.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -88.67 -26.27 21.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.221 -174.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -106.16 140.08 39.68 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.052 0.453 . . . . 0.0 111.372 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -71.14 -20.94 62.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.944 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.553 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 57.2 mttm -64.91 -17.97 64.8 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -60.64 -45.85 92.52 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 173.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.56 ' HA ' HG12 ' A' ' 113' ' ' VAL . 53.2 m-85 -76.12 -32.11 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.006 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.553 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.7 tt0 -57.3 -46.22 83.38 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.996 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -87.75 -24.62 23.74 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.481 -174.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.9 p -76.04 139.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.535 0.684 . . . . 0.0 111.96 -174.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -139.13 159.28 42.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.992 172.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.822 ' HB ' HG12 ' A' ' 19' ' ' VAL . 12.1 t -81.69 138.62 35.24 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.961 0.41 . . . . 0.0 110.434 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.53 -25.3 9.2 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.775 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -85.28 -171.78 3.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.608 0.242 . . . . 0.0 110.797 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 20.0 ttp180 -115.36 133.73 55.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.011 0.434 . . . . 0.0 111.447 -176.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.586 HG23 ' HB2' ' A' ' 17' ' ' ALA . 85.6 t -122.58 129.5 75.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.126 175.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.681 ' HB ' ' HB3' ' A' ' 129' ' ' GLU . 50.3 t -101.86 113.56 38.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.79 129.67 61.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.946 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -131.4 100.52 5.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.807 176.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.82 -12.22 55.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.472 -174.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.18 -7.64 58.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.025 0.44 . . . . 0.0 110.804 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -128.3 -20.99 3.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.868 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.29 59.94 2.79 Favored Glycine 0 CA--C 1.509 -0.336 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.507 ' OH ' ' HD3' ' A' ' 2' ' ' LYS . 60.8 t80 -142.71 135.64 28.19 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.316 -167.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.479 HG13 ' HB2' ' A' ' 3' ' ' PHE . 6.6 p -137.76 124.81 28.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.461 0.648 . . . . 0.0 110.579 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.681 ' HB3' ' HB ' ' A' ' 120' ' ' VAL . 34.5 tt0 -115.96 122.45 45.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.413 -175.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 19.6 tp -106.63 127.53 53.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.945 0.402 . . . . 0.0 110.688 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 131' ' ' ILE . 3.5 mp -122.45 122.07 65.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 174.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.465 ' H ' ' CD ' ' A' ' 132' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.315 -0.91 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.618 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 C--O 1.234 0.25 0 CA-C-O 120.677 0.275 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.513 ' HG2' ' HG2' ' A' ' 129' ' ' GLU . 49.2 mttp -101.7 107.48 18.72 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 177.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -86.76 141.42 28.88 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.27 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.31 127.97 36.31 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.514 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.2 m -120.82 159.02 26.33 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.032 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.444 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 27.1 ttm180 -102.79 115.94 31.58 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 176.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.709 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.0 133.84 44.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.0 -173.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.0 mm -106.94 -49.36 8.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 174.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.425 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 61.7 p -117.42 177.24 4.81 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.786 173.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 10' ' ' ARG . 61.5 mtt180 -101.1 169.49 8.9 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.801 0.334 . . . . 0.0 111.003 -177.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 134.68 153.54 6.89 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.124 178.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -137.84 130.17 29.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.577 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -146.27 164.22 33.02 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.937 0.398 . . . . 0.0 111.391 -175.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.03 149.12 27.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.833 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 160.36 -167.53 35.65 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.142 -1.028 . . . . 0.0 112.148 175.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 50.9 mm-40 -64.57 128.08 34.26 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.535 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.05 122.13 26.94 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.852 -178.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.3 tp -106.22 108.4 19.89 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 175.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.517 ' HB ' ' HB ' ' A' ' 115' ' ' THR . 43.3 t -110.59 113.52 44.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.967 0.413 . . . . 0.0 110.991 -172.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 22' ' ' GLU . 30.2 m -105.0 110.17 22.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.922 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -86.26 26.8 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.263 0.554 . . . . 0.0 110.837 -177.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' THR . 8.0 tp10 -115.44 157.51 23.86 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.76 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -103.4 94.61 5.58 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 pt -85.32 172.1 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.3 0.571 . . . . 0.0 111.445 -175.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.729 ' HB2' HD23 ' A' ' 27' ' ' LEU . 26.0 p -110.26 122.54 47.9 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.957 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -81.21 64.4 5.93 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.319 0.58 . . . . 0.0 110.476 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.729 HD23 ' HB2' ' A' ' 25' ' ' SER . 3.5 mm? -119.74 -57.03 2.0 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.936 174.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.54 44.52 0.69 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.81 -53.15 6.55 Favored Glycine 0 C--O 1.224 -0.47 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.943 -176.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 65.7 mt -98.61 135.51 33.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.833 0.316 . . . . 0.0 110.815 -177.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.418 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 13.1 t70 -67.06 134.78 52.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.268 177.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -68.52 -25.61 65.03 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.221 0.452 . . . . 0.0 112.221 -171.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -110.77 -38.11 5.23 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.231 0.538 . . . . 0.0 111.288 -168.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.551 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -98.94 -14.97 19.31 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.585 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 47' ' ' SER . . . 68.29 21.89 74.3 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.085 -178.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.551 HG12 ' HB ' ' A' ' 34' ' ' THR . 36.4 mm -88.44 127.07 41.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 122.18 0.192 . . . . 0.0 110.625 -177.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 47.1 t -71.62 113.92 9.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -88.62 -28.61 20.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.054 -176.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -65.58 123.01 18.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.588 ' HA ' ' HG3' ' A' ' 44' ' ' LYS . 35.2 t70 -73.26 141.11 47.23 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.968 -173.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 42.0 t -172.81 -73.65 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.071 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -156.58 -51.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.331 179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.407 HG13 ' H ' ' A' ' 43' ' ' ILE . 1.9 pp -82.41 15.31 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.078 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.588 ' HG3' ' HA ' ' A' ' 40' ' ' ASP . 4.5 tmmm? -65.16 124.99 23.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.698 179.233 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 104.4 -15.29 50.3 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.368 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -91.27 159.24 16.13 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.307 0.575 . . . . 0.0 112.07 177.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.505 ' HB3' HD13 ' A' ' 36' ' ' ILE . 2.5 p -103.74 158.54 16.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.246 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.509 HG11 HD21 ' A' ' 53' ' ' LEU . 26.7 m -108.63 20.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.919 -179.511 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.03 91.93 2.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.647 -173.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.96 20.64 27.75 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.001 -0.999 . . . . 0.0 112.91 174.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -110.33 158.97 17.86 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.863 -0.198 . . . . 0.0 110.64 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.46 ' HB ' ' HA ' ' A' ' 17' ' ' ALA . 49.6 mm -95.59 104.58 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.815 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.623 HD13 ' HB3' ' A' ' 78' ' ' PRO . 9.9 mp -85.58 133.34 34.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.17 0.509 . . . . 0.0 111.688 -172.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.61 121.15 59.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.743 176.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.554 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 78.3 m-85 -128.88 144.42 52.41 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.825 0.345 . . . . 0.0 111.332 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -81.17 -11.32 12.17 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.546 2.164 . . . . 0.0 111.883 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.909 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.054 179.857 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 2.0 t80 . . . . . 0 N--CA 1.47 0.565 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 58.9 t -58.85 -33.74 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.929 0.395 . . . . 0.0 111.323 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.433 ' HB3' HD12 ' A' ' 99' ' ' ILE . 87.1 mt -57.73 -31.37 66.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.573 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.6 tp -67.3 -33.99 76.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.105 0.478 . . . . 0.0 110.514 -178.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -66.01 -41.84 90.48 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.972 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.7 mt -57.42 -42.59 82.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.587 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.403 ' N ' ' HB2' ' A' ' 77' ' ' ALA . 34.4 ttt180 -59.78 -51.04 71.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.915 -178.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 55.8 mtmt -75.39 -8.07 55.7 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.985 -174.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.481 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.0 t-20 -92.42 -30.91 15.51 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.988 0.423 . . . . 0.0 109.909 175.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.09 15.41 28.34 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.091 -178.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.481 HG22 ' HB3' ' A' ' 74' ' ' ASN . 20.1 m -117.64 14.17 7.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.888 0.375 . . . . 0.0 111.185 -178.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.403 ' HB2' ' N ' ' A' ' 72' ' ' ARG . . . -73.99 150.11 87.9 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.245 179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.623 ' HB3' HD13 ' A' ' 53' ' ' LEU . 7.9 Cg_exo -71.89 138.47 31.45 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.558 2.172 . . . . 0.0 110.383 171.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.577 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 85.5 mttt -63.44 -42.26 98.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.756 0.313 . . . . 0.0 111.346 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -157.92 153.57 26.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.803 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.575 HG12 ' HB2' ' A' ' 53' ' ' LEU . 52.8 mt -134.07 114.44 19.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.423 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.414 HG23 ' CG2' ' A' ' 102' ' ' VAL . 21.3 mm -100.65 124.22 54.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.554 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 34.9 m-80 -123.35 155.75 36.71 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.018 0.437 . . . . 0.0 111.228 -174.395 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.524 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 88.3 tttt -76.95 -46.98 22.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.502 174.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -116.89 120.71 39.31 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.815 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.4 t -99.51 134.77 41.91 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.721 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.51 141.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.464 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.5 m -66.99 -36.18 81.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.503 -175.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 87.0 mt -61.29 -43.88 97.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.976 0.417 . . . . 0.0 110.353 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.5 mt -64.4 -40.58 89.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.006 177.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.479 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -59.46 -46.57 88.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.527 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 88' ' ' THR . 90.1 t -58.52 -43.65 87.45 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 CA-C-O 120.975 0.417 . . . . 0.0 110.555 179.152 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.27 -41.05 69.73 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.5 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -71.05 -31.28 67.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.463 0.173 . . . . 0.0 111.412 -177.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.56 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.987 0.422 . . . . 0.0 110.971 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.7 mtm -70.29 -32.99 71.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.003 -179.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.43 3.47 49.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.797 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 56.15 43.1 27.35 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.927 0.87 . . . . 0.0 110.362 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 68' ' ' LEU . 63.8 mt -109.77 89.26 7.53 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.671 177.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.425 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 19.1 Cg_endo -56.99 116.0 2.9 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.893 2.395 . . . . 0.0 112.616 -176.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.48 ' H ' HD23 ' A' ' 101' ' ' LEU . 2.6 pt? -118.44 137.07 53.41 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.508 175.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 7' ' ' ALA . 18.9 m -132.48 163.1 38.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.861 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.444 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 14.7 pt-20 -103.81 135.34 45.53 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.848 0.356 . . . . 0.0 110.094 176.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 15.8 m -116.26 130.92 70.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.102 0.477 . . . . 0.0 110.382 175.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -101.92 1.3 36.68 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.127 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -95.94 123.64 39.62 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.984 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.93 -32.79 67.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.371 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 28.6 mtpp -69.89 -23.7 63.28 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -174.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -54.44 -49.43 70.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 174.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.524 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 96.6 m-85 -74.58 -28.25 60.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.981 0.419 . . . . 0.0 110.996 -179.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 43.2 tt0 -66.44 -45.25 80.45 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.599 176.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.21 -39.45 19.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.454 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.4 p -65.45 127.83 27.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-O 121.475 0.655 . . . . 0.0 110.963 -175.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -123.15 135.88 54.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.755 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.517 ' HB ' ' HB ' ' A' ' 19' ' ' VAL . 14.8 t -72.24 113.85 9.71 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-O 121.41 0.624 . . . . 0.0 109.551 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.5 -18.94 3.41 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.392 -176.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . 0.553 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 0.8 OUTLIER -99.02 -171.71 2.14 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.676 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.553 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -114.54 137.34 51.98 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.337 0.589 . . . . 0.0 112.025 -174.92 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 17' ' ' ALA . 84.3 t -120.38 130.33 74.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.743 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.5 t -98.88 111.44 28.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 174.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 88.3 t -96.0 120.71 45.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.134 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -124.71 99.85 6.36 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -86.18 -11.67 51.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.126 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -67.71 -43.01 81.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.015 0.436 . . . . 0.0 110.009 178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -96.38 -23.92 16.39 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.542 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.16 62.93 1.46 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.521 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.528 ' CE1' ' HG3' ' A' ' 129' ' ' GLU . 25.6 p90 -162.41 163.55 27.67 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.772 0.32 . . . . 0.0 110.168 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.26 126.36 58.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.248 175.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.528 ' HG3' ' CE1' ' A' ' 127' ' ' TYR . 39.5 mt-10 -98.56 107.92 20.49 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.095 176.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 60.7 tp -82.45 102.0 11.03 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.358 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 18.1 pt -92.37 109.94 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.455 0.645 . . . . 0.0 110.291 -175.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 . . . . . 0 C--N 1.316 -0.854 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.085 -177.165 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.508 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 13.9 m . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 121.261 0.553 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -130.74 114.93 15.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.739 -176.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.508 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 76.6 m-85 -128.5 164.75 22.1 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.118 0.485 . . . . 0.0 111.036 -176.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -118.49 139.43 51.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.447 174.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 10.3 p -120.21 171.67 8.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.258 -178.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.7 ttt85 -93.88 118.06 30.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.971 0.415 . . . . 0.0 110.116 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.53 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.82 96.52 1.66 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.042 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.468 HD11 ' OE1' ' A' ' 103' ' ' GLU . 49.3 mm -82.2 -43.51 19.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.87 175.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.8 p -125.29 -164.25 1.27 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.293 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 60.7 mtt-85 -118.56 -175.28 2.85 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.705 0.288 . . . . 0.0 110.59 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.564 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 115.71 145.21 8.43 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.04 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 68.8 mtm-85 -141.38 115.2 9.11 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.24 169.38 24.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.871 0.367 . . . . 0.0 111.193 -176.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.553 ' OE1' ' HD2' ' A' ' 118' ' ' ARG . 14.2 pt-20 -135.42 146.77 48.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.87 178.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.98 -173.48 34.48 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 120.079 -1.058 . . . . 0.0 112.098 174.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.62 127.97 34.4 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.45 118.98 22.54 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.905 -177.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.8 tp -102.02 111.42 23.68 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.563 ' HA ' ' CG1' ' A' ' 54' ' ' VAL . 47.1 t -98.87 110.92 27.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.385 0.612 . . . . 0.0 110.522 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.468 HG21 HD11 ' A' ' 24' ' ' ILE . 6.8 m -110.55 132.16 54.43 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.092 -176.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -102.77 -10.02 19.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.13 0.491 . . . . 0.0 110.573 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -97.88 161.47 13.73 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -96.0 141.73 29.06 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.553 0.216 . . . . 0.0 110.468 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 20' ' ' THR . 2.5 mp -114.16 132.89 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 55.2 p -78.73 115.23 18.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.148 0.499 . . . . 0.0 110.722 -178.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.95 -6.3 32.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.333 179.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.05 -30.53 71.5 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 175.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 146.55 51.81 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.48 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.16 21.17 32.64 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.161 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.511 HD13 HG21 ' A' ' 48' ' ' VAL . 53.6 mt -130.75 136.74 57.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 -179.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.592 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.1 t70 -69.46 123.79 22.18 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.608 ' HG2' ' OE1' ' A' ' 33' ' ' GLU . 0.6 OUTLIER -79.28 -12.21 59.94 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -170.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.608 ' OE1' ' HG2' ' A' ' 32' ' ' LYS . 2.4 mp0 -94.33 -41.09 9.61 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 121.137 -0.225 . . . . 0.0 111.254 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.9 p -103.06 -36.97 7.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 -177.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.79 16.45 36.2 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.816 -175.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.0 mm -91.45 128.44 43.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 44' ' ' LYS . 8.4 m -62.96 142.02 17.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.021 0.439 . . . . 0.0 110.912 177.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.592 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 26.9 mmmt -96.12 -3.67 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.487 0.661 . . . . 0.0 110.823 -174.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -92.39 158.86 15.84 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.642 -175.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -92.29 139.28 30.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.371 0.605 . . . . 0.0 112.127 -176.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 48.8 t -179.22 168.7 1.52 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 172.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -68.32 -35.97 78.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.049 0.452 . . . . 0.0 110.428 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 32.3 pt -102.62 12.36 7.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.493 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.52 ' HB2' ' HB3' ' A' ' 41' ' ' CYS . 70.2 mttt -99.44 147.5 25.2 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 176.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.408 ' H ' ' CG2' ' A' ' 37' ' ' VAL . . . 118.48 1.55 15.59 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -175.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -108.82 -179.36 3.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.802 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.6 m -91.83 133.9 35.23 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.933 -171.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.511 HG21 HD13 ' A' ' 30' ' ' ILE . 34.5 m -101.6 4.38 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.3 0.572 . . . . 0.0 110.005 174.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -67.27 100.13 0.78 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.186 -174.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.17 19.99 50.97 Favored Glycine 0 C--N 1.308 -1.001 0 CA-C-N 114.536 -1.211 . . . . 0.0 112.872 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -110.72 155.53 22.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.87 HG13 ' HB3' ' A' ' 80' ' ' ALA . 1.8 mp -84.66 105.48 13.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 175.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 32.1 tp -82.28 126.89 32.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.447 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.563 ' CG1' ' HA ' ' A' ' 19' ' ' VAL . 11.8 p -130.26 106.96 13.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.62 0.724 . . . . 0.0 111.842 177.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.441 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 38.1 p90 -136.16 151.68 73.95 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.175 170.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.91 -55.43 2.33 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.547 2.164 . . . . 0.0 112.808 -177.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.53 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.874 -178.436 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 28.1 p90 . . . . . 0 CA--C 1.53 0.199 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 62.9 t -60.63 -41.79 89.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.983 0.421 . . . . 0.0 110.648 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.428 HD13 ' O ' ' A' ' 68' ' ' LEU . 0.7 OUTLIER -73.38 -32.17 64.33 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.231 0.539 . . . . 0.0 109.871 179.282 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.6 tp -61.33 -32.49 72.38 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.2 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -54.94 -44.23 74.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.213 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 88.0 mt -61.84 -33.15 73.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.005 -178.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.558 ' HD3' ' HA ' ' A' ' 97' ' ' ALA . 8.0 ttp180 -72.16 -35.94 69.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.126 -178.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -61.37 -31.19 71.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.014 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -93.54 -25.17 17.69 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.938 0.399 . . . . 0.0 110.442 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 94.16 26.94 12.94 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.704 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.8 m -107.15 4.56 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.171 0.51 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.96 159.38 73.57 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.733 179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.49 162.38 24.45 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.491 2.127 . . . . 0.0 112.13 175.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -82.83 -28.8 29.94 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.87 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -166.77 165.22 16.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.673 175.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.694 HG23 HD22 ' A' ' 101' ' ' LEU . 8.3 tt -152.07 121.29 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.45 0.643 . . . . 0.0 110.824 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.821 HG23 HG23 ' A' ' 102' ' ' VAL . 2.7 mm -110.21 118.88 58.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -116.39 165.96 12.61 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.364 0.602 . . . . 0.0 111.758 -174.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.22 -31.49 10.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.302 176.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.9 tttm -121.28 122.41 39.83 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.577 176.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 66.5 p -127.68 158.75 36.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.967 0.413 . . . . 0.0 111.681 -175.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.552 ' HB2' HG13 ' A' ' 90' ' ' ILE . 53.8 mt-10 -123.58 157.66 33.2 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.776 173.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.524 ' O ' HG23 ' A' ' 92' ' ' VAL . 89.2 m -60.09 -44.28 94.92 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.107 178.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.9 pt -63.9 -29.89 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.453 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.552 HG13 ' HB2' ' A' ' 87' ' ' GLU . 64.4 mt -66.98 -42.75 89.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.99 -32.96 74.75 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.198 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 88' ' ' THR . 73.1 t -66.69 -49.87 70.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 120.929 0.395 . . . . 0.0 110.543 177.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.35 -44.11 97.35 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.13 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.409 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -64.09 -37.33 87.04 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 111.585 0.216 . . . . 0.0 111.585 -179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.3 -41.76 96.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.807 0.337 . . . . 0.0 111.12 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 66.5 mtm -74.64 -32.09 62.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.897 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.558 ' HA ' ' HD3' ' A' ' 72' ' ' ARG . . . -82.04 -0.61 45.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 176.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 57.32 38.39 28.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.278 0.561 . . . . 0.0 111.233 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.409 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 61.4 mt -111.08 90.93 12.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.198 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.564 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 82.5 Cg_exo -40.57 115.6 0.34 Allowed 'Trans proline' 0 C--N 1.35 0.651 0 C-N-CA 124.027 3.151 . . . . 0.0 113.872 -175.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.694 HD22 HG23 ' A' ' 81' ' ' ILE . 0.1 OUTLIER -108.94 120.67 43.22 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.584 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.821 HG23 HG23 ' A' ' 82' ' ' ILE . 5.5 m -140.5 161.84 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.784 177.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.468 ' OE1' HD11 ' A' ' 8' ' ' ILE . 46.1 mt-10 -101.21 132.99 46.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.529 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.425 HG13 ' CG2' ' A' ' 82' ' ' ILE . 3.4 m -96.48 139.65 18.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 167.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -99.97 -46.76 5.25 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.347 -174.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.419 ' OD1' ' HG3' ' A' ' 108' ' ' LYS . 7.1 t70 -92.8 146.51 23.59 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.218 0.532 . . . . 0.0 111.338 -174.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -71.1 -18.76 62.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.103 -0.953 . . . . 0.0 111.177 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HG3' ' OD1' ' A' ' 106' ' ' ASP . 67.7 mttm -55.08 -33.08 62.47 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -61.31 -40.6 94.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.421 -178.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.01 -31.14 68.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.295 -176.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -77.98 -45.58 23.44 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.902 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.482 ' HB1' HG11 ' A' ' 1' ' ' VAL . . . -66.51 -37.56 85.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.179 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 12.0 p -75.15 129.28 36.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.405 0.621 . . . . 0.0 111.076 -177.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.425 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 71.1 mmtt -118.91 144.12 46.6 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.431 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.9 m -64.76 110.9 2.55 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.96 0.41 . . . . 0.0 110.631 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.89 -7.57 8.78 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.425 -178.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . 0.425 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 12.2 m-20 -87.39 171.84 10.28 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 174.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.553 ' HD2' ' OE1' ' A' ' 14' ' ' GLU . 11.7 ttp180 -115.67 121.94 44.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.824 0.345 . . . . 0.0 110.862 -178.382 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.95 130.07 66.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.187 0.518 . . . . 0.0 110.409 178.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 45.6 t -99.19 111.21 28.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.1 p -102.25 115.23 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.642 0.734 . . . . 0.0 111.754 -174.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . 0.482 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 50.1 t-20 -99.94 94.15 6.14 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 172.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.423 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -82.4 -19.67 38.64 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.108 0.48 . . . . 0.0 110.266 -178.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.78 -39.07 93.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.643 -179.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -107.46 -28.02 10.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.814 177.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.95 64.45 0.99 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.487 -0.863 . . . . 0.0 111.291 -176.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.482 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 35.6 t80 -144.55 124.39 13.44 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -174.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.425 HG23 ' HB2' ' A' ' 3' ' ' PHE . 5.9 m -126.26 118.09 50.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.481 0.657 . . . . 0.0 110.997 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -121.04 123.38 42.23 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.193 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.496 ' HB3' HG23 ' A' ' 1' ' ' VAL . 17.0 tp -103.81 120.59 41.3 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.152 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.44 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -89.43 123.27 41.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--N 1.317 -0.814 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.309 -178.938 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 2' ' ' LYS . 60.6 t . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 1' ' ' VAL . 49.2 mttp 64.34 77.84 0.3 Allowed 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -170.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -98.97 136.79 38.44 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.053 0.454 . . . . 0.0 110.775 -176.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -107.27 110.64 22.72 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.708 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.887 ' SG ' HG12 ' A' ' 104' ' ' VAL . 58.2 m -119.71 -178.73 3.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.489 -174.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.501 ' HB3' ' HG3' ' A' ' 103' ' ' GLU . 17.5 tpt180 -91.3 119.86 31.7 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.996 0.427 . . . . 0.0 110.639 -171.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -93.54 140.05 30.05 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.021 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.402 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.8 mp -114.0 -45.51 4.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.751 177.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 10' ' ' ARG . 3.0 m -109.6 177.55 4.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.401 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' THR . 81.6 mtt180 -112.05 -177.97 3.3 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.539 0.209 . . . . 0.0 110.794 -175.118 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 106.56 172.59 22.97 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.026 -178.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 7.3 ptm180 -149.71 119.73 7.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.044 0.45 . . . . 0.0 110.401 178.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.474 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -125.44 139.25 53.8 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.534 -174.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.26 125.23 44.04 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.925 -177.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.97 -160.91 23.1 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.996 175.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.717 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.9 mt-10 -74.67 130.94 40.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 122.822 0.449 . . . . 0.0 111.036 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.36 128.91 34.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.659 177.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.2 tt -118.97 114.74 23.03 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 177.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.21 126.39 60.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.978 0.418 . . . . 0.0 111.039 -173.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.5 m -129.56 95.35 3.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 177.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -84.49 83.79 7.88 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.123 0.487 . . . . 0.0 110.117 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -160.73 161.05 32.09 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.419 -0.81 . . . . 0.0 108.856 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 87.6 m-85 -101.26 89.14 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.596 ' HB ' ' HG2' ' A' ' 39' ' ' GLU . 32.7 pt -108.66 170.88 2.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.543 -172.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.27 123.01 39.75 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.488 -177.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -78.73 -4.91 51.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.334 0.588 . . . . 0.0 109.96 -178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.1 pp -72.93 -16.21 61.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.147 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.52 44.46 0.72 Allowed Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.29 -84.34 0.37 Allowed Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.265 -179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.461 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.1 mp -92.42 137.8 21.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 178.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -62.01 138.73 58.41 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.694 0.283 . . . . 0.0 110.351 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.541 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.8 pttp -74.5 -8.58 56.79 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -171.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.679 ' HA ' ' ND2' ' A' ' 74' ' ' ASN . 33.4 mt-10 -127.03 -44.47 1.61 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.3 p -96.92 -16.97 20.42 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -177.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.66 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.11 16.74 79.33 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.941 177.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.544 HD13 ' HB3' ' A' ' 47' ' ' SER . 35.5 mm -90.46 133.5 32.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.94 123.14 15.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.89 0.376 . . . . 0.0 110.63 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -87.24 -47.18 9.05 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.759 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.596 ' HG2' ' HB ' ' A' ' 24' ' ' ILE . 4.8 tp10 -62.06 134.76 57.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.671 179.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -93.03 160.85 14.68 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.269 0.557 . . . . 0.0 111.235 -175.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 47.9 t -178.68 -49.63 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -176.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 176.2 -45.98 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 114.642 -1.163 . . . . 0.0 109.718 174.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.78 13.25 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.936 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.2 tmmt? -65.91 128.68 36.99 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 116.74 -21.78 11.15 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.959 -176.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -87.98 156.48 19.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.982 0.42 . . . . 0.0 110.457 177.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.544 ' HB3' HD13 ' A' ' 36' ' ' ILE . 13.3 p -103.02 144.8 30.81 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.944 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.444 HG23 ' H ' ' A' ' 49' ' ' ALA . 0.0 OUTLIER -74.47 -76.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.608 175.046 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.444 ' H ' HG23 ' A' ' 48' ' ' VAL . . . 46.3 81.42 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.925 0.713 . . . . 0.0 112.925 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.09 3.78 88.79 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.64 -0.79 . . . . 0.0 113.303 177.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.717 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 52.0 mtt180 -94.6 162.28 13.86 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.411 -0.464 . . . . 0.0 110.902 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.453 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.6 mp -104.99 120.18 55.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 81' ' ' ILE . 54.8 tp -99.06 132.85 44.08 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.483 -177.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.44 107.3 15.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.038 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 41.0 p90 -135.76 144.58 49.43 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 172.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -55.13 -55.19 3.37 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.824 2.349 . . . . 0.0 112.883 -177.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.414 ' O ' ' HA ' ' A' ' 23' ' ' TYR . . . . . . . . 0 N--CA 1.449 -0.484 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.738 -178.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.463 0.187 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 86.3 t -58.37 -32.88 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.524 ' HA ' HD12 ' A' ' 71' ' ' LEU . 10.3 mp -61.85 -28.22 69.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.512 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 61.6 tp -70.64 -39.8 73.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.905 0.383 . . . . 0.0 110.331 178.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -65.9 -32.35 73.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.911 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.524 HD12 ' HA ' ' A' ' 68' ' ' LEU . 97.3 mt -57.63 -39.55 77.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.488 175.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 49.2 ttp180 -71.52 -33.36 69.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.572 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -62.41 -33.8 75.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.245 0.545 . . . . 0.0 110.295 177.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.679 ' ND2' ' HA ' ' A' ' 33' ' ' GLU . 92.0 m-20 -88.02 -14.33 39.31 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.906 178.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 79.19 13.56 82.75 Favored Glycine 0 N--CA 1.453 -0.205 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.541 178.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.66 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.5 m -106.79 8.68 9.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.127 0.489 . . . . 0.0 110.966 -176.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -70.7 150.45 95.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.483 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.49 147.68 52.56 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.458 2.105 . . . . 0.0 110.562 171.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.474 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 12.0 mttm -71.81 -35.53 69.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.922 0.391 . . . . 0.0 110.533 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.453 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -155.83 151.99 27.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.368 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.545 HG23 ' HB3' ' A' ' 101' ' ' LEU . 3.8 tp -129.52 120.84 51.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.905 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.711 HD12 HG22 ' A' ' 102' ' ' VAL . 4.7 mm -117.32 116.73 52.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.443 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 25.9 m120 -109.1 -179.67 3.91 Favored 'General case' 0 C--O 1.22 -0.471 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 103' ' ' GLU . 39.0 ttmt -82.55 -45.04 15.14 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -141.37 100.45 3.79 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 169.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -74.22 150.39 40.34 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -92.3 147.4 22.95 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.254 -175.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.8 m -52.79 -36.93 59.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.419 -177.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 49.5 mt -56.35 -47.54 81.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.006 178.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.9 mt -68.3 -38.78 79.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.378 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.92 -42.87 94.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.177 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 88' ' ' THR . 93.7 t -66.19 -42.95 92.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.77 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.9 -45.45 73.79 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.769 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.489 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -68.57 -30.06 68.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.677 0.275 . . . . 0.0 111.519 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -62.76 -25.38 68.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.408 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.0 mtm -83.17 -26.42 30.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.349 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.578 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -96.5 1.02 51.09 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.939 -178.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.521 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 1.5 mp0 59.0 47.85 11.6 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.124 0.488 . . . . 0.0 110.855 -175.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.489 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 58.1 mt -107.74 89.39 5.2 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.882 176.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 36.6 Cg_exo -55.87 116.69 3.34 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.904 2.403 . . . . 0.0 112.195 -177.175 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.545 ' HB3' HG23 ' A' ' 81' ' ' ILE . 1.8 pt? -122.71 134.7 54.45 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.44 0.638 . . . . 0.0 110.792 178.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.711 HG22 HD12 ' A' ' 82' ' ' ILE . 14.4 m -130.31 170.16 19.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.562 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 7.9 pt-20 -119.41 132.48 55.83 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.315 0.578 . . . . 0.0 111.676 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.887 HG12 ' SG ' ' A' ' 5' ' ' CYS . 17.3 m -104.47 105.04 17.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.925 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.436 ' HA ' ' HG3' ' A' ' 84' ' ' LYS . 32.6 ttp180 -99.13 27.62 4.97 Favored 'General case' 0 C--N 1.32 -0.717 0 O-C-N 121.837 -0.539 . . . . 0.0 110.614 -177.442 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -123.87 131.88 53.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.125 178.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -71.33 -26.59 62.9 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.212 -176.144 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -65.22 -24.21 67.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.167 -177.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.592 ' O ' HG12 ' A' ' 113' ' ' VAL . 80.6 t80 -65.01 -48.6 73.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -66.69 -25.42 66.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.687 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -78.85 -25.98 44.05 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 115.487 -0.778 . . . . 0.0 111.627 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -94.32 -39.69 10.36 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.032 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.4 p -89.8 137.97 20.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 111.17 -176.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -137.28 157.62 46.24 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.39 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 18' ' ' LEU . 32.6 m -64.24 110.09 2.1 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.492 -175.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.08 -17.37 3.85 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.546 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 -82.66 156.86 23.61 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.966 0.413 . . . . 0.0 111.13 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.0 OUTLIER -89.93 119.38 30.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.079 179.835 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.38 136.87 56.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.244 0.545 . . . . 0.0 111.078 -178.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.0 110.51 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.499 173.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.446 HG11 HD11 ' A' ' 82' ' ' ILE . 66.7 t -92.82 104.44 15.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.693 179.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -107.05 98.75 8.37 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.027 -179.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.12 -9.04 58.34 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.342 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -64.27 -39.41 93.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.581 175.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -102.63 -34.46 9.06 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.863 175.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 98.31 68.2 0.91 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.474 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -166.15 166.18 17.19 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.27 121.51 42.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.349 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -120.69 117.79 28.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.317 0.579 . . . . 0.0 110.678 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.588 HD13 HG23 ' A' ' 113' ' ' VAL . 0.9 OUTLIER -109.43 147.87 32.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.143 178.101 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.404 HG12 ' NH2' ' A' ' 118' ' ' ARG . 46.6 mm -110.01 128.58 66.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 C--N 1.317 -0.815 0 O-C-N 123.954 0.783 . . . . 0.0 109.939 -179.448 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.532 HG23 ' HB3' ' A' ' 130' ' ' LEU . 17.1 m . . . . . 0 N--CA 1.452 -0.341 0 CA-C-O 121.303 0.573 . . . . 0.0 112.219 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.423 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -137.21 140.51 41.77 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.079 173.06 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -127.5 151.09 49.31 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.924 0.392 . . . . 0.0 111.044 -173.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.9 127.02 44.72 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.044 177.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 4.4 p -120.87 173.44 7.23 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.734 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 tpm_? -94.04 121.5 35.59 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 176.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.591 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -86.53 97.39 10.48 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.413 . . . . 0.0 111.302 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.63 -45.12 19.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 173.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.3 172.08 6.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.549 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 55.9 mtt-85 -111.04 176.83 4.87 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.283 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.51 -178.14 16.42 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.668 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -155.51 114.78 3.59 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 156.37 41.25 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -169.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tm-20 -135.85 120.92 18.82 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.041 -0.981 . . . . 0.0 108.735 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.19 162.44 35.72 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 119.717 -1.23 . . . . 0.0 113.4 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.74 140.95 56.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.608 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.94 125.79 30.58 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.969 0.414 . . . . 0.0 111.651 -176.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.51 ' HA ' HG23 ' A' ' 115' ' ' THR . 7.9 tt -111.89 110.43 20.76 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 171.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.1 t -102.7 110.17 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.091 0.472 . . . . 0.0 110.824 -175.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.455 HG23 ' CD2' ' A' ' 18' ' ' LEU . 2.0 p -99.43 112.92 25.04 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.814 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.42 ' HG2' ' H ' ' A' ' 21' ' ' LYS . 44.0 pttt -92.32 0.72 57.47 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.856 0.836 . . . . 0.0 109.105 176.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -79.61 -173.39 3.75 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.54 -1.209 . . . . 0.0 109.675 174.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -121.0 93.99 4.2 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.297 0.57 . . . . 0.0 110.557 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.8 mt -106.21 146.44 12.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.527 -176.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.542 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 33.9 t -131.74 162.27 30.87 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.461 ' HD2' HG12 ' A' ' 90' ' ' ILE . 64.0 m-85 -88.45 23.82 2.11 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.167 0.508 . . . . 0.0 111.007 -177.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.542 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 1.0 OUTLIER -74.93 -14.7 60.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.921 169.466 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.524 ' N ' HD12 ' A' ' 27' ' ' LEU . . . 139.84 57.65 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.727 -178.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.77 -42.23 6.12 Favored Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.866 -178.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.509 HG13 HG12 ' A' ' 37' ' ' VAL . 4.3 mp -93.41 146.46 6.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 20.0 t70 -70.43 138.98 51.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.825 0.345 . . . . 0.0 110.175 176.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.2 ptmt -79.77 -10.49 59.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.439 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 43.0 mt-10 -121.21 -40.45 2.59 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -176.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.0 p -92.57 -18.8 22.63 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.997 0.427 . . . . 0.0 111.384 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.475 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 76.51 11.13 85.43 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.093 -179.013 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.0 mm -86.92 132.37 32.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.509 HG12 HG13 ' A' ' 30' ' ' ILE . 11.8 m -67.87 129.49 32.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.281 0.562 . . . . 0.0 111.355 178.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 72.4 mmtt -84.64 -37.14 21.4 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 174.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -94.51 90.62 6.26 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.512 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.975 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.5 t70 -146.96 -164.47 2.0 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.007 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 45.6 t -166.87 -41.2 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 120.818 0.342 . . . . 0.0 110.469 -177.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -103.93 -48.43 3.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.505 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -111.56 15.93 8.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.891 0.377 . . . . 0.0 111.336 -173.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.975 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 38.6 ttmt -50.26 128.9 20.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.171 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.72 -7.45 12.15 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.107 -175.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.45 ' HB3' ' NH1' ' A' ' 51' ' ' ARG . 22.0 mm-40 -93.3 145.26 24.59 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 110.282 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 34.6 t -97.7 148.39 23.39 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 20.5 m -86.82 2.06 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.983 0.421 . . . . 0.0 110.706 178.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -67.22 92.51 0.27 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.538 -176.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.99 5.36 33.16 Favored Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.328 -0.851 . . . . 0.0 113.443 171.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.502 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 0.8 OUTLIER -123.56 178.29 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 O-C-N 122.65 -0.324 . . . . 0.0 110.461 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.506 HD12 ' HB ' ' A' ' 119' ' ' VAL . 72.2 mt -108.1 130.02 61.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.165 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.598 ' HB3' HG12 ' A' ' 81' ' ' ILE . 60.3 tp -96.1 123.93 39.91 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.706 -176.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 54.4 t -123.79 108.77 21.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.749 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.448 ' HB3' ' OG1' ' A' ' 20' ' ' THR . 53.4 p90 -134.58 144.56 51.36 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.104 174.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 6.2 Cg_exo -74.81 -38.82 1.53 Allowed 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 123.018 2.479 . . . . 0.0 112.027 177.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.609 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.787 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.473 0.687 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.545 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 23.0 m -56.79 -31.12 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.518 HD22 HG23 ' A' ' 67' ' ' VAL . 4.0 mm? -59.13 -40.52 85.73 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 178.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.545 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.3 tp -63.58 -44.65 93.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.194 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -62.13 -45.73 92.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.267 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.545 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 92.7 mt -59.36 -40.38 86.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.589 178.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.653 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -69.12 -37.73 78.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.061 -176.172 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.506 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 32.5 mmmt -70.01 -27.34 64.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.933 0.397 . . . . 0.0 110.709 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -87.61 -21.92 25.06 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.132 0.491 . . . . 0.0 110.435 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.79 20.43 37.0 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.216 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.617 ' HA ' ' HB2' ' A' ' 49' ' ' ALA . 21.9 m -118.41 24.24 4.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.015 0.436 . . . . 0.0 110.791 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -95.44 159.34 32.91 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.801 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 62.5 Cg_endo -76.45 151.69 33.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.178 1.919 . . . . 0.0 111.392 175.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.444 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 89.6 mttt -74.8 -30.96 61.58 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.73 0.3 . . . . 0.0 111.255 -178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.96 161.73 36.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.43 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.598 HG12 ' HB3' ' A' ' 53' ' ' LEU . 71.2 mt -139.36 129.75 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 O-C-N 123.323 0.39 . . . . 0.0 110.176 178.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.601 HG23 HG23 ' A' ' 102' ' ' VAL . 4.6 mm -117.01 125.0 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -120.21 161.79 20.48 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.735 0.302 . . . . 0.0 111.218 -176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.5 tptp -94.64 -38.0 11.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.596 0.712 . . . . 0.0 109.24 171.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -133.14 116.05 15.8 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.545 175.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.8 t -106.95 171.51 7.33 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.453 -177.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.405 ' CD ' ' H ' ' A' ' 88' ' ' THR . 1.4 tm-20 -137.44 159.82 40.85 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -175.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.405 ' H ' ' CD ' ' A' ' 87' ' ' GLU . 4.3 m -52.44 -47.79 66.2 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 122.941 0.496 . . . . 0.0 111.518 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.1 pp -62.92 -28.89 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-O 121.014 0.435 . . . . 0.0 110.86 -178.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.461 HG12 ' HD2' ' A' ' 26' ' ' PHE . 51.1 mt -75.16 -50.91 22.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.168 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.84 -48.36 82.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.084 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.66 -43.54 98.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.0 -41.74 98.48 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.6 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -71.6 -40.32 69.91 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.781 0.324 . . . . 0.0 111.056 -179.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.04 -41.15 91.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.516 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.1 mtm -64.84 -31.56 72.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.542 -177.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.653 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -99.96 5.02 45.23 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.289 0.478 . . . . 0.0 112.289 -175.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 63.07 52.4 2.56 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.71 0.766 . . . . 0.0 109.861 -176.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.513 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 33.3 mm -111.59 89.62 11.15 Favored Pre-proline 0 C--N 1.318 -0.788 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.168 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 79' ' ' LYS . 73.2 Cg_exo -47.89 105.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.558 0 C-N-CA 122.979 2.453 . . . . 0.0 112.324 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 9.8 tt -122.83 129.97 52.33 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.622 -177.142 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.601 HG23 HG23 ' A' ' 82' ' ' ILE . 30.2 m -134.68 164.72 33.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.823 -178.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -110.27 112.53 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.674 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.483 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.2 p -91.99 122.93 43.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.294 0.568 . . . . 0.0 111.113 -175.485 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.26 6.01 49.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.187 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.484 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 9.8 t70 -108.72 126.03 52.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.117 0.484 . . . . 0.0 111.015 -175.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -71.55 -33.64 69.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.721 -177.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.574 ' HE3' ' HA ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -61.54 -26.98 68.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.858 -176.993 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -56.48 -49.0 75.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.817 177.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -70.3 -26.86 63.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.089 -175.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.38 -36.11 46.37 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.235 178.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -85.89 -28.2 24.52 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 10.0 p -81.26 127.06 39.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.48 0.657 . . . . 0.0 111.232 -177.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -122.94 154.82 37.87 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.44 176.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 18' ' ' LEU . 36.7 m -67.87 94.62 0.47 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.065 0.46 . . . . 0.0 110.525 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.32 -29.63 0.97 Allowed Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.181 -178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -71.98 169.37 16.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 174.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 6.9 tmm_? -115.87 132.33 56.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.035 0.445 . . . . 0.0 110.903 -175.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 17' ' ' ALA . 48.2 t -110.43 139.83 32.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.023 -176.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.07 112.57 41.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 172.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.418 HG23 HD13 ' A' ' 52' ' ' ILE . 62.9 t -101.91 114.94 42.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.145 -174.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 -106.06 92.91 4.35 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.5 -6.83 56.07 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.48 . . . . 0.0 110.639 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -73.38 -36.78 66.13 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.58 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -112.49 -4.24 14.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.134 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.431 ' CA ' ' HB2' ' A' ' 7' ' ' ALA . . . 74.73 71.7 1.11 Allowed Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.251 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -158.4 144.99 17.4 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -130.8 122.93 53.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.311 0.576 . . . . 0.0 110.911 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -109.3 118.34 36.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.532 ' HB3' HG23 ' A' ' 1' ' ' VAL . 64.9 tp -93.38 115.14 27.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.015 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 22.6 mm -91.3 111.73 24.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.5 0.667 . . . . 0.0 109.691 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 . . . . . 0 C--N 1.308 -1.21 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.001 -179.224 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.444 ' HD3' ' HG2' ' A' ' 129' ' ' GLU . 87.8 mttt 63.74 96.86 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.486 0.66 . . . . 0.0 110.113 -175.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -110.34 148.0 32.82 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.066 -172.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.78 130.38 39.81 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.289 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.614 ' SG ' HG22 ' A' ' 104' ' ' VAL . 26.0 m -121.43 179.4 4.45 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.03 0.443 . . . . 0.0 111.001 -176.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.646 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 40.2 ttt180 -94.79 121.88 36.84 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.775 178.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.541 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.41 130.71 34.75 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.775 0.321 . . . . 0.0 111.683 -174.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.1 mp -105.32 -48.12 9.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 173.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 26.7 p -117.19 -173.89 2.49 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.957 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -120.69 -177.26 3.43 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.635 0.255 . . . . 0.0 110.649 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 110.46 152.06 13.11 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.247 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.435 HH11 ' HD2' ' A' ' 12' ' ' ARG . 16.7 mtp180 -113.16 136.9 52.21 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.684 0.278 . . . . 0.0 110.271 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -137.35 132.15 33.17 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.433 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.541 ' HG3' HG22 ' A' ' 120' ' ' VAL . 35.6 tt0 -131.11 126.2 35.13 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.947 176.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 177.6 -158.27 23.4 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.048 -1.072 . . . . 0.0 113.086 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -72.2 136.15 46.32 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 122.807 0.443 . . . . 0.0 110.723 -177.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.528 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -99.75 131.94 45.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.384 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.3 tp -118.78 120.67 38.07 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.533 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.57 117.4 47.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.645 0.736 . . . . 0.0 110.194 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 8.9 m -108.48 134.57 51.09 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.497 -176.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.49 -21.54 18.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.194 0.521 . . . . 0.0 109.717 177.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.414 ' H ' HG22 ' A' ' 20' ' ' THR . 13.4 mm-40 -79.06 160.34 27.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.568 -175.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 6.1 p90 -117.67 121.31 40.53 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.68 174.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.0 mp -123.02 123.75 68.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 120.826 0.346 . . . . 0.0 111.138 -174.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.3 p -76.68 127.57 33.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 169.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -74.83 78.67 2.1 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.668 0.747 . . . . 0.0 111.944 -173.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.3 mt -120.06 -47.97 2.36 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 170.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.2 -142.78 3.88 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 113.848 -1.523 . . . . 0.0 110.43 172.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.59 -48.18 3.52 Favored Glycine 0 C--O 1.222 -0.598 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.448 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.1 mp -111.88 131.73 62.46 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 174.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -68.01 123.93 21.99 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.936 0.398 . . . . 0.0 109.952 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 45.8 pttt -80.62 -5.09 56.4 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -172.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -103.92 -33.62 8.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.829 0.347 . . . . 0.0 111.214 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.5 p -109.68 -28.16 8.98 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.914 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.591 ' CA ' HG13 ' A' ' 76' ' ' VAL . . . 89.42 9.7 66.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.43 -177.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.538 HD13 ' HB3' ' A' ' 47' ' ' SER . 48.7 mm -84.05 124.97 40.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.571 0.224 . . . . 0.0 110.614 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 20.7 m -68.78 116.67 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.759 0.79 . . . . 0.0 110.408 175.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 10.4 mmmm -89.58 -24.56 21.68 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.434 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -65.0 132.38 49.08 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.333 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 25.8 t70 -68.03 133.4 48.96 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.069 0.461 . . . . 0.0 111.403 -177.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 23.1 p -174.22 -170.64 0.54 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.516 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -83.23 -16.92 44.56 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.484 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.1 mt -100.17 15.17 4.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 122.12 0.962 . . . . 0.0 109.32 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.402 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 82.1 tttt -62.04 134.85 57.14 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.489 -1.232 . . . . 0.0 111.45 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 98.46 -10.91 63.23 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.572 -0.74 . . . . 0.0 113.231 177.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -92.47 170.45 9.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.307 0.575 . . . . 0.0 111.732 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.538 ' HB3' HD13 ' A' ' 36' ' ' ILE . 6.2 p -110.97 142.43 43.09 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.683 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.1 9.06 8.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.417 0.627 . . . . 0.0 109.881 175.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 76' ' ' VAL . . . -75.24 95.45 3.15 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.21 28.79 12.42 Favored Glycine 0 C--N 1.317 -0.508 0 CA-C-N 114.705 -1.134 . . . . 0.0 113.609 172.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -130.65 177.76 7.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.719 0.26 . . . . 0.0 110.675 174.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.69 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.5 mp -89.37 118.55 34.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.403 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 35.8 tp -106.4 116.6 32.21 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.15 -177.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.48 107.77 23.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.194 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.455 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 36.7 p90 -134.42 153.43 79.23 Favored Pre-proline 0 C--N 1.32 -0.714 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.843 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 -40.1 79.15 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.717 2.278 . . . . 0.0 111.982 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.776 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.25 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.932 0.396 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.437 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 47.8 t -68.41 -26.84 34.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.585 -177.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.611 HD12 ' HA3' ' A' ' 93' ' ' GLY . 94.9 mt -57.92 -32.75 68.08 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.054 178.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.556 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.7 tp -67.5 -46.08 73.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.322 178.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -65.21 -38.24 89.81 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.501 HD12 HD23 ' A' ' 68' ' ' LEU . 94.2 mt -58.43 -45.14 89.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.389 176.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.413 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.2 OUTLIER -68.84 -37.91 79.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.614 -178.042 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -62.93 -33.88 76.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.024 0.44 . . . . 0.0 110.702 176.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -86.35 -18.15 32.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.623 -177.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 95.2 1.31 62.8 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.262 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.591 HG13 ' CA ' ' A' ' 35' ' ' GLY . 71.2 t -79.65 -30.36 13.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 C-N-CA 122.71 0.404 . . . . 0.0 111.585 -175.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.99 144.7 98.9 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.696 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.26 141.86 94.65 Favored 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.304 2.003 . . . . 0.0 110.926 175.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 tttt -74.81 -16.5 60.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.119 0.485 . . . . 0.0 110.005 -175.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.69 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -164.27 142.94 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.518 176.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.494 HG13 ' HG ' ' A' ' 101' ' ' LEU . 9.3 pt -128.68 120.21 51.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.366 0.603 . . . . 0.0 111.115 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG23 ' A' ' 102' ' ' VAL . 1.2 mm -113.1 116.66 53.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -123.16 161.73 23.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 112.076 -171.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -99.46 -34.45 10.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.055 174.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -125.93 131.98 52.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.867 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -130.26 174.44 9.83 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.466 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -135.82 162.45 32.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.896 0.379 . . . . 0.0 110.553 -178.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.503 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.6 m -60.19 -51.57 69.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.47 -177.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.1 pt -58.35 -32.03 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.619 -179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.2 mm -68.7 -45.52 81.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.45 -38.43 89.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.022 178.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 88' ' ' THR . 93.0 t -62.94 -50.48 79.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.716 178.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.611 ' HA3' HD12 ' A' ' 68' ' ' LEU . . . -60.26 -43.97 97.96 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.144 178.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.59 -36.15 82.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 111.38 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -69.18 -42.79 75.38 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.33 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 58.4 mtm -73.86 -36.62 64.87 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.577 -176.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.37 -9.75 49.18 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.764 -176.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.443 ' OE1' ' HA ' ' A' ' 98' ' ' GLU . 2.8 tp10 65.91 72.54 0.4 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.824 0.821 . . . . 0.0 110.161 -175.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.428 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 60.6 mt -127.15 90.11 50.05 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 114.759 -1.109 . . . . 0.0 109.734 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 4.4 Cg_exo -39.3 110.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 123.985 3.123 . . . . 0.0 112.993 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.494 ' HG ' HG13 ' A' ' 81' ' ' ILE . 4.7 tt -119.66 123.43 43.8 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.368 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 82' ' ' ILE . 8.6 m -128.17 139.82 50.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.238 0.542 . . . . 0.0 110.651 176.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 43.6 tt0 -88.92 123.14 32.99 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.54 -178.17 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.614 HG22 ' SG ' ' A' ' 5' ' ' CYS . 96.3 t -107.27 117.72 53.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.793 178.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 24.2 mtm180 -107.44 14.09 26.25 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.237 0.541 . . . . 0.0 110.06 177.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -108.62 130.74 55.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.51 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -71.92 -28.07 63.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.65 -175.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -73.39 -18.25 61.18 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -172.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -63.03 -48.31 79.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.955 0.407 . . . . 0.0 109.984 176.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.408 ' HA ' HG12 ' A' ' 113' ' ' VAL . 88.3 m-85 -71.98 -22.71 61.4 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.364 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -72.81 -42.15 64.15 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.733 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.03 -36.86 30.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.009 -175.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.408 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.5 p -75.65 136.72 24.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-O 121.314 0.578 . . . . 0.0 111.091 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.489 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 9.7 mtmp? -126.18 158.77 34.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.949 176.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 50.0 m -65.16 111.46 2.95 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 172.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.92 1.67 19.16 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.351 -0.928 . . . . 0.0 113.592 176.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . 0.489 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 28.2 m-20 -85.42 177.55 7.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 117.348 0.574 . . . . 0.0 110.519 176.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.419 ' NH2' HG13 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -115.42 119.79 37.42 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.0 110.152 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.528 HG23 ' HB2' ' A' ' 17' ' ' ALA . 36.7 t -109.34 126.52 66.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.156 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.541 HG22 ' HG3' ' A' ' 14' ' ' GLU . 14.6 t -106.96 102.24 13.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 173.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.478 HG23 HG22 ' A' ' 128' ' ' VAL . 7.3 p -108.32 131.66 58.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.279 0.562 . . . . 0.0 111.78 -176.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -116.08 103.87 10.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.467 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.83 -18.71 50.16 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.369 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.2 -30.69 70.57 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.063 0.458 . . . . 0.0 110.588 177.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -108.89 -37.06 5.95 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.44 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 97.39 56.09 1.13 Allowed Glycine 0 N--CA 1.45 -0.386 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -145.04 133.46 21.85 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -172.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 121' ' ' VAL . 49.0 t -118.8 112.32 37.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.057 -177.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.444 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 45.8 mt-10 -106.72 108.47 20.0 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.166 177.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.426 HD23 ' H ' ' A' ' 130' ' ' LEU . 2.0 pt? -106.52 147.8 28.97 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.419 HG13 ' NH2' ' A' ' 118' ' ' ARG . 42.6 mm -112.27 133.86 56.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.06 177.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.418 -177.526 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.1 p . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 121.362 0.601 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.468 ' HD3' ' HE1' ' A' ' 127' ' ' TYR . 97.5 mttt -121.18 140.16 52.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.689 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -115.77 161.71 18.35 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.327 -177.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.01 127.26 50.08 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.158 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.7 p -120.55 176.11 5.66 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.972 0.415 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.473 ' NE ' ' HA ' ' A' ' 6' ' ' ARG . 2.6 tpm_? -98.43 124.75 43.3 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 175.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.06 140.0 46.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.9 0.381 . . . . 0.0 111.82 -175.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 49.1 mm -112.47 -57.26 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 ' HA ' ' A' ' 95' ' ' ALA . 52.7 p -113.13 -164.99 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.627 174.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.501 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 7.9 mpt_? -120.08 167.58 12.06 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.017 0.437 . . . . 0.0 111.486 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.748 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 134.46 145.84 5.31 Favored Glycine 0 CA--C 1.519 0.305 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.69 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.559 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 1.1 tmm_? -139.88 114.14 9.07 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.34 170.32 17.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.636 0.255 . . . . 0.0 111.428 -175.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -110.23 165.5 11.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.393 178.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.438 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -175.43 157.31 23.78 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 173.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.849 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 52.8 mt-10 -61.44 137.37 58.24 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 174.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -78.84 109.2 12.89 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.712 0.291 . . . . 0.0 110.463 -176.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.9 tt -102.4 109.55 21.24 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 173.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.6 t -120.64 114.09 42.43 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.153 -171.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 t -127.5 118.19 23.54 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.736 174.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.409 ' HE2' ' HB3' ' A' ' 110' ' ' PHE . 30.5 ttmt -93.53 20.91 6.76 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.89 0.853 . . . . 0.0 109.118 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.572 ' HG2' ' SG ' ' A' ' 41' ' ' CYS . 5.0 mp0 -97.66 147.68 24.08 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.79 -1.096 . . . . 0.0 109.7 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -82.8 100.61 10.42 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.073 0.463 . . . . 0.0 110.317 175.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.448 HG23 ' HB3' ' A' ' 39' ' ' GLU . 27.9 mm -91.44 1.25 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.269 -176.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.8 m 68.57 -26.81 0.14 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 171.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 24' ' ' ILE . 47.1 t80 75.36 -31.25 0.2 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 123.749 0.82 . . . . 0.0 112.015 175.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -61.72 102.25 0.25 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.042 0.448 . . . . 0.0 110.176 177.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.24 26.13 69.03 Favored Glycine 0 C--N 1.335 0.486 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.2 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -83.61 -15.32 71.18 Favored Glycine 0 C--O 1.224 -0.523 0 C-N-CA 120.867 -0.683 . . . . 0.0 113.797 -173.377 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 59.7 mt -125.8 130.57 72.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 117.492 0.646 . . . . 0.0 111.18 -177.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.506 ' HA ' ' HE2' ' A' ' 38' ' ' LYS . 12.3 t70 -65.57 130.42 43.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.966 175.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.555 ' HA ' HD21 ' A' ' 71' ' ' LEU . 21.2 pttp -84.76 -0.12 52.62 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -171.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -101.69 -53.63 2.93 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.846 0.355 . . . . 0.0 111.608 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.518 HG23 HG12 ' A' ' 36' ' ' ILE . 3.5 t -109.69 -2.68 17.28 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.253 -0.431 . . . . 0.0 112.057 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.45 43.85 91.56 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.54 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.518 HG12 HG23 ' A' ' 34' ' ' THR . 47.3 mm -110.66 131.48 61.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 53.6 t -61.0 123.44 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.806 0.336 . . . . 0.0 110.599 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.506 ' HE2' ' HA ' ' A' ' 31' ' ' ASP . 63.8 mmtt -72.08 -47.99 47.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.221 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 24' ' ' ILE . 7.8 tp10 -62.13 125.48 24.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.629 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.548 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 14.1 t70 -83.11 133.23 35.07 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.329 178.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.572 ' SG ' ' HG2' ' A' ' 22' ' ' GLU . 4.0 t -170.8 39.04 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 75.63 -29.94 0.19 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 114.984 -1.007 . . . . 0.0 111.945 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 41.8 mm -84.17 -10.47 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-O 121.623 0.725 . . . . 0.0 110.45 177.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.548 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 21.8 ttpp -59.64 135.94 57.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.126 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 111.34 -14.8 27.86 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.455 -0.879 . . . . 0.0 113.036 176.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -89.47 142.39 27.71 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.008 0.432 . . . . 0.0 111.236 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.443 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 20.3 m -85.36 136.66 33.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.552 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.4 m -89.05 -6.96 10.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.195 173.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.87 94.62 0.13 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.243 -176.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.67 13.66 49.84 Favored Glycine 0 C--N 1.313 -0.749 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.668 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.849 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 95.9 mtt180 -113.46 166.26 11.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.981 0.419 . . . . 0.0 111.051 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.438 HG12 ' HA3' ' A' ' 15' ' ' GLY . 39.3 mm -95.99 122.15 47.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.169 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HB3' HG12 ' A' ' 81' ' ' ILE . 58.5 tp -93.2 113.26 25.44 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.768 0.318 . . . . 0.0 110.36 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.6 t -102.93 108.16 23.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 176.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.685 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.0 t80 -134.37 140.27 35.3 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.195 -172.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 15.2 Cg_endo -94.13 -56.5 0.01 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.914 2.409 . . . . 0.0 113.38 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.643 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.309 -176.887 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 . . . . . 0 N--CA 1.46 0.069 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.55 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 66.4 t -62.56 -51.4 72.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.676 0.274 . . . . 0.0 110.689 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.27 -39.58 93.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.956 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.501 ' O ' ' HG2' ' A' ' 73' ' ' LYS . 56.4 tp -62.82 -46.08 89.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.565 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.51 -44.71 93.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.422 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.555 HD21 ' HA ' ' A' ' 32' ' ' LYS . 97.3 mt -54.43 -41.59 69.56 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.114 0.483 . . . . 0.0 110.397 177.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -65.04 -37.08 86.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.144 -178.159 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.501 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 34.5 mmtp -69.91 -25.29 63.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.214 -177.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -93.84 -22.82 18.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.285 0.564 . . . . 0.0 110.182 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.37 15.66 37.29 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.221 178.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.47 23.68 3.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.238 0.542 . . . . 0.0 110.701 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.87 156.03 41.03 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.054 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 42.1 Cg_endo -68.14 155.92 67.68 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.4 2.067 . . . . 0.0 112.129 175.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 53.9 mmtt -68.51 -41.86 79.39 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.824 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.444 ' HB2' HG11 ' A' ' 121' ' ' VAL . . . -163.69 165.97 22.71 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.251 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.482 HG12 ' HB3' ' A' ' 53' ' ' LEU . 63.9 mt -131.87 119.34 41.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.094 0.473 . . . . 0.0 110.24 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.631 HG23 HG23 ' A' ' 102' ' ' VAL . 3.8 mm -103.83 116.88 48.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.7 m120 -111.64 164.49 12.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.949 0.404 . . . . 0.0 111.503 -175.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -69.76 -54.14 15.09 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.711 175.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.614 ' HG2' ' OE2' ' A' ' 103' ' ' GLU . 4.8 tttm -139.75 22.59 2.48 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.515 178.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 30.5 m 72.48 124.03 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.618 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.491 ' HB3' ' HB ' ' A' ' 90' ' ' ILE . 8.8 tp10 -84.13 130.54 34.84 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 172.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.6 m -57.5 -50.2 73.84 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.962 0.41 . . . . 0.0 111.66 -173.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.1 mt -68.95 -35.14 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.199 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 87' ' ' GLU . 59.7 mt -69.23 -38.07 77.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.36 -44.77 92.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.416 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -62.26 -49.28 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.994 0.426 . . . . 0.0 110.576 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.92 -42.24 99.72 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.466 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.06 -39.17 92.88 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.704 0.287 . . . . 0.0 111.149 -179.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.439 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -63.13 -41.89 99.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.923 178.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.5 mtm -72.49 -35.96 68.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.498 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.567 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -92.36 5.96 48.68 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 56.92 50.78 11.66 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.449 0.643 . . . . 0.0 110.911 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 62.1 mt -114.29 90.3 20.09 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.816 179.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.748 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 91.6 Cg_exo -35.3 112.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.352 0.733 0 C-N-CA 124.071 3.181 . . . . 0.0 113.998 -176.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.409 HD13 ' N ' ' A' ' 102' ' ' VAL . 0.5 OUTLIER -110.15 128.75 55.64 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.836 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.631 HG23 HG23 ' A' ' 82' ' ' ILE . 16.2 m -136.55 162.18 35.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.343 178.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.614 ' OE2' ' HG2' ' A' ' 85' ' ' LYS . 32.1 tt0 -115.88 119.09 34.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.814 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 106' ' ' ASP . 13.5 t -99.52 128.97 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.888 0.375 . . . . 0.0 110.4 177.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 105' ' ' ARG . 3.2 mmp_? -92.02 24.8 3.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.223 0.535 . . . . 0.0 110.42 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.497 ' H ' HG12 ' A' ' 104' ' ' VAL . 35.9 t70 -141.96 111.9 6.81 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.698 -175.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -69.84 -26.68 64.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.846 178.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.4 ' HD3' ' HA ' ' A' ' 108' ' ' LYS . 68.8 mmtt -63.51 -19.95 65.2 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.527 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.599 ' O ' HG12 ' A' ' 113' ' ' VAL . 49.9 t80 -61.25 -45.1 95.9 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 170.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.409 ' HB3' ' HE2' ' A' ' 21' ' ' LYS . 87.4 m-85 -68.3 -22.05 64.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.277 -177.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -83.64 -32.75 25.5 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.049 0.452 . . . . 0.0 110.522 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.7 -44.34 28.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.185 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.599 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.9 p -83.21 123.5 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 110.149 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -130.21 152.66 49.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.048 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.742 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 21.6 m -58.4 107.49 0.5 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.042 -179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.32 -39.04 0.55 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.331 -0.938 . . . . 0.0 113.449 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . 0.741 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 1.7 t0 -101.09 -166.96 1.36 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 117.286 0.543 . . . . 0.0 110.997 -176.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.741 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -110.03 138.54 46.27 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.33 0.586 . . . . 0.0 112.559 -173.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.624 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.7 t -119.71 122.7 69.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.551 173.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.932 ' HB ' ' HG3' ' A' ' 129' ' ' GLU . 47.1 t -100.06 112.58 33.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.444 HG11 ' HB2' ' A' ' 80' ' ' ALA . 8.9 p -86.54 133.2 30.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.561 -177.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . 0.665 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 44.0 t-20 -126.06 94.64 4.15 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.252 0.549 . . . . 0.0 109.767 177.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.437 ' HB1' ' O ' ' A' ' 9' ' ' THR . . . -90.16 2.66 55.09 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.418 0.627 . . . . 0.0 110.107 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.455 ' HB3' ' OD1' ' A' ' 122' ' ' ASN . 4.5 t70 -73.7 -37.1 65.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.665 175.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -114.11 -15.36 12.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.573 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.06 66.89 1.74 Allowed Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -168.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.665 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 9.2 t80 -146.24 144.75 30.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.146 -0.527 . . . . 0.0 109.744 -167.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 109' ' ' PHE . 60.1 t -126.87 104.87 13.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 175.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.932 ' HG3' ' HB ' ' A' ' 120' ' ' VAL . 9.0 pt-20 -97.05 108.13 20.81 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.502 0.668 . . . . 0.0 109.931 179.169 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.9 tp -85.57 127.83 34.57 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.497 -178.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 5.2 mm -116.76 111.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -178.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.414 ' HA ' ' OD2' ' A' ' 117' ' ' ASP . 12.4 mp0 . . . . . 0 C--N 1.314 -0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.464 HG23 ' HB3' ' A' ' 130' ' ' LEU . 10.8 m . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 121.464 0.649 . . . . 0.0 111.914 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.432 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 28.1 mtpp -107.78 94.21 4.96 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.143 174.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -96.77 155.62 16.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.018 0.437 . . . . 0.0 111.379 -176.145 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.41 126.27 52.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.702 174.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 103' ' ' GLU . 80.3 m -118.93 179.59 4.1 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.029 -177.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 64.4 ttp85 -92.04 116.12 28.66 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -175.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.659 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.65 124.39 24.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.091 -0.958 . . . . 0.0 111.786 -173.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 44.5 mm -102.81 -47.99 10.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.734 176.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.564 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -107.16 -171.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.379 177.558 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 10' ' ' ARG . 39.3 mtt180 -115.33 -178.7 3.44 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 173.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.97 -176.81 36.42 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.846 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -161.14 143.31 12.21 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 -178.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.51 179.07 9.46 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.29 0.567 . . . . 0.0 111.494 -175.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -125.77 160.59 29.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.533 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.57 ' HA3' HG13 ' A' ' 52' ' ' ILE . . . 179.61 155.69 15.82 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.832 171.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.527 ' HB3' ' HD3' ' A' ' 51' ' ' ARG . 28.7 tt0 -75.44 137.95 41.32 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 175.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.515 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -78.0 134.92 37.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.119 0.485 . . . . 0.0 111.825 -169.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.506 HD21 HG21 ' A' ' 43' ' ' ILE . 6.3 tt -130.29 115.41 16.91 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 174.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.549 HG12 ' OG1' ' A' ' 115' ' ' THR . 9.9 p -103.47 130.94 53.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.198 0.523 . . . . 0.0 110.831 -175.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.8 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 29.1 m -108.82 127.52 54.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.031 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -99.88 -1.01 38.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.559 -175.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.453 ' H ' HG22 ' A' ' 20' ' ' THR . 53.4 mm-40 -96.99 158.98 15.17 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.358 0.599 . . . . 0.0 112.188 -173.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -104.38 91.24 3.82 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 27.4 pt -122.35 16.83 5.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -169.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 59.6 p 51.8 -154.54 0.17 Allowed 'General case' 0 CA--C 1.53 0.202 0 O-C-N 123.606 0.566 . . . . 0.0 110.485 -175.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.411 ' HE2' HD11 ' A' ' 68' ' ' LEU . 9.6 t80 -143.64 18.25 1.84 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.064 0.459 . . . . 0.0 110.626 179.239 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.13 -10.05 57.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.316 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.03 130.64 1.25 Allowed Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.183 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.435 ' HA2' ' HB3' ' A' ' 39' ' ' GLU . . . -173.27 -47.37 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.264 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.674 HG13 HG22 ' A' ' 37' ' ' VAL . 4.1 mp -88.27 134.63 27.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.744 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 29.2 t70 -77.89 147.25 35.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.687 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 9.5 ptpp? -82.76 -14.49 54.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.135 -174.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -100.79 -47.82 4.69 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.427 -175.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.9 p -92.91 -37.09 12.44 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.778 0.323 . . . . 0.0 111.735 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.8 20.03 48.91 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.336 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.2 mm -90.24 138.3 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.287 179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.674 HG22 HG13 ' A' ' 30' ' ' ILE . 96.3 t -79.81 102.26 5.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.139 0.495 . . . . 0.0 109.755 174.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.744 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 59.3 mttt -84.32 -28.64 26.93 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.706 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.435 ' HB3' ' HA2' ' A' ' 29' ' ' GLY . 9.4 tp10 -96.14 78.66 3.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.614 0.721 . . . . 0.0 110.384 178.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 1.027 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 9.2 t70 -147.82 -167.78 2.89 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.936 177.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 71.5 m -144.82 -23.14 0.51 Allowed 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -133.86 -47.77 0.8 Allowed 'General case' 0 C--O 1.233 0.225 0 O-C-N 122.031 -0.418 . . . . 0.0 110.796 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.506 HG21 HD21 ' A' ' 18' ' ' LEU . 23.0 mm -75.83 -17.75 15.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 109.227 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 1.027 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 54.3 tttm -44.37 118.23 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 CA-C-N 114.166 -1.379 . . . . 0.0 112.156 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 130.83 -19.13 5.02 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.807 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -93.46 156.36 16.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.056 0.455 . . . . 0.0 111.692 -177.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.0 m -95.94 138.69 33.22 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.423 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.1 m -94.2 -3.69 10.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.993 0.425 . . . . 0.0 110.808 176.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.42 89.51 0.5 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.559 0.695 . . . . 0.0 110.868 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.7 ' HA2' ' HE3' ' A' ' 79' ' ' LYS . . . 112.6 2.98 25.64 Favored Glycine 0 C--N 1.313 -0.741 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.703 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.527 ' HD3' ' HB3' ' A' ' 16' ' ' GLU . 20.2 mmt85 -105.59 156.29 18.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.556 -0.322 . . . . 0.0 110.827 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.706 HG12 ' HB3' ' A' ' 80' ' ' ALA . 29.1 mt -97.29 117.65 42.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 169.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.43 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 28.1 tp -93.56 124.57 37.64 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.957 -171.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 62.6 t -123.85 107.51 18.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.892 0.377 . . . . 0.0 110.195 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.8 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 40.9 p90 -136.01 146.09 55.21 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 177.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.97 -29.55 34.02 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.851 2.367 . . . . 0.0 111.462 175.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.747 176.778 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 . . . . . 0 N--CA 1.471 0.619 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.487 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 29.8 m -62.79 -24.65 36.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -175.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.411 HD11 ' HE2' ' A' ' 26' ' ' PHE . 6.2 mp -69.0 -32.16 71.51 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.664 0.269 . . . . 0.0 110.576 178.171 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.414 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.4 tp -66.43 -38.48 87.5 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -61.21 -48.85 79.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.129 175.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.487 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 67.6 mt -60.59 -41.68 95.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.674 178.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.0 OUTLIER -72.06 -35.61 69.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.097 -176.402 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -59.75 -38.41 81.68 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.434 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -82.6 -29.66 30.02 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 109.876 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 99.14 22.27 13.51 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.561 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.47 4.9 9.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.998 0.428 . . . . 0.0 111.156 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.32 154.54 66.41 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.767 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 27.7 Cg_endo -63.63 147.33 92.86 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.148 1.899 . . . . 0.0 111.075 174.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.7 ' HE3' ' HA2' ' A' ' 50' ' ' GLY . 97.2 mttt -73.32 -27.25 61.42 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.049 0.452 . . . . 0.0 110.725 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.706 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -157.79 157.48 33.43 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.305 176.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.466 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 34.1 mt -136.57 127.39 41.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 178.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.527 HG22 HG13 ' A' ' 104' ' ' VAL . 3.6 mm -121.67 118.26 55.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 11.8 m120 -130.43 -179.84 5.5 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.147 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.434 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 4.1 tmtt? -109.86 -37.91 5.51 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 171.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -103.01 114.84 29.46 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -120.67 141.26 50.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.903 0.382 . . . . 0.0 110.266 177.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.49 ' HB2' HG13 ' A' ' 90' ' ' ILE . 81.2 mm-40 -108.94 159.65 16.64 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.11 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 m -60.01 -45.34 93.06 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.83 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.444 HD12 ' N ' ' A' ' 90' ' ' ILE . 2.5 pp -64.82 -31.08 52.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.725 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.49 HG13 ' HB2' ' A' ' 87' ' ' GLU . 69.3 mt -68.38 -45.79 81.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.984 0.421 . . . . 0.0 109.99 177.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.55 -48.27 82.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.965 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.06 -45.49 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.974 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.68 -43.28 99.47 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.61 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -74.89 -37.15 62.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 111.576 0.213 . . . . 0.0 111.576 -177.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.45 -38.83 85.42 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.737 0.303 . . . . 0.0 111.428 -178.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 59.1 mtm -71.22 -31.03 67.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.039 0.447 . . . . 0.0 111.054 -179.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.414 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.55 -2.86 58.47 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.432 -179.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.543 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 3.9 tp10 62.4 43.95 7.66 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-O 121.49 0.662 . . . . 0.0 110.3 -177.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.0 mt -107.44 88.6 4.21 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.83 175.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 24.3 Cg_exo -62.14 118.22 5.1 Favored 'Trans proline' 0 C--O 1.233 0.267 0 C-N-CA 122.918 2.412 . . . . 0.0 112.665 -174.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.564 HD23 ' OG1' ' A' ' 9' ' ' THR . 1.9 pt? -118.96 147.09 44.43 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.95 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.659 HG12 ' HA ' ' A' ' 7' ' ' ALA . 26.9 m -136.97 158.33 36.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.014 178.288 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.539 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 30.3 tt0 -94.89 119.82 34.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.491 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.527 HG13 HG22 ' A' ' 82' ' ' ILE . 20.7 m -74.25 144.32 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.135 174.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -117.55 23.47 11.73 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.76 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.481 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 10.4 t70 -144.35 127.81 16.95 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -176.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -66.56 -36.76 83.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.367 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.481 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 10.0 mtmp? -67.9 -18.35 64.76 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.324 -175.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -58.98 -39.89 83.17 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -67.69 -29.07 68.24 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.754 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.11 -40.14 60.09 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 177.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.03 -46.55 56.65 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.703 -176.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.0 p -66.0 138.02 23.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 121.106 0.479 . . . . 0.0 111.376 -175.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -138.06 151.07 47.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.989 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.549 ' OG1' HG12 ' A' ' 19' ' ' VAL . 80.4 m -70.17 118.37 12.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.605 -0.271 . . . . 0.0 110.319 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 120.69 -12.5 10.11 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.257 177.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.82 179.33 6.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.829 0.314 . . . . 0.0 111.127 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -109.18 120.81 43.64 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 121.046 0.45 . . . . 0.0 111.344 -175.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 17' ' ' ALA . 52.1 t -123.02 137.39 56.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.485 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.449 ' CG2' ' HB3' ' A' ' 129' ' ' GLU . 6.0 m -114.43 134.56 57.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.654 170.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.402 HG11 ' CB ' ' A' ' 80' ' ' ALA . 11.2 p -112.96 133.95 57.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.165 0.507 . . . . 0.0 110.644 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -129.29 94.85 3.89 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 174.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.39 -16.13 35.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.185 0.516 . . . . 0.0 110.293 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.32 -40.95 73.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.252 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -100.45 -25.26 14.27 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.153 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 90.41 68.76 1.2 Allowed Glycine 0 CA--C 1.516 0.124 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.352 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -158.38 146.94 18.77 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 122.468 0.307 . . . . 0.0 110.832 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.34 125.53 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.705 173.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.449 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 41.1 tt0 -109.1 112.61 24.87 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.234 0.54 . . . . 0.0 110.722 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.464 ' HB3' HG23 ' A' ' 1' ' ' VAL . 55.7 tp -105.86 122.59 46.41 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.957 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.8 mt -115.3 120.49 64.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--N 1.31 -1.148 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.282 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 N--CA 1.454 -0.271 0 CA-C-O 120.934 0.397 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.452 ' HD2' ' N ' ' A' ' 2' ' ' LYS . 11.4 mptt -101.46 113.66 26.96 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -93.85 148.21 22.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.828 0.346 . . . . 0.0 110.764 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.06 125.86 40.0 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.665 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.8 m -120.36 175.14 6.11 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.55 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 40.9 ttm180 -101.28 121.21 41.47 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -69.83 114.05 7.65 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.765 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 mm -90.75 -66.56 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 174.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.551 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 21.2 p -96.18 -170.95 2.2 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 173.072 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.27 164.71 24.98 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.056 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.05 155.54 10.96 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.052 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 57.9 ttt180 -115.87 117.08 29.18 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.908 0.385 . . . . 0.0 110.143 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.424 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -119.01 138.18 53.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.994 0.426 . . . . 0.0 111.352 -175.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.493 ' HG3' HG22 ' A' ' 120' ' ' VAL . 20.6 tt0 -112.0 139.49 47.47 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.053 178.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.405 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -172.7 170.66 43.75 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.473 175.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -82.63 127.48 33.41 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 52' ' ' ILE . . . -90.2 131.58 35.96 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -169.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mp -112.75 130.52 56.04 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.148 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.487 HG11 HG13 ' A' ' 113' ' ' VAL . 48.2 t -119.47 126.16 75.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.552 -172.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.4 t -118.27 139.52 51.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 176.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -91.65 -9.39 44.16 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.239 0.542 . . . . 0.0 110.033 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -95.37 143.86 26.38 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.824 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -85.42 153.62 22.38 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.869 177.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.0 pt -122.0 -178.99 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.197 0.523 . . . . 0.0 111.5 -175.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.3 p -111.32 124.38 52.12 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.767 -0.652 . . . . 0.0 109.641 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -76.36 95.61 3.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.345 0.593 . . . . 0.0 110.824 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 pp -165.83 -162.57 0.57 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.708 -1.133 . . . . 0.0 109.164 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -73.34 67.12 1.53 Allowed Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.579 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.42 -23.03 10.63 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 121.21 -0.519 . . . . 0.0 112.401 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 37' ' ' VAL . 60.3 mt -101.92 138.21 26.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 177.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -69.34 133.02 47.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.605 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 60.8 pttt -78.52 -16.72 57.16 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -173.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.5 mm-40 -94.73 -52.32 4.33 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -174.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.581 HG23 HG12 ' A' ' 36' ' ' ILE . 7.6 t -106.3 -2.94 21.75 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 111.795 0.294 . . . . 0.0 111.795 -176.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.58 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.24 37.8 93.22 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.226 175.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.581 HG12 HG23 ' A' ' 34' ' ' THR . 49.7 mm -104.02 128.74 57.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.458 HG22 HG12 ' A' ' 30' ' ' ILE . 21.3 t -72.29 117.75 16.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.865 0.364 . . . . 0.0 110.181 178.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -83.64 -36.27 23.96 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.266 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -64.98 132.79 50.21 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 176.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.534 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 9.0 t70 -80.38 136.83 36.45 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.287 0.565 . . . . 0.0 111.832 -170.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.454 ' H ' ' HB3' ' A' ' 44' ' ' LYS . 79.4 m -144.55 28.04 1.33 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.033 -0.985 . . . . 0.0 109.105 177.061 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 70.26 -69.12 0.18 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.28 -177.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 46.6 pt -80.39 5.43 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.27 0.557 . . . . 0.0 111.203 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.534 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER -68.18 139.41 56.09 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.254 178.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.94 -1.29 1.72 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.635 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -102.58 159.8 15.13 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.663 0.268 . . . . 0.0 110.569 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.4 p -82.1 121.96 27.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-O 121.28 0.562 . . . . 0.0 110.041 176.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.0 m -86.71 19.26 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.438 -176.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.13 92.16 0.17 Allowed 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.706 0.765 . . . . 0.0 111.128 -176.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.51 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 84.92 24.32 45.65 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 114.735 -1.121 . . . . 0.0 112.23 177.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.452 HH11 ' HD2' ' A' ' 51' ' ' ARG . 12.5 mmt180 -98.08 163.96 12.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.627 0.251 . . . . 0.0 110.728 178.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.483 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.0 mm -102.15 118.37 48.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 175.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.538 ' HB2' HG22 ' A' ' 81' ' ' ILE . 4.3 mm? -106.7 125.3 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.922 0.391 . . . . 0.0 111.221 -177.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.477 ' HB ' HG22 ' A' ' 19' ' ' VAL . 59.7 t -110.7 106.38 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.849 176.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -136.59 148.12 62.43 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.787 176.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.451 ' O ' ' HG2' ' A' ' 84' ' ' LYS . 32.1 Cg_exo -59.61 -45.28 26.46 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.416 2.077 . . . . 0.0 111.955 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.666 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -178.834 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.1 p90 . . . . . 0 C--O 1.231 0.097 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.44 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 34.4 m -66.42 -28.58 43.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.239 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 98.9 mt -62.35 -40.77 97.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.988 0.423 . . . . 0.0 110.168 178.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.7 tp -69.4 -43.12 74.1 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.266 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.504 ' C ' HD22 ' A' ' 70' ' ' ASN . 0.2 OUTLIER -57.36 -49.93 74.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.913 178.477 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.564 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 97.9 mt -63.49 -43.52 97.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.054 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.415 ' C ' ' HD3' ' A' ' 72' ' ' ARG . 0.3 OUTLIER -66.83 -38.95 87.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.708 0.289 . . . . 0.0 110.347 -177.438 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.452 ' HD2' ' O ' ' A' ' 73' ' ' LYS . 2.4 tmmm? -61.48 -32.1 72.09 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.53 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -91.37 -7.73 50.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.267 0.556 . . . . 0.0 110.143 178.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.21 16.34 72.05 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.0 174.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.58 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.9 m -108.25 7.56 9.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.776 0.322 . . . . 0.0 111.448 -177.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.564 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -92.45 159.95 35.79 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.501 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.528 ' HB3' HD23 ' A' ' 53' ' ' LEU . 34.7 Cg_exo -58.41 150.17 69.63 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.373 2.049 . . . . 0.0 111.12 172.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.51 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 79.0 tttt -81.49 -24.68 36.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.151 0.5 . . . . 0.0 109.828 -178.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.483 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -168.37 154.29 6.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.893 176.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.538 HG22 ' HB2' ' A' ' 53' ' ' LEU . 25.5 pt -136.25 146.1 29.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.821 0.343 . . . . 0.0 111.295 -178.441 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.605 HG23 HG23 ' A' ' 102' ' ' VAL . 4.7 mm -118.82 124.22 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 14.2 m120 -122.39 171.22 9.22 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -176.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.451 ' HG2' ' O ' ' A' ' 56' ' ' PRO . 63.1 pttt -96.97 -32.57 11.95 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.4 0.619 . . . . 0.0 110.321 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.412 ' NZ ' ' HA ' ' A' ' 85' ' ' LYS . 1.4 tppm? -138.02 113.15 9.24 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.665 177.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.3 m -99.03 127.68 45.01 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.782 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.68 152.12 22.01 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 16.3 m -56.64 -39.52 73.83 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.693 0.283 . . . . 0.0 110.997 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 80.8 mt -55.38 -41.4 62.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-O 121.335 0.588 . . . . 0.0 110.686 177.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 25.8 mm -71.77 -41.65 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.247 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.41 81.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.227 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -60.31 -45.54 96.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.829 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.22 -48.07 85.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.52 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.28 -33.17 74.73 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.534 0.206 . . . . 0.0 111.472 -178.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.98 -45.07 90.7 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.911 0.386 . . . . 0.0 111.068 178.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.6 mtm -69.02 -33.14 73.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.138 -178.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -85.74 -7.24 58.9 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.54 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.461 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 63.2 mt-10 60.4 48.52 7.74 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.501 0.667 . . . . 0.0 110.471 -177.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.3 90.07 7.85 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.026 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.551 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 50.0 Cg_exo -52.8 115.77 2.46 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.764 2.309 . . . . 0.0 112.202 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pt? -129.77 143.85 51.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.004 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.605 HG23 HG23 ' A' ' 82' ' ' ILE . 17.4 m -136.18 155.29 34.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.918 -178.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.55 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 2.6 pt-20 -102.93 137.08 41.6 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.057 0.456 . . . . 0.0 111.618 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 2.2 m -125.17 109.41 22.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.53 173.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.451 ' H ' ' HD3' ' A' ' 105' ' ' ARG . 0.0 OUTLIER -87.6 17.42 4.65 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.451 0.643 . . . . 0.0 110.156 176.789 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -95.12 123.28 38.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.058 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -71.45 -38.75 71.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.428 -176.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.566 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 62.3 mttm -70.81 -18.83 62.72 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -171.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -56.07 -49.85 72.62 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 171.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -75.72 -26.48 57.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.511 0.672 . . . . 0.0 110.231 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.3 tt0 -65.02 -44.57 88.7 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.314 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -96.84 -27.97 14.46 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.487 HG13 HG11 ' A' ' 19' ' ' VAL . 11.0 p -67.24 134.75 29.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 111.225 -175.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -110.98 157.13 20.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.421 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.443 ' HB ' ' H ' ' A' ' 19' ' ' VAL . 8.8 t -87.41 127.97 35.21 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.483 179.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.57 0.4 24.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.169 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -101.78 -172.1 2.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.808 0.304 . . . . 0.0 110.871 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 118' ' ' ARG . 2.0 ttp180 -103.07 127.37 50.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.368 . . . . 0.0 111.574 -172.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 129' ' ' GLU . 73.9 t -134.07 123.15 43.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.322 176.083 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.493 HG22 ' HG3' ' A' ' 14' ' ' GLU . 81.2 t -114.82 125.05 72.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 6.2 p -107.9 123.89 63.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.456 0.646 . . . . 0.0 111.252 -177.19 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -103.58 95.97 6.41 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.121 173.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.11 6.03 17.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.956 0.408 . . . . 0.0 110.979 -176.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.01 -38.99 79.56 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.264 0.554 . . . . 0.0 109.798 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -115.19 -22.84 9.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.888 175.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 92.72 66.3 1.09 Allowed Glycine 0 C--O 1.228 -0.232 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -174.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -144.29 125.11 14.24 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -169.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 24.6 m -113.33 134.29 56.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.29 0.567 . . . . 0.0 111.823 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.503 ' O ' ' HA ' ' A' ' 119' ' ' VAL . 46.3 mt-10 -96.55 107.79 20.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.17 176.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.8 tp -101.3 108.99 20.77 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 175.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.5 mm -120.13 125.72 74.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.9 0.381 . . . . 0.0 110.297 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 . . . . . 0 C--N 1.318 -0.79 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.426 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 121.443 0.64 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.707 ' HE3' ' HG2' ' A' ' 129' ' ' GLU . 52.0 mtpt -121.49 121.39 37.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.231 -0.895 . . . . 0.0 108.606 170.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.51 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 96.6 m-85 -97.17 150.11 21.25 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.99 0.424 . . . . 0.0 111.37 -173.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.76 122.15 46.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.733 177.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.462 ' SG ' HG21 ' A' ' 102' ' ' VAL . 7.1 p -120.49 171.16 8.74 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.123 -177.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.653 ' HB3' ' HB2' ' A' ' 103' ' ' GLU . 7.8 tpt180 -93.5 115.8 28.31 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 176.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.604 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -74.88 110.31 9.07 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.589 -178.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.2 mm -85.06 -55.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 172.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.586 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -100.17 174.73 6.01 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 171.925 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 10' ' ' ARG . 43.1 mtm180 -119.56 174.7 6.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.804 0.335 . . . . 0.0 110.434 175.169 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.4 144.8 6.84 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.096 -178.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.527 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 60.1 mtm180 -119.16 131.64 55.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 177.582 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.57 145.29 23.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.519 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.06 140.92 52.5 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.158 -0.473 . . . . 0.0 109.754 177.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -170.26 175.79 44.11 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.522 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -67.08 128.15 35.28 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.9 125.29 29.94 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.984 -176.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 tt -108.39 109.07 20.28 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 175.288 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.455 HG22 ' HB ' ' A' ' 54' ' ' VAL . 75.1 t -103.15 128.8 55.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.948 0.404 . . . . 0.0 110.669 -174.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 22' ' ' GLU . 7.2 m -123.94 108.69 12.68 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.523 -177.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -89.54 16.54 7.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.402 0.62 . . . . 0.0 110.315 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.508 ' CG ' HG23 ' A' ' 24' ' ' ILE . 6.0 tp10 -83.87 159.38 21.35 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.419 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . 0.438 ' N ' ' HG3' ' A' ' 22' ' ' GLU . 23.8 m-85 -119.69 81.48 1.73 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.28 0.562 . . . . 0.0 110.007 176.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.508 HG23 ' CG ' ' A' ' 22' ' ' GLU . 18.4 pt -107.63 168.53 3.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.827 0.822 . . . . 0.0 111.744 -176.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.55 123.17 34.0 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 114.306 -1.315 . . . . 0.0 109.063 176.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -56.29 -70.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.205 0 O-C-N 123.276 0.36 . . . . 0.0 110.483 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt 59.28 -85.42 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 O-C-N 123.791 0.682 . . . . 0.0 111.991 176.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 168.75 42.08 0.03 OUTLIER Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.0 -7.91 84.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.255 -174.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.453 HG13 HG12 ' A' ' 37' ' ' VAL . 4.1 mp -79.83 119.49 29.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 176.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.09 127.8 33.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.106 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.463 ' HE3' ' OD1' ' A' ' 70' ' ' ASN . 0.0 OUTLIER -74.64 -10.2 59.31 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -172.749 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -97.81 -35.98 10.35 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.749 0.309 . . . . 0.0 111.34 -176.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.6 p -105.53 -36.42 7.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.342 -0.39 . . . . 0.0 112.013 -178.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.93 15.41 59.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.634 -175.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 49.2 mm -95.44 138.35 21.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.453 HG12 HG13 ' A' ' 30' ' ' ILE . 15.3 m -72.49 116.21 14.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.371 0.605 . . . . 0.0 110.762 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -88.75 -9.41 51.98 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.382 -178.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -90.29 151.16 21.62 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.431 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 10.5 t70 -76.9 134.69 38.89 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.316 -171.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 7.6 p -167.32 173.38 8.94 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 43' ' ' ILE . 5.3 pt-20 -62.08 -36.26 81.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 -178.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.436 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 15.1 pt -105.38 43.54 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 122.053 0.93 . . . . 0.0 110.144 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.431 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 86.4 tttt -67.47 121.53 16.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.778 -179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.71 -2.48 29.0 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.886 -178.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -79.54 155.7 28.09 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.937 0.398 . . . . 0.0 111.052 177.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.1 p -102.8 136.49 42.52 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.326 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.1 m -98.11 -1.36 10.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.905 0.383 . . . . 0.0 110.957 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.31 95.03 0.29 Allowed 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.802 -176.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.08 17.6 39.89 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.196 175.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.5 mmt180 -109.64 150.83 27.66 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.562 HD13 HG23 ' A' ' 121' ' ' VAL . 65.8 mt -96.19 105.26 16.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 177.188 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.593 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -80.61 116.6 20.72 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.373 0.606 . . . . 0.0 111.332 -174.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.455 ' HB ' HG22 ' A' ' 19' ' ' VAL . 61.6 t -114.13 106.94 21.66 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.657 175.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -134.86 148.32 66.56 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.126 176.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.27 -41.5 21.14 Favored 'Trans proline' 0 C--O 1.236 0.388 0 C-N-CA 122.53 2.153 . . . . 0.0 112.319 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 C-N-CA 121.114 -0.565 . . . . 0.0 111.936 -179.236 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.1 m-85 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.45 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 17.4 m -52.3 -36.9 21.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -175.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.45 HD22 ' HB2' ' A' ' 94' ' ' ALA . 5.3 mp -68.85 -34.87 76.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.001 0.429 . . . . 0.0 111.075 -178.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.499 HD13 ' HA ' ' A' ' 97' ' ' ALA . 66.1 tp -70.63 -40.06 73.32 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.044 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.463 ' OD1' ' HE3' ' A' ' 32' ' ' LYS . 12.7 t-20 -56.2 -41.88 76.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.776 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.45 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 80.6 mt -62.59 -41.47 98.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.34 -179.33 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.563 ' NH1' ' HB3' ' A' ' 98' ' ' GLU . 15.2 ttp180 -74.2 -25.06 59.46 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.856 -0.337 . . . . 0.0 111.09 -174.323 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -73.72 -26.09 60.53 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.825 -0.35 . . . . 0.0 111.282 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -92.56 -27.95 17.05 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.898 176.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.87 22.79 7.43 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.476 -0.869 . . . . 0.0 112.522 177.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.434 HG21 ' HA ' ' A' ' 32' ' ' LYS . 30.4 m -114.27 21.05 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.122 0.487 . . . . 0.0 110.882 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -92.02 155.52 43.01 Favored Pre-proline 0 C--O 1.237 0.431 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.428 -177.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.593 ' HB3' HD13 ' A' ' 53' ' ' LEU . 15.7 Cg_exo -69.69 158.9 55.43 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.997 2.465 . . . . 0.0 112.021 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -69.76 -44.69 69.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.057 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.98 164.24 25.78 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.204 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 37.5 mm -127.0 124.64 65.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.428 -178.824 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.1 mm -119.19 116.27 50.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' HG12 ' A' ' 104' ' ' VAL . 13.6 m120 -126.26 157.38 38.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.692 0.282 . . . . 0.0 111.031 -175.028 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 23.5 ttmm -68.89 -52.07 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 173.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.1 tptm -155.6 109.99 2.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.172 171.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.7 t -91.62 167.03 12.5 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.314 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -83.56 152.08 25.05 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.934 0.397 . . . . 0.0 110.854 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 m -58.87 -34.02 71.14 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.148 -178.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.424 HD12 ' N ' ' A' ' 89' ' ' ILE . 3.0 mp -61.22 -39.99 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.098 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 50.0 mt -77.15 -42.4 31.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.413 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.574 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -55.59 -48.76 74.32 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.586 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -71.79 -39.06 67.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.524 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.95 -41.52 99.66 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.601 -178.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.45 ' HB2' HD22 ' A' ' 68' ' ' LEU . . . -74.56 -31.16 62.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.555 0.217 . . . . 0.0 110.809 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -61.28 -38.54 87.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.01 0.433 . . . . 0.0 110.112 175.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 84.2 mtp -66.22 -42.45 88.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.685 177.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.499 ' HA ' HD13 ' A' ' 69' ' ' LEU . . . -80.94 -4.29 54.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.964 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.563 ' HB3' ' NH1' ' A' ' 72' ' ' ARG . 37.7 tt0 60.24 37.75 20.34 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.85 0.833 . . . . 0.0 109.852 -177.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.447 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 60.1 mt -105.11 89.18 2.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.931 175.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.586 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 12.1 Cg_endo -53.47 117.07 3.42 Favored 'Trans proline' 0 C--O 1.234 0.302 0 C-N-CA 123.17 2.58 . . . . 0.0 113.845 -170.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.707 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pp -117.56 148.11 42.19 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.504 171.183 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.0 m -136.34 163.92 32.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.083 -175.533 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.653 ' HB2' ' HB3' ' A' ' 6' ' ' ARG . 43.8 mt-10 -97.08 113.91 25.51 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.875 175.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 7.2 p -110.74 112.7 41.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.653 0.74 . . . . 0.0 109.86 174.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 105' ' ' ARG . 52.4 mtt180 -95.81 28.38 3.1 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.992 -173.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 22.8 t70 -118.07 121.33 40.31 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.625 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -72.6 -33.86 66.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.968 -178.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.416 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 49.5 mmtm -60.6 -35.88 77.2 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 -176.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.502 ' O ' HG12 ' A' ' 113' ' ' VAL . 44.7 t80 -51.8 -46.04 64.09 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.857 177.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -70.18 -22.63 62.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.195 0.522 . . . . 0.0 111.17 -174.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.481 ' O ' ' HE2' ' A' ' 114' ' ' LYS . 11.5 mm-40 -88.51 -28.19 20.95 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.191 176.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.61 -44.31 64.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.803 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.9 p -91.93 133.18 34.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.172 0.51 . . . . 0.0 111.151 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.481 ' HE2' ' O ' ' A' ' 111' ' ' GLU . 74.7 mmtt -128.93 160.87 31.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 10.8 t -63.35 125.44 24.17 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.162 0.506 . . . . 0.0 110.37 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.35 -16.36 11.67 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.855 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -91.24 175.28 6.99 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.42 HH11 ' HD3' ' A' ' 118' ' ' ARG . 1.3 tmm_? -116.24 129.76 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.135 0.493 . . . . 0.0 111.352 -174.18 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 86.6 t -116.41 140.41 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.209 178.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.563 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 48.6 t -104.94 108.21 24.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 172.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.562 HG23 HD13 ' A' ' 52' ' ' ILE . 96.1 t -92.77 119.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.148 0.499 . . . . 0.0 111.264 -175.227 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . 0.527 ' HA ' ' HG2' ' A' ' 12' ' ' ARG . 55.9 t-20 -115.74 93.81 4.42 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -94.36 -0.61 54.78 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 110.378 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -80.72 -40.25 25.63 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.399 177.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -98.75 -28.07 13.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.849 176.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.43 59.66 1.14 Allowed Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.27 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -148.59 146.33 28.2 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.917 0.389 . . . . 0.0 110.451 -174.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.51 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 54.8 t -119.71 108.85 24.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.761 177.136 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.707 ' HG2' ' HE3' ' A' ' 2' ' ' LYS . 39.1 mt-10 -99.81 107.9 20.05 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.961 0.41 . . . . 0.0 110.251 179.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 47.6 tp -93.35 132.66 37.37 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.209 178.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.8 mt -119.22 114.98 46.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.575 0.702 . . . . 0.0 109.5 175.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--N 1.312 -1.052 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.889 179.664 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 45.0 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 121.997 0.903 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mtmm -108.21 122.69 47.44 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.164 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -89.64 136.18 33.18 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 176.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.63 114.99 26.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.678 -176.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HB ' ' A' ' 104' ' ' VAL . 11.7 m -120.33 163.08 18.37 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.38 178.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 45.3 ttt180 -93.74 124.83 38.01 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 120.344 -0.542 . . . . 0.0 109.854 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.483 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.71 137.95 34.05 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.69 -172.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 4.4 mp -103.18 -48.55 10.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 174.122 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.3 p -102.1 169.57 8.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.378 174.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.427 ' HB3' ' OD1' ' A' ' 124' ' ' ASP . 71.8 mtt85 -125.44 -174.75 3.14 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.928 0.394 . . . . 0.0 111.761 -176.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.35 175.85 23.39 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.4 149.38 32.63 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.31 156.19 35.06 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.975 0.417 . . . . 0.0 111.099 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -124.28 132.82 53.59 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.694 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.09 175.33 39.43 Favored Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.051 177.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -72.3 133.21 44.89 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 176.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -79.77 121.54 25.49 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.017 0.436 . . . . 0.0 110.808 -177.183 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.986 HD21 HG21 ' A' ' 43' ' ' ILE . 7.3 tt -113.23 113.59 25.53 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 53.1 t -102.99 109.94 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.105 0.479 . . . . 0.0 110.759 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.745 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 20.9 m -87.37 116.75 25.68 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.348 176.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.901 ' HD3' ' HG3' ' A' ' 42' ' ' GLU . 8.8 mptt -73.37 -25.77 60.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.377 -176.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.482 ' HG3' ' HB3' ' A' ' 41' ' ' CYS . 22.0 mm-40 -91.36 152.97 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -91.14 90.88 8.0 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.956 178.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 pt -86.03 145.39 7.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.135 -178.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.442 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 7.2 m -91.75 150.19 21.23 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.552 -173.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.432 ' CZ ' ' HZ ' ' A' ' 55' ' ' PHE . 74.9 m-85 -86.11 15.17 5.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.905 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.442 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 33.7 mt -73.53 -8.45 55.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.179 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 126.48 70.5 0.18 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.245 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -106.74 -25.63 6.16 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.786 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 37' ' ' VAL . 4.2 mp -92.21 133.74 32.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 -177.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 13.2 t70 -69.68 135.11 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.996 0.426 . . . . 0.0 110.293 175.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 49.9 pttt -73.38 -14.02 61.2 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -171.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -106.65 -44.53 4.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.996 0.427 . . . . 0.0 111.771 -174.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.466 ' HB ' HG12 ' A' ' 36' ' ' ILE . 34.6 p -97.48 -26.88 14.67 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.11 -174.195 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.64 8.5 84.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.559 -175.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.466 HG12 ' HB ' ' A' ' 34' ' ' THR . 34.0 mm -82.56 133.48 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.367 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.49 HG12 HG13 ' A' ' 30' ' ' ILE . 5.5 m -77.39 131.73 34.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.312 0.577 . . . . 0.0 110.974 176.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.449 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 75.1 mmtt -95.39 -14.92 23.41 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.691 177.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -129.01 85.12 2.29 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.674 -176.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.577 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.1 t70 -148.14 -162.79 1.63 Allowed 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.597 -178.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.482 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 44.9 t -155.3 -32.47 0.1 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.553 -175.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.901 ' HG3' ' HD3' ' A' ' 21' ' ' LYS . 17.6 mm-40 -109.53 -47.26 3.4 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -177.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.986 HG21 HD21 ' A' ' 18' ' ' LEU . 40.8 pt -101.28 10.08 8.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.351 0.596 . . . . 0.0 109.919 -177.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.577 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 79.0 tttt -54.57 114.0 1.51 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.604 177.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 114.18 -14.19 21.24 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.374 -176.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -103.71 169.24 8.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.748 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.408 ' HB2' HD13 ' A' ' 36' ' ' ILE . 40.8 t -109.62 152.28 25.75 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.553 -179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.8 m -103.9 3.54 10.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.848 177.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.0 85.48 1.0 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.394 -176.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 116.18 8.26 13.42 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.516 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -114.46 158.83 21.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.0 mt -93.11 117.5 36.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 37.0 tp -90.32 111.16 22.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.579 -173.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 19' ' ' VAL . 61.3 t -119.0 105.95 18.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.413 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.745 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 19.1 p90 -137.48 163.61 47.4 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.603 ' HD2' ' HB2' ' A' ' 55' ' ' PHE . 10.0 Cg_endo -52.56 -54.92 4.33 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.858 2.372 . . . . 0.0 112.707 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.202 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.012 -179.818 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 . . . . . 0 C--O 1.232 0.158 0 N-CA-C 111.765 0.283 . . . . 0.0 111.765 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.543 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 93.4 t -58.13 -45.34 88.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.895 0.379 . . . . 0.0 110.164 176.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -61.7 -38.94 89.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.593 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 54.4 tp -66.86 -40.29 87.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.878 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -69.55 -40.94 76.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.96 0.41 . . . . 0.0 110.492 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.543 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 91.6 mt -62.63 -37.44 86.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.239 176.434 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -63.87 -37.56 87.86 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.216 -178.178 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -69.1 -29.47 67.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.833 0.349 . . . . 0.0 110.749 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.411 ' HB3' HG22 ' A' ' 76' ' ' VAL . 62.1 t30 -89.41 -14.37 35.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.34 0.59 . . . . 0.0 110.055 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 85.92 10.45 75.49 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.531 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.411 HG22 ' HB3' ' A' ' 74' ' ' ASN . 27.3 m -100.74 14.01 5.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -81.4 154.5 71.67 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.35 176.08 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.16 159.14 54.16 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.334 2.023 . . . . 0.0 111.775 176.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -71.33 -31.36 67.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.907 0.384 . . . . 0.0 110.717 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -168.25 164.12 13.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.217 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 66.4 mt -137.33 118.62 17.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.257 -0.429 . . . . 0.0 109.978 179.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.4 HG23 ' CG2' ' A' ' 102' ' ' VAL . 10.1 mm -114.9 118.09 57.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 177.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -119.01 158.28 26.1 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.506 -174.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.576 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 1.5 tmtp? -83.96 -45.19 13.41 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 174.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -141.81 113.07 7.55 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.069 -0.969 . . . . 0.0 108.878 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.6 t -123.57 -176.92 3.57 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.582 -176.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.454 ' H ' HD12 ' A' ' 90' ' ' ILE . 77.9 mt-10 -115.86 150.7 36.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.265 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.8 m -61.92 -37.89 86.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.677 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 51.0 mt -61.08 -39.22 81.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.968 0.414 . . . . 0.0 110.793 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.454 HD12 ' H ' ' A' ' 87' ' ' GLU . 60.4 mt -62.86 -42.13 95.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.055 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.583 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -61.72 -38.4 87.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.89 178.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 88' ' ' THR . 58.3 t -63.87 -43.49 97.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.536 177.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.72 -40.11 97.18 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.13 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.29 -32.67 74.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.748 0.308 . . . . 0.0 111.055 177.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.01 -25.03 67.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 178.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.417 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 45.2 mtt -79.37 -43.87 22.62 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.708 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.5 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -83.49 -0.74 51.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.134 -174.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 64.1 38.53 8.34 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.129 0.49 . . . . 0.0 110.769 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.47 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.0 mt -109.41 90.07 8.02 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 17.7 Cg_endo -58.16 125.01 17.22 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.899 2.399 . . . . 0.0 112.68 -178.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.583 HD21 ' HA ' ' A' ' 91' ' ' ALA . 2.2 pp -127.35 147.52 50.26 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.17 0.509 . . . . 0.0 111.16 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 7' ' ' ALA . 27.4 m -134.56 156.2 39.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.05 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.451 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 42.9 mt-10 -95.92 119.46 34.46 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.583 176.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.576 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 4.5 p -114.45 116.42 52.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.257 0.551 . . . . 0.0 110.176 176.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -91.53 -29.34 17.02 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.783 -177.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -69.39 117.88 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -177.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -68.64 -21.28 64.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.762 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 31.4 mttm -62.16 -19.97 63.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.442 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 113' ' ' VAL . 46.9 t80 -65.52 -51.97 56.03 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 173.197 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -69.7 -26.49 64.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.491 0.662 . . . . 0.0 110.412 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.408 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 39.1 tt0 -70.38 -37.35 74.52 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.543 176.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.45 -54.64 5.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.1 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 109' ' ' PHE . 9.9 p -69.96 138.9 21.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.254 0.549 . . . . 0.0 110.601 -177.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 55.9 mttp -135.04 151.43 50.78 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.956 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.553 HG23 ' HA ' ' A' ' 18' ' ' LEU . 16.2 m -58.16 113.33 1.87 Allowed 'General case' 0 C--N 1.324 -0.519 0 O-C-N 123.353 0.408 . . . . 0.0 110.397 178.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 106.18 31.73 3.99 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.949 -179.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -132.55 173.72 11.02 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 171.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB ' ' A' ' 131' ' ' ILE . 10.1 ttm180 -97.52 122.51 40.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.022 0.439 . . . . 0.0 111.797 -172.211 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.4 t -117.83 124.18 72.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.065 174.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.4 t -107.17 105.05 18.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 174.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.9 p -92.86 132.31 37.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.555 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -127.23 93.51 3.76 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 176.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.05 -13.34 56.0 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.607 -171.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.427 ' OD1' ' HB3' ' A' ' 10' ' ' ARG . 48.3 m-20 -61.57 -34.77 76.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.909 0.385 . . . . 0.0 109.977 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.412 ' HB3' ' CE1' ' A' ' 127' ' ' TYR . 32.1 tt0 -106.5 -27.74 10.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.1 178.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 93.07 70.13 1.13 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.969 175.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.412 ' CE1' ' HB3' ' A' ' 125' ' ' GLU . 46.1 p90 -170.31 162.13 8.42 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.21 179.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.451 HG21 ' CE1' ' A' ' 109' ' ' PHE . 15.0 m -124.61 132.11 71.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.507 178.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -105.42 117.77 34.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.743 179.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.8 tp -94.2 125.4 38.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 177.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.422 ' HB ' ' HD2' ' A' ' 118' ' ' ARG . 31.4 mm -108.13 111.45 35.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--N 1.312 -1.034 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.436 -173.627 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.855 0.36 . . . . 0.0 111.162 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -121.5 111.67 17.55 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.589 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 90.1 m-85 -92.59 149.46 21.34 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.725 0.297 . . . . 0.0 110.77 -177.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 117.66 34.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.809 176.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.553 ' HB3' HG22 ' A' ' 104' ' ' VAL . 4.5 p -120.35 169.14 10.57 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.166 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 44.2 ttp180 -94.69 128.38 41.33 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.596 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.12 127.62 41.32 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.979 0.419 . . . . 0.0 111.458 -174.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.4 mm -101.31 -55.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.549 177.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.679 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -95.42 173.68 7.4 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.553 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.417 ' H ' HG22 ' A' ' 9' ' ' THR . 25.3 mmt180 -121.25 168.18 11.9 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.402 -175.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.68 -174.41 16.54 Favored Glycine 0 N--CA 1.452 -0.256 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.77 154.7 46.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 117.618 0.709 . . . . 0.0 111.147 176.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.465 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -138.61 139.51 38.59 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.959 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 123.92 30.82 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.77 -179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.95 -166.34 37.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 119.585 -1.293 . . . . 0.0 113.39 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -73.19 135.16 44.58 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 122.598 0.359 . . . . 0.0 110.797 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.72 124.95 32.1 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.929 0.395 . . . . 0.0 111.046 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.572 ' HA ' HG23 ' A' ' 115' ' ' THR . 6.5 tt -108.78 110.71 22.16 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.669 ' HA ' ' HB ' ' A' ' 54' ' ' VAL . 47.0 t -104.58 125.7 59.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.269 0.557 . . . . 0.0 112.425 -168.538 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.461 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 17.5 p -137.22 144.98 43.1 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.614 174.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.523 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 15.8 ptpt -128.89 20.14 5.98 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.193 0.52 . . . . 0.0 111.031 175.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -80.57 125.3 29.82 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.192 173.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -77.83 109.46 11.87 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.212 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.75 ' HB ' ' HZ ' ' A' ' 55' ' ' PHE . 43.8 mt -124.45 -7.62 6.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 110.256 -174.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.0 p 48.94 23.25 0.67 Allowed 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 113.596 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.455 ' CD1' HD13 ' A' ' 90' ' ' ILE . 36.9 m-85 64.51 18.34 11.31 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 178.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.2 27.26 0.81 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.176 0.512 . . . . 0.0 109.878 173.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' HA2' ' HG2' ' A' ' 39' ' ' GLU . . . -94.01 -128.39 5.1 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.488 -176.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 177.39 93.38 0.09 OUTLIER Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.416 -177.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.435 HG12 HG22 ' A' ' 37' ' ' VAL . 54.5 mt -92.82 126.67 45.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 170.212 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -62.92 124.31 20.75 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.695 0.283 . . . . 0.0 110.701 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.549 ' HA ' HD23 ' A' ' 71' ' ' LEU . 20.7 pttp -85.08 3.97 36.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -173.368 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -101.47 -36.99 8.62 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.94 0.4 . . . . 0.0 110.818 177.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.2 p -113.22 -19.1 11.93 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.667 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.13 25.01 62.61 Favored Glycine 0 N--CA 1.453 -0.176 0 C-N-CA 120.989 -0.624 . . . . 0.0 111.963 -177.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.3 mm -102.3 127.99 55.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.706 0.289 . . . . 0.0 110.416 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 30' ' ' ILE . 21.8 t -67.0 111.46 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.854 0.359 . . . . 0.0 110.198 177.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -87.24 -27.96 22.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.467 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' HA2' ' A' ' 28' ' ' GLY . 7.7 tp10 -67.76 129.78 40.97 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.492 178.068 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -74.09 133.84 42.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.293 0.568 . . . . 0.0 110.811 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 3.5 p -160.78 35.17 0.15 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.18 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 32.7 mm-40 72.38 -51.64 0.7 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.77 -174.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -88.55 42.36 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.308 0.575 . . . . 0.0 110.896 178.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.3 tttm -73.22 127.39 32.49 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.27 -2.2 29.66 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.166 -176.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -77.37 150.6 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.228 0.537 . . . . 0.0 111.939 178.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 36.0 t -101.36 131.93 47.17 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.782 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.498 ' HB ' ' HG3' ' A' ' 78' ' ' PRO . 31.2 m -105.53 4.72 10.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.964 0.411 . . . . 0.0 110.877 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.76 92.17 1.99 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.55 0.69 . . . . 0.0 111.242 -174.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 105.65 12.07 27.3 Favored Glycine 0 C--N 1.315 -0.595 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.635 176.245 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -110.46 175.3 5.48 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 54.1 mt -110.19 121.24 62.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.562 ' HB3' HG22 ' A' ' 81' ' ' ILE . 54.4 tp -91.46 120.26 32.13 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.746 -174.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.669 ' HB ' ' HA ' ' A' ' 19' ' ' VAL . 67.5 t -101.99 107.97 22.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.785 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 51.4 t80 -133.99 143.3 46.77 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -173.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.523 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 23.8 Cg_endo -62.95 -36.92 57.31 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 121.955 1.77 . . . . 0.0 111.505 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.025 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.287 176.932 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.605 0.241 . . . . 0.0 111.63 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.482 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 26.8 m -67.15 -31.99 55.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.025 -178.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.42 -36.78 77.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.932 0.396 . . . . 0.0 110.357 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.441 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.4 tp -66.15 -39.9 90.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.764 176.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -60.05 -48.61 81.0 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.587 176.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.549 HD23 ' HA ' ' A' ' 32' ' ' LYS . 96.3 mt -57.45 -47.62 81.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.964 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.41 ' HB2' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -66.07 -37.39 85.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -177.393 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.8 mmtt -61.4 -30.2 70.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.5 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.574 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.6 t-20 -89.64 -22.78 22.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.195 0.522 . . . . 0.0 109.877 178.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.27 16.49 55.5 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.385 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.667 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 32.2 m -106.94 13.81 8.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.084 0.469 . . . . 0.0 110.821 -176.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.88 49.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.935 -179.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.498 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 13.1 Cg_exo -68.33 143.12 57.1 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.195 1.93 . . . . 0.0 110.185 170.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.465 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 94.8 mttt -61.58 -33.92 74.71 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.165 0.507 . . . . 0.0 110.618 -179.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.62 155.25 34.36 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.438 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.562 HG22 ' HB3' ' A' ' 53' ' ' LEU . 16.1 pt -124.65 114.76 42.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.082 175.308 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.752 HG23 HG23 ' A' ' 102' ' ' VAL . 4.4 mm -102.86 116.78 47.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.785 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -115.1 175.96 5.27 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.822 0.344 . . . . 0.0 111.154 -173.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -101.37 -40.81 6.92 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 171.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 85' ' ' LYS . 68.4 mmtt -125.15 114.41 18.98 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.502 177.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.1 t -81.15 154.99 26.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.042 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.29 142.38 51.55 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.511 ' O ' HG23 ' A' ' 92' ' ' VAL . 18.1 m -56.26 -50.02 72.56 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 123.536 0.522 . . . . 0.0 112.033 -174.483 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 72.1 mt -65.24 -44.96 95.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 121.054 0.454 . . . . 0.0 110.702 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.455 HD13 ' CD1' ' A' ' 26' ' ' PHE . 63.9 mt -63.98 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.693 -179.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.4 -41.58 94.18 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 88' ' ' THR . 98.9 t -61.86 -44.56 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.54 178.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.6 -44.76 97.08 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.358 179.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.421 ' HB3' HD23 ' A' ' 101' ' ' LEU . . . -67.02 -30.96 71.19 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.594 0.235 . . . . 0.0 111.131 179.296 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.72 -38.11 88.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.541 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.435 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 61.0 mtt -64.26 -45.92 86.01 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.516 0.674 . . . . 0.0 109.91 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -80.14 -1.65 41.19 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 114.992 -1.004 . . . . 0.0 111.697 -175.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 58.9 43.17 18.45 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 121.25 0.548 . . . . 0.0 110.569 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.2 mm -104.18 91.08 3.51 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.751 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.679 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 9.3 Cg_endo -49.96 100.41 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.558 2.838 . . . . 0.0 112.667 -176.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 94' ' ' ALA . 1.5 pp -102.43 137.0 41.25 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.235 0.54 . . . . 0.0 109.994 179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.752 HG23 HG23 ' A' ' 82' ' ' ILE . 35.1 m -135.17 159.23 41.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 8.3 pt-20 -121.06 135.57 55.17 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.365 0.602 . . . . 0.0 111.838 -178.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.571 HG11 ' HB2' ' A' ' 109' ' ' PHE . 32.4 t -115.9 105.04 17.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 170.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 105' ' ' ARG . 14.1 ptt180 -84.16 35.85 0.55 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.95 -170.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -138.55 145.12 40.28 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.679 176.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -71.22 -23.93 62.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.171 -176.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -60.28 -29.24 68.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.582 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.571 ' HB2' HG11 ' A' ' 104' ' ' VAL . 84.6 t80 -61.25 -46.46 90.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.985 0.422 . . . . 0.0 110.312 177.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -71.97 -22.61 61.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.243 -175.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.8 mm-40 -79.04 -36.62 40.71 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.346 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.67 -42.44 22.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.87 -176.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.0 p -79.86 138.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.014 0.435 . . . . 0.0 110.345 -177.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.3 mttp -122.77 151.61 41.45 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.045 -177.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.572 HG23 ' HA ' ' A' ' 18' ' ' LEU . 33.1 m -71.56 95.76 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.101 0.476 . . . . 0.0 109.921 176.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.2 1.95 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.268 -177.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -77.78 166.98 22.27 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.4 177.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.748 HH21 HG13 ' A' ' 131' ' ' ILE . 2.2 tmm_? -107.67 122.87 47.59 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.372 0.606 . . . . 0.0 109.863 -176.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.412 HG23 ' HB2' ' A' ' 17' ' ' ALA . 91.3 t -119.57 139.33 47.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.262 -175.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.9 t -117.05 111.82 36.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.319 171.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.525 HG21 HD11 ' A' ' 82' ' ' ILE . 55.1 t -107.56 117.53 53.45 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.285 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . 0.744 HD21 ' HB2' ' A' ' 124' ' ' ASP . 9.8 t30 -109.97 118.02 35.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 177.013 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -101.15 8.01 42.91 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.37 -174.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.744 ' HB2' HD21 ' A' ' 122' ' ' ASN . 53.5 m-20 -64.99 -41.43 95.43 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 176.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -117.9 -33.43 4.48 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 173.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 108.93 91.84 2.19 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.195 172.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.404 ' HE1' ' HB2' ' A' ' 129' ' ' GLU . 25.6 p90 -159.66 153.35 22.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.949 0.404 . . . . 0.0 110.322 174.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.589 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 84.9 t -116.15 111.21 34.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.831 178.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HB2' ' HE1' ' A' ' 127' ' ' TYR . 26.3 tt0 -92.62 108.37 19.92 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.248 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 59.2 tp -94.6 114.07 25.98 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.908 -176.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.748 HG13 HH21 ' A' ' 118' ' ' ARG . 33.5 mm -111.58 116.95 53.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.364 174.346 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.876 -179.299 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.234 0.238 0 CA-C-O 120.963 0.411 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -126.98 140.78 52.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.937 -174.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -133.59 149.09 51.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.437 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.79 131.72 45.59 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.649 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.0 m -122.09 169.09 11.2 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.321 176.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -96.2 134.59 39.1 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 174.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.23 96.6 4.59 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.922 0.391 . . . . 0.0 111.473 -174.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.494 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 43.8 mm -82.81 -49.37 16.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 174.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.581 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -109.22 176.19 5.18 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 172.604 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.471 ' H ' HG22 ' A' ' 9' ' ' THR . 63.9 mtt180 -126.23 178.13 6.0 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.48 -0.193 . . . . 0.0 110.48 -179.11 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 124' ' ' ASP . . . 97.19 -162.39 21.79 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -174.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -156.41 148.01 22.68 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.695 0.283 . . . . 0.0 110.496 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.407 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -149.66 151.56 33.94 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -137.82 127.77 25.65 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.958 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.64 172.14 39.47 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.324 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -70.38 128.87 37.69 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.005 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.539 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.92 141.69 34.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.267 0.556 . . . . 0.0 111.712 -175.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.5 tt -121.24 114.09 20.88 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 177.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.0 t -102.79 110.84 30.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.196 0.522 . . . . 0.0 111.674 -173.627 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 20' ' ' THR . 9.7 t -152.36 95.63 2.06 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 172.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 0.1 OUTLIER -67.77 -72.2 0.18 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.154 -174.257 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.832 ' HG2' ' HB3' ' A' ' 41' ' ' CYS . 0.3 OUTLIER 51.15 -163.52 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 O-C-N 123.469 0.48 . . . . 0.0 111.794 178.368 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 13.3 p90 -158.59 44.49 0.29 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.443 0.639 . . . . 0.0 110.045 176.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.5 pt -73.29 177.84 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.721 -177.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.1 t -88.22 128.52 35.46 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.338 -178.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -82.91 91.19 7.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -124.97 -77.49 0.59 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.033 177.002 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.45 59.17 0.41 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.6 15.65 45.26 Favored Glycine 0 C--O 1.226 -0.387 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 -177.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.443 HD13 HG21 ' A' ' 48' ' ' VAL . 58.2 mt -134.31 134.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 15.2 t70 -66.26 135.59 54.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.679 0.276 . . . . 0.0 110.357 178.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -81.21 -7.45 59.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -173.012 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -117.65 -30.43 5.47 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.619 HG23 HG12 ' A' ' 36' ' ' ILE . 7.8 t -123.16 -4.88 8.41 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 120.104 -0.638 . . . . 0.0 112.519 179.247 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 70.35 27.95 72.0 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.87 -0.681 . . . . 0.0 113.446 176.202 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.619 HG12 HG23 ' A' ' 34' ' ' THR . 42.5 mm -87.97 129.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 176.447 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.89 128.69 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.019 0.438 . . . . 0.0 111.032 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 74.3 mmtt -87.67 -41.43 13.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.669 -179.123 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -89.97 122.19 32.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.87 -172.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.623 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 21.7 t70 -74.35 133.51 42.52 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.359 0.599 . . . . 0.0 111.087 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.832 ' HB3' ' HG2' ' A' ' 22' ' ' GLU . 59.0 m -123.11 -28.09 4.09 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.896 178.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 175.52 -62.25 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 pt -114.79 71.02 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.295 179.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.623 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 13.3 tmtt? -93.74 140.76 29.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.698 -178.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 136.62 -8.1 3.95 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.915 175.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -103.89 173.02 6.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.239 0.542 . . . . 0.0 111.58 -175.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 m -93.36 137.7 32.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.653 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.443 HG21 HD13 ' A' ' 30' ' ' ILE . 29.7 m -100.76 2.7 10.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.972 0.415 . . . . 0.0 110.399 174.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.32 94.76 0.17 Allowed 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.861 -177.151 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.482 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 97.43 14.04 42.69 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 114.756 -1.111 . . . . 0.0 112.634 176.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 82.4 mtt180 -104.69 164.85 11.46 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.669 0.271 . . . . 0.0 110.574 176.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.505 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.5 mm -95.93 111.46 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.077 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' HG22 ' A' ' 81' ' ' ILE . 18.3 tp -101.7 125.86 48.45 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -173.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.4 t -113.75 128.61 70.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.958 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -131.99 145.87 59.27 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.46 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 60.2 Cg_endo -76.83 -50.31 0.1 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.624 2.216 . . . . 0.0 112.002 175.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.424 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.442 -177.83 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 85.7 m-85 . . . . . 0 N--CA 1.471 0.597 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.77 -39.14 76.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.7 mt -65.07 -34.83 79.35 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.716 0.293 . . . . 0.0 110.847 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.3 tp -65.06 -44.71 88.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.405 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -64.26 -41.49 96.91 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.409 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.57 -38.39 86.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.798 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.468 ' CG ' HD11 ' A' ' 99' ' ' ILE . 2.7 tmt_? -72.04 -39.48 69.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.528 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -64.16 -30.94 71.97 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.278 0.561 . . . . 0.0 110.336 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -84.86 -22.91 29.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.0 178.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.49 23.79 38.64 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.747 176.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.05 -0.26 9.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.057 0.456 . . . . 0.0 111.269 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.14 162.59 40.05 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.685 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.03 147.8 88.44 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.229 1.953 . . . . 0.0 111.099 172.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.482 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 80.3 tttt -73.72 -26.15 60.56 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.05 0.452 . . . . 0.0 110.43 -175.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -166.71 150.19 6.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.753 176.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.511 HG22 ' HB3' ' A' ' 53' ' ' LEU . 15.7 pt -126.69 123.31 62.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.922 0.391 . . . . 0.0 110.564 178.381 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.694 HG23 HG23 ' A' ' 102' ' ' VAL . 5.4 mm -111.01 120.56 61.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.264 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.553 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 12.4 m120 -129.96 167.15 18.67 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -176.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -104.68 -38.83 6.57 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.4 tttp -128.58 103.43 7.1 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.218 174.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.9 t -112.0 156.8 21.57 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 175.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -79.46 145.93 33.01 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -56.87 -34.01 67.42 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.182 0.515 . . . . 0.0 110.986 -176.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 54.8 mt -64.45 -41.15 91.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.822 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.9 mt -71.83 -42.17 69.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.542 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.61 -47.11 80.35 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.304 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.408 ' O ' ' HG3' ' A' ' 96' ' ' MET . 90.1 t -68.22 -42.25 84.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.615 179.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.97 99.15 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.352 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.54 -40.06 92.46 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.785 0.326 . . . . 0.0 110.833 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.506 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -63.64 -37.18 86.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.941 179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.408 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 89.4 mtp -68.39 -37.73 80.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.683 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.14 -1.28 57.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.342 -175.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 62.36 47.32 5.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.414 0.626 . . . . 0.0 110.467 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.468 HD11 ' CG ' ' A' ' 72' ' ' ARG . 44.2 mm -107.29 90.55 5.82 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.587 175.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.3 Cg_endo -48.48 96.51 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.421 2.747 . . . . 0.0 113.277 -175.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.494 ' O ' ' HB ' ' A' ' 8' ' ' ILE . 5.8 tt -102.29 126.0 49.16 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.694 HG23 HG23 ' A' ' 82' ' ' ILE . 11.0 m -127.71 150.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.257 176.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.553 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 6.5 tm-20 -97.8 114.9 27.04 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.507 -177.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 82' ' ' ILE . 14.4 m -71.57 134.12 30.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.333 0.587 . . . . 0.0 111.832 -177.123 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.559 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 1.0 OUTLIER -84.94 -33.95 22.57 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.363 -179.548 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -112.5 140.36 47.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.185 -172.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.34 -20.67 62.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.315 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mmtt -57.54 -24.15 54.46 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.905 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.412 ' CD2' HG11 ' A' ' 104' ' ' VAL . 92.7 t80 -60.65 -46.23 91.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.691 0.281 . . . . 0.0 110.508 178.049 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -65.07 -31.46 72.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.544 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -79.69 -30.91 41.23 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.976 -178.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.38 -33.01 17.02 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.371 -175.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 14.8 p -64.1 134.82 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.083 0.468 . . . . 0.0 110.841 -177.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -116.89 139.57 50.47 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.886 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.4 m -71.34 99.92 2.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.216 175.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.73 -31.6 2.92 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.666 179.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -85.47 161.27 19.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.861 0.362 . . . . 0.0 111.616 -177.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.864 HH21 HG13 ' A' ' 131' ' ' ILE . 18.0 ttp180 -89.17 127.37 35.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.248 0.547 . . . . 0.0 111.61 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.539 HG23 ' HB2' ' A' ' 17' ' ' ALA . 96.2 t -108.13 120.91 60.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.742 175.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.84 101.63 12.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 176.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 3.2 p -102.18 114.88 42.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 121.381 0.61 . . . . 0.0 110.907 -178.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -101.94 93.64 5.38 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 175.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.29 -26.68 62.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.374 -173.147 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.501 ' HB2' ' H ' ' A' ' 11' ' ' GLY . 25.8 t70 -63.38 -22.6 66.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.234 -177.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -120.11 -1.44 10.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.719 0.295 . . . . 0.0 110.708 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.18 62.66 5.42 Favored Glycine 0 C--N 1.332 0.356 0 CA-C-N 116.053 -0.521 . . . . 0.0 112.376 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -152.13 141.8 21.84 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.37 -0.488 . . . . 0.0 110.308 -177.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.5 m -122.97 136.28 60.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.199 0.524 . . . . 0.0 111.441 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -120.73 114.66 21.98 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.379 177.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 42.0 tp -90.49 125.18 35.51 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.864 HG13 HH21 ' A' ' 118' ' ' ARG . 19.3 mm -101.36 111.61 31.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.309 -1.181 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.441 -175.828 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.413 ' HB3' ' HE2' ' A' ' 2' ' ' LYS . 14.3 ptpt -145.18 148.87 34.04 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.815 0.341 . . . . 0.0 111.215 -177.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -136.44 152.95 51.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.734 -0.667 . . . . 0.0 109.977 179.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.79 114.09 25.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.209 175.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.725 ' SG ' HG12 ' A' ' 104' ' ' VAL . 83.9 m -120.24 176.93 5.22 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.215 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.9 tpm_? -94.73 119.84 34.0 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.119 -172.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 102' ' ' VAL . . . -86.69 142.55 28.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.174 -179.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.2 mp -105.97 -54.65 6.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.3 p -98.4 161.31 13.75 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 170.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.573 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 46.0 mtm180 -123.73 -175.85 3.32 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 119.574 -0.85 . . . . 0.0 112.681 -174.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.85 -164.89 14.07 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 -169.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.5 ttp180 -148.76 143.47 26.41 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 117.542 0.671 . . . . 0.0 109.789 177.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.567 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -154.52 152.15 29.74 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.716 0.293 . . . . 0.0 110.96 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.414 ' O ' ' HD2' ' A' ' 79' ' ' LYS . 0.1 OUTLIER -147.81 161.21 41.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.494 178.84 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 147.85 -160.54 28.35 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.155 -1.022 . . . . 0.0 112.453 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -64.4 124.09 20.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.986 0.422 . . . . 0.0 110.444 177.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.84 117.22 21.3 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.254 179.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.505 HD12 HG23 ' A' ' 115' ' ' THR . 13.4 tp -96.54 108.82 21.46 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.42 112.73 40.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.319 0.58 . . . . 0.0 110.96 -174.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -116.45 101.15 8.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.308 176.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -73.59 -12.09 60.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.401 -175.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -71.84 130.12 40.29 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.051 0.453 . . . . 0.0 110.154 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -78.53 69.92 4.8 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.407 0.622 . . . . 0.0 111.338 -177.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -82.14 152.63 4.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.226 176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -116.58 174.73 5.91 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.326 -173.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.493 ' O ' ' HB3' ' A' ' 27' ' ' LEU . 85.3 m-85 -82.97 -163.34 0.71 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.89 -0.596 . . . . 0.0 109.987 175.623 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.5 ' HG ' ' O ' ' A' ' 27' ' ' LEU . 64.9 tp 72.24 14.91 5.46 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.996 0.903 . . . . 0.0 109.831 -176.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.82 44.8 0.12 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.817 177.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.63 -72.51 1.21 Allowed Glycine 0 N--CA 1.452 -0.285 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 174.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.0 mp -85.84 133.31 29.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 170.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.527 ' HB2' ' HG2' ' A' ' 38' ' ' LYS . 29.0 t70 -72.74 146.08 46.66 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.309 0.576 . . . . 0.0 111.475 -175.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HG2' ' HG3' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -82.94 -11.68 57.96 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.958 -173.102 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.538 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 31.0 mt-10 -110.29 -41.32 4.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.636 0.255 . . . . 0.0 111.48 -174.383 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 42.4 p -100.86 -23.01 14.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -177.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.504 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.3 16.84 80.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.521 -175.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.3 mm -99.58 143.78 13.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.5 t -67.98 115.14 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.67 0.271 . . . . 0.0 110.395 177.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.527 ' HG2' ' HB2' ' A' ' 31' ' ' ASP . 30.3 mmtp -81.83 -26.67 34.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.65 146.5 53.77 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.86 -178.496 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -77.28 136.92 38.53 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.546 -177.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 53.1 t -165.22 167.66 17.81 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -177.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -63.8 -36.18 83.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.322 0.582 . . . . 0.0 109.464 175.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.649 ' O ' ' HG2' ' A' ' 46' ' ' GLU . 13.6 pt -108.19 53.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.327 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.607 ' NZ ' ' HB3' ' A' ' 44' ' ' LYS . 0.0 OUTLIER -77.94 132.95 38.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 177.89 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.78 8.51 34.48 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.602 179.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.649 ' HG2' ' O ' ' A' ' 43' ' ' ILE . 32.2 mm-40 -63.53 146.97 52.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.227 0.537 . . . . 0.0 110.888 178.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.0 m -106.34 107.58 18.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.179 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.2 m -82.26 0.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.941 -175.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.23 89.15 0.45 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.298 0.571 . . . . 0.0 111.452 -175.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.91 8.58 29.65 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.401 -0.818 . . . . 0.0 113.003 174.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.6 mpt_? -103.78 172.44 6.8 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.753 0.311 . . . . 0.0 111.057 -179.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 50.1 mm -99.92 104.09 15.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 171.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 45.3 tp -85.71 113.7 22.11 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.342 -170.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -119.66 106.89 19.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.108 0.48 . . . . 0.0 110.496 178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.424 ' HD1' ' HG ' ' A' ' 53' ' ' LEU . 34.2 p90 -136.97 149.86 67.84 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.82 176.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -63.79 -49.6 3.97 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.106 1.871 . . . . 0.0 110.464 172.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.52 0 CA-C-N 115.41 -0.814 . . . . 0.0 113.061 175.624 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 . . . . . 0 N--CA 1.472 0.643 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.508 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 46.8 t -54.31 -45.56 68.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.755 0.312 . . . . 0.0 111.564 -177.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HB3' HD12 ' A' ' 99' ' ' ILE . 84.3 mt -61.28 -36.28 79.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.632 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.71 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 60.4 tp -69.74 -39.76 76.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -59.44 -48.79 80.28 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.876 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 85.2 mt -57.55 -41.08 80.26 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.778 -0.647 . . . . 0.0 111.437 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -71.71 -40.23 69.61 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.306 -178.31 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.475 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 68.3 mttm -62.61 -34.85 77.86 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.248 0.547 . . . . 0.0 109.981 175.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.521 ' HB3' HG22 ' A' ' 76' ' ' VAL . 37.8 t-20 -72.23 -34.0 67.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.008 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.27 6.98 57.45 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.087 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.521 HG22 ' HB3' ' A' ' 74' ' ' ASN . 28.8 m -103.41 10.07 8.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.025 0.441 . . . . 0.0 111.228 -176.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.33 147.12 49.31 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.133 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.77 160.18 49.42 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.683 176.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.528 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 96.6 mttt -69.29 -38.16 78.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.96 0.409 . . . . 0.0 110.251 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 13' ' ' ALA . . . -148.71 158.83 44.42 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.477 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 73.9 mt -132.98 119.58 37.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.88 178.576 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.753 HD12 HG22 ' A' ' 102' ' ' VAL . 9.1 mm -114.2 120.17 63.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.48 172.62 7.21 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.753 0.311 . . . . 0.0 110.465 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 88.0 tttt -91.65 -43.2 9.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.286 0.565 . . . . 0.0 109.55 173.01 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -112.28 118.48 35.39 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.39 177.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.8 t -82.69 159.19 22.67 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.088 177.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.473 ' OE1' HG12 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -144.9 151.65 39.01 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.779 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.484 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.6 m -53.56 -48.51 69.08 Favored 'General case' 0 C--N 1.323 -0.549 0 O-C-N 123.735 0.647 . . . . 0.0 111.036 178.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.473 HG12 ' OE1' ' A' ' 87' ' ' GLU . 31.5 pt -62.77 -35.21 69.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.85 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.486 HG22 HD22 ' A' ' 101' ' ' LEU . 58.1 mt -70.28 -45.04 76.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.67 -45.72 91.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.849 178.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.59 ' O ' ' HG2' ' A' ' 96' ' ' MET . 69.5 t -58.43 -50.88 77.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.43 -43.09 98.76 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.656 -177.364 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.47 -31.22 63.64 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -176.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -66.04 -33.77 76.57 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.689 0.281 . . . . 0.0 110.94 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.59 ' HG2' ' O ' ' A' ' 92' ' ' VAL . 19.2 mmt -66.65 -44.5 81.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.576 0.703 . . . . 0.0 110.596 179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.722 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -95.18 -0.39 53.28 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 114.878 -1.055 . . . . 0.0 112.125 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 56.52 64.58 1.64 Allowed 'General case' 0 C--O 1.235 0.31 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -172.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.534 HD12 ' HB3' ' A' ' 68' ' ' LEU . 54.9 mt -113.6 89.84 16.53 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.811 177.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.458 ' HB3' ' CB ' ' A' ' 123' ' ' ALA . 77.7 Cg_exo -50.14 113.24 0.93 Allowed 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 123.07 2.513 . . . . 0.0 112.564 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.486 HD22 HG22 ' A' ' 90' ' ' ILE . 1.7 pp -125.54 133.8 52.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.233 0.539 . . . . 0.0 110.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.753 HG22 HD12 ' A' ' 82' ' ' ILE . 5.3 m -126.48 152.51 34.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 175.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.634 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 11.9 pt-20 -99.42 119.87 38.69 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.192 0.52 . . . . 0.0 110.268 178.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.725 HG12 ' SG ' ' A' ' 5' ' ' CYS . 33.1 m -97.2 153.71 3.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 3.4 tmt_? -127.62 -15.55 4.98 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.037 0.446 . . . . 0.0 110.842 -176.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.475 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 5.0 t70 -94.49 138.14 32.77 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.407 -170.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -71.73 -30.99 66.22 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.759 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.475 ' HE2' ' OD1' ' A' ' 106' ' ' ASP . 46.4 mtmt -59.94 -28.19 67.42 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.652 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.524 ' O ' HG12 ' A' ' 113' ' ' VAL . 81.6 t80 -65.41 -48.24 73.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.504 177.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -68.15 -26.83 65.97 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.009 -175.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 114' ' ' LYS . 3.3 mm-40 -84.76 -36.55 21.67 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.756 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -67.65 -39.85 84.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.916 0.388 . . . . 0.0 110.751 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 109' ' ' PHE . 8.4 p -93.11 140.01 17.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.662 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.476 ' NZ ' ' HA ' ' A' ' 111' ' ' GLU . 43.1 mmtm -142.12 155.26 45.34 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.777 175.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.505 HG23 HD12 ' A' ' 18' ' ' LEU . 17.3 m -57.46 116.04 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.806 -176.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.73 -34.84 2.23 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.268 -0.967 . . . . 0.0 113.658 175.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -92.29 -174.6 3.78 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.438 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.12 142.87 41.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.221 0.534 . . . . 0.0 111.879 -168.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' A' ' 130' ' ' LEU . 9.9 p -141.17 140.65 31.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.28 174.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.1 t -108.9 119.83 59.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.862 178.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.455 HG22 HG13 ' A' ' 128' ' ' VAL . 53.3 t -114.24 114.6 47.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.113 0.482 . . . . 0.0 111.044 -177.703 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -100.46 99.67 10.32 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -76.74 -8.03 56.51 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.413 -174.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.573 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 20.4 t70 -65.26 -37.87 88.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.091 0.472 . . . . 0.0 109.95 177.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -102.29 -28.23 12.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.619 179.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.98 61.15 1.78 Allowed Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -166.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -136.24 124.28 22.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -165.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 121' ' ' VAL . 21.2 t -123.87 113.67 38.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.712 0.291 . . . . 0.0 110.583 -175.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -107.99 114.58 28.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.379 177.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' A' ' 119' ' ' VAL . 44.8 tp -85.84 129.57 34.79 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 11.2 tt -126.46 113.78 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-O 122.196 0.998 . . . . 0.0 110.347 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.227 0 CA-C-N 113.91 -1.495 . . . . 0.0 109.704 -173.99 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.551 HG23 ' HG3' ' A' ' 2' ' ' LYS . 20.8 m . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.551 ' HG3' HG23 ' A' ' 1' ' ' VAL . 51.8 mttm 69.03 93.21 0.08 Allowed 'General case' 0 N--CA 1.469 0.49 0 O-C-N 123.454 0.471 . . . . 0.0 110.36 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -121.46 149.97 42.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.949 -175.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.14 134.74 41.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.096 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 104' ' ' VAL . 82.9 m -128.46 175.86 8.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.049 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.63 ' HB3' ' HG2' ' A' ' 103' ' ' GLU . 50.2 ttt180 -93.87 120.63 34.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 178.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.566 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -91.29 112.69 24.7 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.976 0.417 . . . . 0.0 111.915 -175.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.6 mp -81.45 -51.47 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.607 177.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.3 p -101.94 -173.67 2.4 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.342 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.648 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 65.8 mmt-85 -124.76 175.23 7.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.558 0.218 . . . . 0.0 110.497 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.64 173.05 25.77 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 12' ' ' ARG . 12.5 ptt180 -142.14 151.13 41.95 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 117.276 0.538 . . . . 0.0 110.802 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.524 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -140.73 138.02 33.89 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.742 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.565 ' HG3' HG22 ' A' ' 120' ' ' VAL . 28.0 tt0 -129.19 122.45 29.78 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.944 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 178.61 -160.4 26.25 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 119.93 -1.129 . . . . 0.0 113.028 176.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.533 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 27.1 mt-10 -70.36 134.19 47.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 122.635 0.374 . . . . 0.0 111.008 -177.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -91.23 125.32 35.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.012 0.434 . . . . 0.0 110.843 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.641 ' HB3' HD13 ' A' ' 53' ' ' LEU . 5.8 tp -117.82 118.49 32.17 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.9 t -102.01 127.05 55.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.208 0.528 . . . . 0.0 111.576 -173.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.475 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 19.2 m -126.18 108.49 11.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.647 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -86.22 8.78 19.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.748 0.309 . . . . 0.0 111.546 -174.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.67 143.68 35.81 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.157 0.503 . . . . 0.0 110.742 178.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -81.99 139.14 34.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.411 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.0 pt -127.55 155.95 39.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.763 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 18.6 p -91.81 2.06 56.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.205 -178.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 72.09 -10.12 0.92 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.34 -178.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -94.94 33.03 1.55 Allowed 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 169.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.23 -175.85 50.93 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.301 -0.863 . . . . 0.0 112.899 -174.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.12 40.77 3.02 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 121.427 -0.416 . . . . 0.0 113.751 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 34.2 mt -79.09 112.44 17.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.419 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 24.2 t70 -57.72 129.55 42.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.129 0.49 . . . . 0.0 110.975 -176.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.421 ' H ' ' HG2' ' A' ' 32' ' ' LYS . 44.9 pttt -82.29 -10.53 59.07 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.013 -173.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -93.71 -42.42 9.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -178.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 p -120.37 -5.2 9.88 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.414 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.94 32.39 80.8 Favored Glycine 0 C--N 1.329 0.143 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.339 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 46.7 mm -90.68 121.27 40.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.21 96.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.369 0.604 . . . . 0.0 109.946 176.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.3 mmmm -85.01 -5.99 59.34 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.565 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -69.75 139.08 53.27 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.65 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -77.23 132.94 38.97 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.282 -175.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 12.8 t -172.08 26.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.952 178.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 69.25 -39.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.8 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 35.9 pt -79.97 12.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.465 0.65 . . . . 0.0 110.497 174.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -57.05 122.91 13.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.803 177.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.8 -6.76 24.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.405 -178.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -85.65 148.44 25.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.9 0.381 . . . . 0.0 111.118 177.006 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 39.1 t -95.6 150.19 20.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 176.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.3 m -105.84 3.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.79 178.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.411 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.52 90.64 0.39 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.635 0.731 . . . . 0.0 111.497 -175.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.9 23.31 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.5 175.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.533 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 98.3 mtt180 -116.08 168.18 10.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.79 0.328 . . . . 0.0 110.518 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.44 HD12 ' N ' ' A' ' 52' ' ' ILE . 3.0 mp -107.93 122.92 62.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.641 HD13 ' HB3' ' A' ' 18' ' ' LEU . 4.6 mm? -96.34 138.45 33.92 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.142 0.496 . . . . 0.0 111.452 -175.388 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.94 119.71 61.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.067 177.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.671 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 90.7 m-85 -129.77 144.97 55.1 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.148 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 20' ' ' THR . 13.0 Cg_exo -71.37 -55.27 0.13 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.337 2.025 . . . . 0.0 111.519 175.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.698 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.361 -178.277 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 50.9 p90 . . . . . 0 N--CA 1.464 0.233 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.475 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 10.5 p -60.66 -33.58 55.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.41 -177.603 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 90.0 mt -68.88 -41.0 78.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.183 0.516 . . . . 0.0 110.484 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.1 tp -66.17 -39.53 89.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.949 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -60.21 -43.34 96.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.531 177.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.9 mt -65.86 -38.42 88.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.534 178.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.548 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 5.0 mmm180 -63.54 -42.83 98.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.233 178.099 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 73' ' ' LYS . 6.7 tmtt? -63.71 -29.21 70.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.402 0.62 . . . . 0.0 110.56 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -86.69 -12.27 48.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.117 0.485 . . . . 0.0 110.319 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 77.8 20.49 73.57 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.306 176.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.414 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.3 m -116.29 14.88 7.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.24 0.543 . . . . 0.0 110.929 -177.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -97.45 158.08 33.72 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.651 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.557 ' HB3' HD23 ' A' ' 53' ' ' LEU . 22.9 Cg_exo -65.37 165.43 22.45 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.665 2.243 . . . . 0.0 111.961 176.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.524 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 54.6 mttm -80.8 -40.19 25.42 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.069 0.461 . . . . 0.0 110.245 173.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.585 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -160.36 158.34 29.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.32 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.56 HG22 ' HB2' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -130.05 127.34 63.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.157 0.504 . . . . 0.0 109.648 174.686 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.555 HG23 HG23 ' A' ' 102' ' ' VAL . 6.5 mm -106.91 116.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.235 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.671 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.0 m120 -115.27 158.65 22.05 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -177.038 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 50.4 tttm -81.69 -33.29 31.29 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 170.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' ' HA ' ' A' ' 85' ' ' LYS . 28.1 tptt -153.92 148.09 25.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.249 173.284 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.0 t -140.51 -179.47 6.04 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.731 -0.213 . . . . 0.0 110.88 -175.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.79 160.15 18.26 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 92' ' ' VAL . 9.1 m -58.5 -45.14 89.36 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.082 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 15.2 mm -55.63 -41.56 65.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 111.193 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 27.5 mm -64.15 -45.48 96.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.361 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.79 -41.78 98.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.253 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 88' ' ' THR . 94.8 t -60.68 -44.34 96.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.053 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -68.64 -41.25 84.54 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.076 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.84 -32.65 74.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.646 0.26 . . . . 0.0 111.125 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.37 -44.07 92.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.283 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.6 mtm -75.53 -39.44 58.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.363 -177.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.548 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -79.12 0.19 29.11 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 57.23 53.08 8.08 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.362 0.601 . . . . 0.0 111.403 -177.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 21.7 mm -113.11 88.06 11.67 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.541 178.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.585 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 1.0 OUTLIER -45.64 117.44 1.76 Allowed 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.319 2.679 . . . . 0.0 112.546 -179.614 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.97 121.0 37.99 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.821 -176.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.566 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.7 m -123.84 142.64 39.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.32 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.63 ' HG2' ' HB3' ' A' ' 6' ' ' ARG . 13.3 pt-20 -100.31 129.38 46.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.204 0.526 . . . . 0.0 110.286 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.546 HG22 ' SG ' ' A' ' 5' ' ' CYS . 11.3 t -90.33 138.13 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.896 -177.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 77.7 mtt180 -89.56 -33.63 16.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.006 0.431 . . . . 0.0 110.603 177.07 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -96.6 139.56 32.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.421 0.629 . . . . 0.0 112.09 -168.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -71.93 -26.96 62.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.754 178.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.6 mttm -65.39 -17.88 64.88 Favored 'General case' 0 CA--C 1.521 -0.141 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -176.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 75.5 t80 -60.43 -46.21 90.84 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 174.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 88.1 m-85 -72.0 -28.96 63.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.098 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -66.24 -45.95 78.86 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.463 176.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.13 -47.31 20.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.227 -176.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.52 133.26 30.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 121.362 0.601 . . . . 0.0 111.605 -173.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -122.76 145.99 47.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.584 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.1 m -66.91 100.39 0.72 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 138.3 -16.65 3.39 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.451 -178.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -83.63 175.33 9.81 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.489 176.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.84 HH21 HG13 ' A' ' 131' ' ' ILE . 21.3 ttp180 -111.93 134.25 53.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.989 -178.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.1 p -124.51 138.29 54.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.201 0.524 . . . . 0.0 110.82 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.565 HG22 ' HG3' ' A' ' 14' ' ' GLU . 40.5 t -111.32 106.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.117 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.4 p -104.06 126.58 58.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.333 0.587 . . . . 0.0 110.959 -178.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.7 t30 -114.98 100.55 8.28 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.572 176.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.26 -0.42 52.28 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.8 -176.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.648 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 28.3 t70 -67.89 -39.15 83.7 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.967 175.047 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -104.8 -30.6 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.303 177.067 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.48 ' HA2' ' HB2' ' A' ' 7' ' ' ALA . . . 96.5 57.61 1.11 Allowed Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -173.059 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 50.8 t80 -138.28 124.69 20.59 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 128' ' ' VAL . 10.8 p -117.35 107.21 21.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.972 0.891 . . . . 0.0 110.106 -178.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.536 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 31.2 tt0 -105.61 108.22 19.62 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.765 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 44.3 tp -84.68 124.83 31.93 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.93 176.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.84 HG13 HH21 ' A' ' 118' ' ' ARG . 23.6 mm -97.66 118.9 44.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--N 1.312 -1.033 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.31 -177.43 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.509 HG23 ' HB3' ' A' ' 130' ' ' LEU . 18.4 m . . . . . 0 N--CA 1.455 -0.199 0 CA-C-O 121.172 0.511 . . . . 0.0 111.037 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.576 ' HB3' ' CE2' ' A' ' 127' ' ' TYR . 53.6 mtmt -129.99 117.71 20.49 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.159 -178.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -115.25 164.71 13.83 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.626 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.44 135.96 53.53 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.874 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' HG21 ' A' ' 102' ' ' VAL . 6.4 p -121.74 168.7 11.52 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.96 0.41 . . . . 0.0 111.136 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.807 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 65.4 ttt180 -95.25 109.21 21.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.705 177.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.636 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -67.23 117.7 9.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.793 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.431 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 50.1 mm -101.51 -60.66 2.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.596 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.6 OUTLIER -96.69 174.44 6.82 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 172.014 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 9' ' ' THR . 52.2 mtt180 -126.53 167.9 14.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.942 0.401 . . . . 0.0 111.327 -176.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.82 159.96 9.38 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.711 -175.017 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.1 mtp85 -128.35 114.57 17.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.609 0.243 . . . . 0.0 110.506 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.468 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -139.21 146.27 40.3 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.056 0.455 . . . . 0.0 111.604 -175.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -133.45 148.25 51.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.334 174.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 172.34 -160.19 31.43 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.306 174.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.681 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.0 mt-10 -70.51 129.77 40.12 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 120.968 0.414 . . . . 0.0 110.843 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.566 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.01 117.3 21.49 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.006 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.536 HD12 HG23 ' A' ' 115' ' ' THR . 12.0 tp -105.71 115.4 30.18 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 176.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.425 ' HA ' ' CG2' ' A' ' 54' ' ' VAL . 11.3 p -100.4 110.8 28.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 122.049 0.928 . . . . 0.0 111.074 -172.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.465 HG23 HG13 ' A' ' 43' ' ' ILE . 10.1 m -106.0 88.92 2.92 Favored 'General case' 0 N--CA 1.44 -0.962 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.031 178.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' ' OE2' ' A' ' 22' ' ' GLU . 21.0 pttp -76.55 -1.06 25.52 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.119 176.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.539 ' OE2' ' HG3' ' A' ' 21' ' ' LYS . 8.5 mm-40 -92.43 160.68 14.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.382 178.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 9.7 p90 -112.67 104.99 13.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.336 0.588 . . . . 0.0 110.322 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.3 mp -100.52 130.24 50.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.993 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.7 p -71.54 121.76 19.28 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -72.97 87.44 1.33 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.248 0.547 . . . . 0.0 111.41 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.425 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.3 tm? -134.86 -68.08 0.54 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.128 176.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -142.1 177.4 21.5 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.653 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.19 -62.76 0.61 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.521 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 57.4 mt -69.67 124.43 25.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.641 0.258 . . . . 0.0 110.626 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -59.21 133.11 55.8 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.513 177.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.459 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 33.5 mmtp -67.09 -21.26 65.88 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.291 0.567 . . . . 0.0 110.098 177.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -100.01 -58.52 1.9 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.738 -172.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.508 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -87.96 -14.03 40.23 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.753 0.649 . . . . 0.0 112.753 -175.379 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.641 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 67.14 29.69 74.78 Favored Glycine 0 CA--C 1.518 0.261 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.598 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.508 HG12 ' HB ' ' A' ' 34' ' ' THR . 47.4 mm -103.84 133.02 48.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 3.9 p -80.32 105.33 9.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.607 0.717 . . . . 0.0 110.308 178.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -80.08 -19.64 46.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.094 -179.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -69.48 135.79 50.63 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.567 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 34.1 t70 -83.87 130.36 34.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.48 -175.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 22' ' ' GLU . 5.8 t 173.56 50.5 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 123.927 0.767 . . . . 0.0 109.23 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 72.42 -47.86 0.67 Allowed 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 123.509 0.724 . . . . 0.0 112.208 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.465 HG13 HG23 ' A' ' 20' ' ' THR . 33.4 mm -77.17 -10.4 13.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.063 0.459 . . . . 0.0 111.078 -176.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.567 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 61.8 tttp -52.89 124.08 13.19 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.976 -0.557 . . . . 0.0 111.663 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.56 -16.67 28.84 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.696 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -87.03 162.43 17.62 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.223 0.535 . . . . 0.0 112.019 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 33.2 p -102.43 150.42 23.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.623 179.242 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.447 HG21 HD13 ' A' ' 30' ' ' ILE . 2.8 t -108.68 -0.04 9.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.367 0.603 . . . . 0.0 110.159 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.32 91.62 0.55 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.833 -171.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.589 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 90.86 23.6 29.9 Favored Glycine 0 C--N 1.317 -0.525 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.21 172.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.681 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 97.5 mtt180 -111.09 169.32 8.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.867 0.365 . . . . 0.0 111.358 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.438 HD12 ' N ' ' A' ' 52' ' ' ILE . 2.3 mp -109.68 113.02 43.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 11.1 mp -102.54 132.45 48.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.962 0.41 . . . . 0.0 111.383 -174.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.529 HG12 ' HB ' ' A' ' 82' ' ' ILE . 10.5 m -109.41 130.95 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.672 176.278 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.589 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 92.7 m-85 -130.49 145.2 56.45 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.421 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.85 -33.63 33.11 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.254 1.97 . . . . 0.0 111.507 174.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.761 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.133 177.854 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 . . . . . 0 N--CA 1.476 0.849 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.87 -42.17 61.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.715 0.293 . . . . 0.0 111.515 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.68 -32.47 72.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.922 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.547 ' HG ' ' HE2' ' A' ' 73' ' ' LYS . 56.8 tp -68.51 -42.83 77.99 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -59.13 -43.91 92.02 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.318 177.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.459 ' CD2' ' HA ' ' A' ' 32' ' ' LYS . 87.8 mt -64.99 -38.62 91.55 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.547 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -68.63 -38.68 80.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.388 -178.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.547 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 52.5 mttm -60.32 -34.27 73.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.212 0.529 . . . . 0.0 110.716 176.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.1 t30 -86.48 -22.65 26.31 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.819 -177.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.09 20.02 44.27 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.391 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.641 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 28.1 m -112.18 13.92 8.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.103 0.478 . . . . 0.0 110.811 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -96.0 160.12 30.73 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.562 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.74 141.24 71.34 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.187 1.925 . . . . 0.0 111.698 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.589 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 89.0 mttt -68.98 -28.11 66.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 110.52 176.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -160.86 147.85 15.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.695 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 63.9 mt -123.4 117.29 50.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 175.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.544 HG22 ' CG2' ' A' ' 104' ' ' VAL . 3.1 mm -110.57 115.22 49.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.589 ' ND2' ' HB2' ' A' ' 55' ' ' PHE . 15.6 m120 -111.54 153.36 26.35 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.272 -177.346 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.63 ' HA ' ' HB ' ' A' ' 104' ' ' VAL . 2.1 tmtp? -66.96 -45.63 77.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 174.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -142.98 120.88 11.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.238 177.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 3.7 m -86.29 150.11 24.58 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.303 -172.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -118.58 155.18 31.37 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 173.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.3 m -49.77 -51.38 39.65 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 123.31 0.644 . . . . 0.0 112.68 -173.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 61.8 mt -57.04 -41.18 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 121.078 0.466 . . . . 0.0 111.441 -176.276 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 20.4 mt -70.1 -43.31 79.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.384 -177.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.9 -43.98 86.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.539 -178.077 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 88' ' ' THR . 97.5 t -62.1 -43.03 97.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.992 0.425 . . . . 0.0 110.864 -179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.4 -43.38 99.14 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.58 -39.45 62.23 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -177.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.442 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -57.87 -46.54 84.71 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.78 -177.073 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.1 mtm -66.11 -30.73 71.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.923 0.392 . . . . 0.0 111.416 -177.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.546 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -88.46 2.2 53.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.576 -179.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 60.72 41.03 15.55 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.118 0.485 . . . . 0.0 110.884 -177.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.9 90.36 2.9 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.458 177.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.2 Cg_endo -48.33 100.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.603 2.868 . . . . 0.0 113.144 -173.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 3.4 tt -99.68 127.37 45.8 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.411 -0.813 . . . . 0.0 108.919 176.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 7' ' ' ALA . 35.2 m -132.12 159.38 43.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.844 -178.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.807 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 25.3 tt0 -89.11 125.46 35.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.528 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.63 ' HB ' ' HA ' ' A' ' 84' ' ' LYS . 90.8 t -86.18 102.21 11.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.022 0.439 . . . . 0.0 110.602 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -78.99 -35.72 42.5 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.36 0.6 . . . . 0.0 109.639 176.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.612 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 17.7 t70 -89.92 101.87 14.57 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.496 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -70.17 -15.58 62.97 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.005 0.431 . . . . 0.0 111.038 -174.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.612 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 30.9 mmmt -62.1 -24.81 67.35 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.887 177.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -59.8 -38.42 81.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.819 177.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.477 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.1 m-85 -71.64 -22.7 61.65 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.883 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.76 -32.17 46.5 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.248 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -86.43 -30.85 21.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.062 -178.181 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.477 HG12 ' HA ' ' A' ' 110' ' ' PHE . 12.5 p -74.87 127.24 36.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.435 0.636 . . . . 0.0 111.825 -176.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.546 ' HE2' ' HA ' ' A' ' 114' ' ' LYS . 8.9 mmpt? -130.18 161.49 31.01 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.164 175.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.536 HG23 HD12 ' A' ' 18' ' ' LEU . 91.1 m -67.41 125.01 24.77 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.809 0.338 . . . . 0.0 110.89 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 103.79 -1.18 45.16 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.277 176.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -85.88 175.26 8.75 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.497 HH21 HD13 ' A' ' 131' ' ' ILE . 18.1 ttp85 -117.18 120.74 39.22 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.371 0.532 . . . . 0.0 110.855 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.566 HG23 ' HB2' ' A' ' 17' ' ' ALA . 76.6 t -118.89 126.65 75.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.695 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.02 110.14 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.0 p -100.4 118.08 46.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.665 0.745 . . . . 0.0 111.421 -176.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -100.73 94.03 5.87 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.004 175.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.8 1.63 42.05 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 122.03 0.919 . . . . 0.0 108.835 173.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -84.49 -1.83 56.34 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.041 -1.436 . . . . 0.0 109.531 175.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.14 -43.17 0.18 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.632 -176.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.41 52.23 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -175.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.576 ' CE2' ' HB3' ' A' ' 2' ' ' LYS . 12.3 t80 -154.76 140.33 17.91 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -170.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 16.7 m -124.7 127.04 72.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.285 0.564 . . . . 0.0 111.351 -177.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -101.88 111.7 24.06 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.958 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.509 ' HB3' HG23 ' A' ' 1' ' ' VAL . 9.6 tt -108.77 129.68 55.38 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.413 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.497 HD13 HH21 ' A' ' 118' ' ' ARG . 3.8 mp -121.71 111.45 31.04 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.803 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 C--N 1.313 -1.003 0 O-C-N 124.485 1.116 . . . . 0.0 110.48 -175.204 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.563 0.697 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.427 ' HE3' ' HG3' ' A' ' 129' ' ' GLU . 55.9 mtpt -133.58 120.54 20.87 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.411 -175.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.416 ' HB2' ' CG2' ' A' ' 128' ' ' VAL . 92.4 m-85 -97.85 150.02 21.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.425 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -101.14 127.72 47.57 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.629 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.508 ' HB3' HG12 ' A' ' 104' ' ' VAL . 4.3 p -120.59 169.9 9.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.308 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.472 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 24.4 tpt180 -94.05 120.59 34.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.552 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.58 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -70.44 119.73 15.04 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.696 -176.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.2 mm -101.95 -47.47 11.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 174.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.535 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -111.95 -165.73 1.02 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.455 176.966 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 10' ' ' ARG . 54.8 mtt180 -132.76 170.1 15.75 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 176.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 113.95 153.75 11.03 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.018 -178.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.57 ' HG3' ' HA ' ' A' ' 122' ' ' ASN . 1.0 OUTLIER -123.34 126.29 46.58 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 177.834 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.555 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -133.28 132.07 40.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.035 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.36 127.76 55.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.399 -178.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -167.98 -179.39 40.51 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.086 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.66 133.32 42.13 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 177.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.527 ' HB2' HG12 ' A' ' 119' ' ' VAL . . . -80.17 120.48 24.34 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.891 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HA ' HG23 ' A' ' 115' ' ' THR . 8.0 tt -107.76 113.83 27.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.2 t -104.04 111.1 32.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.204 0.526 . . . . 0.0 111.094 -175.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.58 130.7 34.88 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 174.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 21.5 mtpp -92.29 -83.2 0.3 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.24 -172.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 44.84 -163.8 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.58 0.705 . . . . 0.0 112.721 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -147.1 100.98 3.36 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 168.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.445 HD11 ' SG ' ' A' ' 41' ' ' CYS . 58.7 mt -112.26 132.59 60.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.914 0.387 . . . . 0.0 111.369 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.8 p -76.46 124.68 27.94 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 171.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -79.91 39.8 0.44 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.088 0.471 . . . . 0.0 111.711 -174.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.37 -30.61 42.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 173.435 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -157.41 -105.4 0.22 Allowed Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 114.816 -1.084 . . . . 0.0 111.096 178.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.85 -41.48 3.05 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.388 174.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 52.3 mt -115.18 142.12 29.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.847 0.356 . . . . 0.0 110.708 -176.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -73.78 136.3 43.59 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.766 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -83.06 -3.3 57.13 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -173.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -112.12 -52.84 2.76 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 122.169 -0.332 . . . . 0.0 111.297 -176.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.1 m -101.28 -15.91 17.13 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.645 -175.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.62 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.95 21.46 68.14 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.503 -0.855 . . . . 0.0 112.402 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 42.9 mm -89.12 132.33 34.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.4 m -64.46 114.91 2.52 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.45 0.643 . . . . 0.0 110.557 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -78.55 -11.16 59.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.89 177.157 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -94.84 149.88 20.78 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.141 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -79.97 135.16 36.33 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.106 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.497 ' H ' ' HB2' ' A' ' 44' ' ' LYS . 56.6 m -148.98 -170.77 3.71 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -176.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -60.68 -52.32 65.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.835 0.35 . . . . 0.0 110.088 175.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.3 51.42 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.385 0.612 . . . . 0.0 111.145 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.497 ' HB2' ' H ' ' A' ' 41' ' ' CYS . 13.0 tmtt? -60.66 127.83 33.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.563 176.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.74 -5.69 12.69 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.136 -178.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -84.49 148.17 26.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.817 0.341 . . . . 0.0 111.099 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.6 m -93.0 113.28 25.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.513 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.627 ' HA ' ' HD3' ' A' ' 51' ' ' ARG . 26.5 m -82.16 19.97 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.79 0.329 . . . . 0.0 111.862 -175.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.419 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -80.14 92.1 5.62 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.174 0.511 . . . . 0.0 111.568 -174.205 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.85 19.65 21.37 Favored Glycine 0 C--N 1.32 -0.337 0 C-N-CA 120.688 -0.767 . . . . 0.0 113.47 171.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.627 ' HD3' ' HA ' ' A' ' 48' ' ' VAL . 7.2 ptm180 -119.96 -179.28 3.87 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 177.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.9 mm -104.06 135.04 43.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.587 ' HB3' HG12 ' A' ' 81' ' ' ILE . 56.1 tp -106.84 125.85 51.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.127 0.489 . . . . 0.0 110.837 -179.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -107.47 112.06 38.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.535 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 19.4 t80 -132.89 142.12 43.55 Favored Pre-proline 0 C--N 1.324 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -173.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -69.98 -56.34 0.14 Allowed 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.168 1.912 . . . . 0.0 112.867 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.472 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.42 -179.163 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.0 p90 . . . . . 0 N--CA 1.461 0.106 0 CA-C-O 120.597 0.237 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.434 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 48.0 t -56.15 -56.86 10.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.306 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 92.6 mt -59.62 -40.87 88.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 -177.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.533 ' O ' ' HG3' ' A' ' 73' ' ' LYS . 62.5 tp -66.63 -51.22 58.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.725 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -56.3 -44.95 80.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 90.3 mt -67.05 -36.36 81.87 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.154 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.645 ' HG3' HD11 ' A' ' 99' ' ' ILE . 0.0 OUTLIER -76.24 -28.4 57.14 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.813 -176.41 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.533 ' HG3' ' O ' ' A' ' 69' ' ' LEU . 8.2 mtpm? -67.97 -35.18 77.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.979 0.418 . . . . 0.0 109.902 176.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -78.69 -25.24 44.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.007 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.89 21.9 32.17 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.413 178.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.62 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.7 m -115.12 12.28 7.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.895 0.378 . . . . 0.0 111.034 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.458 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -97.29 155.33 37.5 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.811 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.542 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 22.3 Cg_exo -64.66 146.34 88.57 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.306 2.004 . . . . 0.0 111.154 174.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.555 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.4 mttt -62.25 -35.81 80.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.878 0.371 . . . . 0.0 111.035 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.518 ' HA ' HG23 ' A' ' 99' ' ' ILE . . . -161.48 158.34 26.42 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.64 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.587 HG12 ' HB3' ' A' ' 53' ' ' LEU . 54.5 mt -131.26 124.11 54.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.591 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.693 HG23 HG23 ' A' ' 102' ' ' VAL . 5.2 mm -103.75 116.77 48.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 22.2 m120 -114.78 156.35 25.04 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.313 0.578 . . . . 0.0 111.742 -175.428 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 82.0 tttt -84.12 -38.33 20.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.415 177.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -123.81 108.25 12.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.718 174.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 19.7 p -78.55 108.85 12.23 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.194 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.618 ' HB3' HG12 ' A' ' 90' ' ' ILE . 0.4 OUTLIER -72.69 135.39 45.38 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.011 -0.736 . . . . 0.0 109.011 177.652 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -56.03 -42.99 77.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.835 -174.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.4 mt -69.19 -32.58 54.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.879 -177.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.618 HG12 ' HB3' ' A' ' 87' ' ' GLU . 49.4 mm -67.23 -39.98 84.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.043 177.237 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.19 -43.69 92.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.13 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.78 -45.16 95.0 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.546 178.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.91 -43.47 82.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.71 -178.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.406 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -61.13 -38.07 85.07 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.953 0.406 . . . . 0.0 111.004 -179.051 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.24 -32.31 73.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.546 -179.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.45 ' HB2' ' HE3' ' A' ' 96' ' ' MET . 67.7 mtm -77.38 -40.46 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.71 0.291 . . . . 0.0 111.406 -177.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.506 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -84.91 -0.94 55.87 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.811 -176.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 60.11 53.95 4.32 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 122.011 0.91 . . . . 0.0 109.78 -173.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.645 HD11 ' HG3' ' A' ' 72' ' ' ARG . 44.3 mm -110.1 88.26 6.84 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.744 175.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 5.4 Cg_endo -47.53 98.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.323 2.682 . . . . 0.0 112.753 -175.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 64.0 tp -92.87 130.97 38.29 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.27 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.693 HG23 HG23 ' A' ' 82' ' ' ILE . 14.1 m -135.41 148.78 28.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.289 177.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.485 ' CD ' ' HE ' ' A' ' 105' ' ' ARG . 39.5 tt0 -100.71 121.69 42.08 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.654 -177.515 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 5' ' ' CYS . 14.2 m -108.92 117.62 54.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.443 0.64 . . . . 0.0 111.132 176.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . 0.485 ' HE ' ' CD ' ' A' ' 103' ' ' GLU . 12.8 mmt180 -93.46 4.5 53.86 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.852 176.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 20.9 t70 -95.67 123.27 39.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.211 -171.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -72.16 -32.51 66.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.018 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 14.2 mptt -65.99 -30.09 70.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.15 -176.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 113' ' ' VAL . 73.6 t80 -54.77 -50.73 67.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.075 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.493 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 89.5 m-85 -69.0 -22.64 64.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.107 0.479 . . . . 0.0 111.168 -175.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -85.57 -34.05 21.57 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.473 -179.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.91 -33.5 34.14 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.485 -178.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.6 p -78.99 125.08 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.28 0.562 . . . . 0.0 110.679 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -118.16 153.63 33.51 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.702 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 18' ' ' LEU . 24.5 m -68.2 94.35 0.51 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.071 0.463 . . . . 0.0 110.214 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.55 -9.71 2.91 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.029 -176.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . 0.479 ' HB3' HD11 ' A' ' 130' ' ' LEU . 82.9 m-20 -80.85 159.39 25.07 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 176.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -103.57 113.9 27.76 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.894 0.378 . . . . 0.0 110.324 176.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.527 HG12 ' HB2' ' A' ' 17' ' ' ALA . 6.5 p -119.92 120.71 64.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.151 0.5 . . . . 0.0 110.18 178.207 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 129' ' ' GLU . 7.7 p -98.63 115.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.556 0.694 . . . . 0.0 109.343 175.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 7.5 p -78.57 128.78 38.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.65 -178.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . 0.57 ' HA ' ' HG3' ' A' ' 12' ' ' ARG . 49.9 t-20 -115.07 94.51 4.77 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.6 -10.37 51.68 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.264 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -75.42 -40.28 57.89 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.249 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -102.32 -14.42 16.94 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.387 -179.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.7 65.67 1.81 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.58 -178.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -152.6 144.61 23.75 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.772 0.32 . . . . 0.0 110.613 -173.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 3' ' ' PHE . 4.1 m -116.7 106.59 20.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.372 0.606 . . . . 0.0 109.708 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HB3' HG13 ' A' ' 120' ' ' VAL . 29.8 tt0 -93.11 108.45 20.04 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.043 -174.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.479 HD11 ' HB3' ' A' ' 117' ' ' ASP . 38.8 tp -97.46 129.69 44.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.136 -175.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 13.2 mm -124.8 120.2 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.867 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 . . . . . 0 C--N 1.313 -1.001 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.707 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.466 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 4.6 m . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.433 0.635 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.53 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 19.5 mtpp -117.64 112.84 21.06 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.979 -176.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.466 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 96.5 m-85 -112.32 156.03 23.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.311 0.577 . . . . 0.0 111.728 -172.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.57 133.03 48.24 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.068 175.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.4 m -119.57 -179.45 3.88 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -177.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.929 ' HA ' ' HE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -101.36 126.02 48.07 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 120.241 -0.584 . . . . 0.0 110.083 174.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.565 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -80.13 128.13 33.14 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.731 -174.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.462 ' HB ' HD12 ' A' ' 101' ' ' LEU . 49.6 mm -112.5 -49.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 174.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.582 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -100.23 172.06 7.4 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 171.433 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.7 mtp180 -127.17 177.24 6.8 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.781 -178.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.78 -158.84 20.26 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -172.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ptt180 -141.87 160.6 39.87 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 117.107 0.453 . . . . 0.0 110.477 175.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.523 ' CB ' ' HB2' ' A' ' 80' ' ' ALA . . . -145.79 159.58 42.99 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.324 -178.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -153.21 143.04 22.06 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.063 -177.273 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.12 175.35 39.56 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.883 -1.151 . . . . 0.0 112.757 175.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -73.41 136.42 44.3 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.564 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.79 128.05 33.21 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.211 0.529 . . . . 0.0 111.841 -175.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.479 HD12 HG23 ' A' ' 115' ' ' THR . 5.2 tp -116.12 110.44 18.86 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.389 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.61 134.84 48.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.232 0.539 . . . . 0.0 111.661 -171.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.538 HG23 ' HB3' ' A' ' 55' ' ' PHE . 2.1 t -146.3 117.62 7.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.245 174.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.433 ' HA ' ' HD2' ' A' ' 21' ' ' LYS . 19.7 tptm -82.65 -8.92 59.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.471 0.653 . . . . 0.0 109.293 176.689 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' HB3' ' A' ' 41' ' ' CYS . 1.5 tm-20 -81.19 146.13 30.65 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 174.223 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -86.07 158.9 19.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.558 -171.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.499 HD12 ' HE2' ' A' ' 44' ' ' LYS . 12.5 tt -150.24 127.51 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.679 0.752 . . . . 0.0 111.032 177.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -76.28 135.09 39.63 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.845 -177.211 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -73.06 -20.05 61.05 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.106 -175.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -65.33 -67.07 0.47 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.747 0.308 . . . . 0.0 110.501 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -114.26 34.9 4.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.663 -0.78 . . . . 0.0 111.509 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -98.34 -19.99 21.56 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.864 -0.684 . . . . 0.0 113.06 -175.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 53.6 mt -129.2 133.73 65.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 117.374 0.587 . . . . 0.0 110.75 -177.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.3 t70 -69.5 128.61 37.11 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.882 176.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -79.02 -7.13 57.84 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.558 -174.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -101.61 -57.67 2.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.994 0.426 . . . . 0.0 110.816 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -101.96 -8.3 21.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -172.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.95 21.88 78.93 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.643 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 37.7 mm -84.49 128.01 39.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 177.18 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 6.3 m -62.27 120.27 8.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.153 0.501 . . . . 0.0 110.545 175.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 21.2 mmmt -88.44 -35.21 17.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.808 -175.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.549 ' O ' ' HD3' ' A' ' 44' ' ' LYS . 31.9 tt0 -77.8 107.7 10.5 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.722 ' HA ' ' HD3' ' A' ' 44' ' ' LYS . 13.2 t70 -110.52 144.61 39.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.269 0.556 . . . . 0.0 112.354 -172.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.63 ' SG ' ' HD2' ' A' ' 44' ' ' LYS . 12.4 p -108.93 -51.08 2.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.476 173.134 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.435 ' HG3' HG23 ' A' ' 43' ' ' ILE . 12.5 pt-20 -172.36 -29.92 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.003 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.435 HG23 ' HG3' ' A' ' 42' ' ' GLU . 18.5 pt -114.86 10.95 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.741 -178.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.722 ' HD3' ' HA ' ' A' ' 40' ' ' ASP . 24.2 mttt -92.59 146.96 23.26 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.176 0.512 . . . . 0.0 110.575 -176.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.01 0.74 1.43 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.724 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 -87.58 158.39 18.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.88 0.371 . . . . 0.0 111.113 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.509 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 35.5 t -89.05 151.84 22.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.882 176.013 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 19.6 m -104.8 10.65 8.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.835 178.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.84 87.93 0.37 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.918 -174.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.61 -2.67 42.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.284 -0.871 . . . . 0.0 113.536 171.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 47' ' ' SER . 0.7 OUTLIER -109.13 -172.28 2.01 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 117.199 0.499 . . . . 0.0 110.856 -178.361 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.528 HG12 ' HB3' ' A' ' 80' ' ' ALA . 72.4 mt -118.44 120.61 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.327 -177.542 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.42 HD12 ' O ' ' A' ' 18' ' ' LEU . 47.4 tp -103.5 121.3 42.56 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.53 106.26 20.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.073 0.463 . . . . 0.0 110.658 -178.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.538 ' HB3' HG23 ' A' ' 20' ' ' THR . 23.6 p90 -137.25 151.79 72.26 Favored Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.851 176.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_exo -62.51 -41.52 32.13 Favored 'Trans proline' 0 CA--C 1.529 0.245 0 C-N-CA 122.458 2.105 . . . . 0.0 112.197 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.443 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.032 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.562 ' CD2' HG23 ' A' ' 67' ' ' VAL . 38.6 p90 . . . . . 0 N--CA 1.454 -0.256 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.562 HG23 ' CD2' ' A' ' 66' ' ' TYR . 76.1 t 72.99 -60.88 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 122.846 0.459 . . . . 0.0 110.467 -174.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 8.3 mp -63.41 -39.42 94.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.1 0.476 . . . . 0.0 109.846 176.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.405 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 56.1 tp -62.26 -40.19 95.37 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.123 175.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.33 -38.89 92.91 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.293 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.502 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 93.7 mt -58.13 -41.2 83.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.555 177.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -67.28 -34.74 78.05 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.564 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -67.12 -25.66 66.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.288 -178.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -100.27 -17.2 17.43 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.126 0.488 . . . . 0.0 110.299 177.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.96 0.17 58.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.942 176.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.5 19.03 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.54 -176.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.411 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -80.84 148.69 65.57 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.351 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 77' ' ' ALA . 11.7 Cg_exo -68.77 154.2 71.63 Favored 'Trans proline' 0 N--CA 1.463 -0.266 0 C-N-CA 122.576 2.184 . . . . 0.0 110.96 175.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.419 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 45.1 mttp -85.06 -32.99 22.57 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.199 179.425 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.528 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -151.42 143.96 24.25 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.796 0.331 . . . . 0.0 111.407 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 40.3 mm -129.41 124.78 60.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 174.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.588 HG23 HG23 ' A' ' 102' ' ' VAL . 3.7 mm -118.05 116.46 51.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -120.03 165.51 14.61 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -175.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.656 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 0.0 OUTLIER -76.54 -28.81 56.46 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.669 0.747 . . . . 0.0 109.956 177.568 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.7 tttm -138.91 130.51 27.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.629 169.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 25.4 p -90.4 155.94 18.58 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 175.048 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -123.06 146.09 47.98 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.709 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 92' ' ' VAL . 21.2 m -57.95 -50.4 73.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.231 -173.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 59.4 mt -58.79 -42.71 86.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.162 0.506 . . . . 0.0 110.663 -178.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 57.4 mt -70.11 -41.35 79.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.511 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.5 93.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.335 -179.349 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 88' ' ' THR . 94.2 t -61.44 -45.48 98.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.694 178.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -66.63 -41.59 93.86 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.406 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.32 -41.88 93.53 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.69 0.281 . . . . 0.0 111.269 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.63 -29.6 69.35 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.021 0.438 . . . . 0.0 110.451 176.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 76.8 mtp -83.33 -30.31 27.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.185 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -96.04 16.68 17.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.868 -177.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.458 ' OE1' ' HD2' ' A' ' 72' ' ' ARG . 3.5 mp0 55.03 41.2 32.02 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.121 0.486 . . . . 0.0 111.297 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.466 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 48.7 mt -115.47 86.06 14.42 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.754 176.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 30.0 Cg_endo -65.58 109.89 1.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.309 2.006 . . . . 0.0 112.167 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.462 HD12 ' HB ' ' A' ' 8' ' ' ILE . 3.1 pp -110.31 151.27 27.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.202 0.525 . . . . 0.0 111.26 179.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.588 HG23 HG23 ' A' ' 82' ' ' ILE . 31.3 m -135.75 162.28 37.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.691 177.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -108.13 126.54 52.89 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.82 0.343 . . . . 0.0 110.98 -175.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.656 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 8.3 m -109.24 123.52 65.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.451 176.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -101.51 12.35 37.45 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.141 0.496 . . . . 0.0 110.201 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 28.6 t70 -107.62 122.73 47.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.022 -177.286 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -71.17 -29.07 64.73 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.629 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 10.2 mtmp? -62.64 -28.72 70.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.074 -177.069 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -60.12 -48.82 80.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.029 178.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -65.79 -26.96 67.93 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.341 0.591 . . . . 0.0 110.835 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -79.73 -27.23 40.61 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.842 -179.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.69 -39.95 12.15 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.835 -177.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.532 ' HA ' HD21 ' A' ' 130' ' ' LEU . 13.6 p -69.3 134.96 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.034 0.445 . . . . 0.0 111.176 -177.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -121.32 151.59 39.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.794 -177.23 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.479 HG23 HD12 ' A' ' 18' ' ' LEU . 71.4 m -71.91 124.43 24.85 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.112 175.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.04 9.42 54.01 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.879 -177.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -97.97 177.14 5.53 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.496 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.6 OUTLIER -116.07 113.79 23.66 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.363 0.602 . . . . 0.0 111.613 -172.914 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 17' ' ' ALA . 45.3 t -113.2 127.96 70.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.68 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.6 t -113.15 117.4 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 172.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.431 HG22 HG12 ' A' ' 128' ' ' VAL . 43.0 t -108.98 123.96 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -106.33 94.98 5.44 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 171.015 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.02 -19.73 62.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.947 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -62.29 -37.73 86.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.098 0.475 . . . . 0.0 109.927 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -87.37 -36.87 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.041 174.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.408 ' HA2' HG11 ' A' ' 102' ' ' VAL . . . 87.15 54.15 2.65 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -167.073 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . 0.409 ' OH ' ' HB3' ' A' ' 2' ' ' LYS . 72.8 t80 -137.14 134.86 36.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.383 -169.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.431 HG12 HG22 ' A' ' 121' ' ' VAL . 28.1 m -120.12 130.69 74.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.061 0.458 . . . . 0.0 110.842 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.53 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 38.8 tt0 -108.27 107.41 18.0 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 175.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 119' ' ' VAL . 60.2 tp -104.76 107.62 18.67 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.928 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.496 HG12 ' NH2' ' A' ' 118' ' ' ARG . 34.5 mm -101.44 110.98 29.67 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 . . . . . 0 C--N 1.313 -1.02 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.584 -177.688 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.988 0.423 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.487 ' HG2' ' HB3' ' A' ' 129' ' ' GLU . 54.3 mttm -93.42 133.45 36.68 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.212 174.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.442 ' CD2' ' HD1' ' A' ' 109' ' ' PHE . 93.5 m-85 -122.13 157.97 30.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.41 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.46 117.13 32.74 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.02 -178.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.6 p -119.6 172.9 7.33 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.16 177.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -104.97 131.95 51.83 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 177.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.618 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.49 134.02 34.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.092 -173.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.494 HD11 ' HG3' ' A' ' 103' ' ' GLU . 2.5 mp -110.58 -51.41 6.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 172.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.574 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -94.36 178.01 5.76 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -122.72 174.74 6.92 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 97.87 -163.44 21.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.687 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 58.9 mtt180 -120.59 148.46 43.84 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 178.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.657 ' HB1' ' HB2' ' A' ' 80' ' ' ALA . . . -129.15 114.68 16.62 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 178.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 79' ' ' LYS . 15.7 tm-20 -133.61 122.01 22.88 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.657 -173.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.03 -173.98 44.74 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.344 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 31.1 mp0 -71.39 138.23 48.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -95.24 123.12 38.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.885 0.374 . . . . 0.0 110.915 178.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.1 mp -104.84 127.03 52.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.113 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.784 HG12 ' HB ' ' A' ' 115' ' ' THR . 13.4 p -102.04 137.67 29.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.852 -173.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.4 m -150.14 107.86 3.68 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 175.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -96.72 65.26 2.17 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.03 -177.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 mm-40 -142.74 161.74 37.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.3 176.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -88.38 81.75 7.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.909 0.385 . . . . 0.0 111.6 -177.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.518 HG22 ' H ' ' A' ' 26' ' ' PHE . 4.3 mp -108.17 112.23 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.694 0 CA-C-O 121.733 0.778 . . . . 0.0 109.749 173.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.3 m -87.38 36.36 0.74 Allowed 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.009 -177.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.518 ' H ' HG22 ' A' ' 24' ' ' ILE . 56.8 m-85 63.88 -81.89 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.223 0.609 . . . . 0.0 111.106 -176.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.2 mt 58.41 -85.4 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 O-C-N 123.896 0.748 . . . . 0.0 111.598 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -158.17 24.59 0.39 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.84 -22.29 79.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.772 -176.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 39.8 mt -92.94 127.61 44.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.961 0.41 . . . . 0.0 110.338 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 38' ' ' LYS . 16.2 t70 -67.27 119.03 11.47 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.957 176.393 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 10.2 ptpp? -83.22 0.6 44.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.645 0.259 . . . . 0.0 111.355 -173.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -85.29 -46.81 10.65 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.899 0.38 . . . . 0.0 110.544 177.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.4 p -125.56 -5.47 7.05 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.991 0.738 . . . . 0.0 112.991 -174.105 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.99 30.86 55.08 Favored Glycine 0 C--O 1.236 0.233 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.41 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 40.9 mm -99.66 123.84 52.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.641 HG21 ' HE3' ' A' ' 44' ' ' LYS . 15.3 t -71.2 104.53 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.244 176.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.453 ' CG ' ' HB2' ' A' ' 31' ' ' ASP . 6.8 mmmm -78.62 -19.99 51.41 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.523 -174.016 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -90.56 110.22 21.36 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.756 178.032 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.491 ' HA ' ' HB3' ' A' ' 44' ' ' LYS . 19.3 t70 -97.81 155.88 16.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.108 0.48 . . . . 0.0 110.966 -178.067 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 18.7 p -141.32 -37.93 0.42 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.322 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -141.02 -62.47 0.48 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.186 -177.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.441 HD12 HG21 ' A' ' 115' ' ' THR . 30.2 pt -133.17 17.52 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.932 -172.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.641 ' HE3' HG21 ' A' ' 37' ' ' VAL . 17.4 tptt -80.97 -173.4 4.24 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.13 0.491 . . . . 0.0 111.565 -168.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.36 -0.44 55.8 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -173.147 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -94.28 179.01 5.44 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.963 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 9.5 m -92.41 132.13 37.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.203 -175.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 28.7 m -106.23 -0.27 10.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.113 0.482 . . . . 0.0 110.003 172.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.86 96.54 0.19 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.546 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.522 ' C ' ' HD2' ' A' ' 51' ' ' ARG . . . 86.12 20.98 54.05 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.266 -1.333 . . . . 0.0 112.517 177.464 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.522 ' HD2' ' C ' ' A' ' 50' ' ' GLY . 4.0 mpt_? -119.01 166.15 13.23 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.719 0.295 . . . . 0.0 110.588 178.332 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.783 HG12 ' HB3' ' A' ' 80' ' ' ALA . 63.3 mt -93.63 122.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.299 -0.409 . . . . 0.0 109.943 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.427 HD21 ' HE2' ' A' ' 55' ' ' PHE . 17.0 tp -99.33 128.0 45.4 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.572 -175.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.9 120.17 60.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.118 0.485 . . . . 0.0 111.215 -177.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . 0.428 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.9 m-85 -133.37 144.49 52.57 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 176.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 14.0 Cg_exo -69.72 -54.21 0.23 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.55 2.167 . . . . 0.0 111.074 175.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.624 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.434 178.577 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 26.4 p90 . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.277 0.56 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.622 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 9.6 p -71.23 -29.79 37.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.401 -175.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.4 mp -66.9 -41.68 86.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.78 -178.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.27 -36.0 80.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 177.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -58.94 -48.33 81.88 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.332 175.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.622 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 81.2 mt -58.4 -40.32 82.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 178.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.521 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -66.78 -42.78 85.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.082 -178.616 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -64.79 -27.97 69.25 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.682 0.277 . . . . 0.0 111.374 -179.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -90.47 -17.8 26.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.19 0.519 . . . . 0.0 110.082 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 83.58 26.8 41.21 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.349 178.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.87 11.6 7.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.152 0.501 . . . . 0.0 110.537 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.439 ' HB1' HD11 ' A' ' 99' ' ' ILE . . . -81.93 158.38 67.68 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.138 -179.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 24.3 Cg_exo -62.16 148.55 93.0 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.192 1.928 . . . . 0.0 110.99 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.506 ' HD3' ' O ' ' A' ' 14' ' ' GLU . 75.5 tttt -84.96 -21.63 29.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.511 . . . . 0.0 109.635 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.783 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -166.49 163.55 17.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.227 175.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.458 HG23 ' HB3' ' A' ' 101' ' ' LEU . 7.9 tt -146.84 114.71 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.288 0.566 . . . . 0.0 110.065 174.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.63 HD12 HG22 ' A' ' 102' ' ' VAL . 7.6 mm -108.55 124.31 64.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.3 m120 -120.93 160.89 22.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.297 -173.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 79.7 tttt -77.11 -37.45 54.21 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 171.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -154.71 154.71 33.32 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 114.711 -1.132 . . . . 0.0 108.57 168.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -143.52 172.63 12.53 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.78 -178.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -107.98 168.19 9.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.597 -177.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.0 m -58.85 -52.15 66.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -173.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 pt -63.5 -30.08 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 C-N-CA 120.638 -0.425 . . . . 0.0 112.067 -174.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.1 mm -64.93 -45.41 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -64.47 -48.02 76.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.051 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 86.9 t -61.81 -46.51 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.18 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.13 -43.87 98.03 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.567 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.558 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -72.21 -35.93 69.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.437 0.161 . . . . 0.0 111.319 -178.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.07 -31.26 69.83 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.139 0.495 . . . . 0.0 110.73 178.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.8 mtm -82.68 -39.88 21.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.625 178.24 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.521 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -80.68 6.84 11.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.024 -178.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 47.9 mt-10 64.23 35.47 10.05 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.263 0.554 . . . . 0.0 110.971 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.53 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 54.2 mt -109.91 88.61 6.97 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.101 178.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 32.8 Cg_exo -58.53 118.04 4.86 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.67 2.247 . . . . 0.0 113.018 -176.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.58 HD21 ' HA ' ' A' ' 91' ' ' ALA . 1.7 pt? -117.34 141.64 48.07 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.251 175.14 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.63 HG22 HD12 ' A' ' 82' ' ' ILE . 31.3 m -138.04 161.56 32.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.928 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.494 ' HG3' HD11 ' A' ' 8' ' ' ILE . 53.2 mt-10 -97.92 116.8 30.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.686 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.592 HG12 HG22 ' A' ' 82' ' ' ILE . 7.2 p -115.23 107.38 22.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.764 0.792 . . . . 0.0 109.187 172.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 8.3 ttm-85 -99.04 14.65 28.46 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.048 -175.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -89.18 120.01 30.18 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.044 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -67.39 -34.71 77.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.391 -175.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 111' ' ' GLU . 32.8 mmtp -69.49 -23.0 63.57 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.32 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.442 ' HD1' ' CD2' ' A' ' 3' ' ' PHE . 87.6 t80 -62.19 -51.04 69.39 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 172.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.402 ' CZ ' HG13 ' A' ' 104' ' ' VAL . 87.0 m-85 -69.7 -25.96 64.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.842 -178.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.439 ' HB2' ' HA ' ' A' ' 108' ' ' LYS . 37.1 mm-40 -74.92 -29.59 61.01 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.009 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.79 -34.03 14.74 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -176.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.7 p -85.15 138.6 18.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.173 0.511 . . . . 0.0 111.375 -175.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -124.48 167.07 14.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.972 173.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.784 ' HB ' HG12 ' A' ' 19' ' ' VAL . 9.8 t -67.55 107.58 2.55 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.725 0.774 . . . . 0.0 110.657 -178.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.15 -24.39 4.23 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.554 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -63.72 151.12 42.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.868 0.334 . . . . 0.0 110.28 179.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.691 HH21 HG13 ' A' ' 131' ' ' ILE . 1.1 tmm_? -96.68 120.37 36.89 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -175.04 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.448 HG22 HD12 ' A' ' 130' ' ' LEU . 46.3 t -120.68 141.2 42.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.757 -175.047 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . 0.486 HG23 ' HB2' ' A' ' 14' ' ' GLU . 9.9 p -124.38 121.1 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 121.763 0.792 . . . . 0.0 109.464 169.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 13' ' ' ALA . 40.2 t -106.54 127.35 62.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.472 -178.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.2 t-20 -93.44 97.48 10.58 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.38 -13.83 51.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.363 -175.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -68.92 -45.11 71.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.158 0.504 . . . . 0.0 109.744 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -93.85 -43.26 8.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.086 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.38 69.22 0.82 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -172.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.7 t80 -161.31 157.62 25.74 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 -172.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -152.99 138.64 11.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.021 -179.032 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HG2' ' A' ' 2' ' ' LYS . 2.2 pm0 -118.75 119.99 36.05 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.356 0.598 . . . . 0.0 110.458 174.142 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.448 HD12 HG22 ' A' ' 119' ' ' VAL . 54.7 tp -84.01 130.54 34.88 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.69 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.691 HG13 HH21 ' A' ' 118' ' ' ARG . 37.1 mm -101.27 120.25 50.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 CA-C-O 121.412 0.625 . . . . 0.0 109.6 177.236 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.198 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.195 -178.129 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.1 pttt -131.06 113.22 13.66 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.513 178.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -93.3 152.85 18.9 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.949 0.404 . . . . 0.0 111.181 -175.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.51 124.39 47.97 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.669 174.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 56.9 m -119.41 174.0 6.63 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.914 0.388 . . . . 0.0 110.82 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 40.7 ttt180 -92.83 111.7 23.4 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -90.84 137.83 32.06 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.569 -171.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.609 HD13 HD12 ' A' ' 101' ' ' LEU . 4.3 mp -103.87 -52.2 8.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 48.7 p -102.95 176.42 5.16 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.771 176.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 61.0 mtt180 -122.37 -175.35 3.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.661 0.267 . . . . 0.0 111.076 -176.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.15 171.83 27.35 Favored Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -175.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.4 HH21 ' CG ' ' A' ' 124' ' ' ASP . 0.0 OUTLIER -140.26 139.5 35.56 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 117.282 0.541 . . . . 0.0 110.52 -178.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.613 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -135.46 145.49 47.23 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.076 0.465 . . . . 0.0 111.65 -174.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -125.21 123.05 38.73 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.083 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.89 176.4 41.93 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 119.68 -1.248 . . . . 0.0 112.528 179.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.66 137.65 39.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 177.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.46 124.81 29.24 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.814 -176.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.404 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.8 tt -119.28 121.23 39.16 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.506 HG12 ' OG1' ' A' ' 115' ' ' THR . 8.9 p -111.4 120.12 61.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.078 0.466 . . . . 0.0 110.185 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.3 t -94.12 -6.74 44.29 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.077 0.465 . . . . 0.0 111.366 -175.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.0 tttt 68.54 -61.07 0.42 Allowed 'General case' 0 CA--C 1.539 0.54 0 CA-C-N 114.958 -1.019 . . . . 0.0 113.605 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -71.64 163.67 27.33 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -82.53 78.2 9.19 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.622 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.6 pt -106.11 135.74 43.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.961 0.41 . . . . 0.0 110.397 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 15.3 t -111.02 178.02 4.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.941 -178.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.41 ' HZ ' HD13 ' A' ' 81' ' ' ILE . 77.7 m-85 -87.53 29.6 0.87 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.257 0.551 . . . . 0.0 111.414 -174.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.556 HD22 HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -65.39 -21.97 66.74 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 171.04 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.95 -127.61 1.44 Allowed Glycine 0 N--CA 1.444 -0.833 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.184 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.688 ' HA2' ' HB2' ' A' ' 39' ' ' GLU . . . 86.59 -43.78 3.27 Favored Glycine 0 C--O 1.221 -0.687 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.847 172.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.461 HG12 HG12 ' A' ' 37' ' ' VAL . 57.3 mt -109.05 136.94 43.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -66.07 130.03 41.85 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.88 -33.31 73.97 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -170.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -109.41 -35.12 6.34 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.48 -0.488 . . . . 0.0 111.887 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.7 m -81.47 -28.57 34.07 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.583 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.832 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.82 19.55 78.82 Favored Glycine 0 C--N 1.329 0.191 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.505 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.456 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.7 mm -95.87 131.06 43.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.461 HG12 HG12 ' A' ' 30' ' ' ILE . 13.9 m -71.39 107.97 2.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.814 0.816 . . . . 0.0 110.218 175.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mmmm -92.35 -10.44 38.21 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.047 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.688 ' HB2' ' HA2' ' A' ' 29' ' ' GLY . 9.8 tp10 -80.8 153.4 27.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.792 177.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -100.04 137.95 37.79 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.244 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 16.3 p -161.27 -56.23 0.05 OUTLIER 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.327 176.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -173.29 -51.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.477 174.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -92.05 44.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.885 0.85 . . . . 0.0 110.156 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -78.76 129.88 35.14 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.409 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 118.64 -16.52 11.3 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.797 179.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.424 ' O ' HG22 ' A' ' 37' ' ' VAL . 26.7 mt-10 -92.86 171.69 8.81 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.299 0.571 . . . . 0.0 111.973 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.456 ' HB3' HD13 ' A' ' 36' ' ' ILE . 15.6 p -105.37 151.12 24.58 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.447 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 30' ' ' ILE . 27.2 m -102.66 18.2 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.773 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.8 95.72 2.96 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.759 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.03 21.07 28.91 Favored Glycine 0 C--N 1.315 -0.619 0 CA-C-N 115.163 -0.926 . . . . 0.0 113.472 170.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.8 ptm180 -123.6 175.0 7.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 80' ' ' ALA . 50.2 mm -99.11 129.51 49.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 -174.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.594 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 3.6 mm? -110.0 130.69 55.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.098 0.475 . . . . 0.0 111.341 -176.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.457 HG21 HG21 ' A' ' 113' ' ' VAL . 52.8 t -117.9 125.7 74.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.662 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.594 ' CE1' ' HB3' ' A' ' 53' ' ' LEU . 27.3 m-85 -131.5 143.92 51.24 Favored Pre-proline 0 C--N 1.327 -0.385 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -73.15 -42.83 0.86 Allowed 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 121.855 1.704 . . . . 0.0 110.57 171.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -176.23 -177.79 45.51 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.59 130.7 4.67 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.902 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.3 ptmm? -74.27 139.38 44.24 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.867 0.365 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.23 -82.57 1.67 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 121.129 -0.558 . . . . 0.0 111.781 -178.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 51.0 m 58.65 31.04 20.7 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.19 0.519 . . . . 0.0 111.54 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 3.8 m -75.23 -23.45 57.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.977 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.556 HG12 HD22 ' A' ' 27' ' ' LEU . 6.0 p -145.5 158.2 12.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.443 ' HA2' HG22 ' A' ' 67' ' ' VAL . . . 153.1 -13.58 0.63 Allowed Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.47 178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -65.4 -22.56 66.8 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 111.499 0.185 . . . . 0.0 111.499 -177.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -96.22 -34.19 11.73 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -177.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.443 HG22 ' HA2' ' A' ' 64' ' ' GLY . 35.3 m -69.39 -32.22 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 111.648 0.24 . . . . 0.0 111.648 -173.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.3 mt -61.0 -38.8 87.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.942 0.401 . . . . 0.0 110.932 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 59.4 tp -71.74 -41.18 68.79 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.561 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -62.62 -44.18 96.93 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.714 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 94.7 mt -62.75 -39.6 94.64 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.614 178.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.516 ' HG2' ' O ' ' A' ' 97' ' ' ALA . 11.3 tpt180 -67.65 -41.47 83.75 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.365 -175.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.33 -10.08 59.24 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 110.898 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -94.98 -16.58 22.65 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.075 0.464 . . . . 0.0 110.399 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.23 11.66 81.93 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.086 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.832 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.2 m -106.65 13.67 8.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.106 0.479 . . . . 0.0 111.011 -177.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.15 155.57 42.75 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.832 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.594 ' HB3' HD23 ' A' ' 53' ' ' LEU . 37.0 Cg_endo -66.42 147.18 82.32 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.487 2.125 . . . . 0.0 111.201 173.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.613 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.2 mttt -68.15 -42.16 80.52 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.867 0.365 . . . . 0.0 111.14 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.534 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -151.4 156.54 40.9 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.778 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.41 HD13 ' HZ ' ' A' ' 26' ' ' PHE . 74.5 mt -132.83 128.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.392 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.713 HG23 HG23 ' A' ' 102' ' ' VAL . 2.3 mm -112.37 128.39 69.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.344 -0.614 . . . . 0.0 109.344 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -126.31 159.55 32.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.879 -178.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.517 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 2.7 tmtp? -92.91 -35.69 13.2 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 173.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -142.58 101.99 3.98 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.813 174.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -95.41 -179.9 4.93 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.802 -174.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.31 150.69 43.26 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.944 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 92' ' ' VAL . 13.1 m -62.52 -37.7 87.06 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.289 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.98 -29.53 47.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 178.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 69.9 mt -71.83 -42.52 69.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB1' HG21 ' A' ' 8' ' ' ILE . . . -59.43 -42.88 92.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.263 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 88' ' ' THR . 57.1 t -62.76 -47.86 90.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.828 179.287 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.2 -43.41 99.16 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.258 178.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.49 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.5 -31.08 71.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.358 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -70.09 -35.11 73.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.911 0.386 . . . . 0.0 111.252 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.1 mtm -81.61 -33.62 31.4 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.139 -178.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.516 ' O ' ' HG2' ' A' ' 72' ' ' ARG . . . -89.99 0.51 57.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.003 -177.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 55.15 61.63 2.84 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 121.829 0.823 . . . . 0.0 110.098 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.49 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.7 mt -123.11 90.05 50.55 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 114.784 -1.098 . . . . 0.0 109.801 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 4.2 Cg_exo -40.04 109.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.348 0.541 0 C-N-CA 123.669 2.912 . . . . 0.0 112.891 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.609 HD12 HD13 ' A' ' 8' ' ' ILE . 1.1 tm? -110.59 120.0 40.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.348 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.713 HG23 HG23 ' A' ' 82' ' ' ILE . 24.7 m -130.36 144.21 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.019 0.438 . . . . 0.0 110.634 178.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -110.16 122.84 48.58 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.03 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.456 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.3 p -98.8 134.45 37.56 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.185 0.517 . . . . 0.0 110.687 -177.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 0.7 OUTLIER -92.79 -14.8 27.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.929 -174.328 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 104' ' ' VAL . 5.6 t70 -109.42 137.61 47.01 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.558 -0.457 . . . . 0.0 111.274 -175.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -72.78 -19.36 61.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.847 -176.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 19.0 mmtp -58.3 -26.6 63.21 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.461 ' O ' HG12 ' A' ' 113' ' ' VAL . 79.9 t80 -61.72 -42.81 99.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.755 0.312 . . . . 0.0 110.3 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.51 ' HA ' HG12 ' A' ' 113' ' ' VAL . 87.6 m-85 -75.16 -24.97 57.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.24 -175.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -74.33 -33.45 63.16 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.484 175.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.16 -41.05 17.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.723 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.4 p -78.27 124.37 36.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 121.777 0.799 . . . . 0.0 111.386 -175.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 114' ' ' LYS . 32.0 mmtp -132.06 153.25 50.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.706 175.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 60.8 m -62.35 114.87 3.74 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 123.195 0.31 . . . . 0.0 110.932 -178.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.6 -32.13 2.17 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 119.792 -1.194 . . . . 0.0 114.395 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.93 -172.11 2.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 117.736 0.768 . . . . 0.0 111.028 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -112.27 126.04 54.82 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.278 0.561 . . . . 0.0 111.905 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.449 HG23 ' HB2' ' A' ' 17' ' ' ALA . 65.8 t -121.52 120.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.892 176.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 60.7 t -89.29 111.83 23.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.759 177.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 41.9 t -95.54 109.02 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.565 -177.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -110.34 99.08 8.17 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.99 -9.35 53.77 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.022 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.4 ' CG ' HH21 ' A' ' 12' ' ' ARG . 18.5 m-20 -63.81 -47.01 82.58 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 174.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -93.2 -31.18 14.86 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.736 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 91.92 59.08 1.35 Allowed Glycine 0 N--CA 1.452 -0.295 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 143.49 29.75 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.793 0.33 . . . . 0.0 110.643 -169.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.53 106.31 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.319 0.581 . . . . 0.0 109.962 174.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 120' ' ' VAL . 39.8 mt-10 -96.3 108.46 20.97 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.665 -174.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.6 tp -81.3 110.05 16.39 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.6 mm -112.74 114.9 48.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -176.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 . . . . . 0 C--N 1.312 -1.041 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.157 -170.604 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.226 -0.162 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.507 ' HD3' ' OH ' ' A' ' 127' ' ' TYR . 74.2 mttt -125.54 145.67 50.01 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.529 -177.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.479 ' HB2' HG13 ' A' ' 128' ' ' VAL . 89.6 m-85 -129.48 161.92 29.3 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.398 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.15 126.65 55.06 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.106 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.43 ' SG ' HG21 ' A' ' 102' ' ' VAL . 5.7 p -119.71 167.74 11.75 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.209 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.567 ' HD3' ' OE2' ' A' ' 103' ' ' GLU . 36.6 ttt180 -93.96 121.95 35.96 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.981 0.42 . . . . 0.0 110.107 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -72.98 102.9 3.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.123 -175.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.556 HG13 HG21 ' A' ' 86' ' ' THR . 50.0 mm -95.91 -43.57 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.11 177.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.7 p -109.57 -165.0 0.97 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.134 177.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -136.43 164.49 28.03 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -177.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.05 161.62 22.77 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.932 -0.652 . . . . 0.0 111.906 -177.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -147.86 154.12 40.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.09 0.445 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.45 164.97 24.3 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.081 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -127.92 127.05 42.66 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 176.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.62 178.92 32.83 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.056 -1.069 . . . . 0.0 112.69 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -74.44 139.86 44.25 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.33 178.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.586 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.56 122.83 27.53 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.07 0.462 . . . . 0.0 111.002 -178.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.3 tt -117.61 117.14 28.59 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 174.438 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.822 HG12 ' HB ' ' A' ' 115' ' ' THR . 8.4 p -101.6 124.99 55.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.442 0.639 . . . . 0.0 110.984 -173.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 1.037 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 13.2 m -95.63 95.03 8.08 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.446 0.641 . . . . 0.0 109.875 179.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -82.25 -2.61 53.1 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.944 -177.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -103.1 130.41 50.25 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.67 -176.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -85.14 98.89 10.72 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -118.95 172.64 5.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 116.253 -0.43 . . . . 0.0 112.007 -170.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.4 p -79.5 122.41 26.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.175 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.564 ' O ' ' HB ' ' A' ' 63' ' ' VAL . 21.5 t80 -85.48 31.26 0.59 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.568 0.699 . . . . 0.0 109.991 -177.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.491 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -68.89 -23.8 64.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.198 177.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 174.37 -103.84 0.19 Allowed Glycine 0 N--CA 1.444 -0.832 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.294 178.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.72 -51.42 2.31 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.548 176.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.436 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.7 mp -87.47 129.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.75 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 27.5 t70 -78.55 139.96 38.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.038 0.447 . . . . 0.0 111.005 179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.492 ' HA ' HD23 ' A' ' 71' ' ' LEU . 0.0 OUTLIER -64.84 -26.33 68.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.548 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 45.4 mt-10 -95.41 -46.88 6.51 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 36' ' ' ILE . 20.7 p -102.88 -19.15 14.76 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -174.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 73.93 20.14 79.74 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.015 -178.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.412 HD13 ' HB3' ' A' ' 47' ' ' SER . 47.2 mm -87.68 133.03 31.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.639 -0.28 . . . . 0.0 110.453 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 8.3 m -74.28 111.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.582 0.706 . . . . 0.0 110.892 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.75 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 57.2 mttt -91.67 -10.89 38.61 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.947 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -66.33 138.27 57.49 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.646 178.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.41 131.42 44.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.38 -172.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 13.6 p 174.55 -178.22 0.1 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.981 -1.008 . . . . 0.0 108.482 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -79.35 -9.27 59.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.274 0.559 . . . . 0.0 110.095 175.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.417 ' O ' ' HB2' ' A' ' 46' ' ' GLU . 24.3 mt -94.26 -8.83 9.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.183 -178.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.1 tmmm? -56.85 125.83 24.23 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.358 0.599 . . . . 0.0 110.372 -178.074 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.25 -24.36 12.64 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.964 -176.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 43' ' ' ILE . 1.1 mm-40 -71.15 162.97 28.54 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.311 0.577 . . . . 0.0 111.656 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.412 ' HB3' HD13 ' A' ' 36' ' ' ILE . 18.2 p -116.89 127.13 53.96 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.61 -178.431 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.414 HG21 HG12 ' A' ' 30' ' ' ILE . 33.4 m -87.53 1.8 5.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.207 -178.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.436 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.25 88.04 0.3 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.923 -177.553 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.53 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 107.36 11.04 26.34 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.519 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 mmm-85 -106.14 156.08 18.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.44 116.58 47.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 176.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.713 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -92.94 124.85 37.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.289 0.566 . . . . 0.0 111.324 -173.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 72.6 t -117.91 107.91 23.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.173 176.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 1.037 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 43.6 p90 -135.7 153.66 77.56 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.461 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -64.07 -49.89 3.42 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 122.591 2.194 . . . . 0.0 111.997 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -176.56 170.17 42.88 Favored Glycine 0 N--CA 1.448 -0.558 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.86 42.04 2.06 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.15 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 46.5 mtpt 64.46 8.96 4.63 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 175.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.96 43.18 74.62 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.557 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.8 p -91.91 125.61 36.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.135 0.493 . . . . 0.0 110.548 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.7 p -88.68 71.2 8.8 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-O 121.54 0.686 . . . . 0.0 111.214 -171.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.823 HG13 ' H ' ' A' ' 65' ' ' SER . 7.1 p -46.67 -35.03 2.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.079 173.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 102.79 -4.57 50.0 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.203 178.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.823 ' H ' HG13 ' A' ' 63' ' ' VAL . 60.7 p 60.06 -154.56 0.37 Allowed 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 123.62 0.768 . . . . 0.0 111.36 178.147 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 72.35 -56.48 0.65 Allowed 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.782 0.833 . . . . 0.0 112.084 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.3 m -60.92 -16.84 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 N-CA-C 112.912 0.708 . . . . 0.0 112.912 -173.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.21 -28.18 69.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.803 0.335 . . . . 0.0 110.699 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.0 tp -62.34 -38.48 89.65 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.423 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -58.22 -47.67 82.77 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.649 178.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.492 HD23 ' HA ' ' A' ' 32' ' ' LYS . 76.4 mt -56.76 -44.43 81.77 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.706 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -72.8 -41.32 65.08 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.745 -176.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -61.85 -33.3 73.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.824 0.345 . . . . 0.0 110.374 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -85.53 -19.68 30.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.126 0.489 . . . . 0.0 110.512 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 86.89 23.44 41.79 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.216 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.523 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.4 m -113.32 12.47 8.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.603 -179.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.467 ' HB1' ' HD2' ' A' ' 78' ' ' PRO . . . -90.91 162.66 32.39 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.713 ' HB3' HD13 ' A' ' 53' ' ' LEU . 43.7 Cg_endo -69.66 149.9 68.1 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.037 1.825 . . . . 0.0 111.434 174.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.53 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 88.4 mttt -69.47 -30.46 68.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.938 0.399 . . . . 0.0 110.75 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -163.77 155.3 16.67 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.457 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 68.5 mt -131.09 127.28 60.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.998 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.453 HG23 HG23 ' A' ' 102' ' ' VAL . 5.5 mm -117.85 120.79 65.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 13.6 m120 -120.03 164.03 16.74 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.645 0.26 . . . . 0.0 110.74 -176.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -79.07 -46.11 18.76 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 174.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 85' ' ' LYS . 44.2 pttt -125.88 112.75 16.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.762 172.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.556 HG21 HG13 ' A' ' 8' ' ' ILE . 5.8 t -92.47 116.3 28.87 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.41 0.624 . . . . 0.0 109.476 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -98.52 167.91 10.52 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.544 -175.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.5 m -53.98 -47.64 71.17 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -169.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 90' ' ' ILE . 9.2 pt -55.56 -46.04 78.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 111.984 0.365 . . . . 0.0 111.984 -178.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.553 HG13 HG13 ' A' ' 89' ' ' ILE . 36.4 mt -76.77 -40.56 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.325 -176.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.528 ' HA ' HD23 ' A' ' 101' ' ' LEU . . . -59.44 -50.64 73.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.564 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 92.3 t -64.87 -42.37 94.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.791 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.35 -45.56 96.19 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.785 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -73.93 -33.01 63.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.552 0.215 . . . . 0.0 111.567 -178.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.8 -40.16 95.96 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.963 0.411 . . . . 0.0 111.512 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 69.7 mtm -74.04 -42.87 59.62 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.244 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -74.3 -14.78 60.95 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -177.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 71.71 59.89 0.16 Allowed 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.662 0.744 . . . . 0.0 109.934 -173.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.1 mt -121.96 89.32 48.23 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.481 177.15 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -38.29 107.56 0.06 OUTLIER 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 123.792 2.994 . . . . 0.0 113.441 -177.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 43.6 tp -128.16 120.72 27.87 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.421 -176.259 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.453 HG23 HG23 ' A' ' 82' ' ' ILE . 20.6 m -135.0 166.76 27.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.195 179.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.567 ' OE2' ' HD3' ' A' ' 6' ' ' ARG . 9.9 pt-20 -113.59 141.16 47.52 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.066 0.46 . . . . 0.0 111.167 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 5.2 m -105.84 140.75 22.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.454 176.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 7.6 tpp180 -88.67 -26.27 21.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.221 -174.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -106.16 140.08 39.68 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.052 0.453 . . . . 0.0 111.372 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -71.14 -20.94 62.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.944 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.553 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 57.2 mttm -64.91 -17.97 64.8 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -60.64 -45.85 92.52 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 173.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.56 ' HA ' HG12 ' A' ' 113' ' ' VAL . 53.2 m-85 -76.12 -32.11 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.006 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.553 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.7 tt0 -57.3 -46.22 83.38 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.996 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -87.75 -24.62 23.74 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.481 -174.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.9 p -76.04 139.68 18.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.535 0.684 . . . . 0.0 111.96 -174.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -139.13 159.28 42.53 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.992 172.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.822 ' HB ' HG12 ' A' ' 19' ' ' VAL . 12.1 t -81.69 138.62 35.24 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.961 0.41 . . . . 0.0 110.434 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.53 -25.3 9.2 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.775 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -85.28 -171.78 3.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.608 0.242 . . . . 0.0 110.797 179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 20.0 ttp180 -115.36 133.73 55.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.011 0.434 . . . . 0.0 111.447 -176.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.586 HG23 ' HB2' ' A' ' 17' ' ' ALA . 85.6 t -122.58 129.5 75.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.126 175.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.681 ' HB ' ' HB3' ' A' ' 129' ' ' GLU . 50.3 t -101.86 113.56 38.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.79 129.67 61.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.946 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -131.4 100.52 5.19 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.807 176.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.82 -12.22 55.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.472 -174.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.18 -7.64 58.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.025 0.44 . . . . 0.0 110.804 178.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -128.3 -20.99 3.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.868 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.29 59.94 2.79 Favored Glycine 0 CA--C 1.509 -0.336 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -173.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.507 ' OH ' ' HD3' ' A' ' 2' ' ' LYS . 60.8 t80 -142.71 135.64 28.19 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.316 -167.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.479 HG13 ' HB2' ' A' ' 3' ' ' PHE . 6.6 p -137.76 124.81 28.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.461 0.648 . . . . 0.0 110.579 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.681 ' HB3' ' HB ' ' A' ' 120' ' ' VAL . 34.5 tt0 -115.96 122.45 45.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.413 -175.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 19.6 tp -106.63 127.53 53.42 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.945 0.402 . . . . 0.0 110.688 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 131' ' ' ILE . 3.5 mp -122.45 122.07 65.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 174.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.465 ' H ' ' CD ' ' A' ' 132' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--N 1.315 -0.91 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.618 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 C--O 1.234 0.25 0 CA-C-O 120.677 0.275 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.513 ' HG2' ' HG2' ' A' ' 129' ' ' GLU . 49.2 mttp -101.7 107.48 18.72 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 177.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -86.76 141.42 28.88 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.27 -176.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.31 127.97 36.31 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.514 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.2 m -120.82 159.02 26.33 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.032 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.444 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 27.1 ttm180 -102.79 115.94 31.58 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 176.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.709 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.0 133.84 44.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.0 -173.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.0 mm -106.94 -49.36 8.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 174.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.425 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 61.7 p -117.42 177.24 4.81 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.786 173.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' A' ' 10' ' ' ARG . 61.5 mtt180 -101.1 169.49 8.9 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.801 0.334 . . . . 0.0 111.003 -177.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 134.68 153.54 6.89 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.124 178.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -137.84 130.17 29.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.577 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -146.27 164.22 33.02 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 120.937 0.398 . . . . 0.0 111.391 -175.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.03 149.12 27.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.833 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 160.36 -167.53 35.65 Favored Glycine 0 N--CA 1.445 -0.757 0 C-N-CA 120.142 -1.028 . . . . 0.0 112.148 175.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 50.9 mm-40 -64.57 128.08 34.26 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.535 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.05 122.13 26.94 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.852 -178.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.3 tp -106.22 108.4 19.89 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 175.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.517 ' HB ' ' HB ' ' A' ' 115' ' ' THR . 43.3 t -110.59 113.52 44.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.967 0.413 . . . . 0.0 110.991 -172.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 22' ' ' GLU . 30.2 m -105.0 110.17 22.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.922 179.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -86.26 26.8 0.99 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.263 0.554 . . . . 0.0 110.837 -177.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.406 ' H ' HG22 ' A' ' 20' ' ' THR . 8.0 tp10 -115.44 157.51 23.86 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.76 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -103.4 94.61 5.58 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 45.5 pt -85.32 172.1 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.3 0.571 . . . . 0.0 111.445 -175.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.729 ' HB2' HD23 ' A' ' 27' ' ' LEU . 26.0 p -110.26 122.54 47.9 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.957 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.551 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 90.7 m-85 -81.21 64.4 5.93 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.319 0.58 . . . . 0.0 110.476 179.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.729 HD23 ' HB2' ' A' ' 25' ' ' SER . 3.5 mm? -119.74 -57.03 2.0 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.936 174.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.54 44.52 0.69 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.81 -53.15 6.55 Favored Glycine 0 C--O 1.224 -0.47 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.943 -176.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 65.7 mt -98.61 135.51 33.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.833 0.316 . . . . 0.0 110.815 -177.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.418 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 13.1 t70 -67.06 134.78 52.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.268 177.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -68.52 -25.61 65.03 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.221 0.452 . . . . 0.0 112.221 -171.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -110.77 -38.11 5.23 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.231 0.538 . . . . 0.0 111.288 -168.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.551 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -98.94 -14.97 19.31 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.585 -175.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 47' ' ' SER . . . 68.29 21.89 74.3 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.085 -178.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.551 HG12 ' HB ' ' A' ' 34' ' ' THR . 36.4 mm -88.44 127.07 41.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 C-N-CA 122.18 0.192 . . . . 0.0 110.625 -177.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 47.1 t -71.62 113.92 9.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -88.62 -28.61 20.54 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.054 -176.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -65.58 123.01 18.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.588 ' HA ' ' HG3' ' A' ' 44' ' ' LYS . 35.2 t70 -73.26 141.11 47.23 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.968 -173.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 42.0 t -172.81 -73.65 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.071 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -156.58 -51.18 0.08 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.331 179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.407 HG13 ' H ' ' A' ' 43' ' ' ILE . 1.9 pp -82.41 15.31 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.078 177.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.588 ' HG3' ' HA ' ' A' ' 40' ' ' ASP . 4.5 tmmm? -65.16 124.99 23.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.698 179.233 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 104.4 -15.29 50.3 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.368 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -91.27 159.24 16.13 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.307 0.575 . . . . 0.0 112.07 177.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.505 ' HB3' HD13 ' A' ' 36' ' ' ILE . 2.5 p -103.74 158.54 16.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.246 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.509 HG11 HD21 ' A' ' 53' ' ' LEU . 26.7 m -108.63 20.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.919 -179.511 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.03 91.93 2.1 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.647 -173.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.96 20.64 27.75 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.001 -0.999 . . . . 0.0 112.91 174.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -110.33 158.97 17.86 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.863 -0.198 . . . . 0.0 110.64 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.46 ' HB ' ' HA ' ' A' ' 17' ' ' ALA . 49.6 mm -95.59 104.58 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.815 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.623 HD13 ' HB3' ' A' ' 78' ' ' PRO . 9.9 mp -85.58 133.34 34.06 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.17 0.509 . . . . 0.0 111.688 -172.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.61 121.15 59.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.743 176.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.554 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 78.3 m-85 -128.88 144.42 52.41 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.825 0.345 . . . . 0.0 111.332 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -81.17 -11.32 12.17 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.546 2.164 . . . . 0.0 111.883 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 137.54 -158.66 24.6 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.054 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 154.96 -142.87 9.34 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -120.42 102.79 8.69 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.868 0.366 . . . . 0.0 110.597 177.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.551 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -96.47 81.73 0.76 Allowed Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.6 t -82.57 -178.29 7.02 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.071 0.463 . . . . 0.0 110.751 -176.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.1 p -66.93 -13.92 62.27 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.078 -175.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.1 t -87.55 -14.91 9.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.892 0.377 . . . . 0.0 110.774 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 26' ' ' PHE . . . -77.27 -24.6 65.55 Favored Glycine 0 N--CA 1.453 -0.204 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.434 -178.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.9 p -80.19 162.65 24.58 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.91 -0.171 . . . . 0.0 111.004 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 2.0 t80 75.58 -43.76 0.5 Allowed 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.373 0.669 . . . . 0.0 111.899 175.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 58.9 t -58.85 -33.74 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.929 0.395 . . . . 0.0 111.323 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.433 ' HB3' HD12 ' A' ' 99' ' ' ILE . 87.1 mt -57.73 -31.37 66.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.573 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 57.6 tp -67.3 -33.99 76.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.105 0.478 . . . . 0.0 110.514 -178.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -66.01 -41.84 90.48 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.972 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.7 mt -57.42 -42.59 82.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.587 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.403 ' N ' ' HB2' ' A' ' 77' ' ' ALA . 34.4 ttt180 -59.78 -51.04 71.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.915 -178.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 55.8 mtmt -75.39 -8.07 55.7 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.985 -174.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.481 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.0 t-20 -92.42 -30.91 15.51 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.988 0.423 . . . . 0.0 109.909 175.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.09 15.41 28.34 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.091 -178.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.481 HG22 ' HB3' ' A' ' 74' ' ' ASN . 20.1 m -117.64 14.17 7.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.888 0.375 . . . . 0.0 111.185 -178.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.403 ' HB2' ' N ' ' A' ' 72' ' ' ARG . . . -73.99 150.11 87.9 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.245 179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.623 ' HB3' HD13 ' A' ' 53' ' ' LEU . 7.9 Cg_exo -71.89 138.47 31.45 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.558 2.172 . . . . 0.0 110.383 171.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.577 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 85.5 mttt -63.44 -42.26 98.66 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.756 0.313 . . . . 0.0 111.346 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -157.92 153.57 26.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.803 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.575 HG12 ' HB2' ' A' ' 53' ' ' LEU . 52.8 mt -134.07 114.44 19.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 110.423 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.414 HG23 ' CG2' ' A' ' 102' ' ' VAL . 21.3 mm -100.65 124.22 54.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.554 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 34.9 m-80 -123.35 155.75 36.71 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.018 0.437 . . . . 0.0 111.228 -174.395 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.524 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 88.3 tttt -76.95 -46.98 22.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.502 174.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -116.89 120.71 39.31 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.815 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.4 t -99.51 134.77 41.91 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.721 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.51 141.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.464 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.5 m -66.99 -36.18 81.6 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.503 -175.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 87.0 mt -61.29 -43.88 97.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.976 0.417 . . . . 0.0 110.353 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.493 HD11 ' HA3' ' A' ' 60' ' ' GLY . 59.5 mt -64.4 -40.58 89.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.006 177.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.479 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -59.46 -46.57 88.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.527 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 88' ' ' THR . 90.1 t -58.52 -43.65 87.45 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 CA-C-O 120.975 0.417 . . . . 0.0 110.555 179.152 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.27 -41.05 69.73 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.5 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -71.05 -31.28 67.67 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.463 0.173 . . . . 0.0 111.412 -177.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.56 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.987 0.422 . . . . 0.0 110.971 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.7 mtm -70.29 -32.99 71.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.003 -179.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -88.43 3.47 49.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.797 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 56.15 43.1 27.35 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.927 0.87 . . . . 0.0 110.362 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 68' ' ' LEU . 63.8 mt -109.77 89.26 7.53 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.671 177.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.425 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 19.1 Cg_endo -56.99 116.0 2.9 Favored 'Trans proline' 0 C--O 1.235 0.364 0 C-N-CA 122.893 2.395 . . . . 0.0 112.616 -176.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.48 ' H ' HD23 ' A' ' 101' ' ' LEU . 2.6 pt? -118.44 137.07 53.41 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.508 175.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 7' ' ' ALA . 18.9 m -132.48 163.1 38.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.861 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.444 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 14.7 pt-20 -103.81 135.34 45.53 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.848 0.356 . . . . 0.0 110.094 176.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 15.8 m -116.26 130.92 70.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.102 0.477 . . . . 0.0 110.382 175.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -101.92 1.3 36.68 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.127 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -95.94 123.64 39.62 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.984 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -71.93 -32.79 67.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.371 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 28.6 mtpp -69.89 -23.7 63.28 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -174.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -54.44 -49.43 70.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 174.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.524 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 96.6 m-85 -74.58 -28.25 60.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.981 0.419 . . . . 0.0 110.996 -179.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 43.2 tt0 -66.44 -45.25 80.45 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.599 176.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -84.21 -39.45 19.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.454 -174.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 110' ' ' PHE . 9.4 p -65.45 127.83 27.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 CA-C-O 121.475 0.655 . . . . 0.0 110.963 -175.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -123.15 135.88 54.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.755 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.517 ' HB ' ' HB ' ' A' ' 19' ' ' VAL . 14.8 t -72.24 113.85 9.71 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-O 121.41 0.624 . . . . 0.0 109.551 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.5 -18.94 3.41 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.392 -176.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . 0.553 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 0.8 OUTLIER -99.02 -171.71 2.14 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.676 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.553 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -114.54 137.34 51.98 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.337 0.589 . . . . 0.0 112.025 -174.92 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 17' ' ' ALA . 84.3 t -120.38 130.33 74.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.743 177.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.5 t -98.88 111.44 28.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 174.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 88.3 t -96.0 120.71 45.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.134 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -124.71 99.85 6.36 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -86.18 -11.67 51.88 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.126 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -67.71 -43.01 81.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.015 0.436 . . . . 0.0 110.009 178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -96.38 -23.92 16.39 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.542 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.16 62.93 1.46 Allowed Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.521 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.528 ' CE1' ' HG3' ' A' ' 129' ' ' GLU . 25.6 p90 -162.41 163.55 27.67 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.772 0.32 . . . . 0.0 110.168 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 13.3 m -131.26 126.36 58.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.248 175.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.528 ' HG3' ' CE1' ' A' ' 127' ' ' TYR . 39.5 mt-10 -98.56 107.92 20.49 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.095 176.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 60.7 tp -82.45 102.0 11.03 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.358 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 18.1 pt -92.37 109.94 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.455 0.645 . . . . 0.0 110.291 -175.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 . . . . . 0 C--N 1.316 -0.854 0 CA-C-N 115.056 -0.974 . . . . 0.0 110.085 -177.165 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.508 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 13.9 m . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 121.261 0.553 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -130.74 114.93 15.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.739 -176.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.508 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 76.6 m-85 -128.5 164.75 22.1 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.118 0.485 . . . . 0.0 111.036 -176.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -118.49 139.43 51.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.447 174.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 10.3 p -120.21 171.67 8.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.258 -178.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.7 ttt85 -93.88 118.06 30.94 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.971 0.415 . . . . 0.0 110.116 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.53 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.82 96.52 1.66 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.042 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.468 HD11 ' OE1' ' A' ' 103' ' ' GLU . 49.3 mm -82.2 -43.51 19.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.87 175.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.8 p -125.29 -164.25 1.27 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.293 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 60.7 mtt-85 -118.56 -175.28 2.85 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.705 0.288 . . . . 0.0 110.59 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.564 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 115.71 145.21 8.43 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.04 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 68.8 mtm-85 -141.38 115.2 9.11 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.24 169.38 24.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.871 0.367 . . . . 0.0 111.193 -176.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.553 ' OE1' ' HD2' ' A' ' 118' ' ' ARG . 14.2 pt-20 -135.42 146.77 48.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.87 178.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.98 -173.48 34.48 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 120.079 -1.058 . . . . 0.0 112.098 174.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.62 127.97 34.4 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.45 118.98 22.54 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.905 -177.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.8 tp -102.02 111.42 23.68 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.563 ' HA ' ' CG1' ' A' ' 54' ' ' VAL . 47.1 t -98.87 110.92 27.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.385 0.612 . . . . 0.0 110.522 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.468 HG21 HD11 ' A' ' 24' ' ' ILE . 6.8 m -110.55 132.16 54.43 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.092 -176.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -102.77 -10.02 19.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.13 0.491 . . . . 0.0 110.573 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -97.88 161.47 13.73 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -96.0 141.73 29.06 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.553 0.216 . . . . 0.0 110.468 -178.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 20' ' ' THR . 2.5 mp -114.16 132.89 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.517 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 55.2 p -78.73 115.23 18.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.148 0.499 . . . . 0.0 110.722 -178.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.95 -6.3 32.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.333 179.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.535 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.05 -30.53 71.5 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 175.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 146.55 51.81 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.452 -0.88 . . . . 0.0 112.48 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.16 21.17 32.64 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.161 179.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.511 HD13 HG21 ' A' ' 48' ' ' VAL . 53.6 mt -130.75 136.74 57.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 -179.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.592 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.1 t70 -69.46 123.79 22.18 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.608 ' HG2' ' OE1' ' A' ' 33' ' ' GLU . 0.6 OUTLIER -79.28 -12.21 59.94 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -170.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.608 ' OE1' ' HG2' ' A' ' 32' ' ' LYS . 2.4 mp0 -94.33 -41.09 9.61 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 121.137 -0.225 . . . . 0.0 111.254 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.9 p -103.06 -36.97 7.96 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 -177.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.79 16.45 36.2 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.816 -175.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.0 mm -91.45 128.44 43.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 44' ' ' LYS . 8.4 m -62.96 142.02 17.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.021 0.439 . . . . 0.0 110.912 177.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.592 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 26.9 mmmt -96.12 -3.67 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.487 0.661 . . . . 0.0 110.823 -174.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -92.39 158.86 15.84 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.642 -175.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -92.29 139.28 30.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.371 0.605 . . . . 0.0 112.127 -176.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 48.8 t -179.22 168.7 1.52 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 172.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -68.32 -35.97 78.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.049 0.452 . . . . 0.0 110.428 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 32.3 pt -102.62 12.36 7.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.493 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.52 ' HB2' ' HB3' ' A' ' 41' ' ' CYS . 70.2 mttt -99.44 147.5 25.2 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 176.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.408 ' H ' ' CG2' ' A' ' 37' ' ' VAL . . . 118.48 1.55 15.59 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -175.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.0 mt-10 -108.82 -179.36 3.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.802 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.6 m -91.83 133.9 35.23 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.933 -171.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.511 HG21 HD13 ' A' ' 30' ' ' ILE . 34.5 m -101.6 4.38 10.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.3 0.572 . . . . 0.0 110.005 174.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -67.27 100.13 0.78 Allowed 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.186 -174.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.17 19.99 50.97 Favored Glycine 0 C--N 1.308 -1.001 0 CA-C-N 114.536 -1.211 . . . . 0.0 112.872 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -110.72 155.53 22.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.87 HG13 ' HB3' ' A' ' 80' ' ' ALA . 1.8 mp -84.66 105.48 13.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 175.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 32.1 tp -82.28 126.89 32.64 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.447 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.563 ' CG1' ' HA ' ' A' ' 19' ' ' VAL . 11.8 p -130.26 106.96 13.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.62 0.724 . . . . 0.0 111.842 177.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.441 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 38.1 p90 -136.16 151.68 73.95 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.175 170.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.91 -55.43 2.33 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.547 2.164 . . . . 0.0 112.808 -177.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 134.43 138.15 3.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.874 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -167.7 -101.79 0.15 Allowed Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.69 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.517 ' O ' ' HA ' ' A' ' 25' ' ' SER . 65.4 tttp -75.63 81.92 2.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.156 0.503 . . . . 0.0 109.807 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -161.98 88.59 0.11 Allowed Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.508 ' HA ' ' OE1' ' A' ' 87' ' ' GLU . 21.9 t -153.9 161.78 41.74 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -178.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 7.6 m 66.71 43.88 2.31 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.899 0.857 . . . . 0.0 110.382 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.625 HG21 HG12 ' A' ' 90' ' ' ILE . 5.1 t -72.26 -27.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.515 177.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 76.35 -77.46 1.39 Allowed Glycine 0 N--CA 1.441 -0.989 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.121 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.7 p 173.13 -77.1 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 O-C-N 124.092 0.525 . . . . 0.0 111.84 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -70.69 -9.5 57.3 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -170.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 62.9 t -60.63 -41.79 89.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.983 0.421 . . . . 0.0 110.648 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.428 HD13 ' O ' ' A' ' 68' ' ' LEU . 0.7 OUTLIER -73.38 -32.17 64.33 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.231 0.539 . . . . 0.0 109.871 179.282 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 56.6 tp -61.33 -32.49 72.38 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.2 -178.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -54.94 -44.23 74.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.213 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 88.0 mt -61.84 -33.15 73.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.005 -178.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.558 ' HD3' ' HA ' ' A' ' 97' ' ' ALA . 8.0 ttp180 -72.16 -35.94 69.17 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.126 -178.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -61.37 -31.19 71.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.014 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -93.54 -25.17 17.69 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.938 0.399 . . . . 0.0 110.442 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 94.16 26.94 12.94 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.704 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 35.8 m -107.15 4.56 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.171 0.51 . . . . 0.0 110.443 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.96 159.38 73.57 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.733 179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.49 162.38 24.45 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.491 2.127 . . . . 0.0 112.13 175.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -82.83 -28.8 29.94 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.87 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -166.77 165.22 16.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.673 175.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.694 HG23 HD22 ' A' ' 101' ' ' LEU . 8.3 tt -152.07 121.29 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.45 0.643 . . . . 0.0 110.824 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.821 HG23 HG23 ' A' ' 102' ' ' VAL . 2.7 mm -110.21 118.88 58.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -116.39 165.96 12.61 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.364 0.602 . . . . 0.0 111.758 -174.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -101.22 -31.49 10.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.302 176.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.9 tttm -121.28 122.41 39.83 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.577 176.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 66.5 p -127.68 158.75 36.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.967 0.413 . . . . 0.0 111.681 -175.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.552 ' HB2' HG13 ' A' ' 90' ' ' ILE . 53.8 mt-10 -123.58 157.66 33.2 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.776 173.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.524 ' O ' HG23 ' A' ' 92' ' ' VAL . 89.2 m -60.09 -44.28 94.92 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.107 178.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 9.9 pt -63.9 -29.89 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.453 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.625 HG12 HG21 ' A' ' 63' ' ' VAL . 64.4 mt -66.98 -42.75 89.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.99 -32.96 74.75 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.198 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 88' ' ' THR . 73.1 t -66.69 -49.87 70.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-O 120.929 0.395 . . . . 0.0 110.543 177.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.35 -44.11 97.35 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.13 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.409 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -64.09 -37.33 87.04 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 111.585 0.216 . . . . 0.0 111.585 -179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.3 -41.76 96.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.807 0.337 . . . . 0.0 111.12 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 66.5 mtm -74.64 -32.09 62.18 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.897 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.558 ' HA ' ' HD3' ' A' ' 72' ' ' ARG . . . -82.04 -0.61 45.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 176.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 57.32 38.39 28.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 121.278 0.561 . . . . 0.0 111.233 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.409 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 61.4 mt -111.08 90.93 12.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.198 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.564 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 82.5 Cg_exo -40.57 115.6 0.34 Allowed 'Trans proline' 0 C--N 1.35 0.651 0 C-N-CA 124.027 3.151 . . . . 0.0 113.872 -175.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.694 HD22 HG23 ' A' ' 81' ' ' ILE . 0.1 OUTLIER -108.94 120.67 43.22 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.584 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.821 HG23 HG23 ' A' ' 82' ' ' ILE . 5.5 m -140.5 161.84 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.784 177.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.468 ' OE1' HD11 ' A' ' 8' ' ' ILE . 46.1 mt-10 -101.21 132.99 46.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.529 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.425 HG13 ' CG2' ' A' ' 82' ' ' ILE . 3.4 m -96.48 139.65 18.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 167.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -99.97 -46.76 5.25 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.347 -174.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.419 ' OD1' ' HG3' ' A' ' 108' ' ' LYS . 7.1 t70 -92.8 146.51 23.59 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.218 0.532 . . . . 0.0 111.338 -174.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -71.1 -18.76 62.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.103 -0.953 . . . . 0.0 111.177 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HG3' ' OD1' ' A' ' 106' ' ' ASP . 67.7 mttm -55.08 -33.08 62.47 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -61.31 -40.6 94.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.421 -178.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.01 -31.14 68.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.295 -176.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -77.98 -45.58 23.44 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.902 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.482 ' HB1' HG11 ' A' ' 1' ' ' VAL . . . -66.51 -37.56 85.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.179 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 12.0 p -75.15 129.28 36.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.405 0.621 . . . . 0.0 111.076 -177.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.425 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 71.1 mmtt -118.91 144.12 46.6 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.431 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.9 m -64.76 110.9 2.55 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.96 0.41 . . . . 0.0 110.631 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.89 -7.57 8.78 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.425 -178.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . 0.425 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 12.2 m-20 -87.39 171.84 10.28 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 174.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.553 ' HD2' ' OE1' ' A' ' 14' ' ' GLU . 11.7 ttp180 -115.67 121.94 44.06 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.824 0.345 . . . . 0.0 110.862 -178.382 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.5 p -111.95 130.07 66.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.187 0.518 . . . . 0.0 110.409 178.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 45.6 t -99.19 111.21 28.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 175.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.1 p -102.25 115.23 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.642 0.734 . . . . 0.0 111.754 -174.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . 0.482 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 50.1 t-20 -99.94 94.15 6.14 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 172.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.423 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -82.4 -19.67 38.64 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.108 0.48 . . . . 0.0 110.266 -178.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.78 -39.07 93.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.643 -179.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -107.46 -28.02 10.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.814 177.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.95 64.45 0.99 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.487 -0.863 . . . . 0.0 111.291 -176.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.482 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 35.6 t80 -144.55 124.39 13.44 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -174.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.425 HG23 ' HB2' ' A' ' 3' ' ' PHE . 5.9 m -126.26 118.09 50.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.481 0.657 . . . . 0.0 110.997 -179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -121.04 123.38 42.23 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.193 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.496 ' HB3' HG23 ' A' ' 1' ' ' VAL . 17.0 tp -103.81 120.59 41.3 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.152 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.44 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -89.43 123.27 41.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--N 1.317 -0.814 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.309 -178.938 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 2' ' ' LYS . 60.6 t . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 1' ' ' VAL . 49.2 mttp 64.34 77.84 0.3 Allowed 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -170.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -98.97 136.79 38.44 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.053 0.454 . . . . 0.0 110.775 -176.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -107.27 110.64 22.72 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.708 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.887 ' SG ' HG12 ' A' ' 104' ' ' VAL . 58.2 m -119.71 -178.73 3.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.489 -174.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.501 ' HB3' ' HG3' ' A' ' 103' ' ' GLU . 17.5 tpt180 -91.3 119.86 31.7 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.996 0.427 . . . . 0.0 110.639 -171.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -93.54 140.05 30.05 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.021 -178.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.402 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.8 mp -114.0 -45.51 4.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.751 177.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.616 HG22 ' H ' ' A' ' 10' ' ' ARG . 3.0 m -109.6 177.55 4.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.401 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' THR . 81.6 mtt180 -112.05 -177.97 3.3 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.539 0.209 . . . . 0.0 110.794 -175.118 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 106.56 172.59 22.97 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.026 -178.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 7.3 ptm180 -149.71 119.73 7.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.044 0.45 . . . . 0.0 110.401 178.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.474 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -125.44 139.25 53.8 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.534 -174.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.26 125.23 44.04 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.925 -177.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.97 -160.91 23.1 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.996 175.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.717 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.9 mt-10 -74.67 130.94 40.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 122.822 0.449 . . . . 0.0 111.036 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.36 128.91 34.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.659 177.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HA ' HG23 ' A' ' 115' ' ' THR . 5.2 tt -118.97 114.74 23.03 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 177.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -105.21 126.39 60.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.978 0.418 . . . . 0.0 111.039 -173.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.5 m -129.56 95.35 3.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 177.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -84.49 83.79 7.88 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.123 0.487 . . . . 0.0 110.117 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -160.73 161.05 32.09 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.419 -0.81 . . . . 0.0 108.856 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 87.6 m-85 -101.26 89.14 3.68 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.596 ' HB ' ' HG2' ' A' ' 39' ' ' GLU . 32.7 pt -108.66 170.88 2.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.543 -172.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.27 123.01 39.75 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.488 -177.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.421 ' HE2' ' HA3' ' A' ' 64' ' ' GLY . 44.3 t80 -78.73 -4.91 51.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.334 0.588 . . . . 0.0 109.96 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.547 ' HA ' HG21 ' A' ' 63' ' ' VAL . 4.1 pp -72.93 -16.21 61.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.147 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.52 44.46 0.72 Allowed Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.451 -0.659 . . . . 0.0 111.451 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.29 -84.34 0.37 Allowed Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.265 -179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.461 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.1 mp -92.42 137.8 21.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 178.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -62.01 138.73 58.41 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.694 0.283 . . . . 0.0 110.351 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.541 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.8 pttp -74.5 -8.58 56.79 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -171.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.679 ' HA ' ' ND2' ' A' ' 74' ' ' ASN . 33.4 mt-10 -127.03 -44.47 1.61 Allowed 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 46.3 p -96.92 -16.97 20.42 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -177.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.66 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.11 16.74 79.33 Favored Glycine 0 C--N 1.329 0.149 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.941 177.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.544 HD13 ' HB3' ' A' ' 47' ' ' SER . 35.5 mm -90.46 133.5 32.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.3 t -62.94 123.14 15.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.89 0.376 . . . . 0.0 110.63 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -87.24 -47.18 9.05 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.759 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.596 ' HG2' ' HB ' ' A' ' 24' ' ' ILE . 4.8 tp10 -62.06 134.76 57.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.671 179.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -93.03 160.85 14.68 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.269 0.557 . . . . 0.0 111.235 -175.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 47.9 t -178.68 -49.63 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -176.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 176.2 -45.98 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 114.642 -1.163 . . . . 0.0 109.718 174.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.78 13.25 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.936 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.2 tmmt? -65.91 128.68 36.99 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 116.74 -21.78 11.15 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.959 -176.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -87.98 156.48 19.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.982 0.42 . . . . 0.0 110.457 177.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.544 ' HB3' HD13 ' A' ' 36' ' ' ILE . 13.3 p -103.02 144.8 30.81 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.944 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.444 HG23 ' H ' ' A' ' 49' ' ' ALA . 0.0 OUTLIER -74.47 -76.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.608 175.046 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.444 ' H ' HG23 ' A' ' 48' ' ' VAL . . . 46.3 81.42 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.925 0.713 . . . . 0.0 112.925 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.09 3.78 88.79 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.64 -0.79 . . . . 0.0 113.303 177.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.717 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 52.0 mtt180 -94.6 162.28 13.86 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.411 -0.464 . . . . 0.0 110.902 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.453 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.6 mp -104.99 120.18 55.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 81' ' ' ILE . 54.8 tp -99.06 132.85 44.08 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.632 -0.258 . . . . 0.0 110.483 -177.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.44 107.3 15.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.038 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 41.0 p90 -135.76 144.58 49.43 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 172.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -55.13 -55.19 3.37 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.824 2.349 . . . . 0.0 112.883 -177.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.414 ' O ' ' HA ' ' A' ' 23' ' ' TYR . . . 165.36 -161.7 35.1 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.738 -178.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . 161.56 -101.61 0.2 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.254 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.45 ' HD2' ' C ' ' A' ' 58' ' ' GLY . 14.0 mptt -125.92 98.44 5.52 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.665 0.269 . . . . 0.0 111.227 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.97 72.18 1.65 Allowed Glycine 0 N--CA 1.453 -0.198 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 176.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.459 ' HB3' ' HB3' ' A' ' 27' ' ' LEU . 9.0 t -80.56 66.98 6.26 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 -171.102 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.587 ' HA ' HG21 ' A' ' 89' ' ' ILE . 24.4 p 53.89 16.91 1.18 Allowed 'General case' 0 N--CA 1.479 1.005 0 N-CA-C 114.688 1.366 . . . . 0.0 114.688 171.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.547 HG21 ' HA ' ' A' ' 27' ' ' LEU . 74.1 t -87.37 -33.63 6.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 O-C-N 122.104 -0.373 . . . . 0.0 111.487 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.421 ' HA3' ' HE2' ' A' ' 26' ' ' PHE . . . -79.36 30.48 2.17 Favored Glycine 0 C--O 1.228 -0.27 0 C-N-CA 120.811 -0.709 . . . . 0.0 113.041 -178.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 8.1 p -90.96 -26.34 19.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.576 0.227 . . . . 0.0 111.448 -177.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -156.24 -21.61 0.1 Allowed 'General case' 0 N--CA 1.463 0.187 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 86.3 t -58.37 -32.88 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.524 ' HA ' HD12 ' A' ' 71' ' ' LEU . 10.3 mp -61.85 -28.22 69.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.512 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 61.6 tp -70.64 -39.8 73.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.905 0.383 . . . . 0.0 110.331 178.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -65.9 -32.35 73.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.911 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.524 HD12 ' HA ' ' A' ' 68' ' ' LEU . 97.3 mt -57.63 -39.55 77.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.488 175.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 49.2 ttp180 -71.52 -33.36 69.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.572 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -62.41 -33.8 75.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.245 0.545 . . . . 0.0 110.295 177.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.679 ' ND2' ' HA ' ' A' ' 33' ' ' GLU . 92.0 m-20 -88.02 -14.33 39.31 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.906 178.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 79.19 13.56 82.75 Favored Glycine 0 N--CA 1.453 -0.205 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.541 178.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.66 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.5 m -106.79 8.68 9.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-O 121.127 0.489 . . . . 0.0 110.966 -176.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -70.7 150.45 95.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.483 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.49 147.68 52.56 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.458 2.105 . . . . 0.0 110.562 171.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.474 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 12.0 mttm -71.81 -35.53 69.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.922 0.391 . . . . 0.0 110.533 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.453 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -155.83 151.99 27.86 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.368 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.545 HG23 ' HB3' ' A' ' 101' ' ' LEU . 3.8 tp -129.52 120.84 51.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.905 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.711 HD12 HG22 ' A' ' 102' ' ' VAL . 4.7 mm -117.32 116.73 52.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.443 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 25.9 m120 -109.1 -179.67 3.91 Favored 'General case' 0 C--O 1.22 -0.471 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 103' ' ' GLU . 39.0 ttmt -82.55 -45.04 15.14 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -141.37 100.45 3.79 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 169.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -74.22 150.39 40.34 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -92.3 147.4 22.95 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.254 -175.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.8 m -52.79 -36.93 59.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.419 -177.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.587 HG21 ' HA ' ' A' ' 62' ' ' THR . 49.5 mt -56.35 -47.54 81.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.006 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 56.9 mt -68.3 -38.78 79.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.378 -177.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.92 -42.87 94.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.177 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 88' ' ' THR . 93.7 t -66.19 -42.95 92.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.77 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.9 -45.45 73.79 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.769 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.489 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -68.57 -30.06 68.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.677 0.275 . . . . 0.0 111.519 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -62.76 -25.38 68.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.408 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.0 mtm -83.17 -26.42 30.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.349 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.578 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -96.5 1.02 51.09 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.939 -178.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.521 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 1.5 mp0 59.0 47.85 11.6 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.124 0.488 . . . . 0.0 110.855 -175.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.489 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 58.1 mt -107.74 89.39 5.2 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.882 176.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 36.6 Cg_exo -55.87 116.69 3.34 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.904 2.403 . . . . 0.0 112.195 -177.175 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.545 ' HB3' HG23 ' A' ' 81' ' ' ILE . 1.8 pt? -122.71 134.7 54.45 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.44 0.638 . . . . 0.0 110.792 178.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.711 HG22 HD12 ' A' ' 82' ' ' ILE . 14.4 m -130.31 170.16 19.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.562 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 7.9 pt-20 -119.41 132.48 55.83 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.315 0.578 . . . . 0.0 111.676 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.887 HG12 ' SG ' ' A' ' 5' ' ' CYS . 17.3 m -104.47 105.04 17.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.925 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.436 ' HA ' ' HG3' ' A' ' 84' ' ' LYS . 32.6 ttp180 -99.13 27.62 4.97 Favored 'General case' 0 C--N 1.32 -0.717 0 O-C-N 121.837 -0.539 . . . . 0.0 110.614 -177.442 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -123.87 131.88 53.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.125 178.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -71.33 -26.59 62.9 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.212 -176.144 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.2 mmtp -65.22 -24.21 67.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.167 -177.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.592 ' O ' HG12 ' A' ' 113' ' ' VAL . 80.6 t80 -65.01 -48.6 73.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -66.69 -25.42 66.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.687 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -78.85 -25.98 44.05 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 115.487 -0.778 . . . . 0.0 111.627 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -94.32 -39.69 10.36 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.032 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.4 p -89.8 137.97 20.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 111.17 -176.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -137.28 157.62 46.24 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.39 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 18' ' ' LEU . 32.6 m -64.24 110.09 2.1 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.492 -175.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.08 -17.37 3.85 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.546 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 -82.66 156.86 23.61 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.966 0.413 . . . . 0.0 111.13 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.0 OUTLIER -89.93 119.38 30.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.079 179.835 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.38 136.87 56.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.244 0.545 . . . . 0.0 111.078 -178.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.0 110.51 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.499 173.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.446 HG11 HD11 ' A' ' 82' ' ' ILE . 66.7 t -92.82 104.44 15.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.693 179.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -107.05 98.75 8.37 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.027 -179.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.12 -9.04 58.34 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.342 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -64.27 -39.41 93.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.581 175.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -102.63 -34.46 9.06 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.863 175.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 98.31 68.2 0.91 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.474 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -166.15 166.18 17.19 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -178.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.27 121.51 42.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.349 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -120.69 117.79 28.43 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.317 0.579 . . . . 0.0 110.678 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.588 HD13 HG23 ' A' ' 113' ' ' VAL . 0.9 OUTLIER -109.43 147.87 32.09 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.143 178.101 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.404 HG12 ' NH2' ' A' ' 118' ' ' ARG . 46.6 mm -110.01 128.58 66.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 C--N 1.317 -0.815 0 O-C-N 123.954 0.783 . . . . 0.0 109.939 -179.448 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.532 HG23 ' HB3' ' A' ' 130' ' ' LEU . 17.1 m . . . . . 0 N--CA 1.452 -0.341 0 CA-C-O 121.303 0.573 . . . . 0.0 112.219 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.423 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -137.21 140.51 41.77 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.079 173.06 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -127.5 151.09 49.31 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.924 0.392 . . . . 0.0 111.044 -173.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.9 127.02 44.72 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.044 177.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 4.4 p -120.87 173.44 7.23 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.734 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 tpm_? -94.04 121.5 35.59 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 176.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.591 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -86.53 97.39 10.48 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.413 . . . . 0.0 111.302 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.63 -45.12 19.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 173.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -104.3 172.08 6.99 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.549 178.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 55.9 mtt-85 -111.04 176.83 4.87 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.283 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.51 -178.14 16.42 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.668 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -155.51 114.78 3.59 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 156.37 41.25 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -169.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tm-20 -135.85 120.92 18.82 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.041 -0.981 . . . . 0.0 108.735 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.19 162.44 35.72 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 119.717 -1.23 . . . . 0.0 113.4 -178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.74 140.95 56.72 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.608 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.94 125.79 30.58 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 120.969 0.414 . . . . 0.0 111.651 -176.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.51 ' HA ' HG23 ' A' ' 115' ' ' THR . 7.9 tt -111.89 110.43 20.76 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 171.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.1 t -102.7 110.17 28.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.091 0.472 . . . . 0.0 110.824 -175.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.455 HG23 ' CD2' ' A' ' 18' ' ' LEU . 2.0 p -99.43 112.92 25.04 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.814 178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.42 ' HG2' ' H ' ' A' ' 21' ' ' LYS . 44.0 pttt -92.32 0.72 57.47 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.856 0.836 . . . . 0.0 109.105 176.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -79.61 -173.39 3.75 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.54 -1.209 . . . . 0.0 109.675 174.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . 0.415 ' HB3' ' HA2' ' A' ' 58' ' ' GLY . 42.1 m-85 -121.0 93.99 4.2 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.297 0.57 . . . . 0.0 110.557 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.486 ' O ' ' HA3' ' A' ' 58' ' ' GLY . 31.8 mt -106.21 146.44 12.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.527 -176.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.542 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 33.9 t -131.74 162.27 30.87 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.461 ' HD2' HG12 ' A' ' 90' ' ' ILE . 64.0 m-85 -88.45 23.82 2.11 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.167 0.508 . . . . 0.0 111.007 -177.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.542 ' HG ' ' HB3' ' A' ' 25' ' ' SER . 1.0 OUTLIER -74.93 -14.7 60.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.921 169.466 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.524 ' N ' HD12 ' A' ' 27' ' ' LEU . . . 139.84 57.65 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.727 -178.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.77 -42.23 6.12 Favored Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.866 -178.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.509 HG13 HG12 ' A' ' 37' ' ' VAL . 4.3 mp -93.41 146.46 6.46 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 20.0 t70 -70.43 138.98 51.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.825 0.345 . . . . 0.0 110.175 176.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HG3' ' HG3' ' A' ' 33' ' ' GLU . 20.2 ptmt -79.77 -10.49 59.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.439 ' HG3' ' HG3' ' A' ' 32' ' ' LYS . 43.0 mt-10 -121.21 -40.45 2.59 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -176.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 36.0 p -92.57 -18.8 22.63 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.997 0.427 . . . . 0.0 111.384 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.475 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 76.51 11.13 85.43 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.093 -179.013 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.0 mm -86.92 132.37 32.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.509 HG12 HG13 ' A' ' 30' ' ' ILE . 11.8 m -67.87 129.49 32.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-O 121.281 0.562 . . . . 0.0 111.355 178.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 72.4 mmtt -84.64 -37.14 21.4 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 174.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -94.51 90.62 6.26 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.512 -178.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.975 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.5 t70 -146.96 -164.47 2.0 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.007 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 45.6 t -166.87 -41.2 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 120.818 0.342 . . . . 0.0 110.469 -177.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -103.93 -48.43 3.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.505 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -111.56 15.93 8.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.891 0.377 . . . . 0.0 111.336 -173.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.975 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 38.6 ttmt -50.26 128.9 20.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.171 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.72 -7.45 12.15 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.107 -175.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.45 ' HB3' ' NH1' ' A' ' 51' ' ' ARG . 22.0 mm-40 -93.3 145.26 24.59 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 110.282 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.472 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 34.6 t -97.7 148.39 23.39 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 20.5 m -86.82 2.06 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.983 0.421 . . . . 0.0 110.706 178.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -67.22 92.51 0.27 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.538 -176.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.99 5.36 33.16 Favored Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.328 -0.851 . . . . 0.0 113.443 171.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.502 ' HD3' ' HB2' ' A' ' 18' ' ' LEU . 0.8 OUTLIER -123.56 178.29 5.26 Favored 'General case' 0 C--N 1.321 -0.633 0 O-C-N 122.65 -0.324 . . . . 0.0 110.461 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.506 HD12 ' HB ' ' A' ' 119' ' ' VAL . 72.2 mt -108.1 130.02 61.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.165 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.598 ' HB3' HG12 ' A' ' 81' ' ' ILE . 60.3 tp -96.1 123.93 39.91 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.706 -176.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 54.4 t -123.79 108.77 21.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.749 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.448 ' HB3' ' OG1' ' A' ' 20' ' ' THR . 53.4 p90 -134.58 144.56 51.36 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.104 174.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 6.2 Cg_exo -74.81 -38.82 1.53 Allowed 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 123.018 2.479 . . . . 0.0 112.027 177.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.95 -165.48 31.88 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.486 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . -170.19 -134.14 1.7 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.13 -1.034 . . . . 0.0 113.284 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -69.2 158.59 34.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.653 0.263 . . . . 0.0 110.573 -178.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -83.09 -27.14 41.69 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.046 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.449 ' O ' HD23 ' A' ' 27' ' ' LEU . 22.8 m -76.61 73.59 3.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.348 0.594 . . . . 0.0 110.305 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.498 HG21 ' HG3' ' A' ' 87' ' ' GLU . 10.7 t -83.7 42.86 0.87 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.542 0.686 . . . . 0.0 111.333 -175.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.3 t -112.41 130.58 65.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.485 0.659 . . . . 0.0 111.196 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 150.86 -76.26 0.24 Allowed Glycine 0 N--CA 1.441 -0.98 0 CA-C-N 114.88 -1.055 . . . . 0.0 111.148 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.541 ' HB2' ' HB ' ' A' ' 89' ' ' ILE . 11.8 t 52.51 -161.03 0.1 Allowed 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.811 0.444 . . . . 0.0 110.959 -177.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 69.32 -31.95 0.22 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.907 0.883 . . . . 0.0 113.298 175.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.545 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 23.0 m -56.79 -31.12 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.518 HD22 HG23 ' A' ' 67' ' ' VAL . 4.0 mm? -59.13 -40.52 85.73 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.906 0.384 . . . . 0.0 110.579 178.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.545 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.3 tp -63.58 -44.65 93.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.194 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -62.13 -45.73 92.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.267 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.545 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 92.7 mt -59.36 -40.38 86.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.589 178.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.653 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -69.12 -37.73 78.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.061 -176.172 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.506 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 32.5 mmmt -70.01 -27.34 64.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.933 0.397 . . . . 0.0 110.709 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 t30 -87.61 -21.92 25.06 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.132 0.491 . . . . 0.0 110.435 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.79 20.43 37.0 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.216 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.617 ' HA ' ' HB2' ' A' ' 49' ' ' ALA . 21.9 m -118.41 24.24 4.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.015 0.436 . . . . 0.0 110.791 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -95.44 159.34 32.91 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.801 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 62.5 Cg_endo -76.45 151.69 33.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.178 1.919 . . . . 0.0 111.392 175.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.444 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 89.6 mttt -74.8 -30.96 61.58 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.73 0.3 . . . . 0.0 111.255 -178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.96 161.73 36.74 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.43 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.598 HG12 ' HB3' ' A' ' 53' ' ' LEU . 71.2 mt -139.36 129.75 31.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 O-C-N 123.323 0.39 . . . . 0.0 110.176 178.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.601 HG23 HG23 ' A' ' 102' ' ' VAL . 4.6 mm -117.01 125.0 73.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -120.21 161.79 20.48 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.735 0.302 . . . . 0.0 111.218 -176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.5 tptp -94.64 -38.0 11.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.596 0.712 . . . . 0.0 109.24 171.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -133.14 116.05 15.8 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.545 175.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.8 t -106.95 171.51 7.33 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.453 -177.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.498 ' HG3' HG21 ' A' ' 62' ' ' THR . 1.4 tm-20 -137.44 159.82 40.85 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -175.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.405 ' H ' ' CD ' ' A' ' 87' ' ' GLU . 4.3 m -52.44 -47.79 66.2 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 122.941 0.496 . . . . 0.0 111.518 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 65' ' ' SER . 2.1 pp -62.92 -28.89 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-O 121.014 0.435 . . . . 0.0 110.86 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.461 HG12 ' HD2' ' A' ' 26' ' ' PHE . 51.1 mt -75.16 -50.91 22.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.168 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.84 -48.36 82.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.084 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.66 -43.54 98.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.923 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.0 -41.74 98.48 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.6 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 99' ' ' ILE . . . -71.6 -40.32 69.91 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.781 0.324 . . . . 0.0 111.056 -179.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.04 -41.15 91.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.516 -178.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.1 mtm -64.84 -31.56 72.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.542 -177.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.653 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -99.96 5.02 45.23 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.289 0.478 . . . . 0.0 112.289 -175.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 63.07 52.4 2.56 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.71 0.766 . . . . 0.0 109.861 -176.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.513 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 33.3 mm -111.59 89.62 11.15 Favored Pre-proline 0 C--N 1.318 -0.788 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.168 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 79' ' ' LYS . 73.2 Cg_exo -47.89 105.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.558 0 C-N-CA 122.979 2.453 . . . . 0.0 112.324 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 9.8 tt -122.83 129.97 52.33 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.622 -177.142 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.601 HG23 HG23 ' A' ' 82' ' ' ILE . 30.2 m -134.68 164.72 33.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.823 -178.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -110.27 112.53 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.674 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.483 HG22 ' H ' ' A' ' 106' ' ' ASP . 7.2 p -91.99 122.93 43.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.294 0.568 . . . . 0.0 111.113 -175.485 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.26 6.01 49.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.187 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.484 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 9.8 t70 -108.72 126.03 52.55 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.117 0.484 . . . . 0.0 111.015 -175.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -71.55 -33.64 69.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.721 -177.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.574 ' HE3' ' HA ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -61.54 -26.98 68.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.858 -176.993 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -56.48 -49.0 75.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.817 177.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -70.3 -26.86 63.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.089 -175.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.38 -36.11 46.37 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.235 178.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -85.89 -28.2 24.52 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 10.0 p -81.26 127.06 39.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.48 0.657 . . . . 0.0 111.232 -177.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -122.94 154.82 37.87 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.44 176.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 18' ' ' LEU . 36.7 m -67.87 94.62 0.47 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.065 0.46 . . . . 0.0 110.525 178.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 151.32 -29.63 0.97 Allowed Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.181 -178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -71.98 169.37 16.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 174.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 6.9 tmm_? -115.87 132.33 56.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.035 0.445 . . . . 0.0 110.903 -175.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 17' ' ' ALA . 48.2 t -110.43 139.83 32.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.023 -176.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.07 112.57 41.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 172.062 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.418 HG23 HD13 ' A' ' 52' ' ' ILE . 62.9 t -101.91 114.94 42.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.145 -174.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 -106.06 92.91 4.35 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -89.5 -6.83 56.07 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.109 0.48 . . . . 0.0 110.639 -176.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -73.38 -36.78 66.13 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.58 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -112.49 -4.24 14.24 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.134 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.431 ' CA ' ' HB2' ' A' ' 7' ' ' ALA . . . 74.73 71.7 1.11 Allowed Glycine 0 N--CA 1.453 -0.209 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.251 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -158.4 144.99 17.4 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -176.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -130.8 122.93 53.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.311 0.576 . . . . 0.0 110.911 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -109.3 118.34 36.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.345 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.532 ' HB3' HG23 ' A' ' 1' ' ' VAL . 64.9 tp -93.38 115.14 27.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.015 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 22.6 mm -91.3 111.73 24.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.5 0.667 . . . . 0.0 109.691 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 . . . . . 0 C--N 1.308 -1.21 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.001 -179.224 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.444 ' HD3' ' HG2' ' A' ' 129' ' ' GLU . 87.8 mttt 63.74 96.86 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.486 0.66 . . . . 0.0 110.113 -175.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -110.34 148.0 32.82 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.066 -172.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.78 130.38 39.81 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.289 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.614 ' SG ' HG22 ' A' ' 104' ' ' VAL . 26.0 m -121.43 179.4 4.45 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.03 0.443 . . . . 0.0 111.001 -176.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.646 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 40.2 ttt180 -94.79 121.88 36.84 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.775 178.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.541 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.41 130.71 34.75 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.775 0.321 . . . . 0.0 111.683 -174.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.1 mp -105.32 -48.12 9.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 173.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 26.7 p -117.19 -173.89 2.49 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.957 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -120.69 -177.26 3.43 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.635 0.255 . . . . 0.0 110.649 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 110.46 152.06 13.11 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.247 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.435 HH11 ' HD2' ' A' ' 12' ' ' ARG . 16.7 mtp180 -113.16 136.9 52.21 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.684 0.278 . . . . 0.0 110.271 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.409 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -137.35 132.15 33.17 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.433 178.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.541 ' HG3' HG22 ' A' ' 120' ' ' VAL . 35.6 tt0 -131.11 126.2 35.13 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.947 176.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 177.6 -158.27 23.4 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.048 -1.072 . . . . 0.0 113.086 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -72.2 136.15 46.32 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 122.807 0.443 . . . . 0.0 110.723 -177.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.528 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -99.75 131.94 45.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.384 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.3 tp -118.78 120.67 38.07 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.533 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.57 117.4 47.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.645 0.736 . . . . 0.0 110.194 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 8.9 m -108.48 134.57 51.09 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.497 -176.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.49 -21.54 18.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.194 0.521 . . . . 0.0 109.717 177.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.414 ' H ' HG22 ' A' ' 20' ' ' THR . 13.4 mm-40 -79.06 160.34 27.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.568 -175.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 6.1 p90 -117.67 121.31 40.53 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.68 174.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.0 mp -123.02 123.75 68.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 120.826 0.346 . . . . 0.0 111.138 -174.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 12.3 p -76.68 127.57 33.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 169.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.882 ' HB2' HG13 ' A' ' 63' ' ' VAL . 97.1 m-85 -74.83 78.67 2.1 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.668 0.747 . . . . 0.0 111.944 -173.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.3 mt -120.06 -47.97 2.36 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 170.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.2 -142.78 3.88 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 113.848 -1.523 . . . . 0.0 110.43 172.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.59 -48.18 3.52 Favored Glycine 0 C--O 1.222 -0.598 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.448 HD12 ' N ' ' A' ' 30' ' ' ILE . 3.1 mp -111.88 131.73 62.46 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 174.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -68.01 123.93 21.99 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.936 0.398 . . . . 0.0 109.952 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 45.8 pttt -80.62 -5.09 56.4 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -172.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -103.92 -33.62 8.78 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.829 0.347 . . . . 0.0 111.214 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.5 p -109.68 -28.16 8.98 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.914 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.591 ' CA ' HG13 ' A' ' 76' ' ' VAL . . . 89.42 9.7 66.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.43 -177.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.538 HD13 ' HB3' ' A' ' 47' ' ' SER . 48.7 mm -84.05 124.97 40.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.571 0.224 . . . . 0.0 110.614 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 20.7 m -68.78 116.67 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.759 0.79 . . . . 0.0 110.408 175.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 10.4 mmmm -89.58 -24.56 21.68 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.434 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.8 tp10 -65.0 132.38 49.08 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.333 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 25.8 t70 -68.03 133.4 48.96 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.069 0.461 . . . . 0.0 111.403 -177.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 23.1 p -174.22 -170.64 0.54 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.516 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -83.23 -16.92 44.56 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.484 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.1 mt -100.17 15.17 4.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 122.12 0.962 . . . . 0.0 109.32 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.402 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 82.1 tttt -62.04 134.85 57.14 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.489 -1.232 . . . . 0.0 111.45 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 98.46 -10.91 63.23 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.572 -0.74 . . . . 0.0 113.231 177.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -92.47 170.45 9.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.307 0.575 . . . . 0.0 111.732 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.538 ' HB3' HD13 ' A' ' 36' ' ' ILE . 6.2 p -110.97 142.43 43.09 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.683 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.1 9.06 8.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.417 0.627 . . . . 0.0 109.881 175.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 76' ' ' VAL . . . -75.24 95.45 3.15 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.21 28.79 12.42 Favored Glycine 0 C--N 1.317 -0.508 0 CA-C-N 114.705 -1.134 . . . . 0.0 113.609 172.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -130.65 177.76 7.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.719 0.26 . . . . 0.0 110.675 174.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.69 HG13 ' HB3' ' A' ' 80' ' ' ALA . 2.5 mp -89.37 118.55 34.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.403 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 35.8 tp -106.4 116.6 32.21 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.15 -177.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.48 107.77 23.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.194 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.455 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 36.7 p90 -134.42 153.43 79.23 Favored Pre-proline 0 C--N 1.32 -0.714 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.843 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -58.22 -40.1 79.15 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.717 2.278 . . . . 0.0 111.982 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.39 -144.02 12.25 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 170.96 -177.02 44.18 Favored Glycine 0 N--CA 1.445 -0.764 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.778 178.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -93.26 104.66 16.82 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.57 80.73 1.37 Allowed Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.985 -0.626 . . . . 0.0 113.009 -173.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 8.0 t -128.35 129.69 46.63 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 4.3 m 66.71 17.46 10.59 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-O 121.467 0.651 . . . . 0.0 110.826 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.904 ' HB ' HD12 ' A' ' 89' ' ' ILE . 69.9 t -70.78 140.81 17.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.326 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.81 65.89 2.15 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.127 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.614 ' HB3' ' HB ' ' A' ' 89' ' ' ILE . 12.0 p -52.07 -39.71 60.1 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 122.714 0.406 . . . . 0.0 111.94 177.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -69.32 -27.52 65.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 110.967 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.437 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 47.8 t -68.41 -26.84 34.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.585 -177.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.611 HD12 ' HA3' ' A' ' 93' ' ' GLY . 94.9 mt -57.92 -32.75 68.08 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.054 178.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.556 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.7 tp -67.5 -46.08 73.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.322 178.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -65.21 -38.24 89.81 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.501 HD12 HD23 ' A' ' 68' ' ' LEU . 94.2 mt -58.43 -45.14 89.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.389 176.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.413 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.2 OUTLIER -68.84 -37.91 79.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.614 -178.042 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 29.3 mtpp -62.93 -33.88 76.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.024 0.44 . . . . 0.0 110.702 176.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -86.35 -18.15 32.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.623 -177.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 95.2 1.31 62.8 Favored Glycine 0 C--O 1.228 -0.278 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.262 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.591 HG13 ' CA ' ' A' ' 35' ' ' GLY . 71.2 t -79.65 -30.36 13.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 C-N-CA 122.71 0.404 . . . . 0.0 111.585 -175.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.99 144.7 98.9 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.696 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.26 141.86 94.65 Favored 'Trans proline' 0 N--CA 1.46 -0.45 0 C-N-CA 122.304 2.003 . . . . 0.0 110.926 175.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 tttt -74.81 -16.5 60.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.119 0.485 . . . . 0.0 110.005 -175.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.69 ' HB3' HG13 ' A' ' 52' ' ' ILE . . . -164.27 142.94 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.518 176.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.494 HG13 ' HG ' ' A' ' 101' ' ' LEU . 9.3 pt -128.68 120.21 51.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.366 0.603 . . . . 0.0 111.115 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG23 ' A' ' 102' ' ' VAL . 1.2 mm -113.1 116.66 53.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 15.0 m120 -123.16 161.73 23.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 112.076 -171.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -99.46 -34.45 10.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.055 174.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -125.93 131.98 52.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.867 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -130.26 174.44 9.83 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.466 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -135.82 162.45 32.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.896 0.379 . . . . 0.0 110.553 -178.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.503 ' O ' HG23 ' A' ' 92' ' ' VAL . 6.6 m -60.19 -51.57 69.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.47 -177.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.904 HD12 ' HB ' ' A' ' 63' ' ' VAL . 9.1 pt -58.35 -32.03 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.619 -179.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.2 mm -68.7 -45.52 81.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.45 -38.43 89.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.022 178.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 88' ' ' THR . 93.0 t -62.94 -50.48 79.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.716 178.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.611 ' HA3' HD12 ' A' ' 68' ' ' LEU . . . -60.26 -43.97 97.96 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.144 178.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.59 -36.15 82.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 111.38 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -69.18 -42.79 75.38 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.33 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 58.4 mtm -73.86 -36.62 64.87 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.577 -176.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.37 -9.75 49.18 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.764 -176.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.443 ' OE1' ' HA ' ' A' ' 98' ' ' GLU . 2.8 tp10 65.91 72.54 0.4 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.824 0.821 . . . . 0.0 110.161 -175.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.428 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 60.6 mt -127.15 90.11 50.05 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 114.759 -1.109 . . . . 0.0 109.734 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 4.4 Cg_exo -39.3 110.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 123.985 3.123 . . . . 0.0 112.993 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.494 ' HG ' HG13 ' A' ' 81' ' ' ILE . 4.7 tt -119.66 123.43 43.8 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.368 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 82' ' ' ILE . 8.6 m -128.17 139.82 50.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.238 0.542 . . . . 0.0 110.651 176.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 43.6 tt0 -88.92 123.14 32.99 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.54 -178.17 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.614 HG22 ' SG ' ' A' ' 5' ' ' CYS . 96.3 t -107.27 117.72 53.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.793 178.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 24.2 mtm180 -107.44 14.09 26.25 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.237 0.541 . . . . 0.0 110.06 177.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -108.62 130.74 55.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.51 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -71.92 -28.07 63.24 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.65 -175.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -73.39 -18.25 61.18 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -172.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -63.03 -48.31 79.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.955 0.407 . . . . 0.0 109.984 176.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.408 ' HA ' HG12 ' A' ' 113' ' ' VAL . 88.3 m-85 -71.98 -22.71 61.4 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.364 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -72.81 -42.15 64.15 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.733 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.03 -36.86 30.01 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.009 -175.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.408 HG12 ' HA ' ' A' ' 110' ' ' PHE . 11.5 p -75.65 136.72 24.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 CA-C-O 121.314 0.578 . . . . 0.0 111.091 -176.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.489 ' HB2' ' OD2' ' A' ' 117' ' ' ASP . 9.7 mtmp? -126.18 158.77 34.74 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.949 176.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 50.0 m -65.16 111.46 2.95 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 172.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 116.92 1.67 19.16 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.351 -0.928 . . . . 0.0 113.592 176.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . 0.489 ' OD2' ' HB2' ' A' ' 114' ' ' LYS . 28.2 m-20 -85.42 177.55 7.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 117.348 0.574 . . . . 0.0 110.519 176.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.419 ' NH2' HG13 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -115.42 119.79 37.42 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.0 110.152 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.528 HG23 ' HB2' ' A' ' 17' ' ' ALA . 36.7 t -109.34 126.52 66.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.156 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.541 HG22 ' HG3' ' A' ' 14' ' ' GLU . 14.6 t -106.96 102.24 13.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 173.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.478 HG23 HG22 ' A' ' 128' ' ' VAL . 7.3 p -108.32 131.66 58.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.279 0.562 . . . . 0.0 111.78 -176.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -116.08 103.87 10.99 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.467 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -79.83 -18.71 50.16 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.369 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.2 -30.69 70.57 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.063 0.458 . . . . 0.0 110.588 177.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -108.89 -37.06 5.95 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.44 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 97.39 56.09 1.13 Allowed Glycine 0 N--CA 1.45 -0.386 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -177.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -145.04 133.46 21.85 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -172.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.478 HG22 HG23 ' A' ' 121' ' ' VAL . 49.0 t -118.8 112.32 37.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.057 -177.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.444 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 45.8 mt-10 -106.72 108.47 20.0 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.166 177.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.426 HD23 ' H ' ' A' ' 130' ' ' LEU . 2.0 pt? -106.52 147.8 28.97 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.419 HG13 ' NH2' ' A' ' 118' ' ' ARG . 42.6 mm -112.27 133.86 56.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.06 177.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.418 -177.526 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.1 p . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 121.362 0.601 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.468 ' HD3' ' HE1' ' A' ' 127' ' ' TYR . 97.5 mttt -121.18 140.16 52.38 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.689 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -115.77 161.71 18.35 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.327 -177.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.01 127.26 50.08 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.158 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.7 p -120.55 176.11 5.66 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.972 0.415 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.473 ' NE ' ' HA ' ' A' ' 6' ' ' ARG . 2.6 tpm_? -98.43 124.75 43.3 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 175.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.528 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -73.06 140.0 46.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.9 0.381 . . . . 0.0 111.82 -175.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.402 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 49.1 mm -112.47 -57.26 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 ' HA ' ' A' ' 95' ' ' ALA . 52.7 p -113.13 -164.99 0.95 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.627 174.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.501 ' HD2' ' N ' ' A' ' 10' ' ' ARG . 7.9 mpt_? -120.08 167.58 12.06 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.017 0.437 . . . . 0.0 111.486 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.748 ' HA3' ' HG3' ' A' ' 100' ' ' PRO . . . 134.46 145.84 5.31 Favored Glycine 0 CA--C 1.519 0.305 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.69 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.559 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 1.1 tmm_? -139.88 114.14 9.07 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.34 170.32 17.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.636 0.255 . . . . 0.0 111.428 -175.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -110.23 165.5 11.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.393 178.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.438 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -175.43 157.31 23.78 Favored Glycine 0 N--CA 1.446 -0.699 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 173.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.849 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 52.8 mt-10 -61.44 137.37 58.24 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 174.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -78.84 109.2 12.89 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.712 0.291 . . . . 0.0 110.463 -176.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.9 tt -102.4 109.55 21.24 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 173.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.6 t -120.64 114.09 42.43 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.153 -171.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 t -127.5 118.19 23.54 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.736 174.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.409 ' HE2' ' HB3' ' A' ' 110' ' ' PHE . 30.5 ttmt -93.53 20.91 6.76 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.89 0.853 . . . . 0.0 109.118 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.572 ' HG2' ' SG ' ' A' ' 41' ' ' CYS . 5.0 mp0 -97.66 147.68 24.08 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.79 -1.096 . . . . 0.0 109.7 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -82.8 100.61 10.42 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.073 0.463 . . . . 0.0 110.317 175.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.448 HG23 ' HB3' ' A' ' 39' ' ' GLU . 27.9 mm -91.44 1.25 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.269 -176.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.8 m 68.57 -26.81 0.14 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 171.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 24' ' ' ILE . 47.1 t80 75.36 -31.25 0.2 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 123.749 0.82 . . . . 0.0 112.015 175.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.552 ' HA ' HG22 ' A' ' 63' ' ' VAL . 3.1 tm? -61.72 102.25 0.25 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.042 0.448 . . . . 0.0 110.176 177.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.24 26.13 69.03 Favored Glycine 0 C--N 1.335 0.486 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.2 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -83.61 -15.32 71.18 Favored Glycine 0 C--O 1.224 -0.523 0 C-N-CA 120.867 -0.683 . . . . 0.0 113.797 -173.377 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 59.7 mt -125.8 130.57 72.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 117.492 0.646 . . . . 0.0 111.18 -177.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.506 ' HA ' ' HE2' ' A' ' 38' ' ' LYS . 12.3 t70 -65.57 130.42 43.24 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.966 175.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.555 ' HA ' HD21 ' A' ' 71' ' ' LEU . 21.2 pttp -84.76 -0.12 52.62 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -171.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -101.69 -53.63 2.93 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.846 0.355 . . . . 0.0 111.608 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.518 HG23 HG12 ' A' ' 36' ' ' ILE . 3.5 t -109.69 -2.68 17.28 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.253 -0.431 . . . . 0.0 112.057 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 66.45 43.85 91.56 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.54 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.518 HG12 HG23 ' A' ' 34' ' ' THR . 47.3 mm -110.66 131.48 61.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 53.6 t -61.0 123.44 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 120.806 0.336 . . . . 0.0 110.599 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.506 ' HE2' ' HA ' ' A' ' 31' ' ' ASP . 63.8 mmtt -72.08 -47.99 47.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.221 178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB3' HG23 ' A' ' 24' ' ' ILE . 7.8 tp10 -62.13 125.48 24.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.629 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.548 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 14.1 t70 -83.11 133.23 35.07 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.329 178.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.572 ' SG ' ' HG2' ' A' ' 22' ' ' GLU . 4.0 t -170.8 39.04 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 75.63 -29.94 0.19 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 114.984 -1.007 . . . . 0.0 111.945 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 41.8 mm -84.17 -10.47 11.66 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-O 121.623 0.725 . . . . 0.0 110.45 177.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.548 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 21.8 ttpp -59.64 135.94 57.83 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.126 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 111.34 -14.8 27.86 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.455 -0.879 . . . . 0.0 113.036 176.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -89.47 142.39 27.71 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.008 0.432 . . . . 0.0 111.236 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.443 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 20.3 m -85.36 136.66 33.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.552 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.4 m -89.05 -6.96 10.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.195 173.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.87 94.62 0.13 Allowed 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.287 -0.87 . . . . 0.0 111.243 -176.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.67 13.66 49.84 Favored Glycine 0 C--N 1.313 -0.749 0 CA-C-N 114.656 -1.156 . . . . 0.0 112.668 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.849 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 95.9 mtt180 -113.46 166.26 11.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.981 0.419 . . . . 0.0 111.051 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.438 HG12 ' HA3' ' A' ' 15' ' ' GLY . 39.3 mm -95.99 122.15 47.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.169 177.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HB3' HG12 ' A' ' 81' ' ' ILE . 58.5 tp -93.2 113.26 25.44 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.768 0.318 . . . . 0.0 110.36 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.6 t -102.93 108.16 23.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 176.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.685 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.0 t80 -134.37 140.27 35.3 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.195 -172.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 15.2 Cg_endo -94.13 -56.5 0.01 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.914 2.409 . . . . 0.0 113.38 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -150.18 138.75 6.9 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.309 -176.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 59' ' ' LYS . . . -110.48 -82.38 1.3 Allowed Glycine 0 N--CA 1.443 -0.864 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 58' ' ' GLY . 38.4 ttmt 174.64 -70.59 0.01 OUTLIER 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.234 0.54 . . . . 0.0 109.734 178.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 138.5 -102.57 0.37 Allowed Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.428 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.2 t 70.24 -165.52 0.16 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 122.871 0.468 . . . . 0.0 110.898 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 5.2 t -102.0 58.12 0.82 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.812 0.815 . . . . 0.0 111.032 -175.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.552 HG22 ' HA ' ' A' ' 27' ' ' LEU . 41.3 t -70.69 -44.92 76.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.353 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.87 -5.88 72.99 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.315 -177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 56.9 p 56.43 12.76 1.11 Allowed 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 113.577 0.954 . . . . 0.0 113.577 177.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -90.31 -6.29 55.27 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 122.094 -0.379 . . . . 0.0 111.891 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.55 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 66.4 t -62.56 -51.4 72.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.676 0.274 . . . . 0.0 110.689 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.27 -39.58 93.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.956 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.501 ' O ' ' HG2' ' A' ' 73' ' ' LYS . 56.4 tp -62.82 -46.08 89.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.565 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.51 -44.71 93.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.422 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.555 HD21 ' HA ' ' A' ' 32' ' ' LYS . 97.3 mt -54.43 -41.59 69.56 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.114 0.483 . . . . 0.0 110.397 177.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -65.04 -37.08 86.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.144 -178.159 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.501 ' HG2' ' O ' ' A' ' 69' ' ' LEU . 34.5 mmtp -69.91 -25.29 63.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.214 -177.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -93.84 -22.82 18.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.285 0.564 . . . . 0.0 110.182 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.37 15.66 37.29 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.221 178.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.47 23.68 3.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.238 0.542 . . . . 0.0 110.701 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -92.87 156.03 41.03 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.054 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 42.1 Cg_endo -68.14 155.92 67.68 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.4 2.067 . . . . 0.0 112.129 175.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 53.9 mmtt -68.51 -41.86 79.39 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.824 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.444 ' HB2' HG11 ' A' ' 121' ' ' VAL . . . -163.69 165.97 22.71 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.251 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.482 HG12 ' HB3' ' A' ' 53' ' ' LEU . 63.9 mt -131.87 119.34 41.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.094 0.473 . . . . 0.0 110.24 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.631 HG23 HG23 ' A' ' 102' ' ' VAL . 3.8 mm -103.83 116.88 48.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.7 m120 -111.64 164.49 12.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.949 0.404 . . . . 0.0 111.503 -175.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -69.76 -54.14 15.09 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.711 175.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.614 ' HG2' ' OE2' ' A' ' 103' ' ' GLU . 4.8 tttm -139.75 22.59 2.48 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.254 -0.578 . . . . 0.0 111.515 178.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 30.5 m 72.48 124.03 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.618 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.491 ' HB3' ' HB ' ' A' ' 90' ' ' ILE . 8.8 tp10 -84.13 130.54 34.84 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 172.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.6 m -57.5 -50.2 73.84 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.962 0.41 . . . . 0.0 111.66 -173.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.1 mt -68.95 -35.14 67.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.199 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 87' ' ' GLU . 59.7 mt -69.23 -38.07 77.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.36 -44.77 92.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.416 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -62.26 -49.28 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.994 0.426 . . . . 0.0 110.576 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.92 -42.24 99.72 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.466 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.06 -39.17 92.88 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.704 0.287 . . . . 0.0 111.149 -179.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.439 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -63.13 -41.89 99.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.923 178.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.5 mtm -72.49 -35.96 68.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.498 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.567 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -92.36 5.96 48.68 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 56.92 50.78 11.66 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.449 0.643 . . . . 0.0 110.911 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 62.1 mt -114.29 90.3 20.09 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.816 179.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.748 ' HG3' ' HA3' ' A' ' 11' ' ' GLY . 91.6 Cg_exo -35.3 112.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.352 0.733 0 C-N-CA 124.071 3.181 . . . . 0.0 113.998 -176.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.409 HD13 ' N ' ' A' ' 102' ' ' VAL . 0.5 OUTLIER -110.15 128.75 55.64 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.836 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.631 HG23 HG23 ' A' ' 82' ' ' ILE . 16.2 m -136.55 162.18 35.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.094 0.473 . . . . 0.0 111.343 178.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.614 ' OE2' ' HG2' ' A' ' 85' ' ' LYS . 32.1 tt0 -115.88 119.09 34.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.814 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 106' ' ' ASP . 13.5 t -99.52 128.97 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.888 0.375 . . . . 0.0 110.4 177.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 105' ' ' ARG . 3.2 mmp_? -92.02 24.8 3.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.223 0.535 . . . . 0.0 110.42 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.497 ' H ' HG12 ' A' ' 104' ' ' VAL . 35.9 t70 -141.96 111.9 6.81 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.698 -175.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -69.84 -26.68 64.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.846 178.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.4 ' HD3' ' HA ' ' A' ' 108' ' ' LYS . 68.8 mmtt -63.51 -19.95 65.2 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.527 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.599 ' O ' HG12 ' A' ' 113' ' ' VAL . 49.9 t80 -61.25 -45.1 95.9 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 170.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.409 ' HB3' ' HE2' ' A' ' 21' ' ' LYS . 87.4 m-85 -68.3 -22.05 64.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.277 -177.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -83.64 -32.75 25.5 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.049 0.452 . . . . 0.0 110.522 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.7 -44.34 28.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.185 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.599 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.9 p -83.21 123.5 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 110.149 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -130.21 152.66 49.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.048 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.742 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 21.6 m -58.4 107.49 0.5 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.042 -179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.32 -39.04 0.55 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.331 -0.938 . . . . 0.0 113.449 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . 0.741 ' HA ' ' NH2' ' A' ' 118' ' ' ARG . 1.7 t0 -101.09 -166.96 1.36 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 117.286 0.543 . . . . 0.0 110.997 -176.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.741 ' NH2' ' HA ' ' A' ' 117' ' ' ASP . 0.0 OUTLIER -110.03 138.54 46.27 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.33 0.586 . . . . 0.0 112.559 -173.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.624 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.7 t -119.71 122.7 69.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.551 173.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.932 ' HB ' ' HG3' ' A' ' 129' ' ' GLU . 47.1 t -100.06 112.58 33.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.444 HG11 ' HB2' ' A' ' 80' ' ' ALA . 8.9 p -86.54 133.2 30.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.561 -177.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . 0.665 ' HB3' ' HB3' ' A' ' 127' ' ' TYR . 44.0 t-20 -126.06 94.64 4.15 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.252 0.549 . . . . 0.0 109.767 177.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.437 ' HB1' ' O ' ' A' ' 9' ' ' THR . . . -90.16 2.66 55.09 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.418 0.627 . . . . 0.0 110.107 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.455 ' HB3' ' OD1' ' A' ' 122' ' ' ASN . 4.5 t70 -73.7 -37.1 65.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.665 175.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -114.11 -15.36 12.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.573 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.06 66.89 1.74 Allowed Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 -168.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.665 ' HB3' ' HB3' ' A' ' 122' ' ' ASN . 9.2 t80 -146.24 144.75 30.08 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.146 -0.527 . . . . 0.0 109.744 -167.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.415 HG11 ' CE1' ' A' ' 109' ' ' PHE . 60.1 t -126.87 104.87 13.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 175.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.932 ' HG3' ' HB ' ' A' ' 120' ' ' VAL . 9.0 pt-20 -97.05 108.13 20.81 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.502 0.668 . . . . 0.0 109.931 179.169 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.9 tp -85.57 127.83 34.57 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.497 -178.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 5.2 mm -116.76 111.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -178.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.414 ' HA ' ' OD2' ' A' ' 117' ' ' ASP . 12.4 mp0 . . . . . 0 C--N 1.314 -0.954 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.464 HG23 ' HB3' ' A' ' 130' ' ' LEU . 10.8 m . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 121.464 0.649 . . . . 0.0 111.914 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.432 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 28.1 mtpp -107.78 94.21 4.96 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.143 174.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -96.77 155.62 16.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.018 0.437 . . . . 0.0 111.379 -176.145 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.41 126.27 52.69 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.702 174.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 103' ' ' GLU . 80.3 m -118.93 179.59 4.1 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.029 -177.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 64.4 ttp85 -92.04 116.12 28.66 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -175.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.659 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -71.65 124.39 24.63 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.091 -0.958 . . . . 0.0 111.786 -173.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 44.5 mm -102.81 -47.99 10.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.734 176.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.564 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -107.16 -171.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.379 177.558 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 10' ' ' ARG . 39.3 mtt180 -115.33 -178.7 3.44 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 173.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.97 -176.81 36.42 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.846 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -161.14 143.31 12.21 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 -178.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.51 179.07 9.46 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.29 0.567 . . . . 0.0 111.494 -175.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -125.77 160.59 29.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.533 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.57 ' HA3' HG13 ' A' ' 52' ' ' ILE . . . 179.61 155.69 15.82 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.832 171.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.527 ' HB3' ' HD3' ' A' ' 51' ' ' ARG . 28.7 tt0 -75.44 137.95 41.32 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 175.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.515 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -78.0 134.92 37.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.119 0.485 . . . . 0.0 111.825 -169.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.506 HD21 HG21 ' A' ' 43' ' ' ILE . 6.3 tt -130.29 115.41 16.91 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 174.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.549 HG12 ' OG1' ' A' ' 115' ' ' THR . 9.9 p -103.47 130.94 53.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.198 0.523 . . . . 0.0 110.831 -175.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.8 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 29.1 m -108.82 127.52 54.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.031 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -99.88 -1.01 38.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.559 -175.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.453 ' H ' HG22 ' A' ' 20' ' ' THR . 53.4 mm-40 -96.99 158.98 15.17 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.358 0.599 . . . . 0.0 112.188 -173.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -104.38 91.24 3.82 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 27.4 pt -122.35 16.83 5.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -169.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.469 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 59.6 p 51.8 -154.54 0.17 Allowed 'General case' 0 CA--C 1.53 0.202 0 O-C-N 123.606 0.566 . . . . 0.0 110.485 -175.492 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.411 ' HE2' HD11 ' A' ' 68' ' ' LEU . 9.6 t80 -143.64 18.25 1.84 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.064 0.459 . . . . 0.0 110.626 179.239 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 pp -85.13 -10.05 57.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.316 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 171.03 130.64 1.25 Allowed Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.183 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.435 ' HA2' ' HB3' ' A' ' 39' ' ' GLU . . . -173.27 -47.37 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.264 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.674 HG13 HG22 ' A' ' 37' ' ' VAL . 4.1 mp -88.27 134.63 27.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.744 ' HB2' ' HE3' ' A' ' 38' ' ' LYS . 29.2 t70 -77.89 147.25 35.15 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.687 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 9.5 ptpp? -82.76 -14.49 54.38 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.135 -174.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -100.79 -47.82 4.69 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.427 -175.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.9 p -92.91 -37.09 12.44 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.778 0.323 . . . . 0.0 111.735 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.8 20.03 48.91 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.336 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 41.2 mm -90.24 138.3 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.287 179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.674 HG22 HG13 ' A' ' 30' ' ' ILE . 96.3 t -79.81 102.26 5.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.139 0.495 . . . . 0.0 109.755 174.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.744 ' HE3' ' HB2' ' A' ' 31' ' ' ASP . 59.3 mttt -84.32 -28.64 26.93 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.706 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.435 ' HB3' ' HA2' ' A' ' 29' ' ' GLY . 9.4 tp10 -96.14 78.66 3.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.614 0.721 . . . . 0.0 110.384 178.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 1.027 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 9.2 t70 -147.82 -167.78 2.89 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.936 177.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 71.5 m -144.82 -23.14 0.51 Allowed 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -133.86 -47.77 0.8 Allowed 'General case' 0 C--O 1.233 0.225 0 O-C-N 122.031 -0.418 . . . . 0.0 110.796 -177.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.506 HG21 HD21 ' A' ' 18' ' ' LEU . 23.0 mm -75.83 -17.75 15.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 109.227 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 1.027 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 54.3 tttm -44.37 118.23 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 CA-C-N 114.166 -1.379 . . . . 0.0 112.156 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 130.83 -19.13 5.02 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.807 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -93.46 156.36 16.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.056 0.455 . . . . 0.0 111.692 -177.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.0 m -95.94 138.69 33.22 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.423 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.1 m -94.2 -3.69 10.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.993 0.425 . . . . 0.0 110.808 176.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.42 89.51 0.5 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.559 0.695 . . . . 0.0 110.868 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.7 ' HA2' ' HE3' ' A' ' 79' ' ' LYS . . . 112.6 2.98 25.64 Favored Glycine 0 C--N 1.313 -0.741 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.703 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.527 ' HD3' ' HB3' ' A' ' 16' ' ' GLU . 20.2 mmt85 -105.59 156.29 18.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.556 -0.322 . . . . 0.0 110.827 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.706 HG12 ' HB3' ' A' ' 80' ' ' ALA . 29.1 mt -97.29 117.65 42.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 169.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.43 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 28.1 tp -93.56 124.57 37.64 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.957 -171.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 62.6 t -123.85 107.51 18.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.892 0.377 . . . . 0.0 110.195 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.8 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 40.9 p90 -136.01 146.09 55.21 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 177.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.97 -29.55 34.02 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.851 2.367 . . . . 0.0 111.462 175.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.71 -60.63 4.79 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.747 176.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 81.14 -65.12 4.04 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -177.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 25' ' ' SER . 59.7 mttm -104.66 128.21 52.64 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -88.28 -37.72 7.54 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.63 177.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.4 m 63.99 -177.06 0.16 Allowed 'General case' 0 CA--C 1.533 0.289 0 CA-C-O 121.149 0.5 . . . . 0.0 111.294 178.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.5 p -119.23 11.32 12.28 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.188 0.518 . . . . 0.0 111.059 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.9 t -129.92 138.53 53.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.429 ' O ' HG22 ' A' ' 67' ' ' VAL . . . 152.4 -11.44 0.65 Allowed Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.038 -178.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 0.8 OUTLIER -71.32 151.37 44.24 Favored 'General case' 0 C--N 1.321 -0.637 0 O-C-N 122.703 -0.292 . . . . 0.0 111.278 178.033 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.408 ' HB2' ' O ' ' A' ' 65' ' ' SER . 44.9 m-85 75.25 -35.46 0.28 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.431 0.9 . . . . 0.0 113.431 174.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.487 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 29.8 m -62.79 -24.65 36.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -175.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.411 HD11 ' HE2' ' A' ' 26' ' ' PHE . 6.2 mp -69.0 -32.16 71.51 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.664 0.269 . . . . 0.0 110.576 178.171 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.414 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 63.4 tp -66.43 -38.48 87.5 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -61.21 -48.85 79.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.129 175.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.487 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 67.6 mt -60.59 -41.68 95.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.674 178.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 72' ' ' ARG . 0.0 OUTLIER -72.06 -35.61 69.33 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.097 -176.402 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -59.75 -38.41 81.68 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.434 178.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -82.6 -29.66 30.02 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 109.876 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 99.14 22.27 13.51 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.561 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.47 4.9 9.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.998 0.428 . . . . 0.0 111.156 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.32 154.54 66.41 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.767 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 27.7 Cg_endo -63.63 147.33 92.86 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.148 1.899 . . . . 0.0 111.075 174.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.7 ' HE3' ' HA2' ' A' ' 50' ' ' GLY . 97.2 mttt -73.32 -27.25 61.42 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.049 0.452 . . . . 0.0 110.725 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.706 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -157.79 157.48 33.43 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.305 176.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.466 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 34.1 mt -136.57 127.39 41.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 178.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.527 HG22 HG13 ' A' ' 104' ' ' VAL . 3.6 mm -121.67 118.26 55.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 11.8 m120 -130.43 -179.84 5.5 Favored 'General case' 0 CA--C 1.518 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.147 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.434 ' HD3' ' O ' ' A' ' 84' ' ' LYS . 4.1 tmtt? -109.86 -37.91 5.51 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 171.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -103.01 114.84 29.46 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -120.67 141.26 50.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.903 0.382 . . . . 0.0 110.266 177.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.49 ' HB2' HG13 ' A' ' 90' ' ' ILE . 81.2 mm-40 -108.94 159.65 16.64 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.11 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 m -60.01 -45.34 93.06 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.83 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.444 HD12 ' N ' ' A' ' 90' ' ' ILE . 2.5 pp -64.82 -31.08 52.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.725 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.49 HG13 ' HB2' ' A' ' 87' ' ' GLU . 69.3 mt -68.38 -45.79 81.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.984 0.421 . . . . 0.0 109.99 177.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.55 -48.27 82.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.965 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.06 -45.49 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.974 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.68 -43.28 99.47 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.61 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.4 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -74.89 -37.15 62.21 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 111.576 0.213 . . . . 0.0 111.576 -177.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.45 -38.83 85.42 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.737 0.303 . . . . 0.0 111.428 -178.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 59.1 mtm -71.22 -31.03 67.1 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.039 0.447 . . . . 0.0 111.054 -179.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.414 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -89.55 -2.86 58.47 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.432 -179.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.543 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 3.9 tp10 62.4 43.95 7.66 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-O 121.49 0.662 . . . . 0.0 110.3 -177.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.4 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 59.0 mt -107.44 88.6 4.21 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.83 175.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' A' ' 98' ' ' GLU . 24.3 Cg_exo -62.14 118.22 5.1 Favored 'Trans proline' 0 C--O 1.233 0.267 0 C-N-CA 122.918 2.412 . . . . 0.0 112.665 -174.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.564 HD23 ' OG1' ' A' ' 9' ' ' THR . 1.9 pt? -118.96 147.09 44.43 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.95 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.659 HG12 ' HA ' ' A' ' 7' ' ' ALA . 26.9 m -136.97 158.33 36.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.014 178.288 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.539 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 30.3 tt0 -94.89 119.82 34.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.491 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.527 HG13 HG22 ' A' ' 82' ' ' ILE . 20.7 m -74.25 144.32 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.135 174.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -117.55 23.47 11.73 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.76 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.481 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 10.4 t70 -144.35 127.81 16.95 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -176.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -66.56 -36.76 83.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.367 178.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.481 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 10.0 mtmp? -67.9 -18.35 64.76 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.324 -175.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -58.98 -39.89 83.17 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -67.69 -29.07 68.24 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.754 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.11 -40.14 60.09 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 177.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.03 -46.55 56.65 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.703 -176.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.0 p -66.0 138.02 23.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 121.106 0.479 . . . . 0.0 111.376 -175.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 35.2 mttm -138.06 151.07 47.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.989 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.549 ' OG1' HG12 ' A' ' 19' ' ' VAL . 80.4 m -70.17 118.37 12.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.605 -0.271 . . . . 0.0 110.319 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 120.69 -12.5 10.11 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.257 177.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.82 179.33 6.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.829 0.314 . . . . 0.0 111.127 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -109.18 120.81 43.64 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-O 121.046 0.45 . . . . 0.0 111.344 -175.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 17' ' ' ALA . 52.1 t -123.02 137.39 56.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.485 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.449 ' CG2' ' HB3' ' A' ' 129' ' ' GLU . 6.0 m -114.43 134.56 57.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.654 170.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.402 HG11 ' CB ' ' A' ' 80' ' ' ALA . 11.2 p -112.96 133.95 57.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-O 121.165 0.507 . . . . 0.0 110.644 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -129.29 94.85 3.89 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 174.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.39 -16.13 35.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.185 0.516 . . . . 0.0 110.293 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -70.32 -40.95 73.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.252 178.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -100.45 -25.26 14.27 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.153 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 90.41 68.76 1.2 Allowed Glycine 0 CA--C 1.516 0.124 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.352 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -158.38 146.94 18.77 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 122.468 0.307 . . . . 0.0 110.832 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.34 125.53 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.705 173.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.449 ' HB3' ' CG2' ' A' ' 120' ' ' VAL . 41.1 tt0 -109.1 112.61 24.87 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.234 0.54 . . . . 0.0 110.722 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.464 ' HB3' HG23 ' A' ' 1' ' ' VAL . 55.7 tp -105.86 122.59 46.41 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.957 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 31.8 mt -115.3 120.49 64.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--N 1.31 -1.148 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.282 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 N--CA 1.454 -0.271 0 CA-C-O 120.934 0.397 . . . . 0.0 110.478 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.452 ' HD2' ' N ' ' A' ' 2' ' ' LYS . 11.4 mptt -101.46 113.66 26.96 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -93.85 148.21 22.35 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.828 0.346 . . . . 0.0 110.764 -176.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.06 125.86 40.0 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.665 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.8 m -120.36 175.14 6.11 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.55 ' HB3' ' CG ' ' A' ' 103' ' ' GLU . 40.9 ttm180 -101.28 121.21 41.47 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.56 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -69.83 114.05 7.65 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.765 -177.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 mm -90.75 -66.56 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 174.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.551 ' OG1' ' HA ' ' A' ' 100' ' ' PRO . 21.2 p -96.18 -170.95 2.2 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 173.072 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -131.27 164.71 24.98 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.056 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.05 155.54 10.96 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.052 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 121' ' ' VAL . 57.9 ttt180 -115.87 117.08 29.18 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.908 0.385 . . . . 0.0 110.143 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.424 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -119.01 138.18 53.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.994 0.426 . . . . 0.0 111.352 -175.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.493 ' HG3' HG22 ' A' ' 120' ' ' VAL . 20.6 tt0 -112.0 139.49 47.47 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.053 178.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.405 ' HA3' HG12 ' A' ' 52' ' ' ILE . . . -172.7 170.66 43.75 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.473 175.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -82.63 127.48 33.41 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 175.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 52' ' ' ILE . . . -90.2 131.58 35.96 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -169.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mp -112.75 130.52 56.04 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.148 171.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.487 HG11 HG13 ' A' ' 113' ' ' VAL . 48.2 t -119.47 126.16 75.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.552 -172.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.4 t -118.27 139.52 51.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.971 176.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -91.65 -9.39 44.16 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.239 0.542 . . . . 0.0 110.033 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -95.37 143.86 26.38 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.824 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.3 p90 -85.42 153.62 22.38 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.869 177.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.418 ' O ' ' HA3' ' A' ' 58' ' ' GLY . 41.0 pt -122.0 -178.99 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.197 0.523 . . . . 0.0 111.5 -175.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.3 p -111.32 124.38 52.12 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.767 -0.652 . . . . 0.0 109.641 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.736 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 1.3 m-85 -76.36 95.61 3.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.345 0.593 . . . . 0.0 110.824 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 pp -165.83 -162.57 0.57 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.708 -1.133 . . . . 0.0 109.164 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -73.34 67.12 1.53 Allowed Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.579 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.42 -23.03 10.63 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 121.21 -0.519 . . . . 0.0 112.401 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.458 HG12 HG22 ' A' ' 37' ' ' VAL . 60.3 mt -101.92 138.21 26.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 177.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -69.34 133.02 47.32 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.605 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 60.8 pttt -78.52 -16.72 57.16 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -173.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.5 mm-40 -94.73 -52.32 4.33 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -174.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.581 HG23 HG12 ' A' ' 36' ' ' ILE . 7.6 t -106.3 -2.94 21.75 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 111.795 0.294 . . . . 0.0 111.795 -176.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.58 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.24 37.8 93.22 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.226 175.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.581 HG12 HG23 ' A' ' 34' ' ' THR . 49.7 mm -104.02 128.74 57.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.458 HG22 HG12 ' A' ' 30' ' ' ILE . 21.3 t -72.29 117.75 16.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.865 0.364 . . . . 0.0 110.181 178.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.5 mmmp? -83.64 -36.27 23.96 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.266 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -64.98 132.79 50.21 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 176.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.534 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 9.0 t70 -80.38 136.83 36.45 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.287 0.565 . . . . 0.0 111.832 -170.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.454 ' H ' ' HB3' ' A' ' 44' ' ' LYS . 79.4 m -144.55 28.04 1.33 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.033 -0.985 . . . . 0.0 109.105 177.061 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 70.26 -69.12 0.18 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.28 -177.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 46.6 pt -80.39 5.43 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.27 0.557 . . . . 0.0 111.203 -177.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.534 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER -68.18 139.41 56.09 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.254 178.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.94 -1.29 1.72 Allowed Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.635 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -102.58 159.8 15.13 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.663 0.268 . . . . 0.0 110.569 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.4 p -82.1 121.96 27.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-O 121.28 0.562 . . . . 0.0 110.041 176.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.0 m -86.71 19.26 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.438 -176.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.13 92.16 0.17 Allowed 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.706 0.765 . . . . 0.0 111.128 -176.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.51 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 84.92 24.32 45.65 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 114.735 -1.121 . . . . 0.0 112.23 177.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.452 HH11 ' HD2' ' A' ' 51' ' ' ARG . 12.5 mmt180 -98.08 163.96 12.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.627 0.251 . . . . 0.0 110.728 178.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.483 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.0 mm -102.15 118.37 48.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 175.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.538 ' HB2' HG22 ' A' ' 81' ' ' ILE . 4.3 mm? -106.7 125.3 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.922 0.391 . . . . 0.0 111.221 -177.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.477 ' HB ' HG22 ' A' ' 19' ' ' VAL . 59.7 t -110.7 106.38 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.849 176.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -136.59 148.12 62.43 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.787 176.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.451 ' O ' ' HG2' ' A' ' 84' ' ' LYS . 32.1 Cg_exo -59.61 -45.28 26.46 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.416 2.077 . . . . 0.0 111.955 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.89 1.66 Allowed Glycine 0 N--CA 1.446 -0.666 0 N-CA-C 111.475 -0.65 . . . . 0.0 111.475 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA3' ' O ' ' A' ' 24' ' ' ILE . . . 138.02 -140.71 11.41 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.173 178.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -92.46 103.21 15.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.915 0.388 . . . . 0.0 110.142 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.736 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -91.57 85.31 1.25 Allowed Glycine 0 N--CA 1.447 -0.621 0 CA-C-N 115.992 -0.549 . . . . 0.0 112.742 -176.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.8 m -78.63 155.79 29.38 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 176.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.587 ' HA ' HG21 ' A' ' 89' ' ' ILE . 12.0 t -68.21 -20.24 64.82 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.774 0.321 . . . . 0.0 111.329 -175.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.8 p -67.2 -28.07 41.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.289 0.566 . . . . 0.0 110.462 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -87.47 11.91 64.53 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.98 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 25.4 t -83.29 -56.03 3.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.936 0.398 . . . . 0.0 110.581 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -78.31 -15.46 58.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.934 -174.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.44 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 34.4 m -66.42 -28.58 43.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.239 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 98.9 mt -62.35 -40.77 97.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.988 0.423 . . . . 0.0 110.168 178.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.7 tp -69.4 -43.12 74.1 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.266 178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.504 ' C ' HD22 ' A' ' 70' ' ' ASN . 0.2 OUTLIER -57.36 -49.93 74.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.913 178.477 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.564 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 97.9 mt -63.49 -43.52 97.01 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.054 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.415 ' C ' ' HD3' ' A' ' 72' ' ' ARG . 0.3 OUTLIER -66.83 -38.95 87.42 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.708 0.289 . . . . 0.0 110.347 -177.438 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.452 ' HD2' ' O ' ' A' ' 73' ' ' LYS . 2.4 tmmm? -61.48 -32.1 72.09 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.53 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -91.37 -7.73 50.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.267 0.556 . . . . 0.0 110.143 178.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.21 16.34 72.05 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.0 174.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.58 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.9 m -108.25 7.56 9.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.776 0.322 . . . . 0.0 111.448 -177.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.564 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -92.45 159.95 35.79 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.501 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.528 ' HB3' HD23 ' A' ' 53' ' ' LEU . 34.7 Cg_exo -58.41 150.17 69.63 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.373 2.049 . . . . 0.0 111.12 172.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.51 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 79.0 tttt -81.49 -24.68 36.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.151 0.5 . . . . 0.0 109.828 -178.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.483 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -168.37 154.29 6.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.893 176.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.538 HG22 ' HB2' ' A' ' 53' ' ' LEU . 25.5 pt -136.25 146.1 29.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.821 0.343 . . . . 0.0 111.295 -178.441 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.605 HG23 HG23 ' A' ' 102' ' ' VAL . 4.7 mm -118.82 124.22 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 14.2 m120 -122.39 171.22 9.22 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -176.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.451 ' HG2' ' O ' ' A' ' 56' ' ' PRO . 63.1 pttt -96.97 -32.57 11.95 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.4 0.619 . . . . 0.0 110.321 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.412 ' NZ ' ' HA ' ' A' ' 85' ' ' LYS . 1.4 tppm? -138.02 113.15 9.24 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.665 177.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.3 m -99.03 127.68 45.01 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.782 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.68 152.12 22.01 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 16.3 m -56.64 -39.52 73.83 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.693 0.283 . . . . 0.0 110.997 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.587 HG21 ' HA ' ' A' ' 62' ' ' THR . 80.8 mt -55.38 -41.4 62.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-O 121.335 0.588 . . . . 0.0 110.686 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 25.8 mm -71.77 -41.65 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.247 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.41 81.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.227 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -60.31 -45.54 96.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.829 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.22 -48.07 85.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.52 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.28 -33.17 74.73 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.534 0.206 . . . . 0.0 111.472 -178.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -63.98 -45.07 90.7 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.911 0.386 . . . . 0.0 111.068 178.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 72.6 mtm -69.02 -33.14 73.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.138 -178.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -85.74 -7.24 58.9 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.54 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.461 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 63.2 mt-10 60.4 48.52 7.74 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.501 0.667 . . . . 0.0 110.471 -177.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.3 90.07 7.85 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.026 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.551 ' HA ' ' OG1' ' A' ' 9' ' ' THR . 50.0 Cg_exo -52.8 115.77 2.46 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.764 2.309 . . . . 0.0 112.202 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pt? -129.77 143.85 51.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.004 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.605 HG23 HG23 ' A' ' 82' ' ' ILE . 17.4 m -136.18 155.29 34.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.918 -178.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.55 ' CG ' ' HB3' ' A' ' 6' ' ' ARG . 2.6 pt-20 -102.93 137.08 41.6 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.057 0.456 . . . . 0.0 111.618 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . . . . . . . . . 2.2 m -125.17 109.41 22.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.53 173.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.451 ' H ' ' HD3' ' A' ' 105' ' ' ARG . 0.0 OUTLIER -87.6 17.42 4.65 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.451 0.643 . . . . 0.0 110.156 176.789 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -95.12 123.28 38.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.058 177.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -71.45 -38.75 71.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.428 -176.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.566 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 62.3 mttm -70.81 -18.83 62.72 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -171.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -56.07 -49.85 72.62 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 171.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -75.72 -26.48 57.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.511 0.672 . . . . 0.0 110.231 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 29.3 tt0 -65.02 -44.57 88.7 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.314 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -96.84 -27.97 14.46 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.487 HG13 HG11 ' A' ' 19' ' ' VAL . 11.0 p -67.24 134.75 29.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 111.225 -175.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -110.98 157.13 20.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.421 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.443 ' HB ' ' H ' ' A' ' 19' ' ' VAL . 8.8 t -87.41 127.97 35.21 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.483 179.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.57 0.4 24.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.169 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -101.78 -172.1 2.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.808 0.304 . . . . 0.0 110.871 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 118' ' ' ARG . 2.0 ttp180 -103.07 127.37 50.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.368 . . . . 0.0 111.574 -172.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 129' ' ' GLU . 73.9 t -134.07 123.15 43.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.322 176.083 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.493 HG22 ' HG3' ' A' ' 14' ' ' GLU . 81.2 t -114.82 125.05 72.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 6.2 p -107.9 123.89 63.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.456 0.646 . . . . 0.0 111.252 -177.19 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -103.58 95.97 6.41 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.121 173.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -82.11 6.03 17.69 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.956 0.408 . . . . 0.0 110.979 -176.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.01 -38.99 79.56 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.264 0.554 . . . . 0.0 109.798 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -115.19 -22.84 9.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.888 175.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 92.72 66.3 1.09 Allowed Glycine 0 C--O 1.228 -0.232 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -174.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -144.29 125.11 14.24 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -169.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 24.6 m -113.33 134.29 56.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 121.29 0.567 . . . . 0.0 111.823 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.503 ' O ' ' HA ' ' A' ' 119' ' ' VAL . 46.3 mt-10 -96.55 107.79 20.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.17 176.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 57.8 tp -101.3 108.99 20.77 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 175.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.5 mm -120.13 125.72 74.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.9 0.381 . . . . 0.0 110.297 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 26.9 mp0 . . . . . 0 C--N 1.318 -0.79 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.426 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 121.443 0.64 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.707 ' HE3' ' HG2' ' A' ' 129' ' ' GLU . 52.0 mtpt -121.49 121.39 37.39 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.231 -0.895 . . . . 0.0 108.606 170.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.51 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 96.6 m-85 -97.17 150.11 21.25 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.99 0.424 . . . . 0.0 111.37 -173.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.76 122.15 46.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.733 177.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.462 ' SG ' HG21 ' A' ' 102' ' ' VAL . 7.1 p -120.49 171.16 8.74 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.123 -177.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.653 ' HB3' ' HB2' ' A' ' 103' ' ' GLU . 7.8 tpt180 -93.5 115.8 28.31 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 176.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.604 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -74.88 110.31 9.07 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.589 -178.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.2 mm -85.06 -55.35 6.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 172.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.586 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -100.17 174.73 6.01 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 171.925 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 10' ' ' ARG . 43.1 mtm180 -119.56 174.7 6.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.804 0.335 . . . . 0.0 110.434 175.169 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.4 144.8 6.84 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.096 -178.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.527 ' HG2' ' HA ' ' A' ' 122' ' ' ASN . 60.1 mtm180 -119.16 131.64 55.89 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 177.582 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.57 145.29 23.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.519 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.06 140.92 52.5 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 116.158 -0.473 . . . . 0.0 109.754 177.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -170.26 175.79 44.11 Favored Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.522 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -67.08 128.15 35.28 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.9 125.29 29.94 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.984 -176.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 tt -108.39 109.07 20.28 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 175.288 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.455 HG22 ' HB ' ' A' ' 54' ' ' VAL . 75.1 t -103.15 128.8 55.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.948 0.404 . . . . 0.0 110.669 -174.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.44 HG22 ' HB3' ' A' ' 22' ' ' GLU . 7.2 m -123.94 108.69 12.68 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.523 -177.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -89.54 16.54 7.56 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.402 0.62 . . . . 0.0 110.315 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.508 ' CG ' HG23 ' A' ' 24' ' ' ILE . 6.0 tp10 -83.87 159.38 21.35 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.419 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . 0.438 ' N ' ' HG3' ' A' ' 22' ' ' GLU . 23.8 m-85 -119.69 81.48 1.73 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.28 0.562 . . . . 0.0 110.007 176.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.508 HG23 ' CG ' ' A' ' 22' ' ' GLU . 18.4 pt -107.63 168.53 3.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.827 0.822 . . . . 0.0 111.744 -176.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.55 123.17 34.0 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 114.306 -1.315 . . . . 0.0 109.063 176.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -56.29 -70.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.205 0 O-C-N 123.276 0.36 . . . . 0.0 110.483 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt 59.28 -85.42 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 O-C-N 123.791 0.682 . . . . 0.0 111.991 176.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 168.75 42.08 0.03 OUTLIER Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.0 -7.91 84.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.255 -174.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.453 HG13 HG12 ' A' ' 37' ' ' VAL . 4.1 mp -79.83 119.49 29.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 176.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.09 127.8 33.98 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.106 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.463 ' HE3' ' OD1' ' A' ' 70' ' ' ASN . 0.0 OUTLIER -74.64 -10.2 59.31 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -172.749 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -97.81 -35.98 10.35 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.749 0.309 . . . . 0.0 111.34 -176.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.6 p -105.53 -36.42 7.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.342 -0.39 . . . . 0.0 112.013 -178.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 88.93 15.41 59.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.634 -175.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 49.2 mm -95.44 138.35 21.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.453 HG12 HG13 ' A' ' 30' ' ' ILE . 15.3 m -72.49 116.21 14.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.371 0.605 . . . . 0.0 110.762 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -88.75 -9.41 51.98 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.382 -178.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -90.29 151.16 21.62 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.431 ' HA ' ' HD2' ' A' ' 44' ' ' LYS . 10.5 t70 -76.9 134.69 38.89 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.316 -171.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 7.6 p -167.32 173.38 8.94 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 43' ' ' ILE . 5.3 pt-20 -62.08 -36.26 81.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 -178.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.436 ' N ' ' HG3' ' A' ' 42' ' ' GLU . 15.1 pt -105.38 43.54 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 122.053 0.93 . . . . 0.0 110.144 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.431 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 86.4 tttt -67.47 121.53 16.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.778 -179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.71 -2.48 29.0 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.886 -178.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -79.54 155.7 28.09 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.937 0.398 . . . . 0.0 111.052 177.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.1 p -102.8 136.49 42.52 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.326 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 28.1 m -98.11 -1.36 10.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.905 0.383 . . . . 0.0 110.957 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -66.31 95.03 0.29 Allowed 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.802 -176.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.08 17.6 39.89 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.196 175.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 2.5 mmt180 -109.64 150.83 27.66 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.562 HD13 HG23 ' A' ' 121' ' ' VAL . 65.8 mt -96.19 105.26 16.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 177.188 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.593 HD13 ' HB3' ' A' ' 78' ' ' PRO . 10.9 mp -80.61 116.6 20.72 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.373 0.606 . . . . 0.0 111.332 -174.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.455 ' HB ' HG22 ' A' ' 19' ' ' VAL . 61.6 t -114.13 106.94 21.66 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.657 175.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -134.86 148.32 66.56 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.126 176.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.27 -41.5 21.14 Favored 'Trans proline' 0 C--O 1.236 0.388 0 C-N-CA 122.53 2.153 . . . . 0.0 112.319 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 167.14 -149.1 14.16 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.114 -0.565 . . . . 0.0 111.936 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 169.48 -140.03 5.9 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.265 -179.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -91.94 139.31 30.78 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.841 0.353 . . . . 0.0 110.912 179.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.508 ' HA2' ' HG3' ' A' ' 87' ' ' GLU . . . -99.16 88.09 0.81 Allowed Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.807 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.7 t -95.78 152.96 18.0 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.985 0.422 . . . . 0.0 110.701 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.1 t -84.49 49.14 1.63 Allowed 'General case' 0 CA--C 1.539 0.522 0 CA-C-O 121.531 0.682 . . . . 0.0 110.618 -176.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HB ' HG21 ' A' ' 89' ' ' ILE . 46.9 t -48.06 -49.09 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 114.982 -1.008 . . . . 0.0 112.658 -176.59 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.62 16.72 38.53 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.944 -176.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 66' ' ' TYR . 90.3 p 60.2 -152.47 0.39 Allowed 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.179 0.592 . . . . 0.0 111.631 173.068 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.464 ' HB2' ' O ' ' A' ' 65' ' ' SER . 58.1 m-85 76.07 -42.9 0.46 Allowed 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.713 0.805 . . . . 0.0 112.721 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.45 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 17.4 m -52.3 -36.9 21.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -175.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.45 HD22 ' HB2' ' A' ' 94' ' ' ALA . 5.3 mp -68.85 -34.87 76.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.001 0.429 . . . . 0.0 111.075 -178.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.499 HD13 ' HA ' ' A' ' 97' ' ' ALA . 66.1 tp -70.63 -40.06 73.32 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.044 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.463 ' OD1' ' HE3' ' A' ' 32' ' ' LYS . 12.7 t-20 -56.2 -41.88 76.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.776 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.45 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 80.6 mt -62.59 -41.47 98.98 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.34 -179.33 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.563 ' NH1' ' HB3' ' A' ' 98' ' ' GLU . 15.2 ttp180 -74.2 -25.06 59.46 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.856 -0.337 . . . . 0.0 111.09 -174.323 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -73.72 -26.09 60.53 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.825 -0.35 . . . . 0.0 111.282 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -92.56 -27.95 17.05 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.516 -0.474 . . . . 0.0 109.898 176.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.87 22.79 7.43 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.476 -0.869 . . . . 0.0 112.522 177.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.434 HG21 ' HA ' ' A' ' 32' ' ' LYS . 30.4 m -114.27 21.05 6.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.122 0.487 . . . . 0.0 110.882 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -92.02 155.52 43.01 Favored Pre-proline 0 C--O 1.237 0.431 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.428 -177.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.593 ' HB3' HD13 ' A' ' 53' ' ' LEU . 15.7 Cg_exo -69.69 158.9 55.43 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.997 2.465 . . . . 0.0 112.021 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -69.76 -44.69 69.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.057 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.98 164.24 25.78 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.204 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.707 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 37.5 mm -127.0 124.64 65.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.428 -178.824 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.1 mm -119.19 116.27 50.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 176.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.406 ' O ' HG12 ' A' ' 104' ' ' VAL . 13.6 m120 -126.26 157.38 38.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.692 0.282 . . . . 0.0 111.031 -175.028 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 23.5 ttmm -68.89 -52.07 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 173.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.1 tptm -155.6 109.99 2.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.172 171.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.7 t -91.62 167.03 12.5 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.314 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.508 ' HG3' ' HA2' ' A' ' 60' ' ' GLY . 2.9 mm-40 -83.56 152.08 25.05 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.934 0.397 . . . . 0.0 110.854 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 m -58.87 -34.02 71.14 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.148 -178.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.462 HG21 ' HB ' ' A' ' 63' ' ' VAL . 3.0 mp -61.22 -39.99 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.098 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 50.0 mt -77.15 -42.4 31.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.413 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.574 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -55.59 -48.76 74.32 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.586 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -71.79 -39.06 67.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.524 179.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.95 -41.52 99.66 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.601 -178.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.45 ' HB2' HD22 ' A' ' 68' ' ' LEU . . . -74.56 -31.16 62.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.555 0.217 . . . . 0.0 110.809 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -61.28 -38.54 87.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.01 0.433 . . . . 0.0 110.112 175.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 84.2 mtp -66.22 -42.45 88.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.685 177.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.499 ' HA ' HD13 ' A' ' 69' ' ' LEU . . . -80.94 -4.29 54.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.964 -178.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.563 ' HB3' ' NH1' ' A' ' 72' ' ' ARG . 37.7 tt0 60.24 37.75 20.34 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.85 0.833 . . . . 0.0 109.852 -177.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.447 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 60.1 mt -105.11 89.18 2.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.931 175.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.586 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 12.1 Cg_endo -53.47 117.07 3.42 Favored 'Trans proline' 0 C--O 1.234 0.302 0 C-N-CA 123.17 2.58 . . . . 0.0 113.845 -170.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.707 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 2.3 pp -117.56 148.11 42.19 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.504 171.183 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.0 m -136.34 163.92 32.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.083 -175.533 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.653 ' HB2' ' HB3' ' A' ' 6' ' ' ARG . 43.8 mt-10 -97.08 113.91 25.51 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.875 175.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 7.2 p -110.74 112.7 41.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 121.653 0.74 . . . . 0.0 109.86 174.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 105' ' ' ARG . 52.4 mtt180 -95.81 28.38 3.1 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.992 -173.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 22.8 t70 -118.07 121.33 40.31 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.625 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -72.6 -33.86 66.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.968 -178.594 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.416 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 49.5 mmtm -60.6 -35.88 77.2 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.029 -176.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.502 ' O ' HG12 ' A' ' 113' ' ' VAL . 44.7 t80 -51.8 -46.04 64.09 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.857 177.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -70.18 -22.63 62.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.195 0.522 . . . . 0.0 111.17 -174.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.481 ' O ' ' HE2' ' A' ' 114' ' ' LYS . 11.5 mm-40 -88.51 -28.19 20.95 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.191 176.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.61 -44.31 64.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.803 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 109' ' ' PHE . 11.9 p -91.93 133.18 34.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.172 0.51 . . . . 0.0 111.151 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.481 ' HE2' ' O ' ' A' ' 111' ' ' GLU . 74.7 mmtt -128.93 160.87 31.32 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 17' ' ' ALA . 10.8 t -63.35 125.44 24.17 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 121.162 0.506 . . . . 0.0 110.37 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.35 -16.36 11.67 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.855 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -91.24 175.28 6.99 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 174.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.42 HH11 ' HD3' ' A' ' 118' ' ' ARG . 1.3 tmm_? -116.24 129.76 56.45 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.135 0.493 . . . . 0.0 111.352 -174.18 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 86.6 t -116.41 140.41 38.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.209 178.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.563 ' HB ' ' HB2' ' A' ' 129' ' ' GLU . 48.6 t -104.94 108.21 24.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 172.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.562 HG23 HD13 ' A' ' 52' ' ' ILE . 96.1 t -92.77 119.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.148 0.499 . . . . 0.0 111.264 -175.227 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . 0.527 ' HA ' ' HG2' ' A' ' 12' ' ' ARG . 55.9 t-20 -115.74 93.81 4.42 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.325 176.049 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -94.36 -0.61 54.78 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 110.378 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -80.72 -40.25 25.63 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.399 177.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -98.75 -28.07 13.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.849 176.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 94.43 59.66 1.14 Allowed Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.27 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -148.59 146.33 28.2 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.917 0.389 . . . . 0.0 110.451 -174.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.51 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 54.8 t -119.71 108.85 24.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.761 177.136 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.707 ' HG2' ' HE3' ' A' ' 2' ' ' LYS . 39.1 mt-10 -99.81 107.9 20.05 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.961 0.41 . . . . 0.0 110.251 179.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 47.6 tp -93.35 132.66 37.37 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.209 178.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 27.8 mt -119.22 114.98 46.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.575 0.702 . . . . 0.0 109.5 175.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--N 1.312 -1.052 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.889 179.664 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 45.0 t . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 121.997 0.903 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mtmm -108.21 122.69 47.44 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.164 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -89.64 136.18 33.18 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 176.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.63 114.99 26.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.678 -176.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.515 ' SG ' ' HB ' ' A' ' 104' ' ' VAL . 11.7 m -120.33 163.08 18.37 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.38 178.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 45.3 ttt180 -93.74 124.83 38.01 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 120.344 -0.542 . . . . 0.0 109.854 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.483 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.71 137.95 34.05 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.69 -172.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 4.4 mp -103.18 -48.55 10.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 174.122 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 21.3 p -102.1 169.57 8.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.378 174.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.427 ' HB3' ' OD1' ' A' ' 124' ' ' ASP . 71.8 mtt85 -125.44 -174.75 3.14 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.928 0.394 . . . . 0.0 111.761 -176.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.35 175.85 23.39 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 -172.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.4 149.38 32.63 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -155.31 156.19 35.06 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.975 0.417 . . . . 0.0 111.099 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -124.28 132.82 53.59 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.694 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.09 175.33 39.43 Favored Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.051 177.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -72.3 133.21 44.89 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 176.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.532 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -79.77 121.54 25.49 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.017 0.436 . . . . 0.0 110.808 -177.183 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.986 HD21 HG21 ' A' ' 43' ' ' ILE . 7.3 tt -113.23 113.59 25.53 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 53.1 t -102.99 109.94 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.105 0.479 . . . . 0.0 110.759 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.745 ' HB ' ' HB3' ' A' ' 55' ' ' PHE . 20.9 m -87.37 116.75 25.68 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.348 176.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.901 ' HD3' ' HG3' ' A' ' 42' ' ' GLU . 8.8 mptt -73.37 -25.77 60.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.377 -176.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.482 ' HG3' ' HB3' ' A' ' 41' ' ' CYS . 22.0 mm-40 -91.36 152.97 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.853 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -91.14 90.88 8.0 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.956 178.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 29.5 pt -86.03 145.39 7.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.135 -178.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.442 ' HB3' ' HG ' ' A' ' 27' ' ' LEU . 7.2 m -91.75 150.19 21.23 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.552 -173.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.795 ' HB2' ' HA2' ' A' ' 60' ' ' GLY . 74.9 m-85 -86.11 15.17 5.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.905 179.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 63' ' ' VAL . 33.7 mt -73.53 -8.45 55.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.179 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 126.48 70.5 0.18 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.245 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -106.74 -25.63 6.16 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.786 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 37' ' ' VAL . 4.2 mp -92.21 133.74 32.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 -177.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.449 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 13.2 t70 -69.68 135.11 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.996 0.426 . . . . 0.0 110.293 175.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 49.9 pttt -73.38 -14.02 61.2 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -171.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -106.65 -44.53 4.45 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.996 0.427 . . . . 0.0 111.771 -174.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.466 ' HB ' HG12 ' A' ' 36' ' ' ILE . 34.6 p -97.48 -26.88 14.67 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.11 -174.195 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.64 8.5 84.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.559 -175.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.466 HG12 ' HB ' ' A' ' 34' ' ' THR . 34.0 mm -82.56 133.48 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.367 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.49 HG12 HG13 ' A' ' 30' ' ' ILE . 5.5 m -77.39 131.73 34.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.312 0.577 . . . . 0.0 110.974 176.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.449 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 75.1 mmtt -95.39 -14.92 23.41 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.691 177.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -129.01 85.12 2.29 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.674 -176.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.577 ' HB3' ' HB2' ' A' ' 44' ' ' LYS . 5.1 t70 -148.14 -162.79 1.63 Allowed 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.597 -178.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.482 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 44.9 t -155.3 -32.47 0.1 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.553 -175.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.901 ' HG3' ' HD3' ' A' ' 21' ' ' LYS . 17.6 mm-40 -109.53 -47.26 3.4 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -177.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.986 HG21 HD21 ' A' ' 18' ' ' LEU . 40.8 pt -101.28 10.08 8.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.351 0.596 . . . . 0.0 109.919 -177.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.577 ' HB2' ' HB3' ' A' ' 40' ' ' ASP . 79.0 tttt -54.57 114.0 1.51 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.604 177.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 114.18 -14.19 21.24 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.374 -176.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -103.71 169.24 8.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.748 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.408 ' HB2' HD13 ' A' ' 36' ' ' ILE . 40.8 t -109.62 152.28 25.75 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.553 -179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.8 m -103.9 3.54 10.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.848 177.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.0 85.48 1.0 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.394 -176.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 116.18 8.26 13.42 Favored Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.516 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -114.46 158.83 21.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.0 mt -93.11 117.5 36.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 37.0 tp -90.32 111.16 22.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.579 -173.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 19' ' ' VAL . 61.3 t -119.0 105.95 18.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.413 178.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.745 ' HB3' ' HB ' ' A' ' 20' ' ' THR . 19.1 p90 -137.48 163.61 47.4 Favored Pre-proline 0 C--N 1.322 -0.625 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.603 ' HD2' ' HB2' ' A' ' 55' ' ' PHE . 10.0 Cg_endo -52.56 -54.92 4.33 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.858 2.372 . . . . 0.0 112.707 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 118.0 145.83 8.0 Favored Glycine 0 N--CA 1.453 -0.202 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.012 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 25' ' ' SER . . . 177.78 125.72 0.93 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.535 -0.841 . . . . 0.0 112.932 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 58.5 mtmt 55.04 90.71 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 174.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.795 ' HA2' ' HB2' ' A' ' 26' ' ' PHE . . . -102.06 -57.04 0.82 Allowed Glycine 0 N--CA 1.447 -0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 175.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 12.3 t 65.24 -172.26 0.18 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.937 0.495 . . . . 0.0 111.004 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.563 ' HA ' HG21 ' A' ' 89' ' ' ILE . 6.6 m -69.49 -25.01 63.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -178.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 27' ' ' LEU . 7.7 p -69.86 -37.35 72.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.971 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.477 ' HA3' ' HB3' ' A' ' 26' ' ' PHE . . . -82.25 59.72 4.88 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.89 -178.134 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.416 ' HB3' HG22 ' A' ' 89' ' ' ILE . 38.1 p -140.87 -70.5 0.37 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.858 0.361 . . . . 0.0 110.952 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -69.55 -16.32 63.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.765 -177.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.543 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 93.4 t -58.13 -45.34 88.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.895 0.379 . . . . 0.0 110.164 176.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -61.7 -38.94 89.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.593 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 54.4 tp -66.86 -40.29 87.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.878 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -69.55 -40.94 76.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.96 0.41 . . . . 0.0 110.492 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.543 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 91.6 mt -62.63 -37.44 86.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.239 176.434 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -63.87 -37.56 87.86 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.216 -178.178 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -69.1 -29.47 67.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.833 0.349 . . . . 0.0 110.749 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.411 ' HB3' HG22 ' A' ' 76' ' ' VAL . 62.1 t30 -89.41 -14.37 35.64 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.34 0.59 . . . . 0.0 110.055 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 85.92 10.45 75.49 Favored Glycine 0 N--CA 1.45 -0.403 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.531 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.411 HG22 ' HB3' ' A' ' 74' ' ' ASN . 27.3 m -100.74 14.01 5.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 -178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -81.4 154.5 71.67 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.35 176.08 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -70.16 159.14 54.16 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.334 2.023 . . . . 0.0 111.775 176.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -71.33 -31.36 67.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.907 0.384 . . . . 0.0 110.717 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -168.25 164.12 13.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.217 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 66.4 mt -137.33 118.62 17.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.257 -0.429 . . . . 0.0 109.978 179.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.4 HG23 ' CG2' ' A' ' 102' ' ' VAL . 10.1 mm -114.9 118.09 57.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 177.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -119.01 158.28 26.1 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.137 0.494 . . . . 0.0 111.506 -174.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.576 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 1.5 tmtp? -83.96 -45.19 13.41 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 174.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -141.81 113.07 7.55 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.069 -0.969 . . . . 0.0 108.878 -178.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.6 t -123.57 -176.92 3.57 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.582 -176.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.454 ' H ' HD12 ' A' ' 90' ' ' ILE . 77.9 mt-10 -115.86 150.7 36.61 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.265 -179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.8 m -61.92 -37.89 86.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.677 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.563 HG21 ' HA ' ' A' ' 62' ' ' THR . 51.0 mt -61.08 -39.22 81.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.968 0.414 . . . . 0.0 110.793 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.648 HD11 ' HA3' ' A' ' 60' ' ' GLY . 60.4 mt -62.86 -42.13 95.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.055 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.583 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -61.72 -38.4 87.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.89 178.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 88' ' ' THR . 58.3 t -63.87 -43.49 97.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.536 177.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.72 -40.11 97.18 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.13 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.29 -32.67 74.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.748 0.308 . . . . 0.0 111.055 177.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.01 -25.03 67.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 178.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.417 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 45.2 mtt -79.37 -43.87 22.62 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.708 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.5 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -83.49 -0.74 51.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.134 -174.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 64.1 38.53 8.34 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.129 0.49 . . . . 0.0 110.769 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.47 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 69.0 mt -109.41 90.07 8.02 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 -179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 99' ' ' ILE . 17.7 Cg_endo -58.16 125.01 17.22 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.899 2.399 . . . . 0.0 112.68 -178.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.583 HD21 ' HA ' ' A' ' 91' ' ' ALA . 2.2 pp -127.35 147.52 50.26 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.17 0.509 . . . . 0.0 111.16 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 7' ' ' ALA . 27.4 m -134.56 156.2 39.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.05 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.451 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 42.9 mt-10 -95.92 119.46 34.46 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.583 176.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.576 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 4.5 p -114.45 116.42 52.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.257 0.551 . . . . 0.0 110.176 176.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -91.53 -29.34 17.02 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.783 -177.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -69.39 117.88 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.736 -177.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -68.64 -21.28 64.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.762 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 31.4 mttm -62.16 -19.97 63.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.442 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 113' ' ' VAL . 46.9 t80 -65.52 -51.97 56.03 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 173.197 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -69.7 -26.49 64.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.491 0.662 . . . . 0.0 110.412 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.408 ' HB3' ' HA ' ' A' ' 108' ' ' LYS . 39.1 tt0 -70.38 -37.35 74.52 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.543 176.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -81.45 -54.64 5.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.1 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 109' ' ' PHE . 9.9 p -69.96 138.9 21.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.254 0.549 . . . . 0.0 110.601 -177.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 55.9 mttp -135.04 151.43 50.78 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.956 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.553 HG23 ' HA ' ' A' ' 18' ' ' LEU . 16.2 m -58.16 113.33 1.87 Allowed 'General case' 0 C--N 1.324 -0.519 0 O-C-N 123.353 0.408 . . . . 0.0 110.397 178.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 106.18 31.73 3.99 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.949 -179.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -132.55 173.72 11.02 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 171.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB ' ' A' ' 131' ' ' ILE . 10.1 ttm180 -97.52 122.51 40.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.022 0.439 . . . . 0.0 111.797 -172.211 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HB2' ' A' ' 17' ' ' ALA . 83.4 t -117.83 124.18 72.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.065 174.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.4 t -107.17 105.05 18.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 174.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.9 p -92.86 132.31 37.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.555 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -127.23 93.51 3.76 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 176.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.05 -13.34 56.0 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.607 -171.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.427 ' OD1' ' HB3' ' A' ' 10' ' ' ARG . 48.3 m-20 -61.57 -34.77 76.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.909 0.385 . . . . 0.0 109.977 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.412 ' HB3' ' CE1' ' A' ' 127' ' ' TYR . 32.1 tt0 -106.5 -27.74 10.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.1 178.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 93.07 70.13 1.13 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.969 175.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.412 ' CE1' ' HB3' ' A' ' 125' ' ' GLU . 46.1 p90 -170.31 162.13 8.42 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.21 179.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.451 HG21 ' CE1' ' A' ' 109' ' ' PHE . 15.0 m -124.61 132.11 71.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.507 178.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -105.42 117.77 34.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.743 179.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.8 tp -94.2 125.4 38.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 177.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.422 ' HB ' ' HD2' ' A' ' 118' ' ' ARG . 31.4 mm -108.13 111.45 35.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--N 1.312 -1.034 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.436 -173.627 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.855 0.36 . . . . 0.0 111.162 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.6 ttmm -121.5 111.67 17.55 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.589 ' HB2' ' HB ' ' A' ' 128' ' ' VAL . 90.1 m-85 -92.59 149.46 21.34 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.725 0.297 . . . . 0.0 110.77 -177.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.2 117.66 34.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.809 176.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.553 ' HB3' HG22 ' A' ' 104' ' ' VAL . 4.5 p -120.35 169.14 10.57 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.166 -177.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 44.2 ttp180 -94.69 128.38 41.33 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 175.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.596 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -95.12 127.62 41.32 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.979 0.419 . . . . 0.0 111.458 -174.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 49.4 mm -101.31 -55.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.549 177.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.679 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -95.42 173.68 7.4 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.553 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.417 ' H ' HG22 ' A' ' 9' ' ' THR . 25.3 mmt180 -121.25 168.18 11.9 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.402 -175.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.68 -174.41 16.54 Favored Glycine 0 N--CA 1.452 -0.256 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.77 154.7 46.39 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 117.618 0.709 . . . . 0.0 111.147 176.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.465 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -138.61 139.51 38.59 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.959 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -130.48 123.92 30.82 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.77 -179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.95 -166.34 37.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 119.585 -1.293 . . . . 0.0 113.39 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -73.19 135.16 44.58 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 122.598 0.359 . . . . 0.0 110.797 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -84.72 124.95 32.1 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.929 0.395 . . . . 0.0 111.046 178.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.572 ' HA ' HG23 ' A' ' 115' ' ' THR . 6.5 tt -108.78 110.71 22.16 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 175.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.669 ' HA ' ' HB ' ' A' ' 54' ' ' VAL . 47.0 t -104.58 125.7 59.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.269 0.557 . . . . 0.0 112.425 -168.538 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.461 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 17.5 p -137.22 144.98 43.1 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.113 -0.949 . . . . 0.0 109.614 174.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.523 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 15.8 ptpt -128.89 20.14 5.98 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.193 0.52 . . . . 0.0 111.031 175.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -80.57 125.3 29.82 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.192 173.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -77.83 109.46 11.87 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.212 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.75 ' HB ' ' HZ ' ' A' ' 55' ' ' PHE . 43.8 mt -124.45 -7.62 6.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 110.256 -174.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.516 ' HA ' ' CA ' ' A' ' 58' ' ' GLY . 22.0 p 48.94 23.25 0.67 Allowed 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 113.596 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.455 ' CD1' HD13 ' A' ' 90' ' ' ILE . 36.9 m-85 64.51 18.34 11.31 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 178.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.2 27.26 0.81 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.176 0.512 . . . . 0.0 109.878 173.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' HA2' ' HG2' ' A' ' 39' ' ' GLU . . . -94.01 -128.39 5.1 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.488 -176.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 177.39 93.38 0.09 OUTLIER Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.416 -177.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.435 HG12 HG22 ' A' ' 37' ' ' VAL . 54.5 mt -92.82 126.67 45.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 170.212 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -62.92 124.31 20.75 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.695 0.283 . . . . 0.0 110.701 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.549 ' HA ' HD23 ' A' ' 71' ' ' LEU . 20.7 pttp -85.08 3.97 36.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -173.368 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -101.47 -36.99 8.62 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.94 0.4 . . . . 0.0 110.818 177.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 22.2 p -113.22 -19.1 11.93 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.667 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.13 25.01 62.61 Favored Glycine 0 N--CA 1.453 -0.176 0 C-N-CA 120.989 -0.624 . . . . 0.0 111.963 -177.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 47.3 mm -102.3 127.99 55.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 120.706 0.289 . . . . 0.0 110.416 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 30' ' ' ILE . 21.8 t -67.0 111.46 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.854 0.359 . . . . 0.0 110.198 177.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -87.24 -27.96 22.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.467 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' HA2' ' A' ' 28' ' ' GLY . 7.7 tp10 -67.76 129.78 40.97 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.492 178.068 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -74.09 133.84 42.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.293 0.568 . . . . 0.0 110.811 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 3.5 p -160.78 35.17 0.15 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.18 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 32.7 mm-40 72.38 -51.64 0.7 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.77 -174.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -88.55 42.36 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.308 0.575 . . . . 0.0 110.896 178.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.3 tttm -73.22 127.39 32.49 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.27 -2.2 29.66 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.166 -176.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -77.37 150.6 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.228 0.537 . . . . 0.0 111.939 178.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 36.0 t -101.36 131.93 47.17 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.782 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.498 ' HB ' ' HG3' ' A' ' 78' ' ' PRO . 31.2 m -105.53 4.72 10.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.964 0.411 . . . . 0.0 110.877 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.76 92.17 1.99 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.55 0.69 . . . . 0.0 111.242 -174.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 105.65 12.07 27.3 Favored Glycine 0 C--N 1.315 -0.595 0 CA-C-N 115.123 -0.944 . . . . 0.0 112.635 176.245 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -110.46 175.3 5.48 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 54.1 mt -110.19 121.24 62.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.562 ' HB3' HG22 ' A' ' 81' ' ' ILE . 54.4 tp -91.46 120.26 32.13 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.746 -174.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.669 ' HB ' ' HA ' ' A' ' 19' ' ' VAL . 67.5 t -101.99 107.97 22.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 174.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.785 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 51.4 t80 -133.99 143.3 46.77 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -173.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.523 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 23.8 Cg_endo -62.95 -36.92 57.31 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 121.955 1.77 . . . . 0.0 111.505 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.16 -154.94 16.53 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.287 176.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.516 ' CA ' ' HA ' ' A' ' 25' ' ' SER . . . -132.05 -143.64 5.18 Favored Glycine 0 N--CA 1.44 -1.044 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 177.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 30.9 ttmt -173.54 -64.58 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -106.71 75.41 0.22 Allowed Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 110.594 -1.003 . . . . 0.0 110.594 172.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.411 ' HB2' ' HG3' ' A' ' 87' ' ' GLU . 50.9 m -104.23 178.35 4.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.397 0.618 . . . . 0.0 112.011 -173.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 85.5 m -154.77 -40.13 0.09 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.091 176.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.9 t -89.06 141.35 14.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.502 174.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 136.4 -7.22 3.98 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.742 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.533 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 12.8 p -90.09 -73.22 0.53 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.001 0.429 . . . . 0.0 111.747 -178.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 -66.51 -27.87 68.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.63 -173.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.482 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 26.8 m -67.15 -31.99 55.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.025 -178.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.42 -36.78 77.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.932 0.396 . . . . 0.0 110.357 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.441 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 57.4 tp -66.15 -39.9 90.16 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.764 176.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -60.05 -48.61 81.0 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.587 176.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.549 HD23 ' HA ' ' A' ' 32' ' ' LYS . 96.3 mt -57.45 -47.62 81.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.964 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.41 ' HB2' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -66.07 -37.39 85.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -177.393 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.8 mmtt -61.4 -30.2 70.4 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.5 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.574 ' HB3' HG22 ' A' ' 76' ' ' VAL . 21.6 t-20 -89.64 -22.78 22.13 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.195 0.522 . . . . 0.0 109.877 178.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.27 16.49 55.5 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.385 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.667 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 32.2 m -106.94 13.81 8.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.084 0.469 . . . . 0.0 110.821 -176.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.88 49.88 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.935 -179.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.498 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 13.1 Cg_exo -68.33 143.12 57.1 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.195 1.93 . . . . 0.0 110.185 170.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.465 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 94.8 mttt -61.58 -33.92 74.71 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.165 0.507 . . . . 0.0 110.618 -179.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.62 155.25 34.36 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.438 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.562 HG22 ' HB3' ' A' ' 53' ' ' LEU . 16.1 pt -124.65 114.76 42.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.082 175.308 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.752 HG23 HG23 ' A' ' 102' ' ' VAL . 4.4 mm -102.86 116.78 47.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.785 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.9 m120 -115.1 175.96 5.27 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.822 0.344 . . . . 0.0 111.154 -173.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 39.2 ttmt -101.37 -40.81 6.92 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 171.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 85' ' ' LYS . 68.4 mmtt -125.15 114.41 18.98 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.502 177.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.1 t -81.15 154.99 26.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.042 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.411 ' HG3' ' HB2' ' A' ' 61' ' ' SER . 1.0 OUTLIER -126.29 142.38 51.55 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.511 ' O ' HG23 ' A' ' 92' ' ' VAL . 18.1 m -56.26 -50.02 72.56 Favored 'General case' 0 C--N 1.323 -0.548 0 O-C-N 123.536 0.522 . . . . 0.0 112.033 -174.483 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.406 HG22 ' HB3' ' A' ' 65' ' ' SER . 72.1 mt -65.24 -44.96 95.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 121.054 0.454 . . . . 0.0 110.702 -176.239 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.455 HD13 ' CD1' ' A' ' 26' ' ' PHE . 63.9 mt -63.98 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.693 -179.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.4 -41.58 94.18 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 88' ' ' THR . 98.9 t -61.86 -44.56 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.54 178.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.533 ' HA3' ' HA ' ' A' ' 65' ' ' SER . . . -62.6 -44.76 97.08 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.358 179.39 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.421 ' HB3' HD23 ' A' ' 101' ' ' LEU . . . -67.02 -30.96 71.19 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.594 0.235 . . . . 0.0 111.131 179.296 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -65.72 -38.11 88.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.541 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.435 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 61.0 mtt -64.26 -45.92 86.01 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.516 0.674 . . . . 0.0 109.91 177.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -80.14 -1.65 41.19 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 114.992 -1.004 . . . . 0.0 111.697 -175.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 58.9 43.17 18.45 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 121.25 0.548 . . . . 0.0 110.569 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 50.2 mm -104.18 91.08 3.51 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.751 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.679 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 9.3 Cg_endo -49.96 100.41 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.558 2.838 . . . . 0.0 112.667 -176.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 94' ' ' ALA . 1.5 pp -102.43 137.0 41.25 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.235 0.54 . . . . 0.0 109.994 179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.752 HG23 HG23 ' A' ' 82' ' ' ILE . 35.1 m -135.17 159.23 41.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 178.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 8.3 pt-20 -121.06 135.57 55.17 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.365 0.602 . . . . 0.0 111.838 -178.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.571 HG11 ' HB2' ' A' ' 109' ' ' PHE . 32.4 t -115.9 105.04 17.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 170.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 105' ' ' ARG . 14.1 ptt180 -84.16 35.85 0.55 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.95 -170.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -138.55 145.12 40.28 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.679 176.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -71.22 -23.93 62.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.171 -176.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -60.28 -29.24 68.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.582 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.571 ' HB2' HG11 ' A' ' 104' ' ' VAL . 84.6 t80 -61.25 -46.46 90.29 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.985 0.422 . . . . 0.0 110.312 177.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -71.97 -22.61 61.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.243 -175.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 32.8 mm-40 -79.04 -36.62 40.71 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.346 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.67 -42.44 22.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.87 -176.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 109' ' ' PHE . 12.0 p -79.86 138.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.014 0.435 . . . . 0.0 110.345 -177.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.3 mttp -122.77 151.61 41.45 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.045 -177.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.572 HG23 ' HA ' ' A' ' 18' ' ' LEU . 33.1 m -71.56 95.76 1.45 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.101 0.476 . . . . 0.0 109.921 176.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.2 1.95 Allowed Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.268 -177.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -77.78 166.98 22.27 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.4 177.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.748 HH21 HG13 ' A' ' 131' ' ' ILE . 2.2 tmm_? -107.67 122.87 47.59 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.372 0.606 . . . . 0.0 109.863 -176.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.412 HG23 ' HB2' ' A' ' 17' ' ' ALA . 91.3 t -119.57 139.33 47.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.262 -175.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.9 t -117.05 111.82 36.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.319 171.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.525 HG21 HD11 ' A' ' 82' ' ' ILE . 55.1 t -107.56 117.53 53.45 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.285 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . 0.744 HD21 ' HB2' ' A' ' 124' ' ' ASP . 9.8 t30 -109.97 118.02 35.32 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 177.013 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -101.15 8.01 42.91 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.37 -174.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.744 ' HB2' HD21 ' A' ' 122' ' ' ASN . 53.5 m-20 -64.99 -41.43 95.43 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 176.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -117.9 -33.43 4.48 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 173.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 108.93 91.84 2.19 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.195 172.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.404 ' HE1' ' HB2' ' A' ' 129' ' ' GLU . 25.6 p90 -159.66 153.35 22.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.949 0.404 . . . . 0.0 110.322 174.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.589 ' HB ' ' HB2' ' A' ' 3' ' ' PHE . 84.9 t -116.15 111.21 34.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.831 178.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HB2' ' HE1' ' A' ' 127' ' ' TYR . 26.3 tt0 -92.62 108.37 19.92 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.248 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 59.2 tp -94.6 114.07 25.98 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.908 -176.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.748 HG13 HH21 ' A' ' 118' ' ' ARG . 33.5 mm -111.58 116.95 53.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.364 174.346 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.905 -1.043 . . . . 0.0 108.876 -179.299 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 C--O 1.234 0.238 0 CA-C-O 120.963 0.411 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -126.98 140.78 52.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.937 -174.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -133.59 149.09 51.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.437 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.79 131.72 45.59 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.649 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 35.0 m -122.09 169.09 11.2 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.321 176.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -96.2 134.59 39.1 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 174.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.23 96.6 4.59 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.922 0.391 . . . . 0.0 111.473 -174.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.494 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 43.8 mm -82.81 -49.37 16.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 174.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.581 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -109.22 176.19 5.18 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 172.604 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.471 ' H ' HG22 ' A' ' 9' ' ' THR . 63.9 mtt180 -126.23 178.13 6.0 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.48 -0.193 . . . . 0.0 110.48 -179.11 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 124' ' ' ASP . . . 97.19 -162.39 21.79 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -174.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -156.41 148.01 22.68 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 120.695 0.283 . . . . 0.0 110.496 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.407 ' HB1' ' HG2' ' A' ' 79' ' ' LYS . . . -149.66 151.56 33.94 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -137.82 127.77 25.65 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.958 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.64 172.14 39.47 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.324 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -70.38 128.87 37.69 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.005 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.539 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.92 141.69 34.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.267 0.556 . . . . 0.0 111.712 -175.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.5 tt -121.24 114.09 20.88 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 177.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.0 t -102.79 110.84 30.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.196 0.522 . . . . 0.0 111.674 -173.627 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 20' ' ' THR . 9.7 t -152.36 95.63 2.06 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 172.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 56' ' ' PRO . 0.1 OUTLIER -67.77 -72.2 0.18 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.154 -174.257 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.832 ' HG2' ' HB3' ' A' ' 41' ' ' CYS . 0.3 OUTLIER 51.15 -163.52 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 O-C-N 123.469 0.48 . . . . 0.0 111.794 178.368 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 13.3 p90 -158.59 44.49 0.29 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.443 0.639 . . . . 0.0 110.045 176.522 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.5 pt -73.29 177.84 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.721 -177.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.877 ' HA ' ' HB2' ' A' ' 59' ' ' LYS . 40.1 t -88.22 128.52 35.46 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.338 -178.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.595 ' O ' ' HB ' ' A' ' 63' ' ' VAL . 23.3 t80 -82.91 91.19 7.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -124.97 -77.49 0.59 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.033 177.002 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.45 59.17 0.41 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.6 15.65 45.26 Favored Glycine 0 C--O 1.226 -0.387 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 -177.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.443 HD13 HG21 ' A' ' 48' ' ' VAL . 58.2 mt -134.31 134.52 54.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HE2' ' A' ' 38' ' ' LYS . 15.2 t70 -66.26 135.59 54.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.679 0.276 . . . . 0.0 110.357 178.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -81.21 -7.45 59.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -173.012 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -117.65 -30.43 5.47 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.619 HG23 HG12 ' A' ' 36' ' ' ILE . 7.8 t -123.16 -4.88 8.41 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 120.104 -0.638 . . . . 0.0 112.519 179.247 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 70.35 27.95 72.0 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.87 -0.681 . . . . 0.0 113.446 176.202 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.619 HG12 HG23 ' A' ' 34' ' ' THR . 42.5 mm -87.97 129.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 176.447 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.89 128.69 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.019 0.438 . . . . 0.0 111.032 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HE2' ' HB2' ' A' ' 31' ' ' ASP . 74.3 mmtt -87.67 -41.43 13.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.669 -179.123 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -89.97 122.19 32.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.87 -172.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.623 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 21.7 t70 -74.35 133.51 42.52 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.359 0.599 . . . . 0.0 111.087 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.832 ' HB3' ' HG2' ' A' ' 22' ' ' GLU . 59.0 m -123.11 -28.09 4.09 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.896 178.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 175.52 -62.25 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 pt -114.79 71.02 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.295 179.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.623 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 13.3 tmtt? -93.74 140.76 29.27 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.698 -178.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 136.62 -8.1 3.95 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.915 175.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -103.89 173.02 6.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.239 0.542 . . . . 0.0 111.58 -175.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 m -93.36 137.7 32.41 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.653 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.443 HG21 HD13 ' A' ' 30' ' ' ILE . 29.7 m -100.76 2.7 10.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.972 0.415 . . . . 0.0 110.399 174.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.32 94.76 0.17 Allowed 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.861 -177.151 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.482 ' HA2' ' HB2' ' A' ' 79' ' ' LYS . . . 97.43 14.04 42.69 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 114.756 -1.111 . . . . 0.0 112.634 176.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 82.4 mtt180 -104.69 164.85 11.46 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.669 0.271 . . . . 0.0 110.574 176.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.505 HD12 ' HB3' ' A' ' 80' ' ' ALA . 51.5 mm -95.93 111.46 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.077 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' HG22 ' A' ' 81' ' ' ILE . 18.3 tp -101.7 125.86 48.45 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -173.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 50.4 t -113.75 128.61 70.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.958 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -131.99 145.87 59.27 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.46 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 21' ' ' LYS . 60.2 Cg_endo -76.83 -50.31 0.1 Allowed 'Trans proline' 0 N--CA 1.463 -0.292 0 C-N-CA 122.624 2.216 . . . . 0.0 112.002 175.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 154.8 86.62 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.424 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.442 -177.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -93.21 -138.52 8.84 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.993 -175.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.877 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 23.4 mtpp -94.18 113.41 25.34 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.85 -44.18 92.49 Favored Glycine 0 C--N 1.329 0.14 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.126 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.8 m 57.43 23.26 8.83 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 173.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.494 ' HA ' ' CD1' ' A' ' 89' ' ' ILE . 4.5 m 60.77 30.45 19.69 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.887 176.291 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.595 ' HB ' ' O ' ' A' ' 26' ' ' PHE . 92.2 t -122.7 149.77 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 176.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 151.76 -47.17 0.58 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.997 -0.62 . . . . 0.0 111.869 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.2 p -70.71 142.55 51.48 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 122.964 -0.139 . . . . 0.0 110.881 -179.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 85.7 m-85 74.11 -52.8 0.69 Allowed 'General case' 0 N--CA 1.471 0.597 0 O-C-N 123.985 0.803 . . . . 0.0 112.498 175.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.77 -39.14 76.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.7 mt -65.07 -34.83 79.35 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.716 0.293 . . . . 0.0 110.847 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.3 tp -65.06 -44.71 88.08 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.405 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -64.26 -41.49 96.91 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.409 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.57 -38.39 86.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.798 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.468 ' CG ' HD11 ' A' ' 99' ' ' ILE . 2.7 tmt_? -72.04 -39.48 69.07 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.528 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -64.16 -30.94 71.97 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.278 0.561 . . . . 0.0 110.336 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -84.86 -22.91 29.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.0 178.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.49 23.79 38.64 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.747 176.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.05 -0.26 9.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.057 0.456 . . . . 0.0 111.269 -179.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -88.14 162.59 40.05 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.685 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.03 147.8 88.44 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.229 1.953 . . . . 0.0 111.099 172.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.482 ' HB2' ' HA2' ' A' ' 50' ' ' GLY . 80.3 tttt -73.72 -26.15 60.56 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.05 0.452 . . . . 0.0 110.43 -175.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.505 ' HB3' HD12 ' A' ' 52' ' ' ILE . . . -166.71 150.19 6.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.753 176.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.511 HG22 ' HB3' ' A' ' 53' ' ' LEU . 15.7 pt -126.69 123.31 62.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.922 0.391 . . . . 0.0 110.564 178.381 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.694 HG23 HG23 ' A' ' 102' ' ' VAL . 5.4 mm -111.01 120.56 61.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.264 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.553 ' O ' ' HA ' ' A' ' 103' ' ' GLU . 12.4 m120 -129.96 167.15 18.67 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -176.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -104.68 -38.83 6.57 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 167.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.4 tttp -128.58 103.43 7.1 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.218 174.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.9 t -112.0 156.8 21.57 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 175.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -79.46 145.93 33.01 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -56.87 -34.01 67.42 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.182 0.515 . . . . 0.0 110.986 -176.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.494 ' CD1' ' HA ' ' A' ' 62' ' ' THR . 54.8 mt -64.45 -41.15 91.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.822 178.317 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 59.9 mt -71.83 -42.17 69.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.542 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.61 -47.11 80.35 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.304 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.408 ' O ' ' HG3' ' A' ' 96' ' ' MET . 90.1 t -68.22 -42.25 84.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.615 179.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.94 -40.97 99.15 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.352 179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.54 -40.06 92.46 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.785 0.326 . . . . 0.0 110.833 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.506 ' HA ' HG23 ' A' ' 9' ' ' THR . . . -63.64 -37.18 86.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.941 179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.408 ' HG3' ' O ' ' A' ' 92' ' ' VAL . 89.4 mtp -68.39 -37.73 80.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.683 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -86.14 -1.28 57.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.342 -175.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 62.36 47.32 5.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.414 0.626 . . . . 0.0 110.467 -176.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.468 HD11 ' CG ' ' A' ' 72' ' ' ARG . 44.2 mm -107.29 90.55 5.82 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.587 175.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.3 Cg_endo -48.48 96.51 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.421 2.747 . . . . 0.0 113.277 -175.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.494 ' O ' ' HB ' ' A' ' 8' ' ' ILE . 5.8 tt -102.29 126.0 49.16 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.694 HG23 HG23 ' A' ' 82' ' ' ILE . 11.0 m -127.71 150.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.257 176.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.553 ' HA ' ' O ' ' A' ' 83' ' ' ASN . 6.5 tm-20 -97.8 114.9 27.04 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.507 -177.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 82' ' ' ILE . 14.4 m -71.57 134.12 30.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.333 0.587 . . . . 0.0 111.832 -177.123 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.559 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 1.0 OUTLIER -84.94 -33.95 22.57 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.363 -179.548 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -112.5 140.36 47.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.185 -172.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.34 -20.67 62.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.315 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mmtt -57.54 -24.15 54.46 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.905 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.412 ' CD2' HG11 ' A' ' 104' ' ' VAL . 92.7 t80 -60.65 -46.23 91.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.691 0.281 . . . . 0.0 110.508 178.049 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -65.07 -31.46 72.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.544 -178.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -79.69 -30.91 41.23 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.976 -178.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.38 -33.01 17.02 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.371 -175.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 14.8 p -64.1 134.82 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.083 0.468 . . . . 0.0 110.841 -177.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -116.89 139.57 50.47 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.886 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.4 m -71.34 99.92 2.05 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.216 175.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.73 -31.6 2.92 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.666 179.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -85.47 161.27 19.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.861 0.362 . . . . 0.0 111.616 -177.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.864 HH21 HG13 ' A' ' 131' ' ' ILE . 18.0 ttp180 -89.17 127.37 35.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.248 0.547 . . . . 0.0 111.61 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.539 HG23 ' HB2' ' A' ' 17' ' ' ALA . 96.2 t -108.13 120.91 60.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.742 175.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.84 101.63 12.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 176.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 3.2 p -102.18 114.88 42.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 121.381 0.61 . . . . 0.0 110.907 -178.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -101.94 93.64 5.38 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 175.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -72.29 -26.68 62.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.374 -173.147 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.501 ' HB2' ' H ' ' A' ' 11' ' ' GLY . 25.8 t70 -63.38 -22.6 66.98 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.234 -177.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -120.11 -1.44 10.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.719 0.295 . . . . 0.0 110.708 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.18 62.66 5.42 Favored Glycine 0 C--N 1.332 0.356 0 CA-C-N 116.053 -0.521 . . . . 0.0 112.376 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -152.13 141.8 21.84 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.37 -0.488 . . . . 0.0 110.308 -177.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.5 m -122.97 136.28 60.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.199 0.524 . . . . 0.0 111.441 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -120.73 114.66 21.98 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.379 177.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 42.0 tp -90.49 125.18 35.51 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.864 HG13 HH21 ' A' ' 118' ' ' ARG . 19.3 mm -101.36 111.61 31.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.309 -1.181 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.441 -175.828 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.413 ' HB3' ' HE2' ' A' ' 2' ' ' LYS . 14.3 ptpt -145.18 148.87 34.04 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.815 0.341 . . . . 0.0 111.215 -177.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -136.44 152.95 51.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.734 -0.667 . . . . 0.0 109.977 179.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.79 114.09 25.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.209 175.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.725 ' SG ' HG12 ' A' ' 104' ' ' VAL . 83.9 m -120.24 176.93 5.22 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.215 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.9 tpm_? -94.73 119.84 34.0 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.119 -172.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 102' ' ' VAL . . . -86.69 142.55 28.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.174 -179.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.2 mp -105.97 -54.65 6.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.3 p -98.4 161.31 13.75 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 170.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.573 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 46.0 mtm180 -123.73 -175.85 3.32 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 119.574 -0.85 . . . . 0.0 112.681 -174.674 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 120.85 -164.89 14.07 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 -169.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.5 ttp180 -148.76 143.47 26.41 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 117.542 0.671 . . . . 0.0 109.789 177.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.567 ' HB3' ' HB2' ' A' ' 80' ' ' ALA . . . -154.52 152.15 29.74 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.716 0.293 . . . . 0.0 110.96 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.414 ' O ' ' HD2' ' A' ' 79' ' ' LYS . 0.1 OUTLIER -147.81 161.21 41.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.494 178.84 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 147.85 -160.54 28.35 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.155 -1.022 . . . . 0.0 112.453 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -64.4 124.09 20.88 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.986 0.422 . . . . 0.0 110.444 177.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -80.84 117.22 21.3 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.254 179.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.505 HD12 HG23 ' A' ' 115' ' ' THR . 13.4 tp -96.54 108.82 21.46 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.42 112.73 40.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.319 0.58 . . . . 0.0 110.96 -174.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -116.45 101.15 8.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.308 176.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -73.59 -12.09 60.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.401 -175.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -71.84 130.12 40.29 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.051 0.453 . . . . 0.0 110.154 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -78.53 69.92 4.8 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.407 0.622 . . . . 0.0 111.338 -177.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -82.14 152.63 4.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.226 176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -116.58 174.73 5.91 Favored 'General case' 0 N--CA 1.431 -1.382 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.326 -173.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.493 ' O ' ' HB3' ' A' ' 27' ' ' LEU . 85.3 m-85 -82.97 -163.34 0.71 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.89 -0.596 . . . . 0.0 109.987 175.623 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.522 HD13 HG21 ' A' ' 63' ' ' VAL . 64.9 tp 72.24 14.91 5.46 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.996 0.903 . . . . 0.0 109.831 -176.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.82 44.8 0.12 Allowed Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.817 177.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.63 -72.51 1.21 Allowed Glycine 0 N--CA 1.452 -0.285 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 174.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 30' ' ' ILE . 4.0 mp -85.84 133.31 29.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 170.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.527 ' HB2' ' HG2' ' A' ' 38' ' ' LYS . 29.0 t70 -72.74 146.08 46.66 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.309 0.576 . . . . 0.0 111.475 -175.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.538 ' HG2' ' HG3' ' A' ' 33' ' ' GLU . 0.0 OUTLIER -82.94 -11.68 57.96 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.036 -0.984 . . . . 0.0 111.958 -173.102 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.538 ' HG3' ' HG2' ' A' ' 32' ' ' LYS . 31.0 mt-10 -110.29 -41.32 4.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.636 0.255 . . . . 0.0 111.48 -174.383 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 42.4 p -100.86 -23.01 14.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -177.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.504 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 75.3 16.84 80.38 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.521 -175.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 50.3 mm -99.58 143.78 13.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.5 t -67.98 115.14 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.67 0.271 . . . . 0.0 110.395 177.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.527 ' HG2' ' HB2' ' A' ' 31' ' ' ASP . 30.3 mmtp -81.83 -26.67 34.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.65 146.5 53.77 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.86 -178.496 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -77.28 136.92 38.53 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.546 -177.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 53.1 t -165.22 167.66 17.81 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -177.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -63.8 -36.18 83.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.322 0.582 . . . . 0.0 109.464 175.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.649 ' O ' ' HG2' ' A' ' 46' ' ' GLU . 13.6 pt -108.19 53.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.327 175.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.607 ' NZ ' ' HB3' ' A' ' 44' ' ' LYS . 0.0 OUTLIER -77.94 132.95 38.12 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 177.89 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.78 8.51 34.48 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.602 179.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.649 ' HG2' ' O ' ' A' ' 43' ' ' ILE . 32.2 mm-40 -63.53 146.97 52.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.227 0.537 . . . . 0.0 110.888 178.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.0 m -106.34 107.58 18.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.179 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.2 m -82.26 0.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.941 -175.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.23 89.15 0.45 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.298 0.571 . . . . 0.0 111.452 -175.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.91 8.58 29.65 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.401 -0.818 . . . . 0.0 113.003 174.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.6 mpt_? -103.78 172.44 6.8 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.753 0.311 . . . . 0.0 111.057 -179.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 50.1 mm -99.92 104.09 15.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 171.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HG ' ' HD1' ' A' ' 55' ' ' PHE . 45.3 tp -85.71 113.7 22.11 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.342 -170.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.1 t -119.66 106.89 19.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.108 0.48 . . . . 0.0 110.496 178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.424 ' HD1' ' HG ' ' A' ' 53' ' ' LEU . 34.2 p90 -136.97 149.86 67.84 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.82 176.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -63.79 -49.6 3.97 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.106 1.871 . . . . 0.0 110.464 172.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.88 139.83 2.13 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.41 -0.814 . . . . 0.0 113.061 175.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.34 5.31 60.73 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.472 177.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 69.1 -85.47 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.231 0.612 . . . . 0.0 111.102 -178.156 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.1 -113.98 1.32 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.067 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 19.6 t -151.72 53.85 0.83 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.963 0.411 . . . . 0.0 110.813 -175.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.61 ' HA ' HG21 ' A' ' 89' ' ' ILE . 19.8 m 73.57 -19.38 0.34 Allowed 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 173.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.522 HG21 HD13 ' A' ' 27' ' ' LEU . 4.3 t -82.52 36.66 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.835 0.826 . . . . 0.0 111.064 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.414 ' HA3' HD12 ' A' ' 89' ' ' ILE . . . -92.98 -14.11 55.37 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.44 177.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.9 p -84.21 166.01 17.91 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 122.875 -0.191 . . . . 0.0 110.927 -178.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 74.37 -44.57 0.56 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.555 0.742 . . . . 0.0 112.216 178.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.508 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 46.8 t -54.31 -45.56 68.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.755 0.312 . . . . 0.0 111.564 -177.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HB3' HD12 ' A' ' 99' ' ' ILE . 84.3 mt -61.28 -36.28 79.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.632 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.71 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 60.4 tp -69.74 -39.76 76.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -59.44 -48.79 80.28 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.876 177.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 85.2 mt -57.55 -41.08 80.26 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.778 -0.647 . . . . 0.0 111.437 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -71.71 -40.23 69.61 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.306 -178.31 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.475 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 68.3 mttm -62.61 -34.85 77.86 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.248 0.547 . . . . 0.0 109.981 175.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.521 ' HB3' HG22 ' A' ' 76' ' ' VAL . 37.8 t-20 -72.23 -34.0 67.98 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.008 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.27 6.98 57.45 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.087 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.521 HG22 ' HB3' ' A' ' 74' ' ' ASN . 28.8 m -103.41 10.07 8.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.025 0.441 . . . . 0.0 111.228 -176.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.33 147.12 49.31 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.133 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.77 160.18 49.42 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.683 176.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.528 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 96.6 mttt -69.29 -38.16 78.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.96 0.409 . . . . 0.0 110.251 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 13' ' ' ALA . . . -148.71 158.83 44.42 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.477 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 73.9 mt -132.98 119.58 37.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.88 178.576 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.753 HD12 HG22 ' A' ' 102' ' ' VAL . 9.1 mm -114.2 120.17 63.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.48 172.62 7.21 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.753 0.311 . . . . 0.0 110.465 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 88.0 tttt -91.65 -43.2 9.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.286 0.565 . . . . 0.0 109.55 173.01 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -112.28 118.48 35.39 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.39 177.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.8 t -82.69 159.19 22.67 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.088 177.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.473 ' OE1' HG12 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -144.9 151.65 39.01 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.779 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.484 ' O ' HG23 ' A' ' 92' ' ' VAL . 2.6 m -53.56 -48.51 69.08 Favored 'General case' 0 C--N 1.323 -0.549 0 O-C-N 123.735 0.647 . . . . 0.0 111.036 178.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.61 HG21 ' HA ' ' A' ' 62' ' ' THR . 31.5 pt -62.77 -35.21 69.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.85 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.486 HG22 HD22 ' A' ' 101' ' ' LEU . 58.1 mt -70.28 -45.04 76.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 178.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.67 -45.72 91.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.849 178.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.59 ' O ' ' HG2' ' A' ' 96' ' ' MET . 69.5 t -58.43 -50.88 77.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.43 -43.09 98.76 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.656 -177.364 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -73.47 -31.22 63.64 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -176.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -66.04 -33.77 76.57 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.689 0.281 . . . . 0.0 110.94 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.59 ' HG2' ' O ' ' A' ' 92' ' ' VAL . 19.2 mmt -66.65 -44.5 81.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.576 0.703 . . . . 0.0 110.596 179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.722 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -95.18 -0.39 53.28 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 114.878 -1.055 . . . . 0.0 112.125 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 56.52 64.58 1.64 Allowed 'General case' 0 C--O 1.235 0.31 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -172.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.534 HD12 ' HB3' ' A' ' 68' ' ' LEU . 54.9 mt -113.6 89.84 16.53 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.811 177.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.458 ' HB3' ' CB ' ' A' ' 123' ' ' ALA . 77.7 Cg_exo -50.14 113.24 0.93 Allowed 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 123.07 2.513 . . . . 0.0 112.564 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.486 HD22 HG22 ' A' ' 90' ' ' ILE . 1.7 pp -125.54 133.8 52.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.233 0.539 . . . . 0.0 110.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.753 HG22 HD12 ' A' ' 82' ' ' ILE . 5.3 m -126.48 152.51 34.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 175.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.634 ' O ' ' HB3' ' A' ' 5' ' ' CYS . 11.9 pt-20 -99.42 119.87 38.69 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.192 0.52 . . . . 0.0 110.268 178.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.725 HG12 ' SG ' ' A' ' 5' ' ' CYS . 33.1 m -97.2 153.71 3.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 105' ' ' ARG . 3.4 tmt_? -127.62 -15.55 4.98 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.037 0.446 . . . . 0.0 110.842 -176.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.475 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 5.0 t70 -94.49 138.14 32.77 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.407 -170.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -71.73 -30.99 66.22 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.759 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.475 ' HE2' ' OD1' ' A' ' 106' ' ' ASP . 46.4 mtmt -59.94 -28.19 67.42 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.652 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.524 ' O ' HG12 ' A' ' 113' ' ' VAL . 81.6 t80 -65.41 -48.24 73.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.504 177.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -68.15 -26.83 65.97 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.009 -175.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 114' ' ' LYS . 3.3 mm-40 -84.76 -36.55 21.67 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.756 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -67.65 -39.85 84.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.916 0.388 . . . . 0.0 110.751 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 109' ' ' PHE . 8.4 p -93.11 140.01 17.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.662 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.476 ' NZ ' ' HA ' ' A' ' 111' ' ' GLU . 43.1 mmtm -142.12 155.26 45.34 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.777 175.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.505 HG23 HD12 ' A' ' 18' ' ' LEU . 17.3 m -57.46 116.04 3.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.806 -176.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.73 -34.84 2.23 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.268 -0.967 . . . . 0.0 113.658 175.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -92.29 -174.6 3.78 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.438 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.12 142.87 41.0 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.221 0.534 . . . . 0.0 111.879 -168.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' A' ' 130' ' ' LEU . 9.9 p -141.17 140.65 31.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.28 174.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.1 t -108.9 119.83 59.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.862 178.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.455 HG22 HG13 ' A' ' 128' ' ' VAL . 53.3 t -114.24 114.6 47.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.113 0.482 . . . . 0.0 111.044 -177.703 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -100.46 99.67 10.32 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . . . -76.74 -8.03 56.51 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.413 -174.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.573 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 20.4 t70 -65.26 -37.87 88.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.091 0.472 . . . . 0.0 109.95 177.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -102.29 -28.23 12.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.619 179.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.98 61.15 1.78 Allowed Glycine 0 N--CA 1.446 -0.648 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 -166.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -136.24 124.28 22.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -165.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 121' ' ' VAL . 21.2 t -123.87 113.67 38.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.712 0.291 . . . . 0.0 110.583 -175.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -107.99 114.58 28.59 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.379 177.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' A' ' 119' ' ' VAL . 44.8 tp -85.84 129.57 34.79 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 11.2 tt -126.46 113.78 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 CA-C-O 122.196 0.998 . . . . 0.0 110.347 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.227 0 CA-C-N 113.91 -1.495 . . . . 0.0 109.704 -173.99 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.551 HG23 ' HG3' ' A' ' 2' ' ' LYS . 20.8 m . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.551 ' HG3' HG23 ' A' ' 1' ' ' VAL . 51.8 mttm 69.03 93.21 0.08 Allowed 'General case' 0 N--CA 1.469 0.49 0 O-C-N 123.454 0.471 . . . . 0.0 110.36 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -121.46 149.97 42.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.949 -175.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.14 134.74 41.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.096 176.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.546 ' SG ' HG22 ' A' ' 104' ' ' VAL . 82.9 m -128.46 175.86 8.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.049 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.63 ' HB3' ' HG2' ' A' ' 103' ' ' GLU . 50.2 ttt180 -93.87 120.63 34.38 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 178.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.566 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -91.29 112.69 24.7 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.976 0.417 . . . . 0.0 111.915 -175.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 8' ' ' ILE . 3.6 mp -81.45 -51.47 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.607 177.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.3 p -101.94 -173.67 2.4 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.342 177.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.648 ' HD2' ' HA ' ' A' ' 124' ' ' ASP . 65.8 mmt-85 -124.76 175.23 7.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.558 0.218 . . . . 0.0 110.497 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.64 173.05 25.77 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 12' ' ' ARG . 12.5 ptt180 -142.14 151.13 41.95 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 117.276 0.538 . . . . 0.0 110.802 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.524 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -140.73 138.02 33.89 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.742 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.565 ' HG3' HG22 ' A' ' 120' ' ' VAL . 28.0 tt0 -129.19 122.45 29.78 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.944 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 178.61 -160.4 26.25 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 119.93 -1.129 . . . . 0.0 113.028 176.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.533 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 27.1 mt-10 -70.36 134.19 47.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 122.635 0.374 . . . . 0.0 111.008 -177.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -91.23 125.32 35.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.012 0.434 . . . . 0.0 110.843 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.641 ' HB3' HD13 ' A' ' 53' ' ' LEU . 5.8 tp -117.82 118.49 32.17 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.9 t -102.01 127.05 55.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.208 0.528 . . . . 0.0 111.576 -173.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.475 ' O ' ' HD3' ' A' ' 56' ' ' PRO . 19.2 m -126.18 108.49 11.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.647 175.012 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -86.22 8.78 19.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.748 0.309 . . . . 0.0 111.546 -174.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.67 143.68 35.81 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.157 0.503 . . . . 0.0 110.742 178.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -81.99 139.14 34.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.411 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.0 pt -127.55 155.95 39.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.763 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 18.6 p -91.81 2.06 56.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.205 -178.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 72.09 -10.12 0.92 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.34 -178.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.558 HD21 ' HA ' ' A' ' 63' ' ' VAL . 2.9 mm? -94.94 33.03 1.55 Allowed 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 169.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.23 -175.85 50.93 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.301 -0.863 . . . . 0.0 112.899 -174.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.12 40.77 3.02 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 121.427 -0.416 . . . . 0.0 113.751 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 34.2 mt -79.09 112.44 17.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 171.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.419 ' HB3' ' H ' ' A' ' 36' ' ' ILE . 24.2 t70 -57.72 129.55 42.38 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.129 0.49 . . . . 0.0 110.975 -176.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.421 ' H ' ' HG2' ' A' ' 32' ' ' LYS . 44.9 pttt -82.29 -10.53 59.07 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.013 -173.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -93.71 -42.42 9.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.897 0.38 . . . . 0.0 110.873 -178.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 p -120.37 -5.2 9.88 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.414 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 66.94 32.39 80.8 Favored Glycine 0 C--N 1.329 0.143 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.339 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 46.7 mm -90.68 121.27 40.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 41.4 t -70.21 96.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.369 0.604 . . . . 0.0 109.946 176.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.3 mmmm -85.01 -5.99 59.34 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.565 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -69.75 139.08 53.27 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.65 175.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -77.23 132.94 38.97 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.282 -175.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 12.8 t -172.08 26.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.189 -0.914 . . . . 0.0 108.952 178.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 69.25 -39.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.8 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 35.9 pt -79.97 12.91 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.465 0.65 . . . . 0.0 110.497 174.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -57.05 122.91 13.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.803 177.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 113.8 -6.76 24.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.405 -178.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -85.65 148.44 25.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.9 0.381 . . . . 0.0 111.118 177.006 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 39.1 t -95.6 150.19 20.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 176.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 27.3 m -105.84 3.21 10.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.79 178.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.411 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -68.52 90.64 0.39 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.635 0.731 . . . . 0.0 111.497 -175.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 100.25 17.9 23.31 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.5 175.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.533 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 98.3 mtt180 -116.08 168.18 10.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.79 0.328 . . . . 0.0 110.518 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.44 HD12 ' N ' ' A' ' 52' ' ' ILE . 3.0 mp -107.93 122.92 62.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.641 HD13 ' HB3' ' A' ' 18' ' ' LEU . 4.6 mm? -96.34 138.45 33.92 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.142 0.496 . . . . 0.0 111.452 -175.388 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.94 119.71 61.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.067 177.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.671 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 90.7 m-85 -129.77 144.97 55.1 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.148 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 20' ' ' THR . 13.0 Cg_exo -71.37 -55.27 0.13 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.337 2.025 . . . . 0.0 111.519 175.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -135.94 108.77 0.7 Allowed Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.361 -178.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -82.34 129.74 9.25 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 175.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 33.3 ttpt -134.9 165.23 25.8 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -175.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 125.25 94.32 0.99 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -178.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.577 ' HA ' HG13 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -107.19 17.23 23.19 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.743 0.782 . . . . 0.0 109.607 -177.318 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 12.9 t -135.36 18.23 3.38 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.992 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.558 ' HA ' HD21 ' A' ' 27' ' ' LEU . 28.1 t -70.07 -49.75 53.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.233 -176.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 109.86 -24.04 20.18 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 -175.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.442 ' HB3' ' CA ' ' A' ' 93' ' ' GLY . 20.3 m 74.46 -33.31 0.25 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.761 0.825 . . . . 0.0 112.992 173.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.96 -23.19 65.13 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 111.802 0.297 . . . . 0.0 111.802 -177.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.475 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 10.5 p -60.66 -33.58 55.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.41 -177.603 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 90.0 mt -68.88 -41.0 78.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.183 0.516 . . . . 0.0 110.484 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 63.1 tp -66.17 -39.53 89.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.949 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -60.21 -43.34 96.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.531 177.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 97.9 mt -65.86 -38.42 88.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.534 178.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.548 ' HG3' ' HB1' ' A' ' 97' ' ' ALA . 5.0 mmm180 -63.54 -42.83 98.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.233 178.099 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 73' ' ' LYS . 6.7 tmtt? -63.71 -29.21 70.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.402 0.62 . . . . 0.0 110.56 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -86.69 -12.27 48.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.117 0.485 . . . . 0.0 110.319 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 77.8 20.49 73.57 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.306 176.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.414 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 35.3 m -116.29 14.88 7.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.24 0.543 . . . . 0.0 110.929 -177.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -97.45 158.08 33.72 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.651 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.557 ' HB3' HD23 ' A' ' 53' ' ' LEU . 22.9 Cg_exo -65.37 165.43 22.45 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.665 2.243 . . . . 0.0 111.961 176.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.524 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 54.6 mttm -80.8 -40.19 25.42 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.069 0.461 . . . . 0.0 110.245 173.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.585 ' HB2' ' HG2' ' A' ' 100' ' ' PRO . . . -160.36 158.34 29.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.32 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.56 HG22 ' HB2' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -130.05 127.34 63.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.157 0.504 . . . . 0.0 109.648 174.686 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.555 HG23 HG23 ' A' ' 102' ' ' VAL . 6.5 mm -106.91 116.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.235 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.671 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 11.0 m120 -115.27 158.65 22.05 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -177.038 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 50.4 tttm -81.69 -33.29 31.29 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 170.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.476 ' HD2' ' HA ' ' A' ' 85' ' ' LYS . 28.1 tptt -153.92 148.09 25.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.249 173.284 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.0 t -140.51 -179.47 6.04 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.731 -0.213 . . . . 0.0 110.88 -175.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.79 160.15 18.26 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 92' ' ' VAL . 9.1 m -58.5 -45.14 89.36 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.082 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.577 HG13 ' HA ' ' A' ' 61' ' ' SER . 15.2 mm -55.63 -41.56 65.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 111.193 178.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 27.5 mm -64.15 -45.48 96.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.361 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.79 -41.78 98.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.253 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 88' ' ' THR . 94.8 t -60.68 -44.34 96.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.053 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.442 ' CA ' ' HB3' ' A' ' 65' ' ' SER . . . -68.64 -41.25 84.54 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.076 179.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.84 -32.65 74.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.646 0.26 . . . . 0.0 111.125 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.37 -44.07 92.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.283 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 71.6 mtm -75.53 -39.44 58.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.363 -177.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.548 ' HB1' ' HG3' ' A' ' 72' ' ' ARG . . . -79.12 0.19 29.11 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 57.23 53.08 8.08 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.362 0.601 . . . . 0.0 111.403 -177.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 21.7 mm -113.11 88.06 11.67 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.541 178.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.585 ' HG2' ' HB2' ' A' ' 80' ' ' ALA . 1.0 OUTLIER -45.64 117.44 1.76 Allowed 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.319 2.679 . . . . 0.0 112.546 -179.614 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 5.8 tt -119.97 121.0 37.99 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.821 -176.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.566 HG12 ' HA ' ' A' ' 7' ' ' ALA . 34.7 m -123.84 142.64 39.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.32 174.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.63 ' HG2' ' HB3' ' A' ' 6' ' ' ARG . 13.3 pt-20 -100.31 129.38 46.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.204 0.526 . . . . 0.0 110.286 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.546 HG22 ' SG ' ' A' ' 5' ' ' CYS . 11.3 t -90.33 138.13 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.896 -177.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 77.7 mtt180 -89.56 -33.63 16.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.006 0.431 . . . . 0.0 110.603 177.07 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -96.6 139.56 32.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.421 0.629 . . . . 0.0 112.09 -168.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -71.93 -26.96 62.5 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.754 178.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 52.6 mttm -65.39 -17.88 64.88 Favored 'General case' 0 CA--C 1.521 -0.141 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -176.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 75.5 t80 -60.43 -46.21 90.84 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 174.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 88.1 m-85 -72.0 -28.96 63.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.098 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -66.24 -45.95 78.86 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.463 176.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -77.13 -47.31 20.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.227 -176.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.52 133.26 30.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 121.362 0.601 . . . . 0.0 111.605 -173.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -122.76 145.99 47.92 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.584 177.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.1 m -66.91 100.39 0.72 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 138.3 -16.65 3.39 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.451 -178.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -83.63 175.33 9.81 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.78 0.324 . . . . 0.0 110.489 176.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.84 HH21 HG13 ' A' ' 131' ' ' ILE . 21.3 ttp180 -111.93 134.25 53.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.989 -178.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 10.1 p -124.51 138.29 54.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.201 0.524 . . . . 0.0 110.82 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.565 HG22 ' HG3' ' A' ' 14' ' ' GLU . 40.5 t -111.32 106.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.117 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.4 p -104.06 126.58 58.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.333 0.587 . . . . 0.0 110.959 -178.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 42.7 t30 -114.98 100.55 8.28 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.572 176.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.26 -0.42 52.28 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.8 -176.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.648 ' HA ' ' HD2' ' A' ' 10' ' ' ARG . 28.3 t70 -67.89 -39.15 83.7 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.967 175.047 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -104.8 -30.6 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.303 177.067 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.48 ' HA2' ' HB2' ' A' ' 7' ' ' ALA . . . 96.5 57.61 1.11 Allowed Glycine 0 N--CA 1.448 -0.518 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -173.059 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 50.8 t80 -138.28 124.69 20.59 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 128' ' ' VAL . 10.8 p -117.35 107.21 21.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.972 0.891 . . . . 0.0 110.106 -178.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.536 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 31.2 tt0 -105.61 108.22 19.62 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.765 -176.11 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 44.3 tp -84.68 124.83 31.93 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.93 176.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.84 HG13 HH21 ' A' ' 118' ' ' ARG . 23.6 mm -97.66 118.9 44.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 . . . . . 0 C--N 1.312 -1.033 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.31 -177.43 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.509 HG23 ' HB3' ' A' ' 130' ' ' LEU . 18.4 m . . . . . 0 N--CA 1.455 -0.199 0 CA-C-O 121.172 0.511 . . . . 0.0 111.037 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.576 ' HB3' ' CE2' ' A' ' 127' ' ' TYR . 53.6 mtmt -129.99 117.71 20.49 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.159 -178.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -115.25 164.71 13.83 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.626 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.44 135.96 53.53 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.874 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' HG21 ' A' ' 102' ' ' VAL . 6.4 p -121.74 168.7 11.52 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.96 0.41 . . . . 0.0 111.136 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.807 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 65.4 ttt180 -95.25 109.21 21.36 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.705 177.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.636 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -67.23 117.7 9.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.793 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.431 ' HB ' ' O ' ' A' ' 101' ' ' LEU . 50.1 mm -101.51 -60.66 2.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 174.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.596 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.6 OUTLIER -96.69 174.44 6.82 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 172.014 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 9' ' ' THR . 52.2 mtt180 -126.53 167.9 14.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.942 0.401 . . . . 0.0 111.327 -176.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 132.82 159.96 9.38 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.711 -175.017 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.1 mtp85 -128.35 114.57 17.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.609 0.243 . . . . 0.0 110.506 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.468 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -139.21 146.27 40.3 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.056 0.455 . . . . 0.0 111.604 -175.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -133.45 148.25 51.74 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.334 174.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 172.34 -160.19 31.43 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.306 174.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.681 ' HB2' ' HG2' ' A' ' 51' ' ' ARG . 50.0 mt-10 -70.51 129.77 40.12 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 120.968 0.414 . . . . 0.0 110.843 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.566 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -81.01 117.3 21.49 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.006 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.536 HD12 HG23 ' A' ' 115' ' ' THR . 12.0 tp -105.71 115.4 30.18 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 176.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.425 ' HA ' ' CG2' ' A' ' 54' ' ' VAL . 11.3 p -100.4 110.8 28.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 122.049 0.928 . . . . 0.0 111.074 -172.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.465 HG23 HG13 ' A' ' 43' ' ' ILE . 10.1 m -106.0 88.92 2.92 Favored 'General case' 0 N--CA 1.44 -0.962 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.031 178.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' ' OE2' ' A' ' 22' ' ' GLU . 21.0 pttp -76.55 -1.06 25.52 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.119 176.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.539 ' OE2' ' HG3' ' A' ' 21' ' ' LYS . 8.5 mm-40 -92.43 160.68 14.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.382 178.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 9.7 p90 -112.67 104.99 13.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.336 0.588 . . . . 0.0 110.322 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.3 mp -100.52 130.24 50.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.993 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.488 ' HB2' ' OG ' ' A' ' 61' ' ' SER . 32.7 p -71.54 121.76 19.28 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 175.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.473 ' HE2' ' HA3' ' A' ' 58' ' ' GLY . 97.3 m-85 -72.97 87.44 1.33 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.248 0.547 . . . . 0.0 111.41 -174.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.425 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.3 tm? -134.86 -68.08 0.54 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.128 176.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -142.1 177.4 21.5 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.653 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.19 -62.76 0.61 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.521 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 57.4 mt -69.67 124.43 25.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.641 0.258 . . . . 0.0 110.626 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -59.21 133.11 55.8 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.513 177.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.459 ' HA ' ' CD2' ' A' ' 71' ' ' LEU . 33.5 mmtp -67.09 -21.26 65.88 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.291 0.567 . . . . 0.0 110.098 177.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -100.01 -58.52 1.9 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.738 -172.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.508 ' HB ' HG12 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -87.96 -14.03 40.23 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.753 0.649 . . . . 0.0 112.753 -175.379 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.641 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 67.14 29.69 74.78 Favored Glycine 0 CA--C 1.518 0.261 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.598 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.508 HG12 ' HB ' ' A' ' 34' ' ' THR . 47.4 mm -103.84 133.02 48.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' A' ' 30' ' ' ILE . 3.9 p -80.32 105.33 9.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.607 0.717 . . . . 0.0 110.308 178.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -80.08 -19.64 46.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.094 -179.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -69.48 135.79 50.63 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.567 ' HA ' ' HB2' ' A' ' 44' ' ' LYS . 34.1 t70 -83.87 130.36 34.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.48 -175.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 22' ' ' GLU . 5.8 t 173.56 50.5 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 123.927 0.767 . . . . 0.0 109.23 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 72.42 -47.86 0.67 Allowed 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 123.509 0.724 . . . . 0.0 112.208 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.465 HG13 HG23 ' A' ' 20' ' ' THR . 33.4 mm -77.17 -10.4 13.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 121.063 0.459 . . . . 0.0 111.078 -176.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.567 ' HB2' ' HA ' ' A' ' 40' ' ' ASP . 61.8 tttp -52.89 124.08 13.19 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 115.976 -0.557 . . . . 0.0 111.663 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.56 -16.67 28.84 Favored Glycine 0 N--CA 1.452 -0.246 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.696 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -87.03 162.43 17.62 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.223 0.535 . . . . 0.0 112.019 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 33.2 p -102.43 150.42 23.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.623 179.242 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.447 HG21 HD13 ' A' ' 30' ' ' ILE . 2.8 t -108.68 -0.04 9.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.367 0.603 . . . . 0.0 110.159 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -69.32 91.62 0.55 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.833 -171.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.589 ' HA2' ' HG3' ' A' ' 79' ' ' LYS . . . 90.86 23.6 29.9 Favored Glycine 0 C--N 1.317 -0.525 0 CA-C-N 115.083 -0.962 . . . . 0.0 113.21 172.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.681 ' HG2' ' HB2' ' A' ' 16' ' ' GLU . 97.5 mtt180 -111.09 169.32 8.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.867 0.365 . . . . 0.0 111.358 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.438 HD12 ' N ' ' A' ' 52' ' ' ILE . 2.3 mp -109.68 113.02 43.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 55' ' ' PHE . 11.1 mp -102.54 132.45 48.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.962 0.41 . . . . 0.0 111.383 -174.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.529 HG12 ' HB ' ' A' ' 82' ' ' ILE . 10.5 m -109.41 130.95 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.672 176.278 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.589 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 92.7 m-85 -130.49 145.2 56.45 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.421 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.85 -33.63 33.11 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 122.254 1.97 . . . . 0.0 111.507 174.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -177.47 -87.41 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.133 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' HA3' ' HE2' ' A' ' 26' ' ' PHE . . . 118.12 148.15 8.51 Favored Glycine 0 N--CA 1.445 -0.744 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -176.055 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -93.99 148.93 21.69 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.933 0.397 . . . . 0.0 110.802 -178.102 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.31 84.64 0.84 Allowed Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.534 -0.757 . . . . 0.0 113.001 -174.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.488 ' OG ' ' HB2' ' A' ' 25' ' ' SER . 25.0 m -95.9 144.73 25.98 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 171.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 62' ' ' THR . 9.9 t -93.97 64.42 3.37 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 122.571 1.177 . . . . 0.0 111.035 -171.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.83 HG13 ' H ' ' A' ' 65' ' ' SER . 12.5 p -60.28 -26.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.213 -1.358 . . . . 0.0 110.851 174.104 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 93.62 -1.43 68.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.525 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.83 ' H ' HG13 ' A' ' 63' ' ' VAL . 21.4 m 66.43 -165.51 0.22 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 122.622 0.369 . . . . 0.0 110.654 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 72.24 -30.07 0.21 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.514 0.726 . . . . 0.0 112.412 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 65' ' ' SER . 98.3 t -54.87 -42.17 61.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.715 0.293 . . . . 0.0 111.515 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.68 -32.47 72.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.922 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.547 ' HG ' ' HE2' ' A' ' 73' ' ' LYS . 56.8 tp -68.51 -42.83 77.99 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -59.13 -43.91 92.02 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.318 177.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.459 ' CD2' ' HA ' ' A' ' 32' ' ' LYS . 87.8 mt -64.99 -38.62 91.55 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.547 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 2.1 tmt_? -68.63 -38.68 80.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.388 -178.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.547 ' HE2' ' HG ' ' A' ' 69' ' ' LEU . 52.5 mttm -60.32 -34.27 73.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.212 0.529 . . . . 0.0 110.716 176.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 60.1 t30 -86.48 -22.65 26.31 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.819 -177.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 90.09 20.02 44.27 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.391 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.641 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 28.1 m -112.18 13.92 8.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.103 0.478 . . . . 0.0 110.811 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -96.0 160.12 30.73 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.562 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.74 141.24 71.34 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.187 1.925 . . . . 0.0 111.698 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.589 ' HG3' ' HA2' ' A' ' 50' ' ' GLY . 89.0 mttt -68.98 -28.11 66.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 110.52 176.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -160.86 147.85 15.35 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.695 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 101' ' ' LEU . 63.9 mt -123.4 117.29 50.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 175.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.544 HG22 ' CG2' ' A' ' 104' ' ' VAL . 3.1 mm -110.57 115.22 49.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.589 ' ND2' ' HB2' ' A' ' 55' ' ' PHE . 15.6 m120 -111.54 153.36 26.35 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.272 -177.346 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.63 ' HA ' ' HB ' ' A' ' 104' ' ' VAL . 2.1 tmtp? -66.96 -45.63 77.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 174.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -142.98 120.88 11.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.238 177.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 3.7 m -86.29 150.11 24.58 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.303 -172.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -118.58 155.18 31.37 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 173.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' HG23 ' A' ' 92' ' ' VAL . 5.3 m -49.77 -51.38 39.65 Favored 'General case' 0 C--N 1.325 -0.5 0 C-N-CA 123.31 0.644 . . . . 0.0 112.68 -173.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 61.8 mt -57.04 -41.18 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 121.078 0.466 . . . . 0.0 111.441 -176.276 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 20.4 mt -70.1 -43.31 79.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.384 -177.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.9 -43.98 86.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.539 -178.077 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 88' ' ' THR . 97.5 t -62.1 -43.03 97.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.992 0.425 . . . . 0.0 110.864 -179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.4 -43.38 99.14 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.58 -39.45 62.23 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -177.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.442 ' HA ' HG21 ' A' ' 9' ' ' THR . . . -57.87 -46.54 84.71 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.78 -177.073 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 73.1 mtm -66.11 -30.73 71.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.923 0.392 . . . . 0.0 111.416 -177.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.546 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -88.46 2.2 53.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.576 -179.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 60.72 41.03 15.55 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 121.118 0.485 . . . . 0.0 110.884 -177.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 65.6 mt -103.9 90.36 2.9 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.458 177.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 8.2 Cg_endo -48.33 100.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.603 2.868 . . . . 0.0 113.144 -173.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 81' ' ' ILE . 3.4 tt -99.68 127.37 45.8 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.411 -0.813 . . . . 0.0 108.919 176.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 7' ' ' ALA . 35.2 m -132.12 159.38 43.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.844 -178.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.807 ' HB3' ' HB3' ' A' ' 6' ' ' ARG . 25.3 tt0 -89.11 125.46 35.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.528 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.63 ' HB ' ' HA ' ' A' ' 84' ' ' LYS . 90.8 t -86.18 102.21 11.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.022 0.439 . . . . 0.0 110.602 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -78.99 -35.72 42.5 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.36 0.6 . . . . 0.0 109.639 176.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.612 ' OD1' ' HB2' ' A' ' 108' ' ' LYS . 17.7 t70 -89.92 101.87 14.57 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.496 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -70.17 -15.58 62.97 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.005 0.431 . . . . 0.0 111.038 -174.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.612 ' HB2' ' OD1' ' A' ' 106' ' ' ASP . 30.9 mmmt -62.1 -24.81 67.35 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.887 177.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -59.8 -38.42 81.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.819 177.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.477 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.1 m-85 -71.64 -22.7 61.65 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.883 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -78.76 -32.17 46.5 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.248 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -86.43 -30.85 21.77 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.062 -178.181 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.477 HG12 ' HA ' ' A' ' 110' ' ' PHE . 12.5 p -74.87 127.24 36.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.435 0.636 . . . . 0.0 111.825 -176.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.546 ' HE2' ' HA ' ' A' ' 114' ' ' LYS . 8.9 mmpt? -130.18 161.49 31.01 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.164 175.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.536 HG23 HD12 ' A' ' 18' ' ' LEU . 91.1 m -67.41 125.01 24.77 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.809 0.338 . . . . 0.0 110.89 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 103.79 -1.18 45.16 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.277 176.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -85.88 175.26 8.75 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.497 HH21 HD13 ' A' ' 131' ' ' ILE . 18.1 ttp85 -117.18 120.74 39.22 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.371 0.532 . . . . 0.0 110.855 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.566 HG23 ' HB2' ' A' ' 17' ' ' ALA . 76.6 t -118.89 126.65 75.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.695 179.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.02 110.14 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 175.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.0 p -100.4 118.08 46.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.665 0.745 . . . . 0.0 111.421 -176.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -100.73 94.03 5.87 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.004 175.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -83.8 1.63 42.05 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 122.03 0.919 . . . . 0.0 108.835 173.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -84.49 -1.83 56.34 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.041 -1.436 . . . . 0.0 109.531 175.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.14 -43.17 0.18 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.632 -176.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.41 52.23 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -175.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.576 ' CE2' ' HB3' ' A' ' 2' ' ' LYS . 12.3 t80 -154.76 140.33 17.91 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -170.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 16.7 m -124.7 127.04 72.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.285 0.564 . . . . 0.0 111.351 -177.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -101.88 111.7 24.06 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.958 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.509 ' HB3' HG23 ' A' ' 1' ' ' VAL . 9.6 tt -108.77 129.68 55.38 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.413 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.497 HD13 HH21 ' A' ' 118' ' ' ARG . 3.8 mp -121.71 111.45 31.04 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.803 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 . . . . . 0 C--N 1.313 -1.003 0 O-C-N 124.485 1.116 . . . . 0.0 110.48 -175.204 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.563 0.697 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.427 ' HE3' ' HG3' ' A' ' 129' ' ' GLU . 55.9 mtpt -133.58 120.54 20.87 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.411 -175.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.416 ' HB2' ' CG2' ' A' ' 128' ' ' VAL . 92.4 m-85 -97.85 150.02 21.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.425 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -101.14 127.72 47.57 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.629 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.508 ' HB3' HG12 ' A' ' 104' ' ' VAL . 4.3 p -120.59 169.9 9.92 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.308 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.472 ' HB3' ' HB3' ' A' ' 103' ' ' GLU . 24.4 tpt180 -94.05 120.59 34.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.552 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.58 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -70.44 119.73 15.04 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.696 -176.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.2 mm -101.95 -47.47 11.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 174.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.535 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.2 OUTLIER -111.95 -165.73 1.02 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.455 176.966 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 10' ' ' ARG . 54.8 mtt180 -132.76 170.1 15.75 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 176.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 113.95 153.75 11.03 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.018 -178.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.57 ' HG3' ' HA ' ' A' ' 122' ' ' ASN . 1.0 OUTLIER -123.34 126.29 46.58 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 177.834 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.555 ' HB1' ' HB3' ' A' ' 79' ' ' LYS . . . -133.28 132.07 40.96 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.035 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -115.36 127.76 55.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.399 -178.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -167.98 -179.39 40.51 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.086 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -74.66 133.32 42.13 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 177.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.527 ' HB2' HG12 ' A' ' 119' ' ' VAL . . . -80.17 120.48 24.34 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.891 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HA ' HG23 ' A' ' 115' ' ' THR . 8.0 tt -107.76 113.83 27.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.2 t -104.04 111.1 32.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.204 0.526 . . . . 0.0 111.094 -175.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.58 130.7 34.88 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 174.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 21.5 mtpp -92.29 -83.2 0.3 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.24 -172.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 44.84 -163.8 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.58 0.705 . . . . 0.0 112.721 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -147.1 100.98 3.36 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 168.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.445 HD11 ' SG ' ' A' ' 41' ' ' CYS . 58.7 mt -112.26 132.59 60.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.914 0.387 . . . . 0.0 111.369 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.8 p -76.46 124.68 27.94 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 171.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -79.91 39.8 0.44 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.088 0.471 . . . . 0.0 111.711 -174.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.37 -30.61 42.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 173.435 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -157.41 -105.4 0.22 Allowed Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 114.816 -1.084 . . . . 0.0 111.096 178.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.85 -41.48 3.05 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.388 174.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 52.3 mt -115.18 142.12 29.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.847 0.356 . . . . 0.0 110.708 -176.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -73.78 136.3 43.59 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.766 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 21.5 pttp -83.06 -3.3 57.13 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -173.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -112.12 -52.84 2.76 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 122.169 -0.332 . . . . 0.0 111.297 -176.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.1 m -101.28 -15.91 17.13 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.645 -175.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.62 ' HA3' ' HB ' ' A' ' 76' ' ' VAL . . . 78.95 21.46 68.14 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.503 -0.855 . . . . 0.0 112.402 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 42.9 mm -89.12 132.33 34.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 177.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.4 m -64.46 114.91 2.52 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.45 0.643 . . . . 0.0 110.557 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.6 mmtm -78.55 -11.16 59.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.89 177.157 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -94.84 149.88 20.78 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.141 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -79.97 135.16 36.33 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.106 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.497 ' H ' ' HB2' ' A' ' 44' ' ' LYS . 56.6 m -148.98 -170.77 3.71 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -176.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -60.68 -52.32 65.64 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.835 0.35 . . . . 0.0 110.088 175.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -116.3 51.42 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.385 0.612 . . . . 0.0 111.145 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.497 ' HB2' ' H ' ' A' ' 41' ' ' CYS . 13.0 tmtt? -60.66 127.83 33.62 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.563 176.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 119.74 -5.69 12.69 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.136 -178.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -84.49 148.17 26.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.817 0.341 . . . . 0.0 111.099 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 14.6 m -93.0 113.28 25.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.513 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.627 ' HA ' ' HD3' ' A' ' 51' ' ' ARG . 26.5 m -82.16 19.97 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.79 0.329 . . . . 0.0 111.862 -175.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.419 ' HB2' ' HA ' ' A' ' 76' ' ' VAL . . . -80.14 92.1 5.62 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.174 0.511 . . . . 0.0 111.568 -174.205 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.85 19.65 21.37 Favored Glycine 0 C--N 1.32 -0.337 0 C-N-CA 120.688 -0.767 . . . . 0.0 113.47 171.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.627 ' HD3' ' HA ' ' A' ' 48' ' ' VAL . 7.2 ptm180 -119.96 -179.28 3.87 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 177.677 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.9 mm -104.06 135.04 43.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.587 ' HB3' HG12 ' A' ' 81' ' ' ILE . 56.1 tp -106.84 125.85 51.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.127 0.489 . . . . 0.0 110.837 -179.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.4 t -107.47 112.06 38.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.535 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 19.4 t80 -132.89 142.12 43.55 Favored Pre-proline 0 C--N 1.324 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -173.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -69.98 -56.34 0.14 Allowed 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.168 1.912 . . . . 0.0 112.867 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 179.21 146.67 6.82 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.42 -179.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.0 161.73 32.62 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.404 ' HB2' ' HE2' ' A' ' 59' ' ' LYS . 30.8 mtmm -106.46 142.52 35.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 117.185 0.493 . . . . 0.0 111.267 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -121.13 45.28 1.24 Allowed Glycine 0 N--CA 1.449 -0.444 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 172.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.9 m -51.12 104.32 0.08 Allowed 'General case' 0 C--O 1.235 0.315 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -172.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.583 ' H ' HD13 ' A' ' 89' ' ' ILE . 2.5 m 55.63 33.83 22.01 Favored 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.538 175.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.874 HG13 ' H ' ' A' ' 65' ' ' SER . 11.6 p -76.56 -24.86 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.324 0.583 . . . . 0.0 110.173 176.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 103.91 -11.59 52.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.894 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.874 ' H ' HG13 ' A' ' 63' ' ' VAL . 19.7 m 65.7 12.26 8.15 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.897 0.479 . . . . 0.0 111.828 176.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -76.67 -18.36 58.6 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.09 -177.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.434 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 48.0 t -56.15 -56.86 10.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.306 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 92.6 mt -59.62 -40.87 88.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 -177.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.533 ' O ' ' HG3' ' A' ' 73' ' ' LYS . 62.5 tp -66.63 -51.22 58.66 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.725 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -56.3 -44.95 80.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 77' ' ' ALA . 90.3 mt -67.05 -36.36 81.87 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.154 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.645 ' HG3' HD11 ' A' ' 99' ' ' ILE . 0.0 OUTLIER -76.24 -28.4 57.14 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.813 -176.41 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.533 ' HG3' ' O ' ' A' ' 69' ' ' LEU . 8.2 mtpm? -67.97 -35.18 77.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.979 0.418 . . . . 0.0 109.902 176.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -78.69 -25.24 44.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.007 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.89 21.9 32.17 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.413 178.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.62 ' HB ' ' HA3' ' A' ' 35' ' ' GLY . 27.7 m -115.12 12.28 7.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.895 0.378 . . . . 0.0 111.034 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.458 ' HB2' ' CB ' ' A' ' 71' ' ' LEU . . . -97.29 155.33 37.5 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.811 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.542 ' HG3' ' HB ' ' A' ' 48' ' ' VAL . 22.3 Cg_exo -64.66 146.34 88.57 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 122.306 2.004 . . . . 0.0 111.154 174.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.555 ' HB3' ' HB1' ' A' ' 13' ' ' ALA . 93.4 mttt -62.25 -35.81 80.1 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.878 0.371 . . . . 0.0 111.035 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.518 ' HA ' HG23 ' A' ' 99' ' ' ILE . . . -161.48 158.34 26.42 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.64 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.587 HG12 ' HB3' ' A' ' 53' ' ' LEU . 54.5 mt -131.26 124.11 54.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.591 178.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.693 HG23 HG23 ' A' ' 102' ' ' VAL . 5.2 mm -103.75 116.77 48.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 22.2 m120 -114.78 156.35 25.04 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.313 0.578 . . . . 0.0 111.742 -175.428 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 110' ' ' PHE . 82.0 tttt -84.12 -38.33 20.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.415 177.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -123.81 108.25 12.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.718 174.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 19.7 p -78.55 108.85 12.23 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.194 -178.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.618 ' HB3' HG12 ' A' ' 90' ' ' ILE . 0.4 OUTLIER -72.69 135.39 45.38 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.011 -0.736 . . . . 0.0 109.011 177.652 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.3 m -56.03 -42.99 77.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.835 -174.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.583 HD13 ' H ' ' A' ' 62' ' ' THR . 60.4 mt -69.19 -32.58 54.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.879 -177.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.618 HG12 ' HB3' ' A' ' 87' ' ' GLU . 49.4 mm -67.23 -39.98 84.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.043 177.237 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.19 -43.69 92.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.13 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.78 -45.16 95.0 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.546 178.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.554 ' CA ' ' HB3' ' A' ' 65' ' ' SER . . . -67.91 -43.47 82.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.71 -178.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.406 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -61.13 -38.07 85.07 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.953 0.406 . . . . 0.0 111.004 -179.051 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -64.24 -32.31 73.85 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.546 -179.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.45 ' HB2' ' HE3' ' A' ' 96' ' ' MET . 67.7 mtm -77.38 -40.46 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.71 0.291 . . . . 0.0 111.406 -177.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.506 ' HB2' ' HA ' ' A' ' 69' ' ' LEU . . . -84.91 -0.94 55.87 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.811 -176.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 60.11 53.95 4.32 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 122.011 0.91 . . . . 0.0 109.78 -173.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.645 HD11 ' HG3' ' A' ' 72' ' ' ARG . 44.3 mm -110.1 88.26 6.84 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.744 175.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 5.4 Cg_endo -47.53 98.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.323 2.682 . . . . 0.0 112.753 -175.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 64.0 tp -92.87 130.97 38.29 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.27 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.693 HG23 HG23 ' A' ' 82' ' ' ILE . 14.1 m -135.41 148.78 28.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.289 177.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.485 ' CD ' ' HE ' ' A' ' 105' ' ' ARG . 39.5 tt0 -100.71 121.69 42.08 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.654 -177.515 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 5' ' ' CYS . 14.2 m -108.92 117.62 54.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.443 0.64 . . . . 0.0 111.132 176.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . 0.485 ' HE ' ' CD ' ' A' ' 103' ' ' GLU . 12.8 mmt180 -93.46 4.5 53.86 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.852 176.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 20.9 t70 -95.67 123.27 39.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.211 -171.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -72.16 -32.51 66.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.018 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 14.2 mptt -65.99 -30.09 70.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.15 -176.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 113' ' ' VAL . 73.6 t80 -54.77 -50.73 67.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.075 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.493 ' CZ ' ' HB2' ' A' ' 84' ' ' LYS . 89.5 m-85 -69.0 -22.64 64.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.107 0.479 . . . . 0.0 111.168 -175.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -85.57 -34.05 21.57 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.473 -179.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -80.91 -33.5 34.14 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.485 -178.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.6 p -78.99 125.08 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.28 0.562 . . . . 0.0 110.679 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -118.16 153.63 33.51 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.702 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 18' ' ' LEU . 24.5 m -68.2 94.35 0.51 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.071 0.463 . . . . 0.0 110.214 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 140.55 -9.71 2.91 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.805 -0.634 . . . . 0.0 112.029 -176.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . 0.479 ' HB3' HD11 ' A' ' 130' ' ' LEU . 82.9 m-20 -80.85 159.39 25.07 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 176.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.3 ttp180 -103.57 113.9 27.76 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.894 0.378 . . . . 0.0 110.324 176.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.527 HG12 ' HB2' ' A' ' 17' ' ' ALA . 6.5 p -119.92 120.71 64.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-O 121.151 0.5 . . . . 0.0 110.18 178.207 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.481 HG13 ' HB3' ' A' ' 129' ' ' GLU . 7.7 p -98.63 115.77 39.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.556 0.694 . . . . 0.0 109.343 175.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 12' ' ' ARG . 7.5 p -78.57 128.78 38.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.65 -178.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . 0.57 ' HA ' ' HG3' ' A' ' 12' ' ' ARG . 49.9 t-20 -115.07 94.51 4.77 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 175.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -87.6 -10.37 51.68 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.264 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -75.42 -40.28 57.89 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.249 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -102.32 -14.42 16.94 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.387 -179.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.7 65.67 1.81 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.58 -178.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -152.6 144.61 23.75 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.772 0.32 . . . . 0.0 110.613 -173.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 3' ' ' PHE . 4.1 m -116.7 106.59 20.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.372 0.606 . . . . 0.0 109.708 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HB3' HG13 ' A' ' 120' ' ' VAL . 29.8 tt0 -93.11 108.45 20.04 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.043 -174.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.479 HD11 ' HB3' ' A' ' 117' ' ' ASP . 38.8 tp -97.46 129.69 44.63 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.136 -175.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 13.2 mm -124.8 120.2 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.867 175.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 . . . . . 0 C--N 1.313 -1.001 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.707 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.466 ' HB ' ' CE2' ' A' ' 3' ' ' PHE . 4.6 m . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.433 0.635 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.53 ' HG2' ' HG3' ' A' ' 129' ' ' GLU . 19.5 mtpp -117.64 112.84 21.06 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.979 -176.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.466 ' CE2' ' HB ' ' A' ' 1' ' ' VAL . 96.5 m-85 -112.32 156.03 23.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.311 0.577 . . . . 0.0 111.728 -172.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.57 133.03 48.24 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.068 175.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.4 m -119.57 -179.45 3.88 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -177.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.929 ' HA ' ' HE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -101.36 126.02 48.07 Favored 'General case' 0 N--CA 1.446 -0.626 0 C-N-CA 120.241 -0.584 . . . . 0.0 110.083 174.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.565 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -80.13 128.13 33.14 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.731 -174.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.462 ' HB ' HD12 ' A' ' 101' ' ' LEU . 49.6 mm -112.5 -49.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 174.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.582 ' HB ' ' HA ' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -100.23 172.06 7.4 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 171.433 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.7 mtp180 -127.17 177.24 6.8 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.641 -0.423 . . . . 0.0 110.781 -178.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.78 -158.84 20.26 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -172.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ptt180 -141.87 160.6 39.87 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 117.107 0.453 . . . . 0.0 110.477 175.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.523 ' CB ' ' HB2' ' A' ' 80' ' ' ALA . . . -145.79 159.58 42.99 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.324 -178.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -153.21 143.04 22.06 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.063 -177.273 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.12 175.35 39.56 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.883 -1.151 . . . . 0.0 112.757 175.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -73.41 136.42 44.3 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.564 ' HB2' HG23 ' A' ' 119' ' ' VAL . . . -80.79 128.05 33.21 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.211 0.529 . . . . 0.0 111.841 -175.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.479 HD12 HG23 ' A' ' 115' ' ' THR . 5.2 tp -116.12 110.44 18.86 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 173.389 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.61 134.84 48.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.232 0.539 . . . . 0.0 111.661 -171.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.538 HG23 ' HB3' ' A' ' 55' ' ' PHE . 2.1 t -146.3 117.62 7.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.245 174.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.433 ' HA ' ' HD2' ' A' ' 21' ' ' LYS . 19.7 tptm -82.65 -8.92 59.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.471 0.653 . . . . 0.0 109.293 176.689 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.408 ' OE1' ' HB3' ' A' ' 41' ' ' CYS . 1.5 tm-20 -81.19 146.13 30.65 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 174.223 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -86.07 158.9 19.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.558 -171.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.499 HD12 ' HE2' ' A' ' 44' ' ' LYS . 12.5 tt -150.24 127.51 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.679 0.752 . . . . 0.0 111.032 177.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.632 ' HA ' ' O ' ' A' ' 58' ' ' GLY . 0.9 OUTLIER -76.28 135.09 39.63 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.845 -177.211 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.49 ' HB2' HG13 ' A' ' 63' ' ' VAL . 81.5 m-85 -73.06 -20.05 61.05 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.106 -175.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -65.33 -67.07 0.47 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.747 0.308 . . . . 0.0 110.501 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -114.26 34.9 4.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.663 -0.78 . . . . 0.0 111.509 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 37' ' ' VAL . . . -98.34 -19.99 21.56 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.864 -0.684 . . . . 0.0 113.06 -175.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 53.6 mt -129.2 133.73 65.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 117.374 0.587 . . . . 0.0 110.75 -177.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.655 ' HB2' ' HD3' ' A' ' 38' ' ' LYS . 19.3 t70 -69.5 128.61 37.11 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.882 176.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -79.02 -7.13 57.84 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.558 -174.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -101.61 -57.67 2.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.994 0.426 . . . . 0.0 110.816 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -101.96 -8.3 21.65 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -172.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.95 21.88 78.93 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.643 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.419 ' H ' ' HB3' ' A' ' 31' ' ' ASP . 37.7 mm -84.49 128.01 39.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 177.18 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 29' ' ' GLY . 6.3 m -62.27 120.27 8.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.153 0.501 . . . . 0.0 110.545 175.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.655 ' HD3' ' HB2' ' A' ' 31' ' ' ASP . 21.2 mmmt -88.44 -35.21 17.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.808 -175.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.549 ' O ' ' HD3' ' A' ' 44' ' ' LYS . 31.9 tt0 -77.8 107.7 10.5 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.722 ' HA ' ' HD3' ' A' ' 44' ' ' LYS . 13.2 t70 -110.52 144.61 39.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.269 0.556 . . . . 0.0 112.354 -172.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.63 ' SG ' ' HD2' ' A' ' 44' ' ' LYS . 12.4 p -108.93 -51.08 2.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.476 173.134 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.435 ' HG3' HG23 ' A' ' 43' ' ' ILE . 12.5 pt-20 -172.36 -29.92 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.003 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.435 HG23 ' HG3' ' A' ' 42' ' ' GLU . 18.5 pt -114.86 10.95 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.741 -178.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.722 ' HD3' ' HA ' ' A' ' 40' ' ' ASP . 24.2 mttt -92.59 146.96 23.26 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.176 0.512 . . . . 0.0 110.575 -176.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.01 0.74 1.43 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.094 -0.574 . . . . 0.0 111.724 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 -87.58 158.39 18.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.88 0.371 . . . . 0.0 111.113 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.509 ' O ' ' HD2' ' A' ' 51' ' ' ARG . 35.5 t -89.05 151.84 22.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.882 176.013 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 19.6 m -104.8 10.65 8.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.835 178.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -68.84 87.93 0.37 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.918 -174.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 104.61 -2.67 42.37 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.284 -0.871 . . . . 0.0 113.536 171.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 47' ' ' SER . 0.7 OUTLIER -109.13 -172.28 2.01 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 117.199 0.499 . . . . 0.0 110.856 -178.361 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.528 HG12 ' HB3' ' A' ' 80' ' ' ALA . 72.4 mt -118.44 120.61 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.327 -177.542 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.42 HD12 ' O ' ' A' ' 18' ' ' LEU . 47.4 tp -103.5 121.3 42.56 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.53 106.26 20.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.073 0.463 . . . . 0.0 110.658 -178.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.538 ' HB3' HG23 ' A' ' 20' ' ' THR . 23.6 p90 -137.25 151.79 72.26 Favored Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.851 176.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_exo -62.51 -41.52 32.13 Favored 'Trans proline' 0 CA--C 1.529 0.245 0 C-N-CA 122.458 2.105 . . . . 0.0 112.197 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.74 -159.01 32.12 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.632 ' O ' ' HA ' ' A' ' 25' ' ' SER . . . 169.05 72.39 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.189 -1.005 . . . . 0.0 113.336 178.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 95.4 mttt 69.33 127.77 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.755 0.788 . . . . 0.0 112.545 172.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.0 74.88 1.81 Allowed Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.24 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.631 ' HB2' HG12 ' A' ' 63' ' ' VAL . 14.9 m -84.41 176.12 8.89 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.826 0.346 . . . . 0.0 110.854 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.2 t -76.73 37.29 0.18 Allowed 'General case' 0 CA--C 1.539 0.522 0 CA-C-O 121.381 0.61 . . . . 0.0 111.261 179.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.631 HG12 ' HB2' ' A' ' 61' ' ' SER . 7.9 p -127.23 149.34 32.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.239 -175.324 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.28 -49.98 0.58 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.794 -0.717 . . . . 0.0 111.731 -179.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.536 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 13.5 m -67.33 -52.15 43.73 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.123 0.487 . . . . 0.0 110.069 177.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.562 ' CD2' HG23 ' A' ' 67' ' ' VAL . 38.6 p90 -94.87 179.91 5.07 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 175.072 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.562 HG23 ' CD2' ' A' ' 66' ' ' TYR . 76.1 t 72.99 -60.88 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 122.846 0.459 . . . . 0.0 110.467 -174.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 8.3 mp -63.41 -39.42 94.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.1 0.476 . . . . 0.0 109.846 176.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.405 ' HA ' ' HB2' ' A' ' 97' ' ' ALA . 56.1 tp -62.26 -40.19 95.37 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.123 175.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -63.33 -38.89 92.91 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.293 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.502 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 93.7 mt -58.13 -41.2 83.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.555 177.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.502 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -67.28 -34.74 78.05 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.564 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -67.12 -25.66 66.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.288 -178.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 62.7 t30 -100.27 -17.2 17.43 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.126 0.488 . . . . 0.0 110.299 177.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.96 0.17 58.86 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.942 176.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -93.5 19.03 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.986 0.422 . . . . 0.0 111.54 -176.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.411 ' HA ' ' HD3' ' A' ' 78' ' ' PRO . . . -80.84 148.69 65.57 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.351 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 77' ' ' ALA . 11.7 Cg_exo -68.77 154.2 71.63 Favored 'Trans proline' 0 N--CA 1.463 -0.266 0 C-N-CA 122.576 2.184 . . . . 0.0 110.96 175.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.419 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 45.1 mttp -85.06 -32.99 22.57 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.199 179.425 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.528 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -151.42 143.96 24.25 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.796 0.331 . . . . 0.0 111.407 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 40.3 mm -129.41 124.78 60.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 174.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.588 HG23 HG23 ' A' ' 102' ' ' VAL . 3.7 mm -118.05 116.46 51.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -120.03 165.51 14.61 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -175.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.656 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 0.0 OUTLIER -76.54 -28.81 56.46 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.669 0.747 . . . . 0.0 109.956 177.568 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 48.7 tttm -138.91 130.51 27.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.629 169.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 25.4 p -90.4 155.94 18.58 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 175.048 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -123.06 146.09 47.98 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.709 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 92' ' ' VAL . 21.2 m -57.95 -50.4 73.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.231 -173.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 59.4 mt -58.79 -42.71 86.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 CA-C-O 121.162 0.506 . . . . 0.0 110.663 -178.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 57.4 mt -70.11 -41.35 79.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.511 -178.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.5 93.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.335 -179.349 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 88' ' ' THR . 94.2 t -61.44 -45.48 98.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.694 178.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.536 ' CA ' ' HA ' ' A' ' 65' ' ' SER . . . -66.63 -41.59 93.86 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.406 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' A' ' 99' ' ' ILE . . . -65.32 -41.88 93.53 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.69 0.281 . . . . 0.0 111.269 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.63 -29.6 69.35 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.021 0.438 . . . . 0.0 110.451 176.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 76.8 mtp -83.33 -30.31 27.58 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.185 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.502 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -96.04 16.68 17.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.868 -177.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.458 ' OE1' ' HD2' ' A' ' 72' ' ' ARG . 3.5 mp0 55.03 41.2 32.02 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.121 0.486 . . . . 0.0 111.297 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.466 ' O ' ' HB1' ' A' ' 94' ' ' ALA . 48.7 mt -115.47 86.06 14.42 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.754 176.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 30.0 Cg_endo -65.58 109.89 1.51 Allowed 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.309 2.006 . . . . 0.0 112.167 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.462 HD12 ' HB ' ' A' ' 8' ' ' ILE . 3.1 pp -110.31 151.27 27.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.202 0.525 . . . . 0.0 111.26 179.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.588 HG23 HG23 ' A' ' 82' ' ' ILE . 31.3 m -135.75 162.28 37.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.691 177.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -108.13 126.54 52.89 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.82 0.343 . . . . 0.0 110.98 -175.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.656 ' O ' ' HA ' ' A' ' 84' ' ' LYS . 8.3 m -109.24 123.52 65.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.451 176.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -101.51 12.35 37.45 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.141 0.496 . . . . 0.0 110.201 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.483 ' OD2' ' HB2' ' A' ' 108' ' ' LYS . 28.6 t70 -107.62 122.73 47.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.022 -177.286 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -71.17 -29.07 64.73 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.629 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HB2' ' OD2' ' A' ' 106' ' ' ASP . 10.2 mtmp? -62.64 -28.72 70.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.074 -177.069 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -60.12 -48.82 80.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.029 178.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -65.79 -26.96 67.93 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.341 0.591 . . . . 0.0 110.835 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -79.73 -27.23 40.61 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.842 -179.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.69 -39.95 12.15 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.835 -177.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.532 ' HA ' HD21 ' A' ' 130' ' ' LEU . 13.6 p -69.3 134.96 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.034 0.445 . . . . 0.0 111.176 -177.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -121.32 151.59 39.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.794 -177.23 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.479 HG23 HD12 ' A' ' 18' ' ' LEU . 71.4 m -71.91 124.43 24.85 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.112 175.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.04 9.42 54.01 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.879 -177.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -97.97 177.14 5.53 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.496 ' NH2' HG12 ' A' ' 131' ' ' ILE . 0.6 OUTLIER -116.07 113.79 23.66 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.363 0.602 . . . . 0.0 111.613 -172.914 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 17' ' ' ALA . 45.3 t -113.2 127.96 70.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.68 -179.073 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.6 t -113.15 117.4 55.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 172.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.431 HG22 HG12 ' A' ' 128' ' ' VAL . 43.0 t -108.98 123.96 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -106.33 94.98 5.44 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 171.015 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.02 -19.73 62.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.947 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -62.29 -37.73 86.66 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.098 0.475 . . . . 0.0 109.927 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -87.37 -36.87 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.041 174.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.408 ' HA2' HG11 ' A' ' 102' ' ' VAL . . . 87.15 54.15 2.65 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -167.073 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . 0.409 ' OH ' ' HB3' ' A' ' 2' ' ' LYS . 72.8 t80 -137.14 134.86 36.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.618 -0.291 . . . . 0.0 110.383 -169.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.431 HG12 HG22 ' A' ' 121' ' ' VAL . 28.1 m -120.12 130.69 74.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 121.061 0.458 . . . . 0.0 110.842 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.53 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 38.8 tt0 -108.27 107.41 18.0 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 175.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 119' ' ' VAL . 60.2 tp -104.76 107.62 18.67 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.928 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.496 HG12 ' NH2' ' A' ' 118' ' ' ARG . 34.5 mm -101.44 110.98 29.67 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 . . . . . 0 C--N 1.313 -1.02 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.584 -177.688 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.988 0.423 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.487 ' HG2' ' HB3' ' A' ' 129' ' ' GLU . 54.3 mttm -93.42 133.45 36.68 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.212 174.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.442 ' CD2' ' HD1' ' A' ' 109' ' ' PHE . 93.5 m-85 -122.13 157.97 30.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.41 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.46 117.13 32.74 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.02 -178.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 7.6 p -119.6 172.9 7.33 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.16 177.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.4 ttp180 -104.97 131.95 51.83 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 177.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.618 ' HA ' HG12 ' A' ' 102' ' ' VAL . . . -84.49 134.02 34.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.142 -0.481 . . . . 0.0 112.092 -173.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.494 HD11 ' HG3' ' A' ' 103' ' ' GLU . 2.5 mp -110.58 -51.41 6.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 172.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.574 ' OG1' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -94.36 178.01 5.76 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -122.72 174.74 6.92 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 97.87 -163.44 21.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.687 -178.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 58.9 mtt180 -120.59 148.46 43.84 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 178.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.657 ' HB1' ' HB2' ' A' ' 80' ' ' ALA . . . -129.15 114.68 16.62 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 178.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.506 ' O ' ' HD3' ' A' ' 79' ' ' LYS . 15.7 tm-20 -133.61 122.01 22.88 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.657 -173.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.03 -173.98 44.74 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.344 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 31.1 mp0 -71.39 138.23 48.98 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 115' ' ' THR . . . -95.24 123.12 38.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.885 0.374 . . . . 0.0 110.915 178.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.1 mp -104.84 127.03 52.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.113 175.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.784 HG12 ' HB ' ' A' ' 115' ' ' THR . 13.4 p -102.04 137.67 29.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.852 -173.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.4 m -150.14 107.86 3.68 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 175.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -96.72 65.26 2.17 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.03 -177.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 mm-40 -142.74 161.74 37.29 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.3 176.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -88.38 81.75 7.16 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.909 0.385 . . . . 0.0 111.6 -177.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.518 HG22 ' H ' ' A' ' 26' ' ' PHE . 4.3 mp -108.17 112.23 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.694 0 CA-C-O 121.733 0.778 . . . . 0.0 109.749 173.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.3 m -87.38 36.36 0.74 Allowed 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.291 -1.322 . . . . 0.0 111.009 -177.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.518 ' H ' HG22 ' A' ' 24' ' ' ILE . 56.8 m-85 63.88 -81.89 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.223 0.609 . . . . 0.0 111.106 -176.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.2 mt 58.41 -85.4 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 O-C-N 123.896 0.748 . . . . 0.0 111.598 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -158.17 24.59 0.39 Allowed Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.84 -22.29 79.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.772 -176.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 39.8 mt -92.94 127.61 44.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.961 0.41 . . . . 0.0 110.338 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 38' ' ' LYS . 16.2 t70 -67.27 119.03 11.47 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.957 176.393 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 10.2 ptpp? -83.22 0.6 44.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.645 0.259 . . . . 0.0 111.355 -173.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 53.4 mm-40 -85.29 -46.81 10.65 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.899 0.38 . . . . 0.0 110.544 177.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.4 p -125.56 -5.47 7.05 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.991 0.738 . . . . 0.0 112.991 -174.105 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.99 30.86 55.08 Favored Glycine 0 C--O 1.236 0.233 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.41 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 40.9 mm -99.66 123.84 52.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.641 HG21 ' HE3' ' A' ' 44' ' ' LYS . 15.3 t -71.2 104.53 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.244 176.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.453 ' CG ' ' HB2' ' A' ' 31' ' ' ASP . 6.8 mmmm -78.62 -19.99 51.41 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.523 -174.016 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -90.56 110.22 21.36 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.756 178.032 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.491 ' HA ' ' HB3' ' A' ' 44' ' ' LYS . 19.3 t70 -97.81 155.88 16.84 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.108 0.48 . . . . 0.0 110.966 -178.067 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 18.7 p -141.32 -37.93 0.42 Allowed 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.322 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -141.02 -62.47 0.48 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.186 -177.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.441 HD12 HG21 ' A' ' 115' ' ' THR . 30.2 pt -133.17 17.52 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.932 -172.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.641 ' HE3' HG21 ' A' ' 37' ' ' VAL . 17.4 tptt -80.97 -173.4 4.24 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.13 0.491 . . . . 0.0 111.565 -168.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.36 -0.44 55.8 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -173.147 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -94.28 179.01 5.44 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.963 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 9.5 m -92.41 132.13 37.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.203 -175.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 78' ' ' PRO . 28.7 m -106.23 -0.27 10.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.113 0.482 . . . . 0.0 110.003 172.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -64.86 96.54 0.19 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.546 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.522 ' C ' ' HD2' ' A' ' 51' ' ' ARG . . . 86.12 20.98 54.05 Favored Glycine 0 N--CA 1.444 -0.807 0 CA-C-N 114.266 -1.333 . . . . 0.0 112.517 177.464 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.522 ' HD2' ' C ' ' A' ' 50' ' ' GLY . 4.0 mpt_? -119.01 166.15 13.23 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.719 0.295 . . . . 0.0 110.588 178.332 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.783 HG12 ' HB3' ' A' ' 80' ' ' ALA . 63.3 mt -93.63 122.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.299 -0.409 . . . . 0.0 109.943 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.427 HD21 ' HE2' ' A' ' 55' ' ' PHE . 17.0 tp -99.33 128.0 45.4 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.572 -175.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.9 120.17 60.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.118 0.485 . . . . 0.0 111.215 -177.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . 0.428 ' O ' ' HA ' ' A' ' 83' ' ' ASN . 13.9 m-85 -133.37 144.49 52.57 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 176.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 55' ' ' PHE . 14.0 Cg_exo -69.72 -54.21 0.23 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.55 2.167 . . . . 0.0 111.074 175.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -165.65 67.87 0.2 Allowed Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.434 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -61.51 -29.38 71.59 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.934 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.554 ' HG3' ' HG3' ' A' ' 87' ' ' GLU . 41.2 ttmt 70.62 166.04 0.29 Allowed 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 123.022 0.529 . . . . 0.0 111.073 178.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.526 ' N ' ' HG2' ' A' ' 59' ' ' LYS . . . -126.81 96.28 0.45 Allowed Glycine 0 N--CA 1.443 -0.865 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 175.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 27.3 m -96.37 95.13 7.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.534 0.207 . . . . 0.0 111.242 -178.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 4.3 m 58.58 45.51 16.09 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-O 121.381 0.61 . . . . 0.0 111.317 175.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' HD12 ' A' ' 89' ' ' ILE . 51.8 t -80.79 -36.4 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.345 -177.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 84.51 -27.02 4.86 Favored Glycine 0 CA--C 1.516 0.15 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.032 -177.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.464 ' HB3' ' HA3' ' A' ' 93' ' ' GLY . 27.6 m 70.14 1.73 3.66 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.358 0.663 . . . . 0.0 112.399 174.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 26.4 p90 -70.81 -29.91 66.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.277 0.56 . . . . 0.0 110.24 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.622 ' O ' ' HG ' ' A' ' 71' ' ' LEU . 9.6 p -71.23 -29.79 37.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.401 -175.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.463 HD13 ' HA ' ' A' ' 65' ' ' SER . 6.4 mp -66.9 -41.68 86.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.78 -178.74 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 48.3 tp -67.27 -36.0 80.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 177.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -58.94 -48.33 81.88 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.332 175.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.622 ' HG ' ' O ' ' A' ' 67' ' ' VAL . 81.2 mt -58.4 -40.32 82.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 178.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.521 ' HG3' ' O ' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -66.78 -42.78 85.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.082 -178.616 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -64.79 -27.97 69.25 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.682 0.277 . . . . 0.0 111.374 -179.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -90.47 -17.8 26.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.19 0.519 . . . . 0.0 110.082 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 83.58 26.8 41.21 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.349 178.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.87 11.6 7.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.152 0.501 . . . . 0.0 110.537 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.439 ' HB1' HD11 ' A' ' 99' ' ' ILE . . . -81.93 158.38 67.68 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.138 -179.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 48' ' ' VAL . 24.3 Cg_exo -62.16 148.55 93.0 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.192 1.928 . . . . 0.0 110.99 171.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.506 ' HD3' ' O ' ' A' ' 14' ' ' GLU . 75.5 tttt -84.96 -21.63 29.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.511 . . . . 0.0 109.635 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.783 ' HB3' HG12 ' A' ' 52' ' ' ILE . . . -166.49 163.55 17.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.227 175.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.458 HG23 ' HB3' ' A' ' 101' ' ' LEU . 7.9 tt -146.84 114.71 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.288 0.566 . . . . 0.0 110.065 174.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.63 HD12 HG22 ' A' ' 102' ' ' VAL . 7.6 mm -108.55 124.31 64.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -177.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.428 ' HA ' ' O ' ' A' ' 55' ' ' PHE . 13.3 m120 -120.93 160.89 22.55 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.297 -173.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 79.7 tttt -77.11 -37.45 54.21 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 171.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -154.71 154.71 33.32 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 114.711 -1.132 . . . . 0.0 108.57 168.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.9 t -143.52 172.63 12.53 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.78 -178.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.554 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 57.7 mm-40 -107.98 168.19 9.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.597 -177.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.0 m -58.85 -52.15 66.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -173.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.585 HD12 ' HB ' ' A' ' 63' ' ' VAL . 36.1 pt -63.5 -30.08 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 C-N-CA 120.638 -0.425 . . . . 0.0 112.067 -174.43 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 47.1 mm -64.93 -45.41 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 101' ' ' LEU . . . -64.47 -48.02 76.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.051 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 86.9 t -61.81 -46.51 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.18 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.464 ' HA3' ' HB3' ' A' ' 65' ' ' SER . . . -63.13 -43.87 98.03 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.567 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.558 ' HB3' HD22 ' A' ' 101' ' ' LEU . . . -72.21 -35.93 69.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.437 0.161 . . . . 0.0 111.319 -178.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -60.07 -31.26 69.83 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.139 0.495 . . . . 0.0 110.73 178.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 68.8 mtm -82.68 -39.88 21.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.625 178.24 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.521 ' O ' ' HG3' ' A' ' 72' ' ' ARG . . . -80.68 6.84 11.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.024 -178.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.489 ' O ' ' HD3' ' A' ' 100' ' ' PRO . 47.9 mt-10 64.23 35.47 10.05 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.263 0.554 . . . . 0.0 110.971 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.53 ' HB ' ' HB1' ' A' ' 94' ' ' ALA . 54.2 mt -109.91 88.61 6.97 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 115.252 -0.886 . . . . 0.0 110.101 178.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HA ' ' HB ' ' A' ' 9' ' ' THR . 32.8 Cg_exo -58.53 118.04 4.86 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.67 2.247 . . . . 0.0 113.018 -176.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.58 HD21 ' HA ' ' A' ' 91' ' ' ALA . 1.7 pt? -117.34 141.64 48.07 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.251 175.14 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.63 HG22 HD12 ' A' ' 82' ' ' ILE . 31.3 m -138.04 161.56 32.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.928 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.494 ' HG3' HD11 ' A' ' 8' ' ' ILE . 53.2 mt-10 -97.92 116.8 30.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.686 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.592 HG12 HG22 ' A' ' 82' ' ' ILE . 7.2 p -115.23 107.38 22.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.764 0.792 . . . . 0.0 109.187 172.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 8.3 ttm-85 -99.04 14.65 28.46 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.048 -175.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -89.18 120.01 30.18 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.044 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -67.39 -34.71 77.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.391 -175.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 111' ' ' GLU . 32.8 mmtp -69.49 -23.0 63.57 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.32 -173.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.442 ' HD1' ' CD2' ' A' ' 3' ' ' PHE . 87.6 t80 -62.19 -51.04 69.39 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 172.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.402 ' CZ ' HG13 ' A' ' 104' ' ' VAL . 87.0 m-85 -69.7 -25.96 64.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.842 -178.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.439 ' HB2' ' HA ' ' A' ' 108' ' ' LYS . 37.1 mm-40 -74.92 -29.59 61.01 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.009 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.79 -34.03 14.74 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -176.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 109' ' ' PHE . 13.7 p -85.15 138.6 18.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.173 0.511 . . . . 0.0 111.375 -175.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 95.1 mttt -124.48 167.07 14.94 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.972 173.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.784 ' HB ' HG12 ' A' ' 19' ' ' VAL . 9.8 t -67.55 107.58 2.55 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.725 0.774 . . . . 0.0 110.657 -178.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.15 -24.39 4.23 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.554 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -63.72 151.12 42.85 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 116.868 0.334 . . . . 0.0 110.28 179.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.691 HH21 HG13 ' A' ' 131' ' ' ILE . 1.1 tmm_? -96.68 120.37 36.89 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -175.04 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.448 HG22 HD12 ' A' ' 130' ' ' LEU . 46.3 t -120.68 141.2 42.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.757 -175.047 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.486 HG23 ' HB2' ' A' ' 14' ' ' GLU . 9.9 p -124.38 121.1 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 121.763 0.792 . . . . 0.0 109.464 169.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 13' ' ' ALA . 40.2 t -106.54 127.35 62.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.472 -178.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ASN . . . . . . . . . . . . . 49.2 t-20 -93.44 97.48 10.58 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 176.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.38 -13.83 51.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.363 -175.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -68.92 -45.11 71.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.158 0.504 . . . . 0.0 109.744 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -93.85 -43.26 8.67 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.086 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 102.38 69.22 0.82 Allowed Glycine 0 N--CA 1.447 -0.577 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -172.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.7 t80 -161.31 157.62 25.74 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 -172.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -152.99 138.64 11.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.021 -179.032 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HG2' ' A' ' 2' ' ' LYS . 2.2 pm0 -118.75 119.99 36.05 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.356 0.598 . . . . 0.0 110.458 174.142 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.448 HD12 HG22 ' A' ' 119' ' ' VAL . 54.7 tp -84.01 130.54 34.88 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.69 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.691 HG13 HH21 ' A' ' 118' ' ' ARG . 37.1 mm -101.27 120.25 50.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 CA-C-O 121.412 0.625 . . . . 0.0 109.6 177.236 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 . . . . . 0 C--N 1.308 -1.198 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.195 -178.129 . . . . . . . . 0 0 . 1 stop_ save_